Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis

Supplementary Material

Table of Contents	Page
Search Strategy	2
Characteristics of Included Studies	3
Description of Studies Excluded at Full-text Stage	65
Nodes Excluded by Steering Committee	145
Disease Severity Judgements	149
Mild to Moderate Studies	149
Severe to Critical Studies	156
Proportion of Non-Severe Patients in Trials with Mixed Severity Populations	168
Studies Included in Analysis for Each Outcome	169
Time to Symptom Resolution Definitions	176
Discrepancies Between Preprint and Peer-reviewed Publications	183
Risk of Bias Assessments	189
Network Plots	251
Complete NMA Results and GRADE	258
Living Network Meta-Analysis Protocol and Extended Methods	289
Detailed Risk of Bias Assessment Guidance	303
Results of Studies Captured after Analysis Date	308

For additional study characteristics and R code, please visit our github: https://github.com/covid19lnma/covid19_lnma/

For trial level data and pairwise forest plots, please visit https://mcmasteru365-my.sharepoint.com/:f:/g/personal/diazmarj_mcmaster_ca/EhhKawVQncFGsxnZGFULZGwBNHZfTIAb5xrGzIkSShramA?e=faspFj

For detailed summary of findings tables, please visit our website: https://www.covid19lnma.com/

Search Strategy

Weekly searches using the Epistemonikos COVID-19 Living Overview of Evidence (COVID-19 LOVE) repository which searches on 42 databases. Detailed search strategy and methods can be found here: Living Overview of the Evidence (L·OVE) (iloveevidence.com) (https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?population=5e7fce7e3d05156b5f5e032a&conditions_or_clinical_findings=603b9fe03d05151f35cf13dc&section=methods&classification=systematic-review)

Previously, we searched daily in the WHO COVID-19 research database which searches on 20 diferent databases. Details of the search strategy and methods can be found here: https://www.who.int/docs/default-source/coronaviruse/who-covid-19-database/who-covid-19-database-search-strategy-(1).pdf?sfvrsn=113c354e_3)

Prior to switching to the Epistemonikos LOVE repository, we ran the search in both databases for an overlapping period of 3 months.

Characteristics of Included Studies

Study	Publication status Registration	Recruitment Period	n	Country	Mean age	% Male	Comorbidities	Type of care	% Oxygen support at baseline	% Vaccination	Treatments (dose and duration)	Outcomes
Abd-Elsalam_2, 2020[1]	Published NCT04447534	Jun 23 to Aug 23, 2020	191	Egypt	43.6	60.7	Diabetes (13.6%) Hypertension (19.4%)	Inpatient	NR	NA	hydroxychloroquine (200 mg twice daily for 6 days), zinc (220 mg twice daily for 15 days) hydroxychloroquine (200 mg twice daily for 6 days)	Mortality Mechanical ventilation Duration of hospitalization
Abd-Elsalam_3, 2021[2]	Pre-print NCT04403555	Mar to Oct 2020	164	Egypt	40.9	50	Cardiac problem (0.0%)	NR	NR	NA	ivermectin (12 mg tablets daily for 3 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Abdeen_2, 2021[3]	Published	NR	16	Israel	NR	NR	NR	Inpatient	NR	NR	colchicine (1 mg twice a day on day 1 and 0.5 mg twice a day for 7 ± 4 days thereafter) standard care/placebo	NR
Abdulamir_2, 2021[4]	Published NCT04753619	Jan to Apr 2021	150	Iraq	49.3	53.3	Asthma (0.7%) Ischemic heart disease (1.3%) Diabetes (8.0%) Hypertension (12.7%)	NR	NR	NR	niclosamide (4 g/day for 1 day and then 3g/day in 3 divided doses for 7 days) standard care/placebo	Mortality Time to symptom/clinical improvement
Abroug, 2023 COVID-VITD[5]	Published NCT04883203	May to Aug 2020	117	Tunisia	42.7	55.6	Asthma (6.8%) Diabetes (12.0%) Hypertension (6.8%)	NR	NR	NA	vitamin D (200,000 IU / 1 ml) standard care/placebo	Time to viral clearance
Abulmeaty, 2021[6]	Published NCT04323228, SCTR No. 20092202	Dec 30, 2020 to Mar, 15 2021	52	Saudi Arabia	48.6	63.6	NR	Inpatient	NR	NR	selenium (15 µg), vitamin A (1500 µg), vitamin C (250 µg), vitamin E (90 µg), zinc (7.5 mg) standard care/placebo	NR
Adhikari, 2022[7]	Data from authors	NR	90	Nepal	NR	NR	NR	NR	NR	NR	Favipiravir (NR) standard care/placebo	NR
Ahmad, 2021[8]	Published	Jun 1 to Jun 15, 2020	150	Pakistan	37.57	95.33	Ischemic heart disease or cardiac arrhythmias (0.0%)	Inpatient	NR	NA	(hydroxy)chloroquine (400 mg twice daily on day one and 200 mg for the next 4 days) (hydroxy)chloroquine (250 mg twice daily for 7 days) standard care/placebo	NR
Ahmed, 2020[9]	Published	NR	72	Bangladesh	42	46	Ischemic heart disease (0.0%) Heart failure (0.0%) Cardiomyopathy (0.0%)	Inpatient	Supplemental oxygen, niv, or iv (0.0%)	NA	Ivermectin (12 mg once daily for 5 days) doxycycline (12 mg single dose), ivermectin (12 mg once daily for 5 days) standard care/placebo	Mechanical ventilation Viral clearance Duration of hospitalization Time to viral clearance
Akbari, 2022[10]	Published IRCT20090609002017N35	May to Jun 2020	52	Iran	42.8	37.5	Ischemic myocardial disease (0.0%) Thromboembolic disease (0.0%)	Outpatient	NR	NA	boron citrate (5 mg twice a day for 2 weeks) oleoylethanolamide (200 mg twice a day for 2 weeks) boron citrate (5 mg twice a day for 2 weeks), oleoylethanolamide (200	NR

											mg twice a day for 2 weeks) standard care/placebo	
AlQahtani, 2022[11 12]	Published NCT04387760	Aug 2020 to Mar 2021	157	Bahrain	44.4	47.8	Chronic lung disease or asthma (7.6%) Heart disease (1.3%) Diabetes (26.1%)	Inpatient	Mv (0.6%) Oxygen therapy (0.6%)	NR	Favipiravir (Day 1: 1600mg twice orally; Day 2-10: 600mg BID) (hydroxy)chloroquine (Day 1: 400mg twice orally; Day 2-10: 200mg twice daily) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Duration of hospitalization
Ali, 2022 CATCO[13] ‡	Published NCT04330690	Aug 14, 2020 to Apr 1, 2021	1282	Canada	65.5	59.8	Chronic respiratory disease (13.9%) Asthma (10.9%) Cardiovascular disease (26.8%) Diabetes (36.1%)	Inpatient Intensive care (21.4%)	Low-flow oxygen (54.4%) High-flow nasal oxygen (23.6%) Noninvasive ventilation (3.5%) Invasive mechanical ventilation (8.7%)	NR	Remdesivir (100mg daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization ICU length of stay Ventilator-free days
Amaravadi, 2021 PATCH[14]	Pre-print NCT04329923	Apr 15 to Jul 14, 2020	34	United States	53	26.5	Asthma (11.8%) Diabetes (8.8%) Hypertension (20.6%)	Outpatient	Unspecified ventilation (0.0%)	NA	(hydroxy)chloroquine (200 mg twice daily for 14 days) standard care/placebo	Mortality Admission to hospital Viral clearance Time to symptom/clinical improvement
Amirsavadkouhi, 2021[15]	Published IRCT20150725023332N4	Apr 20 to Jun 20, 2020	90	Iran	65.2	58.3	Myocardial infarction (2.2%) Cerebrovascular accident (2.2%) Hyperlipidemia (16.7%) Diabetes (17.8%) Hypertension (24.4%)	Inpatient	Intubation (0.0%)	NA	Morphine (3mg every 6 hours for 5 days) fentanyl (1.5 mcg/ kg/ hr infused intravenously for 2 hours on 5 consecutive days) standard care/placebo	NR
Ananworanich_2, 2021[16]	Published NCT04504032	Aug 16, 2020 to Feb 3, 2021	497	United States	49	39.9	Chronic pulmonary disease, chronic obstructive pulmonary disease, pulmonary hypertension (6.1%) Diabetes (27.7%) Hypertension (51.8%)	Outpatient	Unspecified ventilation (0.0%)	NR	prophylactic-dose anticoagulation (rivaroxaban (10 mg daily for 21 days)) standard care/placebo	Mechanical ventilation Mortality Admission to hospital Adverse effects leading to discontinuation Venous thromboembolism Clinically important bleeding
Angkasekwinai, 2022[17]	Published	Aug to Oct 2021	447	Thailand	39.4	43.18	Chronic lung diseases (0.2%) Coronary artery disease (1.8%) Cerebrovascular disease (0.2%) Diabetes (6.9%) Hypertension (11.2%)	Inpatient (7.4%)	Unspecified ventilation (0.0%)	1 dose (47.9%), at least 2 doses (27.1%)	Ivermectin (400–600 µg/kg once daily for 3 days) standard care/placebo	Mortality Admission to hospital
Annweiler, 2022 COVIT-TRIAL[18]	Published NCT04344041	Apr 15 to Dec 17, 2020	260	France	88	41.7	Copd (7.1%) Heart disease (42.5%) Cerebrovascular disease (18.5%) Diabetes (20.5%) Hypertension (69.7%)	Inpatient (65.8%)	Oxygen therapy (20.5%) Mechanical ventilation (0.0%)	NR	vitamin D (single dose 400,000 IU) vitamin D (single dose 50,000 IU)	Mortality
Arefin, 2021[19]	Published NCT04549376	NR	189	Bangladesh	44	84.1	NR	Inpatient	NR	NR	povidone-iodine nasal irrigation (0.4%) (single application) povidone-iodine nasal irrigation (0.5%) (single application)	NR

											povidone-iodine nasal irrigation (0.6%) (single application) povidone-iodine nasal spray (0.5%) (single application) povidone-iodine nasal spray (0.6%) (single application) standard care/placebo	
Arefizadeh, 2023[20]	Published IRCT20220813055675N1	May 10, 2020 to Jan 13, 2021	180	Iran	60.1	75.9	Acute coronary ayndrome (100.0%) Dyslipidemia (50.6%) Percutaneous coronary intervention [pci] (100.0%) Severe heart failure (0.0%) Slow flow coronary artery disease (25.3%) Diabetes (50.6%) Hypertension (47.6%)	Inpatient	NR	NR	P2Y12 inhibitor (ticagrelor (180 mg loading dose followed by 90 mg twice daily for one year)) P2Y12 inhibitor (clopidogrel (600 mg loading dose followed 75 mg daily for one year))	Mortality Duration of hospitalization
Arruda, 2021 ARTAN-C19[21]	Pre-print NCT04712357	Nov 9, 2020 to Aug 13, 2021	227	Brazil	38	35.4	Asthma (6.3%) Heart disease (3.1%) Diabetes (9.8%) Hypertension (17.0%)	Outpatient	NR	NR	HIV reverse transcriptase inhibitor (300 mg emtricitabine and 200 mg tenofovir once daily for 10 days) HIV reverse transcriptase inhibitor (300 mg tenofovir once daily for 10 days) standard care/placebo	Admission to hospital
Atipornwanich_1, 2021 FIGHT-COVID-19[22]	Pre-print NCT04303299	Oct 19, 2020 to Jul 20, 2021	90	Thailand	35.4	43.3	NR	Inpatient	NR	1.10%	hydroxychloroquine, oseltamivir (800 mg/day; 300 mg/day or 4-6 mg/kg/day, for 7-14 days or more) lopinavir, oseltamivir, ritonavir (800 mg/day or 10 mg/kg/day; 300 mg/day or 4-6 mg/kg/day; 200 mg/day or 2.5 mg/kg/day, for 7-14 days or more) darunavir, hydroxychloroquine, oseltamivir, ritonavir (1200 mg/day or 4-6 mg/kg/day; 400 mg/day; 300 mg/day or 4-6 mg/kg/day; 200 mg/day or 2.5 mg/kg/day, for 7-14 days or more)	Mortality Adverse effects leading to discontinuation Time to viral clearance
Avezum, 2022 COPE − Coalition V[23]	Published NCT04466540	May 12, 2020 to July 7, 2021	1372	Brazil	45	46.9	Asthma (13.0%) Lung disease (1.6%) Heart disease (3.4%) Decompensated heart failure (0.0%) Unstable coronary artery disease (0.0%) Long qt-syndrome (0.0%) Diabetes (16.2%) Hypertension (53.4%)	Outpatient	NR	NR	(hydroxy)chloroquine (400 mg twice a day in the first day, followed by 400 mg once daily for seven days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Duration of ventilation Time to symptom/clinical improvement
Avezum_2, 2023 CARE[24]	Published NCT04757857	Dec 30, 2020 to Jan 28, 2022	660	Brazil	61	44.4	Asthma (11.0%) Lung disease (4.1%) Myocardial infarction	Outpatient	NR	NR	prophylactic-dose anticoagulation (10 mg rivaroxaban once daily for	Mortality Mechanical ventilation Admission to hospital

							(2.7%) Stable angina (2.1%) Unstable angina (0.5%) Percutaneous coronary iintervention (3.0%) Cabg surgery (1.4%) Aortic aneurysm (0.6%) Venous thromboembolism (2.6%) Heart failure (1.7%) Stroke (1.5%) Diabetes (35.8%) Hypertension (79.3%)				14 days) standard care/placebo	Venous thromboembolism Clinically important bleeding
Axfors_NCT04333654, 2020 HYDRA[25]	Data from meta-analysis NCT04333654	NR	8	United States, Belgium, France, Netherlands	18-70	NR	NR	Outpatient	NR	NA	(hydroxy)chloroquine (600 mg/day for 10 days) standard care/placebo	Mortality
Axfors_NCT04338698, 2020 PROTECT[25]	Data from meta-analysis NCT04338698	NR	373	Pakistan	≥18	NR	NR	Inpatient	NR	NA	azithromycin, hydroxychloroquine, oseltamivir (250 mg/day for 5 days; 200 mg three times daily for 5 days; 75 mg twice daily for 5 days) azithromycin, oseltamivir (250 mg/day for 5 day; 75 mg twice daily for 5 days) hydroxychloroquine, oseltamivir (200 mg three times daily for 5 days; 75 mg twice daily for 5 days) oseltamivir (75 mg twice daily for 5 days) azithromycin, hydroxychloroquine (250 mg/day for 5 days; 200 mg three times daily for 5 days) azithromycin (250 mg/day for 5 days)	Mortality
Axfors_NCT04340544, 2020 COMIHY[25]	Data from meta-analysis NCT04340544	NR	16	Germany	≥18	NR	NR	Outpatient	NR	NA	(hydroxy)chloroquine (600 mg/day for 7 days) standard care/placebo	Mortality
Axfors_NCT04342221, 2020 COV-HCQ[25]	Data from meta-analysis NCT04342221	NR	27	Germany	≥18	NR	NR	Inpatient	NR	NA	(hydroxy)chloroquine (600 mg/day for 7 days) standard care/placebo	Mortality
Axfors_NCT04342650, 2020 CloroCOVID[25]	Data from meta-analysis NCT04342650	NR	152	Brazil	≥18	NR	NR	Outpatient	NR	NA	(hydroxy)chloroquine (450 mg/day for 5 days) standard care/placebo	Mortality
Babalola, 2021[26]	Published ISRCTN40302986	May to Nov 2020	63	Nigeria	44.3	69.3	Diabetes (3.2%) Hypertension (14.5%)	Inpatient	Intranasal oxygen (8.1%) Ventilator (0.0%)	NA	ivermectin (6 mg every 84 hours twice weekly for 2 weeks) ivermectin (12 mg every 84 hours for 2 weeks) lopinavir-ritonavir (daily for 2 weeks)	Mortality Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Balykova_1, 2020[27]	Published NCT04542694	Jan 6 to Jan 8, 2020	39	Russia	47.3	NR	Chronic heart failure of functional classes iii-iv (0.0%)	Inpatient	NR	NA	favipiravir (600 mg twice daily for 7 days) standard care/placebo	Mortality Time to symptom/clinical improvement

												Mechanical ventilation Viral clearance
Balykova_3, 2022[28]	Published	Sept 2021 to Mar 2022	264	Russia	46.62	37.1	Respiratory disease (7.0%) Heart disease (30.7%) Diabetes (1.1%) Hypertension (32.5%)	Outpatient	Unspecified ventilation (0.0%)	NR	nirmatrelvir-ritonavir (300 mg-100 mg twice a day for 5 days) standard care/placebo	Adverse effects leading to discontinuation Viral clearance
Barco, 2022 OVID[29 30]	Published NCT04400799	Aug 15, 2020 to Jan 14, 2022	475	Germany, Switzerland	56.50	54.03	Copd (1.9%) Atherosclerotic disease (4.7%) Chronic heart failure (0.4%) Diabetes (8.1%) Hypertension (24.4%)	Outpatient	Unspecified ventilation (0.0%)	1 dose (1.9%), 2 doses (5.3%), 3 doses (2.3%)	prophylactic-dose anticoagulation (40 mg enoxaparin once daily for 14 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Venous thromboembolism Clinically important bleeding
Beigel, 2020 ACTT-1[31] ‡	Published NCT04280705	Feb 21 to Apr 19, 2020	1062	United States, Denmark, United Kingdom, Greece, Germany, Korea, Mexico, Spain, Japan, Singapore	58.9	64.4	Chronic respiratory disease (7.6%) Chronic oxygen requirement (2.2%) Asthma (11.4%) Coronary artery disease (11.9%) Congestive heart failure (5.6%) T2DM (30.6%) T1DM (0.9%) Hypertension (50.7%)	Inpatient	Supplemental oxygen (41.0%) High-flow or niv (18.2%) Iv or ecmo (26.8%)	NA	remdesivir (100 mg/day for 10 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement
Berezhanskiy, 2021 RESET[32] ‡	Data from authors NCT04380519	NR	372	Russia	59.1	52.69	Respiratory, thoracic and mediastinal disorders (11.3%) Asthma (3.0%) Bronchitis chronic (2.1%) Chronic obstructive pulmonary disease (1.1%) Cardiac disorders (24.2%) T1DM (7.0%) T2DM (9.9%) Hypertension (49.2%)	Inpatient	Supplemental oxygen (76.3%) Mechanical ventilation [invasive/noninvasive] or ecmo (7.3%)	NR	IL1 inhibitors (80 mg RPH-104, one injection 2 mL) anti-IL6 (64 mg olokizumab, one injection 0.4 mL) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation ICU length of stay Duration of ventilation Time to symptom/clinical improvement
Bernal, 2022 MOVe-OUT[33]	Published NCT04575597	May 6 to Nov 4, 2021	1433	Argentina, Brazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Italy, Japan, Mexico, Philippines, Russia, South Africa, Spain, Taiwan, United Kingdom, Ukraine, United States	44.9	48.7	Chronic obstructive pulmonary disease (4.0%) Heart failure, coronary artery disease, or cardiomyopathies (11.7%) Diabetes (15.9%)	Outpatient	NR	0	molnupiravir (800 mg twice daily for 5 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Viral clearance Duration of hospitalization

Bhushan, 2021[34]	Published CTRI/2020/12/029855	Dec 16, 2020 to Mar 25, 2021	250	India	49.9	70.8	NR	Inpatient	NR	NR	Interferon alpha (1 µg/kg single dose) standard care/placebo	Mortality Mechanical ventilation Viral clearance Duration of hospitalization Time to symptom/clinical improvement
Bishop, 2022 REsCue trial[35]	Published NCT04551911	Nov 2, 2020 to Oct 8, 2021	171	United States	43	41	Asthma (2.2%) Cardiovascular disease (0.0%) Type i (0.8%) Type ii (5.2%) Hypertension (21.6%)	Outpatient	Unspecified ventilation (0.0%)	3%	vitamin D (300 mcg for days 1-3 followed by 60 mcg on days 4-27) standard care/placebo	Time to symptom/clinical improvement
Bosaeed_2, 2022 Avi-Mild-19[36]	Published NCT04464408	Jul 23, 2020 to Aug 4, 2021	245	Saudi Arabia	36.5	67.1	Chronic pulmonary disease (0.9%) Asthma (3.5%) Cardiovascular disease (0.4%) Diabetes (10.8%) Hypertension (6.1%)	Outpatient	NR	NR	favipiravir (1800 mg twice daily day 1 followed by 800 mg twice daily for a total duration of 5 to 7 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Boulware, 2022 ACTIV[37 38]	Pre-print NCT04885530	Aug 10, 2021 to Feb 12, 2022	1407	United States	45	36.8	Copd (1.4%) Asthma (13.0%) Heart disease (4.7%) Diabetes (9.7%) Hypertension (26.1%)	Outpatient	NR	1 dose (1.45), 2 or more doses (64.8%)	inhaled corticosteroids (200 µg fluticasone furoate daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Time to symptom/clinical improvement
Bradbury, 2022 REMAP-CAP[39] ‡	Published NCT02735707	Oct 30, 2020 to Jun 24, 2021	1824	Canada, France, Germany, India, Italy, Nepal, the Netherlands, United Kingdom	55.2	66.3	Respiratory disease (18.8%) Severe cardiovascular disease (4.0%) Diabetes (21.9%)	Inpatient	Imv (31.5%) Niv (34.7%) Hfnc (21.3%) None/supplemental oxygen (12.8%)	NR	aspirin (75 to 100mg once daily for 14 days or until hospital discharge) P2Y12 inhibitor (clopidogrel 75 mg once daily without a loading dose, ticagrelor 60 mg twice daily without a loading dose, prasugrel a 60-mg loading dose followed by 10 mg daily (if aged < 75 years and weight ≥ 60kg) or 5 mg daily (if aged ≥ 75 years or weight <60 kg), for 14 days or until hospital discharge) standard care/placebo	Mortality Mechanical ventilation Ventilator-free days
Bramante_1, 2022 COVID-OUT[40-43]	Published NCT04510194	Dec 30, 2020 to Jan 28, 2022	880	United States	45.5	45.3	Cardiovascular disease (22.9%) Stage 3 or 4 heart failure (0.0%) Diabetes (1.7%)	Outpatient	NR	primary series (49.6%), booster dose (4.5%)	ivermectin (390 to 470 µg per kilogram per day for 3 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Viral clearance
Bramante_2, 2022 COVID-OUT[40-43]	Published NCT04510194	Dec 30, 2020 to Jan 28, 2022	721	United States	44.5	45.8	Cardiovascular disease (26.8%) Stage 3 or 4 heart failure (0.0%) Diabetes (1.1%)	Outpatient	NR	primary series (51.3%), booster dose (4.2%)	fluvoxamine (50mg on day 1 followed by 50mg twice daily through 14 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Viral clearance
Bukhari, 2021[44]	Pre-print NCT04392713	Mar 15 to Jun 15, 2020	100	Pakistan	40.5	84.9	Ischemic heart disease (5.8%) Diabetes (11.6%) Hypertension (13.9%)	Inpatient	NR	NA	ivermectin (12 mg single dose) standard care/placebo	Viral clearance

Buonfrate, 2022 COVER[45]	Published NCT04438850	Jul 31, 2020 to May 26, 2021	93	Italy	47.2	58.1	Respiratory condition (6.5%) Cardiovascular disease (23.7%) Diabetes (3.2%)	Outpatient	Oxygen supplementation (0.0%)	2.20%	ivermectin (600 µg/kg single dose for 5 days) ivermectin (1200 µg/kg single dose for 5 days) standard care/placebo	Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Butler, 2021 PRINCIPLE[46]	Published ISRCTN 86534580	Jul 24 to Dec 14, 2020	1840	United Kingdom	61.1	44.1	Asthma, copd, or lung disease (37.3%) Angina, heart attack, heart failure, atrial fibrillation, valve problems (14.2%) Diabetes (18.0%) Hypertension (41.5%)	Outpatient	NR	NR	doxycycline (100 mg once daily for 6 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization Time to symptom/clinical improvement
Butler_2, 2022 PANORAMIC[47]	Published ISRCTN30448031, EudraCT Number: 2021-005748-31	Dec 8, 2021 to Apr 27, 2022	25783	United Kingdom	56.6	41.4	Lung disease (24.0%) Heart disease (7.6%) Diabetes (11.6%) Hypertension (22.4%)	Outpatient	Unspecified ventilation (0.0%)	1 dose (0.7%), 2 doses (3.8%), 3 doses (92.6%), 4 doses (1.8%), data unavailable (1.1%)	molnupiravir (800mg twice daily for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Byakika-Kibwika, 2021 HONEST trial[48]	Pre-print NCT04860284	Oct to Dec 2020	105	Uganda	32	73.3	Heart disease (0.9%) Diabetes (2.9%) Hypertension (2.9%)	NR	NR	NR	(hydroxy)chloroquine (200 mg twice daily for 5 days) standard care/placebo	Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
COVITOZ_NCT04435717, 2021 COVITOZ-01[49]	Data from meta-analysis NCT04435717	NR	26	Spain	57.5	65.4	NR	Inpatient	NR	NR	IL6 receptor antagonists (8 mg/kg tocilizumab (up to 800 mg) single dose) IL6 receptor antagonists (8 mg/kg tocilizumab up to 800 mg two doses) standard care/placebo	NR
Cairns, 2022[50]	Published NCT04399356	Oct 1, 2020 to Apr 20, 2021	73	United States	36.4	61.2	Asthma (7.5%) Heart condition (1.5%)	Outpatient	Unspecified ventilation (0.0%)	0	Niclosamide (2 g by daily for 7 days) standard care/placebo	Mortality Admission to hospital Viral clearance Time to symptom/clinical improvement Time to viral clearance
Cao_3, 2022[51]	Published NCT05341609, ChiCTR2200057856	Apr 4 to May 2, 2022	822	China	53	49.8	Chronic lung disease (5.7%) Cardiovascular disease, including hypertension (35.1%) Diabetes (10.1%)	NR	Mechanical ventilation (0.0%)	standard course (30.9%), boosted course (44.9%)	VV116 (600 mg every 12 hours on day 1 and 300 mg every 12 hours on days 2 through 5) nirmatrelvir-ritonavir (300 mg of oral nirmatrelvir plus 100 mg of oral ritonavir every 12 hours for 5 days)	Mortality Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Caraco, 2022 MOVe-OUT[52]	Published NCT04575597	initatied in Oct 2020	302	Brazil, Chile, Colombia, France, Germany, Israel, Russia, South Africa,	49.2	52.6	Copd (3.6%) Serious heart conditions (8.3%) Diabetes (16.6%)	Outpatient	NR	NR	Molnupiravir (200 mg twice per day for 5 days) molnupiravir (400 mg twice per day for 5 days) molnupiravir (800 mg twice per day for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance

				Spain, United Kingdom, Ukraine, United States								
Castro-Rodriguez, 2022 ConCorD-19[53]	Pre-print NCT04552379	Dec 2020 to May 2021	341	Chile	40.9	52.8	Asthma (5.0%) Chronic lung disease (0.0%) Heart disease (5.3%) Diabetes (4.7%)	Outpatient	NR	at least 2 doses (34.9%)	interferon beta (subcutaneous) (125 µg on days 1, 6 and 11) standard care/placebo	Mortality Admission to hospital
Cavalcanti, 2020[54]	Published NCT04322123	Mar 29 to Jun 2, 2020	667	Brazil	50.3	58.4	Copd (1.8%) Asthma (6.0%) Heart failure (1.5%) Diabetes (19.1%) Hypertension (38.8%)	Inpatient Intensive care (13.8%)	Supplemental oxygen (41.8%) High-flow, niv, or iv (0.0%)	NA	azithromycin, hydroxychloroquine (500 mg/day for 7 days; 400 mg twice daily for 7 days) (hydroxy)chloroquine (400 mg twice daily for 7 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Chaccour, 2020 SAINT[55 56]	Published NCT04390022	Jul 31 to Sept 11, 2020	24	Spain	26	50	Copd (0.0%) Coronary disease (0.0%) Diabetes (0.0%) Hypertension (0.0%)	Outpatient	NR	NA	ivermectin (400 µg/kg single dose) standard care/placebo	Viral clearance Time to viral clearance
Chachar, 2020[57]	Published	May 1 to Jun 30, 2020	50	Pakistan	41.8	62	Chronic lung disease (0.0%) Cardiovascular disease (8.0%) Diabetes (40.0%) Hypertension (26.0%)	Outpatient	NR	NA	ivermectin (12 mg once, then 12 mg after 12 hours, and 12 mg after 24 hours) standard care/placebo	NR
Chahla, 2021 IVER-Leve[58]	Pre-print NCT04784481	Sept 2020 to Jan 2021	254	Argentina	37.7	47.6	Asthma (1.2%) Diabetes (6.3%) Hypertension (12.6%)	Outpatient	NR	NR	ivermectin (6 mg taken four times every 7 days for 4 weeks) standard care/placebo	Mortality Adverse effects leading to discontinuation Time to symptom/clinical improvement
Chen_1, 2020[59]	Pre-print ChiCTR2000029559	Feb 4 to Feb 28, 2020	62	China	44.7	46.8	NR	Inpatient	NR	NA	(hydroxy)chloroquine (200 mg twice daily for 5 days) standard care/placebo	Time to symptom/clinical improvement
Chen_2, 2021[60 61]‡	Published ChiCTR2000030254	Feb 20 to Mar 1, 2020	240	China	NR	46.6	Diabetes (11.4%) Hypertension (28.0%)	NR	NR	NA	favipiravir (1600 mg twice daily for first day followed by 600 mg twice daily for 6 days) umifenovir (200 mg three times daily for 7 to 10 days)	Mortality Time to symptom/clinical improvement
Chen_3, 2020[62]	Published NCT04261517	Feb 6 to Feb 25, 2020	30	China	48.6	70	Severe lung disease (0.0%) Copd (3.3%) Severe heart disease (0.0%) Diabetes (6.7%) Hypertension (26.7%)	Inpatient	NR	NA	(hydroxy)chloroquine (400 mg once daily for 5 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Chen_4, 2020[63]	Pre-print ChiCTR2000030054	Feb 18 to Mar 30, 2020	48	China	46.9	45.8	Diabetes (18.8%) Hypertension (16.7%)	Inpatient	Supplemental oxygen (72.9%)	NA	(hydroxy)chloroquine (500 mg once daily for 10 days) (hydroxy)chloroquine (200 mg twice daily for 10 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to symptom/clinical

												improvement Time to viral clearance
Chen_5, 2020[64 65]	Published NCT04384380	Apr 1 to May 31, 2020	33	Taiwan	32.9	57.6	Lung disease (0.0%) Cardiac conduction abnormalities at 152 electrocardiographic (0.0%)	Inpatient	Supplemental oxygen (0.0%)	NA	(hydroxy)chloroquine (200 mg twice daily for 7 days) standard care/placebo	Mortality Time to viral clearance
Choudhary, 2022[66]	Published	Jun 5 to Jul 15, 2020	202	India	43	48	Asthma (7.8%) Diabetes (3.6%) Hypertension (12.0%)	Inpatient	NR	NA	(hydroxy)chloroquine (800 mg followed by 600 mg 6-8 hours later. 600 mg once daily for an additional 4 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement
Chuan Huan, 2021[67]	Published NCT04818320	Feb to Jun 2021	500	Malaysia	62.5	48.4	Asthma (7.4%) Chronic pulmonary disease (1.4%) Chronic cardiac disease (15.0%) Congestive heart failure (0.0%) Diabetes (49.8%) Hypertension (80.2%)	Inpatient	Unspecified ventilation (0.0%)	at least one dose (3.6%)	favipiravir (1800 mg twice daily on day 1 followed by 800 mg twice daily until day 5) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay
Clemency, 2021[68]	Pre-print NCT04377711	Jun 11 to Nov 3, 2020	400	United States	43.3	44.8	Asthma (6.5%) Cystic fibrosis (0.0%) Idiopathic pulmonary fibrosis (0.0%) Diabetes (7.5%) Hypertension (22.2%)	Outpatient	Unspecified ventilation (0.0%)	NA	inhaled corticosteroids (320 µg ciclesonide twice daily for 30 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Cohen, 2020 REPLACE COVID trial[69]	Published NCT04338009	Mar 31 to Aug 20, 2020	152	USA, Canada, Mexico, Sweden, Peru, Bolivia, and Argentina	62	55.3	Chronic pulmonary disease; 11.18 (17.1%) Pre-existing cardiac disease; 11.84 (15.8%) Diabetes (52.0%) Hypertension (100.0%)	Inpatient	Supplemental oxygen (80.9%)	NA	ACEi/ARB (continuation of ACEi/ARB at the dose previously prescribed during routine care) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization
Connors, 2021 ACTIV-4B[70]	Published NCT04498273	Sept 2020 to Jun 2021	657	United States	54	40.9	Diabetes (18.3%) Hypertension (35.3%)	Outpatient	NR	NR	aspirin (81 mg once daily for 45 days) prophylactic-dose anticoagulation (2.5 mg apixaban twice daily for 45 days) therapeutic-dose anticoagulation (5 mg apixaban twice daily for 45 days) standard care/placebo	Mortality Admission to hospital Venous thromboembolism Clinically important bleeding
Cools, 2022 ETHIC[71]	Published NCT04492254	Oct 27, 2020 to Nov 8, 2021	219	Belgium, Brazil, India, South Africa, Spain, United Kingdom	59	56	Chronic lung disease that might include asthma, emphysema, chronic obstructive pulmonary disease, or pulmonary fibrosis (12.3%) Vascular disease (16.1%)	Outpatient	Unspecified ventilation (0.0%)	one dose (0.9%), two doses (0.5%) before enrolment; at least one dose (42.5%), two doses	prophylactic-dose anticoagulation (enoxaparin (40 mg once daily if they weighed <100 kg or 40 mg twice daily if they weighed ≥100 kg for 21 days)) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Venous thromboembolism

							Moderate or severe heart valve disease (0.6%) Treated arrhythmia (1.9%) Heart failure (0.6%) Congenital heart disease (0.6%) Previous stroke or transient ischaemic attack (1.9%) Carotid artery disease (1.2%) Previous venous thromboembolism (1.2%) Diabetes (30.9%) Hypertension (70.4%)			(29.7%) after enrolment		Clinically important bleeding
Criner, 2020[72]	Published NCT04252664	NR	584	China	57	61	Asthma (11.0%) Hypertension (39.0%)	Inpatient	Unspecified ventilation (0.0%)	NA	remdesivir (200 mg on day 1, then 100 mg daily for 5 days) remdesivir (200 mg on day 1, then 100 mg daily for 10 days) standard care/placebo	Mortality Adverse effects leading to discontinuation
Crippa, 2021 CANDIDATE[73]	Published NCT04467918	Jul 7 to Oct 16, 2020	105	Brazil	39.7	34.1	Asthma (3.3%) Diabetes (2.2%) Hypertension (4.4%)	Outpatient	NR	NA	cannabidiol (150 mg twice daily for 14 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement Time to viral clearance
Cruz, 2020 ATENEA-Co-300[74 75]	Published IG/CIGB300I/CV/2001	Jun 1 to Jun 16, 2020	20	Cuba	45.4	70	Diabetes (0.0%) Hypertension (25.0%)	Inpatient	NR	NA	CK2 inhibitor (2.5 mg/kg/day for 5 days) standard care/placebo	Adverse effects leading to discontinuation Time to viral clearance
Davoodi_1, 2020[76 77]	Published IRCT2019072704434N1	Mar 16 to Apr 10, 2020	60	Iran	57.7	59.3	Lung disease (1.9%) Diabetes (27.8%)	Outpatient	Supplemental oxygen, niv, or iv (0.0%)	NA	febuxostat (80 mg once daily for 5 days) (hydroxy)chloroquine (200 mg twice daily for 5 days)	Mortality Admission to hospital
De Niet, 2022[78]	Published NCT04636086	Aug 2020 to Aug 2021	50	Belgium	66	53.5	Chronic lung disease (32.6%) Cardiac pathology (37.2%) Diabetes (37.2%) Hypertension (55.8%)	Inpatient	NR	not vaccinated (86.1%), 1 dose (7%), 2 doses (7%)	vitamin D (25,000 IU per day over 4 consecutive days, followed by 25,000 IU per week up to 6 weeks) standard care/placebo	Mortality Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Duration of ventilation Time to symptom/clinical improvement
Doi, 2020[22 79 80]	Published jRCTs041190120	Mar 2 to May 18, 2020	89	Japan	50	61.4	NR	Inpatient	Supplemental oxygen (3.4%)	NA	favipiravir (800 mg twice daily for 10 days) favipiravir (800 mg twice daily for 10 days starting on day 6 of enrolment)	Mortality Mechanical ventilation Viral clearance Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance

Dorward, 2022 PRINCIPLE[81 82]	Published ISRCTN86534580	Mar 4 to May 26, 2021	276	United Kingdom	60.5	46.2	Asthma, copd, lung disease (29.6%) Heart problems (9.2%) Diabetes (12.7%) Hypertension (24.2%)	Outpatient	NR	1 dose (45.5%), 2 doses (12.7%)	colchicine (500 µg daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Duration of hospitalization Time to symptom/clinical improvement
Dubee, 2021 HYCOVID[83-85]	Published NCT04325893	Apr 2 to May 21, 2020	250	France, Monaco	77	48.4	Chronic respiratory disease (11.2%) Heart disease (28.8%) Diabetes (17.2%) Hypertension (53.2%)	Inpatient (98.8%)	Supplemental oxygen (60.4%)	NA	(hydroxy)chloroquine (400 mg twice for first day, 200mg twice daily for 8 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance
Duvignaud, 2022 COVERAGE[86]	Published EudraCT (2020-001435-27); NCT04356495	Dec 29, 2020 to Jul 23, 2021	217	France	62.5	48.8	Copd (3.2%) Ischemic heart disease (5.1%) Cardiac insuffisiency (2.3%) Diabetes (15.2%) Hypertension (41.0%)	Outpatient	Unspecified ventilation (0.0%)	1 dose (12.9%), 2 doses (0.9%)	inhaled corticosteroids (ciclesonide (320 µg twice a day for 10 days)) multivitamin (2 capsules per day for 10 days)	Mortality Mechanical ventilation Admission to hospital Viral clearance Duration of hospitalization Time to symptom/clinical improvement
EPIC-SR, 2021 EPIC-SR [87]	Data from authors NCT05011513	initiated in Aug 2021	854	North America, South America, Europe, Africa, Asia, United States	NR	NR	NR	Outpatient	NR	NR	nirmatrelvir-ritonavir (300 mg nirmatrelvir with 100 mg ritonavir twice daily for 5 days) standard care/placebo	Mortality Admission to hospital Time to symptom/clinical improvement
Eikelboom_1, 2022 ACTCOVID19[88]	Published NCT04324463	Dec 2021 to Feb 2022	3881	Brazil, Canada, Colombia, Ecuador, Egypt, India, Nepal, Pakistan, Philippines, Russia, United Arab Emirates	45	60.55	Chronic lung disease (7.7%) Cardiovascular disease, overall value (4.8%) Coronary disease or myocardial infarction (3.6%) Stroke (0.1%) Peripheral artery disease (0.9%) Diabetes (13.4%) Hypertension (22.1%)	Outpatient	NR	1 dose (5.7%), 2 doses (21.3%)	colchicine (0.6 mg twice daily for 3 days and then 0.6 mg once daily for 25 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation
Eikelboom_2, 2022 ACTCOVID19[88]	Published NCT04324463	Dec 2021 to Feb 2022	3881	Brazil, Canada, Colombia, Ecuador, Egypt, India, Nepal, Pakistan, Philippines, Russia, United Arab Emirates	45	60.55	Chronic lung disease (7.7%) Cardiovascular disease, overall value (4.8%) Coronary disease or myocardial infarction (3.6%) Stroke (0.1%) Peripheral artery disease (0.9%) Diabetes (13.4%) Hypertension (22.1%)	Outpatient	NR	1 dose (5.7%), 2 doses (21.3%)	aspirin (100 mg once daily for 28 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation
Esquivel-Moynelo, 2020 ESPERANZA[89]	Pre-print RPCEC00000307	NR	79	Cuba	38	54	Asthma (6.3%) Cardiac diseases (6.3%) Severe arterial	Inpatient	NR	NA	interferon gamma (subcutaneous) (0.5 MIU twice weekly for 14 days) standard care/placebo	Mortality Viral clearance Time to viral clearance

							hypertension (0.0%) Ischemic heart disease (0.0%) Diabetes (4.8%) Hypertension (22.2%)					
Ezer, 2021 CONTAIN[90]	Published NCT04435795	Sept 15, 2020 to Jun 8, 2021	215	Canada	35	46.3	Asthma, no treatment (4.9%) Ischemic heart disease (0.5%) Diabetes (2.5%) Hypertension (5.9%)	Outpatient	Unspecified ventilation (0.0%)	0	inhaled and intranasal corticosteroid (50 µg twice daily intranasally, or 600 µg twice daily inhaled, for 14 days) standard care/placebo	Mortality Admission to hospital
Fan, 2021[91]	Published ChiCTR2000030022	Feb 20 to Apr 5, 2020	64	China	42.9	44.4	NR	Inpatient	NR	NA	emetine (3.6mg 3 times per day for 10 days) standard care/placebo	NR
Feld, 2020[92 93]	Published NCT04354259	May 18 to Sept 4, 2020	60	Canada	46.7	58.3	Diabetes (5.0%) Hypertension (10.0%)	Outpatient	NR	NA	interferon lambda (subcutaneous) (180 µg single injection) standard care/placebo	Mortality Admission to hospital Viral clearance Time to viral clearance
Ferrarini, 2022 TOFACOV[94]	Published NCT04332042	NR	116	Italy	59.2	69	Severe heart failure [nyha 3 or 4] (0.0%) Severe history of chronic ischemic heart disease (0.0%) Recurrent dvt and pe (0.0%)	Inpatient	Mechanical ventilation (0.0%)	2.60%	JAK inhibitors (10 mg tofacitinib twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization
Fischer_3, 2021[95-98]	Published NCT04405570	NR	202	United States	40.1	48.5	NR	Outpatient	NR	NR	Molnupiravir (200 mg twice per day for 5 days) molnupiravir (400 mg twice per day for 5 days) molnupiravir (800 mg twice per day for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
FitzGerald, 2021 AGILE[99 100]	Pre-print NCT04746183	Jul 17 to Oct 30, 2020	12	United Kingdom	50	25	NR	NR	NR	NA	molnupiravir (300 mg twice daily) molnupiravir (600 mg twice daily) molnupiravir (800 mg twice daily)	NR
Fogleman, 2022[101]	Published NCT04530539	Oct 5, 2020 to Jun 21, 2021	104	United States	52	34.7	Asthma or copd (19.4%) Diabetes (16.3%) Hypertension (25.5%)	Outpatient	NR	2%	vitamin C (1000 mg daily for 14 days) melatonin (10 mg daily for 14 days) standard care/placebo	Mortality Admission to hospital
Fu, 2020[102]	Published ChiCTR2000030262	Mar 23 to May 23, 2020	80	China	35.2	63.8	Diabetes (3.8%) Hypertension (5.0%)	Inpatient	NR	NA	interferon kappa (nebulised), trefoil factor 2 (2 mg/day for 6 days; 5 mg/day for 6 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to viral clearance
George, 2022[103]	Published CTRI/2020/05/025068	Jun 2020 to Feb 2021	112	India	41.3	70.5	NR	Inpatient	Unspecified ventilation (0.0%)	NR	ivermectin (24 mg single dose for adults or 400 µg/kg for children) ivermectin (12 mg single dose for adults or 200 µg/kg for children) standard care/placebo	Mortality Viral clearance Time to symptom/clinical improvement

Ghaderkhani, 2022[104 105]	Published IR.TUMS.VCR.REC.1399.204, 04.13.2020	Apr 20 to Jun 4, 2020	56	Iran	44.4	60.4	NR	Inpatient (3.8%)	NR	NA	umifenovir (200 mg every eight hours for 10 days) standard care/placebo	NR
Ghati, 2022 RESIST[106]	Published CTRI/2020/07/026791	Jul 28, 2020 to Jan 27, 2021	900	India	52	73.7	Coronary artery disease (1.1%) Diabetes (27.7%) Hypertension (28.6%)	Inpatient	Mask or nasal prong (2.8%) High-flow (0.0%) Niv (0.0%) Iv (0.0%)	NR	statins (40 mg atorvastatin daily for 10 days or until discharge) aspirin (75 mg daily for 10 days or until discharge) aspirin, statins (45 mg + 75 mg daily for 10 days or until discharge) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization
Ghaznavi, 2022[107]	Published IRCT20200907048644N1	Oct 2020 to Sept 2021	67	Iran	41	37.3	Asthma (0.0%) Diabetes (0.0%) Hypertension (0.0%)	Inpatient	NR	NR	NSAIDs (two 200 mg celecoxib doses) NSAIDs (200 mg celecoxib daily) NSAIDs (two 250 mg naproxen. doses that were ingested every 12 h)	NR
Golan, 2022 PRESECO[108]	Published NCT04600895	Nov 2020 to Oct 2021	1211	United States, Brazil, Mexico	≥18	45.8	Known infection with a respiratory virus other than sars-cov-2 [e.g., influenza] or any known bacterial infection [affecting the respiratory system or any other system] (0.0%)	Outpatient	NR	11%	favipiravir (oral 1800 mg twice daily on Day 1, 800 mg twice daily on Days 2-10) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Gorial, 2022[109]	Published NCT05151614, Research registry UN 7658	Apr to Aug 2021	80	Iraq	NR	51.2	Asthma (0.1%) Ischemic heart disease (6.2%) Stroke (1.2%) Diabetes (15.0%) Hypertension (33.8%)	Inpatient	NR	NR	colchicine (1 mg daily orally for 7 days then 0.5 mg daily for another 7 days) standard care/placebo	Mortality Time to symptom/clinical improvement
Gottlieb_2, 2021 PINETREE[110-115]	Published NCT04501952, EudraCT Number 2020-003510-12	NR	584	Denmark, Spain, United Kingdom, United States,	50.5	52.1	Chronic lung disease (24.0%) Cardiovascular or cerebrovascular disease (7.8%) Diabetes (61.6%) Hypertension (47.7%)	Outpatient	Unspecified ventilation (0.0%)	0	remdesivir (200 mg on day 1 followed by 100 mg on days 2 and 3) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Guimaraes, 2021 STOP-COVID[116] ‡	Published NCT04469114	Sept 16 to Dec 13, 2020	289	Brazil	56	65	Diabetes (23.5%) Hypertension (50.2%)	Inpatient	Supplemental oxygen (75.4%) Niv, iv, or ecmo (0.0%)	NR	JAK inhibitors (10 mg tofacitinib twice daily for up to 14 days or until hospital discharge) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Duration of ventilation
Guzman-Esquivel, 2022 MEFECOVID-19[117]	Published RPCEC00000388	NR	36	0	39.5	33.3	Asthma (2.8%) Ischemic heart disease (0.0%) Diabetes (5.6%) Hypertension (8.3%)	Outpatient	Unspecified ventilation (0.0%)	0	NSAIDs (mefenamic acid 500 mg every 8 h for 7 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement

Hakamifard, 2021[118]	Published IRCT20180425039414N3	Mar to Apr 2020	73	Iran	36.5	63.9	End-stage lung disease (0.0%) Cardiovascular disease (9.7%) Diabetes (25.0%) Hypertension (25.0%)	Inpatient	Mechanical ventilation, oxygen therapy at home (0.0%)	NA	vitamin C, vitamin E (1 g daily, 400 IU daily until hospital discharge or intensive care unit admission) standard care/placebo	Mortality Duration of hospitalization
Hammond, 2022 EPIC-HR[119 120]	Published NCT04960202	initiated in July 2021	2246	Argentina, Brazil, Bulgaria, Colombia, Czech Republic, Hungary, India, Japan, Malaysia, Mexico, Poland, Puerto Rico, Russia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United States	46	51.1	Diabetes (12.2%) Hypertension (32.9%)	Outpatient	NR	NR	nirmatrelvir-ritonavir (300 mg every 12 hours for 5 days, 100 mg every 12 hours for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Mechanical ventilation Duration of hospitalization ICU length of stay
Han, 2022 RUXCOVID[121] ‡	Published NCT04362137	May 4 to Sept 19, 2020	432	Argentina, Brazil, Colombia, France, Germany, Mexico, Peru, Russia, Spain, Turkey, United Kingdom, United States	56.6	54.4	Diabetes (3.0%) Hypertension (6.7%)	Inpatient	Oxygen by mask or nasal prongs (62.0%) Niv or high-flow (5.1%) Iv (0.0%)	NA	JAK inhibitors (5 mg ruxolitinib twice daily for 14 days with possible extension of treatment to 28 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement ICU length of stay Duration of ventilation
Hinks, 2021 ATOMIC2[122]	Pre-print NCT04381962	Jun 3 to Jan 29, 2021	295	United Kingdom	45.9	51.5	Asthma (18.0%) Chronic pulmonary disease (4.1%) Myocardial infarction (4.1%) Diabetes (8.5%) Hypertension (17.6%)	Inpatient (0.7%)	Unspecified ventilation (0.0%)	NR	azithromycin (500 mg once daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Duration of hospitalization
Holubar, 2022[123 124]	Published NCT04346628	Jul 8, 2020 to Mar 23, 2021	149	United States	42.7	48.9	Chronic lung disease (3.7%) Diabetes (8.9%) Hypertension (10.4%)	Outpatient	NR	1.5%	favipiravir (1800 mg twice daily on day 1, then 800 mg twice daily on days 2-10) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Horby_1, 2020 RECOVERY[125-127]	Published NCT04381936	Mar 19 to Jun 8, 2020	1535	United Kingdom	69.4	58	Chronic lung disease (22.9%) Tuberculosis (0.5%) Heart disease (33.8%) Diabetes (22.3%)	Inpatient	Unspecified ventilation (0.0%)	NA	corticosteroids (systemic) (6 mg dexamethasone once daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization

Horby_2, 2020 RECOVERY[128 129] ‡	Published NCT04381936	Mar 25 to Jun 5, 2020	4716	United Kingdom	65.3	62.2	Lung disease (22.2%) Tuberculosis (0.3%) Heart disease (25.7%) Diabetes (27.2%)	Inpatient	Supplemental oxygen or niv (59.6%) Iv or ecmo (16.8%)	NA	(hydroxy)chloroquine (400 mg twice daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Horby_3, 2020 RECOVERY[130 131] ‡	Published NCT04381936	Mar 19 to Jun 29, 2020	5040	United Kingdom	66.2	61	Chronic lung disease (23.1%) Tuberculosis (0.3%) Heart disease (26.0%) Diabetes (27.5%)	Inpatient	Supplementary oxygen or niv (69.7%) Iv (4.0%)	NA	lopinavir-ritonavir (400 mg/100 mg twice daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Horby_4, 2021 RECOVERY[132 133] ‡	Published ISRCTN (50189673), NCT04381936	Apr 7 to Nov 27, 2020	7763	United Kingdom	65.3	62.1	Chronic lung disease (24.9%) Tuberculosis (0.2%) Heart disease (26.3%) Prolonged qtc interval (0.0%) Diabetes (27.5%)	Inpatient	Supplemental oxygen or niv (76.0%) Iv (5.8%)	NA	azithromycin (500 mg once daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Horby_8, 2022 RECOVERY[134] ‡	Published ISRCTN 50189673, NCT04381936	Feb 2 to Dec 29, 2021	8156	United Kingdom	58.1	65.9	Chronic lung disease (20.4%) Tuberculosis (0.0%) Heart disease (18.2%) Diabetes (23.3%)	Inpatient	Iv (3.1%) Niv (23.6%) Simple oxygen (67.6%)	at least 1 dose (41.9%)	JAK inhibitors (baricitinib (4 mg daily for 10 days or until discharge (patients taking probenecid and children ≥2 <9 recevied 2 mg daily, patients with eGFR ≥30 <60 mL/min/1.73m2 received 2 mg once daily (if ≥9 years old) or on alternate days (if ≥2 <9 years old), patients with eGFR ≥15 <30 mL/min/1.73m2 received 2 mg on alternate days (if ≥9 years old)))) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Hu, 2020[135]	Published ChiCTR2000030058	Feb 20 to Feb 28, 2020	10	China	54.9	30	Copd (10.0%) Hypertension (60.0%)	Inpatient	Mechanical ventilation (0.0%)	NA	leflunomide (20 mg once daily for 10 days) standard care/placebo	Mortality Viral clearance Time to symptom/clinical improvement Time to viral clearance
Huang_2, 2020[136]	Published ChiCTR2000029387	Jan 29 to Feb 25, 2020	101	China	42.5	45.5	Severe lung disease (0.0%) Severe heart disease (0.0%)	Inpatient	NR	NA	ribavirin (400-600 mg three times daily for 14 days) lopinavir-ritonavir (400 mg/100 mg twice daily for 14 days) lopinavir-ritonavir, ribavirin (400 mg/100 mg twice daily for 14 days; 400-600 mg three times daily for 14 days)	Mortality Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance
Hung, 2020[137]	Published NCT04276688	Feb 10 to Mar 20, 2020	127	China	51.3	53.5	Tuberculosis (1.6%) Obstructive sleep apnea (1.6%) Coronary artery disease (7.9%) Cerebrovascular disease (1.6%) Diabetes (13.4%) Hypertension (28.4%)	Inpatient	NR	NA	interferon beta (subcutaneous), ribavirin (1-3 ml every other day for 14 days; 400 mg twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance

Husain, 2020[138]	Pre-print	NR	64	NR	NR	NR	NR	Inpatient	NR	NR	corticosteroid (systemic), doxycycline, intranasal corticosteroid (8 mg methylprednisolone twice daily for 5 days; 200mg stat followed by100 mg twice daily for 10 days; 100 µg mometasone twice daily for 10 days, then 100 µg twice daily for 4 weeks) standard care/placebo	Mortality
Ikeda, 2022[139]	Published jRCTs031200026 / JPRN-jRCTs031200026	May 1, 2020 to Dec 15, 2021	45	Japan	51.7	60	Chronic pulmonary disease (4.4%) Copd (2.2%) Cardiovascular disease (0.0%) Diabetes (20.0%)	Inpatient	Unspecified ventilation (6.7%)	NR	favipiravir (1800 mg twice on day 1, then 800 mg twice a day for 7 days or until clinical improvement was achieved for up to 14 days) favipiravir, serine protease inhibitor (a continuous infusion of nafamostat of 0.2 mg/kg/h single dose plus favipiravir 1800 mg twice on day 1, then 800 mg twice a day for 7 days or until clinical improvement was achieved for up to 14 days)	Mortality Adverse effects leading to discontinuation Time to symptom/clinical improvement
Issak, 2023 TICS-COV19 study[140]	Published NCT04530409	Aug 6, 2021 to May 27, 2022	754	Egypt	46	47.1	Diabetes (39.8%) Hypertension (42.1%)	Outpatient	Unspecified ventilation (0.0%)	0	corticosteroids (systemic) (30 mg methylprednisolone daily for 7 days in moderate cases, then reduced gradually over 14 days; 15 mg daily for 14 days in mild cases) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Ivashchenko, 2020[141 142]	Published NCT04434248	Apr to May 2020	60	Russia	50.7	50	NR	Inpatient	Supplemental oxygen (25.0%)	NA	favipiravir (600 mg twice daily for 14 days) favipiravir (800 mg twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement
Jagannathan, 2021[143-145]	Published NCT04331899	Apr 25 and Jul 17, 2020	120	United States	36	58.3	Asthma (3.3%) Heart disease (3.3%) Diabetes (10.0%) Hypertension (11.7%)	Outpatient	Supplemental oxygen, niv, or iv (0.0%)	NA	interferon lambda (subcutaneous) (180 µg single injection) standard care/placebo	Admission to hospital Time to symptom/clinical improvement Time to viral clearance
Jahangirifard, 2021[146]	Published IRCT20150725023332N3	Apr 20 to Jun 20, 2020	40	Iran	58.4	52.5	Myocardial infarction (0.0%) Cerebrovascular accident (2.5%) Hyperlipidemia (12.5%) Diabetes (15.0%) Hypertension (25.0%)	Inpatient	Intubated (0.0%)	NA	bromelain (200 mg three times daily for 5 days) standard care/placebo	NR
Jalal, 2022[147] ‡	Published NCT04867226	May 8 to Jun 18, 2021	80	Iraq	18-70	50	Ischemic heart disease (11.2%) Diabetes (35.0%) Hypertension (51.2%)	Inpatient (57.5%)	NR	NR	colchicine (oral 0.5 mg twice daily for 14 days (reduced to 0.5 mg/day, in patients with low body weight or developed side	Mortality Adverse effects leading to discontinuation Duration of hospitalization

											effects)) standard care/placebo	
Jardine, 2022 CLARITY[148]	Published NCT04394117	May 5, 2020 to May 26, 2021	787	Australia, India	49	64.2	Chronic respiratory illness (3.0%) Heart failure, ischaemic heart disease, acute myocardial infarction, congenital heart disease, stroke, peripheral vascular disease (2.7%) Diabetes (25.0%) Hypertension (27.3%)	Inpatient	Supplemental oxygen (28.3%)	NR	ACEi/ARB (starting dose of 40 mg telmisartan once daily, with dose escalation permitted within the recommended dosing range, for 28 days) standard care/placebo	Mortality
Jilg _2, 2023 ACTIV-2[149]	Published NCT04518410	NR	224	United States	37	45.4	NR	Outpatient	NR	5.10%	serine protease inhibitors (200 mg camostat every 6 hours for 7 days) standard care/placebo	Mortality Admission to hospital Viral clearance Time to symptom/clinical improvement
Jilg_1, 2022[150]	Data from authors	NR	293	United States	51	42.7	Chronic lung disease (33.2%) Diabetes (25.4%) Hypertension (63.4%)	Outpatient	NR	NR	serine protease inhibitors (200 mg camostat four times a day for 14 days) standard care/placebo	Viral clearance
Johnston, 2021 The COVID-19 Early Treatment Study[151]	Published NCT04354428	Apr 15 to Jul 27, 2020	231	United States	37	43.3	Pulmonary disease (5.2%) Moderate or severe persistent asthma (0.9%) Chronic obstructive pulmonary disease/emphysema, (1.7%) Cardiovascular disease (0.0%) T2DM (6.5%) T1DM (0.9%) Hypertension (11.7%)	Outpatient	NR	NA	(hydroxy)chloroquine (200 mg twice daily for 10 days) azithromycin, hydroxychloroquine (250 mg once daily for 5 days; 200 mg twice daily for 10 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance
Kaizer, 2022 TREATNOW[152]	Published NCT04372628	Sept 1 to Dec 29, 2020	448	United States	40.81	41.48	Asthma (17.9%) Copd (1.3%) Coronary heart disease/heart attack (0.7%) Diabetes (3.8%) Hypertension (17.3%)	Outpatient	Unspecified ventilation (0.0%)	fully vaccinated (20.9%), partially vaccinated (8.5%)	lopinavir, ritonavir (400 mg/100 mg twice daily for 28 doses (14 days total)) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Ventilator-free days Time to symptom/clinical improvement
Kalil, 2020 ACTT-2[153 154] ‡	Published NCT04401579	May 8 to Jul 1, 2020	1033	United States, Singapore, South Korea, Mexico, Japan, Spain, United Kingdom, Denmark	55.4	63.1	Asthma (9.4%) Chronic oxygen requirement (1.6%) Chronic respiratory disease (6.7%) Cardiac valvular disease (2.1%) Congestive heart failure (6.0%) Coronary artery disease (9.8%) T2DM (35.8%) T1DM (1.0%) Hypertension (50.5%)	Inpatient	Supplemental oxygen (54.6%) High-flow or niv (20.9%) Iv or ecmo (10.8%)	NA	JAK inhibitors (4 mg baricitinib daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement
Kalil_2, 2021 ACTT-3[155]	Published NCT04492475	Aug 5 to Nov 11, 2020	152	Japan, Singapore,	59.6	59.9	Asthma (11.8%) Chronic respiratory disease (9.2%)	Inpatient	Unspecified ventilation (0.0%)	NA	interferon beta (nebulised) (44 µg given four times	Mortality Mechanical ventilation

				South Korea, United States			Chronic oxygen requirement (1.3%) Coronary artery disease (13.8%) Cardiac arrhythmias (7.2%) Cardiac valvular disease (2.6%) Congestive heart failure (4.6%) T2DM (37.5%) T1DM (0.7%) Hypertension (58.5%)				every other day) standard care/placebo	Adverse effects leading to discontinuation Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement
Karolyi, 2022 ACOVACT[156] ‡	Published NCT04351724, EUDRACT-NR: 2020–001302-30	Apr 20, 2020 to May 14, 2021	201	Austria	58.6	66.7	Chronic obstructive lung disease (14.9%) Coronary artery disease (13.4%) Congestive heart failure (5.5%) Diabetes (26.9%) Hypertension (52.2%)	Inpatient	No oxygen (17.4%) Low flow oxygen (61.2%) High flow oxygen, niv (16.4%)	NR	lopinavir, ritonavir (200/50 mg two tablets two times daily (normal dose n=4); loading dose of 200/50 mg four tablets twice daily and a maintenance dose of three tablets twice daily (high dose n=96)) serine protease inhibitors (100 mg two tablet camostat twice daily)	Mortality Mechanical ventilation Duration of hospitalization Time to symptom/clinical improvement
Kasgari, 2020[157]	Published IRCT20200328046886N1	Mar 20 to Apr 8, 2020	48	Iran	52.5	37.5	Copd (2.1%) Ischaemic heart disease (22.9%) Diabetes (37.5%) Hypertension (35.4%)	Inpatient	NR	NA	ribavirin, sofosbuvir-daclatasvir (600 mg twice daily for 14 days; 400 mg/60 mg once daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Duration of ventilation
Kasiri, 2021[158]	Published IRCT20190804044429N6	Feb 20 to Jun 30, 2020	80	Iran	34.3	50.6	Asthma (1.3%) Diabetes (1.3%) Hypertension (2.6%)	Outpatient	NR	NA	intranasal corticosteroids (two puffs of 100 µg mometasone twice daily in each nostril for 4 weeks) standard care/placebo	Admission to hospital Adverse effects leading to discontinuation
Kasiri_2, 2023[159]	Published IRCT20190804044429N5	Jul 30, 2020 to Jun 11, 2021	110	Iran	54.6	46.2	Asthma (4.7%) Ischemic heart disease (8.5%) Stroke (0.9%) Dyslipidemia (12.3%) Diabetes (40.6%) Hypertension (31.1%)	Inpatient	Supplemental oxygen (31.1%) Noninvasive ventilation or high-flow oxygen devices (2.8%)	NR	colchicine (2 mg loading dose followed by 0.5 mg twice daily for 7 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation ICU length of stay Time to symptom/clinical improvement
Kerget_1, 2021[160]	Published	Sept to Nov 2020	150	Turkey	33.4	55.3	NR	Inpatient	NR	NA	2-aticyto complex (27000 mcg daily) standard care/placebo	Time to symptom/clinical improvement Time to viral clearance
Khavkina, 2021[161]	Published	NR	244	Russia	NR	NR	NR	Inpatient (16.8%)	NR	NR	favipiravir (800 mg twice daily for 10 days) hydroxychloroquine, intranasal interferon alpha-2b (nebulised) (outpatients), umifenovir (outpatients) (umifenovir (10 days), intranasal interferon alpha-2b (10 days), hydroxychloroquine (10 days)	Mortality Time to viral clearance

											azithromycin, vitamins (NR)	
Khoo_1, 2021 AGILE[162 163]	Published NCT04746183, EudraCT 2020– 001860-27	Jul 17 to Oct 30, 2020	18	United Kingdom	56	27.8	NR	Outpatient	Unspecified ventilation (0.0%)	NA	molnupiravir (300 mg twice daily for 5 days) molnupiravir (600mg twice daily for 5 days) molnupiravir (800mg twice daily for 5 days) standard care/placebo	Mortality Adverse effects leading to discontinuation
Khoo_2, 2022 AGILE CST-2[164]	Published NCT04746183, ISRCTN27106947	Sept 8, 2020 to Mar 16, 2022	180	United Kingdom	42.5	42.78	NR	Outpatient	Unspecified ventilation (0.0%)	1 dose (50%), 2 doses (38.3%), 3 doses (10.6%)	molnupiravir (800 mg twice daily for 5 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Kim_3, 2022[165]	Published NCT04521296	Feb 24 to Jul 28, 2022	342	South Korea	51.4	53.2	Chronic respiratory disease (0.9%) Cardiovascular disease (7.0%) Diabetes (13.5%) High blood pressure (30.4%)	Inpatient	Unspecified ventilation (0.0%)	0	serine protease inhibitors (200 mg camostat three times a day for 14 days) standard care/placebo	Time to symptom/clinical improvement
Kim_4, 2023[166]	Published NCT04343976	Jul 14, 2020 to Jul 16, 2021	14	United States	52.9	78.6	Asthma (21.4%) Chronic pulmonary disease (7.1%) Chronic cardiac disease (21.4%)	Inpatient	0 (high flow nasal cannula, mask, bipap or intubation and mechanical ventilation)	0	interferon lambda (subcutaneous) (180 mcg subcutaneous injection on day 1 and day 7) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Duration of hospitalization
Kinoshita, 2022 CANDLE[167]	Pre-print NCT04657497, jRCT2031200198	Nov 2020 to Mar 2021	155	Japan	55.9	50.3	Chronic respiratory disease (16.1%) Cardiovascular disease (5.2%) Diabetes (17.4%) Hypertension (28.4%)	Inpatient	Unspecified ventilation (0.0%)	0	serine protease inhibitors (600 mg camostat four times daily for up to 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Time to symptom/clinical improvement Time to viral clearance
Kishoria, 2020[168]	Published	NR	35	India	38.5	71.9	Congestive heart failure (0.0%) Chest angina or heart arrhythmia (0.0%)	Inpatient	NR	NR	ivermectin (12 mg single dose) standard care/placebo	Viral clearance
Kumar_5, 2021 ROXANE[169]	Published CTRI/2021/05/033871	Aug 1 to Nov 1, 2020	228	India	52.8	61	Diabetes (30.3%) Hypertension (26.8%)	Inpatient	NR	NA	prophylactic and therapeutic-dose anticoagulation (10 mg or 15 mg daily for duration of hospital stay) prophylactic and therapeutic-dose anticoagulation (40 mg or 60 mg daily for duration of hospital stay)	Adverse effects leading to discontinuation Venous thromboembolism Clinically important bleeding
Krishnan, 2021[170]	Data from authors CTRI/2021/06/033938	NR	736	India	38.3	62.3	Chronic obstructive pulmonary disease (0.1%) Diabetes mellitus (4.4%)	Outpatient	NR	NR	molnupiravir (800 mg twice daily for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance

							T2DM (1.1%) Hypertension (6.6%)					Time to symptom/clinical improvement
Krolewiecki, 2021[171 172]	Published NCT04381884	May 18 to Sept 29, 2020	45	Argentina	40.9	55.6	Chronic lung disease/asthma (11.1%) Diabetes (15.6%) Hypertension (13.3%)	Inpatient	Supplemental oxygen (6.7%)	NA	ivermectin (0.6 mg/kg/day for 5 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation
Lakkireddy, 2021[173]	Published CTRI/2020/12/030083	NR	130	India	45	74.7	diabetes or hypertension (39.1%)	Inpatient	NR	NR	vitamin D (60000 IUs per day for 8 days (for individuals with BMI 18-25) or 10 days (for individuals with BMI > 25)) standard care/placebo	Mortality Adverse effects leading to discontinuation Duration of hospitalization
Lawler_2, 2023 REMAP-CAP[174]	Published NCT02735707	Mar 16, 2021 to Feb 25, 2022	58	Canada, Italy, Netherlands, New Zealand, Saudi Arabia, United Kingdom, United States	55.3	64.3	Respiratory condition (26.8%) Severe cardiovascular disease (5.4%) Diabetes (8.9%)	Inpatient	None/supplemental oxygen (85.7%) High-flow nasal cannula (12.5%) Noninvasive ventilation (1.8%) Invasive mechanical ventilation (0.0%)	NR	ACEi/ARB (ramipril, lisinopril, perindopril, enalapril, trandolapril, captopril at low, moderate, or high doses for up to 10 days) ACEi/ARB (losartan, valsartan, candesartan, irbesartan, temlisartan, olmesartan at low, moderate, or high doses for up to 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization Ventilator-free days
Lenze, 2020[175]	Published NCT04342663	Apr 10 to Aug 5, 2020	181	United States	46	28.3	Asthma (17.1%) Severe underlying lung disease, eg, chronic obstructive pulmonary disease or required home oxygen, interstitial lung disease, pulmonary hypertension (0.0%) Congestive heart failure (0.0%) Diabetes (11.2%) Hypertension (19.7%)	Outpatient	Supplemental oxygen, niv, or iv (0.0%)	NA	fluvoxamine (100 mg three times daily for 15 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Duration of hospitalization Duration of ventilation
Les, 2022 CORTIVID[176]	Published NCT04438980, EudraCT number: 2020-001827-15	May 8, 2020 to Mar 13, 2021	72	Spain	59.2	69	Copd (1.4%) Asthma (2.8%) Bronchiectasis (2.8%) Obstructive sleep apnea syndrome (1.4%) Heart failure (0.0%) Diabetes (18.3%) Hypertension (32.4%)	Inpatient	Unspecified ventilation (0.0%)	NR	corticosteroids (systemic) (120 mg of pulsed methylprednisolone intravenously once daily for 3 consecutive days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Duration of hospitalization
Li, 2020 ELACOI[177]	Published NCT04252885	NR	86	China	49.4	46.5	Respiratory condition (0.0%) Cardiovascular disease (2.3%) Diabetes (2.3%) Hypertension (10.5%)	Inpatient	Mechanical ventilation (0.0%)	NR	lopinavir-ritonavir (200 mg/50 mg twice daily for 7 to 14 days) umifenovir (200 mg three times daily for 7 to 14 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Li_2, 2021[178]	Published ChiCTR2000029638	Feb 10 to Apr 5, 2020	96	China	53.5	46.8	Tuberculosis (3.2%) Copd (1.1%) Heart disease (7.5%) Cerebrovascular disease (5.3%)	Inpatient	Supplemental oxygen (51.1%) High-flow or niv (25.5%)	NA	interferon alpha (nebulised) (12 MIU twice daily for 28 days) interferon alpha (nebulised) (5 MIU twice daily for 28 days)	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance

							Diabetes (9.6%) Hypertension (19.1%)					Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance
Li_4a, 2021[179]	Published ChiCTR2000029898, ChiCTR2000029899, ChiCTR2000031376	NR	65	China	60.1	61.9	Coronary heart disease (12.7%) Diabetes (23.8%) Hypertension (38.1%)	Inpatient	NR	NA	(hydroxy)chloroquine (200 mg twice daily for 5 days) (hydroxy)chloroquine (500 mg twice daily for 3 days, then 250 mg twice daily for 2 days)	Viral clearance Duration of hospitalization Time to symptom/clinical improvement
Lim, 2022 I-TECH[180]	Published NCT04920942	May 31 to Oct 9, 2021	500	Malaysia	62.5	45.5	Chronic pulmonary disease (7.8%) Chronic cardiac disease (11.6%) Cerebrovascular disease (3.9%) Diabetes (53.5%) Hypertension (75.3%)	Inpatient	Unspecified ventilation (0.0%)	1 dose (15.7%), 2 doses (51.8%)	ivermectin (0.4 mg/kg body weight daily for 5 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization
Liu, 2023[181]	Published ChiCTR2200058477	NR	264	China	70.3	53.8	Chronic pulmonary disease (20.1%) Cardiovascular disease (53.4%) Cerebrovascular disease (24.2%) Diabetes (36.7%)	Inpatient	NR	one dose (1.5%), two doses (16.7%), three doses (8.3%)	nirmatrelvir-ritonavir (300 mg of nirmatrelvir plus 100 mg of ritonavir, orally every 12 h for 5 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Duration of hospitalization ICU length of stay Time to viral clearance
Lopes_1, 2022 BRACE CORONA[182]	Published NCT04364893	Apr 9 to Jul 26, 2020	740	Brazil	55.1	59.6	Asthma (3.9%) Coronary heart disease (4.5%) Heart failure (1.4%) Diabetes (31.9%) Hypertension (100.0%)	Inpatient	Mechanical ventilation (0.0%)	NA	standard care/placebo ACEi/ARB (continuation of ACEi/ARB at the dose previously prescribed during routine care)	Mortality Mechanical ventilation Duration of hospitalization
Lopez-Medina, 2021 EPIC[183]	Published NCT04405843	Jul 15 to Nov 30, 2020	476	Colombia	37	42	Respiratory condition (3.0%) Cardiovascular disease (1.8%) Diabetes (5.5%) Hypertension (13.3%)	Inpatient (1.0%)	Supplemental oxygen (0.5%) High-flow or niv or iv (0.0%)	NA	ivermectin (300 µg/kg/day for 5 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Lou, 2020[184 185]	Published ChiCTR2000029544	initiated on Feb 3, 2020	30	China	52.5	72.4	Copd (0.0%) Cardiovascular disease (13.8%) Diabetes (6.9%) Hypertension (20.7%)	Inpatient	Mechanical ventilation (0.0%)	NR	baloxavir marboxil (80 mg once daily for up to 3 doses on days 1, 4, and 7) favipiravir (600 mg three times daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Lowe, 2022 FLARE[186]	Published NCT04499677, EudraCT 2020-002106-68	Oct 6, 2020 to Nov 4, 2021	240	United Kingdom	40	51.2	NR	Outpatient	NR	1 dose (9.2%), 2 doses (41.7%), 3 doses (0.4%)	favipiravir, lopinavir, ritonavir (1,800 mg twice daily on Day 1 followed by 400 mg 4 times daily on Days 2 to 7 of favipiravir and 400 mg/100 mg twice daily on Day 1, followed by 200 mg/50 mg 4 times daily on Days 2 to 7 of lopinavir-	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance

											ritonavir) favipiravir (1,800 mg twice daily on Day 1 followed by 400 mg 4 times daily on Days 2 to 7) lopinavir-ritonavir (400 mg/100 mg twice daily on Day 1, followed by 200 mg/50 mg 4 times daily on Days 2 to 7) standard care/placebo	
Madioko, 2022[187]	Pre-print	May 20, 2021 to Jan 15, 2022	261	Democratic Republic of the Congo	41	49.4	Asthma (2.3%) Tubercolosis (0.4%) Prolonged qtc interval (0.0%) Heart failure (0.0%) Diabetes (3.5%) Hypertension (11.1%)	NR	NR	NR	doubase C (< 80 kg: 3x2 tablets/day for 7 days to be chewed with meals; 80–100 kg: 3x3 tablets/day for seven days to be chewed with meals; > 100 Kg: 3x4 tablets/day for seven days to be chewed with meals) azithromycin, hydroxychloroquine (500 mg the first day, then 250 mg daily from days 2-5; 3x200 mg/day for 10 days)	Mortality
Mahmud, 2021[188]	Published NCT04523831	Jun 1 to Aug 30, 2020	400	Bangladesh	39.5	58.8	Asthma (5.2%) Diabetes (13.2%) Hypertension (14.2%)	NR	Supplemental oxygen (0.0%) Niv (0.0%) Iv (0.0%)	NA	doxycycline, ivermectin (100 mg twice daily for 5 days; 12 mg once) standard care/placebo	Mortality Adverse effects leading to discontinuation Time to symptom/clinical improvement
Marconi, 2021 COV-BARRIER[189] ‡	Published NCT04421027	Jun 11, 2020 to Jan 15, 2021	1525	Argentina, Brazil, Germany, India, Italy, Japan, Korea, Mexico, Russia, Spain, United Kingdom, United States	57.6	63.1	Chronic respiratory disease (4.6%) T1DM (30.0%) Hypertension (47.9%)	Inpatient	Supplemental oxygen (63.4%) High-flow or niv oxygen (24.4%) Iv (0.0%)	NR	JAK inhibitors (baricitinib (4 mg daily for 14 days or until discharge (patients with eGFR≥30 to <60 mL/min/1.73 m² received 2 mg))) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Ventilator-free days Time to symptom/clinical improvement
Marcos, 2021 BEMICOP[190]	Published NCT04604327	Oct 2020 to May 2021	66	Spain	62.6	63.1	Chronic pulmonary disease (16.9%) Cardiopathy (6.2%) Diabetes (7.7%) Hypertension (33.9%)	Inpatient	Oxygen requirement (58.5%)	NR	therapeutic-dose anticoagulation (115 IU/Kg bemiparin once daily, adjusted to body weight (7,500 IU for patients between 50-70 Kg; 10,000 IU for patients weighing >70-100 Kg; 12,500 IU for patients who weighed >100 Kg) for 10 days) standard care/placebo	Mortality Viral clearance Venous thromboembolism Clinically important bleeding
Mariani, 2022 CARED[191]	Published NCT04411446	Aug 2020 to Jun 2021	218	Argentina	59.05	52.75	Asthma or chronic obstructive pulmonary disease (11.9%) Cardiovascular disease (4.6%) Diabetes (26.6%) Hypertension (43.1%)	Inpatient	Oxygen supplementation (21.6%) Invasive or non-invasive mechanical ventilation (0.0%) Greater than 5 litres/minute of	NR	vitamin D (500 000 IU single dose) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization ICU length of stay

									oxygen (0.0%) High-flow oxygen therapy (0.0%)			
McCarthy, 2023 ACTIV[192]	Published NCT04885530	Aug 6, 2021 to May 27, 2022	1331	United States	47	42.8	Asthma (12.7%) Copd (2.3%) Heart disease (4.1%) Diabetes (8.9%) Hypertension (23.6%)	Outpatient	NR	1 dose (1%), at least 2 doses (66.9%)	fluvoxamine (50 mg twice daily for 10 days) standard care/placebo	Mortality Admission to hospital Time to symptom/clinical improvement
McMahon, 2022[193]	Published NCT04445467	Jul 31, 2020 to Sept 19, 2021	199	Australia	35.5	54.8	NR	Inpatient (0.5%)	Supplemental oxygen (0.5%)	NR	favipiravir (1800 mg on day 1, then 800 mg twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Viral clearance
McQuilten, 2022 ASCOT[194]	Published NCT04483960	NR	1574	Australia, India, Nepal, New Zealand	49	59.3	Asthma (2.9%) Chronic lung disease (2.4%) Obstructive sleep apnea (0.5%) Chronic cardiac disease (1.9%) Hypertension (23.7%)	Inpatient	Noninvasive ventilation (0.0%) Invasive mechanical ventilation (0.0%)	30.90%	standard care/placebo intermediate-dose anticoagulation (enoxaparin, tinzaparin, or dalteparin at intermediate dose, adjusted according to the patient's weight and renal function, administered until hospital discharge or until a clinical indication to change the dose occurred) aspirin (aspirin 75–100 mg daily; administered until hospital discharge or until a clinical indication to change the dose occurred) therapeutic-dose anticoagulation (enoxaparin, tinzaparin, or dalteparin at therapeutic dose, adjusted according to the patient's weight and renal function, administered until hospital discharge or until a clinical indication to change the dose occurred)	Mortality Mechanical ventilation Venous thromboembolism Clinically important bleeding Ventilator-free days Time to symptom/clinical improvement
Mirahmadizadeh, 2022[195]	Published IRCT20210213050344N1	Apr 9 to May 20, 2021	393	Iran	39.33	53.96	Severe pulmonary disease (0.0%) Chronic respiratory disease (0.8%) Cardiovascular disease (0.8%) T2DM (3.8%) Hypertension (6.1%)	Outpatient	Unspecified ventilation (0.5%)	NR	ivermectin (ivermectin 12 mg for one day) ivermectin (ivermectin 12 mg for two days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Miyazaki, 2023[196]	Published jRCT2071200023	NR	123	Japan	45.2	60.16	NR	Outpatient	Unspecified ventilation (0.0%)	0	nelfinavir (750 mg three times daily for 14 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Time to symptom/clinical improvement Time to viral clearance
Mohamed, 2022[197]	Published	Aug to Oct 2021	124	Egypt	41.98	58.06	Atrial fibrillation, flutter or vte (0.0%) Hemorrhagic stroke in the last 3 months (0.0%)	Inpatient	NR	NR	intermediate-dose anticoagulation (enoxaparin 0.5 mg/kg every 12 hours until discharge from the hospital) standard care/placebo	Mortality Adverse effects leading to discontinuation Venous thromboembolism Clinically important

												bleeding Duration of hospitalization ICU length of stay
Mohan, 2021 RIVET-COV[198 199]	Published CTRI/2020/06/026001	Jul 28 to Sept 29, 2020	157	India	35.3	88.8	Post-tb sequlae (3.2%) Coronary artery disease (0.8%) Myocardial infarction or heart failure w/in 90 days of enrollment (0.0%) Prolonged corrected qt interval >450 ms (0.0%) Diabetes (8.8%) Hypertension (11.2%)	Inpatient	Supplemental oxygen (8.0%) Mechanical ventilation (0.0%)	NA	ivermectin (single 12 mg oral dose, 200mg/kg) ivermectin (400 µg/kg up to 24 mg as a single dose) standard care/placebo	Mortality Mechanical ventilation Viral clearance Time to symptom/clinical improvement
Monk, 2020[200]	Published 2020-001023-14 & NCT04385095	Mar 30 to May 30, 2020	101	United Kingdom	57.1	59.2	Chronic lung condition (23.5%) Cardiovascular disease (13.3%) Diabetes (12.2%) Hypertension (29.6%)	Inpatient	Supplemental oxygen (65.3%) High-flow or niv (2.0%) Iv (0.0%)	NA	interferon beta (nebulised) (6 MIU once daily for up to 14 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement
Moreira, 2021[201]	Published	NR	39	Brazil	41.1	35.9	Cardiovascular disease (12.8%) Diabetes (10.3%) Hypertension (17.9%)	Outpatient	Unspecified ventilation (0.0%)	NR	corticosteroids, foralumab (6 mg dexamethasone for 3 days; 50 µg for 10 days) foralumab (50 µg for 10 days) standard care/placebo	NR
Mukae, 2022[202 203]	Published jRCT2031210350	Jan 2 to Feb 9, 2022	428	Japan, South Korea	36	58.4	NR	Inpatient (31.1%)	Unspecified ventilation (0.0%)	at least 1 vaccination (85.3%), at least 2 vaccinations (83.6%), at least 3 vaccinations (1.8%)	ensitrelvir (ensitrelvir fumaric acid 375 mg on day 1, followed by 125 mg on days 2 through 5) ensitrelvir (ensitrelvir fumaric acid 750 mg on day 1, followed by 250 mg on days 2 through 5) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Mukae_2, 2022[204-206]	Published jRCT2031210350	Sept 28, 2021 to Jan 1, 2022	45	Japan	39	61.7	NR	Inpatient (34.0%)	Unspecified ventilation (0.0%)	80.9%	ensitrelvir (375 mg on day 1, followed by the maintenance dose (125 mg) on days 2 through 5 without dose modification) ensitrelvir (750 mg on day 1, followed by the maintenance dose (250 mg) on days 2 through 5 without dose modification) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Murugesan, 2021[207]	Published	Oct to Dec 2020	100	India	46.5	74	Copd (1.0%) Major adverse cardiovascular event (0.0%) Recent revascularization < 1 year (0.0%) Heart disease (5.0%) Diabetes (36.0%)	Inpatient	Not requiring intubation at enrolment (0.0%)	NR	JAK inhibitors (tofacitinib 10 mg twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation

Naggie_2, 2022 ACTIV-6[208-210]	Published NCT04885530	Jun 23, 2021 to Feb 4, 2022	1800	United States	47.5	41.4	Asthma (15.2%) Copd (3.6%) Heart disease (4.4%) Diabetes (11.6%) Hypertension (26.1%)	Outpatient	Unspecified ventilation (0.0%)	unvaccinated (51.2%), 1 dose (1.5%), at least 2 doses (47.3%)	ivermectin (400 ug/kg daily for 3 days) standard care/placebo	Mortality Admission to hospital Time to symptom/clinical improvement
Naggie_3, 2023 ACITV-6[211 212]	Published NCT04885530	Jun 23, 2021 to Feb 4, 2022	1344	United States	47.5	40.55	Asthma (14.4%) Copd (2.2%) Heart disease (4.0%) Diabetes (9.2%) Hypertension (26.8%)	Outpatient	Unspecified ventilation (0.0%)	1 dose (0.5%), at least 2 doses (83.6%)	ivermectin (400-600 µg/kg daily for 6 days) standard care/placebo	Mortality Admission to hospital Time to symptom/clinical improvement
Naik_2, 2023[213]	Published	NR	122	India	40-80	NR	Stroke (0.0%) Atrial fibrillation (0.0%)	Inpatient	Low-flow oxygen (1.6%) Noninvasive ventilation or high-flow oxygen (0.8%)	NR	aspirin, colchicine (colchicine 0.5 mg plus aspirin 75 mg twice daily) aspirin (75 mg twice daily)	Mortality Adverse effects leading to discontinuation Duration of hospitalization
Nimitvilai, 2022[214]	Published NCT02045069	Dec 2020 to Apr 2021	118	Thailand	40	45.1	NR	Inpatient	Unspecified ventilation (0.0%)	NR	ivermectin, zinc (0.6 mg/kg once daily ; 200 mg twice daily for 3 days) darunavir/ritonavir, hydroxychloroquine, zinc (400/100mg twice daily; 200mg twice daily; 200mg twice daily for 5 days)	Mortality Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Ogbuagu, 2021[215]	Data from authors NCT04252664	NR	1005	China	NR	NR	NR	Inpatient	NR	NR	remdesivir (100 mg once daily for 5 or 10 days) standard care/placebo	NR
Oldenburg, 2021 ACTION[216]	Published NCT04332107	May 2020 to Mar 2021	263	United States	42.7	33.1	Asthma (12.2%) Copd (1.5%) Stroke (0.8%) Diabetes (3.8%) Hypertension (12.2%)	Outpatient	NR	NR	azithromycin (1.2 g given once orally) standard care/placebo	Mortality Admission to hospital
Omrani, 2020 Q-PROTECT[217]	Published NCT04349592	Apr 13 to Aug 1, 2020	456	Qatar	41	98.5	NR	Outpatient	NR	NA	azithromycin, hydroxychloroquine (200 mg every 7 hours for 7 days; 250 mg once daily for 5 days) (hydroxy)chloroquine (600mg daily for 7 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance
Onal, 2021[218]	Published NCT04377789	Mar 7 to Jul 8, 2020	434	Turkey	56.8	56.4	Copd (6.3%) Asthma (14.0%) Cardiac disease (22.6%) Diabetes (29.4%) Hypertension (39.4%)	Inpatient	NR	NA	bromelain, quercetin, vitamin C (1000mg quercetin, 1000 mg vitamin C and 100 mg bromelain supplementation, daily in 2 divided doses) standard care/placebo	Mortality
Optimus pharma, 2021 OPT-MOL-001[219]	Data from meta-analysis CTRI/2021/06/033992	NR	0	India	18-60	NR	NR	Outpatient	Unspecified ventilation (0.0%)	NR	molnupiravir (800 mg twice daily for 5 days) standard care/placebo	NR
O'Halloran, 2022 ACTIV-1 IM[220 221] ‡	Pre-print NCT04593940	Oct 16, 2020 to Dec 31, 2021	1061	Argentina, Brazil, Mexico, Peru, United States	54.8	60.3	Asthma (8.5%) Copd (4.8%) Tuberculosis (0.7%) Coronary artery disease (6.3%) Heart failure (2.9%) Class iii/iv congestive heart failure (0.0%) Diabetes (27.3%) Hypertension (40.3%)	Inpatient	Iv or ecmo (10.8%) Niv or high flow oxygen devices (33.3%) Supplemental oxygen (52.1%)	NR	TNF inhibitors (single dose intravenous infusion of 5 mg/kg infliximab over at least 2 hours) standard care/placebo	Mortality Time to symptom/clinical improvement

PRINCIPLE Trial Collaborative Group, 2021 PRINCIPLE[222]	Published ISRCTN86534580	Apr 2 to Nov 30, 2020	1979	United Kingdom	60.7	43	Asthma, chronic obstructive pulmonary disease, or lung disease (35.9%) Angina, heart attack, heart failure, atrial fibrillation, or valve problems (14.5%) Diabetes (18.1%) Hypertension (39.7%)	Outpatient	NR	NA	azithromycin (500 mg once daily for three days) standard care/placebo other trial interventions	Mortality Mechanical ventilation Admission to hospital Time to symptom/clinical improvement
Pan_hydroxychloroquine, 2022 SOLIDARITY[223-225] ‡	Published ISRCTN83971151, NCT04315948	Mar 22 to Jan 29, 2021	1865	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Ethiopia, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, North Macedonia, Malaysia, Mali, Norway, Oman, Pakistan, Phillippines, Peru, Portugal, Saudi Arabia, South Africa, Spain, Switzerland	≥18	59.9	Chronic lung disease (6.9%) Asthma (4.9%) Heart disease (21.0%) Diabetes (22.0%)	Inpatient	Supplemental oxygen (54.0%) Ventilation (9.0%)	NR	(hydroxy)chloroquine (800 mg at hour 0, 800 mg at hour 6 and, starting at hour 12, 400 mg every 12 hour for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Pan_interferon, 2022 SOLIDARITY[223-225] ‡	Published ISRCTN83971151, NCT04315948	Mar 22 to Jan 29, 2021	4317	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Ethiopia, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg,	≥18	62.3	Chronic lung disease (5.4%) Asthma (4.3%) Heart disease (22.0%) Diabetes (25.2%)	Inpatient	Supplemental oxygen (69.9%) Ventilation (6.5%)	NR	interferon beta (subcutaneous) (44 µg subcutaneous injection on days 0, 3, and 6; patients on high-flow oxygen, ventilators, or ECMO were given 10 µg/day IV infusion for 6 days when this alternative was available) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization

				North Macedonia, Malaysia, Mali, Norway, Oman, Pakistan, Phillippines, Peru, Portugal, Saudi Arabia, South Africa, Spain, Switzerland								
Pan_lopinavir, 2022 SOLIDARITY[223-225] ‡	Published ISRCTN83971151, NCT04315948	Mar 22 to Jan 29, 2021	2796	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Ethiopia, Finland, France, Honduras, India, Indonesia, Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, North Macedonia, Malaysia, Mali, Norway, Oman, Pakistan, Phillippines, Peru, Portugal, Saudi Arabia, South Africa, Spain, Switzerland	≥18	59.6	Chronic lung disease (6.5%) Asthma (4.5%) Heart disease (21.0%) Diabetes (24.2%)	Inpatient	Supplemental oxygen (53.5%) Ventilation (8.2%)	NR	lopinavir-ritonavir (400 mg/100 mg twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization
Pan_remdesivir, 2022 SOLIDARITY[223-227] ‡	Published ISRCTN83971151, NCT04315948	Mar 22 to Jan 29, 2021	8320	Albania, Argentina, Austria, Belgium, Brazil, Canada, Colombia, Egypt, Ethiopia, Finland, France, Georgia, Honduras, India, Indonesia,	NR	63.3	Chronic lung disease (6.8%) Asthma (5.9%) Heart disease (22.5%) Diabetes (27.2%)	Inpatient	Supplemental oxygen (70.6%) Ventilation (8.5%)	NR	remdesivir (200 mg on day 0 and 100 mg on days 1–9) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization

				Iran, Ireland, Italy, Kuwait, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Mali, Norway, Oman, Pakistan, Peru, Philippines, Portugal, Saudi Arabia, South Africa, Spain, Switzerland								
Panda_1, 2021 SEV COVID Trial[228]	Published CTRI/2020/06/025575	Mar to Oct 2020	40	India	43.3	78.8	Copd (6.1%) Asthma (0.0%) Chronic cardiac disease (6.1%) Diabetes (15.2%) Hypertension (6.1%)	Inpatient	Oxygen supplementation (15.2%)	NA	hydroxychloroquine, ribavirin (400 mg once daily; 600 mg twice daily, for 10 days) standard care/placebo	Mortality Mechanical ventilation Duration of hospitalization Time to viral clearance
Pandit, 2021[229]	Published CTRI/2020/06/026087	Jul 8 to Sept 4, 2020	40	India	49.2	75	Uncontrolled diabetes mellitus (0.0%) Uncontrolled hypertension (0.0%)	Inpatient	NR	NA	interferon alpha (subcutaneous) (1 µg/kg single dose) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Duration of hospitalization
Parienti, 2021 Attenuate R0 Coronavirus[230]	Published NCT04685512	Nov 20, 2020 to Mar 19, 2021	60	France	45.2	43.3	Diabetes (3.3%) Hypertension (5.0%)	Outpatient	Unspecified ventilation (0.0%)	NR	HIV reverse transcriptase inhibitor (200 mg of emtricitabine given once daily and 245 mg of tenofovir disoproxil fumarate given once daily for 7 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation
Pascual-Figal, 2021 COL-COVID[231]	Published NCT04350320	Apr 30 to Dec 4, 2020	103	Spain	51	52.4	Copd (1.0%) Obstructive sleep apnea (6.8%) Cardiovascular disease (2.9%) Cerebrovascular disease (1.9%) Diabetes (14.6%) Hypertension (27.2%)	Inpatient	Niv, iv, ecmo (0.0%)	NR	colchicine (1.5 mg, followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours for 20 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization ICU length of stay Time to symptom/clinical improvement
Piazza, 2023 PREVENT-HD[232]	Published NCT04508023	Aug 2020 to Apr 2022	1284	United States	56	39	Bronchiectasis or pulmonary cavitation (0.0%) Cerebrovascular disease or ischemic stroke (1.4%) Coronary artery disease (5.4%) Heart failure (1.3%) Peripheral artery	Outpatient	NR	2.1%	prophylactic-dose anticoagulation (10 mg rivaroxaban daily for 35 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Venous thromboembolism Clinically important bleeding

							disease (1.3%) Thrombophilia (2.6%) Venous thromboembolism (4.9%) Diabetes (21.3%)					
Plasse, 2022[233]	Published NCT04723537	Dec 10, 2020 to Aug 24, 2021	61	South Africa, Unted States	45.7	44.3	Diabetes (11.5%) Hypertension (36.1%)	Outpatient	Unspecified ventilation (0.0%)	14.8%	serine protease inhibitors (200 mg upamostat once daily for 14 days) serine protease inhibitors (400 mg upamostat once daily for 14 days) standard care/placebo	Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement
Pott-Junior, 2021 IFORS[234]	Published NCT04431466	NR	32	Brazil	49.4	45.2	NR	Inpatient	Oxygen supplementation (20.0%)	NR	ivermectin (100 µg/kg cumulative dose over 7 days) ivermectin (200 µg/kg cumulative dose over 7 days) ivermectin (400 µg/kg cumulative dose over 7 days) standard care/placebo	Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Pourdowlat, 2022[235]	Published IRCT20190810044500N5	Mar 26 to Sept 30, 2020	202	Iran	55.1	63.3	Asthma (3.6%) Cardiovascular disease (5.5%) Diabetes (14.6%) Hypertension (12.7%)	Inpatient (14.8%)	NR	NA	colchicine (3-day course of 0.5 mg followed by a 12-day course of 1 mg) standard care/placebo	Admission to hospital Adverse effects leading to discontinuation
Prabowo, 2021[236]	Published	Feb to Mar 2021	40	Indonesia	NR	NR	NR	Inpatient	NR	NR	colchicine (0.5 mg twice daily for 7 days) standard care/placebo	NR
Purwati, 2021[237]	Published	Jul to Aug 2020	754	Indonesia	37	95.3	NR	Inpatient	NR	NA	azithromycin, lopinavir-ritonavir (500 mg once daily; 200/50 mg twice daily) doxycycline, lopinavir-ritonavir (100mg twice a day; 200/50 mg twice a day) azithromycin, hydroxychloroquine (500 mg once daily; 100 mg twice daily) azithromycin, lopinavir-ritonavir (500 mg once daily; 400/100 mg twice daily) doxycycline, lopinavir-ritonavir (100 mg twice daily; 400/100 mg twice daily) azithromycin (500 mg once daily)	Adverse effects leading to discontinuation Viral clearance
Puskarich, 2021[238,239]	Published NCT04311177	Apr to Nov 2020	117	United States	38.9	50.4	Asthma (10.3%) Copd (0.0%) Chronic bronchitis (0.0%) Obstructive sleep apnea (6.9%) Cardiovascular disease (0.0%)	Outpatient	Unspecified ventilation (0.0%)	NA	ACEi/ARB (losartan (25 mg, twice daily for 10 days (for participants with eGFR > 60 mL/min/1.73 m 2) or once daily (for participants with eGFR 30–60 mL/min/1.73 m 2))) standard care/placebo	Mortality Mechanical ventilation Admission to hospital

							Diabetes (6.0%) Hypertension (7.8%)					
Rahman_1, 2022[240]	Published NCT04402203	May 2020 to Jul 2020	48	Bangladesh	37.8	66	NR	Inpatient	NR	NA	favipiravir (Day 1: 1600 mg twice daily; Days 2-5: 600 mg twice daily) standard care/placebo	Viral clearance
Rahman_2, 2022 COLCOVIDBD[241]	Published NCT04527562	Jan 2 to Feb 9, 2022	299	Bangladesh	47	64.2	Copd/bronchial asthma (7.8%) Ischemic heart disease (4.7%) Diabetes (33.8%) Hypertension (26.7%)	Inpatient	Unspecified ventilation (0.0%)	NR	colchicine (1.2 mg on day 1 followed by 0.6 mg daily for 13 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization
Ramachandran, 2021[242]	Published CTRI/2020/09/027535	Oct 3, 2020 to Apr 28, 2021	132	India	46.7	74.8	Asthma (0.0%) Diabetes (0.0%)	NR	Ecmo (0.0%) Invasive ventilator support (0.0%) Non-invasive ventilator support (0.0%)	NR	umifenovir (800 mg twice daily for 14 days) standard care/placebo	Mortality Viral clearance
Ramakrishnan, 2021 STOIC[243 244]	Published NCT04416399	Jul to Dec 2020	146	United Kingdom	45	42.5	Asthma (15.1%) Cardiovascular disease (8.6%) Diabetes (5.0%)	Outpatient	Supplemental oxygen, niv, or iv (0.0%)	NR	inhaled corticosteroids (800 µg budesonide twice daily until recovered) standard care/placebo	Time to symptom/clinical improvement
Rashad_3, 2021[245]	Published NCT04622891	May to Sept 2020	305	Egypt	44.4	70.2	NR	NR	Unspecified ventilation (0.0%)	NA	azithromycin (500 mg once daily for 7 days) clarithromycin (500 mg twice daily for 7 days) standard care/placebo	Mortality Time to symptom/clinical improvement Time to viral clearance
Rashid, 2021[246]	Published NCT04569825	Aug 1 to Sept 30, 2020	276	Iraq	29.5	28.3	NR	Outpatient	NR	NA	intranasal corticosteroids (0.1 mg/mL betamethasone three times daily until recovery up to 30 days) standard care/placebo	NR
Rastogi, 2020 SHADE[247]	Published NCT04459247	NR	40	India	48.5	50	Hypertension (0.0%)	Inpatient	Iv (0.0%)	NR	vitamin D (60000 IU/5 ml/day for 7 days) standard care/placebo	Adverse effects leading to discontinuation Time to viral clearance
Ravikirti, 2021[248 249]	Published CTRI/2020/08/027225	NR	115	India	52.5	72.3	Copd (0.9%) Asthma (0.9%) Ischemic heart disease (8.9%) Heart failure (1.8%) Diabetes (35.7%) Hypertension (34.8%)	Inpatient	NR	NR	ivermectin (12 mg/day for 2 days) standard care/placebo	Mortality Mechanical ventilation Viral clearance
Reid, 2021[250]	Published ACTRN12620000557932	Jan to Jun 2021	237	Turkey	63.3	50.2	Lung diseases (23.6%) Heart diseases (36.3%) Diabetes (34.6%)	Inpatient	NR	2.2%	vitamin C (50 mg/kg every six hours on day 1, followed by 100 mg/kg every six hours for seven days) standard care/placebo	NR
Reiersen, 2021 STOP-COVID-2[251]	Data from authors NCT04668950	Dec 2020 to May 2021	547	Canada, United States	48	38	Asthma (13.3%) Lung disease (0.7%) Heart disease (1.5%) Diabetes (9.3%) Hypertension (21.4%)	Outpatient	Supplemental oxygen (0.0%)	0	fluvoxamine (100 mg twice daily for 15 days) standard care/placebo	Admission to hospital
Reis_1, 2020 TOGETHER[252]	Data from authors NCT04403100	Jun 2 to Sept 30, 2020	685	Brazil	53	45	Asthma (8.6%) Copd (2.5%) Cardiovascular disease (3.9%) T2DM (13.1%) T1DM (6.3%) Hypertension (49.3%)	Outpatient	Supplemental oxygen, niv, or iv (0.0%)	NA	(hydroxy)chloroquine (400 mg daily for 10 days) lopinavir-ritonavir (400 mg/100 mg twice daily for 10 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Viral clearance

Reis_2, 2021 TOGETHER[253 254]	Published NCT04727424	Jan 20 to Aug 5, 2021	1497	Brazil	50	41.8	Chronic pulmonary disease (0.6%) Asthma (1.9%) Chronic cardiac disease (1.1%) T1DM (3.1%) T2DM (13.1%) Hypertension (13.0%)	Outpatient	Unspecified ventilation (0.0%)	0	fluvoxamine (100 mg twice daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Viral clearance Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement
Reis_3, 2022 TOGETHER[255]	Published NCT04727424	Mar 23 to Aug 6, 2021	1358	Brazil	49	41.8	Chronic pulmonary disease (3.0%) Asthma (8.4%) Lung disease (2.1%) Acute bronchitis (0.0%) Primary arterial hypertension (0.0%) Chronic cardiac disease (1.8%) Cardiovascular disease (40.8%) History of severe ventricular cardiac arrhythmia (0.0%) Long qt syndrome (0.0%) T1DM (0.9%) T2DM (12.4%) Uncontrolled hypertension (8.4%)	Outpatient	NR	NR	ivermectin (400 mcg/kg once daily for 3 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Viral clearance Duration of hospitalization Duration of ventilation Time to symptom/clinical improvement
Reis_5, 2023 TOGETHER[256]	Published NCT04727424	Jan 15 to Jul 6, 2022	1480	Brazil	51	39.2	Asthma (11.5%) Chronic pulmonary disease (2.4%) Chronic cardiac disease (3.9%) Severe ventricular cardiac arrhythmia [ventricular tachycardia, patients with recovered ventricular fibrillation] (0.0%) Long qt syndrome (0.0%) T1DM (2.0%) T2DM (16.9%) Hypertension (44.4%)	Outpatient	NR	1 dose (3.5%), 2 doses (51.7%), 3 doses (41.6%)	fluvoxamine, inhaled corticosteroids (fluvoxamine 100 mg twice daily for 10 days plus inhaled budesonide 800 mcg twice daily for 10 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Reis_6, 2023 TOGETHER[257]	Published NCT04727424	NR	1951	Brazil, Canada	43	42.9	Asthma (9.8%) Chronic pulmonary disease (2.4%) Chronic cardiac disease (2.4%) T2DM (9.3%) Hypertension (29.8%)	Outpatient	NR	1 dose (25.2%), 2 doses (49.3%), 3 doses (8.7%)	interferon lambda (subcutaneous) (180 µg single dose injection) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Duration of ventilation Time to symptom/clinical improvement
Ren, 2020[258]	Published ChiCTR2000029853	Feb 18 to Feb 29, 2020	20	China	52	60	Copd (0.0%) Cardiovascular disease (5.0%) Diabetes (5.0%) Hypertension (5.0%)	Inpatient	Niv or iv (0.0%)	NA	HIV reverse transcriptase inhibitor (5 mg azvudine once daily until discharge) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Duration of

												hospitalization Time to viral clearance
Rezai_2, 2022[259]	Published IRCT20111224008507N4	Feb to Aug 2021	582	Iran	35.46	52.46	Asthma (2.4%) Cardiovascular disorders (2.7%) Diabetes (7.3%) Hypertension (7.8%)	Outpatient	Unspecified ventilation (0.0%)	NR	ivermectin (0.4 mg/kg daily for 3 days) standard care/placebo	Mortality Admission to hospital Viral clearance Time to symptom/clinical improvement
Rodrigues, 2021[260]	Published	Apr 12 to May 13, 2020	84	Brazil	36.5	59.5	NR	Outpatient	NR	NA	azithromycin, hydroxychloroquine standard care/placebo	Mortality Admission to hospital Viral clearance
Roy-Garcia, 2022[261]	Pre-print NCT04964583	Jan to Jun 2021	92	Mexico	37	48.9	Cardiac disorders with qt segment≥450 ms (0.0%) T1DM (0.0%) T2DM (0.0%)	Outpatient	Unspecified ventilation (0.0%)	0	azithromycin, (hydroxy)chloroquine (250 mg daily for 5 days; two 200 mg capsules twice daily for 7 days) standard care/placebo	Admission to hospital Viral clearance
Ruzhentsova, 2020[262]	Pre-print NCT04501783	May 23 to Jun 30, 2020	168	Russia	41.8	47	Moderate or severe chronic obstructive pulmonary disease (0.0%) Asthma (0.0%) Severe chronic cardiovascular disorders (0.0%) Diabetes (0.0%)	Inpatient (24.4%)	Supplemental oxygen (1.8%)	NA	favipiravir (800 mg twice daily for 10 days) standard care/placebo	Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Sabico, 2021[263]	Published SCTR No. 20061006	Jul 29 to Sept 22, 2020	73	Saudi Arabia	49.7	49.3	Asthma (4.3%) Cardiovascular disease (5.8%) Diabetes (50.7%) Hypertension (55.1%)	NR	Unspecified ventilation (0.0%)	NA	vitamin D (5000 IU once daily for 2 weeks) vitamin D (1000 IU once daily for 2 weeks)	Mortality Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement
Sarojvisut, 2022[264]	Published TCTR20220427005	Dec 5, 2020 to Mar 31, 2021	321	Thailand	47.4	38.2	Asthma/copd (2.5%) Diabetes (16.7%) Hypertension (31.6%)	Inpatient	High-flow nasal cannula (0.0%) Mv (0.0%)	2 doses (62.5%)	ivermectin (400 µg/kg/day for 5 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Time to symptom/clinical improvement
Sausa, 2022[265]	Pre-print	Feb to Jul 2021	100	Latvia	65	NR	NR	Inpatient	NR	NR	vitamin D (sublingual sprayable microemulsion of 4,000 IU three times daily for 5 days) standard care/placebo	NR
Schilling, 2023 PLATCOV[266 267]	Published NCT05041907	Sept 30, 2021 to Apr 18, 2022	91	Thailand	28.1	45.4	Respiratory condition (0.0%) Cardiovascular disease (0.0%) Diabetes (0.0%)	Outpatient	Unspecified ventilation (0.0%)	at least 1 dose (95%)	ivermectin (600 µg/kg once daily for seven days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation
Schwartz_1, 2021[268 269]	Data from authors NCT04429711	NR	94	Israel	39.5	80.8	NR	Outpatient	Niv or iv (0.0%)	NR	ivermectin (150 to 300 µg/kg/day for 3 days) standard care/placebo	Viral clearance
Schwartz_2, 2021 ALBERTA HOPE COVID-19[270 271]	Published NCT04329611	Apr 15 to May 22, 2020	148	Canada	46.8	44.6	Asthma (13.5%) Diabetes (19.6%) Hypertension (27.7%)	Outpatient	NR	NA	(hydroxy)chloroquine (200 mg twice daily for 5 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects

												leading to discontinuation Time to symptom/clinical improvement
Seo, 2022[272 273]	Published NCT04711863	Jan 15 to Feb 8, 2021	52	Korea	52.8	59.6	Asthma (0.0%) Chronic lung disease (3.9%) Heart disease (0.0%) Congestive heart failure (0.0%) Diabetes (7.7%) Hypertension (26.9%)	Inpatient	Unspecified ventilation (0.0%)	NR	fluvoxamine (50mg dose on day 1, then increased dose of 100mg twice daily as tolerated until discharge (about 10 days)) standard care/placebo	Adverse effects leading to discontinuation
Sharma, 2022 McGill RAAS-COVID-19[274]	Published NCT04508985	Oct 2020 to Mar 2021	46	Canada	71.5	56.5	Copd (4.3%) Sleep apnea (10.9%) Prior history of heart failure (10.9%) Coronary artery disease (32.6%) Atrial fibrillation/flutter (15.2%) Stroke or transient ischemic attack (6.5%) Diabetes (43.5%) Hypertension (100.0%)	Inpatient	Invasive mechanical ventilation (0.0%)	NR	standard care/placebo ACEi/ARB (continued)	Mortality Mechanical ventilation Duration of hospitalization
Shebley, 2022[275]	Published NCT04644120	Jun 2021 to May 2022	25	Israel, United States	48.2	45.83	NR	Inpatient (41.7%)	Supplementary oxygen (29.2%) High-flow nasal cannula (0.0%) Non-invasive mv (0.0%) Invasive mv (0.0%)	NR	ABBV-47D11 (180 mg single dose) ABBV-47D11 (600 mg single dose) ABBV-47D11 (2400 mg single dose) standard care/placebo	Mortality Time to viral clearance
Shinkai, 2021[276]	Published JapicCTI-205238	NR	156	Japan	45.3	66.7	NR	Inpatient	Unspecified ventilation (0.0%)	NR	favipiravir (800 mg twice daily for 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Time to symptom/clinical improvement
Sholzberg, 2021 RAPID[277 278]	Published NCT04362085, NCT04444700	May 29, 2020 to Apr 12, 2021	465	Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, United States	60	56.8	Chronic pulmonary disease (13.6%) Coronary artery disease (7.3%) Heart failure (3.2%) Atrial fibrillation (0.4%) Cerebrovascular disease (4.1%) Peripheral vascular disease (0.2%) History of venous thromboembolism (1.1%) Diabetes (34.4%) Hypertension (48.4%)	Inpatient	High flow nasal cannula (5.8%) Niv, iv (0.0%)	0.7%	therapeutic-dose anticoagulation (heparin administered up to hospital discharge or day 28) standard care/placebo	Mortality Mechanical ventilation Venous thromboembolism Clinically important bleeding Ventilator-free days
Sinha, 2022[279]	Published CTRI/2021/05/033739	initiated on May 27, 2021	1218	India	35	68.4	Diabetes (0.3%) Hypertension (0.8%)	Outpatient	NR	NR	molnupiravir (800 mg twice daily for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to

												discontinuation Viral clearance Time to symptom/clinical improvement
Sirijatuphat, 2022[280 281]	Published TCTR20200514001	Dec 2020 to Jul 2021	93	Thailand	30.7	35.5	NR	Inpatient	NR	NR	favipiravir (1800 mg twice-daily on Day 1 and 800 mg twice-daily thereafter until clinical improvement or saliva RT-PCR became negative (min-max of 5-14 days)) standard care/placebo	Mortality Adverse effects leading to discontinuation Time to symptom/clinical improvement Time to viral clearance
Skendelas, 2021[282]	Published NCT04343651	Mar to May 2020	4	United States	63.5	50	Single-lung transplant (100.0%) Severe chronic respiratory disease and requirement for long-term oxygen therapy (0.0%)	NR	NR	NA	leronlimab (1-2 weekly 700 mg subcutaneous doses) standard care/placebo	Mechanical ventilation Adverse effects leading to discontinuation
Skipper, 2020[283]	Published NCT04308668	Mar 22 to May 20, 2020	491	United States, Canada	40	45.8	Asthma (10.4%) Chronic lung disease (0.4%) Cardiovascular disease (1.2%) Diabetes (3.9%) Hypertension (11.0%)	Outpatient	Supplemental oxygen, niv, or iv (0.0%)	NA	(hydroxy)chloroquine (600 mg once daily for 5 days) standard care/placebo	Mortality Admission to hospital
Sobngwi, 2021 DOXYCOV[284]	Pre-print NCT04715295	Mar 16 to Apr 9, 2021	194	Cameroon	38.5	52.4	Asthma (1.6%) Severe cardiac disease (0.0%) Treated hypertension (1.1%)	Outpatient	NR	NR	doxycycline (100mg twice daily for 7 days) azithromycin, hydroxychloroquine (500 mg at day 1 and 250 mg from day 2 through 5; 400 mg daily for 5 days)	Admission to hospital Adverse effects leading to discontinuation Viral clearance
Song, 2021[285]	Published NCT04330586	May 8, 2020 to Mar 31, 2021	61	South Korea	46.6	32.8	Chronic airway diseases: asthma and chronic obstructive lung disease (0.0%) Diabetes (14.8%) Hypertension (27.9%)	Inpatient	NR	NR	inhaled corticosteroids (320 ug ciclesonide twice per day for 14 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Duration of hospitalization
Spinner, 2020[286]	Published NCT04292730	Mar 15 to Apr 18, 2020	596	France, Germany, Hong Kong, Italy, Netherlands, Korea, Singapore, Spain, Switzerland, Taiwan, United Kingdom, United States	57	61.1	Asthma (13.9%) Cardiovascular disease (56.3%) Diabetes (39.7%) Hypertension (42.5%)	Inpatient	Supplemental oxygen (15.1%) High-flow or niv (0.9%)	NA	remdesivir (100 mg once daily for 10 days) remdesivir (100 mg once daily for 5 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Duration of hospitalization Time to symptom/clinical improvement
Spivak, 2023 UTAH One trial[287]	Published NCT04342169	Aug 26, 2020 to Sept 19, 2022	367	United States of America	42	52	Chronic pulmonary disease (2.2%) Cardiac conduction delay (0.0%) Ventricular arrhythmia (0.0%) Diabetes (7.6%) Hypertension (14.2%)	Outpatient	Unspecified ventilation (0.0%)	NR	(hydroxy)chloroquine (400 mg twice daily on day 1 followed by 200 mg twice daily for 4 days) standard care/placebo	Mortality Admission to hospital Viral clearance Time to symptom/clinical improvement Time to viral clearance

TOCOVID_EudraCT2020-001442-19, 2021 TOCOVID[49]	Data from meta-analysis EudraCT2020-001442-19	NR	270	Spain	53	63.7	NR	Inpatient Intensive care (100.0%)	NR	NR	IL6 receptor antagonists (162 mg tocilizumab (up to 600 mg) four doses or 400 mg (up to 600 mg) single dose based on patient weight) standard care/placebo	Mortality
Tang_1, 2020[288 289]	Published ChiCTR2000029868	Feb 11 to Feb 29, 2020	150	China	46.1	55	Cardiovascular disease (0.0%) Diabetes (14.0%) Hypertension (6.0%)	Inpatient	NR	NA	(hydroxy)chloroquine (800 mg once daily for 14 to 21 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
Tardif, 2021 COLCORONA[290]	Published NCT04322682	Mar 2020 to Jan 2021	4488	Brazil, Canada, Greece, South Africa, Spain, USA	53.5	46.1	Respiratory condition (26.5%) Mi (3.0%) Hf (0.9%) Diabetes (19.9%) Hypertension (36.3%)	Outpatient	NR	NR	colchicine (0.5 mg twice per day for 3 days and then once per day for 27 days thereafter) standard care/placebo	Mortality Mechanical ventilation Admission to hospital
Tehrani_2, 2022[291]	Published IRCT20211004052664N1	Apr to Sept 2021	78	Iran	52.5	55.1	Chronic respiratory disorders (7.7%) Cardiac disorders (2.6%) Diabetes (30.8%) Hypertension (35.9%)	Outpatient	Unspecified ventilation (0.0%)	NR	favipiravir (1600 mg every 12 h for the first day and 600 mg every 12 h for the next 4 days) standard care/placebo	Admission to hospital Adverse effects leading to discontinuation
Terada-Hirashima, 2022 RACCO[292]	Published jRCTs031190269	Apr 3 to Sept 18, 2020	90	Japan	23.17	49.44	Chronic respiratory disease (0.0%) Congestive heart failure (2.2%) Diabetes (5.6%)	Inpatient	NR	NA	inhaled corticosteroids (400 ug ciclesonide 3 times per day for 7 days) standard care/placebo	Mortality Adverse effects leading to discontinuation
Thomas, 2021 COVID A to Z[293]	Published NCT04342728	Apr 27 to Oct 14, 2020	214	United States	45.2	38.3	Asthma (15.4%) Diabetes (13.6%) Hypertension (32.7%)	Outpatient	NR	NA	vitamin C (8000 mg divided in 2 or 3 doses/day for 10 days) zinc (50 mg/day for 10 days) vitamin C, zinc (8000 mg divided in 2 or 3 doses/day for 10 days; 50 mg/day for 10 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation Time to symptom/clinical improvement
Tobback, 2022[294]	Published NCT04625114	Nov 2020 to Jun 2021	96	Belgium	40	45.6	Diabetes (2.2%) Hypertension (6.7%)	Outpatient	Unspecified ventilation (0.0%)	1 dose (3.3%), 2 doses (1.1%)	serine protease inhibitors (300 mg camostat three times daily for 5 days) standard care/placebo	Admission to hospital Time to symptom/clinical improvement
Udwadia, 2020[295]	Published CTRI/2020/05/025114	May 14 to Jul 3, 2020	150	India	43.3	73.5	Asthma (0.0%) Chronic obstructive lung disease (0.0%) Prolonged qt defined as qtcf greater or equal than 450 msec for men and as qtcf greater or equal than 470 msec for women (0.0%) Severely reduced left ventricular function,ejection fraction greater than 30% (0.0%)	Inpatient	Niv (0.0%) Iv (0.0%) Ecmo (0.0%)	NA	favipiravir (800 mg twice daily up to 14 days) standard care/placebo	Mortality Mechanical ventilation Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance

Vaezi, 2023[296]	Published IRCT20171219037964N3	Apr to Sept 2021	77	Iran	41	55.8	NR	Outpatient	Unspecified ventilation (0.0%)	NR	favipiravir (1600 mg daily PO for 5 days) standard care/placebo	Mortality Admission to hospital Adverse effects leading to discontinuation
Vaira, 2020[297]	Published	NR	18	Italy	42.1	38.9	NR	Outpatient	NR	NR	corticosteroids (systemic) (1 mg/kg/day with tapering of dose for 15 days) standard care/placebo	NR
Vallejos, 2021 IVERCOR-COVID19[298]	Published NCT04529525	Aug 19, 2020 to Feb 22, 2021	501	Argentina	42.5	52.7	Asthma (7.2%) Copd (2.8%) Previous myocardial infarction (1.8%) Previous coronary angioplasty (0.8%) Previous stroke (1.0%) Heart failure (0.8%) Diabetes (9.6%) Hypertension (23.8%)	Outpatient	Unspecified ventilation (0.0%)	NR	ivermectin (12 mg daily for 2 days (>48 and <80 kg); 18 mg daily for 2 days (>80 kg and <110 kg); 24 mg daily for 2 days (>110 kg)) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation
Vyas, 2021[299]	Data from authors CTRI/2021/08/035424	NR	1220	India	36.5	61.6	Diabetes mellitus (0.3%) T2DM (0.2%) Hypertension (1.1%)	Outpatient	NR	NR	molnupiravir (800 mg twice a day for 5 days) standard care/placebo	Mortality Mechanical ventilation Admission to hospital Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement
Wada, 2023 CORVETTE-01[300]	Published NCT04703205	Aug 2020 to Oct 2021	221	Japan	47.7	65.6	Chronic obstructive pulmonary disease (1.9%) Diabetes (13.7%)	NR	NR	7.6%	ivermectin (200 µg/kg, single dose) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Wang_5, 2020[301]	Published ChiCTR 2000030058	Mar 10 to Apr 12, 2020	50	China	55.8	45.8	Copd (4.2%) Coronary artery disease (2.1%) Diabetes (4.2%) Hypertension (25.0%)	Inpatient	NR	NA	leflunomide (50 mg twice daily for 1.5 days, then 20 mg/day for 8 days) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to viral clearance
Yadegarinia, 2020[302]	Published	Mar to Apr 2020	34	Iran	64.1	76.5	Diabetes (47.1%) Hypertension (38.2%)	Inpatient	NR	NA	umifenovir (NR) standard care/placebo	Mortality Duration of hospitalization
Yang, 2022[303]	Published ChiCTR2000032717	Feb 1 to Feb 29, 2020	30	China	48.6	50	NR	NR	NR	NA	standard care/placebo vitamin C (intravenously at a dosage of 10 g/60 kg twice daily, and orally at a dosage of 3 g three times daily)	Time to symptom/clinical improvement Time to viral clearance
Yethindra, 2020[304]	Published	until May 18, 2020	30	Kyrgyzstan	36.5	60	Cardiovascular disease (0.0%)	Inpatient	NR	NA	umifenovir (200 mg three times daily for 1 to 5 days) standard care/placebo	Mortality Time to symptom/clinical improvement
Yu, 2021 PRINCIPLE[305 306]	Published ISRCTN86534580	Nov 27 to Mar 31, 2021	2975	United Kingdom	62.8	46.2	Asthma, copd or lung disease (18.3%) Angina, heart attack, heart failure, af, valve problems (15.4%)	Outpatient	NR	NR	inhaled corticosteroids (800 µg budesonide twice daily for 14 days) standard care/placebo	Mechanical ventilation Time to symptom/clinical improvement

							Diabetes (20.5%) Medication hbp (43.9%)					
Zhao_2, 2021[307]	Published NCT04333589	Mar 27 to May 9, 2020	55	China	55.7	45.5	Coronary heart disease (7.3%) Diabetes (14.6%) Hypertension (30.9%)	Outpatient	NR	NA	favipiravir (600 mg twice daily for 7 days up to 14 days) standard care/placebo	Mortality Viral clearance Time to viral clearance
Zhao_3, 2022[308]	Published ChiCTR2000029621, NCT04260594	Feb 6 to Mar 12, 2020	97	China	46.5	45.4	Severe cardiac disease (0.0%) Clinically significant arrhythmia (0.0%)	Inpatient	Unspecified ventilation (13.4%)	NA	umifenovir (200 mg three times a day for 14 days) standard care/placebo	Adverse effects leading to discontinuation Viral clearance Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance
Zheng_1, 2020[309 310] ‡	Published ChiCTR2000029496	Feb 1 to Feb 20, 2020	89	China	46.7	47.2	Severe lung disease (0.0%) Chronic bronchitis (2.0%) Severe heart disease (0.0%) Coronary heart disease (3.0%) Diabetes (8.1%) Hypertension (6.1%)	Inpatient	NR	NA	novaferon (20 µg twice daily for 7 to 10 days) lopinavir-ritonavir, novaferon (200 mg/50 mg twice daily; 20 µg twice daily, for 7 to 10 days)lopinavir-ritonavir (200 mg/50 mg twice daily for 7 to 10 days)	Adverse effects leading to discontinuation Viral clearance Time to viral clearance
Zhuravel, 2021[311] ‡	Published NCT04623021	Sept 25 to Nov 14, 2020	104	Russia	58.6	49.5	T2DM (10.7%) Hypertension (62.1%)	Inpatient	Supplemental oxygen (91.3%) Hfnc and/or niv (8.7%) Iv and/or ecmo (0.0%)	NA	serine protease inhibitors (4.8 mg/kg/day nafamostat via 24-hour intravenous infusion for 10 days or until hospital discharge) standard care/placebo	Mortality Adverse effects leading to discontinuation Viral clearance Venous thromboembolism Duration of hospitalization Time to symptom/clinical improvement Time to viral clearance
Zou, 2022[312]	Published ChiCTR2200056817	Mar 3 to Mar 21, 2022	116	China	39.9	55.6	NR	Inpatient	NR	2 doses (30.6%), 3 doses (61.1%)	molnupiravir (800 mg twice per day for 5 days) standard care/placebo	Adverse effects leading to discontinuation Viral clearance Time to symptom/clinical improvement Time to viral clearance
da Silva, 2023[313]	Published NCT05033145	May 5 to Nov 27, 2020	281	Brazil	45	39.5	Asthma (2.5%) Bronchitis (5.3%) Respiratory failure (0.0%) Angina (1.1%) Cardiac arrhythmia (2.1%) Cardiac revascularization (0.7%) Coronary angioplasty [stent] (1.4%) History of congestive heart failure [nyha	Outpatient	Mechanical ventilation (0.0%)	NA	HIV reverse transcriptase inhibitor (5 mg daily azvudine for up to 14 days) standard care/placebo	Adverse effects leading to discontinuation Time to symptom/clinical improvement Time to viral clearance

							grade 3/4], untreated symptomatic arrhythmias or myocardial infarction within 6 months (0.0%) Stroke (0.4%) T1DM (2.5%) T2DM (7.1%) Hypertension (29.5%)					
de la Rocha, 2022[314 315]	Pre-print NCT04407507	Jul 21, 2020 to Jan 9, 2021	66	Mexico	38.5	32.1	Cardiovascular disease (7.1%) Diabetes (5.4%) Hypertension (8.9%)	Outpatient	Unspecified ventilation (0.0%)	NR	ivermectin (12 mg per day for 3 days) standard care/placebo	Mortality Viral clearance

‡ This study provides outcome data for patients with non-severe and severe covid-19 separately; however, the baseline characteristics are only reported in aggregate for both populations. The proportion of non-severe patients within this trial is presented in the table titled “Proportion of Non-severe Patients in Trials with Mixed Severity Populations” in the supplementary material.

1. Abd-Elsalam S, Soliman S, Esmail ES, et al. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. *Biological Trace Element Research* 2021;199(10):3642-46. doi: 10.1007/s12011-020-02512-1
2. Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. *Journal of Medical Virology* 2021;93(10):5833-38. doi: 10.1002/jmv.27122
3. Abdeen S, Abu-Fanne R, Bdeir K, et al. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins. *British Journal of Haematology* 2022;196(4):923-27. doi: 10.1111/bjh.17885
4. Abdulamir AS, Gorial FI, Saadi SJ, et al. A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management. *Ann Med Surg (Lond)* 2021;69:102779. doi: 10.1016/j.amsu.2021.102779 [published Online First: 2021/09/14]
5. Abroug H, Maatouk A, Bennasrallah C, et al. Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 Tunisian patients: a randomized-controlled clinical trial. *Trials* 2023;24(1) doi: 10.1186/s13063-023-07114-5
6. Abulmeaty MMA, Aljuraiban GS, Shaikh SM, et al. The Efficacy of Antioxidant Oral Supplements on the Progression of COVID-19 in Non-Critically Ill Patients: A Randomized Controlled Trial. *Antioxidants* 2021;10(5):804. doi: 10.3390/antiox10050804
7. Adhikari P, Koirala J, Shrestha A, et al. Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial. *International Journal of Infectious Diseases* 2022;116:S45-S46. doi: 10.1016/j.ijid.2021.12.109
8. Ahmad B, Ul Hassan N, Sehar B, et al. Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19. *Clinical Medicine & Research* 2021;19(4):179-82. doi: 10.3121/cmr.2021.1659
9. Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *International Journal of Infectious Diseases* 2021;103:214-16. doi: 10.1016/j.ijid.2020.11.191

10. Akbari N, Ostadrahimi A, Tutunchi H, et al. Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial. *J Trace Elem Med Biol* 2022;71:126945. doi: 10.1016/j.jtemb.2022.126945 [published Online First: 2022/02/21]
11. Alqahtani M, Kumar N, Aljawder D, et al. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. *Scientific Reports* 2022;12(1) doi: 10.1038/s41598-022-08794-w
12. Alqahtani M, Kumar N, Aljawder D, et al. Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. *Scientific Reports* 2022;12(1) doi: 10.1038/s41598-022-20899-w
13. Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. *Canadian Medical Association Journal* 2022;194(7):E242-E51. doi: 10.1503/cmaj.211698
14. Amaravadi RK, Giles L, Carberry M, et al. Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial: Cold Spring Harbor Laboratory, 2021.
15. Ali Amirsavadkouhi RS, Nadia Mohammad Zadeh, Saba Ilkhani, Seyed Bashir Mirtajani, Vahid Salimi, Maziar Mahjoubifard, Alireza Jahangirifard. Effects of Morphine and Fentanyl on Patients with COVID-19. *Tanaffos* 2021;20:164-71.
16. Ananworanich J, Mogg R, Dunne MW, et al. Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019. *Clinical Infectious Diseases* 2022;75(1):e473-e81. doi: 10.1093/cid/ciab813
17. Angkasekwinai N, Rattanaumpawan P, Chayakulkeeree M, et al. Safety and Efficacy of Ivermectin for the Prevention and Treatment of COVID-19: A Double-Blinded Randomized Placebo-Controlled Study. *Antibiotics* 2022;11(6):796. doi: 10.3390/antibiotics11060796
18. Annweiler C, Beaudenon M, Gautier J, et al. High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial. *PLOS Medicine* 2022;19(5):e1003999. doi: 10.1371/journal.pmed.1003999
19. Arefin MK, Rumi SKNF, Uddin AKMN, et al. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial. *Indian Journal of Otolaryngology and Head & Neck Surgery* 2022;74(S2):2963-67. doi: 10.1007/s12070-021-02616-7
20. Reza Arefizadeh SHM, Sayied Towfiqie, Seyed Abolfazl Mohsenizadeh, Mehdi Pishgahi. Effect of Ticagrelor Compared to Clopidogrel on Short- term Outcomes of COVID-19 Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Interven- tion; a Randomized Clinical Trial. *Archives of Academic Emergency Medicine* 2023;11(1):e14. doi: https://doi.org/10.22037/aaem.v11i1.1870.
21. Arruda EAG, Pires-Neto RJ, Medeiros MS, et al. Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections: Cold Spring Harbor Laboratory, 2021.

22. Atipornwanich K, Kongsaengdao S, Harnsomburana P, et al. Various combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, high-dose Oseltamivir, and Hydroxychloroquine for the treatment of Covid-19: A randomized controlled trial (FIGHT-COVID-19 Study). doi: http://dx.doi.org/10.2139/ssrn.3936499
23. Avezum A, Oliveira GBF, Oliveira H, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial. *Lancet Reg Health Am* 2022;11:100243. doi: 10.1016/j.lana.2022.100243 [published Online First: 2022/04/06]
24. Avezum ÁOJ, HA; Neves, PDMM; Alves, LBO; Cavalcanti, AB; Rosa, RG; et al. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: The CARE – COALITION VIII Randomised Clinical Trial. 2023 doi: http://dx.doi.org/10.2139/ssrn.4344631
25. Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. *Nature Communications* 2021;12(1) doi: 10.1038/s41467-021-22446-z
26. Babalola O, Bode C, Ajayi A, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos: Cold Spring Harbor Laboratory, 2021.
27. Balykova LA, Pavelkina VF, Shmyreva NV, et al. EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19). *Pharmacy & Pharmacology* 2020;8(3):150-59. doi: 10.19163/2307-9266-2020-8-3-150-159
28. Balykova LA, Selezneva NM, Gorshenina EI, et al. MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION. *Pharmacy & Pharmacology* 2022;10(4):371-86. doi: 10.19163/2307-9266-2022-10-4-371-386
29. Barco S, Schreiber K. COVID-19: ACT trials for colchicine and antithrombotic therapies. *The Lancet Respiratory Medicine* 2022;10(12):1106-08. doi: 10.1016/s2213-2600(22)00368-x
30. Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *The Lancet Haematology* 2022;9(8):e585-e93. doi: 10.1016/s2352-3026(22)00175-2
31. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine* 2020;383(19):1813-26. doi: 10.1056/nejmoa2007764
32. World Health Organization. Unpublished data for RESET (NCT04380519). 2022
33. Jayk Bernal A, Gomes Da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *New England Journal of Medicine* 2022;386(6):509-20. doi: 10.1056/nejmoa2116044
34. Bhushan B L S, Wanve S, Koradia P, et al. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. *International Journal of Infectious Diseases* 2021;111:281-87. doi: 10.1016/j.ijid.2021.08.044

35. Bishop CW, Ashfaq A, Melnick JZ, et al. REsCue trial: Randomized controlled clinical trial with extended-release calcifediol in symptomatic COVID-19 outpatients. *Nutrition* 2023;107:111899. doi: 10.1016/j.nut.2022.111899 [published Online First: 2022/12/19]
36. Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. *Clinical Microbiology and Infection* 2022;28(4):602-08. doi: 10.1016/j.cmi.2021.12.026
37. Naggie S. Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial: Cold Spring Harbor Laboratory, 2022.
38. Boulware DR. Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. *Open Forum Infectious Diseases* 2022;9
39. Florescu, Simin, Stanciu D, Zaharia, Mihaela, et al. Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. *JAMA* 2022;327(13):1247. doi: 10.1001/jama.2022.2910
40. Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. *New England Journal of Medicine* 2022;387(7):599-610. doi: 10.1056/nejmoa2201662
41. Bramante C, Buse JB, Liebovitz, et al. Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 Trial. 2023 doi: http://dx.doi.org/10.2139/ssrn.4375620
42. Bramante CT, Beckman KB, Mehta T, et al. Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial: Cold Spring Harbor Laboratory, 2023.
43. Bramante C, Nicklas J. Phase 3 Clinical Trial of Metformin for Treatment of COVID-19 in Adults With Overweight and Obesity. 40TH ANNUAL MEETING OF THE OBESITY SOCIETY AT OBESITYWEEK, 2022:31-32.
44. Shah Bukhari KH, Asghar A, Perveen N, et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease: Cold Spring Harbor Laboratory, 2021.
45. Buonfrate D, Chesini F, Martini D, et al. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. *Int J Antimicrob Agents* 2022;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516 [published Online First: 2022/01/10]
46. Butler CC, Yu L-M, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet Respiratory Medicine* 2021;9(9):1010-20. doi: 10.1016/s2213-2600(21)00310-6
47. Butler C, Hobbs FDR, Gbinigie O, et al. Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial. *SSRN Electronic Journal* 2022 doi: 10.2139/ssrn.4237902

48. Byakika-Kibwika P, Sekaggya-Wiltshire C, Semakula JR, et al. Safety and Efficacy of Hydroxychloroquine for Treatment of Non-Severe COVID-19 in Adults in Uganda: A Randomized Open Label Phase II Clinical Trial: Research Square Platform LLC, 2021.
49. The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA 2021* 2021;326(6):499-518. doi: doi: 10.1001/jama.2021.11330
50. Cairns DM, Dulko D, Griffiths JK, et al. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19. *JAMA Network Open* 2022;5(2):e2144942. doi: 10.1001/jamanetworkopen.2021.44942
51. Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19. *New England Journal of Medicine* 2023;388(5):406-17. doi: 10.1056/nejmoa2208822
52. Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. *NEJM Evidence* 2022;1(2) doi: 10.1056/evidoa2100043
53. Castro-Rodriguez JA, Fish EN, Kollmann T, et al. Interferon Beta-1α ring prophylaxis to reduce household transmission of SARS-CoV-2: the Containing Coronavirus Disease-19 randomized clinical trial: Cold Spring Harbor Laboratory, 2022.
54. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* 2020;383(21):2041-52. doi: 10.1056/nejmoa2019014
55. Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. *EClinicalMedicine* 2021;32:100720. doi: 10.1016/j.eclinm.2020.100720
56. Chaccour C, Casellas A, Matteo AB-D, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial: Research Square Platform LLC, 2020.
57. Zeeshan Khan Chachar A, Ahmad Khan K, Asif M, et al. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. *International Journal of Sciences* 2020;9(09):31-35. doi: 10.18483/ijsci.2378
58. Chahla RE, Medina Ruiz L, Ortega ES, et al. A RANDOMIZED TRIAL - INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS: Cold Spring Harbor Laboratory, 2021.
59. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial: Cold Spring Harbor Laboratory, 2020.
60. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. 2020 doi: 10.1101/2020.03.17.20037432

61. Chen C, Zhang Y, Huang J, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. *Front Pharmacol* 2021;12:683296. doi: 10.3389/fphar.2021.683296 [published Online First: 2021/09/21]
62. Chen J LD, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2020;49(2):215-19. doi: 10.3785/j.issn.1008-9292.2020.03.03
63. Chen L, Zhang Z-Y, Fu J-G, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study: Cold Spring Harbor Laboratory, 2020.
64. Chen C-P, Lin Y-C, Chen T-C, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). *PLOS ONE* 2020;15(12):e0242763. doi: 10.1371/journal.pone.0242763
65. Chen C-P, Lin Y-C, Chen T-C, et al. A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19). 2020 doi: 10.1101/2020.07.08.20148841
66. Choudhary R, Ali O, Singh BK. Study on Hydroxychloroquinine Sulfate Being Given to the Admitted COVID -19 Positive Patients at Institute of JLNMCH, Bhagalpur, Bihar, India. *Cureus* 2022 doi: 10.7759/cureus.26388
67. Chuah CH, Chow TS, Hor CP, et al. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial. *Clin Infect Dis* 2022;75(1):e432-e39. doi: 10.1093/cid/ciab962 [published Online First: 2021/12/02]
68. Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. A randomized controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections: Cold Spring Harbor Laboratory, 2021.
69. Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. *The Lancet Respiratory Medicine* 2021;9(3):275-84. doi: 10.1016/s2213-2600(20)30558-0
70. Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. *JAMA* 2021;326(17):1703. doi: 10.1001/jama.2021.17272
71. Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. *The Lancet Haematology* 2022;9(8):e594-e604. doi: 10.1016/s2352-3026(22)00173-9
72. Criner GJ, Ahn MY, Huhn G, et al. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. *Open Forum Infectious Diseases* 2020;7:S345–S46. doi: https://doi.org/10.1093/ofid/ofaa439.755
73. Crippa JAS, Pacheco JC, Zuardi AW, et al. Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Cannabis Cannabinoid Res* 2022;7(5):658-69. doi: 10.1089/can.2021.0093 [published Online First: 2021/10/08]

74. Cruz LR, Baladrón I, Rittoles A, et al. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial: Cold Spring Harbor Laboratory, 2020.
75. Cruz LR, Baladrón I, Rittoles A, et al. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial. *ACS Pharmacology & Translational Science* 2021;4(1):206-12. doi: 10.1021/acsptsci.0c00175
76. Davoodi L, Abedi SM, Salehifar E, et al. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. *Int J Clin Pract* 2020;74(11):e13600. doi: 10.1111/ijcp.13600 [published Online First: 2020/07/01]
77. Davoodi L, Abedi SM, Salehifar E, et al. Febuxostat as an alternative therapy in COVID-19: A double-blind randomized clinical trial. *Authorea* 2020 doi: 10.22541/au.159007758.87901715
78. De Niet S, Trémège M, Coffiner M, et al. Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial. *Nutrients* 2022;14(15):3048. doi: 10.3390/nu14153048
79. Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. *Antimicrob Agents Chemother* 2020;64(12) doi: https://doi.org/10.1128/AAC .01897-20. [published Online First: 2020/09/25]
80. Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrob Agents Chemother* 2020;64(12) doi: 10.1128/AAC.01897-20 [published Online First: 2020/09/23]
81. Dorward J, Yu L-M, Hayward G, et al. Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. *British Journal of General Practice* 2022;72(720):e446-e55. doi: 10.3399/bjgp.2022.0083
82. Dorward J, Yu L-M, Hayward G, et al. Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial: Cold Spring Harbor Laboratory, 2021.
83. Dubée V, Roy P-M, Vielle B, et al. A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19: Cold Spring Harbor Laboratory, 2020.
84. Dubée V, Roy P-M, Vielle B, et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. *Clinical Microbiology and Infection* 2021;27(8):1124-30. doi: 10.1016/j.cmi.2021.03.005
85. Lemée; P-MRVDBVOBJ-M, Urbanski; RDSBCBG, Douillet; OSPGAED, et al. Does Hydroxychloroquine Prevent Symptomatic Venous Thromboembolism in Patients with Mild to Moderate COVID-19? [abstract]. *Research and Practice in Thrombosis and Haemostasis* 2023;5
86. Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). *Clinical Microbiology and Infection* 2022;28(7):1010-16. doi: 10.1016/j.cmi.2022.02.031
87. World Health Organization. Unpublished data for EPIC-SR (NCT05011513). 2021

88. Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. *The Lancet Respiratory Medicine* 2022;10(12):1160-68. doi: 10.1016/s2213-2600(22)00299-5
89. Idelsis E-MI, J P-E, Y D-R, et al. Effect of combination of interferon alpha-2b and interferon-gamma or interferon alpha- 2b alone for elimination of SARS-CoV-2 viral RNA. Preliminary results of a randomized controlled clinical trial. 2020 doi: 10.1101/2020.07.29.20164251
90. Ezer N, Belga S, Daneman N, et al. Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. *BMJ* 2021;375:e068060. doi: 10.1136/bmj-2021-068060 [published Online First: 2021/11/04]
91. Fan S, Zhen Q, Chen C, et al. Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study. *J BioX Res* 2021;4(2):53-59. doi: 10.1097/JBR.0000000000000076 [published Online First: 2021/07/14]
92. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon-lambda for the treatment of COVID-19 in outpatients: Cold Spring Harbor Laboratory, 2020.
93. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *The Lancet Respiratory Medicine* 2021;9(5):498-510. doi: 10.1016/s2213-2600(20)30566-x
94. Ferrarini A, Vacca A, Solimando AG, et al. Early administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trial. *European Journal of Clinical Investigation* 2023;53(2) doi: 10.1111/eci.13898
95. Painter WP, Sheahan T, Baric R, et al. Reduction in infectious sars-cov-2 in treatment study of covid-19 with molnupiravir. *Topics in Antiviral Medicine* 2021;29(1):304-05.
96. Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. *Science Translational Medicine* 2022;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430.
97. Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. *Science Translational Medicine* 2022;14(628) doi: 10.1126/scitranslmed.abl7430
98. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19: Cold Spring Harbor Laboratory, 2021.
99. FitzGerald R, Dickinson L, Else L, et al. SALIVA, NASAL & TEAR PK of EIDD-1931 in PATIENTS with COVID-19 RECEIVING MOLNUPIRAVIR. *Topics in Antiviral Medicine* 2022;30:39.
100. Fitzgerald R, Dickinson L, Else L, et al. Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection: Cold Spring Harbor Laboratory, 2021.

101. Fogleman C, Cohen D, Mercier A, et al. A Pilot of a Randomized Control Trial of Melatonin and Vitamin C for Mild-to-Moderate COVID-19. *The Journal of the American Board of Family Medicine* 2022;35(4):695-707. doi: 10.3122/jabfm.2022.04.210529
102. Fu W, Liu Y, Liu L, et al. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. *EClinicalMedicine* 2020;27:100547. doi: 10.1016/j.eclinm.2020.100547
103. George B, Moorthy M, Kulkarni U, et al. Single Dose of Ivermectin is not Useful in Patients with Hematological Disorders and COVID-19 Illness: A Phase II B Open Labelled Randomized Controlled Trial. *Indian Journal of Hematology and Blood Transfusion* 2022;38(4):615-22. doi: 10.1007/s12288-022-01546-w
104. Ghaderkhani S, Khaneshan AS, Salami A, et al. Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial: Research Square Platform LLC, 2020.
105. Ghaderkhani S, Khaneshan AS, Salami A, et al. Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial. *Journal of Iranian Medical Council* 2022 doi: 10.18502/jimc.v5i2.10468
106. Ghati N, Bhatnagar S, Mahendran M, et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial). *BMC Infectious Diseases* 2022;22(1) doi: 10.1186/s12879-022-07570-5
107. Ghaznavi H, Mohammadghasemipour Z, Shirvaliloo M, et al. Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients. *Inflammopharmacology* 2022;30(5):1645-57. doi: 10.1007/s10787-022-01029-4
108. Golan Y, Campos JAS, Woolson R, et al. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. *Clin Infect Dis* 2023;76(3):e10-e17. doi: 10.1093/cid/ciac712 [published Online First: 2022/09/07]
109. Gorial FI, Maulood MF, Abdulamir AS, et al. Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection. *Ann Med Surg (Lond)* 2022;77:103593. doi: 10.1016/j.amsu.2022.103593 [published Online First: 2022/04/19]
110. Hill JA, Vaca C, Mera J, et al. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial. *Open Forum Infectious Diseases* 2021;8:S806–S07. doi: https://doi.org/10.1093/ofid/ofab466.1642
111. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. *New England Journal of Medicine* 2022;386(4):305-15. doi: 10.1056/nejmoa2116846
112. Webb B, Oguchi G, Sachdeva Y, et al. SAFETY OF REMDESIVIR VS PLACEBO IN NON-HOSPITALIZED PATIENTS WITH COVID-19. *Topics in Antiviral Medicine* 2022;30(Supple 1):174.
113. Pan DZ, Odorizzi PM, Schoenichen A, et al. REMDESIVIR in AN OUTPATIENT SETTING IMPROVES BIOMARKERS for PROGRESSION of COVID-19. *Topics in Antiviral Medicine* 2022;30:175.
114. Pan DZ, Odorizzi PM, Schoenichen A, et al. Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting. *Communications Medicine* 2023;3(1) doi: 10.1038/s43856-022-00232-2

115. Brown SM, Katz MJ, Ginde AA, et al. Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. *Infectious Diseases and Therapy* 2023;12(4):1189-203. doi: 10.1007/s40121-023-00789-y
116. Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. *New England Journal of Medicine* 2021;385(5):406-15. doi: 10.1056/nejmoa2101643
117. Guzman-Esquivel J, Galvan-Salazar H, Guzman-Solorzano H, et al. Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID-19: A randomized double-blind placebo-controlled trial. *International Journal of Molecular Medicine* 2022;49(3) doi: 10.3892/ijmm.2022.5084
118. Hakamifard A, Soltani R, Maghsoudi A, et al. The effect of vitamin E and vitamin C in patients with COVID-19 pneumonia; a randomized controlled clinical trial. *Immunopathologia Persa* 2022;8(1):e80 doi: 10.34172/ipp.2022.08
119. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New England Journal of Medicine* 2022;386(15):1397-408. doi: 10.1056/nejmoa2118542
120. Hammond J, Leister-Tebbe H, Gardner A, et al. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits. *Open Forum Infectious Diseases* 2022;9:ofac492.047. doi: https://doi.org/10.1093/ofid/ofac492.047
121. Han MK, Antila M, Ficker JH, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Rheumatology* 2022;4(5):e351-e61. doi: 10.1016/s2665-9913(22)00044-3
122. Hinks TS, Cureton L, Knight R, et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial: Cold Spring Harbor Laboratory, 2021.
123. Holubar M, Subramanian A, Purington N, et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial: Cold Spring Harbor Laboratory, 2021.
124. Holubar M, Subramanian A, Purington N, et al. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. *Clin Infect Dis* 2022;75(11):1883-92. doi: 10.1093/cid/ciac312 [published Online First: 2022/04/22]
125. Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report: Cold Spring Harbor Laboratory, 2020.
126. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. *New England Journal of Medicine* 2021;384(8):693-704. doi: 10.1056/nejmoa2021436
127. Calzetta L, Aiello M, Frizzelli A, et al. Dexamethasone in Patients Hospitalized with COVID-19: Whether, When and to Whom. *Journal of Clinical Medicine* 2021;10(8):1607. doi: 10.3390/jcm10081607
128. Horby PW, Mafham M, Peto L, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: Cold Spring Harbor Laboratory, 2021.

129. Abani O, Abbas A, Abbas F, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet* 2022;399(10325):665-76. doi: 10.1016/s0140-6736(22)00163-5
130. Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet* 2020;396(10259):1345-52. doi: 10.1016/s0140-6736(20)32013-4
131. RECOVERY Collaborative Group. Lopinavir-Ritonavir in Hospitalised Patients with COVID-19: Preliminary Report from a Randomised, Controlled, Open-Label, Platform Trial. 2020 doi: http://dx.doi.org/10.2139/ssrn.3675410
132. Abaleke E, Abbas M, Abbasi S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet* 2021;397(10274):605-12. doi: 10.1016/s0140-6736(21)00149-5
133. Horby PW, Roddick A, Spata E, et al. Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial: Cold Spring Harbor Laboratory, 2020.
134. Horby PW, Emberson JR, Mafham M, et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis: Cold Spring Harbor Laboratory, 2022.
135. Hu K, Wang M, Zhao Y, et al. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. *Virol Sin* 2020;35(6):725-33. doi: 10.1007/s12250-020-00258-7 [published Online First: 2020/07/23]
136. Huang YQ, Tang SQ, Xu XL, et al. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study. *Front Pharmacol* 2020;11:1071. doi: 10.3389/fphar.2020.01071 [published Online First: 2020/08/09]
137. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* 2020;395(10238):1695-704. doi: 10.1016/S0140-6736(20)31042-4 [published Online First: 2020/05/14]
138. Husain P, Ahmed SK, Husain B. Role of doxycycline, oral steroids, and nasal steroid in treatment of anosmia due to COVID-19 with the new insights into the doxycycline activity.: Research Square Platform LLC, 2020.
139. Ikeda M, Okugawa S, Kashiwabara K, et al. Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia. *International Journal of Infectious Diseases* 2023;128:355-63. doi: 10.1016/j.ijid.2022.12.039
140. Issak ER, Amin MM. Timing of corticosteroids in non-severe non-hospitalized COVID-19 patients: open-label, two-center, randomized controlled study (TICS-COV19 study). *The Korean Journal of Internal Medicine* 2023;38(2):207-17. doi: 10.3904/kjim.2022.232
141. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19: Cold Spring Harbor Laboratory, 2020.

142. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clin Infect Dis* 2021;73(3):531-34. doi: 10.1093/cid/ciaa1176 [published Online First: 2020/08/10]
143. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial: Cold Spring Harbor Laboratory, 2020.
144. Jagannathan P, Andrews J, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial: Research Square Platform LLC, 2020.
145. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. *Nature Communications* 2021;12(1) doi: 10.1038/s41467-021-22177-1
146. Jahangirifard A, Omidi A, Sharifzadeh K, et al. The Effect of Bromelain (Anaheal) on Clinical and Para-Clinical Parameters in Hospitalized COVID-19 Patients. *ACTA MEDICA IRANICA* 2021 doi: 10.18502/acta.v59i12.8066
147. Jalal A, Aref S, Albustany D. Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial. *Indian Journal of Rheumatology* 2022;17(2) doi: 10.4103/injr.injr_264_21
148. Jardine MJ, Kotwal SS, Bassi A, et al. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. *BMJ* 2022:e072175. doi: 10.1136/bmj-2022-072175
149. Jilg N, Chew KW, Giganti MJ, et al. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. *Clin Infect Dis* 2023 doi: 10.1093/cid/ciad342 [published Online First: 2023/06/06]
150. Jilg N, Chew KW, Giganti M, et al. CAMOSTAT IS NOT EFFECTIVE for MILD-MODERATE COVID-19 in A PHASE 2 TRIAL of ACTIV-2. *Topics in Antiviral Medicine* 2022;30:41.
151. Johnston C, Brown ER, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. *EClinicalMedicine* 2021;33:100773. doi: 10.1016/j.eclinm.2021.100773
152. Kaizer AM, Shapiro NI, Wild J, et al. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. *International Journal of Infectious Diseases* 2023;128:223-29. doi: 10.1016/j.ijid.2022.12.028
153. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *New England Journal of Medicine* 2021;384(9):795-807. doi: 10.1056/nejmoa2031994
154. Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. *The Lancet Respiratory Medicine* 2021;9(12):1349-51. doi: 10.1016/s2213-2600(21)00358-1
155. Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Respiratory Medicine* 2021;9(12):1365-76. doi: 10.1016/s2213-2600(21)00384-2

156. Karolyi M, Pawelka E, Omid S, et al. Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). *Front Pharmacol* 2022;13:870493. doi: 10.3389/fphar.2022.870493 [published Online First: 2022/08/09]
157. Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. *J Antimicrob Chemother* 2020;75(11):3373-78. doi: 10.1093/jac/dkaa332 [published Online First: 2020/08/20]
158. Kasiri H, Rouhani N, Salehifar E, et al. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial. *Int Immunopharmacol* 2021;98:107871. doi: 10.1016/j.intimp.2021.107871 [published Online First: 2021/06/21]
159. Kasiri H, Ghazaiean M, Rouhani N, et al. The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial. *J Investig Med* 2023;71(2):124-31. doi: 10.1177/10815589221141815 [published Online First: 2023/01/18]
160. Kerget F, Kerget B, Aksakal A, et al. Can 2-Aticyto Complex be an Effective Agent for Recovery of The Symptoms and Enhancing Laboratory Parameters in COVID-19 Patients? *European Journal of Medical and Health Sciences* 2021;3(2):35-39. doi: 10.24018/ejmed.2021.3.2.745
161. Khavkina D, Chukhliaev P, Ruzhentsova T. The Role of SARS-CoV-2 Etiotropic Therapy in Controlling the Spread of Infection. *Epidemiology International Journal* 2021;5(1) doi: 10.23880/eij-16000185
162. Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. *J Antimicrob Chemother* 2021;76(12):3286-95. doi: 10.1093/jac/dkab318 [published Online First: 2021/08/28]
163. Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study: Cold Spring Harbor Laboratory, 2021.
164. Khoo SH, Fitzgerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. *The Lancet Infectious Diseases* 2023;23(2):183-95. doi: 10.1016/s1473-3099(22)00644-2
165. Kim MH, Elbaz J, Jilg N, et al. Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial. *Front Med (Lausanne)* 2023;10:1095828. doi: 10.3389/fmed.2023.1095828 [published Online First: 2023/03/14]
166. Kim MH, Elbaz J, Jilk N, et al. Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial. *Frontiers in medicine* 2023;10 doi: 10.3389/fmed.2023.1095828
167. Kinoshita T, Shinoda M, Nishizaki Y, et al. Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study): Cold Spring Harbor Laboratory, 2022.

168. Kishoria N, Mathur SL, Parmar V, et al. IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY. *Paripex Indian Journal of Research* 2020;9(8):50-3. doi: 10.36106/paripex
169. Kumar D, Kaimaparambil V, Chandralekha S, et al. Oral Rivaroxaban in the Prophylaxis of COVID-19 Induced Coagulopathy. *The Journal of the Association of Physicians of India* 2022;70(2)
170. World Health Organization. Unpublished data on Krishnan and Kumar trials on molnupiravir. 2021
171. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. *eClinicalMedicine* 2021;37:100959. doi: 10.1016/j.eclinm.2021.100959
172. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial. doi: http://dx.doi.org/10.2139/ssrn.3714649
173. Lakkireddy M, Gadiga SG, Malathi RD, et al. RETRACTED ARTICLE: Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease. *Scientific Reports* 2021;11(1) doi: 10.1038/s41598-021-90189-4
174. Writing Committee for the REMAP-CAP Investigators. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. *JAMA* 2023;329(14):1183-96. doi: 10.1001/jama.2023.4480
175. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. *JAMA* 2020;324(22):2292. doi: 10.1001/jama.2020.22760
176. Les I, Loureiro-Amigo J, Capdevila F, et al. Methylprednisolone Pulses in Hospitalized COVID-19 Patients Without Respiratory Failure: A Randomized Controlled Trial. *Front Med (Lausanne)* 2022;9:807981. doi: 10.3389/fmed.2022.807981 [published Online First: 2022/03/18]
177. Li Y, Xie Z, Lin W, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI): Cold Spring Harbor Laboratory, 2020.
178. Li C, Luo F, Liu C, et al. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. *Annals of Medicine* 2021;53(1):391-401. doi: 10.1080/07853890.2021.1890329
179. Li Q, Cui C, Xu F, et al. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. *Science China Life Sciences* 2021;64(4):660-63. doi: 10.1007/s11427-020-1871-4
180. Lim SCL, Hor CP, Tay KH, et al. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities. *JAMA Internal Medicine* 2022;182(4):426. doi: 10.1001/jamainternmed.2022.0189
181. Liu J, Pan X, Zhang S, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. *The Lancet Regional Health - Western Pacific* 2023;33:100694. doi: 10.1016/j.lanwpc.2023.100694

182. Lopes RD, Macedo AVS, De Barros E Silva PGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. *JAMA* 2021;325(3):254. doi: 10.1001/jama.2020.25864
183. López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. *JAMA* 2021;325(14):1426. doi: 10.1001/jama.2021.3071
184. Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. 2020 doi: 10.1101/2020.04.29.20085761
185. Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. *Eur J Pharm Sci* 2021;157:105631. doi: 10.1016/j.ejps.2020.105631 [published Online First: 2020/10/30]
186. Lowe DM, Brown L-AK, Chowdhury K, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. *PLOS Medicine* 2022;19(10):e1004120. doi: 10.1371/journal.pmed.1004120
187. Madioko BM, Rissassi J-RM, Mihigo CB, et al. Incidence of QTc interval prolongation in patients treated for covid-19 with Doubase C or Hydroxychloroquine-azithromycin at University Hospital of Kinshasa: Research Square Platform LLC, 2022.
188. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. *J Int Med Res* 2021;49(5):3000605211013550. doi: 10.1177/03000605211013550 [published Online First: 2021/05/14]
189. Marconi VC, Ramanan AV, De Bono S, et al. Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial: Cold Spring Harbor Laboratory, 2021.
190. Marcos-Jubilar M, Carmona-Torre F, Vidal R, et al. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. *Thrombosis and Haemostasis* 2022;122(02):295-99. doi: 10.1055/a-1667-7534
191. Mariani J, Antonietti L, Tajer C, et al. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: Multicentre randomized controlled clinical trial. *PLOS ONE* 2022;17(5):e0267918. doi: 10.1371/journal.pone.0267918
192. Mccarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19. *JAMA* 2023;329(4):296. doi: 10.1001/jama.2022.24100
193. Mcmahon JH, Lau JSY, Coldham A, et al. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. *eClinicalMedicine* 2022;54:101703. doi: 10.1016/j.eclinm.2022.101703
194. Mcquilten ZK, Venkatesh B, Jha V, et al. Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19. *NEJM Evidence* 2023;2(2) doi: 10.1056/evidoa2200293

195. Mirahmadizadeh A, Semati A, Heiran A, et al. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial. *Respirology* 2022;27(9):758-66. doi: 10.1111/resp.14318
196. Miyazaki T, Hasogaya N, Fukushige Y, et al. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. *Microbiology Spectrum* 2023;11(3) doi: 10.1128/spectrum.04311-22
197. Mohamed AS, Ahmad HM, Abdul-Raheem ASA, et al. Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study. *Res Social Adm Pharm* 2022;18(12):4048-55. doi: 10.1016/j.sapharm.2022.07.004 [published Online First: 2022/07/22]
198. Mohan A, Tiwari P, Suri TM, et al. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. *Journal of Infection and Chemotherapy* 2021;27(12):1743-49. doi: 10.1016/j.jiac.2021.08.021
199. Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial: Research Square Platform LLC, 2021.
200. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet Respiratory Medicine* 2021;9(2):196-206. doi: 10.1016/s2213-2600(20)30511-7
201. Moreira TG, Matos KTF, De Paula GS, et al. Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. *Front Immunol* 2021;12:709861. doi: 10.3389/fimmu.2021.709861 [published Online First: 2021/09/04]
202. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study: Cold Spring Harbor Laboratory, 2022.
203. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. *Clin Infect Dis* 2023;76(8):1403-11. doi: 10.1093/cid/ciac933 [published Online First: 2022/12/09]
204. Mukae H, Yotsuyanagi H, Ohmagari N, et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part: Cold Spring Harbor Laboratory, 2022.
205. Mukae H, Yotsuyanagi H, Ohmagari N, et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. *Antimicrob Agents Chemother* 2022;66(10):e0069722. doi: 10.1128/aac.00697-22 [published Online First: 2022/09/14]

206. Sanaki T, Baba K, Yamamoto A, et al. Investigation of Treatment-Emergent Amino Acid Substitutions in Nonstructural Protein 5 from Ph2a Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor. *Open Forum Infectious Diseases* 2022;9:S484. doi: https://doi.org/10.1093/ofid/ofac492.972
207. Murugesan H, Cs G, Nasreen HS, et al. An Evaluation of Efficacy and Safety of Tofacitinib, A JAK Inhibitor in the Management of Hospitalized Patients with Mild to Moderate COVID-19 - An Open-Label Randomized Controlled Study. *Journal of The Association of Physicians of India* 2021;69(12):11-12.
208. Naggie S. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial: Cold Spring Harbor Laboratory, 2022.
209. Naggie S. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. *Open Forum Infectious Diseases* 2022;9:ofac492.1883. doi: https://doi.org/10.1093/ofid/ofac492.1883
210. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19. *JAMA* 2022;328(16):1595. doi: 10.1001/jama.2022.18590
211. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial: Cold Spring Harbor Laboratory, 2022.
212. Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19. *JAMA* 2023;329(11):888. doi: 10.1001/jama.2023.1650
213. Sunil Naik K, Andhalkar N, Pendse S. Effect of colchicine and aspirin given together in patients with moderate COVID-19. *Contemp Clin Trials Commun* 2023;32:101070. doi: 10.1016/j.conctc.2023.101070 [published Online First: 2023/01/31]
214. Nimitvilai S, Suputtamongkol Y, Poolvivatchaikarn U, et al. A Randomized Controlled Trial of Combined Ivermectin and Zinc Sulfate versus Combined Hydroxychloroquine, Darunavir/Ritonavir, and Zinc Sulfate among Adult Patients with Asymptomatic or Mild Coronavirus-19 Infection. *J Glob Infect Dis* 2022;14(2):69-74. doi: 10.4103/jgid.jgid_281_21 [published Online First: 2022/08/02]
215. Ogbuagu O, Tashima KT, Gunthard HF, et al. Acute Kidney Injury In Patients With Moderate COVID-19 treated With RDV Versus SoC. Conference on Retroviruses and Opportunistic Infections 2021
216. Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection. *JAMA* 2021;326(6):490. doi: 10.1001/jama.2021.11517
217. Omrani AS, Pathan SA, Thomas SA, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. *EClinicalMedicine* 2020;29-30:100645. doi: 10.1016/j.eclinm.2020.100645
218. Önal H, Arslan B, Üçüncü Ergun N, et al. Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial. *TURKISH JOURNAL OF BIOLOGY* 2021;45(SI-1):518-29. doi: 10.3906/biy-2104-16

219. Singh AK, Singh A, Singh R, et al. Molnupiravir in COVID-19: A systematic review of literature. *Diabetes Metab Syndr* 2021;15(6):102329. doi: 10.1016/j.dsx.2021.102329 [published Online First: 2021/11/07]
220. O'Halloran JA, Anstrom KJ, Kedar E, et al. LB1531B. Administration of the TNF-alpha inhibitor, infliximab, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial. *Open Forum Infectious Diseases* 2023;9(Supplement_2) doi: 10.1093/ofid/ofac492.1885
221. O'Halloran JA, Kedar E, Anstrom KJ, et al. Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19. 2022 doi: 10.1101/2022.09.22.22280245
222. Butler CC, Dorward J, Yu L-M, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet* 2021;397(10279):1063-74. doi: 10.1016/s0140-6736(21)00461-x
223. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results: Cold Spring Harbor Laboratory, 2020.
224. WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *New England Journal of Medicine* 2021;384(6):497-511. doi: 10.1056/nejmoa2023184
225. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. *The Lancet* 2022;399(10339):1941-53. doi: 10.1016/s0140-6736(22)00519-0
226. Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. *Nature Communications* 2022;13(1) doi: 10.1038/s41467-022-33825-5
227. Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of Remdesivir on Recovery, Quality of Life, and Long-COVID Symptoms One Year after Hospitalization for COVID-19 Infection: A Randomized Controlled SOLIDARITY Finland Trial. *Open Forum Infectious Diseases* 2022;9:ofac492.965. doi: https://doi.org/10.1093/ofid/ofac492.965
228. Panda PK, Singh BO, Moirangthem B, et al. Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. *Clinical Pharmacology: Advances and Applications* 2021;Volume 13:185-95. doi: 10.2147/cpaa.s325083
229. Pandit A, Bhalani N, Bhushan BLS, et al. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. *International Journal of Infectious Diseases* 2021;105:516-21. doi: 10.1016/j.ijid.2021.03.015
230. Parienti J-J, Prazuck T, Peyro-Saint-Paul L, et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. *eClinicalMedicine* 2021;38:100993. doi: 10.1016/j.eclinm.2021.100993

231. Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, et al. Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID). *International Journal of General Medicine* 2021;Volume 14:5517-26. doi: 10.2147/ijgm.s329810
232. Piazza G, Spyropoulos AC, Hsia J, et al. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. *Circulation* 2023;147(25):1891-901. doi: 10.1161/circulationaha.123.063901
233. Plasse TF, Delgado B, Potts J, et al. A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19. *International Journal of Infectious Diseases* 2023;128:148-56. doi: 10.1016/j.ijid.2022.12.003
234. Pott-Junior H, Paoliello MMB, Miguel AQC, et al. Use of ivermectin in the treatment of Covid-19: A pilot trial. *Toxicol Rep* 2021;8:505-10. doi: 10.1016/j.toxrep.2021.03.003 [published Online First: 2021/03/17]
235. Pourdowlat G, Saghafi F, Mozafari A, et al. Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial. *Phytotherapy Research* 2022;36(2):891-98. doi: 10.1002/ptr.7319
236. Prabowo NA and Apriningsih H. Colchicine reduces the degree of inflammation in COVID-19 patients. *IOP Conference Series: Earth and Environmental Science* 2021;824:012087. doi: 10.1088/1755-1315/824/1/012087
237. Purwati, Budiono, Rachman BE, et al. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo. *Biochemistry Research International* 2021;2021:1-12. doi: 10.1155/2021/6685921
238. Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. *eClinicalMedicine* 2021;37:100957. doi: 10.1016/j.eclinm.2021.100957
239. Michael A. Puskarich M, MS (corresponding), Nathan W. Cummins, MD, , Nicholas E. Ingraham M, David A. Wacker M, PhD, , et al. Effect of losartan on symptomatic outpatients with COVID-19: A randomized clinical trial, 2021.
240. Rahman SMA, Kabir A, Abdullah ABM, et al. Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trial. *Clin Infect Pract* 2022;15:100145. doi: 10.1016/j.clinpr.2022.100145 [published Online First: 2022/05/18]
241. Rahman M, Datta PK, Islam K, et al. Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial. *PLOS ONE* 2022;17(11):e0277790. doi: 10.1371/journal.pone.0277790
242. Ramachandran R, Bhosale V, Reddy H, et al. Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. *International Journal of Infectious Diseases* 2022;115:62-69. doi: 10.1016/j.ijid.2021.11.025
243. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial: Cold Spring Harbor Laboratory, 2021.

244. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *The Lancet Respiratory Medicine* 2021;9(7):763-72. doi: 10.1016/s2213-2600(21)00160-0
245. Rashad A, Nafady A, Hassan MH, et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. *Scientific Reports* 2021;11(1) doi: 10.1038/s41598-021-95900-z
246. Rashid RA, Zgair A, Al-Ani RM. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. *Am J Otolaryngol* 2021;42(5):103033. doi: 10.1016/j.amjoto.2021.103033 [published Online First: 2021/04/12]
247. Rastogi A, Bhansali A, Khare N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad Med J* 2022;98(1156):87-90. doi: 10.1136/postgradmedj-2020-139065 [published Online First: 2020/11/14]
248. Ravikirti, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial: Cold Spring Harbor Laboratory, 2021.
249. Ravikirti, Roy R, Pattadar C, et al. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. *Journal of Pharmacy & Pharmaceutical Sciences* 2021;24:343-50. doi: 10.18433/jpps32105
250. Ried K, Binjemain T, Sali A. Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial. *Cureus* 2021 doi: 10.7759/cureus.19902
251. World Health Organization. Unpublished data on STOP-COVID-2 trial (NCT04668950), 2021.
252. Reis G, Moreira Silva EADS, Medeiros Silva DC, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. *JAMA Network Open* 2021;4(4):e216468. doi: 10.1001/jamanetworkopen.2021.6468
253. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *The Lancet Global Health* 2022;10(1):e42-e51. doi: 10.1016/s2214-109x(21)00448-4
254. Reis G, Dos Santos Moreira Silva EA, Silva DCM, et al. Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial: Cold Spring Harbor Laboratory, 2021.
255. Reis G, Silva EASM, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. *New England Journal of Medicine* 2022;386(18):1721-31. doi: 10.1056/nejmoa2115869

256. Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial. *Ann Intern Med* 2023;176(5):667-75. doi: 10.7326/M22-3305 [published Online First: 2023/04/18]
257. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. *New England Journal of Medicine* 2023;388(6):518-28. doi: 10.1056/nejmoa2209760
258. Ren Z, Luo H, Yu Z, et al. A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. *Adv Sci (Weinh)* 2020;7(19):e2001435. doi: 10.1002/advs.202001435 [published Online First: 2020/10/01]
259. Rezai MS, Ahangarkani F, Hill A, et al. Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. *Front Med (Lausanne)* 2022;9:919708. doi: 10.3389/fmed.2022.919708 [published Online First: 2022/07/06]
260. Rodrigues C, Freitas-Santos RS, Levi JE, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. *Int J Antimicrob Agents* 2021;58(5):106428. doi: 10.1016/j.ijantimicag.2021.106428 [published Online First: 2021/08/29]
261. Roy-García IA, Moreno-Noguez M, Rivas-Ruiz R, et al. "Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19: Randomized, double blind, Placebo controlled trial": Cold Spring Harbor Laboratory, 2022.
262. Ruzhentsova TA OR, Soluyanova TN, Dmitrikova EP, Mustafaev DM, Pokrovskiy KA, Markova TN, Rusanova MG, Kostina NE, Agafina AS, Brook YF, Bronov OY, Shults EI, Filon OV. Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19. *9 Am J Transl Res* 2021;13:12575-87.
263. Sabico S, Enani MA, Sheshah E, et al. Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial. *Nutrients* 2021;13(7):2170. doi: 10.3390/nu13072170
264. Sarojvisut P, Apisarnthanarak A, Jantarathaneewat K, et al. An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand. *Infection & Chemotherapy* 2023;55(1):50. doi: 10.3947/ic.2022.0127
265. Sauša S, Kistkins S, Čirkova O, et al. Rapid elevation of vitamin D level reduces C-reactive protein level in COVID-19 patients with vitamin D insufficiency. 2022 doi: 10.20944/preprints202207.0342.v1
266. Schilling WHK, Jittamala P, Watson JA, et al. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). *Elife* 2023;12 doi: 10.7554/eLife.83201 [published Online First: 2023/02/22]
267. Schilling WH, Jittamala P, Watson JA, et al. Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19: Cold Spring Harbor Laboratory, 2022.

268. Biber A, Mandelboim M, Harmelin G, et al. Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial: Cold Spring Harbor Laboratory, 2021.
269. Biber A, Harmelin G, Lev D, et al. The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial. *International Journal of Infectious Diseases* 2022;122:733-40. doi: 10.1016/j.ijid.2022.07.003
270. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. *CMAJ Open* 2021;9(2):E693-E702. doi: 10.9778/cmajo.20210069
271. Ganesh A, Rosentreter R, Chen Y, et al. Frequency, Persistence, and Patient-reported Outcomes of Neurological Symptoms in Mild COVID-19: Results from the ALBERTA HOPE COVID-19 Trial (P1-1.Virtual). 2022
272. Seo H, Kim H, Bae S, et al. Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial. *Infection & Chemotherapy* 2022;54(1):102. doi: 10.3947/ic.2021.0142
273. Seo H KH, Bae S, Park S, Chung H, Sung HS, Jung J, Kim MJ, Kim SH, Lee SO, Choi SH, Kim YS, Son KY, Chong YP. CORRECTION: Erratum: Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial. *Infection & Chemotherapy* 2022;54(2):391. doi: 10.3947/ic.2022.0300
274. Sharma A, Elharram M, Afilalo J, et al. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. *Am Heart J* 2022;247:76-89. doi: 10.1016/j.ahj.2022.01.015 [published Online First: 2022/02/11]
275. Shebley M, Wang S, Ali I, et al. Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19. *Pharmacology Research & Perspectives* 2023;11(1) doi: 10.1002/prp2.1036
276. Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infectious Diseases and Therapy* 2021;10(4):2489-509. doi: 10.1007/s40121-021-00517-4
277. Sholzberg M, Tang GH, Rahhal H, et al. Heparin for Moderately Ill Patients with Covid-19: Cold Spring Harbor Laboratory, 2021.
278. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. *BMJ* 2021:n2400. doi: 10.1136/bmj.n2400
279. Sinha S, N K, Suram VK, et al. Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India. *Cureus* 2022 doi: 10.7759/cureus.31508

280. Sirijatuphat R, Manosuthi W, Niyomnaitham S, et al. Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study: Cold Spring Harbor Laboratory, 2022.
281. Sirijatuphat R, Manosuthi W, Niyomnaitham S, et al. Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. *Emerging Microbes & Infections* 2022;11(1):2197-206. doi: 10.1080/22221751.2022.2117092
282. Skendelas JP, Phan D, Caputo V, et al. Novel CCR5 Antagonist for the Treatment of Mild-Moderate COVID-19 Infection after Lung Transplant. *The Journal of Heart and Lung Transplantation* 2021;40(4):S315. doi: 10.1016/j.healun.2021.01.891
283. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. *Ann Intern Med* 2020;173(8):623-31. doi: 10.7326/M20-4207 [published Online First: 2020/07/17]
284. Sobngwi E, Zemsi S, Guewo-Fokeng M, et al. Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV): Cold Spring Harbor Laboratory, 2021.
285. Song J-Y, Yoon J-G, Seo Y-B, et al. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. *Journal of Clinical Medicine* 2021;10(16):3545. doi: 10.3390/jcm10163545
286. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. *JAMA* 2020;324(11):1048. doi: 10.1001/jama.2020.16349
287. Adam M. Spivak BJB, Tom Greene RH, Cody S. Olsen JB, Raj Srivastava,, et al. A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. *Micriobiology Spectrum* 2023;11(2):e0467422. doi: 10.1128/spectrum.04674-22.
288. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* 2020:m1849. doi: 10.1136/bmj.m1849
289. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial: Cold Spring Harbor Laboratory, 2020.
290. Tardif J-C, Bouabdallaoui N, L'Allier PL, et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19: Cold Spring Harbor Laboratory, 2021.
291. Tehrani S, Yadegarynia D, Bagherzade A, et al. Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial. *Mediterranean Journal of Infection Microbes and Antimicrobials* 2022;11(1) doi: 10.4274/mjima.galenos.2022.2022.30
292. Terada-Hirashima J, Suzuki M, Tsujimoto Y, et al. Impact of inhaled ciclesonide on asymptomatic or mild COVID-19: A randomized trial. *Drug Discov Ther* 2022;16(5):225-32. doi: 10.5582/ddt.2022.01068 [published Online First: 2022/10/27]
293. Thomas S, Patel D, Bittel B, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection. *JAMA Network Open* 2021;4(2):e210369. doi: 10.1001/jamanetworkopen.2021.0369

294. Tobback E, Degroote S, Buysse S, et al. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. *International Journal of Infectious Diseases* 2022;122:628-35. doi: 10.1016/j.ijid.2022.06.054
295. Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. *Int J Infect Dis* 2021;103:62-71. doi: 10.1016/j.ijid.2020.11.142 [published Online First: 2020/11/20]
296. Vaezi A, Salmasi M, Soltaninejad F, et al. Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. *Advances in Respiratory Medicine* 2023;91(1):18-25. doi: 10.3390/arm91010004
297. Vaira LA, Hopkins C, Petrocelli M, et al. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients. *Rhinology* 2021;59(1):21-25. doi: 10.4193/Rhin20.515 [published Online First: 2020/12/09]
298. Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. *BMC Infectious Diseases* 2021;21(1) doi: 10.1186/s12879-021-06348-5
299. World Health Organization. Unpublished data on Vyas molnupiravir trial (CTRI/2021/08/035424). 2021
300. Wada T, Hibino M, Aono H, et al. Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial. *Front Med (Lausanne)* 2023;10:1139046. doi: 10.3389/fmed.2023.1139046 [published Online First: 2023/06/07]
301. Wang M, Zhao Y, Hu W, et al. Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial. *Clin Infect Dis* 2021;73(11):e4012-e19. doi: 10.1093/cid/ciaa1417 [published Online First: 2020/09/22]
302. Yadegarinia D, Tehrani S, Abolghasemi S, et al. Evaluation of the Efficacy of Arbidol in Comparison with the Standard Treatment Regimen of Hospitalized Patients with Covid-19: A Randomized Clinical Trial. *Archives of Clinical Infectious Diseases* 2020;15(5) doi: 10.5812/archcid.106622
303. Xudong Yang YW, Yongping Liu, Lei Shang, Zhijian Cheng, Liping Fang, Jian Zhang, Yifan Feng, Kuiwei Zhang, Shanjiao Jiang, Xijing He. Traditional Chinese medicine together with high-dose vitamin C improves the therapeutic effect of western medicine against COVID-19. *American Journal of Translational Research* 2022;14(1):501-10.
304. Vityala Y, Tugolbai T, Melis Sholpanbai U, et al. Efficacy of umifenovir in the treatment of mild and moderate COVID-19 patients. *International Journal of Research in Pharmaceutical Sciences* 2020;11(SPL1):506-09. doi: 10.26452/ijrps.v11iSPL1.2839
305. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial: Cold Spring Harbor Laboratory, 2021.

306. Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet* 2021;398(10303):843-55. doi: 10.1016/s0140-6736(21)01744-x
307. Zhao H, Zhang C, Zhu Q, et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. *Int Immunopharmacol* 2021;97:107702. doi: 10.1016/j.intimp.2021.107702 [published Online First: 2021/05/01]
308. Zhao J, Zhang J, Jin Y, et al. A trial of arbidol hydrochloride in adults with COVID-19. *Chin Med J (Engl)* 2022;135(13):1531-8. doi: 10.1097/CM9.0000000000002104 [published Online First: 2022/07/14]
309. Zheng F, Zhou Y, Zhou Z, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. *Int J Infect Dis* 2020;99:84-91. doi: 10.1016/j.ijid.2020.07.053 [published Online First: 2020/08/08]
310. Zheng F, Zhou Y, Zhou Z, et al. A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19. 2020 doi: 10.1101/2020.04.24.20077735
311. Zhuravel SV, Khmelnitskiy OK, Burlaka OO, et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. *eClinicalMedicine* 2021;41:101169. doi: 10.1016/j.eclinm.2021.101169
312. Zou R, Peng L, Shu D, et al. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. *Front Pharmacol* 2022;13:939573. doi: 10.3389/fphar.2022.939573 [published Online First: 2022/07/06]
313. Da Silva Santos PS, Da Fonseca Orcina B, Machado RRG, et al. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial. *Scientific Reports* 2021;11(1) doi: 10.1038/s41598-021-99013-5
314. Rocha CDL, Cid-Lopez MA, Venegas-Lopez BI, et al. Ivermectin compared with placebo in the clinical evolution of Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial: Research Square Platform LLC, 2022.
315. De La Rocha C, Cid-López MA, Venegas-López BI, et al. Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial. *BMC Infectious Diseases* 2022;22(1) doi: 10.1186/s12879-022-07890-6

Description of Studies Excluded at Full-Text Stage
Studies excluded at full-text screening stage (n=1476)

This table does not list prophylaxis or antiviral antibody and cellular treatment studies, which are included in separate published network meta-analyses. References are available upon request.

Study	Title	Reason for Exclusion
Abaluck 2021	Normalizing community mask-wearing: a cluster randomized trial in Bangladesh	Psychological and educational
Abarca 2022	Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial	Vaccine
Abdelalim 2021	Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial	Not exposed to or diagnosed COVID-19
Abdelazim 2022	The effect of intra-nasal tetra sodium pyrophosphate on decreasing elevated nasal calcium and improving olfactory function post COVID-19: a randomized controlled trial.	Not exposed to or diagnosed COVID-19
AbdiNaficy 2023	No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial	Vaccine
Abhishek 2022	Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.	Not exposed to or diagnosed COVID-19
Abhyankar 2023	The Efficacy and Safety of ImusilÂ® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study.	Traditional Chinese medicine
AboElNaga 2022	The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia	Not exposed to or diagnosed COVID-19
Abolghasemi 2020	Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study	Not a randomized trial
Abolghasemi 2021	Impact of time and mechanical ventilation on convalescent plasma in severe/critically ill COVID-19 patients	Not a randomized trial
Abou-Arab 2021	Microvascular flow alterations in critically ill COVID-19 patients: A prospective study.	Not a randomized trial
Abou-Arab 2022	Inhaled steroids improve recovery in community patients with COVID-19	Not a randomized trial
Abu-Raddad 2021	Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.	Not a randomized trial
Acosta-Ampudia 2021	COVID-19 convalescent plasma composition and immunological effects in severe patients	Not a randomized trial
AdelMehraban 2022	Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial	Traditional Chinese medicine
Adler 2022	Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-simile study)	Traditional Chinese medicine
Adly 2021	Telemanagement of Home-Isolated COVID-19 Patients Using Oxygen Therapy With Noninvasive Positive Pressure Ventilation and Physical Therapy Techniques: Randomized Clinical Trial.	Oxygen delivery

Agung Prabowo 2021	Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients	Randomized trial with no results
Agusti 2021	Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19	Not a randomized trial
Ahi 2022	Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial.	Vaccine
Ahmad 2023	Effect of diaphragm manual release versus conventional breathing exercises and prone positioning on physical functional performance in women with COVID-19: A randomized trial.	Exercise or rehabilitation
Ahmadpour 2022	Efficacy of olive leaves extract on the outcomes of hospitalized covid-19 patients: A randomized, triple-blinded clinical trial.	Nutrition and supplements
Ahmed 2021	ROLE OF INTERLEUKIN--6 AND PROCALCITONIN AS INFLAMMATORY BIOMARKERS IN EVALUATING COVID--19 DISEASE SEVERITY ON HRCT CHEST-- AN EXPERIENCE AT CMH QUETTA	Not a randomized trial
Ahn 2022	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults	Vaccine
Ai 2020	Effect of Integrated Traditional Chinese and Western Medicine on T Lymphocyte Subsets of Patients with Normal Type of COVID-19	Traditional Chinese medicine
Ai 2020	Therapeutic effect of integrated traditional Chinese and western medicine on COVID-19 in Guangzhou	Traditional Chinese medicine
Ai 2022	Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study.	Vaccine
Aisa 2022	The effect of edaravone on patients with moderate covid-19: a non-randomized single-center clinical trial	Not a randomized trial
Akahata 2022	Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study (preprint)	Vaccine
Akahata 2023	Safety and Immunogenicity of SARS-CoV-2 Self-Amplifying RNA Vaccine Expressing Anchored RBD: A Randomised, Observer-Blind, Phase 1 Study	Vaccine
Akselim 2022	The Effects of Early Pulmonary Rehabilitation and Diaphragm Kinesiotaping on Diaphragm Muscle Thickness in Patients with Severe COVID-19 Pneumonia in the Intensive Care Unit (preprint)	Not a randomized trial
Alabama 2020	Trial of Hydroxychloroquine In Covid-19 Kinetics	Randomized trial with no results
Alamdari 2020	Application of methylene blue -vitamin C - N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. (Special Issue: Therapeutic targets and pharmacological treatment of COVID-19.)	Not a randomized trial
Alawna 2022	An integrated intervention combining cognitive-behavioural stress management and progressive muscle relaxation improves immune biomarkers and reduces covid-19 severity and progression in patients with covid-19: A randomized control trial	Duplicate
Alawna 2022	An Integrated Intervention Combining CBSM and Progressive Muscle Relaxation Improves Immune Biomarkers and Reduces COVID-19 Severity and Progression in Patients with COVID-19: A Randomized Control Trial.	Exercise or rehabilitation
Albisinni 2021	Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.	Not a randomized trial

Aleem 2021	Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness	Not a randomized trial
Alemanno 2021	COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience.	Not a randomized trial
Al-Haidari 2021	Clinical trial of black seeds against covid â€“ 19 in Kirkuk city/ Iraq	Traditional Chinese medicine
AlHashim 2023	Comparison of Noninvasive Mechanical Ventilation With High-Flow Nasal Cannula, Face-Mask, and Helmet in Hypoxemic Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial.	Oxygen delivery
Alhazzani 2022	Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial.	Oxygen delivery
Ali 2021	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents.	Vaccine
Ali 2023	Impact of Active Cycle of Breathing Technique on Selected Pulmonary Outcomes in Post-COVID Syndrome Patients	Exercise or rehabilitation
Alipour 2022	Acupuncture or cupping plus standard care versus standard care in moderate to severe COVID-19 patients: An assessor-blinded, randomized, controlled trial.	Others
AlKaabi 2021	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial	Vaccine
AlKaabi 2021	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.	Vaccine
AlKaabi 2021	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsA Randomized Clinical Trial: The Journal of the American Medical Association	Vaccine
AlKaabi 2023	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi	Vaccine
Al-Kuraishy 2021	Impact of Sitagliptin in Non-Diabetic Covid-19 Patients.	Not a randomized trial
Almaghlouth 2021	THE USE OF SINGLE THERAPY WITH TOCILIZUMAB VERSUS COMBINATION THERAPY WITH REMDESIVIR IN SARS-COV-2 PATIENTS IN EL PASO TEXAS	Duplicate
Al-Sadawi 2020	Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval	Not a randomized trial
Alsan 2020	Comparison of Knowledge and Information-Seeking Behavior After General COVID-19 Public Health Messages and Messages Tailored for Black and Latinx Communities : A Randomized Controlled Trial.	Not exposed to or diagnosed COVID-19
AlShehry 2021	Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia	Not a randomized trial
AlShehry 2021	Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia (vol 9, pg 16, 2021)	Not a randomized trial
Alsuwaidan 2021	The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study	Not a randomized trial
Altuntas 2021	Convalescent plasma therapy in patients with COVID-19	Not a randomized trial
Alvarado-SÃ¡nchez 2022	Effect of mesenchymal stem cell transplantation compared with placebo on mortality in patients with severe COVID-19: A potential treatment	Not a randomized trial
Alvarez 2020	Home Nitric Oxide Therapy for COVID-19.	Not a randomized trial
Alves 2023	Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.	Vaccine

An 2021	Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial.	Traditional Chinese medicine
An 2022	Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial	Not exposed to or diagnosed COVID-19
An 2022	Ludangshen Oral Liquid for Treatment of Convalescent COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial (preprint)	Not exposed to or diagnosed COVID-19
Anand 2022	EFFICACY OF YOGA-BASED BREATHING INTERVENTION IN COVID-19 POSITIVE, POST-COVID AND HEALTH CARE WORKERS: A RANDOMIZED CLINICAL TRIAL	Exercise or rehabilitation
Anderson 2020	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	Vaccine
Andrani 2020	Effectiveness of helmet CPAP to reduce intubation and mortality rate in patients with COVID-19	Not a randomized trial
Añez 2022	Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial (preprint)	Vaccine
Anez 2023	Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico	Vaccine
Añez 2023	Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.	Vaccine
Ankrum 2020	Can cell therapies halt cytokine storm in severe COVID-19 patients?	Not a randomized trial
Anonymous 2022	Molnupiravir for treatment of COVID-19	Not a randomized trial
Anonymous 2022	Paxlovid for treatment of COVID-19	Not a randomized trial
Anonymous 2022	Molnupiravir pour traiter le Covidâ€‘19	Not a randomized trial
AntoniaAnna 2021	Candesartan as a tentative treatment for COVID-19: a prospective non-randomized open-label study. (Special Issue: Coronavirus (COVID-19) collection.)	Not a randomized trial
Arabi 2022	Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial	Oxygen delivery
Arabi 2022	Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial.	Randomized trial with no results
Arabi 2023	Long-term outcomes of patients with COVID-19 treated with helmet noninvasive ventilation or usual respiratory support: follow-up study of the Helmet-COVID randomized clinical trial.	Oxygen delivery
Aref 2022	Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia	Not exposed to or diagnosed COVID-19
Arends 2022	Antiviral Effects of Voclosporin on SARS-CoV-2 in Immunocompromised Kidney Patients	Others
Arribas 2020	Impact of concomitant hydroxychloroquine use on safety and efficacy of remdesivir in moderate COVID-19 patients	Not a randomized trial

Arrieta 2021	Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.	Not a randomized trial
ArturoChang-Monteagudo 2021	A single dose of SARS CoV 2 FINLAY FR 1A dimeric RBD recombinant vaccine enhances neutralization response in COVID19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial	Vaccine
ArvindChopra 2021	Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial	Traditional Chinese medicine
Aryan 2022	Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trial.	Traditional Chinese medicine
Asano 2021	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: A double-blind, randomized controlled phase 1/2 trial	Vaccine
Aschieri 2020	Hospital mortality and safety of therapeutic vs. prophylactic doses of low molecular weight heparin in COVID-19 patients	Not a randomized trial
Ashraf 2022	Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multicenter placebo-controlled randomized clinical trial.	Nutrition and supplements
Assantachai 2023	Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.	Vaccine
AssistancePubliqueâ€“HÃ´pitauxde Paris(AP-HP) 2023	Immunogenicity and reactogenicity of the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi) compared to a bivalent mRNA vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in adults previously vaccinated with at least 3 d	Randomized trial with no results
Ataniyazov 2022	The effectiveness of anticoagulant therapy in COVID-19 associated ischemic stroke	Not a randomized trial
AteaPharmaceuticals 2023	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19	Randomized trial with no results
Athanasiou 2022	Sleep contribution to immunity response after vaccination against SARS-CoV-2	Others
AtleFretheim 2022	Glasses Against transmission of SARS-CoV-2 in the community (GLASSY): a pragmatic randomized trial	Personal protective equipment
Atmar 2022	Homologous and Heterologous Covid-19 Booster Vaccinations.	Vaccine
Aurer 2022	EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES â€“ A STUDY OF KROHEM	Not a randomized trial
Avdeev 2021	Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.	Not a randomized trial
Avdeev 2021	N-acetylcysteine for the treatment of COVID-19 among hospitalized patients	Not a randomized trial
Awasthi 2021	Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients	Not a randomized trial
Ayerdi 2020	Preventive efficacy of tenofovir/emtricitabine against SARS-CoV-2 among PREP users	Not a randomized trial
Ayub 2022	Clarithromycin in Post COVID-19 Organizing pneumonia	Not a randomized trial
Azhar 2020	Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT	Randomized trial with no results
Azimi 2022	The Efficacy of Hot Footbath in Hospitalized COVID-19 Patients: An Open-Label Randomized Controlled Trial	Exercise or rehabilitation

Azimov 2022	Anticoagulant Therapy in Cerebral Venous Sinuses Thrombosis Prevention among Patients with Severe Covid-19	Not exposed to or diagnosed COVID-19
Babamahmoodi 2021	Effect of a herbal medicine containing Satureja hortensis L., Hypericum perforatum L. and foeniculum vulgare L. on patients with COVID-19 infection	Traditional Chinese medicine
Backer 2021	A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.	Not exposed to or diagnosed COVID-19
Baden 2020	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.	Vaccine
Badran 2022	A pilot randomized controlled trial of supervised, at-home, self-administered transcutaneous auricular vagus nerve stimulation (taVNS) to manage long COVID symptoms	Not exposed to or diagnosed COVID-19
Badran 2022	A pilot randomized controlled trial of supervised, at-home, self-administered transcutaneous auricular vagus nerve stimulation (taVNS) to manage long COVID symptoms (preprint)	Not exposed to or diagnosed COVID-19
BaiyaPhytopharm Co 2023	Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19	Randomized trial with no results
Bakhshaliyev 2021	The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.	Not a randomized trial
Balint 2021	A randomized clinical trial to stimulate the cholinergic anti-inflammatory pathway in patients with moderate COVID-19-pneumonia using a slow-paced breathing technique (preprint)	Exercise or rehabilitation
Balint 2021	A randomized clinical trial to stimulate the cholinergic anti-inflammatory pathway in patients with moderate COVID-19-pneumonia using a slow-paced breathing technique	Oxygen delivery
Balint 2022	A randomized clinical trial to stimulate the cholinergic anti-inflammatory pathway in patients with moderate COVID-19-pneumonia using a slow-paced breathing technique.	Exercise or rehabilitation
Ball 2021	Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia.	Not a randomized trial
Banki 2022	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.	Vaccine
Bao 2020	Successful treatment of patients severely ill with COVID-19	Not a randomized trial
Barati 2023	Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial.	Traditional Chinese medicine
Barda 2023	Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines; randomized trial, 3Â months follow-up.	Vaccine
Bargahi 2022	Effect of Balloon-Blowing on Dyspnea and Oxygenation in Hospitalized COVID-19 Patients: A Pilot Study	Exercise or rehabilitation
Bar-Or 2022	Immune response following mRNA COVID-19 vaccination in patients with multiple sclerosis treated with the Bruton's tyrosine kinase inhibitor evobrutinib	Not a randomized trial
Barrett 2021	Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	Vaccine
BarzinTond 2022	Inflawell R improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial	Traditional Chinese medicine

Bath 2022	Dietary nitrate supplementation for preventing and reducing the severity of winter infections, including COVID-19, in care homes (BEET-Winter): a randomised placebo-controlled feasibility trial.	Nutrition and supplements
Bauer 2022	Randomized controlled phase III trial of C5a specific vilobelimab in mechanically ventilated patients with COVID-19	Inaccessible full text
Bautin 2020	Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia	Not a randomized trial
Bazdyrev 2022	Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial (preprint)	Not exposed to or diagnosed COVID-19
Beaugrand 2022	Children's sleep, a protective factor from acute periods of stress: a COVID confinement experience	Not a randomized trial
Beccacece 2022	Re: 'Remdesivir for the Treatment of COVID-19' by Lee et al	Not a randomized trial
BeijingBorenHospital 2023	Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Malignancies Who Are Persistently Positive for COVID-19	Randomized trial with no results
BeijingDitanHospital 2022	A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19	Randomized trial with no results
BeijingDitanHospital 2022	A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2	Randomized trial with no results
BeijingTiantanHospital 2023	Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19	Randomized trial with no results
BelenguerMuncharaz 2020	Effectiveness of non-invasive ventilation in intensive care unit admitted patients due to SARS-CoV-2 pneumonia	Not a randomized trial
Benenson 2021	BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.	Not a randomized trial
Beni-SuefUniversity 2022	Effect of Diaphragmatic Strengthening Exercises on Diaphragm Muscle Function in Patients With Post Covid-19 Syndrome.	Randomized trial with no results
Beni-SuefUniversity 2023	Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial	Randomized trial with no results
Benotmane 2022	Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients (preprint)	Not a randomized trial
Bentur 2021	Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate â€“ A Potential Treatment for COVID-19	Not exposed to or diagnosed COVID-19
Berger 2022	COVID-19 outcomes in fingolimod- or siponimod - treated patients: clinical trial and post marketing cases	Not a randomized trial
Bergman 2021	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial	Not a randomized trial
BhagwatGunale 2023	A Phase 2/3 observer-blind, randomized, controlled study to determine the safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine in Indian children and adolescents aged 2 to 17 years (preprint)	Vaccine

bhardwaj 2021	Efficacy and Safety of Ayurveda Intervention (AYUSH 64) as add-on therapy for patients with COVID-19 infections â€“ An open labelled, Parallel Group, Randomized controlled clinical trial	Traditional Chinese medicine
Bhat 2023	Effect of Calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial.	Not a randomized trial
Bian 2020	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	Not a randomized trial
Bian 2021	Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.	Not a randomized trial
Bihariesingh-Sanchit 2022	Reduced mortality among COVID-19 ICU patients after treatment with HemoClear convalescent plasma in Suriname (preprint)	Not a randomized trial
Bikdeli 2022	In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.	Not a randomized trial
Bilge 2022	The Effect of Hydroxychloroquine On Ventricular Repolarization Parameters Jtc And Jtpc Intervals In Patients With Covid-19	Not a randomized trial
BinAbdulrahman 2022	The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial	Nutrition and supplements
Biosciences 2020	Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19	Randomized trial with no results
BiotronLimited 2023	A study of the safety and efficacy of 7 days treatment with BIT225 in patients with COVID-19, compared to placebo, including measurement of antiviral activity, clinical recovery and immune biomarkers.	Randomized trial with no results
Blair 2022	Nirmatrelvir plus ritonavir in COVID-19: a profile of its use	Not a randomized trial
Blossey 2022	VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical study.	Not exposed to or diagnosed COVID-19
Blossey 2023	VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study.	Vaccine
Boesing 2022	Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial	Randomized trial with no results
Bologna 2022	Clinical Study on the Efficacy and Safety of Arginine Administered Orally in Association with Other Active Ingredients for the Prevention and Treatment of Sarcopenia in Patients with COVID-19-Related Pneumonia, Hospitalized in a Sub-Intensive Care Unit	Not a randomized trial
Bologna 2022	Clinical study on the efficacy and safety of arginine administered orally in association with other active ingredients for the prevention and treatment of sarcopenia in patients with COVID-19-related pneumonia	Not a randomized trial
Bonelli 2022	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.	Vaccine
Bonifácio 2021	Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. Standard of care for the treatment of hospitalized patients with COVID-19: Preliminary results of a randomized clinical trial (struck: Survival trial using cytokine inhibitors)	Inaccessible full text

Borobia 2021	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial	Vaccine
Borujerdi 2022	Effects of Iranian Polyherbal Syrup (Zufa syrup) on oxygen saturation and clinical symptoms in suspected patients with COVID-19: a triple-blinded, randomized, placebo-controlled trial	Nutrition and supplements
Bosaeed 2021	Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.	Randomized trial with no results
Bosaeed 2021	Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT): An Open-Label, Multicentre, Randomised, Controlled Trial (preprint)	Removed from preprint server
Bosch 2021	Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19	Not a randomized trial
Boyko 2020	The first experience with Angiovit in the combination treatment of acute COVID-19 infection	Not a randomized trial
BrÃ¼ggemann 2021	TChloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals	Not a randomized trial
Bradley 2021	Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.	Not a randomized trial
Braik 2022	Sotrovimab-Flashes of Safety in COVID-19 Patients	Not a randomized trial
Branagan 2022	Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and WaldenstrÃ¶m Macroglobulinemia	Vaccine
Branche 2022	SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses (preprint)	Vaccine
Branche 2023	Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial	Vaccine
Branche 2023	Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.	Vaccine
Branch-Elliman 2020	Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design	Randomized trial with no results
Bravo 2022	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.	Vaccine
Breskin 2022	The effect of remdesivir for the treatment of COVID-19 on mortality among hospitalized patients	Not a randomized trial
Bretthauer 2020	Randomized Re-Opening of Training Facilities during the COVID-19 pandemic	Others
Bronshtein 2022	MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY	Not a randomized trial
Bronshtein 2022	Mesenchymal Stem/Stromal Cells: MESENCURE: A PROFESSIONALIZED CELL THERAPY FOR ARDS REDUCED THE MORTALITY OF SEVERE COVID-19 PATIENTS BY 68% ACCORDING TO A RECENTLY CONCLUDED MULTI-CENTER, CONTROLLED PHASE II STUDY	Not a randomized trial
Bruminhent 2022	An Additional Dose of Viral Vector COVID-19 Vaccine and mRNA COVID-19 Vaccine in Kidney Transplant Recipients: A Randomized Controlled Trial	Vaccine
Bruminhent 2022	An Additional Dose of Viral Vector COVID-19 Vaccine and mRNA COVID-19 Vaccine in Kidney Transplant Recipients: A Randomized Controlled Trial	Vaccine

Brunjes 2022	No Survival Benefit from high-dose Anticoagulation in COVID-19 Patients Conclusion	Not a randomized trial
Bueno 2021	Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile.	Vaccine
Bueno 2021	Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial (preprint)	Vaccine
Bueno 2022	Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.	Vaccine
Bundgaard 2020	Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers : A Randomized Controlled Trial.	Personal protective equipment
Bystroñ 2022	Is it possible to influence the onset and course of COVID-19 infection? (Results of a study by nurses at the University Hospital Ostrava)	Not a randomized trial
Cabanov 2020	Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection	Not a randomized trial
Cai 2020	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study	Not a randomized trial
Cai 2022	Effects and safety of auricular acupressure on depression and anxiety in isolated COVID-19 patients: A single-blind randomized controlled trial	Psychological and educational
Califf 2022	Benefits of Streamlined Point-of-Care Trial Designs: Lessons Learned From the UK RECOVERY Study.	Not a randomized trial
CallejasRubio 2020	Eficacia de los pulsos de corticoides en pacientes con sÃndrome de liberaciÃ³n de citocinas inducido por infecciÃ³n por SARS-CoV-2	Not a randomized trial
Calvani 2023	Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial.	Not exposed to or diagnosed COVID-19
Camilo 2022	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine	Vaccine
Campione 2021	Lactoferrin as antiviral treatment in COVID-19 management: Preliminary evidence	Not a randomized trial
Cannellotto 2021	Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial	Oxygen delivery
Cantarelli 2021	Hepatotoxicity associated with acute tocilizumab treatment in patients with SARS-CoV-2 infection	Not a randomized trial
Cantini 2020	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	Not a randomized trial
Cao 2022	A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial	Vaccine
Capin 2022	Safety, feasibility and initial efficacy of an app-facilitated telerehabilitation (AFTER) programme for COVID-19 survivors: a pilot randomised study.	Exercise or rehabilitation
Capone 2022	GRAd-COV2 vaccine provides potent and durable immunity in a randomised placebo-controlled phase 2 trial (COVITAR) (preprint)	Vaccine
Capone 2023	GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.	Vaccine
Caracciolo 2021	Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.	Not a randomized trial
Carbillon 2021	Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment.	Not a randomized trial

Carr 2020	A new clinical trial to test high-dose vitamin C in patients with COVID-19	Not a randomized trial
Carsetti 2022	Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in beta-Thalassemia: additional dose role	Not a randomized trial
Carta 2022	Previous functional social and behavioral rhythms affect resilience to COVID-19-related stress among old adults.	Not a randomized trial
Carta 2022	Exercise in Older Adults to Prevent Depressive Symptoms at the Time of Covid-19: Results of a Randomized Controlled Trial with Follow-Up	Not exposed to or diagnosed COVID-19
Carvalho 2022	Multidisciplinary rehabilitation in intensive care for COVID-19 - randomized controlled trial	Exercise or rehabilitation
Carvalho 2023	Multidisciplinary rehabilitation in intensive care for COVID-19: randomised controlled trial	Exercise or rehabilitation
Casadevall 2020	A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals	Not a randomized trial
Cass 2023	Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19	Not a randomized trial
Castagna 2020	Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19	Not a randomized trial
Castella 2020	Pilot Study on Cytokine Filtration in COVID-19 ARDS	Randomized trial with no results
Castellano 2021	Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in "non-critically-ill" patients on hemodialysis.	Not a randomized trial
Catalogna 2022	Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: a randomized, sham-controlled trial	Not exposed to or diagnosed COVID-19
Cavanna 2021	Randomised clinical trials on outpatient treatment of SARS-COV-2 infection: Light and shadows.	Not a randomized trial
Cegolon 2022	Early Negativization of SARS-CoV-2 Infection by Nasal Spray of Seawater plus Additives: The RENAISSANCE Open-Label Controlled Clinical Trial.	Not a randomized trial
Center 2020	Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)	Randomized trial with no results
Center 2020	Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19	Randomized trial with no results
Center 2020	Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS	Randomized trial with no results
Center 2020	COVID-19 Patient Positioning Pragmatic Trial	Randomized trial with no results
Center 2020	Pilot Randomized Controlled Trial: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)	Randomized trial with no results
Cesur 2022	Impact of Vitamin D Supplementation on Covid-19 Vaccine Response and IgG Antibodies in Deficient Women: A randomized controlled trial (preprint)	Vaccine
Chabria 2021	Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial	Not exposed to or diagnosed COVID-19
Chakravarty 2023	Depression, Anxiety, and Quality of Life in Patients Treated with Single Infusion Tocilizumab for COVID-19: A Follow-up, Controlled Study	Not a randomized trial
Chalkias 2022	A Bivalent Omicron-containing Booster Vaccine Against Covid-19 (preprint)	Vaccine
Chambers 2020	COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19	Randomized trial with no results

Chammartin 2022	ANTIBODY RESPONSE to SARS-CoV-2 VACCINES and IMMUNODEFICIENCY: A RANDOMIZED TRIAL	Vaccine
Chandra 2022	Efficacy of polyherbal formulations for prevention of COVID-19 infection in high-risk subjects: A randomized open-label controlled clinical trial.	Traditional Chinese medicine
Chandrasekaran 2021	Efficacy of Integrative Siddha Medicine, Kabasura Kudineer with Vitamin C, Zinc Supplementation for the Management of Asymptomatic COVID 19 Cases in Tertiary Hospital: A Randomized Controlled Trial	Traditional Chinese medicine
Chang 2020	Safety and Efficacy of Bronchoscopy in Critically Ill Patients with Coronavirus Disease 2019	Not a randomized trial
Chantasrisawad 2023	The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.	Vaccine
Chappell 2021	First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2 (preprint)	Vaccine
Chappell 2021	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.	Vaccine
Charland 2022	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities.	Vaccine
Chavarria 2021	Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19	Not a randomized trial
Che 2020	Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults	Vaccine
Chen 2020	Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19	Not a randomized trial
Chen 2020	Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients	Not a randomized trial
Chen 2020	Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Coronavirus Disease 2019 Patients With Hyperinflammatory Phenotype.	Not a randomized trial
Chen 2020	The efficacy and safety of traditional Chinese medicines, modified Radix Fici Simplicissimae, combined with Western medicines amongst patients infected with the 2019 novel coronavirus (SARS-CoV-2) in tropical tourist area, China	Traditional Chinese medicine
Chen 2021	Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial	Traditional Chinese medicine
Chen 2021	[A randomized controlled trial study of immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in different immunization schedules].	Vaccine
Chen 2022	Tetrandrine Treatment May Improve Clinical Outcome in Patients with COVID-19	Not a randomized trial
Chen 2022	Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron Era (preprint)	Not a randomized trial
Chen 2022	Traditional Chinese Medicine JingYinGuBiao Formula Therapy Improves the Negative Conversion Rate of SARS-CoV2 in Patients with Mild COVID-19	Traditional Chinese medicine
Chen 2022	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial	Vaccine
Chen 2023	Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.	Others

Chen 2023	Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial	Traditional Chinese medicine
Chen 2023	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.	Not exposed to or diagnosed COVID-19
Chera 2022	Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children	Not a randomized trial
Chinese Clinical Trial Registry	Randomized controlled study to compare the efficacy and safety of recombinant whole human monoclonal antibody injection (F61 injection) in the treatment of moderate novel coronavirus pneumonia (COVID-19) patients with progression to severe risk factors	Randomized trial with no results
Chinese Clinical Trial Registry	Based on the TCM theory of 'TiaoQi TongZhuo', the efficacy study of eletro-acupuncture for olfactory dysfunction after COVID-19 infection: a pilot randomised controlled trial	Randomized trial with no results
Chinese Clinical Trial Registry	The Efficacy of VV116 in trEatment of Non-early moderaTe Covid-19: a multicenter, randomized, double-blind, placebo-controlled clinical trial (EVENT II study)	Randomized trial with no results
Chinese Clinical Trial Registry	Syndrome differentiation treatment of Traditional Chinese Medicine reduces the re-hospitalization rate of discharged elderly patients with COVID-19 infection : a prospective, multicenter, double-blind, randomized controlled study	Randomized trial with no results
Chinese Clinical Trial Registry	A randomized, double-blind, placebo-controlled clinical trial of denosumab in the treatment of bone mass loss in patients with moderate to severe COVID-19 infection	Randomized trial with no results
Chinese Clinical Trial Registry	Effects of stand-alone mindfulness practices for people with long COVID-19 symptoms: A randomized controlled trial	Randomized trial with no results
Chinese Clinical Trial Registry	Qingjin Yiqi Granules for treatment of symptoms after nucleic acid conversion of novel coronavirus infection: a randomized controlled trial	Randomized trial with no results
Chinese Clinical Trial Registry	Non-drug therapy for treating patients with severe COVID-19 infection: a multicenter randomized controlled trial	Randomized trial with no results
Chinese Clinical Trial Registry	Clinical study of dexmedetomidine in the management of prone position ventilation in patients with COVID-19 pneumonia: a single-center, prospective, randomized, double-blind, controlled study	Randomized trial with no results
Chinese Clinical Trial Registry	The Efficacy of VV116 in trEatment of Non-early moderaTe Covid-19: a multicenter, randomized, double-blind, placebo-controlled clinical trial [EVENT I study]	Randomized trial with no results
Chinese Clinical Trial Registry	Anticoagulant evaluation of continuous renal replacement therapy in critically ill patients with COVID-19: nafamostat mesylate combined with regional citrate anticoagulation VS. regional citrate anticoagulation	Randomized trial with no results
Chinese Clinical Trial Registry	A randomized,double-blind,placebo-controlled,dose-exploratory, multicenter clinical study of Reduning granules for the treatment of Covid-19.	Randomized trial with no results
Chinese Clinical Trial Registry	A Multi-center, Randomized, Parallel Controlled, Double-Blinded Clinical Trial to Evaluate the Effectiveness and Safety of Hydrogen-Oxygen Generator with Nebulizer for Adjuvant Treatment of Novel Coronavirus Disease 2019 (COVID-19)	Randomized trial with no results
Chinese Clinical Trial Registry	Effect of an integrated program for awake prone position, based on relaxation, education and nurses' ability, to improve the tolerance of hospitalized adults with COVID-19ï¼ˆI-BREATHï¼‰: a cluster randomized clinical trial	Randomized trial with no results
Chinese Clinical Trial Registry	Pulmonary ultrashort wave therapy for COVID-19 infection: a single-blind, multi-center randomized controlled clinical study	Randomized trial with no results

Chinese Clinical Trial Registry	Treatment of severe/critical COVID-19 patients with Qingjin irrigation solutionï¼ša randomized double-blind placebo-controlled clinical study	Randomized trial with no results
Chinese Clinical Trial Registry	A multicenter, randomized, placebo-controlled clinical study of Renshen Guben oral Liquid in the treatment of post-COVID-19 fatigue syndrome	Randomized trial with no results
Chinese Clinical Trial Registry	A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of SR1375 in patients with moderate/severe novel coronavirus infection (COVID-19)	Randomized trial with no results
ChineseUniversityofHongKong 2023	RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19	Randomized trial with no results
Chitra 2021	An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19 â€“A Randomized Controlled Study	Traditional Chinese medicine
Chitra 2022	An open clinical evaluation of selected siddha regimen in expediting the management of COVID-19 -a randomized controlled study.	Traditional Chinese medicine
Chitre 2022	Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers.	Traditional Chinese medicine
Chiuppesi 2022	Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial	Vaccine
Chopra 2023	Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.	Traditional Chinese medicine
Chowdary 2022	A pilot, open-label, phase II clinical trial of nebulised recombinant tissue-plasminogen activator in patients with COVID-19 acute respiratory distress syndrome: The PACA trial	Not a randomized trial
Chowdhury 2021	A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients	Not a randomized trial
Christian 2023	Safety and efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial.	Others
ChristopheRoman et 2022	Effectiveness of endurance training rehabilitation after hospitalisation in intensive care for COVID-19-related acute respiratory distress syndrome on dyspnoea (RECOVER): a randomised controlled, open-label multicentre trial	Not exposed to or diagnosed COVID-19
Chu 2021	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine	Vaccine
Chuang 2022	Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trial (preprint)	Vaccine
Chuang 2022	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.	Vaccine
Claus 2022	BCG vaccination of healthcare workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomised placebo-controlled trial (preprint)	Not exposed to or diagnosed COVID-19
Claus 2023	BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial.	Vaccine
Clemens 2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil	Vaccine

Clemens 2022	Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, controlled, phase 2 study	Vaccine
clinicaltrials.gov	AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	Randomized trial with no results
clinicaltrials.gov	The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.	Randomized trial with no results
clinicaltrials.gov	BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	Randomized trial with no results
clinicaltrials.gov	MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	Randomized trial with no results
clinicaltrials.gov	LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	Randomized trial with no results
clinicaltrials.gov	VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	Randomized trial with no results
clinicaltrials.gov	PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)	Randomized trial with no results
clinicaltrials.gov	Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study .	Randomized trial with no results
clinicaltrials.gov	Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19	Randomized trial with no results
Coates 2022	A Covid Response - Country Style	Not a randomized trial
Collins 2021	Administration of COVID-19 convalescent plasma in a metropolitan health care system	Not a randomized trial
Collins 2022	UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19	Not a randomized trial
Colombia 2020	Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia	Randomized trial with no results
Comenducci 2021	Glenzocimab, a novel antiplatelet therapy in COVID-19 related acute respiratory distress syndrome (ARDS): the garden study, a phase 2 clinical trial	Randomized trial with no results
Connolly 2021	RCT Abstract - An adaptive randomized controlled trial of non-invasive respiratory strategies in acute respiratory failure patients with COVID-19	Oxygen delivery
Corna 2022	Effects of Aerobic Training in Patients with Subacute COVID-19: A Randomized Controlled Feasibility Trial	Not exposed to or diagnosed COVID-19
Corominas 2023	Safety and immunogenicity of the protein-based PHH-IV compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial (preprint)	Vaccine
Corominas 2023	Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.	Vaccine
Corritori 2021	Multicenter, open-labeled efficacy study of avifavir in patients with COVID-19	Not a randomized trial
Cortese 2022	Evaluating the Endothelial Impairments in COVID-19 Patients Using Near-Infrared Spectroscopy: the HEMOCOVID-19 trial	Not a randomized trial

CostaClemens 2022	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	Vaccine
CostaClemens 2022	Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 study (preprint)	Vaccine
CostantiVilelaCampos 2022	The effect of systemic versus local transcutaneous laser therapy on tension-type cephalea and orofacial pain in post-COVID-19 patients: A pragmatic randomized clinical trial.	Not exposed to or diagnosed COVID-19
Creech 2022	Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age	Vaccine
CyanVacLLC 2023	A Phase 2 Trial of the Immunogenicity and Safety of CVXGA1 Intranasal COVID Vaccine in Healthy Adults	Randomized trial with no results
Czajka 2022	A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemi	Vaccine
Đ’ 2022	Comparative efficacy of ivabradine and beta-blockers in the treatment of tachycardia in patients after COVID-19.	Not exposed to or diagnosed COVID-19
Dabrowski 2023	Humulus lupus extract rich in xanthohumol improves the clinical course in critically ill COVID-19 patients	Not a randomized trial
Dai 2022	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults	Vaccine
Dai 2022	Efficacy and Safety of the RED-Dimer-Based Covid-19 Vaccine ZF2001 in Adults	Vaccine
Dal 2021	Covid-19 Clinical Course and Blood Groups: Turkish Population-Based Study	Not a randomized trial
DalNegro 2022	Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia- a pivotal double-blind, cross-over controlled study	Not exposed to or diagnosed COVID-19
Damle 2022	Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patients.	Traditional Chinese medicine
Dar 2022	Clinical safety and pharmacokinetic evaluation of aqueous extract of Cocculus hirsutus, an anti-viral phytopharmacetical drug as a potential for the treatment of dengue and COVID-19	Not exposed to or diagnosed COVID-19
Dar 2022	Clinical safety and pharmacokinetic evaluation of aqueous extract of Cocculus hirsutus, an anti-viral phytopharmacetical drug as a potential for the treatment of dengue and COVID-19.	Not exposed to or diagnosed COVID-19
daSilva 2023	Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19.	Not a randomized trial
De Marchi 2020	Effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) in patients with severe COVID-19 requiring intubation: a pragmatic randomized placebo-controlled trial	Exercise or rehabilitation
Dehghan 2021	The potential anti-inflammatory effects of zerumbone in covid-19 patients	Not a randomized trial
DelCorral 2022	Home-based respiratory muscle training on quality of life and exercise tolerance in long-term post-COVID-19: Randomized controlled trial.	Not exposed to or diagnosed COVID-19

DeMarchi 2021	Effects of Photobiomodulation Therapy Combined with Static Magnetic Field in Severe COVID-19 Patients Requiring Intubation: A Pragmatic Randomized Placebo-Controlled Trial	Others
Dengiz 2022	Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial	External organ support
Deresinski 2022	COVID-19 Pre-Exposure Prophylaxis	Not a randomized trial
DeRosa 2022	Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate	Vaccine
Deshpande 2022	Potential use of ImmunodaatÂ® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (preprint)	Not exposed to or diagnosed COVID-19
Devalaraja-Narashimha 2022	Association of complement pathways with COVID-19 severity and outcomes	Not a randomized trial
Devos 2020	Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodi	Randomized trial with no results
Devpura 2021	Randomized Placebo-Controlled Pilot Clinical Trial on the Efficacy of Ayurvedic Treatment Regime on COVID-19 Positive Patients	Traditional Chinese medicine
Dhibar 2020	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.	Not a randomized trial
Dhooria 2021	High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (Acronym: COLDSTER)	Duplicate
Dhooria 2021	High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (Acronym: COLDSTER).	Not exposed to or diagnosed COVID-19
Diaz 2020	Geographical disparities in clinical outcomes of severe COVID-19 patients treated with remdesivir	Not a randomized trial
Diener 2022	RECOVERY trial: Acetylsalicylic acid is not effective in hospitalized COVID-19 patients	Not a randomized trial
Dillon 2020	A real-world data study of coronavirus-2019 disease severity in patients with multiple sclerosis treated with ocrelizumab	Not a randomized trial
Dionato 2022	BCG vaccine safety in COVID-19 convalescent adults: BATTLE a randomized controlled trial.	Vaccine
DiStadio 2022	Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial	Not exposed to or diagnosed COVID-19
DiTano 2021	[The AFFIRM-AHF trial: results, impact of COVID-19 and clinical implications].	Not a randomized trial
Diurno 2020	Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience	Not a randomized trial
Dixon 2020	The Relevance of Oxytocin & Dynorphin in COVID-19: Towards a Prophylactic Treatment (preprint)	Not a randomized trial
Dodaran 2023	Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial.	Vaccine

Dominguez-Nicolas 2021	Low-field thoracic magnetic stimulation increases peripheral oxygen saturation levels in coronavirus disease (COVID-19) patients: A single-blind, sham-controlled, crossover study.	Others
Donato 2021	Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.	Not a randomized trial
Dong 2023	Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers.	Traditional Chinese medicine
DosAnjos 2022	Efficacy and Safety of BCG Revaccination With M. bovis BCG Moscow to Prevent COVID-19 Infection in Health Care Workers: A Randomized Phase II Clinical Trial.	Vaccine
Doyno 2022	Paxlovid: Oral Antiviral for the Treatment of COVID-19	Not a randomized trial
Dr 2021	Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I	Randomized trial with no results
Dr 2022	Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III	Randomized trial with no results
Dreher 2022	Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial.	Traditional Chinese medicine
Duan 2020	Clinical Observation of Jinhua Qinggan Granule in Treating Pneumonia Infected by Novel Coronavirus	Traditional Chinese medicine
Dub 2022	High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021.	Not a randomized trial
Dummer 2020	Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications	Randomized trial with no results
Dunkle 2023	Immunogenicity and Safety of NVX-CoV2373 as a Homologous or Heterologous Booster: A Phase 3 Randomized Clinical Trial in Adults	Vaccine
Duong-Quy 2020	The use of exhaled nitric oxide and peak expiratory flow to demonstrate improved breathability and antimicrobial properties of novel face mask made with sustainable filter paper and Folium Plectranthii amboinicii oil: additional option for mask shortage d	Not exposed to or diagnosed COVID-19
Durr 2022	Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: The RECOVERY-RS randomized clinical trial.	Not a randomized trial
Durr 2022	Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial	Not a randomized trial
Dutt 2021	A randomized and comparative study to assess safety and efficacy of supplemental treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with corona virus 2019 (COVID-19)	Traditional Chinese medicine
Ebadollahinatanzi 2022	The effectiveness of herbal combination as complementary treatment process in a patient with COVID-19	Not a randomized trial
Ebell 2022	Nirmatrelvir/Ritonavir Reduces Risk of Hospitalization in At-Risk Outpatients	Not a randomized trial
Ebrahimi 2021	Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID-19: A clinical study	Not a randomized trial
Edara 2021	Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants	Vaccine

Eeg-Olofsson 2022	TTCOV19: timing of tracheotomy in SARS-CoV-2-infected patients: a multicentre, single-blinded, randomized, controlled trial.	Oxygen delivery
Efimov 2021	The effect of azoximer bromide (PolyoxidoniumÂ®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study	Not a randomized trial
Ehrmann 2021	Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial	Oxygen delivery
Ella 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.	Vaccine
Ella 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial	Vaccine
Ella 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial (Jan, 10.1016/S1473-3099(20)30942-7, 2021)	Vaccine
Ella 2021	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial	Vaccine
ElSahly 2021	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.	Vaccine
ElSahly 2022	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial	Vaccine
ElSahly 2022	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial.	Vaccine
Emary 2021	Efficacy of ChAdOx1 nCoV-19Â (AZD1222)Â Vaccine Against SARS-CoV-2 VOCÂ 202012/01Â (B.1.1.7) (preprint)	Vaccine
Emary 2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	Vaccine
Embase 2021	THERAPEUTIC EFFECT of VITAMIN A on COVID-19 PATIENTS and ITS PROPHYLACTIC EFFECT on CONTACTS	Not a randomized trial
English 2021	Results of the cellular immuno-therapy for covid-19 related acute respiratory distress syndrome (circa-phase i trial	Not a randomized trial
Erdem 2020	Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.	Not a randomized trial
Erelel 2021	Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial	Not a randomized trial
Eslami 2020	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	Not a randomized trial
Esposito 2021	Effects of different dialysis techniques on inflammation in maintenance hemodialysis patients with covid-19: A randomized study	External organ support
Estephan 2023	Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.	Vaccine
Fab'entech 2022	A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk of severe outcome	Randomized trial with no results
Facultyofmedicine 2022	Effects of High Dose Vitamin D2 Supplementation on Post-COVID Fatigue and Neuropsychiatric Symptoms of Long COVID: A Randomized Controlled Trial	Not exposed to or diagnosed COVID-19

Fadlyana 2021	A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18â€“59 Years: An Interim Analysis in Indonesia	Vaccine
Fadlyana 2022	Immunogenicity and Safety in Healthy Adults of Full-Dose Versus Half Doses of COVID-19 Vaccine (ChAdOx1-S or BNT162b2) or Full-Dose CoronaVac Administered as a Booster Dose after Priming with Coronavac: A Randomized, Observer-Blinded, Controlled Trial Con	Vaccine
Fadlyana 2023	Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in I	Vaccine
Faisal 2022	Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection	Not a randomized trial
Fakhr 2021	Inhaled High Dose Nitric Oxide is a Safe and Effective Respiratory Treatment in Spontaneous Breathing Hospitalized Patients with COVID-19 pneumonia	Not a randomized trial
Falasca 2020	Efficacy of canakinumab in mild or severe COVID-19 pneumonia	Not a randomized trial
Falsey 2021	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.	Vaccine
Farmaha 2023	Reduction of SARS-CoV-2 salivary viral load with pre-procedural mouth rinses: a randomised, controlled, clinical trial.	Others
Farooq 2022	ROLE OF HONEY AND NIGELLA SATIVA IN THE MANAGEMENT OF COVID-19: HNS-COVID-PK TRIAL	Traditional Chinese medicine
Fazlju 2022	HYSSOP and POLIUM could help to prevent COVID-19 in high-risk population: the results of a parallel randomized placebo-controlled field trial	Traditional Chinese medicine
Fedeli 2022	Antibody response and HIV-1 RNA response following a booster of SARS-CoV-2 vaccination in people living with HIV	Not a randomized trial
Feeney 2020	The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV	Randomized trial with no results
Feily 2020	COVID-19: Pentoxifylline as a potential adjuvant treatment	Not a randomized trial
Feitsma 2023	A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.	Vaccine
Felinska 2021	Surgical Performance Is Not Negatively Impacted by Wearing a Commercial Full-Face Mask with Ad Hoc 3D-Printed Filter Connection as a Substitute for Personal Protective Equipment during the COVID-19 Pandemic: A Randomized Controlled Cross-Over Trial	Personal protective equipment
Feng 2020	Differentiation between COVID-19 and bacterial pneumonia using radiomics of chest computed tomography and clinical features	Not a randomized trial
Feng 2021	Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-kappaB signaling pathway	Not a randomized trial
Feng 2021	Traditional Chinese Medicine Shenhuang Granule in Patients with Severe/Critical COVID-19: A Randomized Controlled Multicenter Trial	Traditional Chinese medicine
Feng 2021	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.	Vaccine

Fereydounnia 2022	The Comparison of the Effectiveness of Respiratory Physiotherapy Plus Myofascial Release Therapy Versus Respiratory Physiotherapy Alone on Cardiorespiratory Parameters in Patients With COVID-19	Exercise or rehabilitation
FernÃ¡ndez-LÃ¡zaro 2022	Glycophosphopeptical AM3 food immunesupplement: A potential adjuvant in the treatment of early-stage SARS-COV-2 infection. A randomized, controlled pilot study	Nutrition and supplements
Fernandez-Montero 2023	Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses	Others
Fezzi 2022	Early prone positioning does not improve the outcome of patients with mild pneumonia due to SARS-CoV-2: results from an open-label, randomized controlled trial (the EPCoT Study) (preprint)	Exercise or rehabilitation
Files 2022	I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.	Randomized trial with no results
Finnigan 2023	Efficacy and Tolerability of AXA1125 (Endogenous Metabolic Modulator) in Fatigue-Predominant Long COVID: A Randomized, Double-Blind, Controlled Study	Not exposed to or diagnosed COVID-19
Fiol-DeRoque 2021	Effectiveness of a Mobile Phone-Based Intervention to Reduce Mental Health Problems in Healthcare Workers During the COVID-19 Pandemic: A Randomized Controlled Trial (PsyCovidApp Trial) (preprint)	Not exposed to or diagnosed COVID-19
Fiorenza 2022	DEXAMETHASONE COMPARED TO USUAL CARE IN PATIENTS WITH COVID-19: EFFECT ON 28-DAY MORTALITY	Not a randomized trial
FirstAffiliatedHospitalofWenzhouMedicalUniversity 2023	A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19.	Randomized trial with no results
FirstAffiliatedHospitalofZhejiangUniversity 2023	Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumoia	Randomized trial with no results
Fisker 2022	Oral Polio Vaccine (OPV) to mitigate the risk of illness and mortality during the COVID-19 pandemic: A cluster-randomised trial in Guinea-Bissau	Vaccine
Fitz-Patrick 2023	Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adultsÂ â‰¥65 years old.	Vaccine
Flaxman 2021	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)	Vaccine
Flaxman 2021	Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) (preprint)	Vaccine
Fleites 2021	HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis	Vaccine
Flisiak 2020	Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study.	Not a randomized trial
Foged 2021	Fidelity, tolerability and safety of acute high-intensity interval training after hospitalisation for COVID-19: a randomised cross-over trial	Not exposed to or diagnosed COVID-19
Folegatti 2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	Vaccine

Folegatti 2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.	Vaccine
Folegatti 2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)	Vaccine
Folegatti 2020	Erratum: Department of Error (The Lancet (2020) 396(10249) (467â€“478), (S0140673620316044), (10.1016/S0140-6736(20)31604-4))	Vaccine
Follmann 2022	Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial (preprint)	Vaccine
Follmann 2023	Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.	Vaccine
FondazionePoliclinicoUniversitarioAgostinoGemelliIRCCS 2021	COVID-19 Pneumonia and Gut Inflammation	Randomized trial with no results
Fong 2020	Impact of aerosol box on intubation during COVID-19: a simulation study of normal and difficult airways	Personal protective equipment
Fong 2022	Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial (preprint)	Vaccine
Fonseca-Gonzalez 2023	Impact of plasmapheresis on severe COVID-19	Others
Formica 2021	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial	Vaccine
Forouzanfar 2022	The Effect of Pomegranate Juice and Sumac Consumption in the Treatment of Outpatients with COVID-19	Nutrition and supplements
Förster 2022	Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) â€“ a randomized controlled trial in primary care	Not exposed to or diagnosed COVID-19
Fragoso-Saavedra 2020	A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 inf	Randomized trial with no results
Fralick 2021	Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial [COVID-PRONE]	Oxygen delivery
Fralick 2022	Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE)	Oxygen delivery
FranciscoHernandez-Bernal 2022	A phase 3, randomised, double-blind, placebo-controlled clinical trial for adult evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine (ABDALA-3 Study).	Vaccine
Frandell 2020	The Effects of Electronic Alert Letters in the Time of COVID-19 (preprint)	Not exposed to or diagnosed COVID-19
Frater 2021	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial	Vaccine

Freeman 2021	Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial.	Vaccine
Fries 2023	Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination.	Vaccine
Frolov 2022	Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	Nutrition and supplements
FrontierBiotechnologiesInc 2023	Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19	Randomized trial with no results
FrontiersEditorial 2021	Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial	Randomized trial with no results
FrontiersEditorial 2022	Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial (Expression of Concern of Vol 8, art no 668698, 2021)	Duplicate
FrontiersEditorial 2022	Expression of Concern: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial (Frontiers in Medicine, (2021), 8, (668698), 10.3389/fmed.2021.668698)	Duplicate
Fu 2022	Auricular acupressure for adverse events following immunization after COVID-19 vaccine injection: A multicentre, blinded, randomized controlled trial.	Others
GÃ¡lvez 2022	Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.	Vaccine
GÃ¼Ã§lÃ¼ 2022	Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching.	Not a randomized trial
Gagneux-Brunon 2021	Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemic	Not a randomized trial
Galvez 2022	Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial (preprint)	Vaccine
Ganesan 2021	Whole lung Irradiation as a Novel treatment for COVID-19: Final Results of the Prospective Randomized trial (WINCOVID trial).	Others
Garcia-Fernandez 2020	Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients	Not a randomized trial
Gardiner 2022	Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID trial): 1 year follow up for safety and pulmonary dysfunction	Not a randomized trial
Gautret 2020	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	Not a randomized trial
Gautret 2020	Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial	Not a randomized trial
Gautret 2021	Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients	Not a randomized trial
Gautret 2021	Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19	Not a randomized trial
Gergi 2020	Thrombo-inflammation response to Tocilizumab in COVID-19	Not a randomized trial
GermÃ¡nÃ□Ã±ez 2022	Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial	Vaccine

Gharbharan 2022	CONVALESCENT PLASMA for OUTPATIENTS with EARLY COVID-19: A RANDOMIZED TRIAL	Not a randomized trial
Gholami 2023	Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70Â years.	Vaccine
Gholinatajjelodar 2023	Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial	External organ support
Giammarioli 2022	Providing respiratory and ventilation care in the face of shifting evidence: current opinion in critical care.	Not a randomized trial
Gilsenan 2022	Adapting to the dynamic landscape of the COVID-19 pandemic: Proposed study design approaches for a postauthorization safety study for Pfizer-BioNtech COVID-19 vaccine in the United States	Not a randomized trial
Giordano 2021	Effect of Single Session Receptive Music Therapy on Anxiety and Vital Parameters in Hospitalized Covid-19 Patients: A Randomized Controlled Trial	Others
Giordano 2022	Effect of single session receptive music therapy on anxiety and vital parameters in hospitalized Covid-19 patients: a randomized controlled trial	Others
Gobeil 2021	Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with Comorbidities	Vaccine
Goepfert 2021	Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.	Vaccine
Gokhale 2020	Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia	Not a randomized trial
Gold 2020	Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial	Others
Goldberg 2021	A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.	Not a randomized trial
Goldin 2021	Treatment-dose LMWH versus prophylactic/intermediate dose heparins in high risk COVID-19 inpatients: Rationale and design of the HEP-COVID Trial.	Randomized trial with no results
Goma 2022	EFFICACY OF OLOCIZUMAB IN TREATMENT OF COVID-19 PATIENTS	Not a randomized trial
Gonda 2022	Safety of oral Molnupiravir administration for hospitalized elderly COVID-19 patients aged 80 years old or older (preprint)	Not a randomized trial
Gong 2021	Efficacy and Safety of Lianhuaqingwen Capsules for the Prevention of Coronavirus Disease 2019: A Prospective Open-Label Controlled Trial	Not a randomized trial
GonzÃ¡lez 2021	A multicenter, open-label, randomized, proof-of-concept phase ii clinical trial to Assess the efficacy and safety of icatibant in patients infected with sars-cov-2 (covid-19) And admitted to hospital units without invasive mechanical ventilation. StudyPro	Randomized trial with no results
GonzÃ¡lez-Castro 2021	High flow oxygen therapy in the treatment of SARS-CoV-2 pneumoniaâ‹† Oxigenoterapia de alto flujo en el tratamiento de la neumonÃa por SARS-CoV-2	Not a randomized trial
Gonzalez-Castro 2021	Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.	Not a randomized trial
Gonzalez-Gerez 2021	Short-Term Effects of a Respiratory Telerehabilitation Program in Confined COVID-19 Patients in the Acute Phase: A Pilot Study	Exercise or rehabilitation
Gopalakrishnan 2022	Effectiveness of early awake self proning strategy in non-intubated patients with COVID-19 hypoxemia: An open-labelled randomized clinical trial from Jodhpur, India	Exercise or rehabilitation

Govind 2020	Clozapine Treatment and Risk of COVID-19	Not a randomized trial
Granados-Montiel 2021	New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).	Randomized trial with no results
Granwehr 2021	BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine	Vaccine
Gras-Valenti 2021	Effectiveness of the first dose of BNT162b2 vaccine to preventing covid-19 in healthcare personnel	Vaccine
Grbovic 2021	The effects of respiratory exercises on partial pressures of gases and anxiety in the acute phase of COVID-19 infection	Not a randomized trial
Grieco 2021	Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial.	Oxygen delivery
Griessbach 2023	Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).	Vaccine
GrubovicRastvorceva 2022	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients-An Open-Label Phase II Clinical Trial	Not a randomized trial
Guan 2020	Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial	Not a randomized trial
Guan 2020	Erratum to hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial	Not a randomized trial
GuangzhouInstituteofRespiratoryDisease 2023	Hydrogen-Oxygen Generator With Nebulizer for Adjuvant Treatment of Novel Coronavirus Disease 2019 (COVID-19)	Randomized trial with no results
Gui 2023	Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.	Vaccine
Guimares 2022	Reducing the viral load of SARS-CoV-2 in the saliva of patients with COVID-19	Not a randomized trial
Guo 2021	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial	Vaccine
Gupta 2020	Determining the usage and efficacy of COVID-19 convalescent plasma harvested at our blood centre	Not a randomized trial
Gupta 2021	Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection	Not a randomized trial
Gupta 2021	Prospective, randomized, open-label, blinded end point, two-arm, comparative clinical study to evaluate the efficacy and safety of a Fixed Ayurvedic Regimen (FAR) as add-on to conventional treatment in the management of mild and moderate COVID-19 patients	Traditional Chinese medicine
Gupta 2022	Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19	Not a randomized trial
Gupta 2022	Improved oxygen saturation and reduced rebreathing with Bains circuit compared to NRBM in covid-19 patients awaiting NIV support	Oxygen delivery

Gupta 2022	Efficacy and Safety of Saline Nasal Irrigation Plus Theophylline for Treatment of COVID-19-Related Olfactory Dysfunction: The SCENT2 Phase 2 Randomized Clinical Trial.	Not exposed to or diagnosed COVID-19
Gyselinck 2021	Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.	Not a randomized trial
Hacibekiroglu 2020	Efficacy of convalescent plasma according to blood groups in COVID-19 patients	Not a randomized trial
Hafez 2022	Is prolonged period of prone position effective and safe in mechanically ventilated patients with SARS-CoV-2? A randomized clinical trial	Oxygen delivery
Hager 2022	Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine	Vaccine
Haibel 2021	Successful treatment of severe COVID-19 pneumonia and cytokine release with simultaneous tocilizumab and anakinra with one-month follow-up	Not a randomized trial
Hajibeygi 2022	Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial	Nutrition and supplements
Halford 2021	SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion	Randomized trial with no results
Halford 2022	Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion	Not a randomized trial
Halperin 2021	Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-cont	Vaccine
Han 2020	RUXCOVID: A phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19-associated cytokine storm	Randomized trial with no results
Han 2021	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	Vaccine
Hansen 2022	High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial.	Not exposed to or diagnosed COVID-19
Hardt 2022	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial	Vaccine
Hariri 2021	Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients.	Not a randomized trial
Harrington 2022	Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralisation in patients with chronic myeloid disorders	Not a randomized trial
Hasanpour 2022	Efficacy of CovexirÂ® (Ferula foetida oleo-gum) treatment in symptomatic improvement of patients with mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial.	Traditional Chinese medicine
Hashem-Dabaghian 2022	Effect of Lavender (Lavandula angustifolia L.) syrup on olfactory dysfunction in COVID-19 infection: A pilot controlled clinical trial	Traditional Chinese medicine

Hashemian 2020	Blood purification techniques, inflammatory mediators and mortality in COVID-19 patients	Not a randomized trial
Hashemian 2021	Efficacy of early prone positioning combined with noninvasive ventilation in COVID-19	Oxygen delivery
Hashemian 2022	Effectiveness of Borage plus syrup on COVID-19 patients in intensive care units	Nutrition and supplements
Hasheminasab 2022	Efficacy of the barley-based remedy, a Persian medicine formula, in coronavirus disease 2019 (COVID-19) hospitalized patients: An open-labeled randomized controlled trial	Nutrition and supplements
Hashim 2020	Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq	Not a randomized trial
Hasina 2021	Music therapy for anxiety level and quality of life of patients infected by covid-19	Others
Havlichek 2020	A Trial of Lopinavir-Ritonavir in Covid-19	Not a randomized trial
Hawkins 2022	Aromatherapy Blend of Thyme, Orange, Clove Bud, and Frankincense Boosts Energy Levels in Post-COVID-19 Female Patients: A Randomized, Double-Blinded, Placebo Controlled Clinical Trial	Not exposed to or diagnosed COVID-19
He 2021	Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up	Not a randomized trial
He 2023	The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages	Vaccine
Heath 2021	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine	Vaccine
Heath 2022	Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial	Vaccine
Heath 2023	Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.	Vaccine
Heinzel 2022	Corrigendum: Three-Month follow-up of heterologous vs. homologous third SARS-CoV-2 vaccination in kidney transplant recipients: Secondary analysis of a randomized controlled trial.	Vaccine
Heitmann 2022	Phase I/II study of a peptide-based COVID-19 vaccine to induce T-cell responses against SARS-CoV-2 in cancer patients with B-cell deficiency	Not a randomized trial
Helianthi 2022	The Adjunctive Effects of Acupuncture for Hospitalized COVID-19 Patients: a Single-Blinded Randomized Clinical Study	Others
Helsingen 2021	Covid-19 transmission in fitness centers in Norway - a randomized trial	Others
Heppy 2023	The effect of Psidium guajava Leaves' extract for mild and asymptomatic corona virus Disease-19.	Traditional Chinese medicine
HernÃ¡ndez-Bernal 2023	A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).	Vaccine
Hernandez 2020	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.	Not a randomized trial
Hernandez-Bernal 2021	Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study) (preprint)	Vaccine
Hernandez-Bernal 2022	Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)	Vaccine

Hernandez-CedeÃ±o 2021	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.	Not a randomized trial
Hess 2021	Reduced Intubation Rates Following Whole-Lung Low-Dose Radiation Therapy (LD-RT) in Patients With COVID-19-Related Pneumonia	Others
Hess 2021	Whole-Lung Low-Dose Radiation Therapy (LD-RT) for Non-Intubated Oxygen-Dependent Patients with COVID-19-Related Pneumonia Receiving Dexamethasone and/or Remdesevir	Others
Hess 2022	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial	Randomized trial with no results
Hintschich 2022	Topical Administration of Mometasone Is Not Helpful in Post-COVID-19 Olfactory Dysfunction	Not exposed to or diagnosed COVID-19
Hirai 2022	[Covid-19 treatment in all divisions and departments.]	Inaccessible full text
Hockele 2022	Pulmonary and Functional Rehabilitation Improves Functional Capacity, Pulmonary Function and Respiratory Muscle Strength in Post COVID-19 Patients: Pilot Clinical Trial.	Not exposed to or diagnosed COVID-19
Holman 2021	Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2	Not exposed to or diagnosed COVID-19
Honda-Okubo 2023	Ability of SpikoGenÂ®, an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants.	Vaccine
Hong 2020	Celebrex adjuvant therapy on COVID-19: An experimental study	Not a randomized trial
Hong 2020	Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication	Not a randomized trial
Hong 2020	Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study	Not a randomized trial
Hong-XingPan 2021	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials	Vaccine
Hosain 2023	Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: a phase 2/3, double-blind, randomized study	Vaccine
HospitalSanCarlos 2023	tDCS in Pos-COVID Syndrome	Randomized trial with no results
Hosseinpoor 2022	Intranasal Corticosteroid Treatment on Recovery of Long-Term Olfactory Dysfunction Due to COVID-19	Not exposed to or diagnosed COVID-19
Hsieh 2021	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study	Vaccine
Hsu 2022	The true effect of traditional Chinese medicine on the clinical outcome of hospitalized patients with COVID-19?	Not a randomized trial
Hu 2020	Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial	Traditional Chinese medicine
Hu 2020	Chansu Injection Improves the Respiratory Function of Severe COVID-19 Patients	Traditional Chinese medicine

Hu 2021	Cinobufacini Improves the Respiratory Function of Severe COVID-19 Patients	Traditional Chinese medicine
Hu 2021	Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242].	Traditional Chinese medicine
Hu 2021	Efficacy and safety of Lianhua Qingwen capsules, a repurposed Chinese herb, in patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial [Phytomedicine 85 (2021) 153242]	Traditional Chinese medicine
Hu 2021	Multi-center clinical observation of honeysuckle oral liquid combined with western medicine in the treatment of common type of COVID-19	Traditional Chinese medicine
Hua 2020	Short-term skin reactions following use of N95 respirators and medical masks	Personal protective equipment
HuahuiHealth 2023	HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2	Randomized trial with no results
Huang 2022	Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: A double-blind, randomized, placebo-controlled phase 2 trial (preprint)	Vaccine
Huang 2023	Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.	Vaccine
Huang 2023	Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-contro	Vaccine
Hui 2022	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial	Vaccine
Hulbert 2021	Respiratory disease, and treatment / thematic poster session a novel approach to medical monitoring during the sars-cov-2 pandemic supporting the activ 4b outpatient anticoagulation trial	Not a randomized trial
Huseini 2022	Effects of Imfluna, an Iranian traditional polyherbal medicine, on COVID-19 symptoms: A randomized, double-blind and placebo-controlled clinical trial	Traditional Chinese medicine
hussien 2022	Efficacy of pentasodium diethylenetriamine pentaacetate in ameliorating anosmia post COVD-19 (preprint)	Not exposed to or diagnosed COVID-19
Iannone 2021	Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa	Vaccine
Ibarra-Estrada 2021	Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to Coronavirus Disease 2019: Results of a Single-Center Randomized Controlled Trial	Oxygen delivery
Ibarra-Estrada 2022	Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to COVID-19: Results of a Single-Center Randomized Controlled Trial	Oxygen delivery
Ibarra-Estrada 2022	Factors for success of awake prone positioning in patients with COVID-19-induced acute hypoxemic respiratory failure: analysis of a randomized controlled trial	Oxygen delivery
Ibrahim 2020	Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase 2 Clinical Trial (preprint)	Removed from preprint server

Ikonomidis 2020	Tocilizumab improves oxidative stress and endothelial glycocalyx: a mechanism that may explain the effects of biological treatment on COVID-19. (Special Issue: COVID-19 and treatments: particular emphasis on potential toxic effects.)	Not exposed to or diagnosed COVID-19
Inocian 2022	Pharmacotherapeutics and Vaccines for COVID-19	Not a randomized trial
Inui 2023	Effect of degalactosylated bovine glycoprotein formulations MAF and M Ñapsules on lymphopenia and clinical outcomes in hospitalized Covid-19 patients: a randomized clinical trial	Nutrition and supplements
Ipe 2022	Correction to: Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.	Not a randomized trial
Ishikawa 2023	One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.	Vaccine
IstanbulUniversity-Cerrahpasa(IUC) 2020	Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients	Randomized trial with no results
Ivan 2023	A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273 (preprint)	Vaccine
Iwata 2022	Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.	Vaccine
Izaguirre-Berrios 2022	Effects of vitamin D in patients with COVID-19 according to associated comorbidity	Not a randomized trial
Izikson 2022	Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.	Vaccine
Jaber 2021	Effect of the use of an endotracheal tube and stylet versus an endotracheal tube alone on first-attempt intubation success: a multicentre, randomised clinical trial in 999 patients.	Not exposed to or diagnosed COVID-19
JainShrimal 2023	Efficacy of integrated tele yoga intervention on physiological and psychological variables in asymptomatic COVID-19 positive patients: A Randomized Control Trial	Exercise or rehabilitation
JainShrimal 2023	Efficacy of Integrated Tele-Yoga Intervention on Physiological and Psychological Variables in Asymptomatic COVID-19 Positive Patients: A Confirmatory Randomized Control Trial.	Exercise or rehabilitation
Jalalizadeh 2022	Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response.	Vaccine
Jamadagni 2022	Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary Outcomes of Randomized controlled trial.	Traditional Chinese medicine
Janapala 2020	Novaferon, treatment in COVID-19 patients.	Not a randomized trial
Janssen 2022	Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial	Vaccine
Jarczak 2022	Effect of the CytoSorb Adsorber on hemodynamic and immunological Parameters in critically ill Patients with COVID-19 - Adjuvant Therapy Witch CYTOSorb in COVID-19 CytoCOV-19	External organ support
Jarczak 2022	Effect of Hemadsorption Therapy in Critically Ill Patients with COVID-19 (CYTOCOV-19): A Prospective Randomized Controlled Pilot Trial	External organ support

Jarczok 2022	A SLOW PACED BREATHING INTERVENTION TO REDUCE IL-6 IN PATIENTS WITH COVID-19-PNEUMONIA - A RANDOMIZED CONTROLLED TRIAL	Oxygen delivery
Javaherian 2021	Safety and efficacy of Pulmonary physiotherapy in hospitalized patients with severe COVID-19 pneumonia (PPTCOVID Study): A prospective, randomised, single-blind, controlled trial	Exercise or rehabilitation
Javaherian 2023	Safety and efficacy of pulmonary physiotherapy in hospitalized patients with severe COVID-19 pneumonia (PPTCOVID study): A prospective, randomised, single-blind, controlled trial.	Exercise or rehabilitation
Javed 2023	Effect Of Eight Hours Per Day Of Intermittent Self Prone Positioning For Seven Days On The Severity Of Covid-19 Pneumonia/ Acute Respiratory Distress Syndrome.	Exercise or rehabilitation
Javid 2022	The effects of Spirulina platensis supplementation on COVID-19 severity in critically ill patients: A randomized clinical trial	Nutrition and supplements
Jayakumar 2021	Standard care vs. awake prone position in adult non-intubated patients with acute hypoxaemic respiratory failure secondary to COVID-19 infection â€“ A multi-centre feasibility randomized controlled trial	Oxygen delivery
Jayanthi 2021	A randomized control study to evaluate the role of herbal immunomodulators in boosting the immunity and overall health of healthcare workers in COVID-19 wards: An exploratory, feedback clinical study	Traditional Chinese medicine
Jayanthi 2022	The role of herbal immunomodulators as adjuvant therapy for asymptomatic and mildly symptomatic covid-19: An exploratory clinical study	Traditional Chinese medicine
JaynierMoya 2023	Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical Trial (preprint)	Not a randomized trial
Jazani 2022	Dose Kelofan Syrup Effective for Clinical Symptoms and Biochemical Factorsin COVID-19 Patients? A double-Blind Clinical Trials	Traditional Chinese medicine
Jessop 2022	A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID	Randomized trial with no results
JiaLiu 2021	Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open label, Randomised Controlled Trial	Traditional Chinese medicine
Jiang 2020	A combination regimen by lopinave/litonawe, emtricitabine and tenofovir alafenamide fumarate for treatment of novel coronavirus pneumonia (TARCoV)	Not a randomized trial
JiangsuCancerInstitute&Hospital 2023	Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia	Randomized trial with no results
Jin 2021	Retraction Note to: Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.	Not a randomized trial
Jin 2022	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial (preprint)	Vaccine
Jin 2022	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.	Vaccine
Jin 2022	Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: twelve-month analyses of a randomized controlled trial	Vaccine

Jing 2022	Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in COVID-19 Patients	Not a randomized trial
Jing-XinLi 2023	Safety, Immunogenicity and Efficacy of Heterologous Boost with an Aerosolized Ad5-nCoV after Two-Dose Priming with Inactivated COVID-19 Vaccines in Adults: A Multicenter, Open-Label Trial	Vaccine
Joglekar 2022	Efficacy and Safety of a Phytopharmaceutical Drug Derived from Cocculus hirsutus in Adults with Moderate COVID-19: a Phase 2, Open-label, Multicenter, Randomized Controlled Trial	Traditional Chinese medicine
JooKim 2022	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device	Vaccine
JoonYoungSong 2023	Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: randomised, active-controlled, observer-blinded, phase 3 trial	Vaccine
JoseDavidSuarez 2023	LACTYFERRINâ„¢ Forte and ZINC Defenseâ„¢ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19	Randomized trial with no results
Joshi 2022	Monoclonal Antibody for COVID Treatment	Not a randomized trial
JuanaClaus 2022	BCG vaccination of healthcare workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomised placebo-controlled trial	Vaccine
JuliaCorominas 2022	Safety and immunogenicity of the protein-based PHH-IV compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.	Vaccine
Jung 2022	Psychological rehabilitation for isolated patients with COVID-19 infection: A randomized controlled study	Psychological and educational
Kaabi 2022	Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial (preprint)	Vaccine
Kaabi 2022	Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.	Vaccine
Kaabi 2023	Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial	Vaccine
Kadali 2021	Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.	Vaccine
Kageyama 2022	Lactobacillus plantarum induces innate cytokine responses that potentially provide a protective benefit against COVID-19: A single-arm, double-blind, prospective trial combined with an in vitro cytokine response assay	Not a randomized trial
Kalil 2021	Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.	Not a randomized trial
Kamalinejad 2021	The Clinical Efficacy of Tiban Syrup as Adjuvant Treatment in Patients with COVID-19: A Randomized, Double-Blind Clinical Trial	Traditional Chinese medicine
Kaminski 2022	Covid-19 morbidity decreases with Tixagevimab/cilgavimab preexposure prophylaxis in kidney transplant recipients non/low vaccine responders.	Not a randomized trial
Kaminski 2022	COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders/low-vaccine responders.	Not a randomized trial
kamran 2020	Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial (preprint)	Not a randomized trial
Kamran 2021	Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial	Not a randomized trial

Kannan 2022	A Randomized, Placebo Controlled, Double Blinded, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of AEV01 for Mild COVID19 in Elderly Patients at Risk of Complications (preprint)	Traditional Chinese medicine
Kara 2021	Effect of a single high dose of Vitamin D-3 on hospital length of stay in patients with moderate to severe COVID-19 A randomized clinical trial	Not a randomized trial
Karaahmet 2020	Potential effect of natural and anabolizan steroids in elderly patient with COVID-19	Not a randomized trial
Karampitsakos 2021	Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.	Not a randomized trial
Karan 2020	Clinical outcomes in patients with COVID-19 infection during phase IV studies of cladribine tablets for treatment of multiple sclerosis	Not a randomized trial
Karina 2021	The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on "Profibrotic Cytokine" IL-1Î² Levels in Severe and Critical COVID-19 Patients: A Preliminary Study	Not a randomized trial
Karina 2021	Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients	Not a randomized trial
Karosanidze 2022	Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial	Traditional Chinese medicine
KatherineSmith 2023	Safety of the NVX-CoV2373 COVID-19 Vaccine in Randomized Placebo-Controlled Clinical Trials	Vaccine
KatiaAlves 2022	Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial	Vaccine
Kaur 2022	Homoeopathy as an Adjuvant to Standard Care in Moderate and Severe Cases of COVID-19: A Single-Blind, Randomized, Placebo-Controlled Study.	Others
KaviSharma 2021	Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease 19 The IONIC Trial	Randomized trial with no results
Kawamata 2021	Efficacy of concurrent administration of tocilizumab with corticosteroids for patients with COVIDâ€□19	Not a randomized trial
Keech 2020	First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine (preprint)	Vaccine
Keech 2020	Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	Vaccine
KeithJosephChappell 2023	Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18â€“55 Years or â‰¥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial	Vaccine
KeLi 2023	Safety, Tolerability, and Immunogenicity of a CpG/Alum Adjuvanted SARS-CoV-2 Recombinant Protein Vaccine (ZR202-CoV) in Healthy Adults: Preliminary Report of a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial	Vaccine
Kellogg 2022	Days Alive and Free of Mechanical Ventilation in Patients with COVID-19-Associated ARDS: Methylprednisolone versus Dexamethasone	Not a randomized trial
Kelly 2023	Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial.	Vaccine
Kerekes 2021	Differential Effect of Vaccine Effectiveness and Safety on COVID-19 Vaccine Acceptance across Socioeconomic Groups in an International Sample	Not a randomized trial

Keschner 2022	Effectiveness of an anti-fog polymer coating in protective eyewear: a blinded, randomised controlled cross-over trial with healthcare providers in an emergency department setting	Personal protective equipment
Keusgen 2022	Medicinal plants for the treatment of long-Covid symptoms	Not exposed to or diagnosed COVID-19
Keyan 2022	Videoconferencing-delivered psychological intervention for the treatment of COVID-19 related psychological distress in University students: study protocol for a randomised controlled trial in India	Randomized trial with no results
Keyhani 2021	A telehealth-based randomized controlled trial: A model for outpatient trials of off-label medications during the COVID-19 pandemic.	Not a randomized trial
Khah 2021	The effect of online mindfulness program on physical pain, stress and depression in the covid-19 patients: A randomized control trail	Psychological and educational
Khairullin 2022	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-inÂ®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.	Vaccine
Khamis 2021	Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial	Not a randomized trial
Khan 2020	Ivermectin treatment may improve the prognosis of patients with COVID-19	Not a randomized trial
Khan 2022	Evaluation of safety and efficacy of Unani Add-on regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases-A Randomised Controlled Clinical Trial	Traditional Chinese medicine
Khan 2022	Efficacy of Combined Visual-Olfactory Training With Patient-Preferred Scents as Treatment for Patients With COVID-19 Resultant Olfactory Loss: A Randomized Clinical Trial	Not exposed to or diagnosed COVID-19
Kharat 2020	Self-proning in COVID-19 patients on low-flow oxygen therapy. A cluster randomised controlled trial	Oxygen delivery
Kharat 2021	Self-proning in COVID-19 patients on low-flow oxygen therapy: a cluster randomised controlled trial	Oxygen delivery
Kharat 2021	Self-proning in covid-19 patients on low-flow Oxygen therapy. A cluster randomised Controlled trial	Oxygen delivery
Kho 2022	Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.	Vaccine
Khobragade 2022	Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India	Vaccine
Khodakarim 2022	Effectiveness of Plasmapheresis Treatment in the Treatment of Patients with COVID-19 Disease	Not a randomized trial
Khorshiddoust 2022	Efficacy of a multiple-indication antiviral herbal drug (SaliraviraÂ®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study	Traditional Chinese medicine
Kienbacher 2021	The use of personal protection equipment does not impair the quality of cardiopulmonary resuscitation: A prospective triple-cross over randomised controlled non-inferiority trial	Personal protective equipment
Kim 2021	Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study.	Not a randomized trial
KimberlyAKrayn yak 2021	SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial	Vaccine

Kinoshita 2022	Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study) (BMC Medicine, (2022), 20, 1, (342), 10.1186/s12916-022-02518-7	Nutrition and supplements
Kintscher 2020	Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System	Not a randomized trial
Kishore 2023	Efficacy of the Unani Regimen as an Add-On to Standard Treatment in Hospitalised RT-PCR-Confirmed Mild to Moderate COVID-19 Patients: An Open-Label Randomized Controlled Trial.	Traditional Chinese medicine
Kjellberg 2021	Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19	Oxygen delivery
Kjellberg 2022	COVID-19 induced acute respiratory distress syndrome treated with Hyperbaric Oxygen: Interim safety report from a multicenter, randomised, open-label phase II clinical trial (COVID-19-HBO) (preprint)	Oxygen delivery
Kloka 2022	Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION	Randomized trial with no results
Koekenbier 2023	Bacillus Calmette-GuÃ©rin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial	Vaccine
Koen 2023	Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).	Vaccine
Koesnoe 2023	Safety of Cov2-Bio COVID-19 Vaccine in Healthy Populations Aged 18 years and Above in Indonesia	Vaccine
Kolev 2022	Echinacea purpurea for the long-term prevention of viral respiratory tract infections during COVID-19 pandemic: A randomized, open, controlled clinical study	Nutrition and supplements
Kolev 2022	Echinacea Purpurea For the Long-Term Prevention of Viral Respiratory Tract Infections During Covid-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study.	Traditional Chinese medicine
Kollias 2020	Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit?	Not a randomized trial
Körper 2021	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies	Not a randomized trial
Korper 2022	Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial	Not a randomized trial
Kosari 2021	The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial.	Others
Koshak 2021	Nigella sativa for the treatment of COVID-19;an open-label randomized controlled clinical trial	Traditional Chinese medicine
Koshak 2021	Nigella Sativa Supplementation Accelerates Recovery from Mild COVID-19: First Randomized Controlled Trial	Traditional Chinese medicine
Kostinov 2022	`Secretory IgA and course of COVID-19 in patients receiving a bacteria-based immunostimulant agent in addition to background therapy (preprint)	Not a randomized trial

Kotfis 2022	Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosisâ€"A Randomized Placebo Controlled Clinical Trial	Duplicate
Kotha 2022	NEPHROTOXICITY OF LIPOSOMAL AMPHOTERICIN B IN PATIENTS WITH RHINO-ORBITO-CEREBRAL MUCORMYCOSIS(ROCM) IN POST COVID PATIENTS -WHAT WE NEED TO KNOW?	Not a randomized trial
Kow 2021	The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.	Not a randomized trial
Kravchenko 2021	Covid-19 in pregnancy: Special characteristics of the course and rational therapy with recombinant interferon alfa-2b formulations	Not a randomized trial
Kremsner 2021	Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : AÂ phaseÂ 1 randomized clinical trial.	Vaccine
Kremsner 2021	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	Vaccine
KrishnaMohanVadrevu 2022	Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial	Vaccine
Kruer 2022	MORTALITY AMONG CRITICALLY ILL PATIENTS WITH COVID-19 WHO RECEIVED TOCILIZUMAB	Not a randomized trial
Kukreja 2022	A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US	Not a randomized trial
Kulchitskaya 2022	Experience in the Use of Physical Factors in the Rehabilitation of Patients after Pneumonia Associated with COVID-19	Exercise or rehabilitation
Kulkarni 2021	A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India (preprint)	Vaccine
Kulkarni 2021	A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India	Vaccine
Kulkarni 2023	Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study	Vaccine
Kumar 2021	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.	Vaccine
Kumbhakar 2022	Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Impact of Hydroxychloroquine (HCQ) as Post-exposure Prophylaxis and Early Treatment for COVID-19	Not a randomized trial
Kus 2022	Potential of High-Titer IgA Convalescent Plasma to Improve Survival and Symptoms in COVID-19 Patients	Not a randomized trial
Kusumawardani 2023	The effectiveness of incentive spirometry exercise on pulmonary function in COVID-19 survivors: a randomized controlled trial study	Exercise or rehabilitation
Kuut 2023	Efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19: results of a randomized controlled trial.	Psychological and educational
LabibSalem 2020	The possible beneficial adjuvant effect of Influenza vaccine to minimize the severity of COVID-19	Not a randomized trial
Lai 2023	The Impact of Vaccination Time on the Antibody Response to an Inactivated Vaccine against SARS-CoV-2 (IMPROVE-2): A Randomized Controlled Trial.	Vaccine

Lakhin 2021	Oxygen-helium gas mixture Â«HelioxÂ» for the treatment of respiratory failure in patients with new coronavirus infection Covid-19 (randomized single-center controlled trial)	Oxygen delivery
Lakkireddy 2021	Author Correction: Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease (Scientific Reports, (2021), 11, 1, (10641), 10.1038/s41598-021-90189-4)	Not a randomized trial
Lanthier 2020	[In patients hospitalized for COVID-19, does dexamethasone reduce 28-days mortality compared to standard treatment?]	Not a randomized trial
Lanthier 2021	In patients hospitalized for COVID-19 with hypoxia and systemic inflammation, does tocilizumab reduce 28-days mortality compared to standard treatment, and is it safe	Not a randomized trial
Latorre 2021	Use and efficacy of tocilizumab in patients with severe COVID-19 pneumonia	Not a randomized trial
Lau 2022	Pilot Phase Results of a Prospective, Randomized Controlled Trial of Narrowband Ultraviolet B Phototherapy in Hospitalized COVID-19 Patients.	Others
Launay 2022	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.	Vaccine
Launay 2022	Immunogenicity and Safety of Beta Adjuvanted Recombinant Booster Vaccine (preprint)	Vaccine
Launay 2022	Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine.	Vaccine
Launay 2022	Immunogenicity against SARS CoV-2 ancestral strain and variants of two new COVID-19 recombinant adjuvanted vaccines compared to BNT162b2 as a third dose following two doses of BNT162b2: a single-blinded multicenter randomized controlled trial	Vaccine
Lazarus 2021	The Safety and Immunogenicity of Concomitant Administration of COVID-19 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV, Multicentre Randomised Controlled Trial with Blinding (ComFluCOV) (preprint)	Vaccine
Lazarus 2021	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial	Vaccine
Lazarus 2022	Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.	Vaccine
Lazarus 2022	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.	Vaccine
Lazarus 2022	Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial	Vaccine
Leal 2022	Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial (preprint)	Vaccine
Leal-MartÃnez 2022	Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial	Nutrition and supplements
LeBon 2021	Efficacy and safety of oral corticosteroids and olfactory training in the management of COVID-19-related loss of smell.	Not a randomized trial

Lee 2022	Pulse Oximetry for Monitoring Patients with Covid-19 at Home - A Pragmatic, Randomized Trial.	Others
LeGouge 2022	Clinical trials in times of pandemic: Adapting without losing quality (1/2). Embed a COVID-19 group in an ongoing trial	Not exposed to or diagnosed COVID-19
Lehingue 2022	Physiologic Effects of the Awake Prone Position Combined With High-Flow Nasal Oxygen on Gas Exchange and Work of Breathing in Patients With Severe COVID-19 Pneumonia: A Randomized Crossover Trial	Exercise or rehabilitation
Lenkens 2020	[Medication and comedication in COVID-19 patients]	Not a randomized trial
Leung 2022	Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine.	Vaccine
Lewis-Wolfson 2022	Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19	Not a randomized trial
Li 2020	Application of CareDose 4D combined with Karl 3D technology in the low dose computed tomography for the follow-up of COVID-19	Diagnostic imaging
Li 2020	Evaluation of low-dose CT protocol of novel coronavirus pneumonia based on infection prevention and control	Diagnostic imaging
Li 2020	Regarding â€œRuxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): AÂ multicenter, single-blind, randomized controlled trialâ€□	Not a randomized trial
Li 2020	COVID-19: Repeatedly Video-Watching vs Combined Video-Watching and Live Demonstration as Training to Healthcare Providers for Donning and Doffing Personal Protective Equipment	Psychological and educational
Li 2020	The Effect of Cognitive Behavioral Therapy on Depression, Anxiety, and Stress in Patients With COVID-19: A Randomized Controlled Trial	Psychological and educational
Li 2020	Convalescent Plasma Treatment in Severe and Life-Threatening COVID-19: A Randomized Controlled Clinical Trial	Randomized trial with no results
Li 2021	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.	Vaccine
Li 2021	Safety, tolerability, pharmacokinetics and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: A randomized, double-blind, placebo-controlled, phase I study.	Not exposed to or diagnosed COVID-19
Li 2021	Shumian capsule improves symptoms of sleep mood disorder in convalescent patients of Corona Virus Disease 2019.	Not exposed to or diagnosed COVID-19
Li 2022	Genetically predicted high IGF-1 levels showed protective effects on COVID-19 susceptibility and hospitalization: a Mendelian randomisation study with data from 60 studies across 25 countries.	Not a randomized trial
Li 2022	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.	Vaccine
Li 2022	Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.	Vaccine
Li 2022	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.	Vaccine

Li 2022	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.	Vaccine
Li 2023	Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.	Vaccine
Li Xingang 2020	Clinical study of glucocorticoids in the treatment of severe patients with novel coronavirus pneumonia	Not a randomized trial
liangjianghuang 2021	Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial	Exercise or rehabilitation
LiangZhang 2022	Intranasal delivery of NS1-deleted influenza virus vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response	Not a randomized trial
Libster 2021	Early convalescent plasma may lower risk and progression of COVID in seniors â€" Argentine trial	Not a randomized trial
Lien 2022	Safety and Immunogenicity of SARS-Cov-2 Vaccine MVC-COV1901â€“ Do Elderly Need a Higher Dose? (preprint)	Vaccine
Lim 2021	Design and Implementation Of ICE-COVID, A Double-Blind Randomised Placebo-Controlled Trial on The Efficacy of Iota-Carrageenan Nasal and Throat Spray for Covid-19 Prophylaxis	Randomized trial with no results
Lim 2022	Home-use Photobiomodulation Device Treatment Outcomes for COVID-19 (preprint)	Others
Lin 2021	Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis	Not a randomized trial
Lin 2021	Mycobacterium vaccae Nebulization in the Treatment of COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial	Others
LindseyRBaden 2021	Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge	Vaccine
LineMNanque 2023	Effect of Distributing Locally Produced Cloth Facemasks on COVID-19-Like Illness and All-Cause Mortality â€" a Cluster-Randomised Controlled Trial in Urban Guinea-Bissau (preprint)	Personal protective equipment
LineMNanque 2023	Effect of Distributing Locally Produced Cloth Facemasks on COVID-19-Like Illness and All-Cause Mortality â€" a Cluster-Randomised Controlled Trial in Urban Guinea-Bissau	Personal protective equipment
Lioznov 2022	Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia (preprint)	Vaccine
Lioznov 2023	Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.	Vaccine
Lisa 2021	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico	Vaccine
Liu 2020	Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19	Exercise or rehabilitation
Liu 2020	[Significance and operation mode of moxibustion intervention for the group under quarantine after close contact with COVID-19]	Exercise or rehabilitation
Liu 2020	Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study	Not a randomized trial
Liu 2020	The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.	Not a randomized trial

Liu 2020	Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study	Randomized trial with no results
Liu 2020	[Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients]	Traditional Chinese medicine
Liu 2021	Effect of qigong exercise and acupressure rehabilitation program on pulmonary function and respiratory symptoms in patients hospitalized with severe COVID-19	Exercise or rehabilitation
Liu 2021	Effect of qigong exercise and acupressure rehabilitation program on pulmonary function and respiratory symptoms in patients hospitalized with severe COVID-19: a randomized controlled trial	Exercise or rehabilitation
Liu 2021	Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.	Not a randomized trial
Liu 2021	The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic.	Randomized trial with no results
Liu 2021	Combination of Hua Shi Bai Du Granule (Q-14) and Standard Care in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open-label, Randomized Controlled Trial	Traditional Chinese medicine
Liu 2021	Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.	Vaccine
Liu 2022	Effectiveness and safety analysis of SanHanHuaShi granules for the treatment of coronavirus disease 2019: Study protocol and statistical analysis plan for a randomized, parallel-controlled, open-label clinical trial	Randomized trial with no results
Liu 2022	Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial (preprint)	Vaccine
Liu 2022	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial	Vaccine
Liu 2022	Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial (preprint)	Vaccine
Liu 2022	Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial	Vaccine
Liu 2022	A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19	Not exposed to or diagnosed COVID-19
Liu 2023	Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].	Vaccine
LiuSTH 2023	Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study.	Not exposed to or diagnosed COVID-19
Llurda-Almuzara 2022	Effects of Adding an Online Exercise Program on Physical Function in Individuals Hospitalized by COVID-19: A Randomized Controlled Trial	Exercise or rehabilitation
Loas 2021	Comment on 'Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial'.	Not a randomized trial

Loc 2022	Traditional Vietnamese medicine Kovir capsule in patients with mild COVID-19: A double-blind randomized controlled trial.	Traditional Chinese medicine
Loc 2023	Traditional Vietnamese medicine Kovir capsule for non-severe COVID-19 patients: A phase III double-blind randomized controlled trial.	Traditional Chinese medicine
Logunov 2021	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.	Vaccine
Logunov 2021	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021)	Vaccine
Longobardi 2023	Effects of a 16-week home-based exercise training programme on health-related quality of life, functional capacity, and persistent symptoms in survivors of severe/critical COVID-19: a randomised controlled trial.	Exercise or rehabilitation
Lopes 2021	Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTlon cOroNavirus)â€“Coalition IV Trial	Randomized trial with no results
Lopez-Zuñiga 2020	High-Dose Corticosteroid Pulse TherapyÂ Increases the Survival Rate in COVID-19 Patients at Risk of Cytokine Storm (preprint)	Not a randomized trial
Love 2022	Daily use of lateral flow devices by contacts of confirmed COVID-19 cases to enable exemption from isolation compared with standard self-isolation to reduce onward transmission of SARS-CoV-2 in England: a randomised, controlled, non-inferiority trial	Personal protective equipment
Lovre 2021	Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial	Randomized trial with no results
Low 2022	A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine	Vaccine
Lu 2021	Jing Si Herbal Drink as a Prospective Adjunctive Therapy for COVID-19 Treatment: Molecular evidence and mechanisms	Not a randomized trial
Lu 2023	Clinical Study on the Emotional Intervention of Patients with Asymptomatic and Mild Novel Coronavirus (COVID-19).	Psychological and educational
LuisCallejasRubio 2020	De Los Pulsos De Corticoides En Pacientes Con SÃndrome De LiberaciÃ³n De Citoquinas Inducido Por InfecciÃ³n Por Sars-Cov-2	Not a randomized trial
Lukhna 2022	Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial.	Others
Luo 2020	Application of chest low-dose CT screening of Corona Virus Disease 2019 with a third-generation dual-source scanner	Diagnostic imaging
Luo 2021	The preventive effect of Xuebijing injection against Cytokine Storm for severe patients with COVID-19: a prospective randomized controlled trial	Traditional Chinese medicine
Luo 2022	A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults	Vaccine
Madabhushi 2020	Time to adapt in the pandemic era: a prospective randomized non -inferiority study comparing time to intubate with and without the barrier box	Personal protective equipment
Madhavan 2022	Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial	Vaccine
Madhi 2021	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	Vaccine

Madhi 2021	Efficacy of the ChAdOxl nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	Vaccine
Madhi 2021	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.	Vaccine
Madhi 2022	Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	Vaccine
Mahajan 2021	Role of Dexamethasone on Oxygen Requirement, Mortality, and Survival Incidence among COVID-19 Patients: Quasi-Experimental Study.	Not a randomized trial
Mahasirimongkol 2022	The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine	Not a randomized trial
Mahevas 2020	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial	Not a randomized trial
Mair 2022	Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer	Not a randomized trial
Majewski 2021	Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.	Not a randomized trial
Majumdar 2023	Adjunct tele-yoga on clinical status at 14 days in hospitalized patients with mild and moderate COVID-19: A randomized control trial.	Exercise or rehabilitation
Malchair 2022	A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study pr	Randomized trial with no results
Mammen 2021	Assessing of the Factors Associated with Mortality Among the Patients of PLACID Trial (A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Dise	Not a randomized trial
Marashian 2022	Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study	Others
Marchese 2023	NVX-CoV2373 Vaccine Efficacy Against Hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial	Vaccine
MariaTsilika 2021	ACTIVATE-2: A DOUBLE-BLIND RANDOMIZED TRIAL OF BCG VACCINATION AGAINST COVID19 IN INDIVIDUALS AT RISK	Vaccine
Marquez-Algaba 2022	COVID-19 Follow-App. Mobile App-Based Monitoring of COVID-19 Patients after Hospital Discharge: A Single-Center, Open-Label, Randomized Clinical Trial	Psychological and educational
Marshall 2020	A phase II trial to promote recovery from COVID-19 with endocrine therapy	Randomized trial with no results
Martin 2022	Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis	Not a randomized trial
Martin-Orozco 2023	Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.	Vaccine

Martins-Filho 2022	Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: A systematic review and meta-analysis of blinded, placebo- controlled, randomized clinical trials (preprint)	Not a randomized trial
Martynova 2022	Effect of recombinant interferon alfa-2b on cytokine production activity of immune system cells in children with COVID-19	Not a randomized trial
MasiÃ¡ 2020	Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19	Not a randomized trial
Masuda 2022	A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: an interim report	Vaccine
Mateo 2020	Remdesivir Reduces Time to Recovery in Adults Hospitalized with COVID-19: A Meaningful Step in Therapeutic Discovery	Not a randomized trial
Matino 2023	Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial.	Nutrition and supplements
Mazaherpour 2022	Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients	Not a randomized trial
McCarthy 2022	Novel Strategies for the Treatment of COVID-19	Not a randomized trial
McClelland 2021	Low-dose whole thorax radiation therapy for COVID-19 pneumonia: inpatient onboarding process for a randomized controlled trial.	Randomized trial with no results
McClellandIii 2021	Low-Dose Whole Thorax Radiation Therapy for COVID-19 Pneumonia: Inpatient Onboarding Process for a Randomized Controlled Trial	External organ support
McEneny-King 2021	Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.	Randomized trial with no results
McNarry 2022	Inspiratory Muscle Training Enhances Recovery Post COVID-19: A Randomised Controlled Trial	Exercise or rehabilitation
McQuade 2021	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates	Not a randomized trial
Mease 2022	EfficacitÃ© et tolÃ©rance Ã long terme de l'upadacitinib chez les patients prÃ©sentant un rhumatisme psoriasique rÃ©fractaire aux traitements biologiques : rÃ©sultats Ã 2 ans de l'Ã©tude de phase III SELECT-PsA 2	Not exposed to or diagnosed COVID-19
MedicalUniversityofVienna 2023	Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged â‰¥60 Years	Randomized trial with no results
MedinaGamero 2021	Efficacy and effectiveness of COVID-19 vaccines	Vaccine
Medina-Pestana 2021	Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results	Not a randomized trial
Megahed 2022	COULD DEXAMETHASONE ADMINISTRATION BE LIFESAVING IN PATIENTS ON IMMUNOSUPPRESSION INFECTED BY COVID 19?	Not a randomized trial
Meister 2021	Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2 (vol 222, pg 1289, 2020)	Not a randomized trial
Memon 2022	A Randomized Control Trial of Ravulizumab for Treatment of Patients with COVID-19 Infection and Kidney Injury	Not exposed to or diagnosed COVID-19
Meng 2020	An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area	Not a randomized trial
Meng 2021	Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: A Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.	Not exposed to or diagnosed COVID-19

Menga 2021	Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial	Oxygen delivery
Menga 2021	Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial.	Oxygen delivery
Mera-Cordero 2021	Double-blind Placebo-controlled Randomized Clinical Trial to Assess the Efficacy of Montelukast in Mild to Moderate Respiratory Symptoms of Patients With Long COVID E-SPERANZA COVID PROJECT Study Protocol (preprint)	Randomized trial with no results
Mera-Cordero 2022	Erratum: Correction to: Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol (Trials (2022) 23 1 (19))	Randomized trial with no results
Mertes 2021	Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation	Randomized trial with no results
Mertes 2022	LEAF- 4L6715 enhances oxygenation in patients with acute respiratory distress syndrome (ARDS) due to severe COVID-19: Final results of a phase I/II clinical trial (preprint)	Not a randomized trial
Mesri 2021	The effects of combination of <i>Zingiber officinale</i> and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial.	Traditional Chinese medicine
Metzger 2022	COVID-19: Does azithromycin plus hydroxychloroquine reduce mortality rate?	Not a randomized trial
Meylan 2021	Safety of the BNT162b2 mRNA vaccine (Pfizer) in a phase 4 trial	Not a randomized trial
Meylan 2021	Safety and efficacy of the Oxford-AstraZeneca vaccine: Interim analysis of four randomized controlled trials	Vaccine
Meza 2021	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials	Not a randomized trial
Miachon 2022	Analysis of the Potential of Blood Transvascular Sublingual with Light-Emitting Diode Irradiation in COVID-19 Patients: A Pilot Clinical Study	Exercise or rehabilitation
MichaelBonelli 2021	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial	Vaccine
MichelleLiu 2023	Disability and COVID-19 Vaccination Policy: A Comparative Study (preprint)	Randomized trial with no results
MikeFralick 2021	Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial	Oxygen delivery
Millat-Martinez 2021	Convalescent plasma for outpatients with early COVID-19 (preprint)	Not a randomized trial
MiriamFezzi 2022	Early prone positioning does not improve the outcome of patients with mild pneumonia due to SARS-CoV-2: results from an open-label, randomized controlled trial (the EPCoT Study).	Exercise or rehabilitation
Moench 2022	A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19 (preprint)	Not exposed to or diagnosed COVID-19
Mohamed 2021	The effect of aerobic exercise on immune biomarkers and symptoms severity and progression in patients with COVID-19: A randomized control trial	Exercise or rehabilitation

MohamedHussein 2022	Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study	Not exposed to or diagnosed COVID-19
MohammadBargahi 2021	Effect of Balloon-Blowing on Dyspnea and Oxygenation in Noncritical Adult Covid19 Patients: A Pilot Study	Exercise or rehabilitation
Mohammadian-Hafshejani 2022	Effectiveness of a social cognitive theory-based distance educational intervention on anxiety in families of patients with COVID 19	Psychological and educational
Mohammadzadeh 2020	Effectiveness of electronic health care and drug monitoring program to prevent COVID-19 and adherence to therapeutic regimen in patients with ischemic heart disease - A pilot study	Others
Moisset 2021	Nasopharyngeal swab-induced pain for SARS-CoV-2 screening: a randomised controlled trial of conventional and self-swabbing.	Not exposed to or diagnosed COVID-19
Mok 2022	A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac.	Vaccine
Molina 2021	Ruxolitinib for the Management of Severe Pneumonia Caused by SARS-CoV-2. Exploring the Combination with dexamethasone	Not a randomized trial
Molino 2022	Randomized placebo-controlled trial of oral tannin supplementation on COVID-19 symptoms, gut dysbiosis and cytokine response	Nutrition and supplements
Mollerup 2021	Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting.	Oxygen delivery
Moniuszko-Malinowska 2021	Convalescent Plasma Transfusion for the Treatment of COVID-19â€”Experience from Poland: A Multicenter Study	Not a randomized trial
Monk 2022	Impact of Treatment of Hospitalised COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial	Not exposed to or diagnosed COVID-19
Montejano 2022	Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Three Countries of LATAM: Argentina, Chile, and Colombia	Not a randomized trial
Moreira 2022	Nasal anti-CD3 mAb (Foralumab) dampens CD3+ T effector function and decreases NKG7 in COVID-19 through a mechanism involving GIMAP-7 and TGFb1 (preprint)	Not a randomized trial
Moreira 2022	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine	Vaccine
Mosadegh 2022	The effect of Nutrition Bio-shield superfood (NBS) on disease severity and laboratory biomarkers in patients with COVID-19: A randomized clinical trial	Nutrition and supplements
Moser 2022	Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19	Not a randomized trial
Mostafavi 2023	Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.	Vaccine
Mousavi 2021	Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, Randomized, Controlled Trial.	Not a randomized trial
MousaviDarzikolaee 2021	Low-dose whole-lung irradiation in severe COVID-19 pneumonia: a controlled clinical trial.	Not a randomized trial
Mugheddu 2020	Safety of secukinumab treatment in COVID-19 affected psoriatic patients.	Not a randomized trial
Mukherjee 2021	Homeopathic Medicines Used as Prophylaxis in Kolkata during the COVID-19 Pandemic: A Community-Based, Cluster-Randomized Trial	Inaccessible full text
Mulhern 2021	Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-COV2 (Ad26.COV2.S) Vaccine in Dialysis Patients.	Vaccine

Mulligan 2020	Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults	Vaccine
Mungmunpuntipantip 2022	Regdanvimab Treatment of COVID-19.	Not a randomized trial
Munro 2022	Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2 (preprint)	Vaccine
Munro 2022	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised t	Vaccine
Munshi 2022	An open-labelled, randomised, controlled, proof of concept clinical trial to evaluate the efficacy of AYUSH interventions (Cap.Torchnil + Tab. Febcin) as add-on therapy in the clinical management of moderate Covid-19 patients.	Traditional Chinese medicine
Munshi 2022	An open labeled, randomized, controlled clinical study to evaluate the efficacy of Torchnil capsules and Febcin tablet as add-on therapy for Covid-19 patients.	Traditional Chinese medicine
Murray 2021	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).	Randomized trial with no results
Myasnikov 2020	Efficacy of Interferon Gamma in the Prevention of SARS-CoV-2 Infection (COVID-19): Results of a Prospective Controlled Trial	Not a randomized trial
Nadler 2022	Sodium Pyruvate Inhalation for COVID-19 Long Hauler Symptoms - An Effective and Inexpensive Treatment	Not exposed to or diagnosed COVID-19
Nagy 2022	The Influence of Manual Diaphragm Release Technique Combined with Inspiratory Muscle Training on Selected Persistent Symptoms in Men with Post-Covid-19 Syndrome: A Randomized Controlled Trial	Not exposed to or diagnosed COVID-19
Nair 2021	Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia.	Oxygen delivery
Nakamura 2022	A Phase 1, Randomized, Placebo-Controlled Study of Molnupiravir in Healthy Japanese to Support Special Approval in Japan to Treat COVID-19	Not exposed to or diagnosed COVID-19
Nakaya 2022	Tratamiento de pacientes con COVID-19 en HemodiÃ¡lisis: Eficacia de Remdesivir Treatment of patients with COVID-19 on Hemodialysis: Efficacy of Remdesivir	Not a randomized trial
Namazi 2020	Ellagic acid can possibly be an adjuvant treatment for COVID-19	Not a randomized trial
Nancy 2022	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)	Vaccine
Nanthapisal 2022	A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines	Vaccine
Narayanababu 2022	Evaluation of Efficacy and Safety of Clevira as an Add on Drug in Mild to Moderate COVID-19 Positive Patients- A Randomised Control Trial	Traditional Chinese medicine
Natarajan 2021	Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized c	Traditional Chinese medicine
NathanielBonfanti 2023	Core warming of coronavirus disease 2019 (COVID-19) patients undergoing mechanical ventilation - a pilot study	Others

NationalResearch Center-InstituteofImmunologyFederalMedical-BiologicalAgencyofRussia 2022	Evaluation of Safety & Efficacy of MIR 19 Â® Inhalation Solution in Patients With Mild COVID-19	Randomized trial with no results
NationalTaiwanUniversityHospital 2022	Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.	Randomized trial with no results
NationalTaiwanUniversityHospital 2023	Teletechnology-assisted Home-based Exercise Program for Severe COVID-19	Randomized trial with no results
NationalTaiwanUniversityHospital 2023	Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities	Randomized trial with no results
Natori 2022	Single Blind Randomized Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as an Additional Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant (SOT) Recipients	Vaccine
Natori 2023	A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients.	Vaccine
NawalAlKaabi 2022	Safety and immunogenicity of a heterologous boost with a recombinant vaccine, NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase 2 randomised, double-blinded, controlled clinical trial	Vaccine
Nay 2023	Prone position versus usual care in hypoxemic COVID-19 patients in medical wards: a randomised controlled trial.	Exercise or rehabilitation
Nayak 2022	Efficacy of individualized homeopathy regimen as an adjunct to standard of care of COVID-19: A randomized, single-blind, placebo-controlled study	Traditional Chinese medicine
Nayak 2022	Efficacy of individualized homeopathy as an adjunct to standard of care of COVID-19: A randomized, single-blind, placebo-controlled study.	Traditional Chinese medicine
Nazir 2022	The effectiveness of high-flow nasal cannula and standard non-rebreathing mask for oxygen therapy in moderate category COVID-19 pneumonia: Randomised controlled trial.	Oxygen delivery
Nesari 2021	Neem (Azadirachta Indica A. Juss) Capsules for Prophylaxis of COVID-19 Infection: A Pilot, Double-Blind, Randomized Controlled Trial	Traditional Chinese medicine
NgocTan 2022	Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trial	Vaccine
Nguyen 2022	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.	Vaccine
Ni 2021	Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial	Traditional Chinese medicine
Nichols 2021	553. Outcomes in Patients Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection After Treatment with Monoclonal Antibody Therapy (MAT) in the Outpatient Setting	Not a randomized trial
Nikolaeva 2023	[In vitro activity of human recombinant interferon gamma against SARS-CoV-2 virus].	Not a randomized trial
Niwa 2021	Safety and efficacy of remdesivir, baricitinib and highâ€□dose steroid combination therapy in patients hospitalized with COVIDâ€□19	Not a randomized trial

Niyomnaitham 2022	Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults (pre	Vaccine
Niyomnaitham 2022	Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial.	Vaccine
Niyomnaitham 2022	Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.	Vaccine
Niyomnaitham 2023	Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.	Vaccine
Niyomnaitham 2023	Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variants	Vaccine
No available	ASCIA 2022 Conference	Not a randomized trial
NoorAzhar 2020	COVID-19 aerosol box as protection from droplet and aerosol contaminations in healthcare workers performing airway intubation: a randomised cross-over simulation study	Personal protective equipment
Not reported	Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic	Removed from preprint server
NovatekPharmaceuticals 2023	Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.	Randomized trial with no results
Novitzky-Basso 2022	A phase 1/2a study of decidual stromal cells for the treatment of COVID-19 ARDS	Not a randomized trial
Ntanasis-Stathopoulos 2022	Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals.	Not a randomized trial
Nuñez 2022	Harm of early dexamethasone for COVID-19 and bias in randomized trials	Not a randomized trial
Nursilawatisyamsi 2021	The effectiveness of poly-herbal adjuvants for the standard treatment of COVID 19 in patients withmoderate degree	Traditional Chinese medicine
Nyirenda 2022	Fluvoxamine for the treatment of COVID-19	Not a randomized trial
Oakes 2021	Effect of Opt-In vs Opt-Out Framing on Enrollment in a COVID-19 Surveillance Testing Program: The COVID SAFE Randomized Clinical Trial.	Not exposed to or diagnosed COVID-19
Ochoa-Azze 2022	Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.	Vaccine
Ogar 2022	Oral Presentation: Adverse Events to COVID-19 Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries	Not a randomized trial
Okan 2022	Evaluating the Efficiency of Breathing Exercises via Telemedicine in Post-Covid-19 Patients: Randomized Controlled Study	Not exposed to or diagnosed COVID-19

Ökmen 2021	Comparison of two different lung ultrasound imaging protocols in COVID-19 pneumonia.	Diagnostic imaging
Okumus 2021	Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.	Not a randomized trial
Olender 2021	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality	Not a randomized trial
Omma 2022	Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Turkey: A randomized trial.	Vaccine
Omranifar 2023	Effect of Aqueous Extract of Violet on Fever in Patients with COVID-19: A Randomized Clinical Trial	Others
OnerCengiz 2021	Effect of deep breathing exercise with Triflo on dyspnoea, anxiety and quality of life in patients receiving covid-19 treatment: A randomized controlled trial	Exercise or rehabilitation
Ortiz 2021	The clinical efficacy of low-dose whole-lung irradiation in moderate-to-severe COVID-19 pneumonia: RTMX-20 trial	Not a randomized trial
Ospina-Tascon 2021	Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial	Oxygen delivery
Ota 2023	Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history.	Vaccine
Othman 2022	Effects of awake-prone positioning on oxygenation and physiological outcomes in non-intubated patients with COVID-19: A randomized controlled trial.	Oxygen delivery
Ozdarendeli 2022	Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials	Vaccine
Ozlu 2021	The effects of progressive muscle relaxation exercises on the anxiety and sleep quality of patients with COVID-19: A randomized controlled study	Exercise or rehabilitation
Ozlu 2022	Efficacy of a home exercise program on balance, kinesiophobia, pain and quality of life in post-COVID-19 patients Efficacy of a home exercise program in post COVID	Exercise or rehabilitation
Pablo-Marcos 2021	[YODADA Y PEROXIDO DE HIDROGENO EN PACIENTES CON COVID-19].	Not a randomized trial
Pablo-Marcos 2022	Utility of mouth rinses with povidone-iodine and hydrogen peroxide in patients with COVID-19 Utilidad de los enjuagues con povidona yodada y perÃ³xido de hidrÃ³geno en pacientes con COVID-19	Not a randomized trial
Padilla 2021	Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California's Central Valley.	Not a randomized trial
Paguntalan 2021	Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Pr	Not exposed to or diagnosed COVID-19
Pan 2021	Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials	Vaccine
Pan 2021	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.	Vaccine
Pan 2021	Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial	Vaccine

Pandit 2021	Effectiveness and safety of thymosin alpha-1 in patients with severe COVID-19: A prospective open-label study	Not a randomized trial
Pang 2020	Efficacy and tolerability of bevacizumab in patients with severe Covid -19	Not a randomized trial
Pang 2022	Qingjin Yiqi granules for post-COVID-19 condition: A randomized clinical trial.	Not exposed to or diagnosed COVID-19
Panigada 2020	Effect of heparin on viscoelastic parameters of COVID-19 critically ill patients. A Viscoelastic Coagulation Monitor (VCM) analysis	Not a randomized trial
Pannus 2022	Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial (preprint)	Vaccine
Pannus 2022	Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial	Vaccine
Papachristofilou 2021	Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study	Others
Papamanoli 2020	76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia	Not a randomized trial
ParcdeSalutMar 2022	Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome	Randomized trial with no results
Patankar 2022	Efficacy and safety of polyherbal formulation as an add-on to standard-of-care in mild-to-moderate COVID-19: A randomized, double-blind, placebo-controlled trial.	Traditional Chinese medicine
Patchen 2021	Genetically Predicted Serum Vitamin D and COVID-19: A Mendelian Randomization Study	Not a randomized trial
PaulRHunter 2021	Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel.	Vaccine
Pehlivan 2022	The effectiveness of POST-DISCHARGE telerehabilitation practices in COVID-19 patients: Tele-COVID study-randomized controlled trial	Exercise or rehabilitation
PekingUnionMedicalCollegeHospital 2023	Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness	Randomized trial with no results
PereMillat-Martinez 2021	Convalescent plasma for outpatients with early COVID-19	Others
Perez-Jacobo 2020	Phase I and Preliminary Results of a Phase II Study (TERAPLASCoV2) of Convalescent Plasma in Patients with Severe and Life-Threatening Pneumonia Caused By Sars-Cov-2	Not a randomized trial
Pérez-Martínez 2021	A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: (RELEASE NCT04578210)	Randomized trial with no results
Pérez-Rodriguez 2022	A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity	Vaccine
Perkins 2022	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial.	Oxygen delivery
Perkins 2022	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial: The Journal of the American Medical Association	Oxygen delivery

Perrone 2021	Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial	Not a randomized trial
Pesko 2022	Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients.	Not a randomized trial
Petrak 2020	Early Tocilizumab Dosing is Associated with Improved Survival In Critically Ill Patients Infected With Sars-CoV-2	Not a randomized trial
Pfeifer 2021	Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.	Not exposed to or diagnosed COVID-19
PfizerInc 2022	AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19 IN HOSPITALIZED PARTICIPANTS WHO ARE IMMUNOCOMPROMISED	Randomized trial with no results
Pham 2021	541. Comparing Patients with Severe COVID-19 Who Improve to the Point of Discharge Following an Abbreviated Course (< 5 Days) of Remdesivir (RDV) Versus a Standard Course (â‰¥5 Days)	Not a randomized trial
Philip 2022	An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial	Not exposed to or diagnosed COVID-19
PhilipeGobeil 2021	Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older	Vaccine
Pierce 2021	Does Preventing Intubation in COVID-19 Save Lives? A CRUSH-COVID Multi-Center Study of the Outcomes of Advanced Respiratory Support Escalation in COVD-19	Not a randomized trial
Pimentel 2021	Effect of immunonutrition on serum levels of C-reactive protein and lymphocytes in patients with COVID-19: a randomized, controlled, double-blind clinical trial.	Nutrition and supplements
Pimpinelli 2021	Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.	Vaccine
Pinto 2023	Prefrontal tDCS modulates autonomic responses in COVID-19 inpatients.	Others
PioLopez 2023	Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents	Vaccine
Piralla 2020	Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?	Not a randomized trial
Pitisuttithum 2021	Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial (preprint)	Vaccine
Pitisuttithum 2022	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial	Vaccine
Pittet 2023	Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.	Vaccine
Plaza 2020	Use of Convalescent Plasma in COVID-19 Patients: Guayaquil, Ecuador Experience	Not a randomized trial
Plaze 2020	Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study	Randomized trial with no results

Plaze 2020	[Repurposing chlorpromazine to treat COVID-19: the reCoVery study]	Randomized trial with no results
Poh 2022	Evaluation of the Safety and Immunogenicity of Different COVID-19 Vaccine Combinations in Healthy Individuals: Study Protocol for a Randomized, Subject-blinded, Controlled Phase 3 Trial [PRIBIVAC] (preprint)	Randomized trial with no results
Poh 2022	Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial	Vaccine
Poh 2022	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.	Vaccine
Polack 2020	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	Vaccine
Polineni 2021	A phase iia, double-blinded, randomized placebo-controlled trial of mapkapk2 inhibition by ati-450 in treatment of moderate-severe covid-19 pneumonia	Randomized trial with no results
Pompeii 2020	Training and Fit Testing of Health Care Personnel for Reusable Elastomeric Half-Mask Respirators Compared With Disposable N95 Respirators	Personal protective equipment
Poncin 2022	Systems on Top of Nasal Cannula Improve Oxygen Delivery in Patients with COVID-19: a Randomized Controlled Trial	Oxygen delivery
Popovych 2021	A randomized, open-label, multicentre, comparative study of therapeutic efficacy, safety, and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb, in the tr	Traditional Chinese medicine
Potere 2020	Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. (Special Issue: Coronavirus (COVID-19) collection.)	Not a randomized trial
Poulakou 2021	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.	Not a randomized trial
Pourfard 2023	The Effect of Tang Forte (Royal Jelly) Capsule on Hypoglycemia and Clinical Course in COVID-19 Patients Under Corticosteroid Therapy.	Nutrition and supplements
Premachandran 2021	AVIFAVIR in Treating Patients with Moderate COVID 19...Ivashchenko AA, Kirill AD, Natalia VV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2021;	Not a randomized trial
Promomed 2023	Safety and Efficacy of the Therapy With BREINMAXÂ® for the Treatment of Patients With Asthenia After COVID-19	Randomized trial with no results
Protti 2022	Lung response to prone positioning in mechanically-ventilated patients with COVID-19	Not a randomized trial
Pu 2020	An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (preprint)	Vaccine
Pu 2021	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: a phase I randomized, double-blinded, controlled trial	Vaccine
Puga-Gomez 2023	Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.	Vaccine
Pulsipher 2021	Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?	Not a randomized trial

Pushkala 2021	Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial (preprint)	Not a randomized trial
Puthanakit 2022	Heterologous Prime-boost of SARS-CoV-2 Inactivated Vaccine and mRNA BNT162b2 among Healthy Thai Adolescents	Vaccine
Putilina 2021	[The result of prospective randomized study CITADEL - the efficacy and safety of drug cytoflavin in postcovid rehabilitation]	Not exposed to or diagnosed COVID-19
Qamar 2020	Protective Effects of CVD and DM Medications in SARS-CoV-2 Infection	Not a randomized trial
Qian 2022	Effect of Awake Prone Positioning by Different Oxygen Delivery Systems in Adults Hospitalized with COVID-19	Oxygen delivery
QiluPharmaceuticalCo 2022	A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19	Randomized trial with no results
QiluPharmaceuticalCo 2023	A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19	Randomized trial with no results
Qingguang 2022	Effectiveness of Liu-zi-jue exercise on coronavirus disease 2019 in the patients: a randomized controlled trial.	Exercise or rehabilitation
RaburnMallory 2021	Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial	Vaccine
RachesElla 2020	Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report	Vaccine
Raffi 2021	536. Clinical Outcomes of Hospitalized COVID-19 Patients Treated with Remdesivir-NEAT ID 909REM Study	Not a randomized trial
Rahman 2022	Methylprednisolone Treatment Versus Standard Supportive Care for Adult COVID-19 Mechanically Ventilated, Acute Respiratory Distress Syndrome Patients	Not a randomized trial
Rais 2021	A Randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of Asymptomatic and Mild COVID-19 patients-Experiences of a Lucknow based Level 2 hospital of Uttar Pradesh, India	Traditional Chinese medicine
Raj 2020	Effect of a novel ayurvedic preparation, Raj Nirvan Bati (rnb), on symptomatic patients of covid-19	Traditional Chinese medicine
Ramacciotti 2021	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial	Not exposed to or diagnosed COVID-19
Ramasamy 2020	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	Vaccine
Ramasamy 2020	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (vol 396, pg 1979, 2020)	Vaccine
Ramos 2021	Effect of rivaroxaban (10mg) versus observation on the risk of thrombosis at discharge in individuals with covid-19	Not exposed to or diagnosed COVID-19
Ramos-Martinez 2021	Effect of bcg revaccination on occupationally exposed medical personnel vaccinated against sars-cov-2	Vaccine

Rampon 2022	Smartphone-guided Self-prone Positioning versus Usual Care in Non-Intubated Hospital Ward Patients with COVID-19: A Pragmatic Randomized Clinical Trial.	Oxygen delivery
Rampon 2022	Smartphone-Guided Self-prone Positioning vsÂ Usual Care in Nonintubated Hospital Ward Patients With COVID-19: A Pragmatic Randomized Clinical Trial.	Oxygen delivery
Ranasinha 2021	Inhaled beclomethasone in the treatment of early COVIDâ€□19: A placeboâ€□controlled, randomized trial	Randomized trial with no results
Rangon 2021	Auricular Neuromodulation for Mass Vagus Nerve Stimulation: Insights From SOS COVID-19 a Multicentric, Randomized, Controlled, Double-Blind French Pilot Study	Others
Rao 2020	AYUSH medicine as add-on therapy for mild category COVID-19; an open label randomised, controlled clinical trial.	Traditional Chinese medicine
Rasmussen 2020	Pulmonary administration of remdesivir in the treatment of COVID-19	Not a randomized trial
Rathod 2022	Essential oil nebulization in mild COVID-19(EONCO): Early phase exploratory clinical trial.	Traditional Chinese medicine
Ratiani 2022	Efficacy of Kan Jang®in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial	Traditional Chinese medicine
Reddy 2020	AYUSH-64 as an add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial	Traditional Chinese medicine
Reig 2020	560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections	Not a randomized trial
Reindl-Schwaighofer 2021	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.	Vaccine
Reino-Gelardo 2023	Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study.	Not a randomized trial
Reis 2021	A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol (preprint)	Randomized trial with no results
Resende 2021	BLOCKADE OF INTERLEUKIN SEVENTEEN (IL-17A) IN HOSPITALIZED COVID-19 PATIENTS - THE BISHOP STUDY	Inaccessible full text
Richier 2021	Efficacy of Tocilizumab in moderate to severe COVID-19: an exposed-unexposed French cohort	Not a randomized trial
Richmond 2021	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	Vaccine
Richmond 2021	Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.	Vaccine
Roa 2022	Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults, a randomized study with SCB-2019 vaccine (preprint)	Vaccine
Robbins 2022	Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.	Vaccine

Rocca 2021	Remdesivir vs tocilizumab in COVID-19: adverse event profiles	Not a randomized trial
Rodrigues 2022	A Single Session of Virtual Reality Improved Tiredness, Shortness of Breath, Anxiety, Depression and Well-Being in Hospitalized Individuals with COVID-19: A Randomized Clinical Trial	Others
Rodriguez 2021	The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19	Not a randomized trial
Rodriguez-Blanco 2021	Short-Term Effects of a Conditioning Telerehabilitation Program in Confined Patients Affected by COVID-19 in the Acute Phase. A Pilot Randomized Controlled Trial	Exercise or rehabilitation
Romero-Ibarguengoitia 2022	Effect of Vitamin D3 supplementation vs. dietary-hygienic measures on SARS-COV-2 infection rates in hospital workers with 25-hydroxyvitamin D3 [25(OH)D3] levels >20 ng/mL (preprint)	Nutrition and supplements
Romero-Ibarguengoitia 2023	Effect of Vitamin D3 Supplementation vs. Dietary-Hygienic Measures on SARS-CoV-2 Infection Rates in Hospital Workers with 25-Hydroxyvitamin D3 [25(OH)D3] Levels â‰¥20 ng/mL	Not a randomized trial
Rosati 2021	539. Impact of Corticosteroids when Combined with Tocilizumab or Remdesivir for the Treatment of Severe SARS-CoV-2	Not a randomized trial
Rose 2023	Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXINÂ®): a non-inferiority phase 4, participant and observer-blinded, randomised study.	Vaccine
Roshandel 2022	A single-center non-blinded randomized clinical trial to assess the safety and effectiveness of PhR160 spray in the treatment of COVID-19 pneumonia	Traditional Chinese medicine
Ruggeri 2021	Use of Defibrotide in Patients with COVID-19 Pneumonia;Results of the Defi-VID19 Phase 2 Trial	Not a randomized trial
Rutkowski 2022	Effectiveness of an Inpatient Virtual Reality-Based Pulmonary Rehabilitation Program among COVID-19 Patients on Symptoms of Anxiety, Depression and Quality of Life: Preliminary Results from a Randomized Controlled Trial	Not exposed to or diagnosed COVID-19
Ryzhikov 2021	A SINGLE BLIND, PLACEBO-CONTROLLED RANDOMIZED STUDY OF THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THE "EPIVACCORONA" VACCINE FOR THE PREVENTION OF COVID-19, IN VOLUNTEERS AGED 18-60 YEARS (PHASE I-II)	Vaccine
Ryzhikov 2021	A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the "EpiVacCorona" Vaccine for the prevention of COVID-19, in volunteers aged 18-60 years (phase I-II) (vol 11, pg 283, 2021)	Vaccine
Ryzhikov 2023	Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III).	Vaccine
Sadeghizadeh 2023	Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: A randomized, double-blinded, placebo-controlled trial.	Others
Sadoff 2020	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (preprint)	Vaccine
Sadoff 2021	Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.	Vaccine
Sadoff 2021	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.	Vaccine
Sadoff 2022	Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.	Vaccine
Sáez-Llorens 2022	Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.	Vaccine

Saez-Llorens 2023	Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].	Vaccine
Safa 2022	Effect of Telephone Counseling on Self-Efficacy in Self-Care Behaviors of Patients with COVID-19	Psychological and educational
SafaeeFakhr 2022	SAFETY AND EFFICACY OF INHALED HIGH-DOSE NITRIC OXIDE IN NON-INTUBATED PATIENTS WITH COVID-19 PNEUMONIA	Not a randomized trial
SafaeiArdestani 2022	The effect of omegaÂ3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVIDÂ19: a randomized clinical trial.	Not a randomized trial
Sahin 2022	Mesenchymal stem cell therapy in COVID-19 pneumonia: a prospective, randomized clinical research	Not a randomized trial
Said 2022	The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial.	Nutrition and supplements
Salazar 2020	Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma	Not a randomized trial
Saleh 2021	Successful treatment of plasmapheresis followed by interferon beta-1a in a child with severe COVID-19	Not a randomized trial
Salim 2023	A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)	Randomized trial with no results
Salimian 2022	Safety and Immunogenicity of a Recombinant Receptor Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine TM) Against COVID-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial	Vaccine
SalvacionUSAInc 2021	LAEH Formulation Nasal Spray to Reduce Viral Load	Randomized trial with no results
Sandercock 2022	Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.	Not a randomized trial
SanduzziZampare lli 2022	A Phase II Study on the Effect of Taurisolo®Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study	Not a randomized trial
Sanger 2021	A randomized controlled clinical trial to evaluate the potential of ayurvedic medicines in patients with mild symptoms of COVID-19	Traditional Chinese medicine
Sankhe 2022	A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India	Traditional Chinese medicine
Sanmamed 2022	Low-dose radiation therapy in the management of COVID-19 pneumonia (LOWRAD-Cov19). Final results of a prospective phase I-II trial	Not a randomized trial
Sanmamed 2022	Low Dose Radiotherapy in the Management of COVID-19 Pneumonia (LOWRAD-Cov19): Final Results	Not a randomized trial
Santos 2023	The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2 - The results of ProBCG: A Multicenter Randomized Clinical Trial in Brazil.	Vaccine
Santoso 2022	Adjuvant Therapy of Eucalyptusoil Significantly Improves Clinical Outcome in COVID 19 Patients	Traditional Chinese medicine
Sanz-Linares 2022	Phase I Clinical Trial to Evaluate the Safety of Baricitinib to Prevent Respiratory Insufficiency Progression in Oncohematological Patients Affected with COVID-19 - BARCOVID19 Study	Not a randomized trial

SaranyaSridhar 2021	Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study	Vaccine
Sardari 2021	Therapeutic effect of thyme (Thymus vulgaris) essential oil on patients with covid19: A randomized clinical trial	Traditional Chinese medicine
Sarfaraz 2022	Is Tocilizumab An Effective Therapy For Severe Covid-19: A Single Center Study	Not a randomized trial
Sarmiento 2021	Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids	Not a randomized trial
Sasidharan 2022	An efficacy and safety report based on randomized controlled single-blinded multi-centre clinical trial of ZingiVir-H, a novel herbo-mineral formulation designed as an add-on therapy in adult patients with mild to moderate COVID-19	Traditional Chinese medicine
Saxena 2022	Comparison of Effect of Non-invasive Ventilation Delivered by Helmet vs Face Mask in Patients with COVID-19 Infection: A Randomized Control Study	Oxygen delivery
Schectman 2023	In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.	Not a randomized trial
Schepens 2022	Prednisolone does not improve olfactory function after COVID-19: a randomized, double-blind, placebo-controlled trial.	Not exposed to or diagnosed COVID-19
Schernthaner 2021	Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).	Not a randomized trial
Schifino 2022	Effects of Non-Invasive Respiratory Supports on inspiratory effort in moderate-severe COVID-19 patients. A randomized physiological study	Oxygen delivery
Schumacher 2020	The impact of respiratory protective equipment on difficult airway management: a randomised, crossover, simulation study	Not exposed to or diagnosed COVID-19
Science 2022	Effect of Wearing a Face Mask on Hand-to-Face Contact by Children in a Simulated School Environment: The Back-to-School COVID-19 Simulation Randomized Clinical Trial.	Personal protective equipment
Scoccianti 2022	Safety and Immunogenicity of Moderna COVID vaccine in radiotherapy patients	Not a randomized trial
Scott 2022	Immunogenicity And Safety of a Virus-Like Particle (VLP) Protein Subunit SARS-CoV-2 Vaccine in Adults: a Phase 1/2 Study	Vaccine
Scotto 2022	Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron Surge (preprint)	Not a randomized trial
Segundo 2021	Immune assessment of BNT162b2 m-RNA-spike based vaccine response in adults	Vaccine
Sehgal 2021	A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1	Others
Seitz 2022	Percutaneous Auricular Vagus Nerve Stimulation Reduces Inflammation in Critical Covid-19 Patients	Others
Selman 2020	Results of a Chilean Nation-Wide Network of Blood Banks for Convalescent Plasma Collection for Pandemic SARS-CoV-2 Treatment	Not a randomized trial
Selvaraj 2021	Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials	Not a randomized trial
Seo 2022	Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	Not exposed to or diagnosed COVID-19

SerumInstituteofIndiaPrivateLimitedPune 2022	Study to check the effect of Covovax vaccine when administered as booster dose in adults in India who have already received two. A phase 3, observer-blind, randomized, controlled study to evaluate the safety and immunogenicity of a booster dose of COVOVAX	Vaccine
Setayesh 2022	Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): a randomized clinical trial	Traditional Chinese medicine
Shabaan 2023	Diode laser in management of loss of taste sensation in patients with post-COVID syndrome: a randomized clinical trial.	Not exposed to or diagnosed COVID-19
Shah 2022	Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial (preprint)	Traditional Chinese medicine
Shah 2022	Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial	Traditional Chinese medicine
Shaikh 2022	To evaluate the efficacy of topical anti-fungal therapy in postoperative cases of COVID Associated Mucormycosis (CAM): A single-blinded randomized control trial	Not exposed to or diagnosed COVID-19
Shakula 2022	Pantohematogen Efficacy Evaluation in Complex Sanatorium Rehabilitation of Patients with post-COVID-19 Syndrome: an Open Randomized Cohort Study	Not exposed to or diagnosed COVID-19
Shalhoub 2022	PIONEER trial: favipiravir to treat moderate COVID-19	Not a randomized trial
ShandongCancerHospitalandInstitute 2023	Oxygen Atomizing Inhalation of EGCG in the Treatment COVID-19 Pneumonia in Cancer Patients	Randomized trial with no results
ShanghaiEastHospital 2023	Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19	Randomized trial with no results
Shanker 2023	A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized Andrographis paniculata formulation) in mild to moderate COVID-19	Nutrition and supplements
Shanmugam 2022	Safety and Efficacy of Siddha Medicine preparation in the management of COVID-19: A Prospective Randomised Open Label Study	Traditional Chinese medicine
Sharma 2022	Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate COVID-19 virus pneumonia: results of stage 1 of the study	Not a randomized trial
Sharma 2022	Effect of Yoga on the Stress, Anxiety, and Depression of COVID-19-Positive Patients: A Quasi-Randomized Controlled Study.	Not a randomized trial
Sharma 2022	Efficacy of add-on Ayurveda and Yoga intervention in health care workers of tertiary care hospital during COVID-19: Randomized controlled trial	Others
Sharma 2022	Randomised trial to determine the effect of vitamin D and zinc supplementation for improving treatment outcomes among patients with COVID-19 in India: trial protocol	Randomized trial with no results
Sharma 2022	Safety and Efficacy of Ayurvedic Formulation â€œGuduchi Ghana Vatiâ€ as a Preventive Remedy in COVID-19 (preprint)	Traditional Chinese medicine
Shaw 2020	Wearing of Cloth or Disposable Surgical Face Masks has no Effect on Vigorous Exercise Performance in Healthy Individuals	Personal protective equipment
Shaw 2022	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.	Vaccine

Shaw 2023	Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.	Vaccine
Shaygan 2023	The effect of interactive virtual psycho-educational interventions via social networks on self-efficacy and anxiety among patients infected with COVID-19 and living in home quarantine: A randomized control trial	Psychological and educational
Sheehan 2022	The CHARTER-Ireland trial: can nebulised heparin reduce acute lung injury in patients with SARS-CoV-2 requiring advanced respiratory support in Ireland: a study protocol and statistical analysis plan for a randomised control trial	Randomized trial with no results
Shegay 2023	World's First Experience of the Low-dose radionuclide inhalation therapy in the treatment of COVID-19-associated viral pneumonia: phase 1/2 clinical trial.	Not a randomized trial
Sheng 2020	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)	Randomized trial with no results
Shenyu 2022	Safety and Immunogenicity of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: a randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China	Vaccine
Shi 2020	Clinical Observation of the Rehabilitation Formula for Banking up Earth to Generate Metal in Treating COVID-19 Patients with Deficiency of Lung and Spleen Syndrome in the Recovery Stage	Traditional Chinese medicine
Shi 2022	Oral Liushen Pill for Patients with Covid-19 : A prospective, randomized, controlled trial (preprint)	Traditional Chinese medicine
ShilongYang 2020	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials	Vaccine
Shimizu 2022	Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults	Not exposed to or diagnosed COVID-19
Shinde 2021	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.	Vaccine
Shinde 2022	Safety and immunogenicity of COVID Influenza Combination Vaccine	Vaccine
Shindo 2021	Japanese, multicenter, phase II trial of combination therapy with favipiravir and methylprednisolone for COVIDâ€□19 patients with nonâ€□critical respiratory failure: the Jâ€□critical trial	Not a randomized trial
Shinkai 2022	Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study (preprint)	Vaccine
Shinkai 2022	Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.	Vaccine
Shogenova 2020	Effect of thermal helium-oxygen mixture on viral load in COVID-19	Oxygen delivery
Shogenova 2021	KalHydrogen inhalation in rehabilitation program of the medical staff recovered from COVID-19.	Not exposed to or diagnosed COVID-19
Shu 2021	Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.	Vaccine
ShujieSi 2022	Safety and Effectiveness of SA58 Nasal Spray against COVID-19 Infection in Medical Personnelï¼šAn Open-label, Blank-controlled Study (preprint)	Not a randomized trial

Shukla 2020	Efficacy and safety of Guduchighana Vati in asymptomatic and mild-to-moderate cases of coronavirus disease-19: A randomized controlled pilot study.	Traditional Chinese medicine
Shukla 2022	Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19	Not a randomized trial
Siewiera 2022	Effectiveness of Hyperbaric Oxygen Therapy in SARS-CoV-2 Pneumonia: The Primary Results of a Randomised Clinical Trial.	Oxygen delivery
Siewiera 2023	Effectiveness of Hyperbaric Oxygen Therapy in SARS-CoV-2 Pneumonia: The Primary Results of a Randomised Clinical Trial	Oxygen delivery
Silveira 2021	Efficacy of Brazilian Green Propolis (EPP-AFÂ®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial	Nutrition and supplements
Simpson 2023	Group-based pulmonary telerehabilitation is feasible, safe, beneficial and well-received in patients who have been hospitalised with COVID-19.	Not exposed to or diagnosed COVID-19
Sinclair 2022	An Open Label, Multicentre, Multi-Dose, Single Arm Treatment Clinical Trial to Determine the Safety and Efficacy of New Natural Health Drink of Earth Tea in Human Adult, Patients with Mild Covid-19	Not a randomized trial
Singer 2022	A Randomized, Controlled, Double-Blind Trial of Inulin to Boost Response to a Third COVID-19 Vaccine Dose in Kidney Transplant Recipients	Vaccine
Singh 2020	In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19;trial stopped for futility	Not a randomized trial
Singh 2021	The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.	Not a randomized trial
Singh 2022	Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre	Not a randomized trial
Singh 2022	Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study	Not a randomized trial
Singh 2022	Interim Analysis of Impact of Adding Low Dose Pulmonary Radiotherapy to Moderate COVID-19 Pneumonia Patients: IMpaCt-RT Study	Others
Singh 2022	AYUSH-64 as an adjunct to Standard Care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India	Traditional Chinese medicine
Singh 2022	Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.	Not exposed to or diagnosed COVID-19
Singh 2023	Immunogenicity and Tolerability of BBV154 (iNCOVACCÂ®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular CovaxinÂ® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial	Vaccine
Sinha 2020	Interleukin-6 Receptor Inhibitor Therapy Is Associated with Improved Outcomes in Patients with Severe COVID-19 Disease (preprint)	Not a randomized trial
Sinha 2022	Efficacy of Bacillus Calmette-GuÃ©rin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial.	Vaccine
Sinitsyn 2022	EFFICACY AND SAFETY OF ULTRA-LOW DOSE INHALED MELPHALAN IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19	Not a randomized trial
SitthichaiKanokudom 2022	Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens	Not a randomized trial
Sivapalan 2020	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan	Randomized trial with no results

Skarda 2022	Sabizabulin for the Treatment of Patients Hospitalized with Moderate-Severe COVID-19 (Requiring Oxygen) Who Were at High Risk for Acute Respiratory Distress Syndrome and Death	Not a randomized trial
Skaria 2022	Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials	Not exposed to or diagnosed COVID-19
Slomski 2022	Angiotensin Receptor Blockers Not Effective Against COVID-19	Not a randomized trial
Slomski 2022	Moderna COVID-19 Vaccine Safe and Effective for Children 6 Months to 5 Years: The Journal of the American Medical Association	Vaccine
Smit 2023	Home monitoring by pulse oximetry of primary care patients with COVID-19: a pilot randomised controlled trial.	Others
Smith 2022	Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE) (preprint)	Randomized trial with no results
Smith 2022	Favipiravir and/or nitazoxanide: a randomized, double-blind, 2Ã—2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).	Randomized trial with no results
Sobieszczyk 2021	Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)	Vaccine
Sobieszczyk 2022	Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination	Vaccine
Sochet 2022	TWICE-DAILY ENOXAPARIN AS PRIMARY THROMBOPROPHYLAXIS IN PEDIATRIC PATIENTS HOSPITALIZED FOR COVID-19	Not a randomized trial
Soleiman-Meigooni 2022	Efficacy of a standardized herbal formulation from Glycyrrhiza glabra L. as an adjuvant treatment in hospitalized patients with COVID-19: A Randomized Controlled trial.	Traditional Chinese medicine
Soliman 2021	Impact of Vitamin D Therapy on the Progress COVID-19: Six Weeks Follow-Up Study of Vitamin D Deficient Elderly Diabetes Patients	Not a randomized trial
Soliman 2022	The impact of glutamine supplementation on the short-term mortality of COVID-19 diseased patients admitted to the ICU: A single-blind randomized clinical trial	Not a randomized trial
Soliman 2022	Could early infusion of fish-oil-based lipid emulsion affect the need for intensive care in moderately diseased COVID-19 patients? A randomized clinical trial	Nutrition and supplements
Song 2022	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial (preprint)	Vaccine
Song 2022	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.	Vaccine
Sonoyama 2022	Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults	Vaccine
Sophie 2021	Virtual reality intervention alleviates dyspnea in patients recovering from COVID pneumonia (preprint)	Others
Soto 2022	Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.	Not a randomized trial
Souissi 2022	Ã‰tude en double aveugle, contrÃ´lÃ©e, randomisÃ©e, Ã©valuant l'efficacitÃ© thÃ©rapeutique d'un retraitement par rituximab a la dose 500	Not exposed to or diagnosed COVID-19

	mgÃ—1 vs 500 mgÃ—2 vs 1 gÃ—1 chez les patients atteints de polyarthrite rhumatoÃ¯de : donnÃ©es prÃ©liminaires Ã 6 mois	
Sova 2021	Inhaled glucocorticoids in treatment of covid-19	Not a randomized trial
Spagnuolo 2021	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (vol 10, 21291, 2020)	Not a randomized trial
Speich 2022	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.	Vaccine
Spiliopoulou 2022	Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19;a singlecenter, prospective study	Not a randomized trial
Spoorthi 2020	Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2	Not a randomized trial
Sridhar 2022	Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.	Vaccine
Srivastava 2021	A double blinded placebo controlled comparative clinical trial to evaluate the effectiveness of Siddha medicines, Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy treatment in the management of symptomatic COVID 19 pat	Randomized trial with no results
Srivastava 2021	Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial	Traditional Chinese medicine
Stange 2022	Echinacea purpurea for the Prevention and Treatment of Viral Respiratory Tract Infections including SARS-CoV-2: an Openlabel RCT	Traditional Chinese medicine
Stasko 2022	A randomized, controlled, feasibility study of RD-X19 in subjects with mild-to-moderate COVID-19 in the outpatient setting.	Others
StefaniaCapone 2022	GRAd-COV2 vaccine provides potent and durable immunity in a randomised placebo-controlled phase 2 trial (COVITAR)	Vaccine
Steffens 2023	Testing persuasive messages about booster doses of COVID-19 vaccines on intention to vaccinate in Australian adults: A randomised controlled trial.	Vaccine
Stephenson 2021	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19	Vaccine
Stephenson 2021	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.	Vaccine
Stockmann 2021	Cytoresc, or cytosorb for COVID-19 patients with vasoplegic shock: A prospective randomized pilot study	Inaccessible full text
Stojcheva 2023	Ensovibep, a SARS-CoV-2 antiviral DARPin, is safe and well tolerated in healthy volunteers: results of a first-in-human, ascending single-dose Phase 1 study.	Not a randomized trial
Strohbehn 2020	COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia.	Not a randomized trial
Strohbehn 2020	COVIDOSE: Low-dose tocilizumab in the treatment of COVID-19 pneumonitis	Randomized trial with no results
Stuart 2021	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	Vaccine
Stuart 2022	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial (vol 399, pg 36, 2022)	Vaccine

SubhashThuluva 2023	Immunogenicity and safety of Biological Es CORBEVAX vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD or COVAXIN: A Prospective double-blind randomised phase III clinical study (preprint)	Vaccine
Sum 2022	Chinese medicine for residual symptoms of COVID-19 recovered patients (long COVID)â€"A double-blind, randomized, and placebo-controlled clinical trial protocol	Randomized trial with no results
Supady 2021	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.	External organ support
Supady 2021	Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial (vol 9, pg 755, 2021)	External organ support
Suppan 2020	Effect of an E-Learning Module on Personal Protective Equipment Proficiency by Prehospital Personnel: Web-Based, Randomized Controlled Trial	Psychological and educational
Suprapti	Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia	Not a randomized trial
Suriyan 2022	A randomized clinical study to evaluate the efficacy and safety of OUTBREAK in mild and moderate COVID19 positive patients	Traditional Chinese medicine
SusanMBueno 2021	Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial	Vaccine
SuvimolNiyomnaitham 2022	Immune responses of the third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variants	Vaccine
SuzhouZelgenBiopharmaceuticalsCo 2023	Efficacy and Safety of Jaktinib in Patients With Severe Novel Noronavirus Pneumonia	Randomized trial with no results
SuzhouZelgenBiopharmaceuticalsCo 2023	An Efficacy and Safety Study of Jacktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia	Randomized trial with no results
Szarpak 2022	Comparison of Vie ScopeÂ® and Macintosh laryngoscopes for intubation during resuscitation by paramedics wearing personal protective equipment	Others
Szu-Min 2021	Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial	Vaccine
Tabarsi 2022	Evaluating the Efficacy and Safety of SpikoGenÂ®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 Spike Protein Vaccine: A Phase 3 Randomized Placebo-Controlled Trial	Vaccine
Tabarsi 2022	Evaluating the efficacy and safety of SpikoGenÂ®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.	Vaccine
Tabarsi 2023	Evaluating the efficacy and safety of SpikoGenÂ®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.	Vaccine
Taghavi 2023	Effectiveness of Fortified Garlic Extract Oral Capsules as Adjuvant Therapy in Hospitalized Patients with Coronavirus Disease 2019: A Triple-Blind Randomized Controlled Clinical Trial.	Traditional Chinese medicine
Takayama 2020	A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo	Randomized trial with no results

	medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and	
Takayama 2022	Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients	Traditional Chinese medicine
Takuva 2021	Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study.	Vaccine
Takuva 2022	Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.	Not a randomized trial
Talele 2021	Randomized Double-Blind, Placebo-Controlled Feasibility Study, Evaluating the Efficacy of Homeopathic Medicines in the Prevention of COVID-19 in a Quarantined Population.	Traditional Chinese medicine
Tan 2020	Effect of Intravenous Lidocaine on Central Venous Puncture Analgesia in Cases of Suspected or Confirmed COVID-19	Others
Tan 2022	Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore	Not a randomized trial
Tan 2022	Early efficacy and safety of the third dose inactivated COVID-19 vaccine among people living with HIV.	Vaccine
Tan 2023	Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.	Vaccine
Tang 2023	Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.	Vaccine
Tanishima 2022	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan (preprint)	Vaccine
Tanriover 2021	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey	Vaccine
Tanriover 2022	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey (vol 398, pg 213, 2021)	Vaccine
Tao 2022	Effect of liushen capsules (pill) on antiviral activity of COVID-19 in vitro and in patients with positive nucleic acid for more than 14 days	Traditional Chinese medicine
Tavakoli 2022	Efficacy of Persian barley water on clinical outcomes of hospitalized moderate-severity COVID-19 patients: a single-blind, add-on therapy, randomized controlled clinical trial	Nutrition and supplements
Tavlueva 2022	Characteristics of Olokizumab Pharmacokinetics in Patients with Novel Coronavirus Infection Covid-19	Not a randomized trial
Tavukcuoglu 2023	Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination.	Vaccine
Tebas 2021	Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster	Vaccine
Tendler 2022	EVALUATION OF INHALED VASODILATORS IN ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19	Not a randomized trial
Tercero 2022	Interim Results of a Phase I Study Investigating a Cord Blood-Derived Natural Killer Cell Therapy for Patients Hospitalized with COVID-19	Not a randomized trial

Terentes-Printzios 2022	The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness	Vaccine
Terpos 2020	Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors;Results of a Phase 2 Clinical Study	Not a randomized trial
Teymouri 2023	The effect of Fingolimod on patients with moderate to severe COVID-19	Not a randomized trial
Thakar 2022	Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19 - An open-label randomized controlled pilot study.	Traditional Chinese medicine
TheFirstAffiliated HospitalofHunan UniversityofTraditionalChineseMedicine 2023	Acupuncture as an Adjunctive Therapy for Covid-19 Omicron Randomised Controlled Trial in Patients With Moderate/Severe Pneumonia	Randomized trial with no results
TheUniversityofQueensland 2023	A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.	Randomized trial with no results
Thomas 2021	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.	Vaccine
Thomas 2021	COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine	Vaccine
Thomas 2021	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial	Vaccine
Thomas 2022	A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19-The UK Phyto-V Study	Traditional Chinese medicine
Thomas 2022	A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19	Not exposed to or diagnosed COVID-19
Thomopoulos 2022	ADMINISTRATION OF CONVALESCENT PLASMA FOR THE TREATMENT OF SEVERE COVID-19: RESULTS OF A MULTICENTER PHASE II TRIAL	Not a randomized trial
Thuluva 2022	Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (preprint)	Vaccine
Thuluva 2022	Safety, tolerability and immunogenicity of Biological Eâ€™s CORBEVAXâ„¢ vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study (preprint)	Vaccine
Thuluva 2022	Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials	Vaccine
Thuluva 2022	Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.	Vaccine
Thuluva 2023	Immunogenicity and safety of Biological E's CORBEVAXâ„¢ vaccine compared to COVISHIELDâ„¢ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.	Vaccine

Tian 2021	Efficacy and safety of short-wave diathermy treatment for moderate COVID-19 patients: a prospective, double-blind, randomized controlled clinical study	Exercise or rehabilitation
Tian 2022	Efficacy and safety of short-wave diathermy treatment for moderate COVID-19 patients: a prospective, double-blind, randomized controlled clinical study	Exercise or rehabilitation
Tinedo-Lopez 2021	Are mouthwashes effective in preventing or reducing SARS-CoV-2 viral load in the oral cavity?	Not a randomized trial
Toback 2021	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial	Vaccine
Tobar 2022	Electroencephalography spectral edge frequency and suppression rate-guided sedation in patients with COVID-19: A randomized controlled trial.	Others
Todorovic 2022	The Effects of Nitrate-Based Nutritional Formula on Oxygen Saturation and Patient-Reported Outcomes in COVID-19 Patients: A Randomized Controlled Trial	Nutrition and supplements
Toledo-RomanÃ 2023	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial	Vaccine
Toledo-Romani 2021	Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination	Vaccine
Toledo-Romani 2022	Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults	Vaccine
Toledo-Romaní 2022	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial (preprint)	Vaccine
Toniati 2020	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	Not a randomized trial
Torales 2022	An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study (preprint)	Vaccine
Torales 2022	An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.	Vaccine
Tornero 2022	Non-invasive Vagus Nerve Stimulation for COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)	Others
Torres 2021	Effect of Physician-Delivered COVID-19 Public Health Messages and Messages Acknowledging Racial Inequity on Black and White Adults' Knowledge, Beliefs, and Practices Related to COVID-19: A Randomized Clinical Trial	Not exposed to or diagnosed COVID-19
ToshioInui 2023	The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 Patients (preprint)	Nutrition and supplements
Tosun 2022	Effect of Tocilizumab Use on Mortality in COVID-19 Patients Admitted to Intensive Care Unit	Not a randomized trial
Tragoonrungsea 2022	Corticosteroid nasal irrigation as early treatment of olfactory dysfunction in COVID-19: A prospective randomised controlled trial.	Others
Troyer 2022	EFFECT OF TOCILIZUMAB ON OUTCOMES OF COVID PATIENTS WITH OBESITY	Not a randomized trial

TsetsegsaikhanBatmunkh 2023	Immunogenicity, Safety, and Reactogenicity of a Half- Versus Full-Dose BNT162b2 (Pfizer-Biontech) Booster Following a Two-Dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac Priming Schedule in Mongolia: A Randomised, Controlled, Non-Inferiority Trial	Vaccine
Tsilika 2022	Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk	Vaccine
Tsuchiya 2023	Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S: Results of a Phase 1, Randomized, Double-blind, Placebo-controlled COVID-19 Vaccine Trial in Japan	Vaccine
Tsvetkova 2022	[The role of systemic ozone therapy in the rehabilitation of patients after COVID-19]	Exercise or rehabilitation
Tunbridge 2022	Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients	Randomized trial with no results
Turgut 2022	Title: A novel low-dose self-amplifying mRNA vaccine (GRT-R910) induces strong and broad boost in cellular and humoral immune response following primary series with a chimpanzee adenovirus SARS-CoV-2 vaccination	Vaccine
Ujjan 2022	The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19-Results from a pragmatic randomized clinical trial.	Traditional Chinese medicine
Ujjan 2022	The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19â€"Results from a pragmatic randomized clinical trial	Traditional Chinese medicine
Umemura 2021	Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.	Not a randomized trial
Upadhyaya 2022	BAMLANIVIMAB PLUS ETESEVIMAB for the TREATMENT of COVID-19 in PEDIATRIC PATIENTS	Not a randomized trial
Upton 2022	Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial	Vaccine
Urbanowicz 2021	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection.	Vaccine
Utami 2022	OPTIMAL DOSE OF VITAMIN D FOR COVID-19 TREATMENT	Not a randomized trial
ValerieGOUNANT 2021	Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses	Vaccine
Valim 2022	Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project	Vaccine
Vanassche 2020	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study (vol 21, 1005, 2020)	Randomized trial with no results
Vandormael 2021	Effect of a wordless, animated, social media video intervention on COVID-19 prevention: an online randomized controlled trial of 15,163 adults in the USA, Mexico, UK, Germany, and Spain.	Not exposed to or diagnosed COVID-19
VanessaTeixeiradoAmaral 2022	Cardiovascular, respiratory and functional effects of tele-supervised home-based exercise training in individuals recovering from COVID-19 hospitalization: A randomized clinical trial	Exercise or rehabilitation
vanGoor 2021	Remote Hospital Care for Recovering COVID-19 Patients Using Telemedicine: A Randomised Controlled Trial.	Others

Vanhoutte 2022	Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.	Vaccine
VanWyk 2021	Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)	Not exposed to or diagnosed COVID-19
Varanasi 2022	Comparative Effectiveness of Pre-Identified Homeopathic Medicines in Asymptomatic COVID-19 Individuals Receiving Standard Care-An Open-Label, Randomized, Controlled Exploratory Trial.	Traditional Chinese medicine
Varela 2022	Effectiveness and adherence to closed face shields in the prevention of COVID-19 transmission: a non-inferiority randomized controlled trial in a middle-income setting (COVPROSHIELD)	Personal protective equipment
Varghese 2022	SARS-CoV-2 infection is associated with an increased risk of idiopathic acute pancreatitis but not pancreatic exocrine insufficiency or diabetes: long-term results of the COVIDPAN study	Not a randomized trial
Varnasseri 2022	The Effects of Add-on Therapy of Phyllanthus Emblica (Amla) on Laboratory Confirmed COVID-19 Cases: A Randomized, Double-blind, Controlled Trial.	Traditional Chinese medicine
Varshochi 2022	Efficacy and Safety of Novel Herbal Tablets in COVID-19 Patients in Hospital Stay Days, ICU Admission and Mortality Rate Thereof: An Ppen-Label, Single-Blind Randomized Clinical Trial	Traditional Chinese medicine
Vathsala 2022	Comparative outcomes after early Sotrovimab administration in vaccinated and unvaccinated kidney transplant recipients with SARS-CoV-2 infection during the Delta and Omicron BA.1 surges.	Not a randomized trial
Vazquez 2021	Hydroxychloroquine in the COVID-19 treatment	Not a randomized trial
Veer Singh 2021	The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in taste dysgeusia in COVID-19 patients	Not a randomized trial
Velez 2022	Infliximab as a potential treatment for COVID-19.	Not a randomized trial
Vercueil 2021	Efficacy of Serotherapy on an N501Y Variant of SARS-CoV-2 in a Patient With Chronic Lymphocytic Leukemia	Not a randomized trial
Vergori 2020	Prophylactic dose of low-molecular-weight heparin (LMWH) might not be sufficient to mitigate the clinical scenario in patients with COVID-19 and severe pneumonia	Not a randomized trial
Verma 2022	Effectiveness of crocodile breathing versus prone position in patients with COVID-19: A pilot study	Exercise or rehabilitation
Vestito 2022	Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study.	Not a randomized trial
Villa 2020	Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study	Not a randomized trial
Villar 2020	Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial	Not exposed to or diagnosed COVID-19
Vinke 2022	Ferric carboxymaltose and SARS-CoV-2 vaccination-induced immunogenicity in kidney transplant recipients with iron deficiency: The COVAC-EFFECT randomized controlled trial	Vaccine
Vityala 2021	Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19.	Not a randomized trial

VivekShinde 2021	Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant	Vaccine
Vlake 2021	Intensive Care Unit-Specific Virtual Reality (ICU-VR) for Critically Ill COVID-19 Patients: A Multicenter, Randomized Controlled Trial.	Others
Vowels 2021	Partner Support and Goal Outcomes during COVID-19: A Mixed Methods Study	Not a randomized trial
Voysey 2020	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	Vaccine
Voysey 2021	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	Vaccine
Voysey 2021	Single DoseÂ Administration,Â AndÂ TheÂ Influence OfÂ TheÂ Timing OfÂ TheÂ Booster DoseÂ On Immunogenicity and Efficacy OfÂ ChAdOx1 nCoV-19Â (AZD1222)Â Vaccine (preprint)	Vaccine
Voysey 2021	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (vol 397, pg 99, 2021)	Vaccine
Voysey 2021	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials	Vaccine
Voysey 2021	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (vol 397, pg 881, 2021)	Vaccine
Waits 2022	Safety and Immunogenicity of MVC-COV1901 Vaccine in Older Adults: Phase 2 Randomized Dose-Comparison Trial	Vaccine
Wakita 2021	Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests.	Not a randomized trial
Walsh 2020	RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study (preprint)	Vaccine
Walsh 2020	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.	Vaccine
Wand 2022	Intravenous Alpha-1 Antitrypsin Therapy for Critically Ill COVID-19 Patients	Not a randomized trial
Wang 2020	Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study	Not a randomized trial
Wang 2020	Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial	Traditional Chinese medicine
Wang 2021	Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study	Not a randomized trial
Wang 2021	Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study	Not a randomized trial
wang 2021	Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine (preprint)	Not a randomized trial
Wang 2022	UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern (preprint)	Not a randomized trial
Wang 2022	Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial (preprint)	Vaccine
Wang 2022	Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in	Vaccine

	Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Pha	
Wang 2022	Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.	Vaccine
Wang 2023	Exercise from home improves physical performanceï¼šA study conducted specifically for COVID-19	Exercise or rehabilitation
Wang 2023	Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.	Not exposed to or diagnosed COVID-19
Wanjarkhedkar 2020	A prospective clinical study of an Ayurveda regimen in COVID 19 patients	Traditional Chinese medicine
Wanjarkhedkar 2022	A prospective clinical study of an Ayurveda regimen in COVID 19 patients.	Traditional Chinese medicine
Ward 2020	Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants	Vaccine
Ward 2021	Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.	Vaccine
Watanabe 2022	JAPAN PROSPECTIVE MULTICENTER STUDY FOR OPTIMIZATION OF COVID-19 VACCINATIONS BASED ON THE IMMUNE RESPONSE AND SAFETY PROFILE IN INFLAMMATORY BOWEL DISEASE PATIENTS: INTERIM ANALYSES	Not a randomized trial
WataruAkahata 2023	Safety and Immunogenicity of SARS-CoV-2 Self-Amplifying RNA Vaccine Expressing Anchored RBD: A Randomised, Observer-Blind, Phase 1 Study (preprint)	Vaccine
Wehrmann 2020	Vitamin C for protection against SARS-CoV-2 and for treatment of COVID-19	Not a randomized trial
Wei 2020	Early antiviral therapy of abidol combined with lopinavir/ritonavir and recombinant interferon Î±-2b for patients with COVID-19 in Zhejiang: A multicenter prospective study	Not a randomized trial
Wei 2023	Safety and Efficacy of Oral administrated Cepharathine in Non-hospitalized, asymptomatic or mild COVID-19 patients: A Double-blind, Randomized, Placebo-controlled Trial	Nutrition and supplements
Weinbergerova 2021	Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients	Not a randomized trial
Welzel 2023	Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial.	Not exposed to or diagnosed COVID-19
Wen 2020	[Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019]	Traditional Chinese medicine
Wenban 2021	Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalized Covid-19 patients.	Not a randomized trial
Wenguang 2022	Randomized controlled study of a diagnosis and treatment plan for moderate coronavirus disease 2019 that integrates Traditional Chinese and Western Medicine	Traditional Chinese medicine
WestlakePharmaceuticals(Hangzhou)Co 2023	Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection	Randomized trial with no results
WestVacBiopharmaCo 2023	Phase I Clinical Trial of Recombinant Variant COVID-19 Vaccine (Sf9 Cell) (WSK-V102)	Randomized trial with no results

White 2022	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic	Not a randomized trial
Winokur 2023	Bivalent Omicron BA.1â€“Adapted BNT162b2 Booster in Adults Older than 55 Years	Vaccine
Wise 2021	Vaccinating against covid and flu at same time is safe, study shows	Vaccine
Wise 2022	Tocilizumab in Severe COVID-19: A Quasi-Randomized Study in a Real-World Setting (preprint)	Not a randomized trial
Wolak 2021	Inhaled nitric oxide for the treatment of COVID-19 and other viral pneumonias in adults	Randomized trial with no results
Wong 2022	Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes.	Not a randomized trial
World Health Organization 2022	Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination: interim guidance, 1 October 2022: second addendum to Evaluation of COVID-19 vaccine effectiveness: interim guidance	Not a randomized trial
Wu 2020	Identification and validation of a novel clinical signature to predict the prognosis in confirmed COVID-19 patients	Not a randomized trial
Wu 2020	Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs	Not a randomized trial
Wu 2021	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	Vaccine
Wu 2021	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.	Vaccine
Wu 2021	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab in Chinese Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Phase 1 Study.	Not exposed to or diagnosed COVID-19
Wu 2023	Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged â‰¥18 years: a randomised, double-blind, phase 2b trial.	Vaccine
Wu Haiyan 2020	Effect of emotional care based on traditional Chinese medicine combining respiratory muscle training on depression and anxiety among patients with COVID-19	Traditional Chinese medicine
Wuang Yuling 2020	Clinical study on the treatment of patients with novel coronavirus pneumonia and asymptomatic infection with integrated traditional Chinese and western medicine	Traditional Chinese medicine
Wynne 2022	The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV (preprint)	Vaccine
Xia 2020	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials	Vaccine
Xia 2020	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	Vaccine
Xia 2021	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	Vaccine

Xia 2022	Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.	Vaccine
Xia 2022	The efficacy and safety of an intranasal spray COVID-19 vaccine in a randomized double-blind placebo-controlled phase â…¢ trial during Omicron period	Vaccine
Xiao 2020	Analysis of the value of traditional Chinese medicine Shufeng Jiedu Capsule combined with Arbidol in the treatment of mild novel coronavirus pneumonia	Not a randomized trial
Xiao 2020	Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial	Traditional Chinese medicine
Xiao 2020	Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial. (Special Issue: Pharmacoepidemiology and pathogenetics of 2019-nCoV.)	Traditional Chinese medicine
Xie 2020	Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19	Not a randomized trial
Xie 2023	Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.	Not a randomized trial
Xin 2022	Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials	Vaccine
Xiong 2020	Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial	Not a randomized trial
Xu 2021	Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.	Traditional Chinese medicine
Xu 2023	Effect of an inactivated coronavirus disease 2019 vaccine, CoronaVac, on blood coagulation and glucose: a randomized, controlled, open-label phase IV clinical trial.	Vaccine
Xue Ping 2020	Observation on the application of short- and medium-term low-dose glucocorticoids in the treatment of common novel coronavirus pneumonia in the elderly	Not a randomized trial
Xuedong 2022	Shugan Jieyu capsule improve sleep and emotional disorder in coronavirus disease 2019 convalescence patients: a randomized, double-blind, placebo-controlled trial	Not exposed to or diagnosed COVID-19
Xuedong 2023	Effects of Shengmai Yin on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial	Not exposed to or diagnosed COVID-19
Yadav 2021	Humoral Response to One and Two Doses of ChAdOx1-S Vaccine in Patients on Hemodialysis	Not a randomized trial
Yagovkina 2022	Vaccination With Oral Polio Vaccine Reduces COVID-19 Incidence.	Vaccine
Yamaguchi 2022	Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19	Not a randomized trial
Yamamoto 2022	Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild COVID-19: protocol for an exploratory, multicentre, double-blinded, randomised controlled trial (PLATEAU study)	Randomized trial with no results
Yan 2020	Large-scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules. [Chinese]	Traditional Chinese medicine
Yan 2020	Effects and Safety of Herbal Medicines among Community-dwelling Residents during COVID-19 Pandemic: A Large Prospective, Randomized Controlled Trial (RCT)	Traditional Chinese medicine

Yan 2022	Phase 3 Trial (in progress) of the SYK Inhibitor Fostamatinib in Patients Hospitalized with COVID-19: Protocol and Study Implementation Updates	Randomized trial with no results
Yan 2022	Use of platelet-rich plasma for COVID-19 related olfactory loss, a randomized controlled trial	Not exposed to or diagnosed COVID-19
Yang 2020	Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab	Not a randomized trial
Yang 2021	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials	Vaccine
Yang 2023	Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVacÂ®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China	Vaccine
Yanik 2021	Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome	Not a randomized trial
Yao 2022	Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population. Secondary Study Based on a Randomized Clinical Trial (preprint)	Vaccine
Yarahmadi 2022	Effect of Prone Position on Clinical Outcomes of Non-Intubated Patients with Covid-19: A Randomized Clinical Trial	Exercise or rehabilitation
Yarahmadi 2022	Novel Clinical Trial Design for the Study of the Effect of Prone Position on Clinical Outcomes of COVID-19 Patients.	Exercise or rehabilitation
Yassini 2022	Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in Adults (preprint)	Vaccine
Yassini 2023	Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults.	Vaccine
Yau 2022	BOOST KIDNEY: A Randomized Controlled Trial of Third Dose BNT162b2 vs. mRNA-1273 COVID-19 Vaccination in CKD and Dialysis Patients	Vaccine
Yavelov 2022	Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial.	Not a randomized trial
Ye 2020	Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019	Not a randomized trial
Ye 2020	Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China	Traditional Chinese medicine
YongliangFeng 2021	Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine in High-Risk Occupational Population: a randomized, parallel, controlled clinical trial	Vaccine
Yotsuyanagi 2023	A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).	Randomized trial with no results
Younie 2020	Improving young children's handwashing behaviour and understanding of germs: The impact of A Germ's Journey educational resources in schools and public spaces.	Psychological and educational
Yousefi 2022	Adjuvant Pomegranate Juice Intake Improves the Inflammatory Status and Clinical Outcomes of Hospitalized COVID-19 Patients: An Exploratory Randomized and Placebo-Controlled Trialâ€‹ (preprint)	Nutrition and supplements
Yousefi 2023	Adjuvant Pomegranate Juice Intake Improves the Inflammatory Status of Hospitalized COVID-19 Patients: A Randomized and Placebo-Controlled Trial.	Nutrition and supplements
Youssef 2021	Vip in the treatment of critical COVID-19 respiratory failure in patients with severe comorbidities	Not a randomized trial

Yu 2020	Effects of Lianhua Qingwen Granules Plus Arbidol on Treatment of Mild Corona Virus Disease-19. [Chinese]	Traditional Chinese medicine
Yu 2022	PRINCIPLES OF GLUCOCORTICOSTEROID ADMINISTRATION IN PATIENTS WITH COVID-19	Not a randomized trial
YuanLiu 2022	Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Re-combinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial.	Vaccine
Yuehong 2023	Effectiveness and safety of Jinshuibao capsules in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial	Not exposed to or diagnosed COVID-19
Yuehong 2023	Effectiveness of Xiangsha Liujun pills on decreased digestive function in convalescent patients of coronavirus disease 2019: a randomized, double blind, placebo controlled clinical trial.	Not exposed to or diagnosed COVID-19
Yuksel 2021	Addition of convalescent plasma to systemic corticosteroids in early phase of COVID-19	Not a randomized trial
Zaitsev 2022	ONGOING SYMPTOMATIC COVID-19 â€“ PHARMACOTHERAPY POSSIBILITIES	Not a randomized trial
Zapolnik 2023	A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemi	Vaccine
Zeng 2020	Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia	Randomized trial with no results
Zeng 2021	[Moxibustion on mental disorder in close contacts of coronavirus disease 2019: a randomized controlled trial].	Traditional Chinese medicine
Zeng 2021	Therapeutic Effects of Traditional Chinese Medicine (Maxingshigan-Weijing Decoction) on COVID-19: an open-label randomized controlled trial	Traditional Chinese medicine
Zeng 2021	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials	Vaccine
Zeng 2022	Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.	Vaccine
Zha 2020	Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)	Not a randomized trial
Zhang 2020	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19	Not a randomized trial
Zhang 2020	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial (preprint)	Vaccine
Zhang 2020	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.	Vaccine
Zhang 2021	SIM01 as a novel microbiome replacement therapy for COVID-19: An open-label pilot study	Not a randomized trial

Zhang 2021	Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients	Not a randomized trial
Zhang 2021	Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.	Vaccine
Zhang 2021	A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2	Not exposed to or diagnosed COVID-19
Zhang 2022	Intranasal delivery of NS1-deleted influenza virus vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response (preprint)	Not a randomized trial
Zhang 2022	Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study	Traditional Chinese medicine
Zhang 2022	Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial	Vaccine
Zhang 2023	Effect of five-elements music therapy combined with Baduanjin qigong on patients with mild COVID-19.	Others
Zhang 2023	Oral Liushen pill for patients with COVID-19: A prospective randomized controlled trial.	Traditional Chinese medicine
Zhao 2020	Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a	Traditional Chinese medicine
Zhdanov 2020	Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study). [Russian]	Not a randomized trial
Zhong 2022	Acupuncture for olfactory dysfunction in infected COVID-19 patients: study protocol for a randomized, sham-controlled clinical trial	Randomized trial with no results
Zhou 2020	Interferon-a2b treatment for COVID-19	Not a randomized trial
Zhou 2020	Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19.	Not a randomized trial
Zhou 2022	Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19.	Not a randomized trial
Zhu 2020	Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19	Not a randomized trial
Zhu 2022	Nebulized Exosomes Derived from Allogenic Adipose Tissue Mesenchymal Stromal Cells in Patients with Severe COVID-19: A Pilot Study (preprint)	Not a randomized trial
Zhu 2022	Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged â‰¥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.	Vaccine
Zhu Xiaoqing 2020	Research on the application value of psychological nursing in pregnant women with suspected novel coronavirus pneumonia	Psychological and educational
Zilberman-Itskovich 2022	Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial.	Not exposed to or diagnosed COVID-19
Zolotovskaia 2021	[Post-COVID-19 asthenic syndrome]	Not a randomized trial

Zulbaran-Rojas 2022	Safety and efficacy of electrical stimulation for lower-extremity muscle weakness in intensive care unit 2019 Novel Coronavirus patients: A phase I double-blinded randomized controlled trial	Exercise or rehabilitation
Zulbaran-Rojas 2023	Electrical stimulation to regain lower extremity muscle perfusion and endurance in patients with post-acute sequelae of SARS CoV-2: A randomized controlled trial.	Exercise or rehabilitation
Zupanets 2021	Quercetin effectiveness in patients with COVID-19 associated pneumonia	Inaccessible full text

Studies to be Considered at Next Update

Study	Title	Status
Guan 2023	Impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.	Included
Stone 2023	Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19	Included
Moghaddam 2023	High-dose vitamin D supplementation is related to an improvement in serum alkaline phosphatase in COVID-19 patients; a randomized double-blinded clinical trial.	Included - awaiting severity classification
Weis 2023	Amantadine for COVID-19 treatment (ACT study): a randomized, double-blinded, placebo-controlled clinical trial.	Included
Amra 2023	Steroid in the Treatment of Outpatient COVID-19: A Multicenter Randomized Controlled Trial.	Included
Belperio 2023	Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.	Included
Okugawa 2023	Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicenter randomized controlled clinical trial.	Included - awaiting severity classification
Yotsuyanagi 2023	Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial	Included
Pan 2023	An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection.	Included - awaiting severity classification
Rauch-Kröhnert 2023	Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial.	Included - awaiting severity classification
Partap 2023	Vitamin D and Zinc Supplementation to Improve Treatment Outcomes among COVID-19 Patients in India: Results from a Double-Blind Randomized Placebo-Controlled Trial.	Included
Reiersen 2023	The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial.	Included
Zuily 2023	Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, rando	Included - awaiting severity classification

Solomon 2023	Effect of the P-selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.	Included
O'Halloran 2023	Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.	Included - awaiting severity classification
Siripongboonsitti 2023	Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study).	Included
Jittamala 2023	Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV).	Included
Naggie 2023	Erratum: effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: a Randomized Clinical Trial (JAMA (2022) 328: 16 (1595-1603) DOI: 10.1001/jama.2022.18590)	Included
Khoo 2023	Correction to Lancet Infect Dis 2022; published online Oct 19. https: //doi.org/10.1016/S1473-3099(22)00644-2 (The Lancet Infectious Diseases, (S1473309922006442), (10.1016/S1473-3099(22)00644-2))	Included
Tanaka 2023	Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial.	Included - drug awaiting classification
Yu 2023	Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.	Included - awaiting drug and severity classification
Huang 2023	Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.	Included - drug awaiting classification
Zhao 2023	Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.	Included - drug awaiting classification
Sgalla 2023	A randomized trial of pamrevlumab in patients with COVID-19 pneumonia.	Included - awaiting drug and severity classification
Mabrey 2023	Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia.	Included - drug awaiting classification
Boffito 2023	A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study).	Included - drug awaiting classification
Gérain 2023	NASAFYTOL¬Æ supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial.	Included - drug awaiting classification

Maranda 2023	Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.	Included - drug awaiting classification
Hess 2023	Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial.	Included - awaiting drug and severity classification
ThierryFumeaux 2023	Oral Pamapimod-Pioglitazone Combination (KIN001) vs Placebo in Hospitalized Non-Critically Ill COVID-19 Patients: The KINETIC (KIN001) to Reduce the Risk of EndoTracheal Intubation in COVID) Phase 2, Randomised, Double Blind, Placebo-Controlled Trial	Included - drug awaiting classification
Iwahori 2023	A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19.	Included - drug awaiting classification
Badaro 2023	A randomized clinical trial to evaluate the efficacy of L-carnitine L-tartrate to modulate the effects of SARS-CoV-2 infection.	Included - awaiting drug and severity classification
Ison 2023	Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and E	Included - drug awaiting classification
Martin 2023	Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19.	Included - drug awaiting classification
François 2023	Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.	Included - awaiting drug and severity classification
El-Tanani 2023	Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients.	Included - awaiting drug and severity classification
Foidart 2023	Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study.	Included - drug awaiting classification
Shahbazi 2023	Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trial.	Included - drug awaiting classification
Wang 2023	Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.	Included - drug awaiting classification
Robinson 2023	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.	Included - awaiting drug and severity classification

ColadoSimão 2023	Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial.	Included - awaiting drug and severity classification
Tran 2023	Therapeutic Efficacy of A Free Oral Spray on the Symptoms and Course of Moderate and Severe COVID-19 in the Field Hospital.	Included - awaiting drug and severity classification
Manomaipiboon 2022	Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial	Included

Nodes Excluded by Steering Committee

(acetyl)cysteine	intranasal hypertonic polymer spray
13 cis retinoic acid	intranasal xylitol
2-deoxy-D-glucose	iota-carrageenan nasal spray, povidone-iodine mouthwash
5-alpha reductase inhibitor	itraconazole
99mTc-methylene diphosphonate	ivermectin nasal spray
Abatacept	ivermectin, metformin
acebilustat	L-arginine
AgNPs	L-carnitine tartrate, N-acetylcysteine, nicotinamide riboside, serine
almitrine bismesylate	lactobacilli spray
alpha lipoic acid	lactoferrin
amantadine	LAU-7b
amiodarone	levamisole
ammonium chloride	lincomycin
ammonium glycyrrhizate plus povidone-iodine oropharyngeal spray, dipotassium glycyrrhizinate plus povidone-iodine nasal spray	lithium carbonate
AMP5A	LY3127804
AMY-101	melatonin
andrographolide	metformin
antihepaciviral	metformin glycinate
aprotinin	methylene blue
ArtemiC	metisoprinol
artemisinin	mouthwash and a dentifrice both containing antimicrobial phthalocyanine derivative
aspirin, dipyridamole	mouthwash containing an antiviral phthalocyanine derivative
aspirin, niacinamide, potassium iodide, promethazine hydrochloride, sodium selenate, vitamin C, vitamin D, zinc sulphate monohydrate (APMV2020)	nanocurcumin

Aterixen	nasal chloroquine
ATI-450	niclosamaide
atovaquone	nicotine
AZD1656	nitazoxanide
azelastine	nitric oxide
azelastine nasal spray	nitrilotriacetic acid trisodium salt
B vitamins (dexpanthenol, nicotinamide, riboflavin, thiamine)	NK1 antagonist
baloxavir marboxil	omega 3
BCc1, Hep-S	OP-101
BCG vaccine	organosulfur
benzalkoniumchloride mouthrinse	P2Et
berberine	palmitoylethanolamide
beta-cyclodextrin, citrox mouthwash	paracetamol (acetaminophen)
beta-glucans	PCSK9 inhibitor
boswellic acids, glycyrrhizin	pentoxifylline
brensocatib	pirfenidone
bromhexine	polymerized type I collagen
bromhexine hydrochloride	povidone iodine
calcium channel blockers	povidone-iodine mouthwash
calcium release-activated calcium inhibitor	povidone-iodine nasal irrigation
CCK-A agonist and CCK-B antagonist (PNB001)	povidone-iodine nasal irrigation, povidone-iodine mouthwash
CD24Fc	probiotics
cefepime	progesterone
CERC-002	prolastin (alpha-1 antitrypsin)
cetylpyridinium chloride mouth rinse, hydrogen peroxide mouth rinse, hypochlorous acid mouth rinse, povidone-iodine mouth rinse	prolectin-M
cetylpyridinium chloride mouthwash	prostacyclin infusion
chlorhexidine digluconate lozenges	proxalutamide
chlorhexidine mouthwash	pyridostigmine
chlorpheniramine maleate	quercetin

curcumin, piperine	raloxifene
curcumin, quercetin, vitamin D	ravulizumab
curcumin, virgin coconut oil	Reamberin infusion
curcumin, vitamin C, zinc	recombinant erythropoietin
curcuminoids, andrographolides, resveratrol, zinc, selenium, piperine	reparixin
defibrotide	resveratrol
degarelix	resveratrol, zinc
dextromethorphan	Reyanning
DFV890	RP7214
diammonium glycyrrhizinate	sabizabulin
dimethyl fumarate	saline
dornase alfa (nebulised)	saline irrigation
edaravone	saline irrigation, saline mouthwash
electrolyzed saline	saline irrigation, surfactant
enisamium	saline irrigation, triamcinolone acetonide
enpatoran	saline mouthwash
ensovibep (MP0420)	senicapoc
essential oils mouthwash	sentinox spray
ethanol spray	SGLT2 inhibitors
ethanol-based mouthwash	sildenafil
ethinylestradiol, norelgestromin	sitagliptin
exosomes overexpressing CD24	sitagliptin, spironolactone
exosomes overexpressing CD25	sodium bicarbonate nasal irrigation
famotidine	sodium bicarbonate solution
fenofibrate	sodium chloride
fluoxetine	sodium tanshinone IIA sulfonate
fluvoxamine, metformin	spironolactone
foralumab	stabilised, synthetic sulforaphane
gabapentin	statins, folic acid, L-arginine, nebivolol, nicorandil
gabapentin, leukotriene receptor antagonists	steam inhalation

hesperidin	sulodexide
hydrogen peroxide	synbiotic
hydrogen peroxide (nebulised)	synthetic VIP
hydrogen peroxide mouthwash	systemic ozone
hydrogen peroxide plus chlorhexidine mouthwash	tafenoquine
hypertonic saline, surfactant	thalidomide
hypochlorous acid solution	thymoquinone
Ingavirin	thymosin α1
inhaled (acetyl)cysteine	tranilast
inhaled calcium-rich hypertonic salt solution	triiodothyronine
inhaled ethanol	TXA-127
inhaled GB0139 (galectin-3 inhibitor)	unfractionated heparin nebulization
inhaled nebulised unfractionated heparin	vidofludimus calcium
inhaled prostacyclin	vitamin A
inhaled recombinant granulocyte macrophage colony-stimulating factor	xanthohumol
inhaled saline	xiyanping
inhaled SARS-CoV-2-specific siRNA-peptide dendrimer (MIR 19)	zilucoplan
inhaled sodium bicarbonate	zinc

Disease Severity Judgements

Mild to Moderate Studies

Study	WHO criteria and/or Author-defined	Respiratory Support	Other	Included in network meta-analysis
Abd-Elsalam_2, 2020	X			
Abd-Elsalam_3, 2021	X			X
Abdeen_2, 2021	X			
Abdulamir_2, 2021	X			X
Abroug, 2023	X			
Abulmeaty, 2021	X			
Adhikari, 2022	X			
Ahmad, 2021	X			
Ahmed, 2020	X			X
Akbari, 2022	X			
Ali, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
AlQahtani, 2022		X		X
Amaravadi, 2021	X			X
Amirsavadkouhi, 2021	X			
Ananworanich_2, 2021	X			X
Angkasekwinai, 2022	X			X
Annweiler, 2022		X		
Arefin, 2021	X			
Arefizadeh, 2023			75% of participants had oxygen saturation of at least 94%. Many of the rest probably had oxygen saturation above 90%.	
Arruda, 2021	X			X
Atipornwanich_1, 2021	X			
Avezum_2, 2023	X			X
Avezum, 2022	X			X
Axfors_NCT04333654, 2020			Outpatients	X
Axfors_NCT04338698, 2020	X			X
Axfors_NCT04340544, 2020	X			X
Axfors_NCT04342221, 2020			Disease severe enough to require hospitalizationl QTc interval lower than 450 msec; Exclusion Criteria: Respiratory rate >24/min	X
Axfors_NCT04342650, 2020	X			X
Babalola, 2021	X			X
Balykova_1, 2020	X			X
Balykova_3, 2022		X		X
Barco, 2022	X			X

Beigel, 2020	X		Mixed disease severity trial; subgroup data extracted according to author definitions	X
Berezhanskiy, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	
Bernal, 2022	X			X
Bhushan, 2021	X			X
Bishop, 2022		X		
Bosaeed_2, 2022	X			X
Boulware, 2022	X			X
Bradbury, 2022	X		Mixed disease severity trial; subgroup data extracted according to author definitions	X
Bramante_1, 2022			Outpatients	X
Bramante_2, 2022			Outpatients	X
Bukhari, 2021	X			
Buonfrate, 2022		X		X
Butler_2, 2022		X		X
Butler, 2021			Outpatients	X
Byakika-Kibwika, 2021	X			X
Cairns, 2022		X		X
Cao_3, 2022	X			X
Caraco, 2022	X			X
Castro-Rodriguez, 2022			Outpatients	X
Cavalcanti, 2020		X		X
Chaccour, 2020	X			
Chachar, 2020	X			
Chahla, 2021	X			X
Chen_1, 2020	X			X
Chen_2, 2021	X		Mixed disease severity trial; subgroup data extracted according to author definitions	X
Chen_3, 2020	X			X
Chen_4, 2020	X			X
Chen_5, 2020	X			X
Choudhary, 2022	X			X
Chuan Huan, 2021	X			X
Clemency, 2021		X		X
Cohen, 2020	X			X
Connors, 2021			Outpatients	X
Cools, 2022		X		X
COVITOZ_NCT04435717, 2021	X			X
Criner, 2020	X			X
Crippa, 2021	X			
Cruz, 2020			Patients have asymptomatic, moderate, and severe illness (Table 1). ~80% of patients are asymptomatic.	

da Silva, 2023	X			X
Davoodi_1, 2020		X		
de la Rocha, 2022	X			X
De Niet, 2022	X			X
Doi, 2020		X		
Dorward, 2022			Outpatients	X
Dubee, 2021			Patients were eligible if they had at least one of the following risk factors for worsening: (i) need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (SpO2 >94%) or a ratio of oxygen partial pressure to fractional inspired oxygen less than or equal to 300 mmHg (PaO2/FiO2 ≤300 mmHg); (ii) age ≥75 years; (iii) age between 60 and 74 years and presence of at least one of the following comorbidities: obesity (body mass index ≥30 kg/m2), arterial hypertension requiring treatment, or diabetes mellitus requiring treatment.	X
Duvignaud, 2022	X			X
Eikelboom_1, 2022			Outpatient	X
Eikelboom_2, 2022			Outpatient	X
EPIC-SR, 2021	X			X
Esquivel-Moynelo, 2020	X			
Ezer, 2021		X		X
Fan, 2021	X			
Feld, 2020			Outpatients	X
Ferrarini, 2022	X			X
Fischer_3, 2021			Outpatients	X
FitzGerald, 2021	X			
Fogleman, 2022			Outpatients	
Fu, 2020			Patients were included if their peripheral capillary oxygen saturation (SpO2) was >94% on room air at screening.	
George, 2022	X			X
Ghaderkhani, 2022	X			
Ghati, 2022	X			X
Ghaznavi, 2022	X			
Golan, 2022	X			X
Gorial, 2022	X			X
Gottlieb_2, 2021		X		X
Guimaraes, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Guzman-Esquivel, 2022	X			
Hakamifard, 2021	X			
Hammond, 2022			FDA guidelines and nonhospitalized patients	X
Han, 2022	X		Mixed disease severity trial; subgroup data extracted according to WHO criteria	X
Hinks, 2021		X		X

Holubar, 2022	X			X
Horby_1, 2020	X			X
Horby_2, 2020		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Horby_3, 2020		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Horby_4, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Horby_8, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Hu, 2020	X			
Huang_2, 2020	X			
Hung, 2020	X			
Husain, 2020	X			
Ikeda, 2022	X			
Issak, 2023		X		X
Ivashchenko, 2020	X			X
Jagannathan, 2021		X		X
Jahangirifard, 2021	X			
Jalal, 2022	X		Mixed disease severity trial; subgroup data extracted according to author definitions	X
Jardine, 2022			28% required oxygen at baseline. The median WHO scale score was 3 (interquartile range 3-4).	X
Jilg _2, 2023	X			X
Jilg_1, 2022			Outpatients	
Johnston, 2021			Outpatients	X
Kaizer, 2022			Outpatients	X
Kalil_2, 2021		X		X
Kalil, 2020	X		Mixed disease severity trial; subgroup data extracted according to WHO criteria	X
Karolyi, 2022	X		Mixed disease severity trial; subgroup data extracted according to WHO criteria	X
Kasgari, 2020	X			
Kasiri_2, 2023			67% of patients did not require oxygen. Only three patients were on high-flow or NIMV at baseline.	X
Kasiri, 2021	X			
Kerget_1, 2021			Unclear, judged as mild/moderate by content experts	
Khavkina, 2021	X			
Khoo_1, 2021		X		X
Khoo_2, 2022	X			X
Kim_3, 2022		X		X
Kim_4, 2023	X			X
Kinoshita, 2022		X		X
Kishoria, 2020	X			
Kumar_5, 2022	X			

Krishnan, 2021	X			X
Krolewiecki, 2021	X			X
Lakkireddy, 2021	X			X
Lawler_2, 2023	X			X
Lenze, 2020	X			X
Les, 2022		X		X
Li_2, 2021	X			
Li_4a, 2021		X		
Li, 2020	X			X
Lim, 2022	X			X
Liu, 2023	X			X
Lopes_1, 2022	X			X
Lopez-Medina, 2021	X			X
Lou, 2020		X	Only 1/3 ended up hospitalized for O2 so at baseline vast majority must have been outpatients	X
Lowe, 2022	X			X
Madioko, 2022	X			X
Mahmud, 2021		X		X
Marconi, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Marcos, 2021	X			X
Mariani, 2022		X		X
McCarthy, 2023			Outpatients	X
McMahon, 2022	X			X
McQuilten, 2022			We excluded patients who were already receiving intensive respiratory (noninvasive ventilation or invasive mechanical ventilation) or cardiovascular support. The lower range of the lowest oxygen saturation on ambient air was 92%	X
Mirahmadizadeh, 2022	X			X
Miyazaki, 2023	X			
Mohamed, 2022			Hospitatized patients with pneumonia without hypoxia (positive imaging and SpO2 >= 92%). Baseline oxygen saturation of 96%.	X
Mohan, 2021	X			X
Monk, 2020	X			X
Moreira, 2021	X			
Mukae_2, 2022		X		X
Mukae, 2022	X			X
Murugesan, 2021	X			X
Naggie_2, 2022		X		X
Naggie_3, 2023		X		X
Naik_2, 2023	X			
Nimitvilai, 2022	X			

O'Halloran, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	
Ogbuagu, 2021	X			
Oldenburg, 2021			Outpatients	X
Omrani, 2020	X			X
Onal, 2021			O2: Oxygen support was needed in 34.4% total (32.4% of the patients in the standard treatment group and 51% of the QCB treatment group). In the standard treatment group, 8/380 patients required intensive care due to respiratory failure. (Author-defined moderate-severe: 66.6% had SpO2 >93%, 33.4% had <93%. (93% is hx WHO guideline, current is 90%). Majority of patients had bilateral ground-glass opacities, but only 8.3% had diffuse ground-glass opacities and air broncograms.)	
Optimus pharma, 2021	X			
Pan_hydroxychloroquine, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Pan_interferon, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Pan_lopinavir, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Pan_remdesivir, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Panda_1, 2021		X		
Pandit, 2021	X			
Parienti, 2021	X			X
Pascual-Figal, 2021			Unclear, judged as mild/moderate by content experts	X
Piazza, 2023			Outpatients	X
Plasse, 2022		X		X
Pott-Junior, 2021	X			X
Pourdowlat, 2022			Unclear, judged as mild/moderate by content experts	X
Prabowo, 2021	X			
PRINCIPLE Trial Collaborative Group, 2021		X		X
Purwati, 2021	X			
Puskarich, 2021		X		X
Rahman_1, 2022	X			
Rahman_2, 2022	X			X
Ramachandran, 2021	X			X
Ramakrishnan, 2021	X			X
Rashad_3, 2021	X			X
Rashid, 2021	X			
Rastogi, 2020	X			X
Ravikirti, 2021	X			X
Reid, 2021			Unclear, judged as mild/moderate by content experts	
Reiersen, 2021		X		X

Reis_1, 2020		X		X
Reis_2, 2021		X		X
Reis_3, 2022			Outpatient	X
Reis_5, 2023			Outpatients	X
Reis_6, 2023			Outpatients	X
Ren, 2020	X			
Rezai_2, 2022		X		X
Rodrigues, 2021	X			X
Roy-Garcia, 2022	X			X
Ruzhentsova, 2020	X			X
Sabico, 2021	X			
Sarojvisut, 2022		X		X
Sausa, 2022			Only 29% had oxygen at baseline. No patient important outcomes reported.	
Schilling, 2023		X		X
Schwartz_1, 2021		X		
Schwartz_2, 2021			Outpatients	X
Seo, 2022	X			X
Sharma, 2022	X			X
Shebley, 2022			Only 29% had oxygen at baseline. Most were outpatients.	
Shinkai, 2021	X			X
Sholzberg, 2021	X			X
Sinha, 2022	X			X
Sirijatuphat, 2022	X			X
Skendelas, 2021	X			
Skipper, 2020	X			X
Sobngwi, 2021	X			
Song, 2021	X			X
Spinner, 2020	X			X
Spivak, 2023		X		X
Tang_1, 2020	X		The definition of disease severity of covid-19 was based on the fifth version of the Chinese guideline for the management of covid-19	X
Tardif, 2021	X			X
Tehrani_2, 2022	X			X
Terada-Hirashima, 2022			Patients admitted with COVID-19 were screened, and those with no signs of pneumonia on chest X-rays (CXR) were deemed eligible	X
Thomas, 2021			Outpatients	
Tobback, 2022		X		X
TOCOVID_EudraCT2020-001442-19, 2021	X			X
Udwadia, 2020		X		X
Vaezi, 2023		X		X

Vaira, 2020			Outpatients	
Vallejos, 2021		X		X
Vyas, 2021	X			X
Wada, 2023	X			X
Wang_5, 2020			Patients enrolled have prolonged post viral shedding.	
Yadegarinia, 2020			Unclear, judged as mild/moderate by content experts	X
Yang, 2022	X			
Yethindra, 2020	X			X
Yu, 2021			Outpatient	X
Zhao_2, 2021	X			X
Zhao_3, 2022	X			X
Zheng_1, 2020	X		Mixed disease severity trial; subgroup data extracted according to author definitions	
Zhuravel, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support	X
Zou, 2022	X			X

Severe to Critical Studies

Study	WHO criteria and/or Author-defined	Respiratory Support	Other
Abdeen_1, 2021			All patients in ICU
Absalon-Aguilar, 2021		X	
Abuhasira, 2021			64% required oxygen at baseline.
Ader_1, 2021		X	
Ader_2, 2022		X	
Adrian, 2021	X		
Agusti, 2022			81.5% chest x-ray found bilateral pneumonia, 18.5% unilateral pneumonia
Alavi-Moghaddam, 2021	X		
Ali_2, 2022		X	
Ali, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Alsultan, 2021			Admission criteria patients were oxygen saturation ≤93% plus at least one of the following: (1) respiratory rate ≥30 breaths/min, (2) infiltrates >50% on CT scan, and (3) arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen ratio (FiO2) <300 mmHg.
Aman, 2021		X	
Angus, 2020		X	
Arabi, 2021		X	

ARCHITECTS_NCT04412772, 2021		X	
Arnardottir, 2021			Unclear, judged as severe/critical by context experts
Arribas, 2021			More severe/critical than mild/moderate (≥50% required oxygen at baseline)
Asadi, 2021			Unclear, judged as severe/critical by expert clinicians
Atipornwanich_2, 2021			respiratory symptoms and abnormal findings on chest imaging confirmed by a blinded radiologist
Audemard-Verger, 2022		X	
Axfors_ChiCTR2000031204, 2020			Clinically diagnosed with pneumonia, onset within 7 days
Axfors_NCT04323527, 2020			respiratory rate higher than 24 breathing incursions per minute AND/OR heart rate higher than 125 beats per minute (in the absence of fever) AND/OR peripheral oxygen saturation lower than 90% in ambient air AND/OR shock (defined as mean arterial pressure less than 65 mmHg, requiring vasopressor or oliguria or lowering level of consciousness)
Axfors_NCT04345289, 2020			Evidence of pneumonia given by at least one of the following: SpO2 ≤93% on ambient air or PaO2/FiO2 <300 mmHg/40 kPa OR Radiographic findings compatible with COVID-19 pneumonia
Axfors_NCT04345692, 2020			At least one of the following: Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) or Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤94% on room air
Axfors_NL8490, 2020			Patient has moderate to severe COVID-19. This will be defined as patients with NEWS-2 score = 5.
Babalola_2, 2021			Unclear, judged as severe/critical by expert clinicians
Balykova_2, 2020			Unclear, judged as severe/critical by expert clinicians
Bari, 2022		X	
Barratt-Due, 2021			Eligibility criteria were adult patients (≥18 years) with SARS-CoV-2 infection confirmed by PCR who were admitted to the hospital ward or intensive care unit (ICU) with no anticipated transfer to a non-study hospital within 72 hours of inclusion.
Barrett_P1, 2021		X	
Barrett_P2, 2021		X	
Bauer, 2021		X	
Beigel, 2020	X		Mixed disease severity trial; subgroup data extracted according to author definitions
Beigmohammadi, 2021		X	
Berezhanskiy, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Bikdeli_1, 2021		X	
Bikdeli_2, 2022		X	
Blondon, 2022		X	

Bosaeed, 2021		X	
Bosteels, 2021		X	
Bouadma, 2022		X	
Bradbury, 2022	X		Mixed disease severity trial; subgroup data extracted according to author definitions
Branch-Elliman, 2022			Unclear, judged as severe/critical by expert clinicians
Broman, 2022		X	
Brown, 2020		X	
Bugarin, 2023		X	
Cabral_2, 2022			Unclear, judged as severe/critical by expert clinicians
Cafardi, 2022		X	
Cannata-Andia, 2022			All patients were hospitalized and 83.1% of participants had pulmonary involvement.
Cao_1, 2020		X	
Cao_2, 2020		X	
Caricchio, 2021	X		
Castillo, 2020			Patients hospitalized with COVID-19 infection clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1)
Cecconi, 2022	X		
Cervero, 2022		X	
Chen_2, 2021	X		Mixed disease severity trial; subgroup data extracted according to author definitions
Cheng, 2020		X	
Chowdhury, 2022			All patients in ICU
Clemente-Moragon, 2021		X	
Coppock, 2022		X	
Corral-Gudino, 2020			Moderate to severe disease with abnormal gas exchange: (a) partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2 or PaFi) < 300, (b) arterial oxygen saturation/fraction of inspired oxygen (SaO2/FiO2 or SaFi) < 400 or (c) at least two criteria of the BRESCIA-COVID Respiratory Severity Scale (BCRSS)
Coutre, 2022		X	
COV-AID_NCT04330638, 2021		X	
COVIDOSE2-SSA_NCT04479358, 2021		X	
Cremer_1, 2020		X	

Cremer_2, 2021		X	
Criner_2, 2022		X	
Darazam_1, 2021	X		
Darazam_2, 2021	X		
Darazam_3, 2021	X		
Darban, 2021			All patients in ICU
Davoodi_2, 2021			All had CT changes
Davoudi-Monfared, 2020		X	
Deftereos, 2020			65% required oxygen at baseline
Dequin, 2020		X	
Dhar, 2023			All were inpatients at a time that resources were extremely constrained; there was almost certainly a higher threshold for admission than usual. Also, a substantial proportion (~20%) required ICU admission, suggesting that the patients were severe.
Diaz, 2021		X	
Doaei, 2021			All patients in ICU
Duarte, 2021		X	
Edalatifard, 2020		X	
Eid, 2021			Unclear, judged as severe/critical by expert clinicians
Eikelboom_3, 2022		X	
Eikelboom_4, 2022		X	
Elamir, 2021			More severe/critical than mild/moderate (≥50% required oxygen at baseline)
Elmekaty, 2022		X	
Elshafie, 2022		X	
Eltahan, 2023		X	
Ely, 2022		X	
Fakharian, 2021		X	
Farahani, 2020			All patients in ICU
Finberg, 2021			74% required oxygen at baseline
Fisher_1, 2021	X		
Fisher_2, 2021	X		
Freilich, 2022			Unclear, judged as severe/critical by expert clinicians
Furtado, 2020		X	
Gaitan-Duarte, 2021		X	

Gaitán-Duarte, 2022		X	
Galan, 2021			average oxygen saturation < 90%
Garofalo, 2022		X	
Gautam, 2021			Unclear, SpO2 less than 93 required to be eligible so assumed most received oxygen
Geriak, 2021		X	
Ghafoori, 2022	X		
Ghanei, 2021	X		
Goldman, 2020		X	
Golovatyuk, 2022			64% required oxygen at baseline.
Gonzalez, 2021			average oxygen saturation < 90%
Gordon_1, 2021		X	
Gordon_2, 2021	X		
Gotberg, 2022			Unclear, judged as severe/critical by content experts
Guimaraes, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Gunst, 2021			2/3 of patients severe by WHO
Gyselinck, 2022		X	
Habibi Dastenae, 2022		X	
Haeberle, 2021		X	
Hamed, 2021	X		
Han, 2022	X		Mixed disease severity trial; subgroup data extracted according to WHO criteria
Haroon, 2022		X	
Hassaniazad_2, 2022			all patients were hospitilized due to an oxygen saturation (SpO2) of ≤93% or/and respiratory rate (RR) of 30; one outcome implies patients received supplemental oxygen (just not NIV or IV)
Hepprich, 2022			75% required oxygen at baseline
Hermine_2, 2021			All patients in ICU
Hermine_3, 2021		X	
Hermine_toci, 2020		X	
Hermine, 2020		X	
Hernandez-Cardenas, 2021		X	
Heydari, 2022			Unclear, judged as severe/critical by content experts
HMO-020-0224_NCT04377750, 2021			Radiographic evidence of infiltrates on chest radiograph (CXR) or computed tomography (CT)

Horby_2, 2020		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Horby_3, 2020		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Horby_4, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Horby_5, 2021		X	
Horby_6, 2021			Patients admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. 4.66% of participants were receiving IV, 26.75% were receiving NIV, and 68.58% were either receiving no oxygen therapy or receiving supplementary oxygen therapy.
Horby_7, 2021			Unclear, judged as severe/critical by expert clinicians
Horby_8, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Huang_1, 2020			>80% had CT changes
ImmCoVA_NCT04412291, 2021			Oxygen needed to maintain SpO2 at ≥93%
Jalal, 2022	X		Mixed disease severity trial; subgroup data extracted according to author definitions
Jamaati, 2021	X		
JamaliMoghadamSiahkali, 2021	X		
Jeronimo, 2020		X	
Johansson, 2021		X	
Kalantari, 2021			average oxygen saturation < 90%
Kalil, 2020	X		Mixed disease severity trial; subgroup data extracted according to WHO criteria
Karampitsakos, 2022			PaO2/FiO2 <200
Karolyi, 2022	X		Mixed disease severity trial; subgroup data extracted according to WHO criteria
Karonova_2, 2022			55% severe/critical, rest mild/moderate
Kazempour, 2021			average oxygen saturation < 90%
Kerget_2, 2022			Unclear, judged as severe/critical by context experts
Khamis, 2020			Patients with confirmed SARS-CoV-2 infection by RT-PCR test on respiratory tract specimens, moderate to severe COVID-19 pneumonia according to the WHO interim guidelines case definitions; 80% had bilateral infilitrates
Kharazmi, 2021		X	
Khodashahi, 2020			Unclear, judged as severe/critical by expert clinicians
Kotfis, 2022		X	

Kumar_3, 2021		X	
Kumar_4, 2022			All patients in ICU
Kumar, 2021	X		
Kumarasamy, 2022	X		
Kumari, 2020	X		
Kurth, 2022		X	
Kyriazopoulou, 2021		X	
Labbani-Motlagh, 2022			Mean PF ratio <200 and 49% required high-flow or NIMV at baseline.
Lawler, 2021	X		
Lemos, 2020		X	
Lescure, 2021		X	
Leucker, 2021		X	
Li_4b, 2021		X	
Lomakin, 2021	X		
Lonze, 2022		X	
Lopes_2, 2021		X	
Lopes_3, 2021			75% required oxygen at baseline
Lyngbakken, 2020			All reverse transcriptase polymerase chain reaction (RT-qPCR) SARS- CoV-2 positive patients 18 years of age or older were eligible for study inclusion, if they had moderately severe COVID-19 at admission (NEWS2 of 6 or less).
Maghbooli, 2021			Unclear, judged as severe/critical by expert clinicians
Mahajan, 2021		X	
Majidi, 2021			All patients in ICU
Malchair, 2023		X	
Malik, 2022		X	
Mallat, 2021			Unclear, judged as severe/critical by expert clinicians
Mansour, 2020			Unclear, judged as severe/critical by expert clinicians
Marazzato, 2022	X		
Marconi, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Mariette, 2021		X	
Maskin, 2021		X	
Mastrorosa_1, 2022	X		
Mastrorosa_2, 2022		X	

Miller_1, 2021		X	
Moazen, 2022			peripheral oxygen saturation (SpO2)< 94% on room air and at sea level, a ratio of partial pressure of oxygen/fraction of inspired oxygen< 300mmHg, and respiratory rate > 30 breaths per minute or lung infiltrates > 50%
Monk_2, 2022		X	
Montejano_1, 2022			63% severe/critical
Montejano_2, 2022		X	Approximately 75% of participants were on some form of oxygen therapy.
Morales-Ortega, 2023			64% required oxygen at baseline.
Morici, 2021		X	
Munch_1, 2021		X	
Munch_2, 2021		X	
Munoz-Rivas, 2022			Adults who required admission to a conventional (noncritical) hospital ward due to COVID-19 pneumonia were included if they also met any of the following criteria: a) baseline oxygen saturation ≤94%, b) D-dimer > 1000 µg/L, c) C Reactive Protein (CRP) > 150 mg/L, or d) interleukin-6 (IL6) > 40 pg/mL), d) need for oxygen therapy or pAO2/FiO2<300mmHg or estimated PaO2/FiO2 based on SpO2/FiO2<300 mmHg.
Murai, 2021		X	
Naik, 2021		X	
Najmeddin, 2021		X	
Narayanasamy, 2022		X	
Nekoukar, 2021			Participants had lung CT compatible with moderate COVID-19 (Involvement of up to 3 or 4 lung lobes with an area less than one-third of the volume of each lobe or involvement of one or two lobes with a larger area in the CT scan of the patient) or arterial O2 saturation (O2 Sat%) of 90-93%.
Neuenschwander, 2022		X	
Niaee, 2020	X		
Nojomi, 2020			average oxygen saturation < 90%
O'Halloran, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Odeyemi, 2022		X	
Oliynyk, 2021			All patients in ICU
Ortega Martinez, 2021		X	
Pan_hydroxychloroquine, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Pan_interferon, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support

Pan_lopinavir, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Pan_remdesivir, 2022		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Panda_2, 2021	X		
Patel_2, 2021		X	
Perepu, 2021			Unclear, judged as severe/critical by expert clinicians
Perricone, 2023		X	
Pisarevsky, 2021			Patients were hospitalized and had pneumonia. Treatment aimed to reduce proinflammatory cytokines.
Poor, 2022		X	
Postle, 2021		X	
Puskarich_2, 2022		X	
Quinn, 2022		X	
Rabbani, 2022			Unclear, judged as severe/critical by content experts
Rabie, 2023		X	
Rahmani, 2020		X	
Ranjbar, 2021			Hospitalized patients with an O2 saturation of less than 92 in room air on admission (48.8% had SpO2 <85%)
Rashad_2, 2021		X	
Rashidi, 2021		X	
Réa-Neto, 2021		X	
REMDACTA_NCT04409262, 2021		X	
Resende, 2021	X		
Rezai, 2022			Unclear, judged as severe/critical by context experts
Robbins, 2022	X		
Rosales Renteria, 2022	X		
Rosas, 2021			Eligible patients had blood oxygen saturation ≤93% or partial pressure of oxygen/fraction of inspired oxygen <300 mm/Hg.
Rutgers, 2021		X	
Safa, 2022			All patients in ICU
Sahraei, 2022			mild to moderate ARDS (based on the Berlin Criteria, an American-European Consensus Community (AECC) guideline for staging the severity of ARDS: the PaO2 to FiO2 ratio between 100 to 300 OR The SpO2 to FiO2 ratio of 143 to 343)
Salama, 2020			Unclear, judged as severe/critical by expert clinicians
Salehzadeh, 2020			Pulmonary involvement seen in CT-Scan
Salvarani_2, 2022		X	

Salvarani, 2020			Unclear, assumed severe/critical based on the statement suggesting that a pulmonologist selected patients on the basis of ARDS
Sánchez-Conde, 2022		X	
Sancho-López, 2021		X	
SARCOVID_NCT04357808, 2021		X	
Sarhan_2, 2022	X		
Sarhan, 2021	X		
SARICOR_EudraCT2020-001531-27, 2021			Virological diagnosis of Sars-CoV2 infection (PCR) Acute respiratory failure Radiographic pneumonia, defined as any/ changing new lung infiltrate Patient breathing spontaneously, required more than 50% oxygen and MEWS score > 7. If intubated, intubated less than 24 hours with PaO2/Fio2 ratio ≤ 200 and PEEP ≥ 5 cm H2O.
Sasson, 2022			Unclear, judged as severe/critical by expert clinicians
Sedighiyan, 2021			Patients were hospitalized and the intervention was designed to mediate inflammation-related COVID-19 symptoms, suggesting more severe disease.
Sekhavati, 2020			significant findings compatible with radiographic imaging of COVID-19 pulmonary involvement
Self, 2020			65% required oxygen at baseline
Seong, 2021		X	
Sethi, 2021			All patients in ICU
Shah_2, 2023		X	
Shenoy, 2021		X	
Siami, 2021			Unclear, judged as severe/critical by expert clinicians
Siami, 2022			most had low oxygen saturation [46.60 (<90%), 29.13 (90-93%), 24.27 (>93%)]
SILCOR_EudraCT2020-001413-20, 2021			Hospitalized patients with laboratory confirmed SARS-CoV-2 infection illness of more than 5 days of duration with evidence of pneumonia and either: Non-critical - with pneumonia in radiological progression or Progressive respiratory failure at the last 24-48 hours; Patient with a maximum O2 support of 35%
Silva Borba, 2020		X	
Singh_1, 2021		X	
Singh, 2022			All patients had PaO2/FiO2 <200
Sivapalan, 2021			More severe/critical than mild/moderate (≥50% required oxygen at baseline)
Sivapalasingam_P2, 2021			77% required oxygen at baseline
Sivapalasingam_P3_C1, 2021	X		
Sivapalasingam_P3_C2_Critical, 2021		X	

Sivapalasingam_P3_C3_Critical, 2021		X	
Soin, 2021		X	
Solanich, 2021		X	
Solaymani-Dodaran, 2021			Typical ground glass appearance on chest CT scan in need of hospital admission due to a SpO2 reduction of 93% or less were eligible to enter this study. Median SpO2 was 89
Spyropoulos, 2021		X	
Sterne_NCT04244591, 2020			All patients in ICU
Sterne_NCT04325061, 2020		X	
Stone_2, 2023			This is squarely mixed population with 34% of patients requiring oxygen at baseline, but seemingly sicker population (based on deaths and need for intensive care). Considered as severe/critical
Stone, 2020		X	
STORM_NCT04345445, 2021		X	
Strich, 2021		X	
Tabarsi, 2021			Unclear, judged as severe/critical by expert clinicians
Taboada, 2021		X	
Talaschian, 2021		X	
Tam, 2022			Unclear, judged as severe/critical by content experts
Tang_2, 2021			71% required oxygen at baseline
Tavares, 2021			Lower quartile of WHO ordinal scale IQR is 3 and 4 suggesting most received O2
Tehrani, 2021	X		
Temesgen, 2021		X	
Terada, 2022			Unclear, judged as severe/critical by content experts
The CORIMUNO-19 Collaborative group, 2021		X	
The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, 2021		X	
Tomazini, 2020		X	
Tornling, 2021			72% required oxygen at baseline
Toroghi, 2021		X	
Troseid, 2022	X		
Ulrich, 2020			65% required oxygem at baseline
Veiga, 2021		X	
Vlaar_2, 2022		X	

Vlaar, 2020		X	
Wang_1, 2020		X	
Wang_2, 2020			Unclear, all hospitalized patients
Wang_3, 2020			Unclear, all hospitalized patients
Wang_4, 2020			74% required oxygen at baseline
Welén, 2021		X	
Wilkinson, 2021		X	
Winthrop, 2022		X	
Wu, 2020			Unclear, all had CT anomalies and either fever or respiratory symptoms
Zhang_1, 2021		X	
Zhao_1, 2020	X		
Zheng_1, 2020	X		Mixed disease severity trial; subgroup data extracted according to author definitions
Zhuravel, 2021		X	Mixed disease severity trial; subgroup data extracted according to baseline respiratory support
Zurita-Cruz, 2022		X	

Proportion of Non-Severe Patients in Trials with Mixed Severity Populations

Study	N Total	% Non-Severe
Ali, 2022	324	6.79
Beigel, 2020	1062	9.89
Berezhanskiy, 2021	372	16.40
Bradbury, 2022	1824	14.42
Chen_2, 2021	240	87.08
Guimaraes, 2021	289	24.57
Han, 2022	432	32.64
Horby_2, 2020	4716	23.58
Horby_3, 2020	5040	26.21
Horby_4, 2021	7764	18.13
Horby_8, 2022	8156	5.70
Jalal, 2022	80	56.25
Kalil, 2020	1033	13.75
Karolyi, 2022	201	78.61
Marconi, 2021	1525	12.20
O'Halloran, 2022	1061	3.77
Pan_hydroxychloroquine, 2022	1865	36.68
Pan_interferon, 2022	4317	23.42
Pan_lopinavir, 2022	2796	37.98
Pan_remdesivir, 2022	8320	20.79
Zheng_1, 2020	89	94.38
Zhuravel, 2021	104	89.42

Studies Included in Analysis for Each Outcome

Mortality	Abd-Elsalam_3	Ferrarini	Mohan
	Abdulamir_2	Fischer_3	Monk
	AlQahtani	George	Mukae
	Ali	Ghati	Mukae_2
	Amaravadi	Golan	Murugesan
	Ananworanich_2	Gorial	Naggie_2
	Angkasekwinai	Gottlieb_2	Naggie_3
	Avezum	Guimaraes	Oldenburg
	Avezum_2	Hammond	Omrani
	Axfors_NCT04333654	Han	PRINCIPLE Trial Collaborative Group
	Axfors_NCT04338698	Hinks	Pan_hydroxychloroquine
	Axfors_NCT04340544	Holubar	Pan_interferon
	Axfors_NCT04342221	Horby_1	Pan_lopinavir
	Axfors_NCT04342650	Horby_2	Pan_remdesivir
	Babalola	Horby_3	Pascual-Figal
	Balykova_1	Horby_4	Piazza
	Barco	Horby_8	Puskarich
	Beigel	Issak	Rahman_2
	Bernal	Ivashchenko	Ramachandran
	Bhushan	Jalal	Rashad_3
	Bosaeed_2	Jardine	Ravikirti
	Boulware	Jilg_2	Reis_1
	Bradbury	Johnston	Reis_2
	Bramante_1	Kaizer	Reis_3
	Bramante_2	Kalil	Reis_5
	Butler	Kalil_2	Reis_6

	Butler_2	Kasiri_2	Rezai_2
	COVITOZ_NCT04435717_B	Khoo_1	Rodrigues
	Cairns	Khoo_2	Sarojvisut
	Cao_3	Kim_4	Schilling
	Caraco	Kinoshita	Schwartz_2
	Castro-Rodriguez	Krishnan	Sharma
	Cavalcanti	Krolewiecki	Shinkai
	Chahla	Lakkireddy	Sholzberg
	Chen_2	Lawler_2	Sinha
	Chen_3	Lenze	Sirijatuphat
	Chen_4	Les	Skipper
	Chen_5	Li	Song
	Choudhary	Lim	Spinner
	Chuan Huan	Liu	Spivak
	Clemency	Lopes_1	TOCOVID_EudraCT2020-001442-19
	Cohen	Lopez-Medina	Tang_1
	Connors	Lou	Tardif
	Cools	Lowe	Terada-Hirashima
	Criner	Madioko	Udwadia
	De Niet	Mahmud	Vaezi
	Dorward	Marconi	Vallejos
	Dubee	Marcos	Vyas
	Duvignaud	Mariani	Wada
	EPIC-SR	McCarthy	Yadegarinia
	Eikelboom_1	McMahon	Yethindra
	Eikelboom_2	McQuilten	Zhao_2
	Ezer	Mirahmadizadeh	de la Rocha
	Feld	Mohamed	

Mechanical Ventilation	Abd-Elsalam_3	Hammond	Pan_interferon
	Ahmed	Hinks	Pan_lopinavir
	Ali	Horby_1	Pan_remdesivir
	Ananworanich_2	Ivashchenko	Pascual-Figal
	Avezum	Kaizer	Pott-Junior
	Avezum_2	Kasiri_2	Puskarich
	Balykova_1	Khoo_2	Rahman_2
	Beigel	Kim_4	Ravikirti
	Bernal	Krolewiecki	Reis_2
	Bhushan	Lawler_2	Reis_3
	Boulware	Lenze	Reis_5
	Bradbury	Les	Reis_6
	Bramante_1	Lim	Ruzhentsova
	Bramante_2	Liu	Sarojvisut
	Butler	Lopes_1	Schwartz_2
	Cavalcanti	Lopez-Medina	Sharma
	Chuan Huan	Lou	Shinkai
	Cohen	Mariani	Sholzberg
	Cools	McMahon	Spinner
	Dorward	McQuilten	Tardif
	Dubee	Mirahmadizadeh	Udwadia
	Duvignaud	Mohan	Vallejos
	Ferrarini	Murugesan	Vyas
	Ghati	PRINCIPLE Trial Collaborative Group	Yu
	Guimaraes	Pan_hydroxychloroquine	
Adverse Events Leading to Discontinuation	AlQahtani	Hammond	Piazza
	Ananworanich_2	Holubar	Plasse
	Babalola	Issak	Pott-Junior

	Balykova_3	Ivashchenko	Pourdowlat
	Barco	Jalal	Rahman_2
	Beigel	Johnston	Rastogi
	Bernal	Kasiri_2	Reis_1
	Bosaeed_2	Khoo_1	Reis_5
	Buonfrate	Khoo_2	Ruzhentsova
	Byakika-Kibwika	Kinoshita	Sarojvisut
	Cao_3	Krishnan	Schilling
	Caraco	Krolewiecki	Schwartz_2
	Chahla	Lakkireddy	Seo
	Chen_3	Lenze	Shinkai
	Chen_4	Les	Sinha
	Choudhary	Li	Sirijatuphat
	Chuan Huan	Lim	Song
	Clemency	Liu	Tang_1
	Cools	Lopez-Medina	Tehrani_2
	Criner	Lowe	Terada-Hirashima
	Dubee	Mahmud	Udwadia
	Eikelboom_1	Mirahmadizadeh	Vaezi
	Eikelboom_2	Mukae	Vallejos
	Fischer_3	Mukae_2	Vyas
	Ghati	Omrani	Wada
	Golan	Parienti	Zou
	Gottlieb_2	Pascual-Figal	da Silva
Admission to Hospital	Amaravadi	Ezer	Parienti
	Ananworanich_2	Feld	Piazza
	Angkasekwinai	Fischer_3	Plasse
	Arruda	Gottlieb_2	Pourdowlat

	Avezum	Hammond	Reiersen
	Avezum_2	Hinks	Reis_1
	Barco	Holubar	Reis_2
	Bernal	Issak	Reis_3
	Bosaeed_2	Jagannathan	Reis_5
	Boulware	Jilg_2	Reis_6
	Bramante_1	Johnston	Rezai_2
	Bramante_2	Kaizer	Rodrigues
	Buonfrate	Khoo_2	Roy-Garcia
	Butler_2	Krishnan	Ruzhentsova
	Caraco	Lenze	Schilling
	Castro-Rodriguez	Lopez-Medina	Schwartz_2
	Choudhary	Lowe	Sinha
	Clemency	McCarthy	Skipper
	Connors	McMahon	Spivak
	Cools	Mirahmadizadeh	Tardif
	Dorward	Naggie_2	Tehrani_2
	Duvignaud	Naggie_3	Tobback
	EPIC-SR	Oldenburg	Vaezi
	Eikelboom_1	Omrani	Vallejos
	Eikelboom_2	PRINCIPLE Trial Collaborative Group	Vyas
Venous Thromboembolism	Ananworanich_2	Cools	Piazza
	Avezum_2	Marcos	Sholzberg
	Barco	McQuilten	
	Connors	Mohamed	
Clinically Important Bleeding	Ananworanich_2	Cools	Piazza
	Avezum_2	Marcos	Sholzberg
	Barco	McQuilten	

	Connors	Mohamed	
Length of Hospital Stay	Abd-Elsalam_3	Ghati	Pan_interferon
	Ahmed	Hammond	Pan_lopinavir
	AlQahtani	Johnston	Pan_remdesivir
	Bhushan	Lakkireddy	Pascual-Figal
	Butler	Lawler_2	Rahman_2
	Cavalcanti	Lim	Reis_3
	Chen_4	Liu	Sharma
	Chuan Huan	Lopes_1	Spinner
	Cohen	Mariani	Udwadia
	De Niet	Pan_hydroxychloroquine	
Time to Symptom Resolution	Abdulamir_2	Holubar	Reis_3
	Amaravadi	Issak	Reis_6
	Avezum	Ivashchenko	Rezai_2
	Balykova_1	Jagannathan	Ruzhentsova
	Beigel	Jilg_2	Sarojvisut
	Bhushan	Johnston	Schwartz_2
	Bosaeed_2	Kaizer	Sinha
	Boulware	Karolyi	Sirijatuphat
	Buonfrate	Kasiri_2	Spinner
	Butler	Kim_3	Spivak
	Butler_2	Kinoshita	Tang_1
	Byakika-Kibwika	Krishnan	Tobback
	Cairns	Lopez-Medina	Udwadia
	Cao_3	Lou	Vyas
	Chahla	Mahmud	Yethindra
	Chen_1	McCarthy	Yu
	Chen_2	McQuilten	Zhao_3

	Chen_3	Mirahmadizadeh	Zhuravel
	Chen_4	Mohan	Zou
	Choudhary	Naggie_2	da Silva
	Clemency	Naggie_3	
	EPIC-SR	PRINCIPLE Trial Collaborative Group	
	George	Pascual-Figal	
	Golan	Plasse	
	Gorial	Ramakrishnan	

Time to Symptom Resolution Definitions

Study	Interventions	Time to symptom resolution or time to clinical improvement criteria
Abdulamir_2, 2021	niclosamide, standard care	Time to recovery.
Amaravadi, 2021	hydroxychloroquine, placebo	The first occurrence of the lowest symptom score (For each symptom patients would report a score of 1 (mild), 2 (moderate), or 3 (severe). A computer algorithm would then generate the daily COVID-19 symptom score for the patient.).
Avezum, 2022	hydroxychloroquine, placebo	Days to fever resolution
Balykova_1, 2023	favipiravir, standard care	A comparative evaluation of time periods (in days) had been made until fever disappeared. A criterion for this indicator was the body temperature lower than 37.2 for 3 days in succession, without an intake of antipyretic drugs.
Beigel, 2020	remdesivir, placebo	The time to recovery, defined as the first day, during the 28 days after enrollment, on which a patient satisfied categories 1, 2, or 3 on the eight-category ordinal scale. The categories are as follows: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (Covid-19–related or other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); and 8, death.
Bhushan, 2021	pegylated interferon alfa-2b, standard care	Two-point improvement in the WHO 7-point ordinal scale.
Bosaeed_2, 2022	favipiravir, placebo	Normalization of fever and respiratory symptoms and relief of cough (or other relevant symptoms at enrolment) maintained for at least 72 hours
Boulware, 2022	inhaled fluticasone furoate, placebo	Time to sustained recovery was the number of days between the receipt of study drug and achieving 3 consecutive days without COVID-19 symptoms, as affirmatively reported by study participants.
Buonfrate, 2022	ivermectin (600 µg/kg), ivermectin (1200 µg/kg), placebo	Time to clinical resolution (if symptomatic) was calculated as the time from randomization to clinical resolution or death.
Butler, 2021	doxycycline, standard care	Time to sustained recovery (date the participant reported feeling recovered and subsequently remained well until 28 days after randomization)

Butler_2, 2022	molnupiravir, standard care	Time to sustained alleviation of symptoms (date symptoms first reported as minor or none and subsequently remained minor or none until 28 days)
Byakika-Kibwika, 2021	hydroxychloroquine, standard care	Time to symptom clearance.
Cairns, 2022	niclosamide, placebo	Symptom resolution was defined as the first day that all symptoms reported at day 1 had resolved
Cao_3, 2022	nirmatrelvir-ritonavir, VV116	Sustained clinical recovery was defined as the alleviation of all Covid-19–related target symptoms to a total symptom score of 0 or 1 (range, 0 to 33, with higher scores indicating greater severity) for 2 consecutive days.
Chahla, 2021	ivermectin, standard care	Time to improvement of COVID-19 symptoms: systematic symptoms and upper airway symptoms.
Chen_1, 2020	hydroxychloroquine, standard care	Time to body temperature recovery.
Chen_2, 2021	favipiravir, umifenovir	Clinical recovery was defined as continuous (>72 h) recovery of body temperature, respiratory rate, oxygen saturation and cough relief after treatment, with the following quantitative criteria: axillary temperature ≤36.6°C, respiratory frequency ≤24 times/min, oxygen saturation ≥98% without oxygen inhalation, and mild or no cough.
Chen_3, 2020	hydroxychloroquine, standard care	Time to body temperature normalization.
Chen_4, 2020	chloroquine, hydroxychloroquine, standard care	Patients were considered to have achieved clinical recovery when they had met all of the following criteria for at least 48 hours: 1. axillary body temperature ≤36.9°C or oral body temperature ≤37.2°C; 2. complete relief of all symptoms other than cough; 3. cough graded as mild or absent on a patient-reported scale of severe, moderate, mild, absent.
Choudhary, 2022	hydroxychloroquine, placebo	Time to recovery.
Clemency, 2021	ciclesonide, placebo	The time to alleviation of COVID-19-related symptoms was defined as being symptom-free for a continuous period of at least 24 hours (i.e., at least 3 consecutive AM/PM assessments), as self-reported in the participant's eDiary.
EPIC-SR, 2021	nirmatrelvir-ritonavir, placebo	Time (days) to sustained alleviation of all targeted COVID-19 sign / symptoms through Day 28 in the mITT1 cohort (≤5days since symptom onset). 4 consecutive days of absent symptoms if baseline symptom severity was absent or mild. 4 consecutive days of mild or absent symptoms if baseline symptom severity was moderate or severe.
George, 2022	ivermectin (12 mg), ivermectin (24 mg), standard care	Time to symptom resolution.
Golan, 2022	favipiravir, placebo	Time to Sustained Clinical Recovery, calculated as the number of days from start of study medication to sustained symptom alleviation, defined by: Oxygen saturation ≥94% at rest, and Oral temperature <38.0°C, and all COVID-19-

		associated symptoms reaching a score of mild or none for 4 consecutive days
Gorial, 2022	colchicine, standard care	Defined as time to cure since start of treatment
Holubar, 2022	favipiravir, placebo	We defined time until initial resolution of symptoms as time from randomization until the first of two consecutive days without symptoms.
Issak	corticosteroids (systemic), standard care/placebo	Return-to-daily activity was defined as returns to work, return to their home works for women, return to their previous activities before catching COVID-19.
Ivashchenko, 2020	favipiravir (600 mg BID), favipiravir (800 mg BID), standard care	Time to normal temperature
Jagannathan, 2021	peginterferon lambda-1a, placebo	Defined as time until the first day when no symptoms were reported sustained throughout the study
Jilg _2, 2023	camostat, placebo	Time to improvement of all 13 targeted COVID-19 symptoms through day 28 from the start of investigational treatment (day 0) to the first of 2 consecutive days when all symptoms scored as moderate or severe at day 0 were scored as mild or absent
Johnston, 2021	hydroxychloroquine, azithromycin + hydroxychloroquine, placebo	To determine if HCQ or HCQ/AZ was associated with faster symptom resolution among those that had COVID-19 symptoms at baseline, we analyzed the time to COVID-19 symptom resolution by Day 14. COVID-19 was defined as two of the following: fever (≥380C), chills, rigors, myalgia, headache, sore throat, new olfactory or taste disorders, or one of the following: cough, shortness of breath or difficulty breathing.17 COVID-19 symptoms were graded by the highest self-reported symptom on a 5-point scale.
Kaizer, 2022	lopinavir/ritonavir, placebo	For “Time to Symptom Resolution”, the calculation uses the latest observation with any reported symptoms. If symptoms were still reported on day 29, the outcome is imputed as 30 days. Further, even if someone was symptom free earlier in the study (e.g., on the surveys from day 7-16), if they reported a symptom on day 29 their outcome was imputed as 30 days.
Karolyi, 2022	lopinavir/ritonavir, camostat mesylate	Time (in days) to sustained (≥48 h) improvement ≥1 point in the WHO clinical progression scale
Karolyi, 2022	lopinavir/ritonavir, camostat mesylate	Time to sustained improvement of at least two categories compared to the status at baseline measured on the WHO ordinal scale.
Kasiri_2, 2023	colchicine, placebo	Eight-point ordinal scale. This scores of this scale were defined as follows: (1) not hospitalized and no activity limitation; (2) not hospitalized with activity limitation or needing home oxygen, or both; (3) hospitalized, no need for supplemental oxygen and continuous medical care (applied in case hospitalization is prolonged for infection control or other nonmedical reasons); (4) hospitalized, no need for supplemental oxygen yet requiring continuous medical care (because of COVID-19 or other medical conditions); (5)

		hospitalized, needing supplemental oxygen; (6), hospitalized, needing noninvasive ventilation or high-flow oxygen devices; (7) hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation; and (8) death. A score 1 or 2 was considered as clinical recovery
Kim_3, 2022	camostat mesylate, placebo	Clinical improvement was defined as symptom severity of “none” or “mild” in a four-point scale (0, none; 1, mild; 2, moderate; and 3, severe) for at least 24 h in COVID-19 patients who had baseline symptoms (within 24 h prior to the first administration) of febrile sense, cough, shortness of breath, chills, muscle aches, headache, and sore throat
Kinoshita, 2022	camostate mesilate, placebo	"Date of the first confirmed resolution of clinical symptoms” – “Date of randomization” + 1
Krishnan, 2021	molnupiravir, standard care	Time to clinical improvement based on at least two-point improvement in 11-Point ordinal scale by WHO
Lopez-Medina, 2021	ivermectin, placebo	Time from randomization until complete resolution of symptoms within the 21-day follow-up period.
Lou, 2020	baloxavir marboxil, favipiravir, standard care	The primary efficacy end point was the percentage of subjects with viral negative by Day 13 14 and the time from randomization to clinical improvement, defined as the time from 14 randomization to an improvement of two points (from the status at randomization) on a 15 seven-category ordinal scale or live discharge from the hospital, whichever came first. The 16 ordinal scale, which is refer to National Early Warning Score 2 (NEWS2), have been used as 17 end points in clinical trials in patients hospitalized with COVID-19.
Mahmud, 2021	doxycycline/ivermectin, placebo	Clinical recovery was defined as a normal body temperature for at least 3 days, improved respiratory symptoms defined as no shortness of breath and respiratory rate <25 breaths/minute, and oxygen saturation >93% without supplemental oxygen.
McCarthy, 2023	fluvoxamine, placebo	Time to sustained recovery, defined as the third of 3 consecutive days without symptoms
McQuilten, 2022	standard care, intermediate-dose anticoagulation, aspirin, therapeutic-dose anticoagulation	Time to clinical recovery was taken as the first day from the index admission at which the patient had a WHO outcome score of =< 3. For participants whose WHO outcome score was >3 on the day of hospital discharge, their day of recovery was counted as the first day after discharge.
Mirahmadizadeh, 2022	ivermectin (12 mg), ivermectin (24 mg), placebo	First day during the follow-up period in which the subject reported a severity score of 0
Mohan, 2021	ivermectin 12 mg, ivermectin 24 mg, placebo	Days to symptom resolution
Naggie_2, 2022	ivermectin, placebo	Time to achieve three consecutive days without COVID-19 symptoms
Naggie_3, 2023	ivermectin, placebo	TIme to sustained recovery, defined as at least 3 consecutive days without symptoms

PRINCIPLE Trial Collaborative Group, 2021	azithromycine, standard care	"Time to first reported recovery: the first instance that a participant reported feeling recovered (ascertained by answering the question, “Do you feel recovered today? ie, symptoms associated with illness are no longer a problem. Yes/No”)"
Pascual-Figal, 2021	colchicine, standard care	Day to one grade improvement on WHO score: 1. Not hospitalized, no limitation of activities; 2. Not hospitalized, limitation of activities; 3. Hospitalized, not requiring supplemental gen; 4. Hospitalized, requiring supplemental oxygen by mask or nasal prongs; 5. Hospitalized, non-invasive lation or high flow oxygen; 6. Hospitalized, intubation and mechanical ventilation or ECMO; 7. Death
Plasse, 2022	upamostat (200 mg), upamostat (400 mg), placebo	Sustained recovery: recovery as defined below with no new or recurrent symptoms for at least 14 days or until the last questionnaire is completed, whichever came first; and all symptoms: the resolution of all symptoms except for preexisting symptoms present as mild.
Ramakrishnan, 2021	inhaled budesonide, standard care	Secondary outcomes included clinical recovery as defined by self-reported time to symptom resolution.
Rashad_3, 2021	azithromycin, clarithromycin, standard care	Time to fever resolution. Patient was considered a febrile if body temprature < 37.2 C for two consecutive days.
Reis_3, 2022	ivermectin, placebo	Time to clinical recovery, as assessed with the use of the WHO clinical progression scale
Reis_6, 2023	pegylated interferon lambda, placebo	Time to recovery as reported by patients
Rezai_2, 2022	ivermectin, placebo	Time to resolution of fever
Ruzhentsova, 2020	favipiravir, standard care	The time to clinical improvement was defined as a reduction of patient clinical status on at least 1 score according to WHO 8-Category Ordinal Scale for Clinical Improvement compared to screening. The categories were as follows: 0 - no clinical or virological evidence of infection, 1 – ambulatory, no limitation of activities; 2 - ambulatory, limitation of activities; 3 - hospitalized, no oxygen therapy; 4 - hospitalized, oxygen by mask or nasal prongs; 5 - hospitalized, severe disease, non-invasive ventilation or high-flow oxygen; 6 - hospitalized, severe disease, intubation, and mechanical ventilation; 7 - hospitalized, severe disease, intubation + additional organ support - pressors, RRT, ECMO; and 8 – death [9].
Sarojvisut, 2022	ivermectin, standard care	Duration of illness, resolution of symptoms was defined as an improvement in the WHO-category ordinal scale by 2 points.
Schwartz_2, 2021	hydroxychloroquine, placebo	The number of days from randomization to symptom resolution.
Sinha, 2022	molnupiravir, standard care	The proportion of patients with 2-point decrease in “WHO Clinical Progression Scale” (Clinical Improvement)
Sirijatuphat, 2022	favipiravir, standard care	Sustained clinical improvement was defined as an improvement (reduced NEWS from baseline or score of <1) for 7 days or until discharge.

Spinner, 2020	remdesivir (10 days), remdesivir (5 days), standard care	"Time to recovery (improvement from a baseline score of 2-5 to a score of 6 or 7 or from a baseline score of 6 to a score of 7) Site investigators assessed clinical status daily from day 1 through day 14 or hospital discharge on a 7-point ordinal scale11,12 consisting of the following categories: 1, death; 2, hos pitalized, requiring invasive mechanical ventilation or extra corporeal membrane oxygenation; 3, hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices; 4, hospitalized, requiring low-flow supplemental oxygen; 5, hospitalized, not requiring supplemental oxygen but requir ing ongoing medical care (related or not to COVID-19); 6, hos pitalized, not requiring supplemental oxygen orongoing medi cal care; and 7, not hospitalized (eTable 1 in Supplement 3)."
Spivak, 2023	hydroxychloroquine, placebo	Any of the following core symptom(s) exceeded the permissible threshold: not experiencing fever and chills; extremely mild for shortness of breath, diarrhea, and muscle aches; and mild cough and tiredness
Tang_1, 2020	hydroxychloroquine, placebo	The definition of the alleviation of clinical symptoms was resolving from fever to an axillary temperature of 36.6°C or below, normalisation of SpO2 (>94% on room air), and disappearance of O2 respiratory symptoms including nasal congestion, cough, sore throat, sputum production, and shortness of breath.
Tobback, 2022	camostat mesylate, placebo	Improvement of the five most self-reported symptoms in at least one point from baseline on the 5-point Likert scale, whichever came first
Udwadia, 2020	favipiravir, standard care	Clinical cure was based on clinician assessment and defined as recovery of fever (axillary temperature ≤97.8°F), respiratory rate of ≤20 breaths/minute, oxygen saturation ≥98% without oxygen supplementation (which was later revised to align with the discharge criterion of ≥95% oxygen saturation issued by the Indian Ministry of Health prior to the start of the study), and cough relief (mild or no cough) maintained for ≥72 hours.
Vyas, 2021	molnupiravir, standard care	Clinical improvement was measured by using 11 point WHO clinical progression scale detailed in Table 13. A decrease of at least two points on the 11-point scale (0 to 10) compared to the baseline value (e.g., from 3 to 1) considered as Clinical Improvement. Time to clinical improvement was defined as the elapsed time (in days) from randomization to the earliest day of observed improvement.
Yethindra, 2020	umifenovir, standard care	Body temperature amelioration over 72 h.
Yu, 2021	inhaled budesonide, standard care	The first instance that a participant reports feeling recovered

Zhao_3, 2022	arbidol, standard-of-care	Clinical recovery was defined as clinical symptom remission and two consecutively negative nucleic acid detections (24 h interval for each time). The symptom remission was defined as the disappearance of fever, cough, dyspnea, myalgia, and other related respiratory symptoms; or the improvement of oxygen saturation (no adjuvant oxygen therapy or oxygen saturation >95% on room air).
Zhuravel, 2021	nafamostat, standard care	Time to recovery defined by either discharge from hospital or hospitalisation for infection-control purposes only (no longer requiring oxygen and medical care for COVID-19 pneumonia).
Zou, 2022	molnupiravir, standard care/placebo	The duration of fever, time of symptom alleviation and laboratory test results were collected to evaluate the overall health condition associated with COVID-19.
da Silva, 2023	azvudine, placebo	End of fever

Discrepancies Between Preprint and Peer-Reviewed Publications

Study	Differences between pre-print vs peer-reviewed publication
Abdulamir_2, 2021	The peer-reviewed report includes a second trial registration. Funding is reported as none in the peer-reviewed report. Age, smoking, respiratory condition, CVD, diabetes, and hypertension are not included in the peer-reviewed report. Since patients included in the preprint and peer-reviewed paper are the same, we retained extractions from the preprint. Follow-up time for mortality is 30 days in the peer-reviewed report. Follow-up time for time to recovery (cure) is no longer reported in the peer-reviewed report. Mean and variance for time to recovery (cure) changed. We rated mortality and time-to-symptom resolution at probably high risk of bias for selective reporting. The peer-reviewed paper includes follow- up times that contradict the trial registration.
Abroug, 2022; COVID-VITD	The peer-reviewed publication described the measure of variability for the outcome of viral clearance as an IQR instead of a CI; values remained the same.
Avezum_2, 2023; CARE	No substantive differences between the preprint and peer-reviewed publications.
Babalola, 2021	The peer-reviewed paper reports that lopinavir-ritonavir is part of standard care. The peer-reviewed paper reports more details on randomization and allocation concealment. Risk of bias due to randomization changed from probably low to definitely low.
Barco, 2022; OVID	Predefined 90 day analysis reports on some outcomes at 90 days (hospitalization, VTE, important bleeding) but results are unchanged.
Bramante_1, 2022; COVID-OUT	No substantive differences between the preprint and peer-reviewed publications.
Bramante_2, 2022; COVID-OUT	No substantive differences between the preprint and peer-reviewed publications.
Buonfrate, 2022; COVER	The peer-reviewed publication specifies an additional source of funding (not-for-profit) and reports additional information (number of participanta analyzed and IQR) for the outcome of time to clinical resolution.
Butler_2, 2022; PANORAMIC	The peer-reviewed publication described how 75 participants were considered ineligible after randomization and subsequently excluded. This resulted in some changes to the baseline characteristics. Additionally, there were changes to the number of participants analyzed in all outcomes and the number of participants who died, were admitted to hospital, or experienced adverse events leading to discontinuation in the molnupiravir group and the number of participants hospitalized in the control group all increased by 1-3 patients. The IQR for the molnupiravir group's time to sustained symptom resolution decreased by 1 day.
Chaccour, 2020; SAINT	No substantive differences between the preprint and peer-reviewed publications.
Chen_2, 2021	The peer-reviewed publication reports mean oxygen saturation levels at baseline whereas the preprint does not.
Chen_5, 2020	No substantive differences between the preprint and peer-reviewed publications.
Cruz, 2020; ATENEA-Co-300	No substantive differences between the preprint and peer-reviewed publications.

da Silva, 2023	The peer-reviewed publication reports funding sources (industry, government). The preprint reported additional exclusion criteria regarding cardiovascular health. The preprint reported aditional information regarding oxygen saturation and duration of treatment. We retained this information.
Dorward, 2021; PRINCIPLE	The peer-reviewed publication clarified the follow-up time to be 28 days.
Dubee, 2021; HYCOVID	The preprint did not include information on allocation concealment but the publication reported on allocation concealment. The risk of bias due to randomization changed from probably low to definitely low.
Esther, 2022	The peer-reviwed publication reports that enrollment was discontinued following interim analysis and described additional sources of funding (not-for-profit).
Feld, 2020	The peer-reviewed publication reports % with diabetes and hypertension whereas the preprint does not.
Fischer_3, 2021	The peer-reviewed publication reports an additional outcome, time to symptom resolution.
Ghaderkhani, 2020	No substantive differences between the preprint and peer-reviewed publications.
Ghati, 2021; RESIST	No substantive differences between the preprint and peer-reviewed publications.
Gottlieb_2, 2021; PINETREE	No substantive differences between the preprint and peer-reviewed publications.
Holubar, 2021	No substantive differences between the preprint and peer-reviewed publications.
Horby_1, 2020; RECOVERY (dexamethasone)	Number of males/females differ between the preprint and the peer- reviewed publications. Number of patients with positive PCR tests at baseline differ between the preprint and the peer-reviewed publications. There are more events for mortality and invasive mechanical ventilation in the peer-reviewed publication compared to the preprint. Discrepancies between the preliminary and final report: % female who are pregnant changed. % with confirmed COVID-19 at baseline changed. The number of events for mechanical ventilation among those who were not vented at baseline was greater in the final report compared to the preliminary report. Compared to the preliminary report, the final report includes a Kaplan Meier curve on discharge from hospital. The IQR for duration of hospital stay was extracted from the final report. Compared to the preliminary report, the final report includes a Kaplan Meier curve on successful removal from invasive mechanical ventilation. The median and IQR for duration of ventilation was extracted from the final report.
Horby_3, 2020; RECOVERY (lopinavir-ritonavir)	There are more patients with baseline positive PCR results reported in the publication than in the preprint. The published report includes additional mortality events that likely accrued since the preprint was released. The published report includes additional mechanical ventilation events that likely accrued since the preprint was released. The published report includes IQR for duration of hospitalization and the preprint does not.

Horby_4, 2021; RECOVERY (azithromycin)	% with confirmed COVID-19 at baseline changed. The number of patients randomized to the usual care group was one less in the peer-reviewed publication compared to the preprint. There were more events for mortality at 28 days in the peer-reviewed publication compared to the preprint. The number of patients analyzed for this outcome in the usual care group is one less in the peer-reviewed publication compared to the preprint. There were more events for mechanical ventilation among those not vented at baseline in the peer-reviewed publication compared to the preprint. The number of patients analyzed for this outcome in the usual care group is one less in the peer-reviewed publication compared to the preprint.
Horby_8, 2022; RECOVERY (baricitinib)	The peer-reviewed publication reported more participants had confirmed COVID-19 at baseline, an additional death in the baricitinib group, and an additional participant requiring mechanical ventilation in the standard care group.
Huang_2, 2020	Adverse events leading to discontinuation was reported in the peer- reviewed publication but not in the preprint.
Ivashchenko, 2020	Age, % male, oxygen saturation, and C-reactive protein are reported in the supplementary appendix of the preprint. The peer-reviewed publication does not include a supplementary appendix. % with pregnancy is only reported in the peer-reviewed publication. There was one more event for mortality reported in the peer-reviewed publication compared to the preprint. Adverse events leading to discontinuation was not reported in the preprint but was reported in the peer-reviewed publication.
Jagannathan, 2021	The publication reports the proportion of patients with respiratory conditions. The publication reports the proportion of patients with cardiovascular disease. The publication reports the proportion of patients with diabetes. The publication reports the proportion of patients with hypertension.
Johnston, 2021; The COVID-19 Early Treatment Study	No substantive differences between the preprint and peer-reviewed publications.
Khoo_1, 2021; AGILE	The peer-reviewed publication reported mortality for up to 29 days instead of 15. This reduced the risk of bias due to selective reporting for this outcome to low risk.
Khoo_2, 2022; AGILE CST-2	No substantive differences between the preprint and peer-reviewed publications.
Krolewiecki, 2021	The trial registration was incorrectly reported in the preprint. The publication additionally reports mortality. Duration of follow-up changed from 7 days to 30 days for mechanical ventilation.
Li, 2020; ELACOI	No substantive differences between the preprint and peer-reviewed publications.
Li_2, 2021	The preprint reports duration of hospital stay whereas the peer-reviewed publication does not. The data was retained in our analyses.
Lopes_1, 2021; BRACE CORONA	No substantive differences between the preprint and peer-reviewed publications.
Lopez-Medina, 2021; EPIC	The final report includes one more event for mortality in the placebo group. The final report includes mechanical ventilation at day 8.
Lou, 2020	No substantive differences between the preprint and peer-reviewed publications.
Marconi, 2021; COV-BARRIER	The peer-reviewed report includes 60 day mortality whereas the preprint only includes 28 day mortality.

	The peer-reviewed report includes more details on randomization. The risk of bias rating changed from probably low to definitely low risk of bias. The peer-reviewed report includes a protocol in the supplementary appendix. We changed selective reporting for outcomes mechanical ventilation, AEs leading to discontinuation, and time to improvement from probably low to definitely low risk of bias.
McCarthy, 2023; ACTIV-6 (fluvoxamine)	The peer-reviewed publication only reports median age and slight change in % vaccinated. In the peer-reviewed publication, the participant flow chart indicates that pregnant patients were excluded.
McMahon, 2022	No substantive differences between the preprint and peer-reviewed publications.
Mohan, 2021; RIVET-COV	No substantive differences between the preprint and peer-reviewed publications.
Mukae, 2022	The peer-reviewed publication reported % vaccinated.
Naggie_3, 2023; ACTIV-6 (ivermectin)	No substantive differences between the preprint and peer-reviewed publications.
Onal, 2021	Age, % male, % smoking, % respiratory condition, % cardiovascular disease, % diabetes, % hypertension, % confirmed covid-19, and baseline oxygen saturation changed. The number of participants randomized to the standard care group decreased in the peer-reviewed publication compared to the preprint. The peer-reviewed publication reported different values for mortality (number analyzed and number of events).
Pan_remdesivir, 2022; SOLIDARITY	The peer-reviewed publication specific that pharmaceutical companies provided the study interventions. Discrepancies between interim report and final publication: The final report specified early termination, additional countries, and a greater number of participants randomized. The final publication reported different values for the percentage of males, current smokers, chronic lung disease, asthma, heart disease, diabetes, and oxygen therapy (supplemental oxygen and ventilation). The final publication reports different outcome data for mortality, mechanical ventilation, and duration of hospitalization.
Pan_hydroxychloroquine, 2022; SOLIDARITY	The peer-reviewed publication specific that pharmaceutical companies provided the study interventions. Discrepancies between interim report and final publication: The final report specified early termination, additional countries, and a greater number of participants randomized. The final publication reported different values for the percentage of males, current smokers, chronic lung disease, asthma, heart disease, diabetes, and oxygen therapy (supplemental oxygen and ventilation). The final publication reports different outcome data for mortality, mechanical ventilation, and duration of hospitalization.
Pan_lopinavir-ritonavir, 2022; SOLIDARITY	The peer-reviewed publication specific that pharmaceutical companies provided the study interventions. The peer-reviewed publication reported that an additional 2 participants in each group received mechanical ventilation. Discrepancies between interim report and final publication:

	The final report specified early termination, additional countries, and a greater number of participants randomized. The final publication reported different values for the percentage of males, current smokers, chronic lung disease, asthma, heart disease, diabetes, and oxygen therapy (supplemental oxygen and ventilation). The final publication reports different outcome data for mortality, mechanical ventilation, and duration of hospitalization.
Pan_interferon, 2022; SOLIDARITY	The peer-reviewed publication specific that pharmaceutical companies provided the study interventions. Discrepancies between interim report and final publication: The final report specified early termination, additional countries, and a greater number of participants randomized. The final publication reported different values for the percentage of males, current smokers, chronic lung disease, asthma, heart disease, diabetes, and oxygen therapy (supplemental oxygen and ventilation). The final publication reports different outcome data for mortality, mechanical ventilation, and duration of hospitalization.
Panda_1, 2021; SEV COVID Trial	No substantive differences between the preprint and peer-reviewed publications.
Puskarich_1, 2021	The publication reports on mortality, ventilation, and admission to hospital that were not reported in the preprint.
Ramachandran, 2021	No substantive differences between the preprint and peer-reviewed publications.
Ramakrishnan , 2021; STOIC	The publication additionally reports patients with asthma at baseline. The publication additionally reports patients with cardiovascular disease at baseline. The publication additionally reports patients with diabetes at baseline. The publication additionally reports 95% confidence intervals for time to symptom resolution. For the preprint, interquartile ranges were extracted from the KM curve.
Rashad_3, 2021	The peer-reviwed publication reports mortality after 7 days and provides details on allocation concealment which decreased the risk of bias.
Ravikirti, 2021	No substantive differences between the preprint and peer-reviewed publications.
Reis_2, 2021; TOGETHER	N randomized changed from the preprint to the publication. % male, smokers, respiratory condition, cvd, diabetes, and hypertension changed from the preprint to the publication. The publication reports mechanical ventilation, which was not reported in the preprint. Results for mortality, hospitalization, viral clearance, duration of hospitalization, duration of ventilation, and time to viral clearance changed between the preprint and the publication.
Schilling, 2022; PLATCOV	The peer-reviewed publication reported % vaccinated. The peer-reviewed publication reported mortality and different values for the number of participants experiecing adverse effects lleading to discontinuation. The peer-reviewed publication reported additional information which changed the study status to completed, terminated early.
Sholzberg, 2021; RAPID	The peer-reviewed publication reported % high flow nasal cannula oxygen use. The number of participants experiecing venous thromboembolism in the standard care decreased by 1 in the peer-reviewed publication.

Sinha, 2022	The peer-reviwed publication described additional baseline characteristics including the trial registration number. The peer-reviewed publication provided additional trial information which decreased the risk of bias. The peer-reviewed publication reported continuous outcome data as meadian (IQR) instead of mean (SD).
Sirijatuphat, 2022	The peer-reviewed publication reported % vaccinated.
Tang_1, 2020	Mortality was reported in the peer-reviewed publication but not in the preprint.
Tardif, 2021; COLCORONA	The publication additionally lists an institutional source of funding that was not specified in the preprint. The publication lists Greece as a country in which the trial was conducted. Age changed from the preprint to publication.
Yu, 2021; PRINCIPLE (inhaled budesonide)	Age, % male, current or unspecified smokers, former smokers, respiratory condition, cardiovascular disease, diabetes, hypertension, ACE inhibitors/ARB use, confirmed COVID-19, and N randomized changed between the peer-reviewed paper and preprint. The peer-reviewed paper reports secondary outcomes among those who were concurrently randomized, irrespective of SARS-COV-2 status (Table S2). The preprint reports secondary outcomes among those who were concurrently randomized, but SARS-COV-2 positive. The peer-reviewed paper reports mortality at 28 days. The preprint only reports events for mortality and/or hospitalization at 28 days. The peer-reviewed paper reports duration of hospital stay and admission to hospital. The preprint did not report duration of hospital stay. We changed our risk of bias rating for selective reporting for mechanical ventilation to definitely low risk of bias. Initially data was only presented among those who were SARS-COV-2 positive. The peer-reviewed paper, however, reports data for all patients, irrespective of SARS-COV-2 status.
Zheng_1, 2020	Chronic bronchitis is only reported in the peer-reviewed publication. Coronary heart disease is only reported in the peer-reviewed publication. Diabetes is only reported in the peer-reviewed publication. Hypertension is only reported in the peer-reviewed publication. Lymphopenia is only reported in the peer-reviewed publication.

Risk of Bias Assessments

Mortality (page 190)
Mechanical Ventilation (page 208)
Admission to Hospital (page 215)
Adverse Events Leading to Discontinuation (page 222)
Venous Thromboembolism (page 233)
Clinically Important Bleeding (page 235)
Length of Hospital Stay (page 237)
Time to Symptom Resolution (page 243)

MORTALITY									
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**
(hydroxy)chloroquine	favipiravir			105					
		176630, 171138, 123445	AlQahtani	105	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
(hydroxy)chloroquine	febuxostat			54					
		Davoodi, 7586	Davoodi_1	54	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
(hydroxy)chloroquine	hydroxychloroquine, zinc			191					
		21407	Abd-Elsalam_2	191	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
(hydroxy)chloroquine	lopinavir-ritonavir			458					
		Reis_1	Reis_1	458	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
(hydroxy)chloroquine	standard care/placebo			6528					
		xx, 8444, 14989	Horby_2	1112	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		776, 3321	Tang_1	150	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		C158	Chen_3	30	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		6987	Chen_4	48	probably high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		Chen (Cheng-Pin), 8057	Chen_5	33	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		8565	Skipper	465	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		9166, 22152	Cavalcanti	448	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		38308, 16085	Dubee	247	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		1_NCT04342650	Axfors_NCT04342650	152	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		1_NCT04333654	Axfors_NCT04333654	8	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		1_NCT04342221	Axfors_NCT04342221	27	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		1_NCT04340544	Axfors_NCT04340544	16	probably high risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		20005	Omrani	297	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Reis_1	Reis_1	441	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		Johnston, 33489	Johnston	154	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

		33028	Amaravadi	31	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Schwartz_2, 50053, 148103 (abstract)	Schwartz_2	148	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		124337	Avezum	1369	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		176630, 171138, 123445	AlQahtani	103	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		150649	Choudhary	198	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		198019	Spivak	367	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Pan_hydroxychloroquine, 15632, 140619	Pan_hydroxychloroquine	684	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
ABBV-47D11	standard care/placebo			24					
		192505	Shebley	24	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ACEi/ARB	standard care/placebo			1785					
		26081	Cohen	152	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27349, 126661	Lopes_1	659	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Puskarich, 49084	Puskarich	117	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		zzz, 109482, 103501	Sharma	46	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		181729	Jardine	755	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198944	Lawler_2	56	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
HIV reverse transcriptase inhibitor	standard care/placebo			80					
		8469	Ren	20	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		50792	Parienti	60	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
IL1 inhibitors	standard care/placebo			39					
		RESET_CL04041078	Berezhanskiy	39	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
IL6 receptor antagonists	standard care/placebo			277					
		COVITOZ_NCT04435717_B	COVITOZ_NCT04435717_B	7	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		TOCOVID_EudraCT2020-001442-19	TOCOVID_EudraCT2020-001442-19	270	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

Interferon alpha	standard care/placebo			250					
		60209, 59366	Bhushan	250	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
JAK inhibitors	standard care/placebo			1221					
		Kalil	Kalil	142	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		48879	Guimaraes	71	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		103785	Murugesan	100	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		181088, 170316, 152202, 116018	Horby_8	465	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		181887	Ferrarini	116	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		RUXCOVID, 123597	Han	141	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Marconi v2, Marconi, 62263	Marconi	186	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAIDs	standard care/placebo			36					
		102953	Guzman-Esquivel	36	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
P2Y12 inhibitor	standard care/placebo			173					
		121620	Bradbury	173	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
TNF inhibitors	standard care/placebo			40					
		170237, 166985	O'Halloran	40	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
anti-IL6	IL1 inhibitors			38					
		RESET_CL04041078	Berezhanskiy	38	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
anti-IL6	standard care/placebo			45					
		RESET_CL04041078	Berezhanskiy	45	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
antihepaciviral	standard care/placebo			61					

		89969	Song_3	61	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aspirin	P2Y12 inhibitor			157					
		121620	Bradbury	157	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	aspirin, colchicine			122					
		191566	Naik_2	122	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	high risk of bias
aspirin	aspirin, statins			442					
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	intermediate-dose anticoagulation			884					
		198551	McQuilten	884	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	prophylactic-dose anticoagulation			279					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			5674					
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67646	Connors	280	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		121620	Bradbury	196	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		170476b	Eikelboom_2	3881	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	877	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	statins			442					
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	therapeutic-dose anticoagulation			618					
		67646	Connors	287	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

		198551	McQuilten	331	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, statins	standard care/placebo			440					
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, statins	statins			442					
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
multivitamin	inhaled corticosteroids			204					
		119102	Duvignaud	204	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin	azithromycin, hydroxychloroquine			120					
		1_NCT04338698	Axfors_NCT04338698	120	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	azithromycin, hydroxychloroquine, oseltamivir			125					
		1_NCT04338698	Axfors_NCT04338698	125	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	azithromycin, oseltamivir			125					
		1_NCT04338698	Axfors_NCT04338698	125	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	clarithromycin			206					
		58017	Rashad_3	206	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	hydroxychloroquine, oseltamivir			123					
		1_NCT04338698	Axfors_NCT04338698	123	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin	oseltamivir			124					
		1_NCT04338698	Axfors_NCT04338698	124	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias

azithromycin	standard care/placebo			3228					
		29803, 22569	Horby_4	1408	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		34434	PRINCIPLE Trial Collaborative Group	1125	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		40804	Hinks	292	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Oldenburg	Oldenburg	197	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		58017	Rashad_3	206	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin, hydroxychloroquine	azithromycin, hydroxychloroquine, oseltamivir			123					
		1_NCT04338698	Axfors_NCT04338698	123	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	azithromycin, oseltamivir			123					
		1_NCT04338698	Axfors_NCT04338698	123	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	doubase C			261					
		186652	Madioko	261	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin, hydroxychloroquine	hydroxychloroquine, oseltamivir			121					
		1_NCT04338698	Axfors_NCT04338698	121	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	oseltamivir			122					
		1_NCT04338698	Axfors_NCT04338698	122	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	standard care/placebo			84					
		60017	Rodrigues	84	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin, hydroxychloroquine, oseltamivir	azithromycin, oseltamivir			128					
		1_NCT04338698	Axfors_NCT04338698	128	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias

azithromycin, hydroxychloroquine, oseltamivir	hydroxychloroquine, oseltamivir			126					
		1_NCT04338698	Axfors_NCT04338698	126	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine, oseltamivir	oseltamivir			127					
		1_NCT04338698	Axfors_NCT04338698	127	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, oseltamivir	hydroxychloroquine, oseltamivir			126					
		1_NCT04338698	Axfors_NCT04338698	126	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, oseltamivir	oseltamivir			127					
		1_NCT04338698	Axfors_NCT04338698	127	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
azithromycin, vitamins	favipiravir			188					
		Khavkina	Khavkina	188	probably high risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
azithromycin, vitamins	hydroxychloroquine, intranasal interferon alpha-2b (nebulised) (outpatients), umifenovir (outpatients)			132					
		Khavkina	Khavkina	132	probably high risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
baloxavir marboxil	favipiravir			19					
		Lou (1), Lou, 2637	Lou	19	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo			20					
		Lou (1), Lou, 2637	Lou	20	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
bromelain, quercetin, vitamin C	standard care/placebo			429					
		Onal, 62827	Onal	429	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias

cannabidiol	standard care/placebo			91					
		66954	Crippa	91	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
clarithromycin	standard care/placebo			198					
		58017	Rashad_3	198	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
colchicine	standard care/placebo			9306					
		45870, 28222	Tardif	4488	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64385	Pascual-Figal	103	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		126654	Gorial	80	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		148468	Jalal	80	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		170476a	Eikelboom_1	3881	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		189925	Kasiri_2	106	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		WWW, 64351, 132467	Dorward	276	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		181441	Rahman_2	292	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
corticosteroid (systemic), doxycycline, intranasal corticosteroid	standard care/placebo			64					
		Husain	Husain	64	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
corticosteroids (systemic)	standard care/placebo			2358					
		8619, 7002, 33381	Horby_1	1535	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		119197	Les	71	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		188971	Issak	752	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
corticosteroids (systemic), IL6 receptor antagonists	standard care/placebo			12					
		COVITOZ_NCT04435717_A	COVITOZ_NCT04435717_A	12	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

darunavir, hydroxychloroquine, oseltamivir, ritonavir	hydroxychloroquine, oseltamivir			60					
		Atipornwanich, 85719	Atipornwanich_1	60	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
darunavir, hydroxychloroquine, oseltamivir, ritonavir	lopinavir, oseltamivir, ritonavir			60					
		Atipornwanich, 85719	Atipornwanich_1	60	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
darunavir/ritonavir, hydroxychloroquine, zinc	ivermectin, zinc			113					
		149042	Nimitvilai	113	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
doxycycline	standard care/placebo			1792					
		Butler_doxyclycline, 55459	Butler	1792	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
doxycycline, ivermectin	standard care/placebo			400					
		43517	Mahmud	400	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ensitrelvir	standard care/placebo			489					
		186176, 154719	Mukae	421	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		190668, 166914, 136644	Mukae_2	68	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
estradiol	standard care/placebo			80					
		73230	Seth	80	probably high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	low risk of bias
favipiravir	favipiravir, lopinavir, ritonavir			120					
		175562	Lowe	120	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	favipiravir, serine protease inhibitor			45					
		187449	Ikeda	45	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

favipiravir	hydroxychloroquine, intranasal interferon alpha-2b (nebulised) (outpatients), umifenovir (outpatients)			168					
		Khavkina	Khavkina	168	probably high risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias
favipiravir	lopinavir-ritonavir			119					
		175562	Lowe	119	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo			3153					
		Lou (1), Lou, 2637	Lou	19	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		9978, 10287, 10147	Ivashchenko	60	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Udwadia, 24988	Udwadia	148	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27459	Balykova_1	39	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		40875	Zhao_2	55	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		60646	Shinkai	156	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		82839	Chuan Huan	500	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		115094, 101414	Bosaeed_2	231	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		176630, 171138, 123445	AlQahtani	106	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		161363, 140965	Sirijatuphat	93	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		197807	Vaezi	77	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		171423, 140982	McMahon	190	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		78612, 131613	Holubar	149	probably low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		175562	Lowe	119	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		165067	Golan	1211	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	umifenovir			209					
		64558, 173	Chen_2	209	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir, lopinavir, ritonavir	lopinavir-ritonavir			121					
		175562	Lowe	121	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

favipiravir, lopinavir, ritonavir	standard care/placebo			121					
		175562	Lowe	121	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo			3562					
		18818	Lenze	152	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		Reis_2, 70784	Reis_2	1497	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		192307, 190544 (abstract), 190538 (abstract), 178322, 170176	McCarthy	1261	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199460, 199417b, 198094b, 185619, 158890b	Bramante_2	652	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine, inhaled corticosteroids	standard care/placebo			1476					
		199030	Reis_5	1476	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, oseltamivir	lopinavir, oseltamivir, ritonavir			60					
		Atipornwanich, 85719	Atipornwanich_1	60	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, oseltamivir	oseltamivir			125					
		1_NCT04338698	Axfors_NCT04338698	125	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, ribavirin	standard care/placebo			40					
		66882_non severe, 46308_non severe	Panda_1	40	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
inhaled and intranasal corticosteroid	standard care/placebo			203					
		Ezer	Ezer	203	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
inhaled corticosteroids	standard care/placebo			1827					
		57833	Song	61	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Clemency	Clemency	400	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		174329	Terada-Hirashima	89	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

		148346	Boulware	1277	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon alpha (subcutaneous)	standard care/placebo			39					
		35022	Pandit	39	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
interferon beta (nebulised)	standard care/placebo			250					
		18657	Monk	98	low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		Kalil_2	Kalil_2	152	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta (subcutaneous)	standard care/placebo			1334					
		140952	Castro-Rodriguez	323	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pan_interferon, 15632, 140619	Pan_interferon	1011	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta (subcutaneous), ribavirin	standard care/placebo			127					
		2942	Hung	127	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon gamma (subcutaneous)	standard care/placebo			63					
		9880	Esquivel-Moynelo	63	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
interferon kappa (nebulised), trefoil factor 2	standard care/placebo			80					
		13797	Fu	80	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
interferon lambda (subcutaneous)	standard care/placebo			2009					
		28233, 18418	Feld	60	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		194504	Reiss	1949	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198087	Kim_4		low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
intermediate-dose anticoagulation	standard care/placebo			1323					
		150820	Mohamed	124	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

		198551	McQuilten	1199	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
intermediate-dose anticoagulation	therapeutic-dose anticoagulation			653					
		198551	McQuilten	653	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
ivermectin	lopinavir-ritonavir			60					
		Babalola, 25394	Babalola	60	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ivermectin	standard care/placebo			9255					
		Krolewiecki, 49440	Krolewiecki	45	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ravikirti, 53436	Ravikirti	112	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Mohan, 60006	Mohan	152	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Lopez, 41159, 34416	Lopez-Medina	398	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Abd-Elsalam_3, 47181	Abd-Elsalam_3	164	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Chahla	Chahla	254	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		51938	Vallejos	501	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ed Mills Trial 3, 124954	Reis_3	1358	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		136610	de la Rocha	66	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		135398, 134102	Lim	490	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		139291	George	112	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		190536, 174779, 140955	Naggie_2	1591	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		144602	Mirahmadizadeh	391	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		188964	Sarojvisut	317	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		147197_outpatients	Rezai_2	549	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		197965, 148339	Schilling	86	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		EP13	Angkasekwinai	447	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		197971, 186579	Naggie_3	1206	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199460, 199417a, 198094a, 185619, 158890a	Bramante_1	802	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199420	Wada	214	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

leflunomide	standard care/placebo			58					
		8784	Hu	10	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		13540	Wang_5	48	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
lopinavir, ritonavir	standard care/placebo			446					
		187455	Kaizer	446	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	lopinavir-ritonavir, ribavirin			68					
		2615, 10067	Huang_2	68	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	ribavirin			69					
		2615, 10067	Huang_2	69	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo			3025					
		234, 1243	Li	51	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		14883, 14781	Horby_3	1321	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Reis_1	Reis_1	471	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		175562	Lowe	120	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pan_lopinavir-ritonavir, 15632, 140619	Pan_lopinavir-ritonavir	1062	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin			65					
		2615, 10067	Huang_2	65	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
melatonin	standard care/placebo			66					
		152706	Fogleman	66	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
melatonin	vitamin C			64					
		152706	Fogleman	64	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias

molnupiravir	standard care/placebo			30332					
		Fischer, 93227, 46473, 115962, 107295	Fischer_3	202	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		CR216-21	Vyas	1220	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CTRI/2021/06/033938	Krishnan	730	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kumar_2 peer-reviewed, HCR/III/MOLCOV/04/2021-01, 141709	Sinha	1218	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		MOVe-OUT (MK4482-002), 99382_O, 89408, 192177, 140640	Bernal	1411	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		171448, 155444, 148276	Khoo_2	180	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		EP10	Caraco	299	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		PANORAMIC_M1, PANORAMIC_M, 187307	Butler_2	25054	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		90037, 60623, 41971, 141785	Khoo_1	18	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
mouthwash containing an antiviral phthalocyanine derivative	standard care/placebo			41					
		Sergio da Silva Santos	Sergio da Silva Santos	41	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
nelfinavir	standard care/placebo			123					
		199093, 190673	Miyazaki	123	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
niclosamide	standard care/placebo			217					
		Abdulamir_2, 61289	Abdulamir_2	150	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		110236	Cairns	67	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nirmatrelvir-ritonavir	VV116			771					
		XXX (VV116 versus Nirmatrelvir–Ritonavir trial)	Cao_3	771	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
nirmatrelvir-ritonavir	standard care/placebo			3342					
		Pfizer PPT_2, EPIC-SR	EPIC-SR	854	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		193343	Liu	264	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

		Pfizer PPT_1, PF-07321332, EPIC-HR, EP14, 190785, 113697	Hammond	2224	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic-dose anticoagulation	standard care/placebo			3352					
		67646	Connors	271	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		179899, 145930	Barco	472	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		145931	Cools	219	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Avezum, 196875	Avezum_2	657	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199126	Piazza	1284	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64008, 199334	Ananworanich_2	449	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation			278					
		67646	Connors	278	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
remdesivir	standard care/placebo			3586					
		11347	Spinner	584	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias
		39725	Criner	584	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Gottlieb_2, 92530, 88424, 87256, 199003, 191209, 142114, 141652	Gottlieb_2	562	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pan_remdesivir, 175794, 15632, 140619	Pan_remdesivir	1730	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		168396, 115843, 103826	Ali	21	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		3821, 27861, 15633	Beigel	105	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ribavirin, sofosbuvir-daclatasvir	standard care/placebo			48					
		11010	Kasgari	48	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
serine protease inhibitors	standard care/placebo			369					
		126799	Kinoshita	153	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199428, 141740	Jilg_2	216	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

statins	standard care/placebo			440					
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
therapeutic-dose anticoagulation	standard care/placebo			1455					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67889	Marcos	65	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Sholzberg, 68845	Sholzberg	465	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	646	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
umifenovir	standard care/placebo			187					
		12798	Yethindra	30	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		24810	Yadegarinia	34	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		Ramachandran, 77223	Ramachandran	123	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin C	standard care/placebo			164					
		31458	Thomas	98	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		152706	Fogleman	66	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
vitamin C	vitamin C, zinc			106					
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
vitamin C	zinc			106					
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
vitamin C, vitamin E	standard care/placebo			72					
		68016	Hakamifard	72	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin C, zinc	standard care/placebo			108					
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias

vitamin C, zinc	zinc			116					
		31458	Thomas	116	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
vitamin D	standard care/placebo			391					
		44830	Lakkireddy	130	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		139609	Mariani	218	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		152018	De Niet	43	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
zinc	standard care/placebo			108					
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias

MECHANICAL VENTILATION									
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**
(hydroxy)chloroquine	hydroxychloroquine, zinc			191					
		21407	Abd-Elsalam_2	191	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
(hydroxy)chloroquine	standard care/placebo			2896					
		9166, 22152	Cavalcanti	448	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		38308, 16085	Dubee	247	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Schwartz_2, 50053, 148103 (abstract)	Schwartz_2	148	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		124337	Avezum	1369	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pan_hydroxychloroquine, 15632, 140619	Pan_hydroxychloroquine	684	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
ACEi/ARB	standard care/placebo			1030					
		26081	Cohen	152	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27349, 126661	Lopes_1	659	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Puskarich, 49084	Puskarich	117	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		zzz, 109482, 103501	Sharma	46	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198944	Lawler_2	56	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
Interferon alpha	standard care/placebo			222					
		60209, 59366	Bhushan	222	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
JAK inhibitors	standard care/placebo			403					
		48879	Guimaraes	71	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		103785	Murugesan	100	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		181887	Ferrarini	232	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
P2Y12 inhibitor	standard care/placebo			89					
		121620	Bradbury	89	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

aspirin	P2Y12 inhibitor			76					
		121620	Bradbury	76	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	aspirin, statins			442					
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	intermediate-dose anticoagulation			884					
		198551	McQuilten	884	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			1437					
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		121620	Bradbury	119	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	878	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	statins			442					
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	therapeutic-dose anticoagulation			331					
		198551	McQuilten	331	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, statins	standard care/placebo			440					
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, statins	statins			442					
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
multivitamin	inhaled corticosteroids			215					
		119102	Duvignaud	215	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

azithromycin	standard care/placebo			1413					
		34434	PRINCIPLE Trial Collaborative Group	1121	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		40804	Hinks	292	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	favipiravir			19					
		Lou (1), Lou, 2637	Lou	19	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo			20					
		Lou (1), Lou, 2637	Lou	20	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine	standard care/placebo			5265					
		45870, 28222	Tardif	4488	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64385	Pascual-Figal	103	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		189925	Kasiri_2	106	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		WWW, 64351, 132467	Dorward	276	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		181441	Rahman_2	292	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
corticosteroids (systemic)	standard care/placebo			1606					
		8619, 7002, 33381	Horby_1	1535	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		119197	Les	71	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
doxycycline	standard care/placebo			856					
		Butler_doxyclycline, 55459	Butler	856	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
estradiol	standard care/placebo			1378					
		73230	Seth	1378	probably high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo			1279					
		Lou (1), Lou, 2637	Lou	19	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

		9978, 10287, 10147	Ivashchenko	60	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		32588	Ruzhentsova	168	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Udwadia, 24988	Udwadia	147	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		60646	Shinkai	156	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		82839	Chuan Huan	500	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		171423, 140982	McMahon	190	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		27460	Balykova_1	39	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias
fluvoxamine	standard care/placebo			2301					
		18818	Lenze	152	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		Reis_2, 70784	Reis_2	1497	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		199460, 199417b, 198094b, 185619, 158890b	Bramante_2	652	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine, inhaled corticosteroids	standard care/placebo			1476					
		199030	Reis_5	1476	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, ribavirin	standard care/placebo			33					
		66882_non severe, 46308_non severe	Panda_1	33	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
inhaled corticosteroids	standard care/placebo			2780					
		148346	Boulware	1277	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Yu, 57300	Yu	1503	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
interferon alpha (subcutaneous)	standard care/placebo			39					
		35022	Pandit	39	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
interferon beta (subcutaneous)	standard care/placebo			1011					
		Pan_interferon, 15632, 140619	Pan_interferon	1011	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

interferon beta (subcutaneous), ribavirin	standard care/placebo			127					
		2942	Hung	127	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
interferon lambda (subcutaneous)	standard care/placebo			1959					
		194504	Reiss	1945	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198087	Kim_4	14	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
intermediate-dose anticoagulation	standard care/placebo			1200					
		198551	McQuilten	1200	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
intermediate-dose anticoagulation	therapeutic-dose anticoagulation			653					
		198551	McQuilten	653	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
ivermectin	standard care/placebo			4806					
		Krolewiecki, 49440	Krolewiecki	45	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ahmed	Ahmed	45	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Ravikirti, 53436	Ravikirti	112	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Mohan, 60006	Mohan	152	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Lopez, 41159, 34416	Lopez-Medina	398	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Abd-Elsalam_3, 47181	Abd-Elsalam_3	164	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		35667	Pott-Junior	31	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		51938	Vallejos	501	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ed Mills Trial 3, 124954	Reis_3	1358	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		135398, 134102	Lim	490	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		144602	Mirahmadizadeh	391	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		188964	Sarojvisut	317	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199460, 199417a, 198094a, 185619, 158890a	Bramante_1	802	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
leronlimab	standard care/placebo			4					

		36109	Skendelas	4	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir, ritonavir	standard care/placebo			446					
		187455	Kaizer	446	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo			1062					
		Pan_lopinavir-ritonavir, 15632, 140619	Pan_lopinavir-ritonavir	1062	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
molnupiravir	standard care/placebo			2746					
		CR216-21	Vyas	1220	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		MOVe-OUT (MK4482-002), 99382_O, 89408, 192177, 140640	Bernal	1346	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		171448, 155444, 148276	Khoo_2	180	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nirmatrelvir-ritonavir	standard care/placebo			2349					
		193343	Liu	264	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Pfizer PPT_1, PF-07321332, EPIC-HR, EP14, 190785, 113697	Hammond	2085	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic-dose anticoagulation	standard care/placebo			1267					
		145931	Cools	219	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Avezum, 196875	Avezum_2	657	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64008, 199334	Ananworanich_2	391	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
remdesivir	standard care/placebo			2441					
		11347	Spinner	584	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias
		Pan_remdesivir, 175794, 15632, 140619	Pan_remdesivir	1730	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		168396, 115843, 103826	Ali	22	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		3821, 27861, 15633	Beigel	105	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

ribavirin, sofosbuvir-daclatasvir	standard care/placebo			48					
		11010	Kasgari	48	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
serine protease inhibitors	standard care/placebo			153					
		126799	Kinoshita	153	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
statins	standard care/placebo			440					
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
therapeutic-dose anticoagulation	standard care/placebo			1112					
		Sholzberg, 68845	Sholzberg	465	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		198551	McQuilten	647	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin D	standard care/placebo			218					
		139609	Mariani	218	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

ADMISSION TO HOSPITAL									
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**
(hydroxy)chloroquine	azithromycin, hydroxychloroquine			61					
		140973	Roy-Garcia	61	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias
(hydroxy)chloroquine	febuxostat			54					
		Davoodi, 7586	Davoodi_1	54	probably high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
(hydroxy)chloroquine	lopinavir-ritonavir			458					
		Reis_1	Reis_1	458	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
(hydroxy)chloroquine	standard care/placebo			3477					
		8565	Skipper	465	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		20005	Omrani	304	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Reis_1	Reis_1	441	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		Johnston, 33489	Johnston	154	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		33028	Amaravadi	31	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Schwartz_2, 50053, 148103 (abstract)	Schwartz_2	148	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		124337	Avezum	1372	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		140973	Roy-Garcia	62	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias
		150649	Choudhary	198	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		198019	Spivak	302	probably high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	low risk of bias
ACEi/ARB	standard care/placebo			117					
		Puskarich, 49084	Puskarich	117	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
HIV reverse transcriptase inhibitor	standard care/placebo			182					
		50792	Parienti	60	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Arruda	Arruda	122	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

NSAIDs	standard care/placebo			36					
		102953	Guzman-Esquivel	36	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
aspirin	prophylactic-dose anticoagulation			279					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			4161					
		67646	Connors	280	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		170476b	Eikelboom_2	3881	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	therapeutic-dose anticoagulation			287					
		67646	Connors	287	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
multivitamin	inhaled corticosteroids			204					
		119102	Duvignaud	204	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin	standard care/placebo			1618					
		34434	PRINCIPLE Trial Collaborative Group	1129	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		40804	Hinks	292	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Oldenburg	Oldenburg	197	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	doxycycline			187					
		Sobngwi	Sobngwi	187	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
azithromycin, hydroxychloroquine	standard care/placebo			145					
		60017	Rodrigues	84	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		140973	Roy-Garcia	61	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	high risk of bias
cannabidiol	standard care/placebo			91					

		66954	Crippa	91	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine	standard care/placebo			8830					
		45870, 28222	Tardif	4488	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		113545	Pourdowlat	172	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		170476a	Eikelboom_1	3881	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		WWW, 64351, 132467	Dorward	289	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
corticosteroids (systemic)	standard care/placebo			752					
		188971	Issak	752	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	favipiravir, lopinavir, ritonavir			120					
		175562	Lowe	120	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	lopinavir-ritonavir			119					
		175562	Lowe	119	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo			971					
		32588	Ruzhentsova	127	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		115094, 101414	Bosaeed_2	231	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		197807	Vaezi	77	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		171423, 140982	McMahon	190	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		162133	Tehrani_2	78	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		78612, 131613	Holubar	149	probably low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		175562	Lowe	119	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir, lopinavir, ritonavir	lopinavir-ritonavir			121					
		175562	Lowe	121	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

favipiravir, lopinavir, ritonavir	standard care/placebo			121					
		175562	Lowe	121	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo			4125					
		18818	Lenze	152	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		Reis_2, 70784	Reis_2	1497	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		STOP-COVID-2	Reiersen	547	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		192307, 190544 (abstract), 190538 (abstract), 178322, 170176	McCarthy	1277	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199460, 199417b, 198094b, 185619, 158890b	Bramante_2	652	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine, inhaled corticosteroids	standard care/placebo			1476					
		199030	Reis_5	1476	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
inhaled and intranasal corticosteroid	standard care/placebo			203					
		Ezer	Ezer	203	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
inhaled corticosteroids	standard care/placebo			1677					
		Clemency	Clemency	400	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		148346	Boulware	1277	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta (subcutaneous)	standard care/placebo			323					
		140952	Castro-Rodriguez	323	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon lambda (subcutaneous)	standard care/placebo			2129					
		28233, 18418	Feld	60	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Jagannathan Peer Review, Jagannathan, 19514	Jagannathan	120	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		194504	Reiss	1949	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
intranasal corticosteroids	standard care/placebo			80					

		48548	Kasiri	80	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ivermectin	standard care/placebo			7388					
		Lopez, 41159, 34416	Lopez-Medina	398	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		51938	Vallejos	501	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Buonfrate, 100160	Buonfrate	59	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ed Mills Trial 3, 124954	Reis_3	1358	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		190536, 174779, 140955	Naggie_2	1591	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		144602	Mirahmadizadeh	391	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		147197_outpatients	Rezai_2	549	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		197965, 148339	Schilling	86	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		EP13	Angkasekwinai	447	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		197971, 186579	Naggie_3	1206	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199460, 199417a, 198094a, 185619, 158890a	Bramante_1	802	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir, ritonavir	standard care/placebo			446					
		187455	Kaizer	446	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo			591					
		Reis_1	Reis_1	471	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		175562	Lowe	120	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
melatonin	standard care/placebo			66					
		152706	Fogleman	66	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
melatonin	vitamin C			64					
		152706	Fogleman	64	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
molnupiravir	standard care/placebo			30221					

		Fischer, 93227, 46473, 115962, 107295	Fischer_3	202	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		CR216-21	Vyas	1220	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CTRI/2021/06/033938	Krishnan	640	low risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias
		Kumar_2 peer-reviewed, HCR/III/MOLCOV/04/2021-01, 141709	Sinha	1218	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		MOVe-OUT (MK4482-002), 99382_O, 89408, 192177, 140640	Bernal	1408	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		171448, 155444, 148276	Khoo_2	180	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		EP10	Caraco	299	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		PANORAMIC_M1, PANORAMIC_M, 187307	Butler_2	25054	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
niclosamide	standard care/placebo			67					
		110236	Cairns	67	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nirmatrelvir-ritonavir	standard care/placebo			3078					
		Pfizer PPT_2, EPIC-SR	EPIC-SR	854	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pfizer PPT_1, PF-07321332, EPIC-HR, EP14, 190785, 113697	Hammond	2224	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic-dose anticoagulation	standard care/placebo			3347					
		67646	Connors	271	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		179899, 145930	Barco	472	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Avezum, 196875	Avezum_2	657	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199126	Piazza	1284	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64008, 199334	Ananworanich_2	444	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias
		145932	Cools	219	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation			278					
		67646	Connors	278	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
remdesivir	standard care/placebo			562					

		Gottlieb_2, 92530, 88424, 87256, 199003, 191209, 142114, 141652	Gottlieb_2	562	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
serine protease inhibitors	standard care/placebo			373					
		145987	Tobback	96	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		191504	Plasse	61	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199428, 141740	Jilg_2	216	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
therapeutic-dose anticoagulation	standard care/placebo			279					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin C	standard care/placebo			164					
		31458	Thomas	98	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		152706	Fogleman	66	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
vitamin C	vitamin C, zinc			106					
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
vitamin C	zinc			106					
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
vitamin C, zinc	standard care/placebo			108					
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
vitamin C, zinc	zinc			116					
		31458	Thomas	116	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
zinc	standard care/placebo			108					
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias	low risk of bias

ADVERSE EFFECT LEADING TO DISCONTINUATION									
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**
(hydroxy)chloroquine	favipiravir			105					
		176630, 171138, 123445	AlQahtani	105	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
(hydroxy)chloroquine	lopinavir-ritonavir			439					
		Reis_1	Reis_1	439	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
(hydroxy)chloroquine	standard care/placebo			1915					
		776, 3321	Tang_1	150	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		C158	Chen_3	30	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		6987	Chen_4	48	probably high risk of bias	probably low risk of bias	high risk of bias	high risk of bias	low risk of bias
		38308, 16085	Dubee	244	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		20005	Omrani	304	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Reis_1	Reis_1	427	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		Johnston, 33489	Johnston	154	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Byakika-Kibwika	Byakika-Kibwika	105	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Schwartz_2, 50053, 148103 (abstract)	Schwartz_2	148	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		176630, 171138, 123445	AlQahtani	103	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		150649	Choudhary	202	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
ACEi/ARB	standard care/placebo			152					
		26081	Cohen	152	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
CK2 inhibitor	standard care/placebo			20					
		26887, 13070	Cruz	20	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
HIV reverse transcriptase inhibitor	standard care/placebo			361					
		8469	Ren	20	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias

		50792	Parienti	60	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		placeholder, 186749	da Silva	281	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
JAK inhibitors	standard care/placebo			116					
		181887	Ferrarini	116	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
NSAIDs	standard care/placebo			36					
		102953	Guzman-Esquivel	36	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
antihepaciviral	standard care/placebo			61					
		89969	Song_3	61	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin	aspirin, colchicine			122					
		191566	Naik_2	122	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	high risk of bias
aspirin	aspirin, statins			450					
		Ghati, 148872	Ghati	450	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin	standard care/placebo			4332					
		Ghati, 148872	Ghati	451	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		170476b	Eikelboom_2	3881	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin	statins			449					
		Ghati, 148872	Ghati	449	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin, statins	standard care/placebo			451					
		Ghati, 148872	Ghati	451	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
aspirin, statins	statins			449					

		Ghati, 148872	Ghati	449	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
azithromycin	azithromycin, hydroxychloroquine			242					
		31471	Purwati	242	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	azithromycin, lopinavir-ritonavir			378					
		31471	Purwati	378	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin	doxycycline, lopinavir-ritonavir			372					
		31471	Purwati	372	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin, hydroxychloroquine	azithromycin, lopinavir-ritonavir			382					
		31471	Purwati	382	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin, hydroxychloroquine	doxycycline			187					
		Sobngwi	Sobngwi	187	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
azithromycin, hydroxychloroquine	doxycycline, lopinavir-ritonavir			376					
		31471	Purwati	376	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
azithromycin, lopinavir-ritonavir	doxycycline, lopinavir-ritonavir			512					
		31471	Purwati	512	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
cannabidiol	standard care/placebo			91					
		66954	Crippa	91	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine	standard care/placebo			4664					
		64385	Pascual-Figal	103	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		113545	Pourdowlat	202	low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias

		148468	Jalal	80	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		170476a	Eikelboom_1	3881	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		189925	Kasiri_2	106	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		181441	Rahman_2	292	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
corticosteroids (systemic)	standard care/placebo			823					
		119197	Les	71	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		188971	Issak	752	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
darunavir, hydroxychloroquine, oseltamivir, ritonavir	hydroxychloroquine, oseltamivir			60					
		Atipornwanich, 85719	Atipornwanich_1	60	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
darunavir, hydroxychloroquine, oseltamivir, ritonavir	lopinavir, oseltamivir, ritonavir			60					
		Atipornwanich, 85719	Atipornwanich_1	60	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
darunavir/ritonavir, hydroxychloroquine, zinc	ivermectin, zinc			115					
		149042	Nimitvilai	115	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
doxycycline, ivermectin	standard care/placebo			400					
		43517	Mahmud	400	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ensitrelvir	standard care/placebo			489					
		186176, 154719	Mukae	421	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		190668, 166914, 136644	Mukae_2	68	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
favipiravir	favipiravir, lopinavir, ritonavir			120					
		175562	Lowe	120	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

favipiravir	favipiravir, serine protease inhibitor			45					
		187449	Ikeda	45	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
favipiravir	lopinavir-ritonavir			119					
		175562	Lowe	119	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo			3091					
		9978, 10287, 10147	Ivashchenko	60	probably high risk of bias	high risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		32588	Ruzhentsova	163	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Udwadia, 24988	Udwadia	148	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		60646	Shinkai	156	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		82839	Chuan Huan	500	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		115094, 101414	Bosaeed_2	231	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		176630, 171138, 123445	AlQahtani	106	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		161363, 140965	Sirijatuphat	93	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		197807	Vaezi	77	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		162133	Tehrani_2	78	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		78612, 131613	Holubar	149	probably low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		175562	Lowe	119	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		165067	Golan	1211	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir, lopinavir, ritonavir	lopinavir-ritonavir			121					
		175562	Lowe	121	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir, lopinavir, ritonavir	standard care/placebo			121					
		175562	Lowe	121	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo			204					
		18818	Lenze	152	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias

		143562, 128273	Seo	52	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine, inhaled corticosteroids	standard care/placebo			1480					
		199030	Reis_5	1480	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
hydroxychloroquine, oseltamivir	lopinavir, oseltamivir, ritonavir			60					
		Atipornwanich, 85719	Atipornwanich_1	60	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
inhaled corticosteroids	standard care/placebo			551					
		57833	Song	61	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Clemency	Clemency	400	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		174329	Terada-Hirashima	90	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
interferon beta (nebulised)	standard care/placebo			98					
		18657	Monk	98	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
interferon beta (subcutaneous), ribavirin	standard care/placebo			127					
		2942	Hung	127	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
interferon kappa (nebulised), trefoil factor 2	standard care/placebo			80					
		13797	Fu	80	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
interferon lambda (subcutaneous)	standard care/placebo			14					
		198087	Kim_4	14	low risk of bias	probably low risk of bias	low risk of bias	probably high risk of bias	probably low risk of bias
intermediate-dose anticoagulation	standard care/placebo			124					
		150820	Mohamed	124	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
intranasal corticosteroids	standard care/placebo			80					

		48548	Kasiri	80	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ivermectin	lopinavir-ritonavir			60					
		Babalola, 25394	Babalola	60	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
ivermectin	standard care/placebo			2820					
		Krolewiecki, 49440	Krolewiecki	45	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Lopez, 41159, 34416	Lopez-Medina	398	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		35667	Pott-Junior	31	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		Chahla	Chahla	254	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		51938	Vallejos	501	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Buonfrate, 100160	Buonfrate	93	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		135398, 134102	Lim	490	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		144602	Mirahmadizadeh	391	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		188964	Sarojvisut	317	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		197965, 148339	Schilling	86	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		199420	Wada	214	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
leflunomide	standard care/placebo			50					
		13540	Wang_5	50	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
leronlimab	standard care/placebo			4					
		36109	Skendelas	4	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
lopinavir-ritonavir	lopinavir-ritonavir, novaferon			56					
		2338, 10121	Zheng_1	56	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
lopinavir-ritonavir	lopinavir-ritonavir, ribavirin			68					
		2615, 10067	Huang_2	68	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias

lopinavir-ritonavir	novaferon			56					
		2338, 10121	Zheng_1	56	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
lopinavir-ritonavir	ribavirin			69					
		2615, 10067	Huang_2	69	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo			623					
		234, 1243	Li	51	low risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		Reis_1	Reis_1	452	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias
		175562	Lowe	120	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir, novaferon	novaferon			56					
		2338, 10121	Zheng_1	56	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin			65					
		2615, 10067	Huang_2	65	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
molnupiravir	standard care/placebo			31091					
		Fischer, 93227, 46473, 115962, 107295	Fischer_3	202	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CR216-21	Vyas	1217	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		CTRI/2021/06/033938	Krishnan	730	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Kumar_2 peer-reviewed, HCR/III/MOLCOV/04/2021-01, 141709	Sinha	1218	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		147182	Zou	108	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		MOVe-OUT (MK4482-002), 99382_O, 89408, 192177, 140640	Bernal	1411	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		171448, 155444, 148276	Khoo_2	180	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		EP10	Caraco	299	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		PANORAMIC_M1, PANORAMIC_M, 187307	Butler_2	25708	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias

		90037, 60623, 41971, 141785	Khoo_1	18	probably high risk of bias	high risk of bias	low risk of bias	high risk of bias	low risk of bias
mouthwash containing an antiviral phthalocyanine derivative	standard care/placebo			41					
		Sergio da Silva Santos	Sergio da Silva Santos	41	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
nelfinavir	standard care/placebo			123					
		199093, 190673	Miyazaki	123	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
nirmatrelvir-ritonavir	VV116			771					
		XXX (VV116 versus Nirmatrelvir–Ritonavir trial)	Cao_3	771	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
nirmatrelvir-ritonavir	standard care/placebo			2752					
		193343	Liu	264	low risk of bias	low risk of bias	low risk of bias	high risk of bias	probably high risk of bias
		198856	Balykova_3	264	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		Pfizer PPT_1, PF-07321332, EPIC-HR, EP14, 190785, 113697	Hammond	2224	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic and therapeutic-dose anticoagulation	prophylactic and therapeutic-dose anticoagulation			228					
		117092	Kumar_5	228	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias
prophylactic-dose anticoagulation	standard care/placebo			2337					
		179899, 145930	Barco	472	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		199126	Piazza	1197	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64008, 199334	Ananworanich_2	449	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		145933	Cools	219	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
remdesivir	standard care/placebo			1846					
		11347	Spinner	596	low risk of bias	high risk of bias	probably low risk of bias	probably high risk of bias	low risk of bias
		39725	Criner	584	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably high risk of bias

		Gottlieb_2, 92530, 88424, 87256, 199003, 191209, 142114, 141652	Gottlieb_2	562	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		3821, 27861, 15633	Beigel	104	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ribavirin, sofosbuvir-daclatasvir	standard care/placebo			48					
		11010	Kasgari	48	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
serine protease inhibitors	standard care/placebo			214					
		126799	Kinoshita	153	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		191504	Plasse	61	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
statins	standard care/placebo			450					
		Ghati, 148872	Ghati	450	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
umifenovir	standard care/placebo			97					
		149310	Zhao	97	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
vitamin C	standard care/placebo			98					
		31458	Thomas	98	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C	vitamin C, zinc			106					
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C	zinc			106					
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C, zinc	standard care/placebo			108					
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin C, zinc	zinc			116					

		31458	Thomas	116	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	low risk of bias
vitamin D	standard care/placebo			213					
		18926	Ratogi	40	probably high risk of bias	probably low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		44830	Lakkireddy	130	high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		152020	De Niet	43	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
zinc	standard care/placebo			108					
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	low risk of bias

VENOUS THROMBOEMBOLISM									
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**
aspirin	intermediate-dose anticoagulation			877					
		198551	McQuilten	877	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
aspirin	prophylactic-dose anticoagulation			279					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			1150					
		67646	Connors	280	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	870	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
aspirin	therapeutic-dose anticoagulation			613					
		67646	Connors	287	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	326	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
intermediate-dose anticoagulation	standard care/placebo			1315					
		150820	Mohamed	124	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		198551	McQuilten	1191	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
intermediate-dose anticoagulation	therapeutic-dose anticoagulation			647					
		198551	McQuilten	647	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
prophylactic-dose anticoagulation	standard care/placebo			3350					
		67646	Connors	271	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		179899, 145930	Barco	470	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Avezum, 196875	Avezum_2	657	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias

		199126	Piazza	1284	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		64008, 199334	Ananworanich_2	449	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		145934	Cools	219	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation			278					
		67646	Connors	278	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
therapeutic-dose anticoagulation	standard care/placebo			1449					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67889	Marcos	65	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias
		Sholzberg, 68845	Sholzberg	465	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		198551	McQuilten	640	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
prophylactic and therapeutic-dose anticoagulation	prophylactic and therapeutic-dose anticoagulation			228					
		117092	Kumar_5	228	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias

CLINICALLY IMPORTANT BLEEDING									
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**
aspirin	intermediate-dose anticoagulation			879					
		198551	McQuilten	879	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	prophylactic-dose anticoagulation			279					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			1151					
		67646	Connors	280	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	871	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	therapeutic-dose anticoagulation			614					
		67646	Connors	287	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		198551	McQuilten	327	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
intermediate-dose anticoagulation	standard care/placebo			1316					
		150820	Mohamed	124	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		198551	McQuilten	1192	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
intermediate-dose anticoagulation	therapeutic-dose anticoagulation			648					
		198551	McQuilten	648	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic-dose anticoagulation	standard care/placebo			3261					
		67646	Connors	271	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		179899, 145930	Barco	468	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		Avezum, 196875	Avezum_2	657	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199126	Piazza	1197	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

		64008, 199334	Ananworanich_2	449	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		145935	Cools	219	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation			278					
		67646	Connors	278	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
therapeutic-dose anticoagulation	standard care/placebo			1449					
		67646	Connors	279	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		67889	Marcos	65	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		Sholzberg, 68845	Sholzberg	465	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias
		198551	McQuilten	640	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
prophylactic and therapeutic-dose anticoagulation	prophylactic and therapeutic-dose anticoagulation			228					
		117092	Kumar_5	228	low risk of bias	probably high risk of bias	low risk of bias	high risk of bias	low risk of bias

LENGTH OF HOSPITAL STAY										
Treatment 1	**Treatment 2**	**Trial**	**First author**	**N**	**Randomization**	**Deviations from the intended intervention**	**Missing outcome data**	**Measurement of outcome**	**Selection of the reported results**	**Other (Competing risks)**
(hydroxy)chloroquine	favipiravir			105						
		176630, 171138, 123445	AlQahtani	105	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
(hydroxy)chloroquine	hydroxychloroquine, zinc			191						
		21407	Abd-Elsalam_2	191	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
(hydroxy)chloroquine	standard care/placebo			1289						
		6987	Chen_4	48	probably high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		9166, 22152	Cavalcanti	448	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Johnston, 33489	Johnston	6	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		176630, 171138, 123445	AlQahtani	103	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		Pan_hydroxychloroquine, 15632, 140619	Pan_hydroxychloroquine	684	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ACEi/ARB	standard care/placebo			913						
		26081	Cohen	152	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		27349, 126661	Lopes_1	659	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		zzz, 109482, 103501	Sharma	46	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		198944	Lawler_2	56	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
HIV reverse transcriptase inhibitor	standard care/placebo			20						
		8469	Ren	20	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
Interferon alpha	standard care/placebo			222						
		60209, 59366	Bhushan	222	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
JAK inhibitors	standard care/placebo			116						

		181887	Ferrarini	116	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
aspirin	aspirin, colchicine			122						
		191566	Naik_2	122	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias
aspirin	aspirin, statins			442						
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			440						
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	statins			442						
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, statins	standard care/placebo			440						
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin, statins	statins			442						
		Ghati, 148872	Ghati	442	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
multivitamin	inhaled corticosteroids			24						
		119102	Duvignaud	24	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
azithromycin	standard care/placebo			32						
		40804	Hinks	32	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
colchicine	standard care/placebo			404						
		64385	Pascual-Figal	103	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
		WWW, 64351, 132467	Dorward	9	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

		181441	Rahman_2	292	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
corticosteroids (systemic)	standard care/placebo			71						
		119197	Les	71	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
doxycycline	standard care/placebo			1728						
		Butler_doxyclycline, 55459	Butler	1728	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
estradiol	standard care/placebo			80						
		73230	Seth	80	probably high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo			753						
		Udwadia, 24988	Udwadia	147	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		82839	Chuan Huan	500	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		176630, 171138, 123445	AlQahtani	106	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
fluvoxamine	standard care/placebo			179						
		18818	Lenze	4	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		Reis_2, 70784	Reis_2	175	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
hydroxychloroquine, ribavirin	standard care/placebo			33						
		66882_non severe, 46308_non severe	Panda_1	33	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
inhaled corticosteroids	standard care/placebo			61						
		57833	Song	61	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
interferon alpha (subcutaneous)	standard care/placebo			39						
		35022	Pandit	39	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias

interferon beta (nebulised)	standard care/placebo			98						
		18657	Monk	98	low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably high risk of bias	low risk of bias
interferon beta (subcutaneous)	standard care/placebo			578						
		Pan_interferon, 15632, 140619	Pan_interferon	578	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta (subcutaneous), ribavirin	standard care/placebo			127						
		2942	Hung	127	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon kappa (nebulised), trefoil factor 2	standard care/placebo			80						
		13797	Fu	80	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon lambda (subcutaneous)	standard care/placebo			14						
		198087	Kim_4	14	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
intermediate-dose anticoagulation	standard care/placebo			124						
		150820	Mohamed	124	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
ivermectin	standard care/placebo			873						
		Ahmed	Ahmed	45	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		Abd-Elsalam_3, 47181	Abd-Elsalam_3	164	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Ed Mills Trial 3, 124954	Reis_3	174	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		135398, 134102	Lim	490	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
leflunomide	standard care/placebo			48						
		13540	Wang_5	48	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	lopinavir-ritonavir, ribavirin			68						
		2615, 10067	Huang_2	68	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias

lopinavir-ritonavir	ribavirin			69						
		2615, 10067	Huang_2	69	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	standard care/placebo			1062						
		Pan_lopinavir-ritonavir, 15632, 140619	Pan_lopinavir-ritonavir	1062	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin			65						
		2615, 10067	Huang_2	65	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
molnupiravir	standard care/placebo			115						
		MOVe-OUT (MK4482-002), 99382_O, 89408, 192177, 140640	Bernal	115	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
mouthwash containing an antiviral phthalocyanine derivative	standard care/placebo			41						
		Sergio da Silva Santos	Sergio da Silva Santos	41	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
nirmatrelvir-ritonavir	standard care/placebo			337						
		193343	Liu	264	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pfizer PPT_1, PF-07321332, EPIC-HR, EP14, 190785, 113697	Hammond	73	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
remdesivir	standard care/placebo			2314						
		11347	Spinner	584	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Pan_remdesivir, 175794, 15632, 140619	Pan_remdesivir	1730	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
ribavirin, sofosbuvir-daclatasvir	standard care/placebo			48						
		11010	Kasgari	48	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias

statins	standard care/placebo			440						
		Ghati, 148872	Ghati	440	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
umifenovir	standard care/placebo			131						
		24810	Yadegarinia	34	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
		149310	Zhao	97	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
vitamin C, vitamin E	standard care/placebo			72						
		68016	Hakamifard	72	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
vitamin D	standard care/placebo			348						
		44830	Lakkireddy	87	high risk of bias	probably low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		139609	Mariani	218	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		152020	De Niet	43	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias

TIME TO SYMPTOM RESOLUTION

Treatment 1	Treatment 2	Trial	First author	N	Randomization	Deviations from the intended intervention	Missing outcome data	Measurement of outcome	Selection of the reported results	Other (Competing risks)
(hydroxy)chloroquine	standard care/placebo			1448						
		434	Chen_1	62	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably low risk of bias
		776, 3321	Tang_1	150	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		C158	Chen_3	30	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		6987	Chen_4	43	probably high risk of bias	probably low risk of bias	high risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		Johnston, 33489	Johnston	132	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		33028	Amaravadi	31	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		Byakika-Kibwika	Byakika-Kibwika	65	low risk of bias	probably low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	probably low risk of bias
		Schwartz_2, 50053, 148103 (abstract)	Schwartz_2	124	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		124337	Avezum	305	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		150649	Choudhary	198	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		198019	Spivak	308	probably high risk of bias	probably low risk of bias	high risk of bias	high risk of bias	low risk of bias	low risk of bias
HIV reverse transcriptase inhibitor	standard care/placebo			281						
		placeholder, 186749	da Silva	281	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
Interferon alpha	standard care/placebo			222						
		60209, 59366	Bhushan	222	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably high risk of bias	probably high risk of bias
JAK inhibitors	standard care/placebo			141						
		RUXCOVID, 123597	Han	141	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
NSAIDs	standard care/placebo			36						
		102953	Guzman-Esquivel	36	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
TNF inhibitors	standard care/placebo			40						
		170237, 166985	O'Halloran	40	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

aspirin	intermediate-dose anticoagulation			896						
		198551	McQuilten	896	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	standard care/placebo			893						
		198551	McQuilten	893	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
aspirin	therapeutic-dose anticoagulation			333						
		198551	McQuilten	333	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
multivitamin	inhaled corticosteroids			157						
		119102	Duvignaud	157	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
azithromycin	clarithromycin			206						
		58017	Rashad_3	206	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
azithromycin	standard care/placebo			1541						
		34434	PRINCIPLE Trial Collaborative Group	1129	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		58017	Rashad_3	206	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
baloxavir marboxil	favipiravir			19						
		Lou (1), Lou, 2637	Lou	19	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
baloxavir marboxil	standard care/placebo			20						
		Lou (1), Lou, 2637	Lou	20	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
cannabidiol	standard care/placebo			92						
		66954	Crippa	92	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

clarithromycin	standard care/placebo			198							
		58017	Rashad_3	198	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably high risk of bias	low risk of bias
colchicine	standard care/placebo			565							
		64385	Pascual-Figal	103	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	probably high risk of bias
		126654	Gorial	80	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		189925	Kasiri_2	106	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		WWW, 64351, 132467	Dorward	276	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
corticosteroids (systemic)	standard care/placebo			752							
		188971	Issak	752	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
doxycycline	standard care/placebo			898							
		Butler_doxyclycline, 55459	Butler	898	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
doxycycline, ivermectin	standard care/placebo			363							
		43517	Mahmud	363	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	favipiravir, serine protease inhibitor			45							
		187449	Ikeda	45	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	standard care/placebo			2034							
		Lou (1), Lou, 2637	Lou	19	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		9978, 10287, 10147	Ivashchenko	60	probably high risk of bias	high risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		32588	Ruzhentsova	168	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
		Udwadia, 24988	Udwadia	102	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
		27459	Balykova_1	39	probably high risk of bias	high risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		115094, 101414	Bosaeed_2	231	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		161363, 140965	Sirijatuphat	93	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

		78612, 131613	Holubar	135	probably low risk of bias	low risk of bias	probably high risk of bias	low risk of bias	low risk of bias	low risk of bias
		165067	Golan	1187	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
favipiravir	umifenovir			236						
		64558, 173	Chen_2	236	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
fluvoxamine	standard care/placebo			2733						
		Reis_2, 70784	Reis_2	1495	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		192307, 190544 (abstract), 190538 (abstract), 178322, 170176	McCarthy	1238	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
fluvoxamine, inhaled corticosteroids	standard care/placebo			1476						
		199030	Reis_5	1476	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
inhaled corticosteroids	standard care/placebo			3773						
		Clemency	Clemency	400	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		38831, 29771	Ramakrishnan	139	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
		148346	Boulware	1277	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Yu, 57300	Yu	1957	probably low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	probably low risk of bias
interferon beta (nebulised)	standard care/placebo			250						
		18657	Monk	98	low risk of bias	low risk of bias	high risk of bias	high risk of bias	low risk of bias	low risk of bias
		Kalil_2	Kalil_2	152	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
interferon beta (subcutaneous), ribavirin	standard care/placebo			127						
		2942	Hung	127	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
interferon lambda (subcutaneous)	standard care/placebo			2065						
		Jagannathan Peer Review, Jagannathan, 19514	Jagannathan	120	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias
		194504	Reiss	1945	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias

intermediate-dose anticoagulation	standard care/placebo			1223							
		198551	McQuilten	1223	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
intermediate-dose anticoagulation	therapeutic-dose anticoagulation			663							
		198551	McQuilten	663	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
ivermectin	standard care/placebo			6074							
		Mohan, 60006	Mohan	97	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	
		Lopez, 41159, 34416	Lopez-Medina	398	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		Chahla	Chahla	254	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	
		Buonfrate, 100160	Buonfrate	61	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	
		Ed Mills Trial 3, 124954	Reis_3	1358	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		139291	George	112	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	
		190536, 174779, 140955	Naggie_2	1591	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		144602	Mirahmadizadeh	391	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		188964	Sarojvisut	317	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
		147197_outpatients	Rezai_2	289	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias	
		197971, 186579	Naggie_3	1206	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
leflunomide	standard care/placebo			10							
		8784	Hu	10	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	
lopinavir, ritonavir	serine protease inhibitors			158							
		157677	Karolyi	158	probably high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	
lopinavir, ritonavir	standard care/placebo			446							
		187455	Kaizer	446	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	

lopinavir-ritonavir	lopinavir-ritonavir, ribavirin			38						
		2615, 10067	Huang_2	38	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir	ribavirin			42						
		2615, 10067	Huang_2	42	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
lopinavir-ritonavir, ribavirin	ribavirin			36						
		2615, 10067	Huang_2	36	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
molnupiravir	standard care/placebo			22245						
		Fischer, 93227, 46473, 115962, 107295	Fischer_3	0	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		CR216-21	Vyas	1220	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		CTRI/2021/06/033938	Krishnan	640	low risk of bias	probably low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Kumar_2 peer-reviewed, HCR/III/MOLCOV/04/2021-01, 141709	Sinha	1218	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	probably low risk of bias	low risk of bias
		147182	Zou	108	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	high risk of bias	low risk of bias
		PANORAMIC_M1, PANORAMIC_M, 187307	Butler_2	19059	low risk of bias	probably low risk of bias	high risk of bias	high risk of bias	low risk of bias	low risk of bias
nelfinavir	standard care/placebo			112						
		199093, 190673	Miyazaki	112	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
niclosamide	standard care/placebo			213						
		Abdulamir_2, 61289	Abdulamir_2	150	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably high risk of bias	probably low risk of bias
		110236	Cairns	63	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
nirmatrelvir-ritonavir	VV116			771						
		XXX (VV116 versus Nirmatrelvir–Ritonavir trial)	Cao_3	771	low risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
nirmatrelvir-ritonavir	standard care/placebo			662						
		Pfizer PPT_2, EPIC-SR	EPIC-SR	662	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias

remdesivir	standard care/placebo			815						
		11347	Spinner	584	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias
		Gottlieb_2, 92530, 88424, 87256, 199003, 191209, 142114, 141652	Gottlieb_2	126	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		3821, 27861, 15633	Beigel	105	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
serine protease inhibitors	standard care/placebo			888						
		70176	Zhuravel	93	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		126799	Kinoshita	105	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias	low risk of bias
		185098	Kim_3	323	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		145987	Tobback	90	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		191504	Plasse	61	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		199428, 141740	Jilg_2	216	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
therapeutic-dose anticoagulation	standard care/placebo			660						
		198551	McQuilten	660	low risk of bias	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
traditional Chinese medicine	standard care/placebo			20						
		112761	Yang	20	low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
traditional Chinese medicine	traditional Chinese medicine, vitamin C			20						
		112761	Yang	20	low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
traditional Chinese medicine, vitamin C	standard care/placebo			20						
		112761	Yang	20	low risk of bias	low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias
umifenovir	standard care/placebo			117						
		12798	Yethindra	20	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
		149310	Zhao	97	probably high risk of bias	probably low risk of bias	low risk of bias	high risk of bias	low risk of bias	low risk of bias

2-aticyto complex	standard care/placebo			133							
		Kerget	Kerget_1	133	probably high risk of bias	probably low risk of bias	probably low risk of bias	high risk of bias	probably low risk of bias	low risk of bias
vitamin C	standard care/placebo			98							
		31458	Thomas	98	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C	vitamin C, zinc			106							
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C	zinc			106							
		31458	Thomas	106	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C, zinc	standard care/placebo			108							
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin C, zinc	zinc			116							
		31458	Thomas	116	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias
vitamin D	standard care/placebo			190							
		180757	Bishop	147	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias
		152022	De Niet	43	probably low risk of bias	low risk of bias	low risk of bias	low risk of bias	low risk of bias	probably high risk of bias
zinc	standard care/placebo			108							
		31458	Thomas	108	low risk of bias	probably low risk of bias	probably high risk of bias	high risk of bias	probably low risk of bias	probably low risk of bias

Network Plots

Mortality



Mechanical Ventilation



Admission to Hospital



Adverse Effects Leading to Discontinuation



Venous Thromboembolism



Clinically Important Bleeding



Length of Hospital Stay



Time to Symptom Resolution



Complete NMA Results and GRADE

Mortality (page 259)
Mechanical Ventilation (page 269)
Admission to Hospital (page 274)
Adverse Events Leading to Discontinuation (page 278)
Venous Thromboembolism (page 282)
Clinically Important Bleeding (page 282)
Length of Hospital Stay (page 283)
Time to Symptom Resolution (page 285)

MORTALITY																												
Comparison		Direct estimate							Indirect estimate							Network estimate												
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					Reasons for downgrading
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
ACEi/ARB	standard care/placebo	1.17	0.67	2.05	0.51	-0.99	3.14	LOW	NA	NA	NA	NA	NA	NA	NA	1.19	0.66	2.17	0.77	-1.06	3.63	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	standard care/placebo	0.87	0.54	1.39	-0.40	-1.38	1.16	HIGH	NA	NA	NA	NA	NA	NA	NA	0.8	0.48	1.29	-0.53	-1.6	0.95	Direct	HIGH	Not serious	Not Serious	HIGH	
aspirin, statins	standard care/placebo	1.14	0.37	3.46	0.41	-1.88	7.31	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.44	0.48	4.34	2.05	-1.56	9.66	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
multivitamin	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	4.001E+11	0	3.203E+40	623.08	-3	997	VERY LOW	4.001E+11	0	3.203E+40	623.08	-3	997	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	standard care/placebo	1.03	0.63	1.66	0.08	-1.10	1.98	HIGH	0.33	0	2.67E+25	-2	-3	997	VERY LOW	1.03	0.57	1.87	0.24	-1.36	2.83	Direct	HIGH	Not serious	Very serious	LOW	
azithromycin, hydroxychloroquine	standard care/placebo	1	0.02	51.94	0.00	-2.94	132.15	VERY LOW	0.45	0.01	6.59	-1.64	-2.96	16.44	VERY LOW	0.44	0.01	5.76	0.76	-2.97	14.53	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	standard care/placebo	0.64	0.38	1.08	-1.08	-1.87	0.24	HIGH	NA	NA	NA	NA	NA	NA	NA	0.58	0.33	1.01	-1.19	-2.04	0	Direct	HIGH	Not serious	Very serious	LOW	
corticosteroids (systemic)	standard care/placebo	1.12	0.57	1.83	0.35	-1.28	2.49	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.07	0.53	1.65	0.17	-1.48	1.98	Direct	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
doubase C	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	0	0	9.931E+09	167.67	-3	997	VERY LOW	0	0	9.931E+09	167.67	-3	997	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	standard care/placebo	3.13	0.58	16.91	6.32	-1.26	45.41	LOW	NA	NA	NA	NA	NA	NA	NA	3.53	0.7	26.29	15.04	-1.15	78.33	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx2
doxycycline, ivermectin	standard care/placebo	0.14	0.01	2.78	-2.58	-2.98	5.30	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-2.98	-3	-2.94	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	standard care/placebo	0.53	0.03	8.59	-1.42	-2.90	22.19	VERY LOW	NA	NA	NA	NA	NA	NA	NA	65.53	0	2.802E+17	145	-3	996.99	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	standard care/placebo	1.16	0.46	2.96	0.48	-1.63	5.83	LOW	274687.91	0	1.141E+23	995.79	-3	997	VERY LOW	3.75	0.91	21.6	16.13	-0.39	73.63	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	standard care/placebo	0.71	0.35	1.43	-0.88	-1.95	1.28	LOW	NA	NA	NA	NA	NA	NA	NA	0.68	0.3	1.51	-0.75	-2.11	1.72	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	standard care/placebo	3	0.12	74.77	5.96	-2.64	180.67	VERY LOW	NA	NA	NA	NA	NA	NA	NA	3606.71	0.42	1.977E+17	835.08	0.96	997	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	standard care/placebo	1.07	0.76	1.49	0.21	-0.72	1.47	HIGH	NA	NA	NA	NA	NA	NA	NA	1.06	0.68	1.55	0.15	-1.03	1.59	Direct	HIGH	Not serious	Not Serious	HIGH	
IL6 receptor antagonists	standard care/placebo	0.88	0.05	15.43	-0.35	-2.85	41.36	VERY LOW	NA	NA	NA	NA	NA	NA	NA	6832.53	0	7.668E+19	213.37	-3	996.99	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	standard care/placebo	0.93	0.02	47.85	-0.2	-2.95	122.86	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	5.551E+21	96.97	-3	997	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	standard care/placebo	0.99	0.14	7.11	-0.04	-2.59	17.94	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	306715142	148.38	-3	997	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
Interferon alpha	standard care/placebo	5.51	0.26	117.47	13.3	-2.22	258.16	VERY LOW	NA	NA	NA	NA	NA	NA	NA	630576.65	2.84	2.699E+18	867.5	16.67	997	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	standard care/placebo	0.74	0.09	6.32	-0.79	-2.74	15.65	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.63	0.07	5.57	0.08	-2.8	10.04	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	standard care/placebo	0.71	0.31	1.64	-0.85	-2.07	1.91	LOW	NA	NA	NA	NA	NA	NA	NA	0.68	0.28	1.63	-0.7	-2.21	2.14	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	standard care/placebo	0.45	0.08	2.57	-1.66	-2.77	4.66	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.21	0	1.78	-1.75	-2.97	2.87	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
intermediate-dose anticoagulation	standard care/placebo	0.88	0.46	1.7	-0.36	-1.63	2.1	LOW	NA	NA	NA	NA	NA	NA	NA	0.69	0.35	1.29	-0.81	-1.95	0.99	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	standard care/placebo	0.8	0.53	1.21	-0.6	-1.42	0.64	HIGH	95015446	0	1.635E+37	997.00	-3.00	997.00	VERY LOW	0.75	0.48	1.18	-0.69	-1.64	0.59	Direct	HIGH	Not serious	Not Serious	HIGH	
JAK inhibitors	standard care/placebo	0.77	0.4	1.5	-0.69	-1.81	1.48	LOW	NA	NA	NA	NA	NA	NA	NA	0.72	0.34	1.49	-0.66	-2	1.53	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	standard care/placebo	1.25	0.86	1.83	0.75	-0.43	2.47	HIGH	0	0	1.221E+17	-3.00	-3.00	997.00	VERY LOW	1.3	0.84	2.17	1.11	-0.49	3.81	Direct	HIGH	Not serious	Not Serious	HIGH	
molnupiravir	standard care/placebo	0.36	0.15	0.83	-1.93	-2.54	-0.5	LOW	NA	NA	NA	NA	NA	NA	NA	0.22	0.06	0.6	-2.23	-2.78	-1.19	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
niclosamide	standard care/placebo	1	0.21	4.7	0.01	-2.35	10.95	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.97	0.16	6.33	1.82	-2.52	16.56	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
nirmatrelvir-ritonavir	standard care/placebo	0.43	0.15	1.27	-1.7	-2.56	0.8	LOW	NA	NA	NA	NA	NA	NA	NA	0.22	0.07	0.62	-2.25	-2.8	-1.15	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
prophylactic-dose anticoagulation	standard care/placebo	0.8	0.34	1.86	-0.61	-1.98	2.58	LOW	NA	NA	NA	NA	NA	NA	NA	0.74	0.28	1.95	-0.42	-2.15	2.89	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
P2Y12 inhibitor	standard care/placebo	0.29	0.09	0.96	-2.13	-2.74	-0.11	LOW	NA	NA	NA	NA	NA	NA	NA	0.28	0.07	0.86	-2.01	-2.79	-0.39	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
remdesivir	standard care/placebo	0.73	0.45	1.21	-0.79	-1.66	0.62	HIGH	NA	NA	NA	NA	NA	NA	NA	0.75	0.43	1.28	-0.71	-1.75	0.87	Direct	HIGH	Not serious	Not Serious	HIGH	
serine protease inhibitors	standard care/placebo	1.91	0.16	23.2	2.72	-2.53	62.26	VERY LOW	NA	NA	NA	NA	NA	NA	NA	4102881.1	11.93	2.632E+16	844	-0.15	997	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
statins	standard care/placebo	0.99	0.32	3.11	-0.03	-2.05	6.26	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.25	0.39	3.89	1.41	-1.81	8.39	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
therapeutic-dose anticoagulation	standard care/placebo	1.16	0.44	2.97	0.47	-1.67	5.85	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.81	0.35	1.88	-0.24	-1.88	2.81	Direct	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
umifenovir	standard care/placebo	1.01	0.22	4.59	0.02	-2.33	10.61	VERY LOW	0.03	0	1.844E+20	-2.91	-3.00	997.00	VERY LOW	1.01	0.15	6.62	1.79	-2.57	16.59	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
vitamin D	standard care/placebo	1.1	0.41	2.95	0.31	-1.76	5.81	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.09	0.43	2.9	0.77	-1.77	5.85	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
VV116	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	0	0	1.863E+23	313.73	-3.00	997.00	VERY LOW	0	0	1.863E+23	313.73	-3	997	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	aspirin	NA	NA	NA	NA	NA	NA	NA	1.5	0.7	3.31	1.30	-1.07	4.33	LOW	1.5	0.7	3.31	1.3	-1.07	4.33	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	aspirin, statins	NA	NA	NA	NA	NA	NA	NA	0.83	0.24	2.94	-1.28	-9.14	3.50	VERY LOW	0.83	0.24	2.94	-1.28	-9.14	3.5	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	multivitamin	NA	NA	NA	NA	NA	NA	NA	0	0	35523.51	-622.31	-997.80	5.35		0	0	35523.51	-622.31	-997.8	5.35	Indirect		Not serious	Extremely serious		
ACEi/ARB	azithromycin	NA	NA	NA	NA	NA	NA	NA	1.16	0.5	2.68	0.52	-2.64	3.77	LOW	1.16	0.5	2.68	0.52	-2.64	3.77	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	2.72	0.19	105.03	0.01	-13.91	5.60	VERY LOW	2.72	0.19	105.03	0.01	-13.91	5.6	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	colchicine	NA	NA	NA	NA	NA	NA	NA	2.06	0.9	4.75	1.96	-0.23	5.01	LOW	2.06	0.9	4.75	1.96	-0.23	5.01	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.14	0.55	2.8	0.60	-2.01	3.87	VERY LOW	1.14	0.55	2.8	0.6	-2.01	3.87	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
ACEi/ARB	doubase C	NA	NA	NA	NA	NA	NA	NA	1810.18	0	1.28E+20	-166.90	-996.88	6.32		1810.18	0	1.28E+20	-166.9	-996.88	6.32	Indirect		Not serious	Extremely serious		
ACEi/ARB	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.34	0.04	1.92	-14.27	-77.45	2.42	VERY LOW	0.34	0.04	1.92	-14.27	-77.45	2.42	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	8.269E+11	45.23	4.304E+65	3.75	1.90	6.60	VERY LOW	8.269E+11	45.23	4.304E+65	3.75	1.9	6.6	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.02	0	183105.91	-144.23	-996.70	6.27	VERY LOW	0.02	0	183105.91	-144.23	-996.7	6.27	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.32	0.05	1.53	-15.36	-72.80	1.61	VERY LOW	0.32	0.05	1.53	-15.36	-72.8	1.61	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.77	0.65	4.82	1.52	-1.55	4.69	LOW	1.77	0.65	4.82	1.52	-1.55	4.69	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	2.77	-834.31	-997.90	-0.26	VERY LOW	0	0	2.77	-834.31	-997.9	-0.26	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.14	0.57	2.39	0.62	-1.76	3.73	LOW	1.14	0.57	2.39	0.62	-1.76	3.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	511833533	-212.60	-996.61	6.10	VERY LOW	0	0	511833533	-212.6	-996.61	6.1	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.225E+11	0	3.913E+26	-96.20	-996.76	6.43	VERY LOW	1.225E+11	0	3.913E+26	-96.2	-996.76	6.43	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1665.57	0	327719953	-147.61	-996.92	6.15	VERY LOW	1665.57	0	327719953	-147.61	-996.92	6.15	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.43	-866.73	-997.95	-15.85	VERY LOW	0	0	0.43	-866.73	-997.95	-15.85	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1.9	0.21	17.3	0.69	-9.47	5.22	VERY LOW	1.9	0.21	17.3	0.69	-9.47	5.22	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.76	0.6	5.1	1.47	-1.97	4.76	LOW	1.76	0.6	5.1	1.47	-1.97	4.76	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	5.71	0.62	313.83	2.52	-2.33	5.88	VERY LOW	5.71	0.62	313.83	2.52	-2.33	5.88	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.74	0.73	4.21	1.58	-1.00	4.69	LOW	1.74	0.73	4.21	1.58	-1	4.69	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.59	0.76	3.37	1.46	-0.81	4.55	LOW	1.59	0.76	3.37	1.46	-0.81	4.55	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.67	0.67	4.31	1.43	-1.44	4.60	LOW	1.67	0.67	4.31	1.43	-1.44	4.6	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.92	0.42	1.89	-0.34	-3.65	2.93	LOW	0.92	0.42	1.89	-0.34	-3.65	2.93	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	molnupiravir	NA	NA	NA	NA	NA	NA	NA	5.46	1.67	23.36	3.00	0.90	5.95	LOW	5.46	1.67	23.36	3	0.9	5.95	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.23	0.17	7.87	-1.05	-15.80	4.57	VERY LOW	1.23	0.17	7.87	-1.05	-15.8	4.57	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.38	1.66	19.89	3.02	0.89	5.95	LOW	5.38	1.66	19.89	3.02	0.89	5.95	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.63	0.52	5.05	1.19	-2.61	4.64	LOW	1.63	0.52	5.05	1.19	-2.61	4.64	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	4.21	1.17	18.37	2.78	0.35	5.78	LOW	4.21	1.17	18.37	2.78	0.35	5.78	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.6	0.71	3.62	1.48	-0.97	4.54	LOW	1.6	0.71	3.62	1.48	-0.97	4.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.1	-843.23	-997.97	0.86	VERY LOW	0	0	0.1	-843.23	-997.97	0.86	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	statins	NA	NA	NA	NA	NA	NA	NA	0.96	0.27	3.57	-0.64	-7.91	3.79	VERY LOW	0.96	0.27	3.57	-0.64	-7.91	3.79	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.49	0.51	4.1	1.01	-2.59	4.43	VERY LOW	1.49	0.51	4.1	1.01	-2.59	4.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
ACEi/ARB	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.18	0.17	8.98	-1.02	-15.93	4.71	VERY LOW	1.18	0.17	8.98	-1.02	-15.93	4.71	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.1	0.35	3.35	0.00	-5.45	3.89	VERY LOW	1.1	0.35	3.35	0	-5.45	3.89	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	VV116	NA	NA	NA	NA	NA	NA	NA	1.738E+10	0	2.952E+26	-312.96	-997.38	6.04	VERY LOW	1.738E+10	0	2.952E+26	-312.96	-997.38	6.04	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	aspirin, statins	0.37	0.09	1.47	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.55	0.18	1.66	-2.58	-10.03	1.11	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	multivitamin	NA	NA	NA	NA	NA	NA	NA	0	0	24380.77	-623.61	-998.44	3.43	VERY LOW	0	0	24380.77	-623.61	-998.44	3.43	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

MORTALITY																													
Comparison		Direct estimate							Indirect estimate							Network estimate													
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE						
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
aspirin	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.78	0.35	1.62	-0.77	-3.58	1.38	LOW	0.78	0.35	1.62	-0.77	-3.58	1.38	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	1.81	0.13	68.24	-1.29	-14.99	3.21	VERY LOW	1.81	0.13	68.24	-1.29	-14.99	3.21	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.37	0.65	2.92	0.66	-0.95	2.37	LOW	1.37	0.65	2.92	0.66	-0.95	2.37	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.76	0.39	1.7	-0.69	-2.82	1.44	VERY LOW	0.76	0.39	1.7	-0.69	-2.82	1.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
aspirin	doubase C	NA	NA	NA	NA	NA	NA	NA	1200.66	0	8.817E+19	-168.20	-997.96	3.83	VERY LOW	1200.66	0	8.817E+19	-168.2	-997.96	3.83	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.23	0.03	1.21	-15.57	-78.81	0.76	VERY LOW	0.23	0.03	1.21	-15.57	-78.81	0.76	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	5.594E+11	29.68	3.269E+65	2.45	1.35	3.95	VERY LOW	5.594E+11	29.68	3.269E+65	2.45	1.35	3.95	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.01	0	115793.07	-145.53	-997.72	3.81	VERY LOW	0.01	0	115793.07	-145.53	-997.72	3.81	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.21	0.04	0.97	-16.65	-74.10	0.10	LOW	0.21	0.04	0.97	-16.65	-74.1	0.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.18	0.45	2.99	0.23	-2.45	2.28	LOW	1.18	0.45	2.99	0.23	-2.45	2.28	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.88	-835.60	-998.48	-1.61	VERY LOW	0	0	1.88	-835.6	-998.48	-1.61	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.75	0.41	1.46	-0.68	-2.47	1.18	LOW	0.75	0.41	1.46	-0.68	-2.47	1.18	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	295940802	-213.89	-997.59	3.68	VERY LOW	0	0	295940802	-213.89	-997.59	3.68	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	8.518E+10	0	2.389E+26	-97.5	-997.83	3.86	VERY LOW	8.518E+10	0	2.389E+26	-97.5	-997.83	3.86	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1105.81	0	180571973	-148.9	-997.84	3.76	VERY LOW	1105.81	0	180571973	-148.9	-997.84	3.76	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.29	-868.03	-998.53	-17.24	VERY LOW	0	0	0.29	-868.03	-998.53	-17.24	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1.26	0.14	11.42	-0.61	-10.61	2.95	VERY LOW	1.26	0.14	11.42	-0.61	-10.61	2.95	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.17	0.42	3.27	0.17	-2.85	2.33	LOW	1.17	0.42	3.27	0.17	-2.85	2.33	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	3.84	0.42	195.43	1.22	-3.49	3.47	VERY LOW	3.84	0.42	195.43	1.22	-3.49	3.47	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	intermediate-dose anticoagulation	1.45	0.59	3.56	NA	NA	NA	LOW	0.62	0.14	2.6	NA	NA	NA	LOW	1.16	0.55	2.43	0.28	-1.63	1.95	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.06	0.54	2.04	0.16	-1.51	1.93	LOW	1.06	0.54	2.04	0.16	-1.51	1.93	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.12	0.46	2.67	0.13	-2.32	2.15	LOW	1.12	0.46	2.67	0.13	-2.32	2.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.61	0.29	1.17	-1.64	-4.62	0.52	LOW	0.61	0.29	1.17	-1.64	-4.62	0.52	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.64	1.19	13.84	1.7	0.21	3.32	LOW	3.64	1.19	13.84	1.7	0.21	3.32	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.82	0.12	5.18	-2.34	-17.18	2.45	VERY LOW	0.82	0.12	5.18	-2.34	-17.18	2.45	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.57	1.11	13.07	1.72	0.22	3.33	LOW	3.57	1.11	13.07	1.72	0.22	3.33	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	prophylactic-dose anticoagulation	0.94	0.02	47.89	NA	NA	NA	VERY LOW	1.05	0.35	3.23	NA	NA	NA	LOW	1.09	0.36	3.19	-0.1	-3.58	2.25	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	P2Y12 inhibitor	2.42	0.7	8.36	NA	NA	NA	LOW	NA	NA	NA	NA	NA	NA	NA	2.78	0.91	10.9	1.48	-0.23	3.08	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.07	0.5	2.23	0.18	-1.75	2.01	LOW	1.07	0.5	2.23	0.18	-1.75	2.01	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.07	-844.53	-998.51	-0.64	VERY LOW	0	0	0.07	-844.53	-998.51	-0.64	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	statins	0.42	0.1	1.73	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.63	0.2	2.07	-1.93	-8.79	1.42	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	therapeutic-dose anticoagulation	0.3	0.1	0.88	NA	NA	NA	LOW	2.42	0.77	8.2	NA	NA	NA	VERY LOW	0.99	0.37	2.56	-0.29	-3.49	1.89	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.8	0.11	5.61	-2.32	-17.2	2.47	VERY LOW	0.8	0.11	5.61	-2.32	-17.2	2.47	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.73	0.24	2.12	-1.29	-6.46	1.68	VERY LOW	0.73	0.24	2.12	-1.29	-6.46	1.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	VV116	NA	NA	NA	NA	NA	NA	NA	1.151E+10	0	1.834E+26	-314.26	-998.2	3.73	VERY LOW	1.151E+10	0	1.834E+26	-314.26	-998.2	3.73	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin, statins	multivitamin	NA	NA	NA	NA	NA	NA	NA	0	0	45833.93	-621.03	-998.18	8.98	VERY LOW	0	0	45833.93	-621.03	-998.18	8.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	azithromycin	NA	NA	NA	NA	NA	NA	NA	1.4	0.4	4.81	1.81	-2.75	9.62	VERY LOW	1.4	0.4	4.81	1.81	-2.75	9.62	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	3.29	0.21	151.6	1.29	-12.96	11.03	VERY LOW	3.29	0.21	151.6	1.29	-12.96	11.03	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA	NA	2.48	0.71	8.54	3.24	-0.6	10.87	VERY LOW	2.48	0.71	8.54	3.24	-0.6	10.87	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.38	0.42	4.99	1.88	-2.23	9.68	VERY LOW	1.38	0.42	4.99	1.88	-2.23	9.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	doubase C	NA	NA	NA	NA	NA	NA	NA	2057.67	0	1.536E+20	-165.62	-996.95	11.82	VERY LOW	2057.67	0	1.536E+20	-165.62	-996.95	11.82	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.4	0.04	2.91	-12.99	-76.19	6.02	VERY LOW	0.4	0.04	2.91	-12.99	-76.19	6.02	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.011E+12	48.92	5.464E+65	5.03	1.4	12.64	VERY LOW	1.011E+12	48.92	5.464E+65	5.03	1.4	12.64	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.02	0	242285	-142.95	-996.27	11.64	VERY LOW	0.02	0	242285	-142.95	-996.27	11.64	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.38	0.05	2.32	-14.08	-71.72	4.98	VERY LOW	0.38	0.05	2.32	-14.08	-71.72	4.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	2.13	0.53	8.44	2.81	-1.63	10.5	VERY LOW	2.13	0.53	8.44	2.81	-1.63	10.5	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	3.75	-833.03	-998.38	0.66	VERY LOW	0	0	3.75	-833.03	-998.38	0.66	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.37	0.43	4.48	1.9	-2.06	9.6	VERY LOW	1.37	0.43	4.48	1.9	-2.06	9.6	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	583929024	-211.31	-996.03	11.14	VERY LOW	0	0	583929024	-211.31	-996.03	11.14	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.457E+11	0	4.605E+26	-94.92	-996.44	12.06	VERY LOW	1.457E+11	0	4.605E+26	-94.92	-996.44	12.06	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1937.36	0	356409176	-146.33	-996.68	11.43	VERY LOW	1937.36	0	356409176	-146.33	-996.68	11.43	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.58	-865.45	-998.42	-15.1	VERY LOW	0	0	0.58	-865.45	-998.42	-15.1	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	2.31	0.19	26.37	1.97	-8.71	10.69	VERY LOW	2.31	0.19	26.37	1.97	-8.71	10.69	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.12	0.51	8.66	2.75	-1.91	10.53	VERY LOW	2.12	0.51	8.66	2.75	-1.91	10.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	7.08	0.61	412.11	3.8	-1.89	11.68	VERY LOW	7.08	0.61	412.11	3.8	-1.89	11.68	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	2.09	0.6	7.47	2.86	-1.18	10.51	VERY LOW	2.09	0.6	7.47	2.86	-1.18	10.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.91	0.59	6.33	2.74	-1.12	10.36	VERY LOW	1.91	0.59	6.33	2.74	-1.12	10.36	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.03	0.53	7.32	2.71	-1.56	10.44	VERY LOW	2.03	0.53	7.32	2.71	-1.56	10.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.1	0.33	3.55	0.94	-3.65	8.68	VERY LOW	1.1	0.33	3.55	0.94	-3.65	8.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	6.6	1.54	34.14	4.28	0.5	11.94	VERY LOW	6.6	1.54	34.14	4.28	0.5	11.94	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.46	0.17	12.05	0.23	-15.12	9.84	VERY LOW	1.46	0.17	12.05	0.23	-15.12	9.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	6.47	1.36	32.84	4.3	0.53	11.92	VERY LOW	6.47	1.36	32.84	4.3	0.53	11.92	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.97	0.45	8.29	2.47	-2.55	10.38	VERY LOW	1.97	0.45	8.29	2.47	-2.55	10.38	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	5.07	1.1	28.51	4.06	0.16	11.67	VERY LOW	5.07	1.1	28.51	4.06	0.16	11.67	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.93	0.56	6.43	2.76	-1.21	10.43	VERY LOW	1.93	0.56	6.43	2.76	-1.21	10.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.13	-841.95	-998.36	1.31	VERY LOW	0	0	0.13	-841.95	-998.36	1.31	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	statins	1.15	0.38	3.45	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.14	0.35	3.92	0.64	-5.43	7.15	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.79	0.46	6.85	2.29	-2.55	9.99	VERY LOW	1.79	0.46	6.85	2.29	-2.55	9.99	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.43	0.16	12.52	0.26	-14.98	9.84	VERY LOW	1.43	0.16	12.52	0.26	-14.98	9.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.31	0.3	5.72	1.28	-5.11	9.41	VERY LOW	1.31	0.3	5.72	1.28	-5.11	9.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	VV116	NA	NA	NA	NA	NA	NA	NA	2.063E+10	0	3.068E+26	-311.68	-997.67	11.04	VERY LOW	2.063E+10	0	3.068E+26	-311.68	-997.67	11.04	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	azithromycin	NA	NA	NA	NA	NA	NA	NA	3.93E+11	0	2.72E+40	622.83	-4.55	998.1	VERY LOW	3.93E+11	0	2.72E+40	622.83	-4.55	998.1	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	8.996E+11	0	2.634E+40	622.32	-8.22	999.89	VERY LOW	8.996E+11	0	2.634E+40	622.32	-8.22	999.89	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	colchicine	NA	NA	NA	NA	NA	NA	NA	6.906E+11	0	5.384E+40	624.27	-2.48	998.89	VERY LOW	6.906E+11	0	5.384E+40	624.27	-2.48	998.89	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	3.794E+11	0	3.071E+40	622.91	-4.23	998.19	VERY LOW	3.794E+11	0	3.071E+40	622.91	-4.23	998.19	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	doubase C	NA	NA	NA	NA	NA	NA	NA	1.871E+13	0	1.121E+51	455.4	-907.98	1000	VERY LOW	1.871E+13	0	1.121E+51	455.4	-907.98	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	doxycycline	NA	NA	NA	NA	NA	NA	NA	9.861E+10	0	1.005E+40	608.04	-35.56	997.48	VERY LOW	9.861E+10	0	1.005E+40	608.04	-35.56	997.48	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.94E+25	560.52	8.263E+81	626.06	-0.02	1000	VERY LOW	1.94E+25	560.52	8.263E+81	626.06	-0.02	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	699509547	0	1.103E+36	478.08	-905.44	1000	VERY LOW	699509547	0	1.103E+36	478.08	-905.44	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

MORTALITY

Comparison		Direct estimate							Indirect estimate							Network estimate										Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
multivitamin	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.018E+11	0	1.104E+40	606.95	-43.61	996.38	VERY LOW	1.018E+11	0	1.104E+40	606.95	-43.61	996.38	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	5.9E+11	0	4.759E+40	623.83	-3.56	998.94	VERY LOW	5.9E+11	0	4.759E+40	623.83	-3.56	998.94	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	4566876.3	0	7.177E+36	-212	-1000	971.61	VERY LOW	4566876.3	0	7.177E+36	-212	-1000	971.61	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	3.772E+11	0	2.817E+40	622.93	-3.96	997.79	VERY LOW	3.772E+11	0	2.817E+40	622.93	-3.96	997.79	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	11439811	0	4.047E+36	409.71	-954.65	1000	VERY LOW	11439811	0	4.047E+36	409.71	-954.65	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	3.287E+23	0	2.114E+56	526.11	-670.22	1000	VERY LOW	3.287E+23	0	2.114E+56	526.11	-670.22	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	inhaled corticosteroids	5.3	0.25	113.2	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	3.504E+10	15.41	1.651E+48	474.7	0	1000	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	10157.32	0	8.384E+29	-244.42	-1000	906.62	VERY LOW	10157.32	0	8.384E+29	-244.42	-1000	906.62	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	6.561E+11	0	1.703E+40	623	-6.59	999.66	VERY LOW	6.561E+11	0	1.703E+40	623	-6.59	999.66	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	6.405E+11	0	5.468E+40	623.78	-3.78	999.02	VERY LOW	6.405E+11	0	5.468E+40	623.78	-3.78	999.02	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.736E+12	0	1.318E+41	624.82	-3.43	999.94	VERY LOW	2.736E+12	0	1.318E+41	624.82	-3.43	999.94	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5.937E+11	0	5.525E+40	623.89	-3.21	998.79	VERY LOW	5.937E+11	0	5.525E+40	623.89	-3.21	998.79	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	ivermectin	NA	NA	NA	NA	NA	NA	NA	5.102E+11	0	4.37E+40	623.77	-3.12	998.47	VERY LOW	5.102E+11	0	4.37E+40	623.77	-3.12	998.47	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	5.723E+11	0	4.05E+40	623.74	-3.43	998.83	VERY LOW	5.723E+11	0	4.05E+40	623.74	-3.43	998.83	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.101E+11	0	2.425E+40	621.97	-5.42	997.26	VERY LOW	3.101E+11	0	2.425E+40	621.97	-5.42	997.26	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.808E+12	0	1.608E+41	625.31	-1.29	999.72	VERY LOW	1.808E+12	0	1.608E+41	625.31	-1.29	999.72	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	niclosamide	NA	NA	NA	NA	NA	NA	NA	3.944E+11	0	5.484E+40	621.26	-11.16	999.25	VERY LOW	3.944E+11	0	5.484E+40	621.26	-11.16	999.25	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.891E+12	0	2.007E+41	625.33	-1.31	999.74	VERY LOW	1.891E+12	0	2.007E+41	625.33	-1.31	999.74	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5.954E+11	0	3.449E+40	623.5	-4.23	999	VERY LOW	5.954E+11	0	3.449E+40	623.5	-4.23	999	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	1.651E+12	0	1.108E+41	625.09	-1.76	999.69	VERY LOW	1.651E+12	0	1.108E+41	625.09	-1.76	999.69	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	remdesivir	NA	NA	NA	NA	NA	NA	NA	5.436E+11	0	4.246E+40	623.79	-3.19	998.57	VERY LOW	5.436E+11	0	4.246E+40	623.79	-3.19	998.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	325718.89	0	8.691E+29	-220.92	-1000	946.46	VERY LOW	325718.89	0	8.691E+29	-220.92	-1000	946.46	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	statins	NA	NA	NA	NA	NA	NA	NA	3.696E+11	0	2.435E+40	621.67	-7.77	998.5	VERY LOW	3.696E+11	0	2.435E+40	621.67	-7.77	998.5	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5.212E+11	0	5.569E+40	623.32	-4.41	998.72	VERY LOW	5.212E+11	0	5.569E+40	623.32	-4.41	998.72	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	umifenovir	NA	NA	NA	NA	NA	NA	NA	4.017E+11	0	3.421E+40	621.29	-12.02	999.37	VERY LOW	4.017E+11	0	3.421E+40	621.29	-12.02	999.37	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	vitamin D	NA	NA	NA	NA	NA	NA	NA	3.821E+11	0	2.171E+40	622.31	-6.45	998.51	VERY LOW	3.821E+11	0	2.171E+40	622.31	-6.45	998.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	VV116	NA	NA	NA	NA	NA	NA	NA	6.561E+20	0	4.037E+36	309.35	-873.95	1000	VERY LOW	6.561E+20	0	4.037E+36	309.35	-873.95	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	azithromycin, hydroxychloroquine	1.97	0.17	22.72	NA	NA	NA	VERY LOW	10323.07	0	5.554E+29	NA	NA	NA	VERY LOW	2.31	0.19	83.48	-0.51	-13.7	4.33	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.76	0.81	4.07	1.43	-0.53	4.18	LOW	1.76	0.81	4.07	1.43	-0.53	4.18	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.97	0.49	2.53	0.08	-2.29	3.29	VERY LOW	0.97	0.49	2.53	0.08	-2.29	3.29	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
azithromycin	doubase C	NA	NA	NA	NA	NA	NA	NA	1512.29	0	1.111E+20	-167.43	-997.41	5.49	VERY LOW	1512.29	0	1.111E+20	-167.43	-997.41	5.49	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.29	0.04	1.64	-14.79	-78.15	1.78	VERY LOW	0.29	0.04	1.64	-14.79	-78.15	1.78	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	7.455E+11	36.2	4.549E+65	3.22	1.58	5.82	VERY LOW	7.455E+11	36.2	4.549E+65	3.22	1.58	5.82	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.02	0	150536.37	-144.76	-997.15	5.44	VERY LOW	0.02	0	150536.37	-144.76	-997.15	5.44	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.27	0.04	1.23	-15.88	-73.38	0.99	LOW	0.27	0.04	1.23	-15.88	-73.38	0.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.52	0.57	4.12	1	-1.96	3.94	LOW	1.52	0.57	4.12	1	-1.96	3.94	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	2.64	-834.83	-998.19	-0.75	VERY LOW	0	0	2.64	-834.83	-998.19	-0.75	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.97	0.5	2.09	0.09	-2.02	3.02	LOW	0.97	0.5	2.09	0.09	-2.02	3.02	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	408168240	-213.12	-996.95	5.2	VERY LOW	0	0	408168240	-213.12	-996.95	5.2	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.048E+11	0	3.39E+26	-96.72	-997.2	5.62	VERY LOW	1.048E+11	0	3.39E+26	-96.72	-997.2	5.62	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1374.25	0	248593602	-148.13	-997.2	5.31	VERY LOW	1374.25	0	248593602	-148.13	-997.2	5.31	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.37	-867.26	-998.27	-16.29	VERY LOW	0	0	0.37	-867.26	-998.27	-16.29	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1.62	0.18	15.46	0.16	-9.88	4.41	VERY LOW	1.62	0.18	15.46	0.16	-9.88	4.41	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.52	0.53	4.49	0.95	-2.29	4.04	LOW	1.52	0.53	4.49	0.95	-2.29	4.04	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	4.87	0.54	246.7	1.99	-2.83	5.11	VERY LOW	4.87	0.54	246.7	1.99	-2.83	5.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.5	0.64	3.66	1.05	-1.34	3.92	LOW	1.5	0.64	3.66	1.05	-1.34	3.92	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.36	0.66	2.89	0.93	-1.15	3.71	LOW	1.36	0.66	2.89	0.93	-1.15	3.71	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.44	0.57	3.71	0.9	-1.79	3.9	LOW	1.44	0.57	3.71	0.9	-1.79	3.9	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.79	0.35	1.64	-0.87	-4	2.11	LOW	0.79	0.35	1.64	-0.87	-4	2.11	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	4.72	1.48	18.2	2.47	0.58	5.15	LOW	4.72	1.48	18.2	2.47	0.58	5.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.05	0.15	6.94	-1.57	-16.47	3.84	VERY LOW	1.05	0.15	6.94	-1.57	-16.47	3.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.6	1.44	17.28	2.49	0.58	5.16	LOW	4.6	1.44	17.28	2.49	0.58	5.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.4	0.45	4.33	0.67	-3.01	3.83	LOW	1.4	0.45	4.33	0.67	-3.01	3.83	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	3.63	1.05	15.73	2.25	0.01	4.96	LOW	3.63	1.05	15.73	2.25	0.01	4.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.38	0.62	3.12	0.95	-1.32	3.74	LOW	1.38	0.62	3.12	0.95	-1.32	3.74	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.09	-843.76	-998.23	0.3	VERY LOW	0	0	0.09	-843.76	-998.23	0.3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	statins	NA	NA	NA	NA	NA	NA	NA	0.82	0.23	3.04	-1.16	-8.36	3.07	VERY LOW	0.82	0.23	3.04	-1.16	-8.36	3.07	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.28	0.45	3.5	0.49	-3.04	3.44	VERY LOW	1.28	0.45	3.5	0.49	-3.04	3.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
azithromycin	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.03	0.14	7.56	-1.55	-16.49	3.95	VERY LOW	1.03	0.14	7.56	-1.55	-16.49	3.95	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.94	0.3	2.84	-0.52	-5.82	3.16	VERY LOW	0.94	0.3	2.84	-0.52	-5.82	3.16	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	VV116	NA	NA	NA	NA	NA	NA	NA	1.541E+10	0	2.299E+26	-313.48	-997.72	5.27	VERY LOW	1.541E+10	0	2.299E+26	-313.48	-997.72	5.27	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	colchicine	NA	NA	NA	NA	NA	NA	NA	0.77	0.02	10.24	1.95	-2.39	15.71	VERY LOW	0.77	0.02	10.24	1.95	-2.39	15.71	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.43	0.01	5.98	0.59	-4.19	14.46	VERY LOW	0.43	0.01	5.98	0.59	-4.19	14.46	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
azithromycin, hydroxychloroquine	doubase C	1.12	0.02	57.3	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	486.23	0	3.33E+19	-166.92	-999.64	14.51	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.11	0	2.72	-14.28	-78.75	9.17	VERY LOW	0.11	0	2.72	-14.28	-78.75	9.17	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.051E+11	13.9	8.179E+64	3.74	0.01	17.51	VERY LOW	3.051E+11	13.9	8.179E+64	3.74	0.01	17.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0	0	52508.48	-144.24	-999.01	15.79	VERY LOW	0	0	52508.48	-144.24	-999.01	15.79	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.11	0	2.02	-15.37	-73.86	7.01	VERY LOW	0.11	0	2.02	-15.37	-73.86	7.01	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.65	0.02	9.4	1.51	-3.73	15.28	VERY LOW	0.65	0.02	9.4	1.51	-3.73	15.28	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	2.38	-834.32	-999.94	-1.82	VERY LOW	0	0	2.38	-834.32	-999.94	-1.82	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.42	0.01	5.54	0.61	-3.93	14.38	VERY LOW	0.42	0.01	5.54	0.61	-3.93	14.38	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	201004931	-212.61	-998.95	13.48	VERY LOW	0	0	201004931	-212.61	-998.95	13.48	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	3.48E+10	0	1.26E+26	-96.21	-999.26	15.54	VERY LOW	3.48E+10	0	1.26E+26	-96.21	-999.26	15.54	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	463.04	0	170968519	-147.62	-999.33	14.24	VERY LOW	463.04	0	170968519	-147.62	-999.33	14.24	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.29	-866.74	-999.94	-17.11	VERY LOW	0	0	0.29	-866.74	-999.94	-17.11	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	0.65	0.01	20.38	0.68	-10.9	15.11	VERY LOW	0.65	0.01	20.38	0.68	-10.9	15.11	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.64	0.02	10.04	1.46	-4.05	15.24	VERY LOW	0.64	0.02	10.04	1.46	-4.05	15.24	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.27	0.03	193.88	2.5	-4.55	16.57	VERY LOW	2.27	0.03	193.88	2.5	-4.55	16.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.64	0.02	9.11	1.57	-3.15	15.37	VERY LOW	0.64	0.02	9.11	1.57	-3.15	15.37	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

MORTALITY																											
Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
azithromycin, hydroxychloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.59	0.02	8.05	1.45	-2.97	15.27	VERY LOW	0.59	0.02	8.05	1.45	-2.97	15.27	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.62	0.01	8.93	1.42	-3.58	15.21	VERY LOW	0.62	0.01	8.93	1.42	-3.58	15.21	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.33	0.01	4.47	-0.36	-5.72	13.51	VERY LOW	0.33	0.01	4.47	-0.36	-5.72	13.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.08	0.05	32.73	2.99	-1.16	16.7	VERY LOW	2.08	0.05	32.73	2.99	-1.16	16.7	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.42	0.01	11.64	-1.06	-17.38	14.13	VERY LOW	0.42	0.01	11.64	-1.06	-17.38	14.13	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.94	0.05	34	3.01	-1.22	16.69	VERY LOW	1.94	0.05	34	3.01	-1.22	16.69	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.6	0.01	9	1.18	-4.82	15.11	VERY LOW	0.6	0.01	9	1.18	-4.82	15.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	1.56	0.04	27.3	2.77	-1.75	16.53	VERY LOW	1.56	0.04	27.3	2.77	-1.75	16.53	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.59	0.02	8.18	1.47	-3.11	15.27	VERY LOW	0.59	0.02	8.18	1.47	-3.11	15.27	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-843.24	-999.96	-1.11	VERY LOW	0	0	0.04	-843.24	-999.96	-1.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	statins	NA	NA	NA	NA	NA	NA	NA	0.34	0.01	6.06	-0.65	-9.9	13.77	VERY LOW	0.34	0.01	6.06	-0.65	-9.9	13.77	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.54	0.01	8.22	1	-4.7	14.84	VERY LOW	0.54	0.01	8.22	1	-4.7	14.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
azithromycin, hydroxychloroquine	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.43	0.01	10.11	-1.03	-17.52	13.91	VERY LOW	0.43	0.01	10.11	-1.03	-17.52	13.91	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.4	0.01	6.28	-0.01	-7.46	14.17	VERY LOW	0.4	0.01	6.28	-0.01	-7.46	14.17	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	VV116	NA	NA	NA	NA	NA	NA	NA	4.199E+09	0	5.948E+25	-312.97	-999.73	12.37	VERY LOW	4.199E+09	0	5.948E+25	-312.97	-999.73	12.37	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.56	0.27	1.28	-1.35	-3.38	0.58	VERY LOW	0.56	0.27	1.28	-1.35	-3.38	0.58	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
colchicine	doubase C	NA	NA	NA	NA	NA	NA	NA	838.17	0	5.916E+19	-168.86	-998.49	2.86	VERY LOW	838.17	0	5.916E+19	-168.86	-998.49	2.86	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.16	0.02	0.91	-16.23	-79.54	0.01	VERY LOW	0.16	0.02	0.91	-16.23	-79.54	0.01	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.981E+11	23.35	2.2E+65	1.79	0.91	3	VERY LOW	3.981E+11	23.35	2.2E+65	1.79	0.91	3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.01	0	93716.54	-146.19	-998.32	2.83	VERY LOW	0.01	0	93716.54	-146.19	-998.32	2.83	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.15	0.02	0.76	-17.32	-74.85	-0.67	VERY LOW	0.15	0.02	0.76	-17.32	-74.85	-0.67	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.86	0.32	2.21	-0.43	-3.08	1.42	LOW	0.86	0.32	2.21	-0.43	-3.08	1.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.49	-836.27	-998.95	-2.22	VERY LOW	0	0	1.49	-836.27	-998.95	-2.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.55	0.28	1.1	-1.34	-3.02	0.3	LOW	0.55	0.28	1.1	-1.34	-3.02	0.3	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	220798262	-214.55	-998.24	2.73	VERY LOW	0	0	220798262	-214.55	-998.24	2.73	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	6.025E+10	0	1.879E+26	-98.16	-998.38	2.92	VERY LOW	6.025E+10	0	1.879E+26	-98.16	-998.38	2.92	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	792.5	0	140005183	-149.57	-998.41	2.8	VERY LOW	792.5	0	140005183	-149.57	-998.41	2.8	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.21	-868.69	-998.98	-17.8	VERY LOW	0	0	0.21	-868.69	-998.98	-17.8	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
colchicine	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	0.92	0.1	8.77	-1.27	-11.22	2.07	VERY LOW	0.92	0.1	8.77	-1.27	-11.22	2.07	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
colchicine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.86	0.3	2.45	-0.49	-3.44	1.47	LOW	0.86	0.3	2.45	-0.49	-3.44	1.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.77	0.31	138.98	0.56	-4.06	2.5	VERY LOW	2.77	0.31	138.98	0.56	-4.06	2.5	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.85	0.36	1.98	-0.38	-2.39	1.3	LOW	0.85	0.36	1.98	-0.38	-2.39	1.3	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.77	0.37	1.57	-0.5	-2.07	1.02	LOW	0.77	0.37	1.57	-0.5	-2.07	1.02	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.81	0.32	2.06	-0.53	-2.91	1.28	LOW	0.81	0.32	2.06	-0.53	-2.91	1.28	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.45	0.2	0.89	-2.3	-5.18	-0.33	LOW	0.45	0.2	0.89	-2.3	-5.18	-0.33	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.7	0.82	10.28	1.04	-0.27	2.4	LOW	2.7	0.82	10.28	1.04	-0.27	2.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.6	0.08	3.86	-3.01	-17.8	1.63	VERY LOW	0.6	0.08	3.86	-3.01	-17.8	1.63	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
colchicine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.6	0.81	9.29	1.06	-0.28	2.41	LOW	2.6	0.81	9.29	1.06	-0.28	2.41	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.8	0.25	2.41	-0.77	-4.18	1.36	LOW	0.8	0.25	2.41	-0.77	-4.18	1.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.05	0.58	8.58	0.82	-1.02	2.3	LOW	2.05	0.58	8.58	0.82	-1.02	2.3	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.78	0.35	1.7	-0.48	-2.29	1.1	LOW	0.78	0.35	1.7	-0.48	-2.29	1.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.05	-845.19	-998.97	-0.98	VERY LOW	0	0	0.05	-845.19	-998.97	-0.98	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	statins	NA	NA	NA	NA	NA	NA	NA	0.46	0.13	1.72	-2.59	-9.67	0.91	VERY LOW	0.46	0.13	1.72	-2.59	-9.67	0.91	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.73	0.25	2.02	-0.95	-4.16	1.1	VERY LOW	0.73	0.25	2.02	-0.95	-4.16	1.1	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
colchicine	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.58	0.08	4.16	-2.98	-17.83	1.68	VERY LOW	0.58	0.08	4.16	-2.98	-17.83	1.68	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
colchicine	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.54	0.17	1.58	-1.96	-7.14	0.94	VERY LOW	0.54	0.17	1.58	-1.96	-7.14	0.94	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	VV116	NA	NA	NA	NA	NA	NA	NA	7.811E+09	0	1.368E+26	-314.92	-998.71	2.78	VERY LOW	7.811E+09	0	1.368E+26	-314.92	-998.71	2.78	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
corticosteroids (systemic)	doubase C	NA	NA	NA	NA	NA	NA	NA	1522.7	0	1.057E+20	-167.51	-997.38	4.83	VERY LOW	1522.7	0	1.057E+20	-167.51	-997.38	4.83	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.29	0.04	1.59	-14.87	-78.02	1.57	VERY LOW	0.29	0.04	1.59	-14.87	-78.02	1.57	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	7.114E+11	38.67	4.114E+65	3.14	1.47	4.98	VERY LOW	7.114E+11	38.67	4.114E+65	3.14	1.47	4.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.02	0	153606.59	-144.84	-997.16	4.77	VERY LOW	0.02	0	153606.59	-144.84	-997.16	4.77	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.27	0.04	1.23	-15.96	-73.42	0.82	VERY LOW	0.27	0.04	1.23	-15.96	-73.42	0.82	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.56	0.53	3.81	0.92	-2.12	3.24	VERY LOW	1.56	0.53	3.81	0.92	-2.12	3.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	2.62	-834.91	-998.26	-0.85	VERY LOW	0	0	2.62	-834.91	-998.26	-0.85	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1	0.48	1.83	0.01	-2.11	2.14	VERY LOW	1	0.48	1.83	0.01	-2.11	2.14	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	382389393	-213.2	-996.99	4.67	VERY LOW	0	0	382389393	-213.2	-996.99	4.67	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.124E+11	0	3.089E+26	-96.8	-997.09	4.87	VERY LOW	1.124E+11	0	3.089E+26	-96.8	-997.09	4.87	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1364.51	0	254026716	-148.21	-997.29	4.7	VERY LOW	1364.51	0	254026716	-148.21	-997.29	4.7	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.36	-867.34	-998.38	-16.42	VERY LOW	0	0	0.36	-867.34	-998.38	-16.42	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
corticosteroids (systemic)	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1.64	0.18	14.91	0.08	-9.97	3.84	VERY LOW	1.64	0.18	14.91	0.08	-9.97	3.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.54	0.51	4.16	0.87	-2.36	3.28	VERY LOW	1.54	0.51	4.16	0.87	-2.36	3.28	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	4.95	0.53	254.68	1.91	-2.89	4.43	VERY LOW	4.95	0.53	254.68	1.91	-2.89	4.43	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.52	0.6	3.36	0.97	-1.46	3.16	VERY LOW	1.52	0.6	3.36	0.97	-1.46	3.16	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.4	0.62	2.64	0.85	-1.22	2.93	VERY LOW	1.4	0.62	2.64	0.85	-1.22	2.93	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.47	0.55	3.45	0.83	-1.87	3.12	VERY LOW	1.47	0.55	3.45	0.83	-1.87	3.12	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.82	0.32	1.49	-0.95	-4.32	1.47	VERY LOW	0.82	0.32	1.49	-0.95	-4.32	1.47	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	4.79	1.44	18.35	2.39	0.53	4.34	VERY LOW	4.79	1.44	18.35	2.39	0.53	4.34	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.06	0.15	6.75	-1.65	-16.47	3.34	VERY LOW	1.06	0.15	6.75	-1.65	-16.47	3.34	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
corticosteroids (systemic)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.65	1.42	16.25	2.41	0.5	4.35	VERY LOW	4.65	1.42	16.25	2.41	0.5	4.35	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.43	0.42	4.18	0.59	-3.08	3.21	VERY LOW	1.43	0.42	4.18	0.59	-3.08	3.21	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	3.68	1	14.79	2.18	-0.12	4.21	VERY LOW	3.68	1	14.79	2.18	-0.12	4.21	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.41	0.59	2.87	0.88	-1.44	2.99	VERY LOW	1.41	0.59	2.87	0.88	-1.44	2.99	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.08	-843.84	-998.33	0.08	VERY LOW	0	0	0.08	-843.84	-998.33	0.08	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	0.83	0.22	2.93	-1.24	-8.43	2.63	VERY LOW	0.83	0.22	2.93	-1.24	-8.43	2.63	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
corticosteroids (systemic)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.31	0.41	3.43	0.41	-3.22	2.96	VERY LOW	1.31	0.41	3.43	0.41	-3.22	2.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.03	0.14	7.12	-1.63	-16.6	3.44	VERY LOW	1.03	0.14	7.12	-1.63	-16.6	3.44	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
corticosteroids (systemic)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.95	0.3	2.7	-0.6	-5.9	2.62	VERY LOW	0.95	0.3	2.7	-0.6	-5.9	2.62	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
corticosteroids (systemic)	VV116	NA	NA	NA	NA	NA	NA	NA	1.456E+10	0	2.49E+26	-313.56	-997.72	4.69	VERY LOW	1.456E+10	0	2.49E+26	-313.56	-997.72	4.69	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
doubase C	doxycycline	NA	NA	NA	NA	NA	NA	NA	0	0	3.05E+09	152.64	-68.67	994.33	VERY LOW	0	0	3.05E+09	152.64	-68.67	994.33	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

MORTALITY																											
Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
doubase C	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	3.063E+11	0	1.629E+52	170.65	-0.06	1000	VERY LOW	3.063E+11	0	1.629E+52	170.65	-0.06	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0	0	2.201E+11	22.67	-999.98	998.13	VERY LOW	0	0	2.201E+11	22.67	-999.98	998.13	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	favipiravir	NA	NA	NA	NA	NA	NA	NA	0	0	2.033E+09	151.55	-75.79	993.63	VERY LOW	0	0	2.033E+09	151.55	-75.79	993.63	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0	0	1.682E+10	168.43	-4.39	998.34	VERY LOW	0	0	1.682E+10	168.43	-4.39	998.34	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	564880.79	-667.4	-1000	669.09	VERY LOW	0	0	564880.79	-667.4	-1000	669.09	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	9.419E+09	167.52	-4.44	997.25	VERY LOW	0	0	9.419E+09	167.52	-4.44	997.25	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	3.56E+11	-45.69	-999.36	999.96	VERY LOW	0	0	3.56E+11	-45.69	-999.36	999.96	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	9014094.8	0	1.779E+26	70.71	-1000	1000	VERY LOW	9014094.8	0	1.779E+26	70.71	-1000	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.65	0	4.926E+12	19.3	-999.99	999.91	VERY LOW	0.65	0	4.926E+12	19.3	-999.99	999.91	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	4157.38	-699.83	-1000	0	VERY LOW	0	0	4157.38	-699.83	-1000	0	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doubase C	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	0	0	1.711E+10	167.59	-11.03	998.91	VERY LOW	0	0	1.711E+10	167.59	-11.03	998.91	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doubase C	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	1.56E+10	168.38	-4.8	998.39	VERY LOW	0	0	1.56E+10	168.38	-4.8	998.39	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	5.754E+10	169.42	-5.3	999.71	VERY LOW	0	0	5.754E+10	169.42	-5.3	999.71	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	1.422E+10	168.48	-3.79	998.24	VERY LOW	0	0	1.422E+10	168.48	-3.79	998.24	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	ivermectin	NA	NA	NA	NA	NA	NA	NA	0	0	1.316E+10	168.36	-3.44	998.01	VERY LOW	0	0	1.316E+10	168.36	-3.44	998.01	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	1.389E+10	168.33	-4.37	998.21	VERY LOW	0	0	1.389E+10	168.33	-4.37	998.21	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	7.65E+09	166.56	-6.41	996.52	VERY LOW	0	0	7.65E+09	166.56	-6.41	996.52	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0	0	5.009E+10	169.9	-1.7	999.44	VERY LOW	0	0	5.009E+10	169.9	-1.7	999.44	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	niclosamide	NA	NA	NA	NA	NA	NA	NA	0	0	9.917E+09	165.86	-16.22	998.14	VERY LOW	0	0	9.917E+09	165.86	-16.22	998.14	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doubase C	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	4.668E+10	169.92	-1.7	999.49	VERY LOW	0	0	4.668E+10	169.92	-1.7	999.49	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	1.452E+10	168.1	-5.47	998.29	VERY LOW	0	0	1.452E+10	168.1	-5.47	998.29	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0	0	3.426E+10	169.68	-2.43	999.39	VERY LOW	0	0	3.426E+10	169.68	-2.43	999.39	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	remdesivir	NA	NA	NA	NA	NA	NA	NA	0	0	1.353E+10	168.38	-3.71	998.09	VERY LOW	0	0	1.353E+10	168.38	-3.71	998.09	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	4222.83	-676.33	-1000	842.28	VERY LOW	0	0	4222.83	-676.33	-1000	842.28	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doubase C	statins	NA	NA	NA	NA	NA	NA	NA	0	0	8.174E+09	166.27	-10.64	997.46	VERY LOW	0	0	8.174E+09	166.27	-10.64	997.46	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doubase C	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	1.385E+10	167.91	-5.44	998	VERY LOW	0	0	1.385E+10	167.91	-5.44	998	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
doubase C	umifenovir	NA	NA	NA	NA	NA	NA	NA	0	0	1.213E+10	165.88	-16.99	998.29	VERY LOW	0	0	1.213E+10	165.88	-16.99	998.29	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doubase C	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0	9.561E+09	166.91	-8.27	997.52	VERY LOW	0	0	9.561E+09	166.91	-8.27	997.52	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doubase C	VV116	NA	NA	NA	NA	NA	NA	NA	122841.48	0	1.386E+30	-146.05	-1000	1000	VERY LOW	122841.48	0	1.386E+30	-146.05	-1000	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	2.524E+12	127.05	1.16E+66	18.02	1.83	81.28	VERY LOW	2.524E+12	127.05	1.16E+66	18.02	1.83	81.28	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0.05	0	598816.21	-129.96	-992.35	70.87	VERY LOW	0.05	0	598816.21	-129.96	-992.35	70.87	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.93	0.08	11.02	-1.09	-65.58	66.77	VERY LOW	0.93	0.08	11.02	-1.09	-65.58	66.77	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	5.31	0.85	43.81	15.79	-0.73	78.95	VERY LOW	5.31	0.85	43.81	15.79	-0.73	78.95	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	11.13	-820.04	-997.74	7.56	VERY LOW	0	0	11.13	-820.04	-997.74	7.56	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	3.37	0.64	25.71	14.89	-1.42	78.07	VERY LOW	3.37	0.64	25.71	14.89	-1.42	78.07	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	1.383E+09	-198.33	-993.18	65.03	VERY LOW	0	0	1.383E+09	-198.33	-993.18	65.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	3.662E+11	0	1.101E+27	-81.93	-992.61	74.84	VERY LOW	3.662E+11	0	1.101E+27	-81.93	-992.61	74.84	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	5284.48	0	1.119E+09	-133.34	-994.47	72.22	VERY LOW	5284.48	0	1.119E+09	-133.34	-994.47	72.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	1.83	-852.46	-997.86	-7.61	VERY LOW	0	0	1.83	-852.46	-997.86	-7.61	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	5.93	0.36	95.69	14.96	-5.32	78.76	VERY LOW	5.93	0.36	95.69	14.96	-5.32	78.76	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	5.22	0.82	45.98	15.74	-0.92	79	VERY LOW	5.22	0.82	45.98	15.74	-0.92	79	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	18.17	1.19	1164.08	16.78	-0.16	80.03	VERY LOW	18.17	1.19	1164.08	16.78	-0.16	80.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5.16	0.9	42.95	15.85	-0.57	79.2	VERY LOW	5.16	0.9	42.95	15.85	-0.57	79.2	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	ivermectin	NA	NA	NA	NA	NA	NA	NA	4.71	0.88	36.08	15.73	-0.54	78.96	VERY LOW	4.71	0.88	36.08	15.73	-0.54	78.96	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	5	0.83	40.87	15.7	-0.78	78.96	VERY LOW	5	0.83	40.87	15.7	-0.78	78.96	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.71	0.49	20.57	13.93	-2.7	77.09	VERY LOW	2.71	0.49	20.57	13.93	-2.7	77.09	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	molnupiravir	NA	NA	NA	NA	NA	NA	NA	16.99	2.32	153.44	17.27	1.04	80.54	VERY LOW	16.99	2.32	153.44	17.27	1.04	80.54	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	niclosamide	NA	NA	NA	NA	NA	NA	NA	3.66	0.3	52.69	13.22	-10.63	76.98	VERY LOW	3.66	0.3	52.69	13.22	-10.63	76.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	16.16	2.33	160.5	17.29	1.03	80.63	VERY LOW	16.16	2.33	160.5	17.29	1.03	80.63	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4.89	0.71	40.69	15.46	-1.38	78.74	VERY LOW	4.89	0.71	40.69	15.46	-1.38	78.74	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	12.75	1.66	136.78	17.05	0.72	80.31	VERY LOW	12.75	1.66	136.78	17.05	0.72	80.31	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	remdesivir	NA	NA	NA	NA	NA	NA	NA	4.77	0.86	37.58	15.75	-0.64	79.06	VERY LOW	4.77	0.86	37.58	15.75	-0.64	79.06	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.38	-828.96	-997.8	8.51	VERY LOW	0	0	0.38	-828.96	-997.8	8.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	statins	NA	NA	NA	NA	NA	NA	NA	2.88	0.39	26.17	13.63	-4.98	76.82	VERY LOW	2.88	0.39	26.17	13.63	-4.98	76.82	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4.41	0.7	36.78	15.28	-1.51	78.44	VERY LOW	4.41	0.7	36.78	15.28	-1.51	78.44	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
doxycycline	umifenovir	NA	NA	NA	NA	NA	NA	NA	3.62	0.3	54.12	13.25	-10.75	76.89	VERY LOW	3.62	0.3	54.12	13.25	-10.75	76.89	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	vitamin D	NA	NA	NA	NA	NA	NA	NA	3.29	0.47	29.39	14.27	-3.49	77.82	VERY LOW	3.29	0.47	29.39	14.27	-3.49	77.82	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	VV116	NA	NA	NA	NA	NA	NA	NA	4.811E+10	0	9.97E+26	-298.69	-996.38	59.12	VERY LOW	4.811E+10	0	9.97E+26	-298.69	-996.38	59.12	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	ensitrelvir	NA	NA	NA	NA	NA	NA	NA	0	0	4.42	-147.98	-999.99	0.06	VERY LOW	0	0	4.42	-147.98	-999.99	0.06	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0	0	0.01	-19.11	-76.63	-2.57	VERY LOW	0	0	0.01	-19.11	-76.63	-2.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-2.22	-4.71	-0.85	VERY LOW	0	0	0.04	-2.22	-4.71	-0.85	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	0	-838.05	-1000	-3.96	VERY LOW	0	0	0	-838.05	-1000	-3.96	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-3.13	-4.59	-1.91	VERY LOW	0	0	0.03	-3.13	-4.59	-1.91	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	496.32	-216.34	-999.99	0	VERY LOW	0	0	496.32	-216.34	-999.99	0	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0	0	6.11E+17	-99.95	-1000	0.03	VERY LOW	0	0	6.11E+17	-99.95	-1000	0.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	649.78	-151.36	-1000	0.02	VERY LOW	0	0	649.78	-151.36	-1000	0.02	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0	-870.48	-1000	-19.55	VERY LOW	0	0	0	-870.48	-1000	-19.55	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-3.06	-13.03	-0.17	VERY LOW	0	0	0.03	-3.06	-13.03	-0.17	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-2.28	-5.12	-0.75	VERY LOW	0	0	0.04	-2.28	-5.12	-0.75	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.17	-1.23	-5.84	-0.02	VERY LOW	0	0	0.17	-1.23	-5.84	-0.02	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-2.17	-3.98	-1	VERY LOW	0	0	0.04	-2.17	-3.98	-1	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-2.29	-3.59	-1.31	VERY LOW	0	0	0.03	-2.29	-3.59	-1.31	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-2.32	-4.52	-0.95	VERY LOW	0	0	0.03	-2.32	-4.52	-0.95	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-4.09	-6.8	-2.46	VERY LOW	0	0	0.02	-4.09	-6.8	-2.46	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0	0	0.11	-0.75	-1.8	-0.19	VERY LOW	0	0	0.11	-0.75	-1.8	-0.19	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	niclosamide	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-4.79	-19.54	-0.45	VERY LOW	0	0	0.03	-4.79	-19.54	-0.45	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	0.12	-0.73	-1.85	-0.17	VERY LOW	0	0	0.12	-0.73	-1.85	-0.17	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-2.56	-5.88	-0.82	VERY LOW	0	0	0.04	-2.56	-5.88	-0.82	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0	0	0.09	-0.97	-2.6	-0.19	VERY LOW	0	0	0.09	-0.97	-2.6	-0.19	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

MORTALITY																											
Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
doxycycline, ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-2.27	-3.86	-1.18	VERY LOW	0	0	0.04	-2.27	-3.86	-1.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0	-846.98	-1000	-2.85	VERY LOW	0	0	0	-846.98	-1000	-2.85	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline, ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-4.38	-11.36	-1.15	VERY LOW	0	0	0.02	-4.38	-11.36	-1.15	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	0.03	-2.74	-5.8	-1.06	VERY LOW	0	0	0.03	-2.74	-5.8	-1.06	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
doxycycline, ivermectin	umifenovir	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-4.77	-19.58	-0.37	VERY LOW	0	0	0.02	-4.77	-19.58	-0.37	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-3.75	-8.84	-1.19	VERY LOW	0	0	0.02	-3.75	-8.84	-1.19	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline, ivermectin	VV116	NA	NA	NA	NA	NA	NA	NA	0	0	3.5E+20	-316.71	-1000	0.02	VERY LOW	0	0	3.5E+20	-316.71	-1000	0.02	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	favipiravir	NA	NA	NA	NA	NA	NA	NA	13.33	0	7.094E+16	128.87	-72.9	991.19	VERY LOW	13.33	0	7.094E+16	128.87	-72.9	991.19	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	102.35	0	4.499E+17	145.76	-4.36	998.13	VERY LOW	102.35	0	4.499E+17	145.76	-4.36	998.13	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.01	0	7.606E+11	-690.07	-1000	387.62	VERY LOW	0.01	0	7.606E+11	-690.07	-1000	387.62	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	62.54	0	2.992E+17	144.85	-4.43	997.11	VERY LOW	62.54	0	2.992E+17	144.85	-4.43	997.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0.47	0	9.721E+11	-68.36	-999.97	999.92	VERY LOW	0.47	0	9.721E+11	-68.36	-999.97	999.92	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	6.558E+13	0	6.044E+35	48.03	-1000	999.98	VERY LOW	6.558E+13	0	6.044E+35	48.03	-1000	999.98	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	831868.79	0	1.39E+19	-3.38	-999.99	999.81	VERY LOW	831868.79	0	1.39E+19	-3.38	-999.99	999.81	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	9.381E+09	-722.5	-1000	0	VERY LOW	0	0	9.381E+09	-722.5	-1000	0	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ensitrelvir	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	106.11	0	6.611E+17	144.92	-11.1	998.65	VERY LOW	106.11	0	6.611E+17	144.92	-11.1	998.65	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ensitrelvir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	91.72	0	4.258E+17	145.7	-4.75	998.16	VERY LOW	91.72	0	4.258E+17	145.7	-4.75	998.16	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	460.6	0	2.776E+18	146.75	-5.17	999.45	VERY LOW	460.6	0	2.776E+18	146.75	-5.17	999.45	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	93.45	0	4.064E+17	145.81	-3.76	998.09	VERY LOW	93.45	0	4.064E+17	145.81	-3.76	998.09	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	ivermectin	NA	NA	NA	NA	NA	NA	NA	86.08	0	3.611E+17	145.69	-3.44	997.9	VERY LOW	86.08	0	3.611E+17	145.69	-3.44	997.9	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	95.55	0	3.858E+17	145.66	-4.2	997.97	VERY LOW	95.55	0	3.858E+17	145.66	-4.2	997.97	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	51.28	0	2.067E+17	143.89	-6.38	996.23	VERY LOW	51.28	0	2.067E+17	143.89	-6.38	996.23	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	289.91	0	1.298E+18	147.23	-1.68	999.36	VERY LOW	289.91	0	1.298E+18	147.23	-1.68	999.36	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	niclosamide	NA	NA	NA	NA	NA	NA	NA	68.9	0	2.833E+17	143.19	-17.35	997.82	VERY LOW	68.9	0	2.833E+17	143.19	-17.35	997.82	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ensitrelvir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	301.26	0	1.573E+18	147.25	-1.68	999.4	VERY LOW	301.26	0	1.573E+18	147.25	-1.68	999.4	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	89.03	0	2.779E+17	145.42	-5.44	997.99	VERY LOW	89.03	0	2.779E+17	145.42	-5.44	997.99	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	241.79	0	1.138E+18	147.01	-2.37	999.18	VERY LOW	241.79	0	1.138E+18	147.01	-2.37	999.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	remdesivir	NA	NA	NA	NA	NA	NA	NA	89.74	0	3.787E+17	145.71	-3.64	997.89	VERY LOW	89.74	0	3.787E+17	145.71	-3.64	997.89	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	4.084E+10	-699	-1000	0	VERY LOW	0	0	4.084E+10	-699	-1000	0	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ensitrelvir	statins	NA	NA	NA	NA	NA	NA	NA	51.04	0	2.612E+17	143.6	-10.38	996.69	VERY LOW	51.04	0	2.612E+17	143.6	-10.38	996.69	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ensitrelvir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	88.26	0	3.099E+17	145.24	-5.39	997.71	VERY LOW	88.26	0	3.099E+17	145.24	-5.39	997.71	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
ensitrelvir	umifenovir	NA	NA	NA	NA	NA	NA	NA	66.46	0	2.956E+17	143.21	-16.63	997.25	VERY LOW	66.46	0	2.956E+17	143.21	-16.63	997.25	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ensitrelvir	vitamin D	NA	NA	NA	NA	NA	NA	NA	60.41	0	2.194E+17	144.24	-8.16	997.25	VERY LOW	60.41	0	2.194E+17	144.24	-8.16	997.25	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ensitrelvir	VV116	NA	NA	NA	NA	NA	NA	NA	1.811E+11	0	3.42E+31	-168.73	-1000	999.99		1.811E+11	0	3.42E+31	-168.73	-1000	999.99	Indirect		Not serious	Extremely serious		
favipiravir	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	5.63	1.11	39.35	16.88	-0.05	74.35	VERY LOW	5.63	1.11	39.35	16.88	-0.05	74.35	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	11.93	-818.95	-996.87	14.18	VERY LOW	0	0	11.93	-818.95	-996.87	14.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	favipiravir	0.35	0.01	8.79	NA	NA	NA	VERY LOW	0.32	0.04	1.75	NA	NA	NA	VERY LOW	0.28	0.05	1.19	-15.98	-73.42	0.65	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	1.499E+09	-197.24	-991.25	63.42	VERY LOW	0	0	1.499E+09	-197.24	-991.25	63.42	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	4.002E+11	0	1.178E+27	-80.84	-992.85	75.1	VERY LOW	4.002E+11	0	1.178E+27	-80.84	-992.85	75.1	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	5552.7	0	812502866	-132.25	-992.32	65.68	VERY LOW	5552.7	0	812502866	-132.25	-992.32	65.68	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	1.7	-851.37	-997.1	0.6	VERY LOW	0	0	1.7	-851.37	-997.1	0.6	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	6.4	0.45	85.71	16.05	-3.89	73.62	VERY LOW	6.4	0.45	85.71	16.05	-3.89	73.62	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	5.55	1.02	39.82	16.83	-0.14	74.61	VERY LOW	5.55	1.02	39.82	16.83	-0.14	74.61	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	19.64	1.37	1062.84	17.87	1.03	75.68	VERY LOW	19.64	1.37	1062.84	17.87	1.03	75.68	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5.49	1.19	35.23	16.94	0.16	74.56	LOW	5.49	1.19	35.23	16.94	0.16	74.56	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA	NA	4.99	1.11	30.94	16.82	0.18	74.36	LOW	4.99	1.11	30.94	16.82	0.18	74.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	5.39	1.03	34.48	16.79	-0.04	74.19	VERY LOW	5.39	1.03	34.48	16.79	-0.04	74.19	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	lopinavir-ritonavir	1.02	0.02	52.41	NA	NA	NA	VERY LOW	3.27	0.71	20.17	NA	NA	NA	LOW	2.91	0.63	17.11	15.01	-1.9	72.52	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	17.78	3.21	148.97	18.36	1.78	75.87	VERY LOW	17.78	3.21	148.97	18.36	1.78	75.87	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	niclosamide	NA	NA	NA	NA	NA	NA	NA	3.8	0.37	44.82	14.31	-9.09	72.02	VERY LOW	3.8	0.37	44.82	14.31	-9.09	72.02	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	17.26	2.91	141	18.37	1.76	75.8	VERY LOW	17.26	2.91	141	18.37	1.76	75.8	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5.29	0.91	36.08	16.55	-0.74	74.29	VERY LOW	5.29	0.91	36.08	16.55	-0.74	74.29	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	13.69	2.19	114.38	18.14	1.47	75.71	VERY LOW	13.69	2.19	114.38	18.14	1.47	75.71	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	5.15	1.07	30.49	16.84	0.14	74.3	LOW	5.15	1.07	30.49	16.84	0.14	74.3	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.36	-827.87	-996.63	6.25	VERY LOW	0	0	0.36	-827.87	-996.63	6.25	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	statins	NA	NA	NA	NA	NA	NA	NA	3.08	0.47	24.31	14.72	-3.86	72.5	VERY LOW	3.08	0.47	24.31	14.72	-3.86	72.5	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4.86	0.86	31.02	16.37	-0.8	74.02	VERY LOW	4.86	0.86	31.02	16.37	-0.8	74.02	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
favipiravir	umifenovir	1.13	0.02	57.94	NA	NA	NA	VERY LOW	4.38	0.39	70.31	NA	NA	NA	VERY LOW	3.91	0.34	46.17	14.34	-8.5	71.68	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	3.56	0.53	24.7	15.36	-2.42	72.51	VERY LOW	3.56	0.53	24.7	15.36	-2.42	72.51	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	VV116	NA	NA	NA	NA	NA	NA	NA	5.69E+10	0	9.075E+26	-297.6	-995.68	59.72	VERY LOW	5.69E+10	0	9.075E+26	-297.6	-995.68	59.72	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.77	-835.83	-999	-1.94	VERY LOW	0	0	1.77	-835.83	-999	-1.94	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.64	0.27	1.62	-0.91	-2.91	1.88	LOW	0.64	0.27	1.62	-0.91	-2.91	1.88	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	251954733	-214.12	-998.01	4.22	VERY LOW	0	0	251954733	-214.12	-998.01	4.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	6.94E+10	0	2.208E+26	-97.72	-998.23	4.52	VERY LOW	6.94E+10	0	2.208E+26	-97.72	-998.23	4.52	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	934.26	0	170705430	-149.13	-998.36	4.3	VERY LOW	934.26	0	170705430	-149.13	-998.36	4.3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.25	-868.26	-999.04	-17.31	VERY LOW	0	0	0.25	-868.26	-999.04	-17.31	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1.07	0.1	11.07	-0.84	-10.91	3.37	VERY LOW	1.07	0.1	11.07	-0.84	-10.91	3.37	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.99	0.31	3.28	-0.05	-3.29	2.94	LOW	0.99	0.31	3.28	-0.05	-3.29	2.94	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	3.27	0.32	165.23	0.99	-3.77	4.05	VERY LOW	3.27	0.32	165.23	0.99	-3.77	4.05	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.98	0.35	2.78	0.05	-2.22	2.78	LOW	0.98	0.35	2.78	0.05	-2.22	2.78	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.9	0.36	2.25	-0.07	-1.98	2.56	LOW	0.9	0.36	2.25	-0.07	-1.98	2.56	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.94	0.32	2.87	-0.09	-2.7	2.73	LOW	0.94	0.32	2.87	-0.09	-2.7	2.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.52	0.2	1.29	-1.87	-4.89	1.02	LOW	0.52	0.2	1.29	-1.87	-4.89	1.02	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.1	0.87	13.67	1.47	-0.27	4.06	LOW	3.1	0.87	13.67	1.47	-0.27	4.06	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.68	0.09	5.01	-2.57	-17.27	2.76	VERY LOW	0.68	0.09	5.01	-2.57	-17.27	2.76	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.02	0.82	12.79	1.49	-0.26	4.08	LOW	3.02	0.82	12.79	1.49	-0.26	4.08	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.92	0.26	3.19	-0.33	-3.99	2.71	LOW	0.92	0.26	3.19	-0.33	-3.99	2.71	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.39	0.6	11.22	1.26	-0.88	3.85	LOW	2.39	0.6	11.22	1.26	-0.88	3.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.91	0.34	2.41	-0.04	-2.16	2.64	LOW	0.91	0.34	2.41	-0.04	-2.16	2.64	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2

MORTALITY																												
Comparison		Direct estimate							Indirect estimate							Network estimate												
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					GRADE			
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
fluvoxamine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-844.76	-999.05	-0.72	VERY LOW	0	0	0.06	-844.76	-999.05	-0.72	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	statins	NA	NA	NA	NA	NA	NA	NA	0.54	0.13	2.23	-2.16	-9.27	1.99	VERY LOW	0.54	0.13	2.23	-2.16	-9.27	1.99	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.84	0.25	2.61	-0.51	-3.86	2.39	VERY LOW	0.84	0.25	2.61	-0.51	-3.86	2.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
fluvoxamine	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.67	0.09	5.4	-2.55	-17.44	2.9	VERY LOW	0.67	0.09	5.4	-2.55	-17.44	2.9	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.62	0.18	2.14	-1.52	-6.85	2.11	VERY LOW	0.62	0.18	2.14	-1.52	-6.85	2.11	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	VVI16	NA	NA	NA	NA	NA	NA	NA	9.524E+09	0	1.614E+26	-314.48	-998.73	4.22	VERY LOW	9.524E+09	0	1.614E+26	-314.48	-998.73	4.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	3466.57	0.38	1.82E+17	834.92	0.97	997.87	VERY LOW	3466.57	0.38	1.82E+17	834.92	0.97	997.87	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	1.11	0	6.917E+16	621.71	-542.24	1000	VERY LOW	1.11	0	6.917E+16	621.71	-542.24	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	9.715E+15	0	4.09E+39	738.11	-1.5	1000	VERY LOW	9.715E+15	0	4.09E+39	738.11	-1.5	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	28172588	0	1.621E+20	686.7	-26.94	1000	VERY LOW	28172588	0	1.621E+20	686.7	-26.94	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.01	0	3.289E+10	-32.42	-992.11	967.01	VERY LOW	0.01	0	3.289E+10	-32.42	-992.11	967.01	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	5647.68	0.61	4.534E+17	834.99	1.47	999.74	VERY LOW	5647.68	0.61	4.534E+17	834.99	1.47	999.74	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	5273.03	0.57	2.567E+17	835.78	1.7	999.08	VERY LOW	5273.03	0.57	2.567E+17	835.78	1.7	999.08	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	22327.63	1.94	7.691E+17	836.82	2.94	999.96	VERY LOW	22327.63	1.94	7.691E+17	836.82	2.94	999.96	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	5262.91	0.59	3.055E+17	835.89	1.83	998.84	VERY LOW	5262.91	0.59	3.055E+17	835.89	1.83	998.84	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	4792.18	0.52	2.743E+17	835.77	1.7	998.54	VERY LOW	4792.18	0.52	2.743E+17	835.77	1.7	998.54	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	5315.54	0.62	3.063E+17	835.74	1.62	998.88	VERY LOW	5315.54	0.62	3.063E+17	835.74	1.62	998.88	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2758.44	0.32	1.225E+17	833.96	0.08	997.34	VERY LOW	2758.44	0.32	1.225E+17	833.96	0.08	997.34	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	18346.24	1.57	6.733E+17	837.31	3.22	999.74	VERY LOW	18346.24	1.57	6.733E+17	837.31	3.22	999.74	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	niclosamide	NA	NA	NA	NA	NA	NA	NA	4511.3	0.35	1.366E+17	833.26	0.07	999.38	VERY LOW	4511.3	0.35	1.366E+17	833.26	0.07	999.38	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	15985.06	1.76	1.044E+18	837.32	3.31	999.76	VERY LOW	15985.06	1.76	1.044E+18	837.32	3.31	999.76	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4949.19	0.53	1.565E+17	835.5	1.51	999.03	VERY LOW	4949.19	0.53	1.565E+17	835.5	1.51	999.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	15171.29	1.41	7.495E+17	837.09	3.05	999.74	VERY LOW	15171.29	1.41	7.495E+17	837.09	3.05	999.74	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	4725.41	0.58	2.359E+17	835.79	1.76	998.64	VERY LOW	4725.41	0.58	2.359E+17	835.79	1.76	998.64	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	2.42E+10	-8.92	-993.36	994.01	VERY LOW	0	0	2.42E+10	-8.92	-993.36	994.01	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	statins	NA	NA	NA	NA	NA	NA	NA	3062.91	0.35	1.308E+17	833.67	0	998.64	VERY LOW	3062.91	0.35	1.308E+17	833.67	0	998.64	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4659.48	0.53	1.716E+17	835.32	1.41	998.75	VERY LOW	4659.48	0.53	1.716E+17	835.32	1.41	998.75	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
fluvoxamine, inhaled corticosteroids	umifenovir	NA	NA	NA	NA	NA	NA	NA	3610.42	0.33	1.607E+17	833.28	0.64	999.43	VERY LOW	3610.42	0.33	1.607E+17	833.28	0.64	999.43	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA	NA	3283.52	0.38	1.56E+17	834.31	0.29	998.59	VERY LOW	3283.52	0.38	1.56E+17	834.31	0.29	998.59	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	VVI16	NA	NA	NA	NA	NA	NA	NA	2.275E+17	0	4.754E+32	521.35	-729.91	1000	VERY LOW	2.275E+17	0	4.754E+32	521.35	-729.91	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	IL6 receptor antagonists	NA	NA	NA	NA	NA	NA	NA	0	0	419603175	-213.21	-996.9	4.34	VERY LOW	0	0	419603175	-213.21	-996.9	4.34	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	1.119E+11	0	3.244E+26	-96.82	-997.13	4.51	VERY LOW	1.119E+11	0	3.244E+26	-96.82	-997.13	4.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1421.22	0	237621588	-148.23	-997.14	4.33	VERY LOW	1421.22	0	237621588	-148.23	-997.14	4.33	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.38	-867.35	-997.94	-16.37	VERY LOW	0	0	0.38	-867.35	-997.94	-16.37	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1.65	0.18	14.7	0.07	-9.91	3.61	VERY LOW	1.65	0.18	14.7	0.07	-9.91	3.61	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.54	0.58	4.07	0.85	-2.18	3.02	LOW	1.54	0.58	4.07	0.85	-2.18	3.02	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	4.97	0.58	247.12	1.9	-2.8	4.11	VERY LOW	4.97	0.58	247.12	1.9	-2.8	4.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.53	0.71	3.2	0.96	-1.2	2.85	LOW	1.53	0.71	3.2	0.96	-1.2	2.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.4	0.74	2.51	0.84	-0.89	2.54	LOW	1.4	0.74	2.51	0.84	-0.89	2.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.47	0.62	3.39	0.81	-1.66	2.83	LOW	1.47	0.62	3.39	0.81	-1.66	2.83	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	lopinavir-ritonavir	0.23	0.01	4.79	NA	NA	NA	VERY LOW	0.86	0.42	1.54	NA	NA	NA	LOW	0.81	0.4	1.43	-0.96	-3.98	1.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	4.84	1.64	17.23	2.38	0.85	3.99	LOW	4.84	1.64	17.23	2.38	0.85	3.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.07	0.16	6.7	-1.66	-16.36	3.13	VERY LOW	1.07	0.16	6.7	-1.66	-16.36	3.13	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.68	1.57	16.12	2.4	0.85	3.96	LOW	4.68	1.57	16.12	2.4	0.85	3.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.44	0.48	4.11	0.57	-2.91	2.92	LOW	1.44	0.48	4.11	0.57	-2.91	2.92	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	3.7	1.11	14.98	2.16	0.18	3.86	LOW	3.7	1.11	14.98	2.16	0.18	3.86	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.41	0.7	2.74	0.86	-1.13	2.67	LOW	1.41	0.7	2.74	0.86	-1.13	2.67	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.08	-843.85	-997.92	0.18	VERY LOW	0	0	0.08	-843.85	-997.92	0.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	statins	NA	NA	NA	NA	NA	NA	NA	0.84	0.25	2.87	-1.25	-8.35	2.34	VERY LOW	0.84	0.25	2.87	-1.25	-8.35	2.34	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.31	0.49	3.32	0.39	-2.95	2.68	VERY LOW	1.31	0.49	3.32	0.39	-2.95	2.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
(hydroxy)chloroquine	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.04	0.15	7.14	-1.64	-16.59	3.17	VERY LOW	1.04	0.15	7.14	-1.64	-16.59	3.17	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.97	0.33	2.6	-0.62	-5.83	2.41	VERY LOW	0.97	0.33	2.6	-0.62	-5.83	2.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	VVI16	NA	NA	NA	NA	NA	NA	NA	1.485E+10	0	2.277E+26	-313.58	-997.53	4.33	VERY LOW	1.485E+10	0	2.277E+26	-313.58	-997.53	4.33	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	3.009E+15	0	4.89E+31	116.4	-999.59	999.98	VERY LOW	3.009E+15	0	4.89E+31	116.4	-999.59	999.98	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	45320499	0	1.794E+24	64.99	-999.22	999.32	VERY LOW	45320499	0	1.794E+24	64.99	-999.22	999.32	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	1.406E+17	-654.14	-1000	557.96	VERY LOW	0	0	1.406E+17	-654.14	-1000	557.96	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	8530.05	0	1.305E+20	213.28	-9.78	998.43	VERY LOW	8530.05	0	1.305E+20	213.28	-9.78	998.43	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	10132.06	0	1.161E+20	214.07	-4.5	997.95	VERY LOW	10132.06	0	1.161E+20	214.07	-4.5	997.95	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	40049.04	0	6.843E+20	215.11	-4.66	999.5	VERY LOW	40049.04	0	6.843E+20	215.11	-4.66	999.5	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	10071.95	0	1.047E+20	214.17	-3.6	997.99	VERY LOW	10071.95	0	1.047E+20	214.17	-3.6	997.99	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	ivermectin	NA	NA	NA	NA	NA	NA	NA	9272.42	0	9.963E+19	214.05	-3.37	997.73	VERY LOW	9272.42	0	9.963E+19	214.05	-3.37	997.73	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	9718.34	0	1.158E+20	214.03	-4.08	997.93	VERY LOW	9718.34	0	1.158E+20	214.03	-4.08	997.93	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5261.18	0	5.722E+19	212.25	-6.15	996.17	VERY LOW	5261.18	0	5.722E+19	212.25	-6.15	996.17	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	molnupiravir	NA	NA	NA	NA	NA	NA	NA	34289	0	2.888E+20	215.59	-1.59	999.23	VERY LOW	34289	0	2.888E+20	215.59	-1.59	999.23	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	niclosamide	NA	NA	NA	NA	NA	NA	NA	7521.04	0	7.17E+19	211.55	-15.82	997.34	VERY LOW	7521.04	0	7.17E+19	211.55	-15.82	997.34	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	31624.9	0	2.89E+20	215.61	-1.61	999.25	VERY LOW	31624.9	0	2.89E+20	215.61	-1.61	999.25	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	9630.59	0	9.276E+19	213.79	-5.25	997.99	VERY LOW	9630.59	0	9.276E+19	213.79	-5.25	997.99	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	23950.87	0	2.824E+20	215.38	-2.24	999.15	VERY LOW	23950.87	0	2.824E+20	215.38	-2.24	999.15	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	remdesivir	NA	NA	NA	NA	NA	NA	NA	9415.85	0	9.962E+19	214.07	-3.54	997.83	VERY LOW	9415.85	0	9.962E+19	214.07	-3.54	997.83	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	9.601E+10	-630.64	-1000	173.3	VERY LOW	0	0	9.601E+10	-630.64	-1000	173.3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
IL6 receptor antagonists	statins	NA	NA	NA	NA	NA	NA	NA	5338.66	0	6.192E+19	211.96	-10.07	996.65	VERY LOW	5338.66	0	6.192E+19	211.96	-10.07	996.65	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	9347.55	0	8.18E+19	213.61	-5.17	997.62	VERY LOW	9347.55	0	8.18E+19	213.61	-5.17	997.62	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
IL6 receptor antagonists	umifenovir	NA	NA	NA	NA	NA	NA	NA	7285.56	0	9.556E+19	211.57	-15.6	997.12	VERY LOW	7285.56	0	9.556E+19	211.57	-15.6	997.12	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists	vitamin D	NA	NA	NA	NA	NA	NA	NA	6121.3	0	6.784E+19	212.6	-7.97	997.23	VERY LOW	6121.3	0	6.784E+19	212.6	-7.97	997.23	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
IL6 receptor antagonists	VVI16	NA	NA	NA	NA	NA	NA	NA	2.623E+11	0	5.221E+38	-100.36	-999.98	997.58	VERY LOW	2.623E+11	0	5.221E+38	-100.36	-999.98	997.58	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.199E+27	-51.41	-1000	999.13	VERY LOW	0	0	1.199E+27	-51.41	-1000	999.13	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	5.27E+19	-770.53	-1000	193.85	VERY LOW	0	0	5.27E+19	-770.53	-1000	193.85	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	0	0	1.212E+22	96.89	-11.67	998.63	VERY LOW	0	0	1.212E+22	96.89	-11.67	998.63	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	8.118E+21	97.67	-4.92	998.26	VERY LOW	0	0	8.118E+21	97.67	-4.92	998.26	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

MORTALITY																											
Comparison		Direct estimate							Indirect estimate							Network estimate											
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
inhaled and intranasal corticosteroid	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	2.104E+22	98.71	-5.25	999.5	VERY LOW	0	0	2.104E+22	98.71	-5.25	999.5	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	7.925E+21	97.78	-3.86	998.13	VERY LOW	0	0	7.925E+21	97.78	-3.86	998.13	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	ivermectin	NA	NA	NA	NA	NA	NA	NA	0	0	7.381E+21	97.66	-3.53	998.03	VERY LOW	0	0	7.381E+21	97.66	-3.53	998.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	8.344E+21	97.63	-4.38	998.07	VERY LOW	0	0	8.344E+21	97.63	-4.38	998.07	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	4.141E+21	95.86	-6.62	996.41	VERY LOW	0	0	4.141E+21	95.86	-6.62	996.41	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0	0	2.38E+22	99.2	-1.73	999.41	VERY LOW	0	0	2.38E+22	99.2	-1.73	999.41	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	niclosamide	NA	NA	NA	NA	NA	NA	NA	0	0	4.777E+21	95.15	-18.55	997.98	VERY LOW	0	0	4.777E+21	95.15	-18.55	997.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	3.237E+22	99.22	-1.76	999.45	VERY LOW	0	0	3.237E+22	99.22	-1.76	999.45	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	8.102E+21	97.39	-5.65	997.94	VERY LOW	0	0	8.102E+21	97.39	-5.65	997.94	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0	0	2.37E+22	98.98	-2.47	999.29	VERY LOW	0	0	2.37E+22	98.98	-2.47	999.29	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	remdesivir	NA	NA	NA	NA	NA	NA	NA	0	0	7.382E+21	97.68	-3.78	998.04	VERY LOW	0	0	7.382E+21	97.68	-3.78	998.04	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	1.848E+14	-747.03	-1000	737.37	VERY LOW	0	0	1.848E+14	-747.03	-1000	737.37	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	statins	NA	NA	NA	NA	NA	NA	NA	0	0	4.613E+21	95.56	-10.86	997.01	VERY LOW	0	0	4.613E+21	95.56	-10.86	997.01	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	6.287E+21	97.21	-5.61	997.87	VERY LOW	0	0	6.287E+21	97.21	-5.61	997.87	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
inhaled and intranasal corticosteroid	umifenovir	NA	NA	NA	NA	NA	NA	NA	0	0	5.106E+21	95.18	-17.91	998.09	VERY LOW	0	0	5.106E+21	95.18	-17.91	998.09	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0	5.114E+21	96.2	-8.56	997.36	VERY LOW	0	0	5.114E+21	96.2	-8.56	997.36	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	VVI16	NA	NA	NA	NA	NA	NA	NA	35.83	0	5.592E+41	-216.76	-1000	644.37	VERY LOW	35.83	0	5.592E+41	-216.76	-1000	644.37	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	32911.91	-719.12	-1000	656.92	VERY LOW	0	0	32911.91	-719.12	-1000	656.92	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	0	0	610360302	148.29	-11.32	998.69	VERY LOW	0	0	610360302	148.29	-11.32	998.69	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	474015225	149.08	-4.61	998.34	VERY LOW	0	0	474015225	149.08	-4.61	998.34	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	2.642E+09	150.12	-5.02	999.62	VERY LOW	0	0	2.642E+09	150.12	-5.02	999.62	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	440358621	149.19	-3.65	998.14	VERY LOW	0	0	440358621	149.19	-3.65	998.14	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	0	0	395554842	149.07	-3.42	997.87	VERY LOW	0	0	395554842	149.07	-3.42	997.87	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	424320660	149.04	-4.11	998	VERY LOW	0	0	424320660	149.04	-4.11	998	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	243259662	147.26	-6.26	996.37	VERY LOW	0	0	243259662	147.26	-6.26	996.37	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0	0	1.439E+09	150.61	-1.6	999.45	VERY LOW	0	0	1.439E+09	150.61	-1.6	999.45	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	niclosamide	NA	NA	NA	NA	NA	NA	NA	0	0	336096877	146.56	-16.75	998.01	VERY LOW	0	0	336096877	146.56	-16.75	998.01	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	1.342E+09	150.62	-1.64	999.41	VERY LOW	0	0	1.342E+09	150.62	-1.64	999.41	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	394101875	148.8	-5.31	998.14	VERY LOW	0	0	394101875	148.8	-5.31	998.14	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0	0	1.118E+09	150.39	-2.3	999.35	VERY LOW	0	0	1.118E+09	150.39	-2.3	999.35	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	0	0	398544612	149.09	-3.61	998.01	VERY LOW	0	0	398544612	149.09	-3.61	998.01	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	869.94	-695.62	-1000	0	VERY LOW	0	0	869.94	-695.62	-1000	0	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	statins	NA	NA	NA	NA	NA	NA	NA	0	0	254240188	146.97	-10.27	997.09	VERY LOW	0	0	254240188	146.97	-10.27	997.09	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	322224801	148.62	-5.25	997.89	VERY LOW	0	0	322224801	148.62	-5.25	997.89	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
inhaled corticosteroids	umifenovir	NA	NA	NA	NA	NA	NA	NA	0	0	233910705	146.59	-17.71	997.95	VERY LOW	0	0	233910705	146.59	-17.71	997.95	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0	306001328	147.61	-8.05	997.44	VERY LOW	0	0	306001328	147.61	-8.05	997.44	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	VVI16	NA	NA	NA	NA	NA	NA	NA	3.678E+09	0	1.378E+31	-165.35	-999.67	957.7	VERY LOW	3.678E+09	0	1.378E+31	-165.35	-999.67	957.7	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
Interferon alpha	interferon beta (nebulised)	NA	NA	NA	NA	NA	NA	NA	1003064.1	3.88	4.584E+18	867.42	16.67	999.75	VERY LOW	1003064.1	3.88	4.584E+18	867.42	16.67	999.75	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	880953.39	3.88	3.942E+18	868.2	17.46	999.13	VERY LOW	880953.39	3.88	3.942E+18	868.2	17.46	999.13	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	5391585.2	13.12	1.705E+19	869.25	18.61	999.96	VERY LOW	5391585.2	13.12	1.705E+19	869.25	18.61	999.96	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	915952.7	3.98	3.841E+18	868.31	17.43	998.88	VERY LOW	915952.7	3.98	3.841E+18	868.31	17.43	998.88	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	ivermectin	NA	NA	NA	NA	NA	NA	NA	825190.87	3.68	3.854E+18	868.19	17.33	998.56	VERY LOW	825190.87	3.68	3.854E+18	868.19	17.33	998.56	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	829609.18	3.99	3.728E+18	868.16	17.55	998.94	VERY LOW	829609.18	3.99	3.728E+18	868.16	17.55	998.94	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	491069.04	2.13	2.023E+18	866.39	15.58	997.38	VERY LOW	491069.04	2.13	2.023E+18	866.39	15.58	997.38	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2702668	10.65	1.264E+19	869.73	18.78	999.75	VERY LOW	2702668	10.65	1.264E+19	869.73	18.78	999.75	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	niclosamide	NA	NA	NA	NA	NA	NA	NA	590196.02	1.83	3.242E+18	865.68	14.68	999.43	VERY LOW	590196.02	1.83	3.242E+18	865.68	14.68	999.43	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3060013.9	12.53	1.225E+19	869.75	18.87	999.78	VERY LOW	3060013.9	12.53	1.225E+19	869.75	18.87	999.78	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	899801.98	3.82	3.462E+18	867.92	16.99	999.08	VERY LOW	899801.98	3.82	3.462E+18	867.92	16.99	999.08	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2268002.4	9.69	9.511E+18	869.51	18.84	999.75	VERY LOW	2268002.4	9.69	9.511E+18	869.51	18.84	999.75	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	remdesivir	NA	NA	NA	NA	NA	NA	NA	841961.86	3.75	3.701E+18	868.21	17.27	998.68	VERY LOW	841961.86	3.75	3.701E+18	868.21	17.27	998.68	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.87	0	2.246E+12	23.5	-979.58	996.88	VERY LOW	0.87	0	2.246E+12	23.5	-979.58	996.88	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	statins	NA	NA	NA	NA	NA	NA	NA	518232.88	2.02	2.147E+18	866.1	15.71	998.7	VERY LOW	518232.88	2.02	2.147E+18	866.1	15.71	998.7	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	771753.13	3.36	3.369E+18	867.74	16.96	998.78	VERY LOW	771753.13	3.36	3.369E+18	867.74	16.96	998.78	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
Interferon alpha	umifenovir	NA	NA	NA	NA	NA	NA	NA	496823.44	2.29	2.069E+18	865.71	15.66	999.46	VERY LOW	496823.44	2.29	2.069E+18	865.71	15.66	999.46	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	vitamin D	NA	NA	NA	NA	NA	NA	NA	544258.72	2.5	2.5E+18	866.73	16.41	998.65	VERY LOW	544258.72	2.5	2.5E+18	866.73	16.41	998.65	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	VVI16	NA	NA	NA	NA	NA	NA	NA	2.995E+16	0	7.701E+33	553.77	-910.48	1000	VERY LOW	2.995E+16	0	7.701E+33	553.77	-910.48	1000	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.92	0.09	9.52	0.78	-3.68	10.77	VERY LOW	0.92	0.09	9.52	0.78	-3.68	10.77	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	3.27	0.14	211.05	1.83	-4.12	11.88	VERY LOW	3.27	0.14	211.05	1.83	-4.12	11.88	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.92	0.1	8.64	0.89	-2.79	10.91	VERY LOW	0.92	0.1	8.64	0.89	-2.79	10.91	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.84	0.09	7.88	0.77	-2.64	10.73	VERY LOW	0.84	0.09	7.88	0.77	-2.64	10.73	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.89	0.09	8.33	0.74	-3.27	10.73	VERY LOW	0.89	0.09	8.33	0.74	-3.27	10.73	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.48	0.05	4.44	-1.03	-5.42	8.96	VERY LOW	0.48	0.05	4.44	-1.03	-5.42	8.96	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.98	0.28	32.81	2.31	-0.87	12.38	VERY LOW	2.98	0.28	32.81	2.31	-0.87	12.38	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.62	0.03	12.39	-1.73	-17.57	9.74	VERY LOW	0.62	0.03	12.39	-1.73	-17.57	9.74	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.83	0.27	32.62	2.33	-0.88	12.3	VERY LOW	2.83	0.27	32.62	2.33	-0.88	12.3	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.87	0.08	8.45	0.5	-4.37	10.44	VERY LOW	0.87	0.08	8.45	0.5	-4.37	10.44	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.26	0.19	26.28	2.09	-1.48	12.08	VERY LOW	2.26	0.19	26.28	2.09	-1.48	12.08	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.84	0.09	7.5	0.79	-2.79	10.75	VERY LOW	0.84	0.09	7.5	0.79	-2.79	10.75	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.08	-843.92	-999.74	-0.82	VERY LOW	0	0	0.08	-843.92	-999.74	-0.82	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	statins	NA	NA	NA	NA	NA	NA	NA	0.5	0.04	5.72	-1.32	-9.45	9.2	VERY LOW	0.5	0.04	5.72	-1.32	-9.45	9.2	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.78	0.08	7.96	0.32	-4.31	10.4	VERY LOW	0.78	0.08	7.96	0.32	-4.31	10.4	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
interferon beta (nebulised)	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.64	0.03	11.55	-1.71	-17.32	9.72	VERY LOW	0.64	0.03	11.55	-1.71	-17.32	9.72	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.58	0.05	5.55	-0.68	-7.06	9.78	VERY LOW	0.58	0.05	5.55	-0.68	-7.06	9.78	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (nebulised)	VVI16	NA	NA	NA	NA	NA	NA	NA	6.422E+09	0	2.111E+26	-313.65	-999.29	9.89	VERY LOW	6.422E+09	0	2.111E+26	-313.65	-999.29	9.89	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	3.28	0.32	169.45	1.05	-3.8	4.44	VERY LOW	3.28	0.32	169.45	1.05	-3.8	4.44	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon beta (subcutaneous)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.99	0.33	2.95	0.11	-2.28	3.14	LOW	0.99	0.33	2.95	0.11	-2.28	3.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.91	0.33	2.43	-0.01	-2.01	2.93	LOW	0.91	0.33	2.43	-0.01	-2.01	2.93	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.96	0.29	3.03	-0.04	-2.7	3.13	LOW	0.96	0.29	3.03	-0.04	-2.7	3.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.52	0.18	1.38	-1.81	-5	1.44	LOW	0.52	0.18	1.38	-1.81	-5	1.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2

MORTALITY																											
Comparison		Direct estimate							Indirect estimate							Network estimate											
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
interferon beta (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.13	0.81	14.41	1.53	-0.34	4.46	LOW	3.13	0.81	14.41	1.53	-0.34	4.46	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.7	0.09	4.98	-2.52	-17.33	3.05	VERY LOW	0.7	0.09	4.98	-2.52	-17.33	3.05	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.07	0.77	13.27	1.55	-0.29	4.44	LOW	3.07	0.77	13.27	1.55	-0.29	4.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.93	0.24	3.34	-0.28	-4.03	3.15	LOW	0.93	0.24	3.34	-0.28	-4.03	3.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.42	0.57	12.2	1.31	-0.92	4.32	LOW	2.42	0.57	12.2	1.31	-0.92	4.32	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.92	0.31	2.59	0.01	-2.22	3.04	LOW	0.92	0.31	2.59	0.01	-2.22	3.04	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-844.7	-999.12	-0.72	VERY LOW	0	0	0.06	-844.7	-999.12	-0.72	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon beta (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	0.55	0.13	2.28	-2.11	-9.32	2.32	VERY LOW	0.55	0.13	2.28	-2.11	-9.32	2.32	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.85	0.24	2.82	-0.46	-3.98	2.78	VERY LOW	0.85	0.24	2.82	-0.46	-3.98	2.78	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
interferon beta (subcutaneous)	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.68	0.08	5.55	-2.49	-17.43	3.1	VERY LOW	0.68	0.08	5.55	-2.49	-17.43	3.1	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.62	0.16	2.28	-1.47	-6.87	2.44	VERY LOW	0.62	0.16	2.28	-1.47	-6.87	2.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	VV116	NA	NA	NA	NA	NA	NA	NA	1.011E+10	0	1.547E+26	-314.43	-998.73	4.49	VERY LOW	1.011E+10	0	1.547E+26	-314.43	-998.73	4.49	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.31	0.01	2.77	-0.94	-3.43	3.84	VERY LOW	0.31	0.01	2.77	-0.94	-3.43	3.84	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.28	0.01	2.51	-1.06	-3.1	3.58	VERY LOW	0.28	0.01	2.51	-1.06	-3.1	3.58	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.29	0.01	2.75	-1.09	-3.93	3.74	VERY LOW	0.29	0.01	2.75	-1.09	-3.93	3.74	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.16	0	1.38	-2.86	-6.11	1.95	VERY LOW	0.16	0	1.38	-2.86	-6.11	1.95	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.98	0.02	11.05	0.48	-1.33	5.08	VERY LOW	0.98	0.02	11.05	0.48	-1.33	5.08	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.19	0	3.79	-3.56	-18.45	3.17	VERY LOW	0.19	0	3.79	-3.56	-18.45	3.17	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon lambda (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.95	0.02	10.67	0.5	-1.36	5.15	VERY LOW	0.95	0.02	10.67	0.5	-1.36	5.15	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.28	0.01	3.07	-1.32	-5.12	3.61	VERY LOW	0.28	0.01	3.07	-1.32	-5.12	3.61	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0.72	0.01	8.87	0.26	-2.04	4.99	VERY LOW	0.72	0.01	8.87	0.26	-2.04	4.99	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.28	0.01	2.56	-1.04	-3.36	3.67	VERY LOW	0.28	0.01	2.56	-1.04	-3.36	3.67	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-845.75	-999.95	-1.45	VERY LOW	0	0	0.02	-845.75	-999.95	-1.45	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
interferon lambda (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	0.16	0	1.96	-3.15	-10.44	2.37	VERY LOW	0.16	0	1.96	-3.15	-10.44	2.37	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon lambda (subcutaneous)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.26	0	2.46	-1.51	-5.08	3.32	VERY LOW	0.26	0	2.46	-1.51	-5.08	3.32	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
interferon lambda (subcutaneous)	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.19	0	4.06	-3.54	-18.49	3.12	VERY LOW	0.19	0	4.06	-3.54	-18.49	3.12	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon lambda (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.18	0	1.96	-2.51	-8	2.62	VERY LOW	0.18	0	1.96	-2.51	-8	2.62	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon lambda (subcutaneous)	VV116	NA	NA	NA	NA	NA	NA	NA	3.087E+09	0	3.922E+25	-315.47	-999.85	4.48	VERY LOW	3.087E+09	0	3.922E+25	-315.47	-999.85	4.48	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
intermediate-dose anticoagulation	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.91	0.41	2	-0.12	-1.86	1.89	LOW	0.91	0.41	2	-0.12	-1.86	1.89	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0.96	0.36	2.56	-0.15	-2.64	2.14	LOW	0.96	0.36	2.56	-0.15	-2.64	2.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.53	0.23	1.13	-1.92	-4.88	0.44	LOW	0.53	0.23	1.13	-1.92	-4.88	0.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.16	0.96	12.39	1.42	-0.13	3.34	LOW	3.16	0.96	12.39	1.42	-0.13	3.34	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.7	0.1	4.7	-2.63	-17.39	2.32	VERY LOW	0.7	0.1	4.7	-2.63	-17.39	2.32	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
intermediate-dose anticoagulation	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.1	0.91	11.65	1.44	-0.15	3.35	LOW	3.1	0.91	11.65	1.44	-0.15	3.35	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.94	0.29	2.94	-0.39	-3.89	2.16	LOW	0.94	0.29	2.94	-0.39	-3.89	2.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.42	0.67	10.55	1.2	-0.73	3.18	LOW	2.42	0.67	10.55	1.2	-0.73	3.18	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.92	0.39	2.15	-0.1	-2.07	1.98	LOW	0.92	0.39	2.15	-0.1	-2.07	1.98	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-844.81	-998.86	-0.82	VERY LOW	0	0	0.06	-844.81	-998.86	-0.82	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
intermediate-dose anticoagulation	statins	NA	NA	NA	NA	NA	NA	NA	0.55	0.15	2.04	-2.21	-9.23	1.51	VERY LOW	0.55	0.15	2.04	-2.21	-9.23	1.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulation	therapeutic-dose anticoagulation	0.19	0.06	0.54	NA	NA	NA	LOW	3.93	0.85	19.46	NA	NA	NA	VERY LOW	0.86	0.3	2.31	-0.57	-3.69	1.75	Direct	HIGH	Serious	Very serious	VERY LOW	Imprecisionx2
intermediate-dose anticoagulation	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.68	0.09	4.99	-2.6	-17.42	2.41	VERY LOW	0.68	0.09	4.99	-2.6	-17.42	2.41	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
intermediate-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.63	0.19	1.94	-1.58	-6.73	1.61	VERY LOW	0.63	0.19	1.94	-1.58	-6.73	1.61	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulation	VV116	NA	NA	NA	NA	NA	NA	NA	9.837E+09	0	1.479E+26	-314.54	-998.54	3.65	VERY LOW	9.837E+09	0	1.479E+26	-314.54	-998.54	3.65	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.06	0.45	2.45	-0.03	-2.41	1.85	LOW	1.06	0.45	2.45	-0.03	-2.41	1.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	lopinavir-ritonavir	0.51	0.01	26.6	NA	NA	NA	VERY LOW	0.57	0.28	1.07	NA	NA	NA	LOW	0.58	0.29	1.07	-1.8	-4.66	0.26	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.45	1.16	13.08	1.54	0.15	2.97	LOW	3.45	1.16	13.08	1.54	0.15	2.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.77	0.11	4.82	-2.51	-17.26	2.22	VERY LOW	0.77	0.11	4.82	-2.51	-17.26	2.22	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.37	1.12	11.45	1.56	0.15	3.02	LOW	3.37	1.12	11.45	1.56	0.15	3.02	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.03	0.34	2.92	-0.27	-3.76	1.97	LOW	1.03	0.34	2.92	-0.27	-3.76	1.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.65	0.78	10.87	1.32	-0.54	2.86	LOW	2.65	0.78	10.87	1.32	-0.54	2.86	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.01	0.49	2.1	0.02	-1.8	1.69	LOW	1.01	0.49	2.1	0.02	-1.8	1.69	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-844.69	-998.55	-0.68	VERY LOW	0	0	0.06	-844.69	-998.55	-0.68	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	0.6	0.18	2.09	-2.09	-9.13	1.4	VERY LOW	0.6	0.18	2.09	-2.09	-9.13	1.4	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.95	0.35	2.37	-0.45	-3.64	1.65	VERY LOW	0.95	0.35	2.37	-0.45	-3.64	1.65	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
ivermectin	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.75	0.11	5.19	-2.48	-17.34	2.19	VERY LOW	0.75	0.11	5.19	-2.48	-17.34	2.19	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ivermectin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.69	0.24	1.98	-1.46	-6.65	1.51	VERY LOW	0.69	0.24	1.98	-1.46	-6.65	1.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	VV116	NA	NA	NA	NA	NA	NA	NA	1.038E+10	0	1.773E+26	-314.42	-998.28	3.43	VERY LOW	1.038E+10	0	1.773E+26	-314.42	-998.28	3.43	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
JAK inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.55	0.22	1.28	-1.77	-4.8	0.89	LOW	0.55	0.22	1.28	-1.77	-4.8	0.89	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.31	0.91	13.82	1.57	-0.12	3.84	LOW	3.31	0.91	13.82	1.57	-0.12	3.84	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.73	0.1	4.99	-2.48	-17.25	2.68	VERY LOW	0.73	0.1	4.99	-2.48	-17.25	2.68	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
JAK inhibitors	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.23	0.91	12.47	1.59	-0.1	3.83	LOW	3.23	0.91	12.47	1.59	-0.1	3.83	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.97	0.28	3.2	-0.24	-3.86	2.65	LOW	0.97	0.28	3.2	-0.24	-3.86	2.65	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.52	0.65	11.5	1.35	-0.78	3.73	LOW	2.52	0.65	11.5	1.35	-0.78	3.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.96	0.39	2.38	0.05	-2.08	2.51	LOW	0.96	0.39	2.38	0.05	-2.08	2.51	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-844.66	-998.92	-0.74	VERY LOW	0	0	0.06	-844.66	-998.92	-0.74	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
JAK inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.57	0.15	2.26	-2.07	-9.22	1.88	VERY LOW	0.57	0.15	2.26	-2.07	-9.22	1.88	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.89	0.28	2.71	-0.42	-3.81	2.35	VERY LOW	0.89	0.28	2.71	-0.42	-3.81	2.35	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
JAK inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.71	0.09	5.4	-2.45	-17.28	2.67	VERY LOW	0.71	0.09	5.4	-2.45	-17.28	2.67	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
JAK inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.66	0.19	2.09	-1.43	-6.68	2.03	VERY LOW	0.66	0.19	2.09	-1.43	-6.68	2.03	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	VV116	NA	NA	NA	NA	NA	NA	NA	1.05E+10	0	1.557E+26	-314.39	-998.53	4.11	VERY LOW	1.05E+10	0	1.557E+26	-314.39	-998.53	4.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	6.01	2	22.69	3.34	1.46	6.12	LOW	6.01	2	22.69	3.34	1.46	6.12	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.35	0.2	8.43	-0.7	-15.43	4.75	VERY LOW	1.35	0.2	8.43	-0.7	-15.43	4.75	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
lopinavir-ritonavir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.85	1.92	20.89	3.36	1.42	6.14	LOW	5.85	1.92	20.89	3.36	1.42	6.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.78	0.61	5.23	1.54	-2.12	4.76	LOW	1.78	0.61	5.23	1.54	-2.12	4.76	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	4.62	1.4	19.33	3.12	0.91	5.95	LOW	4.62	1.4	19.33	3.12	0.91	5.95	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.74	0.88	3.73	1.82	-0.41	4.68	LOW	1.74	0.88	3.73	1.82	-0.41	4.68	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.12	-842.89	-997.38	1.11	VERY LOW	0	0	0.12	-842.89	-997.38	1.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
lopinavir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	1.04	0.31	3.73	-0.29	-7.41	4.01	VERY LOW	1.04	0.31	3.73	-0.29	-7.41	4.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.63	0.63	4.16	1.35	-2.07	4.38	VERY LOW	1.63	0.63	4.16	1.35	-2.07	4.38	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2

MORTALITY																														
Comparison		Direct estimate							Indirect estimate							Network estimate														
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE							
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading			
lopinavir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.31	0.19	9.26	-0.68	-15.47	4.91	VERY LOW	1.31	0.19	9.26	-0.68	-15.47	4.91	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.2	0.42	3.44	0.35	-4.94	4.12	VERY LOW	1.2	0.42	3.44	0.35	-4.94	4.12	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
lopinavir-ritonavir	VV116	NA	NA	NA	NA	NA	NA	NA	1.87E+10	0	2.739E+26	-312.62	-996.92	6.18	VERY LOW	1.87E+10	0	2.739E+26	-312.62	-996.92	6.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
molnupiravir	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.22	0.02	1.78	-4.05	-18.78	0.42	VERY LOW	0.22	0.02	1.78	-4.05	-18.78	0.42	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
molnupiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.96	0.2	4.84	0.02	-1.24	1.23	LOW	0.96	0.2	4.84	0.02	-1.24	1.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
molnupiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.29	0.06	1.25	-1.81	-5.16	0.18	LOW	0.29	0.06	1.25	-1.81	-5.16	0.18	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
molnupiravir	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0.76	0.15	4.06	-0.22	-1.98	1.13	LOW	0.76	0.15	4.06	-0.22	-1.98	1.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.29	0.08	0.94	-1.52	-3.25	-0.05	LOW	0.29	0.08	0.94	-1.52	-3.25	-0.05	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
molnupiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-846.23	-999.75	-2.01	VERY LOW	0	0	0.02	-846.23	-999.75	-2.01	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
molnupiravir	statins	NA	NA	NA	NA	NA	NA	NA	0.17	0.03	0.84	-3.64	-10.7	-0.21	VERY LOW	0.17	0.03	0.84	-3.64	-10.7	-0.21	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
molnupiravir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.27	0.06	0.99	-1.99	-5.13	-0.06	VERY LOW	0.27	0.06	0.99	-1.99	-5.13	-0.06	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2			
molnupiravir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.21	0.02	1.84	-4.02	-18.79	0.5	VERY LOW	0.21	0.02	1.84	-4.02	-18.79	0.5	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
molnupiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.2	0.04	0.82	-3	-8.14	-0.19	VERY LOW	0.2	0.04	0.82	-3	-8.14	-0.19	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
molnupiravir	VV116	NA	NA	NA	NA	NA	NA	NA	2.585E+09	0	4.118E+25	-315.96	-999.62	1.6	VERY LOW	2.585E+09	0	4.118E+25	-315.96	-999.62	1.6	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
niclosamide	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.42	0.56	41.06	4.06	-0.46	18.78	VERY LOW	4.42	0.56	41.06	4.06	-0.46	18.78	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.33	0.17	11.15	2.24	-3.59	17.01	VERY LOW	1.33	0.17	11.15	2.24	-3.59	17.01	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	3.47	0.43	34.97	3.83	-0.96	18.63	VERY LOW	3.47	0.43	34.97	3.83	-0.96	18.63	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.31	0.21	9.12	2.53	-2.35	17.43	VERY LOW	1.31	0.21	9.12	2.53	-2.35	17.43	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.1	-842.18	-999.41	0.92	VERY LOW	0	0	0.1	-842.18	-999.41	0.92	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	statins	NA	NA	NA	NA	NA	NA	NA	0.79	0.09	6.59	0.41	-8.56	15.63	VERY LOW	0.79	0.09	6.59	0.41	-8.56	15.63	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.2	0.17	9.41	2.06	-3.71	16.79	VERY LOW	1.2	0.17	9.41	2.06	-3.71	16.79	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3			
niclosamide	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.99	0.08	13.12	0.02	-15.87	15.84	VERY LOW	0.99	0.08	13.12	0.02	-15.87	15.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.91	0.11	7.42	1.05	-6.31	15.98	VERY LOW	0.91	0.11	7.42	1.05	-6.31	15.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
niclosamide	VV116	NA	NA	NA	NA	NA	NA	NA	1.111E+10	0	2.756E+26	-311.91	-998.9	15.3	VERY LOW	1.111E+10	0	2.756E+26	-311.91	-998.9	15.3	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
nirmatrelvir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.3	0.06	1.29	-1.82	-5.2	0.24	LOW	0.3	0.06	1.29	-1.82	-5.2	0.24	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
nirmatrelvir-ritonavir	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	0.8	0.15	4.15	-0.24	-1.98	1.16	LOW	0.8	0.15	4.15	-0.24	-1.98	1.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
nirmatrelvir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.3	0.08	0.95	-1.54	-3.24	-0.04	LOW	0.3	0.08	0.95	-1.54	-3.24	-0.04	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
nirmatrelvir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-846.25	-999.77	-2.16	VERY LOW	0	0	0.02	-846.25	-999.77	-2.16	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
nirmatrelvir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	0.18	0.03	0.86	-3.65	-10.7	-0.26	VERY LOW	0.18	0.03	0.86	-3.65	-10.7	-0.26	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
nirmatrelvir-ritonavir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.28	0.06	1.04	-2.01	-5.12	-0.02	VERY LOW	0.28	0.06	1.04	-2.01	-5.12	-0.02	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2			
nirmatrelvir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.22	0.02	1.9	-4.04	-18.82	0.5	VERY LOW	0.22	0.02	1.9	-4.04	-18.82	0.5	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
nirmatrelvir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.2	0.04	0.82	-3.01	-8.15	-0.22	VERY LOW	0.2	0.04	0.82	-3.01	-8.15	-0.22	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
nirmatrelvir-ritonavir	VV116	0.99	0.02	50.45	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	3.103E+09	0	4.588E+25	-315.98	-999.63	1.61	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
prophylactic-dose anticoagulation	P2Y12 inhibitor	NA	NA	NA	NA	NA	NA	NA	2.62	0.6	13.2	1.59	-0.83	5.04	LOW	2.62	0.6	13.2	1.59	-0.83	5.04	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
prophylactic-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.99	0.32	3.04	0.29	-2.12	3.7	LOW	0.99	0.32	3.04	0.29	-2.12	3.7	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
prophylactic-dose anticoagulation	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.07	-844.42	-999.08	-0.17	VERY LOW	0	0	0.07	-844.42	-999.08	-0.17	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
prophylactic-dose anticoagulation	statins	NA	NA	NA	NA	NA	NA	NA	0.59	0.13	2.69	-1.83	-9.1	2.96	VERY LOW	0.59	0.13	2.69	-1.83	-9.1	2.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation	1.06	0.02	54.08	NA	NA	NA	VERY LOW	0.89	0.24	3.07	NA	NA	NA	VERY LOW	0.92	0.26	3.17	-0.18	-3.82	3.58	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
prophylactic-dose anticoagulation	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.72	0.09	5.93	-2.21	-17.18	3.84	VERY LOW	0.72	0.09	5.93	-2.21	-17.18	3.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
prophylactic-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.67	0.18	2.55	-1.19	-6.65	3.14	VERY LOW	0.67	0.18	2.55	-1.19	-6.65	3.14	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
prophylactic-dose anticoagulation	VV116	NA	NA	NA	NA	NA	NA	NA	1.014E+10	0	1.812E+26	-314.15	-998.65	5.12	VERY LOW	1.014E+10	0	1.812E+26	-314.15	-998.65	5.12	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
P2Y12 inhibitor	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.38	0.09	1.32	-1.3	-3.11	0.63	LOW	0.38	0.09	1.32	-1.3	-3.11	0.63	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2			
P2Y12 inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-846.01	-999.75	-2	VERY LOW	0	0	0.02	-846.01	-999.75	-2	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
P2Y12 inhibitor	statins	NA	NA	NA	NA	NA	NA	NA	0.23	0.04	1.11	-3.42	-10.41	0.16	VERY LOW	0.23	0.04	1.11	-3.42	-10.41	0.16	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
P2Y12 inhibitor	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.35	0.07	1.4	-1.77	-4.94	0.51	VERY LOW	0.35	0.07	1.4	-1.77	-4.94	0.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2			
P2Y12 inhibitor	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.28	0.03	2.56	-3.8	-18.67	1.01	VERY LOW	0.28	0.03	2.56	-3.8	-18.67	1.01	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
P2Y12 inhibitor	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.26	0.05	1.12	-2.78	-7.92	0.24	VERY LOW	0.26	0.05	1.12	-2.78	-7.92	0.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
P2Y12 inhibitor	VV116	NA	NA	NA	NA	NA	NA	NA	4.208E+09	0	6.746E+25	-315.74	-999.59	2.28	VERY LOW	4.208E+09	0	6.746E+25	-315.74	-999.59	2.28	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
remdesivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-844.71	-998.66	-0.59	VERY LOW	0	0	0.06	-844.71	-998.66	-0.59	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
remdesivir	statins	NA	NA	NA	NA	NA	NA	NA	0.6	0.17	2.1	-2.12	-9.18	1.57	VERY LOW	0.6	0.17	2.1	-2.12	-9.18	1.57	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
remdesivir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.93	0.33	2.52	-0.47	-3.7	1.81	VERY LOW	0.93	0.33	2.52	-0.47	-3.7	1.81	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2			
remdesivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.74	0.1	5.39	-2.5	-17.32	2.37	VERY LOW	0.74	0.1	5.39	-2.5	-17.32	2.37	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
remdesivir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.68	0.22	2.01	-1.48	-6.67	1.54	VERY LOW	0.68	0.22	2.01	-1.48	-6.67	1.54	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
remdesivir	VV116	NA	NA	NA	NA	NA	NA	NA	1.043E+10	0	1.757E+26	-314.44	-998.38	3.57	VERY LOW	1.043E+10	0	1.757E+26	-314.44	-998.38	3.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
serine protease inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	3058912.4	8.59	2.447E+16	842.6	-0.7	998.65	VERY LOW	3058912.4	8.59	2.447E+16	842.6	-0.7	998.65	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
serine protease inhibitors	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4591650	13.84	3.886E+16	844.24	0.36	998.79	VERY LOW	4591650	13.84	3.886E+16	844.24	0.36	998.79	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3			
serine protease inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	3979672.2	10.02	3.259E+16	842.21	0.22	999.48	VERY LOW	3979672.2	10.02	3.259E+16	842.21	0.22	999.48	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
serine protease inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	4009030.5	10.34	2.751E+16	843.23	-0.56	998.66	VERY LOW	4009030.5	10.34	2.751E+16	843.23	-0.56	998.66	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
serine protease inhibitors	VV116	NA	NA	NA	NA	NA	NA	NA	1.104E+17	0	3.83E+32	530.27	-875.01	1000	VERY LOW	1.104E+17	0	3.83E+32	530.27	-875.01	1000	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3			
statins	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.56	0.37	6.31	1.65	-2.95	8.73	VERY LOW	1.56	0.37	6.31	1.65	-2.95	8.73	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2			
statins	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.24	0.13	11.23	-0.39	-15.52	8.51	VERY LOW	1.24	0.13	11.23	-0.39	-15.52	8.51	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.14	0.25	5.05	0.64	-5.51	8.12	VERY LOW	1.14	0.25	5.05	0.64	-5.51	8.12	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2			
statins	VV116	NA	NA	NA	NA	NA	NA	NA	1.684E+10	0	2.298E+26	-312.32	-998.07	9.95	VERY LOW	1.684E+10	0	2.298E+26	-312.32	-998.07	9.95	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
therapeutic-dose anticoagulation	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.82	0.11	6.56	-2.03	-16.89	3.81	VERY LOW	0.82	0.11	6.56	-2.03	-16.89	3.81	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3			
therapeutic-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.74	0.21	2.59	-1.01	-6.34	3.05	VERY LOW	0.74	0.21	2.59	-1.01	-6.34	3.05	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2			
therapeutic-dose anticoagulation	VV116	NA	NA	NA	NA	NA	NA	NA	1.135E+10	0	2.084E+26	-313.97	-998.44	5.28	VERY LOW	1.135E+10	0	2.084E+26	-313.97	-998.44	5.28	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3			
umifenovir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.93	0.11	7.65	1.03	-6.42	16.23	VERY LOW	0.93	0.11	7.65	1.03	-6.42	16.23	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
umifenovir	VV116	NA	NA	NA	NA	NA	NA	NA	1.189E+10	0	2.483E+26	-311.94	-999.08	16.7	VERY LOW	1.189E+10	0	2.483E+26	-311.94	-999.08	16.7	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			
vitamin D	VV116	NA	NA	NA	NA	NA	NA	NA	1.525E+10	0	2.735E+26	-312.96	-998.09	7.78	VERY LOW	1.525E+10	0	2.735E+26	-312.96	-998.09	7.78	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3			

MECHANICAL VENTILATION																												
Comparison		Direct estimate							Indirect estimate								Network estimate											
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
ACEi/ARB	standard care/placebo	0.88	0.45	1.74	-2.30	-10.87	14.29	HIGH	NA	NA	NA	NA	NA	NA	NA	0.87	0.49	1.59	-1.59	-10.07	11.64	Direct	HIGH	Not serious	Not Serious	HIGH	
aspirin	standard care/placebo	0.93	0.46	1.83	-1.38	-10.79	16.00	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.86	0.47	1.5	-2.27	-10.54	9.67	Direct	HIGH	Not serious	Not Serious	HIGH	
aspirin, statins	standard care/placebo	1.33	0.24	7.29	6.49	-15.05	109.50	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.68	0.54	5.12	18.22	-9.05	74.9	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
multivitamin	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	0	0	0.08	-19.62	-20	-16.18	VERY LOW	0	0	0.08	-19.62	-20	-16.18	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	standard care/placebo	0.61	0.12	3.21	-7.63	-17.59	41.57	LOW	NA	NA	NA	NA	NA	NA	NA	0.59	0.11	2.38	-4.53	-17.69	29.53	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	standard care/placebo	0.59	0.3	1.18	-8.08	-13.96	3.45	HIGH	NA	NA	NA	NA	NA	NA	NA	0.58	0.3	1.1	-7.74	-13.97	1.89	Direct	HIGH	Not serious	Very serious	LOW	
corticosteroids (systemic)	standard care/placebo	0.79	0.25	2.62	-4.05	-14.94	30.76	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.78	0.38	1.57	-3.53	-12.38	11.02	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline	standard care/placebo	0.49	0.07	3.42	-10.10	-18.57	45.29	LOW	NA	NA	NA	NA	NA	NA	NA	0.46	0.09	2.16	-7.56	-18.33	21.3	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	standard care/placebo	1.26	0.57	2.79	4.97	-8.56	33.96	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.46	0.63	3.45	11.31	-7.21	45.57	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine	standard care/placebo	0.79	0.29	2.21	-4.11	-14.06	23.17	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.77	0.38	1.58	-3.37	-12.32	11.49	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine, inhaled corticosteroids	standard care/placebo	3	0.09	96.61	37.77	-18.10	643.50	VERY LOW	NA	NA	NA	NA	NA	NA	NA	14316883	0.79	1.061E+19	845.59	1.31	980	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	standard care/placebo	1.32	0.71	2.46	6.29	-5.80	27.80	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.38	0.78	2.47	8.72	-4.34	28.73	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	standard care/placebo	1.03	0.28	3.80	0.50	-14.38	52.01	LOW	NA	NA	NA	NA	NA	NA	NA	1.02	0.37	2.77	3.29	-12.28	34.32	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	standard care/placebo	2.13	0.14	33.61	21.7	-17.25	386.82	VERY LOW	NA	NA	NA	NA	NA	NA	NA	2.35	0.19	78.73	91.59	-16.12	621.08	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	standard care/placebo	0.88	0.19	4.06	-2.35	-16.12	56.54	LOW	NA	NA	NA	NA	NA	NA	NA	0.88	0.35	2.16	-0.68	-12.94	22.18	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
interferon lambda (subcutaneous)	standard care/placebo	0.81	0.18	3.89	-3.68	-16.34	53.61	LOW	NA	NA	NA	NA	NA	NA	NA	0.76	0.2	2.79	-0.91	-15.86	34.48	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	standard care/placebo	0.67	0.15	2.89	-6.6	-16.88	35.63	LOW	NA	NA	NA	NA	NA	NA	NA	0.56	0.27	1.08	-8.21	-14.62	1.74	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	standard care/placebo	0.67	0.41	1.1	-6.46	-11.75	2.04	HIGH	NA	NA	NA	NA	NA	NA	NA	0.66	0.4	1.07	-6.52	-12.14	1.12	Direct	HIGH	Not serious	Not Serious	HIGH	
JAK inhibitors	standard care/placebo	0.37	0.12	1.13	-12.47	-17.47	2.56	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.34	0.12	0.87	-12.46	-17.53	-2.98	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
lopinavir-ritonavir	standard care/placebo	1.06	0.33	3.77	1.11	-13.22	51.44	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.04	0.47	2.4	2.81	-10.45	27.33	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
molnupiravir	standard care/placebo	0.46	0.14	1.61	-10.66	-17.15	11.76	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.39	0.13	1.06	-10.96	-17.36	1.69	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
nirmatrelvir-ritonavir	standard care/placebo	0.92	0.21	3	-1.65	-15.68	37.78	LOW	NA	NA	NA	NA	NA	NA	NA	0.88	0.38	1.93	-0.92	-12.37	17.65	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
prophylactic-dose anticoagulation	standard care/placebo	1.36	0.43	4.72	7.03	-11.26	67.92	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.49	0.6	3.93	12.99	-7.78	54.25	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
remdesivir	standard care/placebo	0.65	0.25	1.42	-6.87	-14.84	8.19	LOW	NA	NA	NA	NA	NA	NA	NA	0.69	0.37	1.17	-5.82	-12.53	3	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
statins	standard care/placebo	1.16	0.21	6.47	3.15	-15.77	96.66	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.46	0.46	4.53	13.7	-10.93	66.38	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
therapeutic-dose anticoagulation	standard care/placebo	1.31	0.45	4.25	6.09	-10.81	59.86	LOW	NA	NA	NA	NA	NA	NA	NA	1.19	0.63	2.31	5.04	-7.49	25.13	Direct	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
vitamin D	standard care/placebo	1.02	0.22	4.74	0.35	-15.56	68.16	LOW	NA	NA	NA	NA	NA	NA	NA	1.01	0.41	2.59	2.74	-11.74	30.5	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	aspirin	NA	NA	NA	NA	NA	NA	NA	1.02	0.45	2.38	0.69	-13.86	16.53	LOW	1.02	0.45	2.38	0.69	-13.86	16.53	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	aspirin, statins	NA	NA	NA	NA	NA	NA	NA	0.52	0.14	1.86	-19.81	-77.24	11.09	VERY LOW	0.52	0.14	1.86	-19.81	-77.24	11.09	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	multivitamin	NA	NA	NA	NA	NA	NA	NA	1.017E+09	9.74	1.678E+26	18.03	8.89	31.38	VERY LOW	1.017E+09	9.74	1.678E+26	18.03	8.89	31.38	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	azithromycin	NA	NA	NA	NA	NA	NA	NA	1.48	0.33	8.97	2.94	-32.11	22.91	LOW	1.48	0.33	8.97	2.94	-32.11	22.91	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	colchicine	NA	NA	NA	NA	NA	NA	NA	1.5	0.64	3.59	6.15	-6.76	21.02	LOW	1.5	0.64	3.59	6.15	-6.76	21.02	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.12	0.45	2.88	1.94	-14.86	18.20	LOW	1.12	0.45	2.88	1.94	-14.86	18.2	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.91	0.36	11.36	5.97	-23.45	24.09	VERY LOW	1.91	0.36	11.36	5.97	-23.45	24.09	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.6	0.21	1.64	-12.90	-48.22	10.03	LOW	0.6	0.21	1.64	-12.9	-48.22	10.03	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.13	0.45	2.88	1.78	-15.32	18.17	LOW	1.13	0.45	2.88	1.78	-15.32	18.17	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.15	-847.18	-989.45	-2.58	VERY LOW	0	0	1.15	-847.18	-989.45	-2.58	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
ACEi/ARB	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.63	0.28	1.45	-10.31	-32.15	8.63	LOW	0.63	0.28	1.45	-10.31	-32.15	8.63	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.85	0.27	2.71	-4.88	-36.96	16.40	VERY LOW	0.85	0.27	2.71	-4.88	-36.96	16.4	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.36	0.01	4.99	-93.17	-622.43	16.69	VERY LOW	0.36	0.01	4.99	-93.17	-622.43	16.69	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
ACEi/ARB	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1	0.34	2.98	-0.91	-25.30	17.61	LOW	1	0.34	2.98	-0.91	-25.3	17.61	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.14	0.27	4.88	-0.68	-37.21	20.29	LOW	1.14	0.27	4.88	-0.68	-37.21	20.29	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.57	0.65	4.09	6.62	-6.33	21.62	LOW	1.57	0.65	4.09	6.62	-6.33	21.62	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.33	0.63	2.9	4.93	-6.58	19.57	LOW	1.33	0.63	2.9	4.93	-6.58	19.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.6	0.84	8.48	10.87	-1.60	25.50	LOW	2.6	0.84	8.48	10.87	-1.6	25.5	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.83	0.3	2.27	-4.40	-29.97	14.57	LOW	0.83	0.3	2.27	-4.4	-29.97	14.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.23	0.7	7.92	9.37	-5.74	24.73	LOW	2.23	0.7	7.92	9.37	-5.74	24.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.37	2.81	-0.67	-21.30	17.64	LOW	0.99	0.37	2.81	-0.67	-21.3	17.64	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.58	0.19	1.68	-14.57	-56.28	10.36	LOW	0.58	0.19	1.68	-14.57	-56.28	10.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ACEi/ARB	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.26	0.58	3.03	4.23	-8.00	19.67	VERY LOW	1.26	0.58	3.03	4.23	-8	19.67	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	statins	NA	NA	NA	NA	NA	NA	NA	0.6	0.17	2.21	-15.29	-68.59	13.53	VERY LOW	0.6	0.17	2.21	-15.29	-68.59	13.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ACEi/ARB	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.73	0.3	1.75	-6.63	-28.51	11.79	VERY LOW	0.73	0.3	1.75	-6.63	-28.51	11.79	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
ACEi/ARB	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.86	0.28	2.55	-4.32	-33.69	15.94	LOW	0.86	0.28	2.55	-4.32	-33.69	15.94	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	aspirin, statins	0.37	0.06	2.22	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.51	0.16	1.6	-20.5	-75.24	7.26	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	multivitamin	NA	NA	NA	NA	NA	NA	NA	928044275	10.26	1.644E+26	17.34	8.50	29.48	VERY LOW	928044275	10.26	1.644E+26	17.34	8.5	29.48	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	azithromycin	NA	NA	NA	NA	NA	NA	NA	1.45	0.32	8.98	2.25	-32.72	21.25	LOW	1.45	0.32	8.98	2.25	-32.72	21.25	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.47	0.62	3.49	5.47	-7.33	18.95	LOW	1.47	0.62	3.49	5.47	-7.33	18.95	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.1	0.43	2.74	1.25	-16.03	16.13	LOW	1.1	0.43	2.74	1.25	-16.03	16.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.86	0.36	10.65	5.28	-24.64	22.57	LOW	1.86	0.36	10.65	5.28	-24.64	22.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.59	0.2	1.59	-13.58	-49.02	8.70	LOW	0.59	0.2	1.59	-13.58	-49.02	8.7	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.11	0.43	2.72	1.09	-16.16	16.01	LOW	1.11	0.43	2.72	1.09	-16.16	16.01	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.11	-847.86	-989.82	-3.12	VERY LOW	0	0	1.11	-847.86	-989.82	-3.12	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.62	0.27	1.39	-11.00	-32.77	6.70	LOW	0.62	0.27	1.39	-11	-32.77	6.7	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.84	0.26	2.62	-5.56	-37.92	14.53	VERY LOW	0.84	0.26	2.62	-5.56	-37.92	14.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.36	0.01	4.61	-93.86	-623.01	16.15	VERY LOW	0.36	0.01	4.61	-93.86	-623.01	16.15	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.98	0.33	2.82	-1.60	-26.07	15.79	LOW	0.98	0.33	2.82	-1.6	-26.07	15.79	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.13	0.27	4.59	-1.37	-37.58	18.47	LOW	1.13	0.27	4.59	-1.37	-37.58	18.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	intermediate-dose anticoagulation	1.65	0.41	6.64	NA	NA	NA	LOW	NA	NA	NA	NA	NA	NA	NA	1.55	0.73	3.32	5.93	-4.83	17.53	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.3	0.6	2.77	4.25	-7.28	17.47	LOW	1.3	0.6	2.77	4.25	-7.28	17.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.55	0.81	7.97	10.18	-2.23	23.63	LOW	2.55	0.81	7.97	10.18	-2.23	23.63	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.82	0.29	2.14	-5.09	-31.25	13.16	LOW	0.82	0.29	2.14	-5.09	-31.25	13.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.19	0.68	7.54	8.68	-6.43	22.60	LOW	2.19	0.68	7.54	8.68	-6.43	22.6	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.97	0.36	2.62	-1.35	-21.74	15.40	LOW	0.97	0.36	2.62	-1.35	-21.74	15.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.57	0.18	1.64	-15.26	-57.98	8.94	LOW	0.57	0.18	1.64	-15.26	-57.98	8.94	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.24	0.56	2.81	3.55	-8.43	17.09	VERY LOW	1.24	0.56	2.81	3.55	-8.43	17.09	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	statins	0.42	0.07	2.6	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.58	0.18	1.89	-15.98	-66.97	9.81	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	therapeutic-dose anticoagulation	0.42	0.09	1.94	NA	NA	NA	LOW	0.91	0.29	2.85	NA	NA	NA		0.71	0.31	1.59	-7.32	-28.29	9.05	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2

MECHANICAL VENTILATION																														
Comparison		Direct estimate							Indirect estimate							Network estimate														
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE							
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
aspirin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.84	0.28	2.41	-5.01	-34.47	14.31	LOW	0.84	0.28	2.41	-5.01	-34.47	14.31	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin, statins	multivitamin	NA	NA	NA	NA	NA	NA	NA	1.885E+09	18.53	3.601E+26	37.84	10.34	94.64	VERY LOW	1.885E+09	18.53	3.601E+26	37.84	10.34	94.64	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	azithromycin	NA	NA	NA	NA	NA	NA	NA	2.86	0.47	22.86	22.75	-21.39	81.65	VERY LOW	2.86	0.47	22.86	22.75	-21.39	81.65	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA	NA	2.9	0.77	10.61	25.97	-3.18	82.98	VERY LOW	2.9	0.77	10.61	25.97	-3.18	82.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.17	0.57	8.15	21.75	-9.55	79.27	VERY LOW	2.17	0.57	8.15	21.75	-9.55	79.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	doxycycline	NA	NA	NA	NA	NA	NA	NA	3.72	0.53	25.99	25.78	-14.20	84.24	VERY LOW	3.72	0.53	25.99	25.78	-14.2	84.24	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.16	0.27	4.66	6.92	-37.77	67.45	VERY LOW	1.16	0.27	4.66	6.92	-37.77	67.45	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	2.19	0.57	8.26	21.59	-9.74	78.77	VERY LOW	2.19	0.57	8.26	21.59	-9.74	78.77	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	2.16	-827.37	-987.68	15.68	VERY LOW	0	0	2.16	-827.37	-987.68	15.68	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.22	0.34	4.3	9.50	-25.58	68.10	VERY LOW	1.22	0.34	4.3	9.5	-25.58	68.1	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.65	0.36	7.44	14.94	-27.62	74.58	VERY LOW	1.65	0.36	7.44	14.94	-27.62	74.58	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.7	0.02	11.02	-73.36	-600.87	62.14	VERY LOW	0.7	0.02	11.02	-73.36	-600.87	62.14	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.93	0.45	8.15	18.90	-17.07	77.07	VERY LOW	1.93	0.45	8.15	18.9	-17.07	77.07	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.22	0.39	12.51	19.13	-25.93	78.08	VERY LOW	2.22	0.39	12.51	19.13	-25.93	78.08	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin, statins	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	3.06	0.84	11.09	26.43	-2.31	82.81	VERY LOW	3.06	0.84	11.09	26.43	-2.31	82.81	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.57	0.74	8.7	24.74	-3.79	81.98	VERY LOW	2.57	0.74	8.7	24.74	-3.79	81.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	5.05	1.1	22.26	30.68	1.98	87.59	VERY LOW	5.05	1.1	22.26	30.68	1.98	87.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.61	0.39	6.33	15.41	-21.93	73.68	VERY LOW	1.61	0.39	6.33	15.41	-21.93	73.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	molnupiravir	NA	NA	NA	NA	NA	NA	NA	4.35	0.95	20.21	29.18	-0.88	86.51	VERY LOW	4.35	0.95	20.21	29.18	-0.88	86.51	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.92	0.48	7.71	19.15	-14.44	77.72	VERY LOW	1.92	0.48	7.71	19.15	-14.44	77.72	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.12	0.25	4.72	5.24	-45.46	66.27	VERY LOW	1.12	0.25	4.72	5.24	-45.46	66.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.45	0.7	8.76	24.05	-4.66	81.29	VERY LOW	2.45	0.7	8.76	24.05	-4.66	81.29	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	statins	1.15	0.23	5.62	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.16	0.35	3.75	4.52	-39.01	51.42	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin, statins	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.41	0.38	5	13.18	-21.3	70.97	VERY LOW	1.41	0.38	5	13.18	-21.3	70.97	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.67	0.38	6.93	15.49	-24.5	74.61	VERY LOW	1.67	0.38	6.93	15.49	-24.5	74.61	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
multivitamin	azithromycin	NA	NA	NA	NA	NA	NA	NA	0	0	0.13	-15.09	-49.29	-1.73	VERY LOW	0	0	0.13	-15.09	-49.29	-1.73	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	colchicine	NA	NA	NA	NA	NA	NA	NA	0	0	0.16	-11.88	-21.71	-4.99	VERY LOW	0	0	0.16	-11.88	-21.71	-4.99	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0	0	0.11	-16.09	-30.81	-6.67	VERY LOW	0	0	0.11	-16.09	-30.81	-6.67	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	doxycycline	NA	NA	NA	NA	NA	NA	NA	0	0	0.21	-12.06	-41.04	-1.03	VERY LOW	0	0	0.21	-12.06	-41.04	-1.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-30.93	-65.2	-12.23	VERY LOW	0	0	0.06	-30.93	-65.2	-12.23	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0	0	0.11	-16.25	-31.25	-6.73	VERY LOW	0	0	0.11	-16.25	-31.25	-6.73	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	0	-865.21	-1000	-21.27	VERY LOW	0	0	0	-865.21	-1000	-21.27	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-28.34	-48.5	-14.79	VERY LOW	0	0	0.06	-28.34	-48.5	-14.79	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	inhaled corticosteroids	0.11	0	2.61	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0	0	0.07	-22.9	-53.7	-7.24	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0	0	0.05	-111.2	-640.73	-3.49	VERY LOW	0	0	0.05	-111.2	-640.73	-3.49	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.1	-18.94	-41.9	-6.3	VERY LOW	0	0	0.1	-18.94	-41.9	-6.3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0	0	0.13	-18.71	-54.3	-3.48	VERY LOW	0	0	0.13	-18.71	-54.3	-3.48	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	0.15	-11.41	-21.55	-4.35	VERY LOW	0	0	0.15	-11.41	-21.55	-4.35	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0	0	0.13	-13.1	-20.92	-6.85	VERY LOW	0	0	0.13	-13.1	-20.92	-6.85	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	0	0	0.25	-7.16	-16.78	-1.57	VERY LOW	0	0	0.25	-7.16	-16.78	-1.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	0.09	-22.43	-47.14	-8.72	VERY LOW	0	0	0.09	-22.43	-47.14	-8.72	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0	0	0.23	-8.66	-21.46	-1.77	VERY LOW	0	0	0.23	-8.66	-21.46	-1.77	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0	0	0.1	-18.7	-37.38	-6.81	VERY LOW	0	0	0.1	-18.7	-37.38	-6.81	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-32.6	-74.06	-11.51	VERY LOW	0	0	0.06	-32.6	-74.06	-11.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0	0	0.12	-13.8	-22.85	-6.33	VERY LOW	0	0	0.12	-13.8	-22.85	-6.33	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	statins	NA	NA	NA	NA	NA	NA	NA	0	0	0.06	-33.32	-86.06	-8.48	VERY LOW	0	0	0.06	-33.32	-86.06	-8.48	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0	0	0.07	-24.66	-44.9	-11.66	VERY LOW	0	0	0.07	-24.66	-44.9	-11.66	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
multivitamin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0	0	0.09	-22.35	-50.22	-7.51	VERY LOW	0	0	0.09	-22.35	-50.22	-7.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.01	0.16	4.77	3.21	-14.19	38.06	LOW	1.01	0.16	4.77	3.21	-14.19	38.06	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.76	0.12	3.71	-1	-21.85	34.24	VERY LOW	0.76	0.12	3.71	-1	-21.85	34.24	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.27	0.13	11.43	3.03	-29.81	39.94	VERY LOW	1.27	0.13	11.43	3.03	-29.81	39.94	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.4	0.06	2.07	-15.84	-54.37	22.88	VERY LOW	0.4	0.06	2.07	-15.84	-54.37	22.88	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.76	0.12	3.67	-1.16	-22.12	34.32	VERY LOW	0.76	0.12	3.67	-1.16	-22.12	34.32	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	0.85	-850.12	-997.17	-7.61	VERY LOW	0	0	0.85	-850.12	-997.17	-7.61	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.42	0.07	1.95	-13.25	-39.04	23.78	LOW	0.42	0.07	1.95	-13.25	-39.04	23.78	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.58	0.08	3.22	-7.82	-43.09	29.92	VERY LOW	0.58	0.08	3.22	-7.82	-43.09	29.92	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.24	0.01	4.21	-96.11	-623.01	24.36	VERY LOW	0.24	0.01	4.21	-96.11	-623.01	24.36	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.67	0.1	3.63	-3.85	-31.97	32.55	VERY LOW	0.67	0.1	3.63	-3.85	-31.97	32.55	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.75	0.09	5.23	-3.62	-42.65	34.8	VERY LOW	0.75	0.09	5.23	-3.62	-42.65	34.8	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.06	0.17	5.14	3.68	-13.87	38.22	VERY LOW	1.06	0.17	5.14	3.68	-13.87	38.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.9	0.15	3.92	1.99	-13.95	36.5	LOW	0.9	0.15	3.92	1.99	-13.95	36.5	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.74	0.25	9.92	7.93	-9.08	42.15	VERY LOW	1.74	0.25	9.92	7.93	-9.08	42.15	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.56	0.08	2.85	-7.34	-36.55	29.55	VERY LOW	0.56	0.08	2.85	-7.34	-36.55	29.55	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.5	0.21	9.01	6.43	-12.91	41.55	VERY LOW	1.5	0.21	9.01	6.43	-12.91	41.55	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.67	0.1	3.44	-3.61	-27.92	32.58	VERY LOW	0.67	0.1	3.44	-3.61	-27.92	32.58	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.39	0.06	2.15	-17.51	-62.38	22.22	VERY LOW	0.39	0.06	2.15	-17.51	-62.38	22.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.85	0.15	3.96	1.29	-15.63	36.01	VERY LOW	0.85	0.15	3.96	1.29	-15.63	36.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	statins	NA	NA	NA	NA	NA	NA	NA	0.4	0.05	2.45	-18.23	-73.75	24.3	VERY LOW	0.4	0.05	2.45	-18.23	-73.75	24.3	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.49	0.08	2.28	-9.57	-35.3	26.68	VERY LOW	0.49	0.08	2.28	-9.57	-35.3	26.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
azithromycin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.58	0.08	3.06	-7.27	-39.3	30.1	VERY LOW	0.58	0.08	3.06	-7.27	-39.3	30.1	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.75	0.29	1.95	-4.21	-20.01	9	LOW	0.75	0.29	1.95	-4.21	-20.01	9	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.27	0.23	7.62	-0.19	-29.45	15.18	VERY LOW	1.27	0.23	7.62	-0.19	-29.45	15.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.4	0.13	1.14	-19.05	-53.56	1.85	LOW	0.4	0.13	1.14	-19.05	-53.56	1.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.75	0.29	1.96	-4.38	-20.53	8.9	LOW	0.75	0.29	1.96	-4.38	-20.53	8.9	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	0.72	-853.33	-993.46	-8.66	VERY LOW	0	0	0.72	-853.33	-993.46	-8.66	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.42	0.18	0.99	-16.47	-37.36	-0.23	LOW	0.42	0.18	0.99	-16.47	-37.36	-0.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.57	0.17	1.87	-11.03	-42.77	7.61	VERY LOW	0.57	0.17	1.87	-11.03	-42.77	7.61	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2

MECHANICAL VENTILATION

Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
Treatment 1	Treatment 2	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			GRADE					
		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
colchicine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.24	0.01	3.3	-99.33	-628.74	9.84	VERY LOW	0.24	0.01	3.3	-99.33	-628.74	9.84	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
colchicine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.66	0.22	2.03	-7.07	-30.91	8.85	LOW	0.66	0.22	2.03	-7.07	-30.91	8.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.76	0.18	3.26	-6.84	-42.79	11.59	LOW	0.76	0.18	3.26	-6.84	-42.79	11.59	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.05	0.41	2.78	0.46	-11.27	12.18	LOW	1.05	0.41	2.78	0.46	-11.27	12.18	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.89	0.4	1.97	-1.22	-11.39	9.96	LOW	0.89	0.4	1.97	-1.22	-11.39	9.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.73	0.54	5.72	4.72	-6.61	15.91	LOW	1.73	0.54	5.72	4.72	-6.61	15.91	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.55	0.2	1.55	-10.55	-35.97	5.85	LOW	0.55	0.2	1.55	-10.55	-35.97	5.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.48	0.46	5.28	3.22	-10.98	15.22	LOW	1.48	0.46	5.28	3.22	-10.98	15.22	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.66	0.24	1.9	-6.82	-26.59	8.52	LOW	0.66	0.24	1.9	-6.82	-26.59	8.52	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.39	0.12	1.15	-20.73	-62.51	2.43	LOW	0.39	0.12	1.15	-20.73	-62.51	2.43	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.84	0.37	2.05	-1.92	-12.78	9.82	VERY LOW	0.84	0.37	2.05	-1.92	-12.78	9.82	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	statins	NA	NA	NA	NA	NA	NA	NA	0.4	0.11	1.51	-21.45	-74.46	5.41	VERY LOW	0.4	0.11	1.51	-21.45	-74.46	5.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.49	0.19	1.18	-12.79	-34.1	3.08	VERY LOW	0.49	0.19	1.18	-12.79	-34.1	3.08	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
colchicine	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.57	0.19	1.73	-10.48	-39.04	7.05	LOW	0.57	0.19	1.73	-10.48	-39.04	7.05	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.7	0.3	10.5	4.03	-25.86	23.26	VERY LOW	1.7	0.3	10.5	4.03	-25.86	23.26	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.53	0.17	1.56	-14.84	-50.15	8.79	LOW	0.53	0.17	1.56	-14.84	-50.15	8.79	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.01	0.36	2.71	-0.16	-17.58	16.99	LOW	1.01	0.36	2.71	-0.16	-17.58	16.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.04	-849.12	-991.77	-4.39	VERY LOW	0	0	1.04	-849.12	-991.77	-4.39	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.56	0.22	1.4	-12.25	-34.4	7.42	LOW	0.56	0.22	1.4	-12.25	-34.4	7.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.76	0.22	2.61	-6.82	-38.91	15.15	VERY LOW	0.76	0.22	2.61	-6.82	-38.91	15.15	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.33	0.01	4.4	-95.11	-625.24	15.09	VERY LOW	0.33	0.01	4.4	-95.11	-625.24	15.09	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.89	0.28	2.79	-2.85	-27.46	16.51	LOW	0.89	0.28	2.79	-2.85	-27.46	16.51	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.02	0.23	4.42	-2.62	-39.09	18.89	LOW	1.02	0.23	4.42	-2.62	-39.09	18.89	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.4	0.53	3.89	4.68	-8.6	20.85	LOW	1.4	0.53	3.89	4.68	-8.6	20.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.18	0.5	2.82	2.99	-8.79	18.63	LOW	1.18	0.5	2.82	2.99	-8.79	18.63	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.32	0.7	7.87	8.93	-4.03	24.66	LOW	2.32	0.7	7.87	8.93	-4.03	24.66	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.74	0.25	2.15	-6.34	-32.4	13.31	LOW	0.74	0.25	2.15	-6.34	-32.4	13.31	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2	0.58	7.21	7.43	-8.09	23.49	LOW	2	0.58	7.21	7.43	-8.09	23.49	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.87	0.31	2.65	-2.61	-23.25	16.66	LOW	0.87	0.31	2.65	-2.61	-23.25	16.66	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.52	0.15	1.6	-16.51	-58.91	8.61	LOW	0.52	0.15	1.6	-16.51	-58.91	8.61	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.12	0.47	2.91	2.29	-10.05	18.81	VERY LOW	1.12	0.47	2.91	2.29	-10.05	18.81	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA	NA	0.53	0.14	2.07	-17.23	-70.8	11.97	VERY LOW	0.53	0.14	2.07	-17.23	-70.8	11.97	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.65	0.24	1.65	-8.57	-30.91	10.48	VERY LOW	0.65	0.24	1.65	-8.57	-30.91	10.48	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.76	0.24	2.39	-6.26	-35.65	14.65	LOW	0.76	0.24	2.39	-6.26	-35.65	14.65	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.31	0.05	1.86	-18.86	-55.68	15.57	VERY LOW	0.31	0.05	1.86	-18.86	-55.68	15.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.59	0.1	3.31	-4.19	-23.71	25.75	VERY LOW	0.59	0.1	3.31	-4.19	-23.71	25.75	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	0.7	-853.14	-997.87	-10.25	VERY LOW	0	0	0.7	-853.14	-997.87	-10.25	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.33	0.06	1.75	-16.28	-40.5	15.31	VERY LOW	0.33	0.06	1.75	-16.28	-40.5	15.31	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.44	0.06	2.78	-10.84	-44.46	21.97	VERY LOW	0.44	0.06	2.78	-10.84	-44.46	21.97	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.19	0	3.55	-99.14	-629.31	17.63	VERY LOW	0.19	0	3.55	-99.14	-629.31	17.63	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.52	0.08	3.15	-6.88	-33.58	24.41	VERY LOW	0.52	0.08	3.15	-6.88	-33.58	24.41	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.6	0.07	4.56	-6.65	-44.23	26.58	VERY LOW	0.6	0.07	4.56	-6.65	-44.23	26.58	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.82	0.14	4.52	0.65	-15.02	30.18	VERY LOW	0.82	0.14	4.52	0.65	-15.02	30.18	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.7	0.12	3.52	-1.03	-15.1	28.14	LOW	0.7	0.12	3.52	-1.03	-15.1	28.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.36	0.19	8.91	4.9	-10.39	34.21	VERY LOW	1.36	0.19	8.91	4.9	-10.39	34.21	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.44	0.07	2.48	-10.37	-38.86	21.35	VERY LOW	0.44	0.07	2.48	-10.37	-38.86	21.35	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.18	0.17	7.78	3.4	-14.66	33.3	VERY LOW	1.18	0.17	7.78	3.4	-14.66	33.3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.52	0.08	3.05	-6.63	-29.73	24.36	VERY LOW	0.52	0.08	3.05	-6.63	-29.73	24.36	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.3	0.04	1.85	-20.54	-63.85	14.95	VERY LOW	0.3	0.04	1.85	-20.54	-63.85	14.95	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
doxycycline	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.66	0.12	3.51	-1.73	-16.8	27.85	VERY LOW	0.66	0.12	3.51	-1.73	-16.8	27.85	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	statins	NA	NA	NA	NA	NA	NA	NA	0.31	0.04	2.15	-21.26	-76.55	17.28	VERY LOW	0.31	0.04	2.15	-21.26	-76.55	17.28	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
doxycycline	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.38	0.06	2.06	-12.6	-37.01	18.55	VERY LOW	0.38	0.06	2.06	-12.6	-37.01	18.55	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
doxycycline	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.45	0.07	2.76	-10.29	-41.07	21.97	VERY LOW	0.45	0.07	2.76	-10.29	-41.07	21.97	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.9	0.63	5.94	14.67	-8.81	50	LOW	1.9	0.63	5.94	14.67	-8.81	50	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1.96	-834.28	-986.07	9.54	VERY LOW	0	0	1.96	-834.28	-986.07	9.54	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.06	0.39	2.99	2.58	-24.85	39.23	LOW	1.06	0.39	2.99	2.58	-24.85	39.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.42	0.4	5.43	8.02	-28.26	46.24	VERY LOW	1.42	0.4	5.43	8.02	-28.26	46.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.62	0.02	8.94	-80.28	-610.41	41.31	VERY LOW	0.62	0.02	8.94	-80.28	-610.41	41.31	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.67	0.5	5.84	11.98	-17.73	48.51	LOW	1.67	0.5	5.84	11.98	-17.73	48.51	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.92	0.42	9.25	12.21	-27.88	50.96	LOW	1.92	0.42	9.25	12.21	-27.88	50.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	2.63	0.91	8.26	19.51	-1.67	54.49	LOW	2.63	0.91	8.26	19.51	-1.67	54.49	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.23	0.85	5.99	17.83	-2.25	52.35	LOW	2.23	0.85	5.99	17.83	-2.25	52.35	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	4.38	1.24	16.25	23.77	3.09	58.36	LOW	4.38	1.24	16.25	23.77	3.09	58.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.39	0.44	4.54	8.5	-21.9	45.25	LOW	1.39	0.44	4.54	8.5	-21.9	45.25	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.78	1.03	14.87	22.27	-0.08	57.12	LOW	3.78	1.03	14.87	22.27	-0.08	57.12	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.66	0.52	5.55	12.23	-14.47	48.97	LOW	1.66	0.52	5.55	12.23	-14.47	48.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.98	0.27	3.37	-1.68	-47.26	37.92	LOW	0.98	0.27	3.37	-1.68	-47.26	37.92	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.11	0.79	6.24	17.13	-3.56	52.27	VERY LOW	2.11	0.79	6.24	17.13	-3.56	52.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	statins	NA	NA	NA	NA	NA	NA	NA	1	0.25	4.35	-2.4	-58.36	40.88	VERY LOW	1	0.25	4.35	-2.4	-58.36	40.88	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.22	0.43	3.55	6.26	-20.88	41.7	VERY LOW	1.22	0.43	3.55	6.26	-20.88	41.7	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
favipiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.44	0.42	5.06	8.57	-24.8	46.23	LOW	1.44	0.42	5.06	8.57	-24.8	46.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0	0	1	-848.96	-991.73	-5.04	VERY LOW	0	0	1	-848.96	-991.73	-5.04	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.56	0.22	1.42	-12.09	-34.1	7.61	LOW	0.56	0.22	1.42	-12.09	-34.1	7.61	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.75	0.22	2.62	-6.65	-39.32	15.42	VERY LOW	0.75	0.22	2.62	-6.65	-39.32	15.42	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.32	0.01	4.49	-94.95	-624.01	15.97	VERY LOW	0.32	0.01	4.49	-94.95	-624.01	15.97	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.88	0.28	2.79	-2.69	-27.41	16.79	LOW	0.88	0.28	2.79	-2.69	-27.41	16.79	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.01	0.23	4.39	-2.46	-39.21	19.4	LOW	1.01	0.23	4.39	-2.46	-39.21	19.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2

MECHANICAL VENTILATION																										
Comparison		Direct estimate							Indirect estimate							Network estimate										
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
fluvoxamine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.39	0.53	3.86	4.84	-8.52	21.37	LOW	1.39	0.53	3.86	4.84	-8.52	21.37	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.17	0.5	2.83	3.15	-8.55	19.01	LOW	1.17	0.5	2.83	3.15	-8.55	19.01	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.3	0.7	7.76	9.09	-3.8	25.01	LOW	2.3	0.7	7.76	9.09	-3.8	25.01	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.74	0.25	2.15	-6.18	-32.24	13.98	LOW	0.74	0.25	2.15	-6.18	-32.24	13.98	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.98	0.58	7.25	7.59	-7.9	24.14	LOW	1.98	0.58	7.25	7.59	-7.9	24.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.87	0.3	2.68	-2.44	-23.24	16.84	LOW	0.87	0.3	2.68	-2.44	-23.24	16.84	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.52	0.15	1.61	-16.35	-58.56	9.42	LOW	0.52	0.15	1.61	-16.35	-58.56	9.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.11	0.47	2.93	2.46	-10.15	19.16	VERY LOW	1.11	0.47	2.93	2.46	-10.15	19.16	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	statins	NA	NA	NA	NA	NA	NA	NA	0.53	0.14	2.06	-17.07	-70.16	12.11	VERY LOW	0.53	0.14	2.06	-17.07	-70.16	12.11	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.65	0.24	1.65	-8.41	-30.58	10.75	VERY LOW	0.65	0.24	1.65	-8.41	-30.58	10.75	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
fluvoxamine	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.76	0.23	2.38	-6.1	-35.21	14.99	LOW	0.76	0.23	2.38	-6.1	-35.21	14.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	10187581	0.57	8.044E+18	836.86	-8.97	983.3	VERY LOW	10187581	0.57	8.044E+18	836.86	-8.97	983.3	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	13477066	0.73	1.028E+19	842.3	-1.15	991.41	VERY LOW	13477066	0.73	1.028E+19	842.3	-1.15	991.41	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	3604342.8	0.15	5.763E+18	754	-86.69	994.93	VERY LOW	3604342.8	0.15	5.763E+18	754	-86.69	994.93	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	16041184	0.85	1.18E+19	846.27	2.72	992.19	VERY LOW	16041184	0.85	1.18E+19	846.27	2.72	992.19	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	18443822	0.85	1.877E+19	846.5	1.76	995.2	VERY LOW	18443822	0.85	1.877E+19	846.5	1.76	995.2	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	26060466	1.34	1.981E+19	853.79	9.55	994.11	VERY LOW	26060466	1.34	1.981E+19	853.79	9.55	994.11	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	21984539	1.11	1.658E+19	852.11	7.78	991.6	VERY LOW	21984539	1.11	1.658E+19	852.11	7.78	991.6	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	43928769	2.34	3.554E+19	858.05	13.68	997.21	VERY LOW	43928769	2.34	3.554E+19	858.05	13.68	997.21	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	13444088	0.73	1.045E+19	842.78	-1.56	989.52	VERY LOW	13444088	0.73	1.045E+19	842.78	-1.56	989.52	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	37997465	1.82	3.113E+19	856.55	12.05	996.99	VERY LOW	37997465	1.82	3.113E+19	856.55	12.05	996.99	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	16671146	0.86	1.219E+19	846.51	1.92	991.67	VERY LOW	16671146	0.86	1.219E+19	846.51	1.92	991.67	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	9590945.2	0.51	6.285E+18	832.6	-9.93	986.83	VERY LOW	9590945.2	0.51	6.285E+18	832.6	-9.93	986.83	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	20219742	1.11	1.567E+19	851.41	7.04	991.98	VERY LOW	20219742	1.11	1.567E+19	851.41	7.04	991.98	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	statins	NA	NA	NA	NA	NA	NA	NA	9660056	0.48	8.757E+18	831.89	-10.23	989.53	VERY LOW	9660056	0.48	8.757E+18	831.89	-10.23	989.53	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	12165565	0.64	9.178E+18	840.54	-2.5	986.55	VERY LOW	12165565	0.64	9.178E+18	840.54	-2.5	986.55	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
fluvoxamine, inhaled corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA	NA	13541235	0.74	1.066E+19	842.85	-1.55	990.84	VERY LOW	13541235	0.74	1.066E+19	842.85	-1.55	990.84	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
(hydroxy)chloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.35	0.42	4.4	5.44	-27.77	31.52	VERY LOW	1.35	0.42	4.4	5.44	-27.77	31.52	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.59	0.02	7.68	-82.86	-613.09	30.77	VERY LOW	0.59	0.02	7.68	-82.86	-613.09	30.77	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.58	0.55	4.64	9.4	-17.17	33.75	LOW	1.58	0.55	4.64	9.4	-17.17	33.75	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.81	0.44	7.76	9.63	-28.48	36.29	LOW	1.81	0.44	7.76	9.63	-28.48	36.29	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	2.49	1.03	6.36	16.93	0.66	38.26	LOW	2.49	1.03	6.36	16.93	0.66	38.26	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.11	0.99	4.54	15.24	-0.03	36.25	LOW	2.11	0.99	4.54	15.24	-0.03	36.25	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	4.11	1.35	13.08	21.18	5.39	42.22	LOW	4.11	1.35	13.08	21.18	5.39	42.22	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.33	0.47	3.53	5.91	-21.69	30.41	LOW	1.33	0.47	3.53	5.91	-21.69	30.41	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.54	1.13	12.07	19.68	1.69	41.24	LOW	3.54	1.13	12.07	19.68	1.69	41.24	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.56	0.6	4.35	9.65	-13.48	33.1	LOW	1.56	0.6	4.35	9.65	-13.48	33.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.92	0.3	2.73	-4.26	-47.93	25.34	LOW	0.92	0.3	2.73	-4.26	-47.93	25.34	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	2	0.91	4.66	14.55	-1.14	35.86	VERY LOW	2	0.91	4.66	14.55	-1.14	35.86	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	statins	NA	NA	NA	NA	NA	NA	NA	0.95	0.27	3.47	-4.98	-59.8	28.01	VERY LOW	0.95	0.27	3.47	-4.98	-59.8	28.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.16	0.48	2.76	3.68	-20.64	27.58	VERY LOW	1.16	0.48	2.76	3.68	-20.64	27.58	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
(hydroxy)chloroquine	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.36	0.45	4.02	5.99	-25.19	31.38	LOW	1.36	0.45	4.02	5.99	-25.19	31.38	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled corticosteroids	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.43	0.01	6.46	-88.3	-618.87	30.86	VERY LOW	0.43	0.01	6.46	-88.3	-618.87	30.86	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled corticosteroids	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.17	0.3	4.45	3.96	-24.61	37.98	VERY LOW	1.17	0.3	4.45	3.96	-24.61	37.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.34	0.26	7.09	4.19	-35.23	40.09	VERY LOW	1.34	0.26	7.09	4.19	-35.23	40.09	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.84	0.56	6.4	11.49	-7.53	43.39	VERY LOW	1.84	0.56	6.4	11.49	-7.53	43.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.57	0.51	4.64	9.81	-7.75	41.26	VERY LOW	1.57	0.51	4.64	9.81	-7.75	41.26	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	3.04	0.76	13.1	15.75	-2.6	47.39	VERY LOW	3.04	0.76	13.1	15.75	-2.6	47.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.98	0.27	3.45	0.48	-28.9	34.48	VERY LOW	0.98	0.27	3.45	0.48	-28.9	34.48	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.63	0.63	11.39	14.25	-6.24	46.35	VERY LOW	2.63	0.63	11.39	14.25	-6.24	46.35	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.16	0.32	4.27	4.21	-20.95	37.79	VERY LOW	1.16	0.32	4.27	4.21	-20.95	37.79	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.69	0.17	2.57	-9.7	-54.86	27.97	VERY LOW	0.69	0.17	2.57	-9.7	-54.86	27.97	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.48	0.48	4.88	9.11	-9.12	40.87	VERY LOW	1.48	0.48	4.88	9.11	-9.12	40.87	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	statins	NA	NA	NA	NA	NA	NA	NA	0.71	0.16	3.2	-10.42	-66.68	30.34	VERY LOW	0.71	0.16	3.2	-10.42	-66.68	30.34	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.86	0.26	2.76	-1.76	-28.13	31.74	VERY LOW	0.86	0.26	2.76	-1.76	-28.13	31.74	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
inhaled corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA	NA	1	0.26	3.87	0.55	-32.06	35.43	VERY LOW	1	0.26	3.87	0.55	-32.06	35.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.75	0.18	97.98	92.26	-21.88	621.03	VERY LOW	2.75	0.18	97.98	92.26	-21.88	621.03	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	3.21	0.18	123.28	92.49	-28.08	622.26	VERY LOW	3.21	0.18	123.28	92.49	-28.08	622.26	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	4.33	0.32	154.01	99.79	-9.27	628.52	VERY LOW	4.33	0.32	154.01	99.79	-9.27	628.52	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	ivermectin	NA	NA	NA	NA	NA	NA	NA	3.63	0.28	115.66	98.11	-10.85	627.48	VERY LOW	3.63	0.28	115.66	98.11	-10.85	627.48	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	7.22	0.47	259.82	104.04	-4.88	633.96	VERY LOW	7.22	0.47	259.82	104.04	-4.88	633.96	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.27	0.16	81.3	88.77	-26.43	617.33	VERY LOW	2.27	0.16	81.3	88.77	-26.43	617.33	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	molnupiravir	NA	NA	NA	NA	NA	NA	NA	6.22	0.4	231.77	102.54	-7.01	632.36	VERY LOW	6.22	0.4	231.77	102.54	-7.01	632.36	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.7	0.19	98.26	92.51	-19.85	622.87	VERY LOW	2.7	0.19	98.26	92.51	-19.85	622.87	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.6	0.11	58.13	78.6	-45.63	605.28	VERY LOW	1.6	0.11	58.13	78.6	-45.63	605.28	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.46	0.27	117.77	97.41	-11.5	627.46	VERY LOW	3.46	0.27	117.77	97.41	-11.5	627.46	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	statins	NA	NA	NA	NA	NA	NA	NA	1.65	0.1	66.25	77.88	-55.66	605.39	VERY LOW	1.65	0.1	66.25	77.88	-55.66	605.39	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
Interferon alpha	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.97	0.15	68.41	86.54	-26.62	616.51	VERY LOW	1.97	0.15	68.41	86.54	-26.62	616.51	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Inconsistency, Imprecisionx3
Interferon alpha	vitamin D	NA	NA	NA	NA	NA	NA	NA	2.33	0.16	84.67	88.85	-28.45	618.18	VERY LOW	2.33	0.16	84.67	88.85	-28.45	618.18	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon beta (subcutaneous)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.15	0.24	5.65	0.23	-37.36	28.92	LOW	1.15	0.24	5.65	0.23	-37.36	28.92	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.58	0.51	5.05	7.53	-8.65	31.6	LOW	1.58	0.51	5.05	7.53	-8.65	31.6	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.34	0.47	3.75	5.84	-8.74	29.48	LOW	1.34	0.47	3.75	5.84	-8.74	29.48	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.62	0.69	9.96	11.78	-3.86	35.39	LOW	2.62	0.69	9.96	11.78	-3.86	35.39	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.84	0.24	2.79	-3.49	-31.6	23.26	LOW	0.84	0.24	2.79	-3.49	-31.6	23.26	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.26	0.58	9.24	10.28	-7.75	34.45	LOW	2.26	0.58	9.24	10.28	-7.75	34.45	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.3	3.46	0.25	-22.18	26.4	LOW	0.99	0.3	3.46	0.25	-22.18	26.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.59	0.15	2.07	-13.66	-56.87	17.33	LOW	0.59	0.15	2.07	-13.66	-56.87	17.33	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2

MECHANICAL VENTILATION																											
Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
Treatment 1	Treatment 2	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			GRADE					
		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
interferon beta (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.27	0.45	3.85	5.15	-10.22	29.36	VERY LOW	1.27	0.45	3.85	5.15	-10.22	29.36	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	0.6	0.14	2.63	-14.38	-68.79	20.05	VERY LOW	0.6	0.14	2.63	-14.38	-68.79	20.05	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon beta (subcutaneous)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.73	0.24	2.22	-5.72	-30.08	20.4	VERY LOW	0.73	0.24	2.22	-5.72	-30.08	20.4	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
interferon beta (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.86	0.23	3.1	-3.41	-34.12	24.5	LOW	0.86	0.23	3.1	-3.41	-34.12	24.5	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.38	0.32	6.1	7.3	-11.1	43.37	LOW	1.38	0.32	6.1	7.3	-11.1	43.37	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.16	0.29	4.72	5.61	-11.82	41.22	LOW	1.16	0.29	4.72	5.61	-11.82	41.22	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	2.28	0.45	11.56	11.55	-6.56	47.42	LOW	2.28	0.45	11.56	11.55	-6.56	47.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.73	0.15	3.32	-3.72	-33.41	33.88	LOW	0.73	0.15	3.32	-3.72	-33.41	33.88	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.96	0.37	10.53	10.05	-10.11	45.89	LOW	1.96	0.37	10.53	10.05	-10.11	45.89	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.87	0.19	4.1	0.01	-25.2	37.17	LOW	0.87	0.19	4.1	0.01	-25.2	37.17	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.51	0.1	2.47	-13.89	-58.38	26.32	LOW	0.51	0.1	2.47	-13.89	-58.38	26.32	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon lambda (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.11	0.27	4.71	4.91	-12.96	41.14	VERY LOW	1.11	0.27	4.71	4.91	-12.96	41.14	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon lambda (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	0.52	0.09	2.99	-14.61	-70.05	29.05	VERY LOW	0.52	0.09	2.99	-14.61	-70.05	29.05	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
interferon lambda (subcutaneous)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.64	0.15	2.68	-5.95	-32.45	31.42	VERY LOW	0.64	0.15	2.68	-5.95	-32.45	31.42	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
interferon lambda (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.75	0.15	3.72	-3.64	-36.4	35.07	LOW	0.75	0.15	3.72	-3.64	-36.4	35.07	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.84	0.35	1.96	-1.68	-11.85	9.7	LOW	0.84	0.35	1.96	-1.68	-11.85	9.7	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.65	0.49	5.53	4.25	-7.21	15.73	LOW	1.65	0.49	5.53	4.25	-7.21	15.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.53	0.17	1.48	-11.02	-36.48	5.68	LOW	0.53	0.17	1.48	-11.02	-36.48	5.68	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.42	0.41	5.04	2.75	-11.47	14.97	LOW	1.42	0.41	5.04	2.75	-11.47	14.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.63	0.22	1.82	-7.28	-27.08	8.2	LOW	0.63	0.22	1.82	-7.28	-27.08	8.2	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.37	0.11	1.14	-21.19	-63.1	1.79	LOW	0.37	0.11	1.14	-21.19	-63.1	1.79	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.8	0.33	2	-2.38	-13.42	9.73	VERY LOW	0.8	0.33	2	-2.38	-13.42	9.73	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulation	statins	NA	NA	NA	NA	NA	NA	NA	0.38	0.1	1.4	-21.91	-74.55	4.44	VERY LOW	0.38	0.1	1.4	-21.91	-74.55	4.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulation	therapeutic-dose anticoagulation	0.25	0.06	1.15	NA	NA	NA	LOW	NA	NA	NA	NA	NA	NA	NA	0.46	0.19	1.08	-13.25	-33.51	1.57	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
intermediate-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.55	0.17	1.66	-10.94	-39.85	6.97	LOW	0.55	0.17	1.66	-10.94	-39.85	6.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	JAK inhibitors	NA	NA	NA	NA	NA	NA	NA	1.95	0.67	6.03	5.94	-5	15.48	LOW	1.95	0.67	6.03	5.94	-5	15.48	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.63	0.24	1.6	-9.33	-34.63	6.28	LOW	0.63	0.24	1.6	-9.33	-34.63	6.28	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.69	0.56	5.49	4.44	-9.66	14.88	LOW	1.69	0.56	5.49	4.44	-9.66	14.88	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.74	0.29	1.96	-5.6	-25.04	8.43	LOW	0.74	0.29	1.96	-5.6	-25.04	8.43	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.44	0.14	1.22	-19.51	-61.24	2.93	LOW	0.44	0.14	1.22	-19.51	-61.24	2.93	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.95	0.47	2.08	-0.7	-11.19	9.55	VERY LOW	0.95	0.47	2.08	-0.7	-11.19	9.55	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	0.45	0.13	1.6	-20.22	-73.49	5.91	VERY LOW	0.45	0.13	1.6	-20.22	-73.49	5.91	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.55	0.24	1.22	-11.56	-32.59	3.17	VERY LOW	0.55	0.24	1.22	-11.56	-32.59	3.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
ivermectin	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.65	0.22	1.79	-9.26	-37.81	7.3	LOW	0.65	0.22	1.79	-9.26	-37.81	7.3	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.32	0.09	1.12	-15.27	-40.57	0.98	LOW	0.32	0.09	1.12	-15.27	-40.57	0.98	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.86	0.21	3.68	-1.5	-15.15	10.07	LOW	0.86	0.21	3.68	-1.5	-15.15	10.07	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.38	0.11	1.39	-11.54	-30.98	3.39	LOW	0.38	0.11	1.39	-11.54	-30.98	3.39	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.22	0.05	0.83	-25.44	-67.06	-2.35	LOW	0.22	0.05	0.83	-25.44	-67.06	-2.35	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
JAK inhibitors	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.49	0.16	1.53	-6.64	-17.09	4.99	VERY LOW	0.49	0.16	1.53	-6.64	-17.09	4.99	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	statins	NA	NA	NA	NA	NA	NA	NA	0.23	0.05	1.06	-26.16	-79.24	0.05	VERY LOW	0.23	0.05	1.06	-26.16	-79.24	0.05	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
JAK inhibitors	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.28	0.08	0.9	-17.5	-38.51	-1.96	VERY LOW	0.28	0.08	0.9	-17.5	-38.51	-1.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
JAK inhibitors	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.33	0.08	1.23	-15.19	-43.72	2.13	LOW	0.33	0.08	1.23	-15.19	-43.72	2.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	2.69	0.74	10.63	13.77	-4.64	39.71	LOW	2.69	0.74	10.63	13.77	-4.64	39.71	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.18	0.39	3.9	3.73	-19.44	31.28	LOW	1.18	0.39	3.9	3.73	-19.44	31.28	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.7	0.2	2.33	-10.17	-53.62	21.96	LOW	0.7	0.2	2.33	-10.17	-53.62	21.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.51	0.59	4.36	8.63	-7.32	34.31	VERY LOW	1.51	0.59	4.36	8.63	-7.32	34.31	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	0.72	0.18	3.01	-10.89	-65.16	25.01	VERY LOW	0.72	0.18	3.01	-10.89	-65.16	25.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.88	0.31	2.5	-2.23	-26.59	24.8	VERY LOW	0.88	0.31	2.5	-2.23	-26.59	24.8	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.03	0.3	3.51	0.08	-30.86	29.01	LOW	1.03	0.3	3.51	0.08	-30.86	29.01	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
molnupiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.44	0.12	1.67	-10.04	-30.17	7.35	LOW	0.44	0.12	1.67	-10.04	-30.17	7.35	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
molnupiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.26	0.06	1.01	-23.94	-66.01	0.4	LOW	0.26	0.06	1.01	-23.94	-66.01	0.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.57	0.17	1.84	-5.14	-16.42	9.39	VERY LOW	0.57	0.17	1.84	-5.14	-16.42	9.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
molnupiravir	statins	NA	NA	NA	NA	NA	NA	NA	0.27	0.05	1.24	-24.66	-77.91	3.21	VERY LOW	0.27	0.05	1.24	-24.66	-77.91	3.21	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
molnupiravir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.33	0.09	1.07	-16	-37.57	1.63	VERY LOW	0.33	0.09	1.07	-16	-37.57	1.63	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
molnupiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.38	0.09	1.48	-13.69	-42.56	5.72	LOW	0.38	0.09	1.48	-13.69	-42.56	5.72	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
nirmatrelvir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.59	0.16	1.94	-13.91	-57.47	14.5	LOW	0.59	0.16	1.94	-13.91	-57.47	14.5	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
nirmatrelvir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.28	0.49	3.43	4.9	-9.58	24.5	VERY LOW	1.28	0.49	3.43	4.9	-9.58	24.5	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
nirmatrelvir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	0.61	0.15	2.44	-14.62	-69.08	17.24	VERY LOW	0.61	0.15	2.44	-14.62	-69.08	17.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
nirmatrelvir-ritonavir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.74	0.25	2.04	-5.97	-30.09	16.48	VERY LOW	0.74	0.25	2.04	-5.97	-30.09	16.48	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
nirmatrelvir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.87	0.24	2.87	-3.66	-34.46	20.67	LOW	0.87	0.24	2.87	-3.66	-34.46	20.67	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
prophylactic-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.17	0.75	7.04	18.81	-4.06	61.14	VERY LOW	2.17	0.75	7.04	18.81	-4.06	61.14	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
prophylactic-dose anticoagulation	statins	NA	NA	NA	NA	NA	NA	NA	1.03	0.25	4.72	-0.72	-58.15	48.76	VERY LOW	1.03	0.25	4.72	-0.72	-58.15	48.76	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.25	0.41	3.93	7.94	-21.39	50.71	VERY LOW	1.25	0.41	3.93	7.94	-21.39	50.71	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
prophylactic-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.47	0.41	5.57	10.25	-24.65	53.86	LOW	1.47	0.41	5.57	10.25	-24.65	53.86	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
remdesivir	statins	NA	NA	NA	NA	NA	NA	NA	0.48	0.13	1.67	-19.52	-72.85	7.03	VERY LOW	0.48	0.13	1.67	-19.52	-72.85	7.03	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
remdesivir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.58	0.23	1.32	-10.87	-32.57	4.28	VERY LOW	0.58	0.23	1.32	-10.87	-32.57	4.28	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
remdesivir	vitamin D	NA	NA	NA	NA	NA	NA	NA	0.68	0.22	1.9	-8.56	-37.44	8.61	VERY LOW	0.68	0.22	1.9	-8.56	-37.44	8.61	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
statins	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.22	0.32	4.39	8.66	-23.72	62.56	VERY LOW	1.22	0.32	4.39	8.66	-23.72	62.56	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Inconsistency, Imprecisionx2
statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.44	0.32	6.21	10.97	-27.1	66.12	VERY LOW	1.44	0.32	6.21	10.97	-27.1	66.12	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
therapeutic-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA	NA	1.17	0.38	3.63	2.31	-27.88	27.9	VERY LOW	1.17	0.38	3.63	2.31	-27.88	27.9	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2

ADMISSION TO HOSPITAL																													
Comparison		Direct estimate							Indirect estimate							Network estimate							GRADE					Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit						
aspirin	standard care/placebo	0.79	0.24	2.25	-6.21	-22.72	34.95	LOW	NA	NA	NA	NA	NA	NA	NA	0.78	0.4	1.46	-5.31	-17.83	13.57	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	0.42	0.09	1.93	-13	-27.32	26.47	LOW	0.42	0.09	1.93	-13	-27.32	26.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	standard care/placebo	0.99	0.47	2.2	-0.40	-15.67	33.64	LOW	NA	NA	NA	NA	NA	NA	NA	1.05	0.59	1.97	3.07	-12.27	27.31	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin, hydroxychloroquine	standard care/placebo	4.17	0.39	45.07	84.34	-18.19	552.29	VERY LOW	NA	NA	NA	NA	NA	NA	NA	400742647	19.58	1.028E+20	845.18	84.09	970	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	standard care/placebo	0.79	0.4	1.43	-6.03	-17.70	12.36	LOW	NA	NA	NA	NA	NA	NA	NA	0.79	0.52	1.15	-5.88	-14.17	4.47	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
corticosteroids (systemic)	standard care/placebo	0.43	0.1	1.86	-16.82	-26.91	24.43	LOW	NA	NA	NA	NA	NA	NA	NA	0.43	0.2	0.9	-15.99	-23.93	-2.63	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	standard care/placebo	1.14	0.58	2.26	4.09	-12.43	35.36	LOW	NA	NA	NA	NA	NA	NA	NA	1.07	0.61	1.89	3.2	-11.63	25.18	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	standard care/placebo	0.76	0.44	1.28	-7.00	-16.51	8.13	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.73	0.44	1.15	-7.44	-16.41	4.56	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine, inhaled corticosteroids	standard care/placebo	0.87	0.17	4.62	-3.69	-24.92	95.10	LOW	NA	NA	NA	NA	NA	NA	NA	0.87	0.26	2.83	1.12	-21.84	52.47	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	standard care/placebo	1.1	0.2	5.94	2.82	-23.72	125.15	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1.15	0.25	6.43	18.75	-22.29	142.63	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	standard care/placebo	0.87	0.56	1.37	-3.77	-12.91	10.65	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.91	0.61	1.39	-1.97	-11.61	11.38	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled and intranasal corticosteroid	standard care/placebo	1.92	0.28	13.19	26.03	-21.44	259.76	VERY LOW	NA	NA	NA	NA	NA	NA	NA	2.07	0.45	10.94	47.38	-16.46	231.54	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled corticosteroids	standard care/placebo	0.64	0.17	2.35	-10.64	-24.62	37.71	LOW	NA	NA	NA	NA	NA	NA	NA	0.6	0.18	1.8	-8.86	-24.35	22.72	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
interferon beta (subcutaneous)	standard care/placebo	0.77	0.18	3.38	-6.75	-24.6	64.54	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.77	0.34	1.71	-4.99	-19.5	20.49	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
interferon lambda (subcutaneous)	standard care/placebo	0.63	0.27	1.61	-10.97	-21.85	17.31	LOW	NA	NA	NA	NA	NA	NA	NA	0.61	0.31	1.24	-10.21	-20.69	7.24	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
ivermectin	standard care/placebo	0.84	0.6	1.16	-4.74	-11.68	4.77	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.85	0.61	1.18	-4.02	-11.4	5.35	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
lopinavir-ritonavir	standard care/placebo	1.04	0.44	2.55	1.15	-16.7	43.21	LOW	NA	NA	NA	NA	NA	NA	NA	0.86	0.43	1.73	-2.57	-16.79	20.62	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
molnupiravir	standard care/placebo	0.66	0.39	1.02	-9.95	-18.01	0.52	LOW	NA	NA	NA	NA	NA	NA	NA	0.66	0.44	0.92	-9.82	-16.66	-2.28	Direct	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
nirmatrelvir-ritonavir	standard care/placebo	0.16	0.06	0.47	-24.96	-28.11	-15.66	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.15	0.07	0.32	-24.99	-27.86	-20.19	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
prophylactic-dose anticoagulation	standard care/placebo	1.06	0.69	1.62	1.77	-9.2	17.65	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.06	0.69	1.62	2.45	-9.05	17.76	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
remdesivir	standard care/placebo	0.27	0.05	1.41	-21.76	-28.42	11.8	LOW	NA	NA	NA	NA	NA	NA	NA	0.25	0.07	0.77	-20.93	-27.79	-6.69	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
serine protease inhibitors	standard care/placebo	0.8	0.23	2.67	-5.95	-22.93	46.25	LOW	NA	NA	NA	NA	NA	NA	NA	0.78	0.27	2.16	-2.85	-21.12	34.46	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
therapeutic-dose anticoagulation	standard care/placebo	1.91	0.12	30.1	25.91	-26.25	452.13	VERY LOW	NA	NA	NA	NA	NA	NA	NA	2.85	0.24	29.78	90.33	-22.39	442.64	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	multivitamin	NA	NA	NA	NA	NA	NA	NA	1.85	0.35	9.92	7.69	-33.32	32.76	LOW	1.85	0.35	9.92	7.69	-33.32	32.76	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.74	0.29	1.73	-8.39	-35.88	15.90	LOW	0.74	0.29	1.73	-8.39	-35.88	15.9	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	0.04	-850.49	-986.59	-89.2	VERY LOW	0	0	0.04	-850.49	-986.59	-89.2	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	0.99	0.46	2.11	0.57	-15.79	21.36	LOW	0.99	0.46	2.11	0.57	-15.79	21.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.83	0.67	4.84	10.68	-7.82	31.30	LOW	1.83	0.67	4.84	10.68	-7.82	31.3	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.73	0.3	1.7	-8.51	-33.88	15.77	LOW	0.73	0.3	1.7	-8.51	-33.88	15.77	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.07	0.48	2.39	2.13	-15.29	23.05	LOW	1.07	0.48	2.39	2.13	-15.29	23.05	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.9	0.23	3.48	-6.43	-59.58	24.40	LOW	0.9	0.23	3.48	-6.43	-59.58	24.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.67	0.11	3.47	-24.06	-148.54	23.14	VERY LOW	0.67	0.11	3.47	-24.06	-148.54	23.14	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.86	0.39	1.8	-3.34	-22.04	17.66	LOW	0.86	0.39	1.8	-3.34	-22.04	17.66	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.38	0.06	1.96	-52.69	-237.67	15.08	VERY LOW	0.38	0.06	1.96	-52.69	-237.67	15.08	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
aspirin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.3	0.36	4.94	3.55	-30.56	28.65	LOW	1.3	0.36	4.94	3.55	-30.56	28.65	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.02	0.36	2.8	-0.32	-28.95	23.70	VERY LOW	1.02	0.36	2.8	-0.32	-28.95	23.7	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.27	0.48	3.23	4.89	-16.91	26.64	LOW	1.27	0.48	3.23	4.89	-16.91	26.64	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.92	0.44	1.86	-1.29	-17.26	18.93	LOW	0.92	0.44	1.86	-1.29	-17.26	18.93	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.91	0.34	2.3	-2.74	-29.30	21.07	LOW	0.91	0.34	2.3	-2.74	-29.3	21.07	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.17	0.58	2.53	4.51	-9.80	24.91	VERY LOW	1.17	0.58	2.53	4.51	-9.8	24.91	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
aspirin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.15	1.87	14.02	19.68	6.20	38.78	LOW	5.15	1.87	14.02	19.68	6.2	38.78	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	prophylactic-dose anticoagulation	0.31	0.01	9.67	NA	NA	NA	VERY LOW	0.79	0.36	1.75	NA	NA	NA	LOW	0.73	0.34	1.57	-7.76	-27.74	14.06	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.09	0.83	12.43	15.62	-3.13	36.13	LOW	3.09	0.83	12.43	15.62	-3.13	36.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.3	3.38	-2.46	-41.42	24.79	LOW	1.01	0.3	3.38	-2.46	-41.42	24.79	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	therapeutic-dose anticoagulation	0.2	0.01	5.24	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.27	0.03	3.24	-95.64	-447.69	18.28	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	azithromycin	NA	NA	NA	NA	NA	NA	NA	0.4	0.07	2.03	-16.08	-46.02	25.69	LOW	0.4	0.07	2.03	-16.08	-46.02	25.69	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	0.02	-858.18	-996.57	-97.32	VERY LOW	0	0	0.02	-858.18	-996.57	-97.32	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	colchicine	NA	NA	NA	NA	NA	NA	NA	0.54	0.11	2.63	-7.12	-26.05	32.66	LOW	0.54	0.11	2.63	-7.12	-26.05	32.66	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.99	0.17	5.41	2.99	-18.01	43.04	VERY LOW	0.99	0.17	5.41	2.99	-18.01	43.04	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.39	0.07	2.01	-16.20	-44.48	25.37	LOW	0.39	0.07	2.01	-16.2	-44.48	25.37	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.58	0.11	2.91	-5.56	-25.79	34.65	LOW	0.58	0.11	2.91	-5.56	-25.79	34.65	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.49	0.07	3.44	-14.12	-69.10	32.22	VERY LOW	0.49	0.07	3.44	-14.12	-69.1	32.22	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.36	0.04	3.17	-31.75	-156.75	27.27	VERY LOW	0.36	0.04	3.17	-31.75	-156.75	27.27	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.46	0.09	2.23	-11.03	-32.41	29.29	LOW	0.46	0.09	2.23	-11.03	-32.41	29.29	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.2	0.02	1.71	-60.38	-245.57	16.64	VERY LOW	0.2	0.02	1.71	-60.38	-245.57	16.64	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	inhaled corticosteroids	0.71	0.16	3.17	NA	NA	NA	LOW	NA	NA	NA	NA	NA	NA	NA	0.71	0.25	1.99	-4.14	-24.54	20.41	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.55	0.1	3.1	-8.01	-39.07	33.86	VERY LOW	0.55	0.1	3.1	-8.01	-39.07	33.86	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
multivitamin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.69	0.12	3.66	-2.8	-27.3	37.42	LOW	0.69	0.12	3.66	-2.8	-27.3	37.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.5	0.1	2.37	-8.98	-27.29	30.69	LOW	0.5	0.1	2.37	-8.98	-27.29	30.69	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.49	0.09	2.62	-10.43	-39.51	31.31	LOW	0.49	0.09	2.62	-10.43	-39.51	31.31	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.64	0.13	3.12	-3.18	-20.42	36.62	VERY LOW	0.64	0.13	3.12	-3.18	-20.42	36.62	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
multivitamin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.79	0.49	15.55	11.99	-3.44	51.57	VERY LOW	2.79	0.49	15.55	11.99	-3.44	51.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.4	0.08	1.92	-15.45	-38.21	25.00	LOW	0.4	0.08	1.92	-15.45	-38.21	25	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
multivitamin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.69	0.24	12.23	7.93	-13.55	47.96	VERY LOW	1.69	0.24	12.23	7.93	-13.55	47.96	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.55	0.08	3.45	-10.15	-51.83	33.42	VERY LOW	0.55	0.08	3.45	-10.15	-51.83	33.42	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
multivitamin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.15	0.01	2.62	-103.33	-456.06	17.81	VERY LOW	0.15	0.01	2.62	-103.33	-456.06	17.81	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	azithromycin, hydroxychloroquine	NA	NA	NA	NA	NA	NA	NA	0	0	0.05	-842.10	-980.87	-81.64	VERY LOW	0	0	0.05	-842.1	-980.87	-81.64	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.34	0.67	2.86	8.95	-9.66	34.67	LOW	1.34	0.67	2.86	8.95	-9.66	34.67	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	2.46	0.96	6.62	19.06	-1.05	44.82	LOW	2.46	0.96	6.62	19.06	-1.05	44.82	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.99	0.43	2.28	-0.12	-27.13	28.54	LOW	0.99	0.43	2.28	-0.12	-27.13	28.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.45	0.69	3.26	10.52	-8.99	36.49	LOW	1.45	0.69	3.26	10.52	-8.99	36.49	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.21	0.32	4.83	1.95	-51.54	36.66	LOW	1.21	0.32	4.83	1.95	-51.54	36.66	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.91	0.15	4.67	-15.67	-140.77	34.81	VERY LOW	0.91	0.15	4.67	-15.67	-140.77	34.81	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.16	0.56	2.43	5.04	-15.34	30.77	LOW	1.16	0.56	2.43	5.04	-15.34	30.77	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.51	0.09	2.66	-44.31	-229.54	26.12	VERY LOW	0.51	0.09	2.66	-44.31	-229.54	26.12	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3

ADMISSION TO HOSPITAL																												
Comparison		Direct estimate							Indirect estimate							Network estimate												
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					Reasons for downgrading
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
azithromycin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.76	0.51	6.72	11.94	-22.97	41.58	LOW	1.76	0.51	6.72	11.94	-22.97	41.58	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.37	0.51	3.81	8.06	-21.51	36.96	VERY LOW	1.37	0.51	3.81	8.06	-21.51	36.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.71	0.69	4.41	13.28	-9.91	39.91	LOW	1.71	0.69	4.41	13.28	-9.91	39.91	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.24	0.63	2.53	7.10	-10.89	32.39	LOW	1.24	0.63	2.53	7.1	-10.89	32.39	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.23	0.5	3.07	5.64	-22.15	33.86	LOW	1.23	0.5	3.07	5.64	-22.15	33.86	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.59	0.81	3.44	12.89	-4.20	38.54	VERY LOW	1.59	0.81	3.44	12.89	-4.2	38.54	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
azithromycin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	6.96	2.68	19.09	28.06	12.06	52.42	LOW	6.96	2.68	19.09	28.06	12.06	52.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.99	0.48	2.14	0.63	-21.22	27.60	LOW	0.99	0.48	2.14	0.63	-21.22	27.6	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	4.19	1.19	16.63	24.01	3.48	49.66	LOW	4.19	1.19	16.63	24.01	3.48	49.66	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.36	0.42	4.64	5.92	-34.78	37.55	LOW	1.36	0.42	4.64	5.92	-34.78	37.55	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
azithromycin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.37	0.03	4.71	-87.25	-439.94	30.12	VERY LOW	0.37	0.03	4.71	-87.25	-439.94	30.12	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	colchicine	NA	NA	NA	NA	NA	NA	NA	514486565	25.11	1.252E+20	851.06	89.43	983.15	VERY LOW	514486565	25.11	1.252E+20	851.06	89.43	983.15	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	948061565	46.29	2.443E+20	861.17	100.04	993.17	VERY LOW	948061565	46.29	2.443E+20	861.17	100.04	993.17	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	favipiravir	NA	NA	NA	NA	NA	NA	NA	364391720	18.32	1.093E+20	841.98	81.32	980.26	VERY LOW	364391720	18.32	1.093E+20	841.98	81.32	980.26	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	556556917	27.25	1.444E+20	852.62	90.80	985.41	VERY LOW	556556917	27.25	1.444E+20	852.62	90.8	985.41	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	468286104	22.12	1.169E+20	844.06	83.64	990.51	VERY LOW	468286104	22.12	1.169E+20	844.06	83.64	990.51	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	361354490	15.72	8.459E+19	826.43	70.44	990.88	VERY LOW	361354490	15.72	8.459E+19	826.43	70.44	990.88	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	azithromycin, hydroxychloroquine	0.18	0.01	4.99	NA	NA	NA	VERY LOW	0	0	0.5	NA	NA	NA	VERY LOW	0	0	0.05	-847.15	-980.52	-86.33	Direct	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	191180774	9.34	4.141E+19	797.8	37.48	983.73	VERY LOW	191180774	9.34	4.141E+19	797.8	37.48	983.73	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	723448558	32.14	1.541E+20	854.04	93.62	993.2	VERY LOW	723448558	32.14	1.541E+20	854.04	93.62	993.2	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	525053122	25.58	1.296E+20	850.17	89.5	988.27	VERY LOW	525053122	25.58	1.296E+20	850.17	89.5	988.27	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
azithromycin, hydroxychloroquine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	655887606	31.76	1.6E+20	855.38	94.27	989.71	VERY LOW	655887606	31.76	1.6E+20	855.38	94.27	989.71	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	478817461	23.51	1.144E+20	849.2	88.54	980.53	VERY LOW	478817461	23.51	1.144E+20	849.2	88.54	980.53	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	462927031	22.83	1.195E+20	847.75	86.88	985.46	VERY LOW	462927031	22.83	1.195E+20	847.75	86.88	985.46	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	614162433	30.24	1.591E+20	854.99	93.53	985.83	VERY LOW	614162433	30.24	1.591E+20	854.99	93.53	985.83	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3
azithromycin, hydroxychloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.685E+09	126.66	6.408E+20	870.17	109.2	997.57	VERY LOW	2.685E+09	126.66	6.408E+20	870.17	109.2	997.57	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	381407914	18.14	9.294E+19	842.73	81.03	977.89	VERY LOW	381407914	18.14	9.294E+19	842.73	81.03	977.89	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.647E+09	79.31	4.651E+20	866.11	104.95	997.29	VERY LOW	1.647E+09	79.31	4.651E+20	866.11	104.95	997.29	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	532551412	25.13	1.452E+20	848.03	87.65	989.84	VERY LOW	532551412	25.13	1.452E+20	848.03	87.65	989.84	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
azithromycin, hydroxychloroquine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	140184504	5.04	3.146E+19	754.85	-1.6	989.38	VERY LOW	140184504	5.04	3.146E+19	754.85	-1.6	989.38	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.84	0.78	4.28	10.11	-5.6	23.41	LOW	1.84	0.78	4.28	10.11	-5.6	23.41	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.74	0.36	1.46	-9.08	-32.58	8.99	LOW	0.74	0.36	1.46	-9.08	-32.58	8.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.08	0.58	2.01	1.56	-13.11	15.42	LOW	1.08	0.58	2.01	1.56	-13.11	15.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.9	0.26	3.22	-7	-58.96	18.89	LOW	0.9	0.26	3.22	-7	-58.96	18.89	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.68	0.12	3.22	-24.63	-148.75	18.55	VERY LOW	0.68	0.12	3.22	-24.63	-148.75	18.55	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.87	0.47	1.5	-3.91	-19.73	10.15	LOW	0.87	0.47	1.5	-3.91	-19.73	10.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.38	0.07	1.82	-53.26	-237.65	11.71	LOW	0.38	0.07	1.82	-53.26	-237.65	11.71	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.3	0.4	4.55	2.98	-29.45	22.24	LOW	1.3	0.4	4.55	2.98	-29.45	22.24	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.02	0.41	2.49	-0.89	-27.7	17.26	VERY LOW	1.02	0.41	2.49	-0.89	-27.7	17.26	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.28	0.56	2.81	4.33	-15.22	19.2	LOW	1.28	0.56	2.81	4.33	-15.22	19.2	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.93	0.54	1.52	-1.86	-14.42	10.71	MODERATE	0.93	0.54	1.52	-1.86	-14.42	10.71	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.91	0.4	1.99	-3.31	-28.08	14.42	LOW	0.91	0.4	1.99	-3.31	-28.08	14.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.18	0.71	2.08	3.94	-6.87	16.53	LOW	1.18	0.71	2.08	3.94	-6.87	16.53	Indirect	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
colchicine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.17	2.17	12.44	19.11	9.5	29.91	LOW	5.17	2.17	12.44	19.11	9.5	29.91	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.74	0.41	1.31	-8.33	-25.71	7.13	LOW	0.74	0.41	1.31	-8.33	-25.71	7.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.11	0.94	11.46	15.05	-1.15	27.97	LOW	3.11	0.94	11.46	15.05	-1.15	27.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.01	0.34	3.08	-3.03	-41.02	18.49	LOW	1.01	0.34	3.08	-3.03	-41.02	18.49	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
colchicine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.27	0.03	3.38	-96.21	-448.48	17.36	VERY LOW	0.27	0.03	3.38	-96.21	-448.48	17.36	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.4	0.15	1.02	-19.18	-42.69	0.56	LOW	0.4	0.15	1.02	-19.18	-42.69	0.56	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.59	0.24	1.45	-8.54	-23.26	7.54	LOW	0.59	0.24	1.45	-8.54	-23.26	7.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.49	0.12	2.04	-17.11	-69.29	9.97	LOW	0.49	0.12	2.04	-17.11	-69.29	9.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.37	0.06	2.01	-34.74	-159.2	9.27	VERY LOW	0.37	0.06	2.01	-34.74	-159.2	9.27	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.47	0.19	1.09	-14.02	-29.79	2.15	LOW	0.47	0.19	1.09	-14.02	-29.79	2.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.21	0.03	1.13	-63.37	-248.08	2.34	VERY LOW	0.21	0.03	1.13	-63.37	-248.08	2.34	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
corticosteroids (systemic)	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.71	0.19	2.89	-7.12	-40.01	13.96	LOW	0.71	0.19	2.89	-7.12	-40.01	13.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.56	0.18	1.68	-11	-37.84	8.89	VERY LOW	0.56	0.18	1.68	-11	-37.84	8.89	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.7	0.25	1.93	-5.78	-25.33	11.38	LOW	0.7	0.25	1.93	-5.78	-25.33	11.38	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.51	0.22	1.14	-11.97	-24.58	3.13	LOW	0.51	0.22	1.14	-11.97	-24.58	3.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.5	0.18	1.36	-13.42	-38.22	6.05	LOW	0.5	0.18	1.36	-13.42	-38.22	6.05	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.65	0.29	1.54	-6.17	-17.3	9.13	VERY LOW	0.65	0.29	1.54	-6.17	-17.3	9.13	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
corticosteroids (systemic)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.82	0.96	8.38	9	-0.27	22.63	LOW	2.82	0.96	8.38	9	-0.27	22.63	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.4	0.17	0.96	-18.43	-36.07	-0.86	LOW	0.4	0.17	0.96	-18.43	-36.07	-0.86	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.69	0.44	7.22	4.94	-11.51	20.44	LOW	1.69	0.44	7.22	4.94	-11.51	20.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.55	0.16	1.99	-13.14	-51.33	9.96	LOW	0.55	0.16	1.99	-13.14	-51.33	9.96	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
corticosteroids (systemic)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.15	0.01	1.94	-106.32	-458.61	7.43	VERY LOW	0.15	0.01	1.94	-106.32	-458.61	7.43	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
favipiravir	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.47	0.71	3.14	10.64	-8.52	34.57	LOW	1.47	0.71	3.14	10.64	-8.52	34.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.23	0.33	4.73	2.07	-51.77	35.73	LOW	1.23	0.33	4.73	2.07	-51.77	35.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.93	0.15	4.64	-15.55	-139.97	33.35	VERY LOW	0.93	0.15	4.64	-15.55	-139.97	33.35	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
favipiravir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.17	0.58	2.35	5.16	-14.94	29.12	LOW	1.17	0.58	2.35	5.16	-14.94	29.12	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.52	0.09	2.62	-44.19	-228.83	25.13	LOW	0.52	0.09	2.62	-44.19	-228.83	25.13	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.77	0.52	6.7	12.06	-22.84	40.06	LOW	1.77	0.52	6.7	12.06	-22.84	40.06	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.39	0.52	3.73	8.19	-21.31	35.24	VERY LOW	1.39	0.52	3.73	8.19	-21.31	35.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.74	0.7	4.29	13.4	-9.83	38.16	LOW	1.74	0.7	4.29	13.4	-9.83	38.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.26	0.65	2.42	7.22	-10.4	30.47	LOW	1.26	0.65	2.42	7.22	-10.4	30.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	lopinavir-ritonavir	1.02	0.05	21.62	NA	NA	NA	VERY LOW	1.26	0.5	3.17	NA	NA	NA	LOW	1.24	0.51	2.99	5.76	-21.55	32.17	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2

ADMISSION TO HOSPITAL

Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
favipiravir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.61	0.84	3.25	13.01	-3.81	36.19	VERY LOW	1.61	0.84	3.25	13.01	-3.81	36.19	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
favipiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	7.04	2.76	18.7	28.19	12.68	50.44	LOW	7.04	2.76	18.7	28.19	12.68	50.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.01	0.49	2.06	0.75	-21.03	25.6	LOW	1.01	0.49	2.06	0.75	-21.03	25.6	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	4.22	1.21	16.73	24.13	4.1	47.74	LOW	4.22	1.21	16.73	24.13	4.1	47.74	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.38	0.43	4.53	6.05	-33.82	36.11	LOW	1.38	0.43	4.53	6.05	-33.82	36.11	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.38	0.03	4.6	-87.13	-440.38	29.52	VERY LOW	0.38	0.03	4.6	-87.13	-440.38	29.52	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.84	0.23	3	-8.57	-60.62	18.36	LOW	0.84	0.23	3	-8.57	-60.62	18.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.63	0.11	3.04	-26.19	-151.02	17.48	VERY LOW	0.63	0.11	3.04	-26.19	-151.02	17.48	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.8	0.41	1.47	-5.48	-21.8	9.78	LOW	0.8	0.41	1.47	-5.48	-21.8	9.78	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.35	0.06	1.71	-54.83	-239.49	10.75	LOW	0.35	0.06	1.71	-54.83	-239.49	10.75	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.2	0.36	4.35	1.42	-31.19	21.85	LOW	1.2	0.36	4.35	1.42	-31.19	21.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.94	0.37	2.37	-2.45	-29.52	16.59	VERY LOW	0.94	0.37	2.37	-2.45	-29.52	16.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.18	0.5	2.7	2.76	-17.22	19.05	LOW	1.18	0.5	2.7	2.76	-17.22	19.05	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.86	0.47	1.49	-3.42	-16.6	10.59	LOW	0.86	0.47	1.49	-3.42	-16.6	10.59	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.84	0.36	1.91	-4.88	-29.92	13.99	LOW	0.84	0.36	1.91	-4.88	-29.92	13.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.09	0.61	2.03	2.37	-9.2	16.33	VERY LOW	1.09	0.61	2.03	2.37	-9.2	16.33	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
fluvoxamine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.78	1.93	11.81	17.54	7.34	29.98	LOW	4.78	1.93	11.81	17.54	7.34	29.98	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.68	0.36	1.28	-9.89	-27.84	6.76	LOW	0.68	0.36	1.28	-9.89	-27.84	6.76	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.87	0.85	10.77	13.49	-3.12	27.84	LOW	2.87	0.85	10.77	13.49	-3.12	27.84	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.93	0.3	2.95	-4.6	-42.89	18.14	LOW	0.93	0.3	2.95	-4.6	-42.89	18.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.25	0.02	3.12	-97.77	-450.92	16.32	VERY LOW	0.25	0.02	3.12	-97.77	-450.92	16.32	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.74	0.09	5.19	-17.63	-144.31	52.4	VERY LOW	0.74	0.09	5.19	-17.63	-144.31	52.4	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
fluvoxamine, inhaled corticosteroids	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.95	0.26	3.31	3.09	-24.63	55.63	LOW	0.95	0.26	3.31	3.09	-24.63	55.63	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.42	0.05	2.91	-46.26	-233.04	40.28	VERY LOW	0.42	0.05	2.91	-46.26	-233.04	40.28	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
fluvoxamine, inhaled corticosteroids	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.44	0.28	7.64	9.99	-30.22	64.57	LOW	1.44	0.28	7.64	9.99	-30.22	64.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.13	0.27	4.74	6.11	-29.54	59.96	VERY LOW	1.13	0.27	4.74	6.11	-29.54	59.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine, inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.42	0.35	5.55	11.33	-18.77	63.81	LOW	1.42	0.35	5.55	11.33	-18.77	63.81	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.03	0.29	3.5	5.14	-20.34	56.81	LOW	1.03	0.29	3.5	5.14	-20.34	56.81	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.01	0.25	3.88	3.69	-30.66	56.87	LOW	1.01	0.25	3.88	3.69	-30.66	56.87	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.32	0.38	4.63	10.94	-13.83	62.78	VERY LOW	1.32	0.38	4.63	10.94	-13.83	62.78	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
fluvoxamine, inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.73	1.38	23.72	26.11	2.5	77.62	LOW	5.73	1.38	23.72	26.11	2.5	77.62	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.82	0.23	2.87	-1.32	-30.21	51.59	LOW	0.82	0.23	2.87	-1.32	-30.21	51.59	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.47	0.66	19.13	22.05	-5.59	74.09	LOW	3.47	0.66	19.13	22.05	-5.59	74.09	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.12	0.23	5.42	3.97	-41.35	59.56	LOW	1.12	0.23	5.42	3.97	-41.35	59.56	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine, inhaled corticosteroids	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.3	0.02	4.64	-89.21	-442.51	39.36	VERY LOW	0.3	0.02	4.64	-89.21	-442.51	39.36	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
HIV reverse transcriptase inhibitor	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.27	0.27	7.26	20.72	-23.57	144.73	VERY LOW	1.27	0.27	7.26	20.72	-23.57	144.73	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.56	0.06	5.38	-28.63	-221.63	118	VERY LOW	0.56	0.06	5.38	-28.63	-221.63	118	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.95	0.29	15.16	27.61	-27.29	152.64	VERY LOW	1.95	0.29	15.16	27.61	-27.29	152.64	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.51	0.27	9.94	23.74	-26.94	148.72	VERY LOW	1.51	0.27	9.94	23.74	-26.94	148.72	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.89	0.36	11.86	28.95	-17.33	153.41	VERY LOW	1.89	0.36	11.86	28.95	-17.33	153.41	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.36	0.29	7.86	22.77	-20.15	147.19	VERY LOW	1.36	0.29	7.86	22.77	-20.15	147.19	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.35	0.25	8.29	21.32	-28.03	145.85	VERY LOW	1.35	0.25	8.29	21.32	-28.03	145.85	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.75	0.37	10.27	28.57	-13.68	152.69	VERY LOW	1.75	0.37	10.27	28.57	-13.68	152.69	Indirect	MODERATE	Not serious	Very serious	VERY LOW	B, Inconsistency, Imprecision
HIV reverse transcriptase inhibitor	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	7.66	1.39	49.82	43.74	2.42	167.65	VERY LOW	7.66	1.39	49.82	43.74	2.42	167.65	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.09	0.23	6.3	16.3	-29.09	141.23	VERY LOW	1.09	0.23	6.3	16.3	-29.09	141.23	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	remdesivir	NA	NA	NA	NA	NA	NA	NA	4.67	0.69	38.21	39.68	-4.49	164.1	VERY LOW	4.67	0.69	38.21	39.68	-4.49	164.1	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.5	0.24	10.9	21.6	-37.06	145.87	VERY LOW	1.5	0.24	10.9	21.6	-37.06	145.87	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
HIV reverse transcriptase inhibitor	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.41	0.03	8.22	-71.58	-424.19	106.07	VERY LOW	0.41	0.03	8.22	-71.58	-424.19	106.07	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
(hydroxy)chloroquine	inhaled and intranasal corticosteroid	NA	NA	NA	NA	NA	NA	NA	0.44	0.08	2.12	-49.35	-233.79	16.58	LOW	0.44	0.08	2.12	-49.35	-233.79	16.58	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.52	0.47	5.3	6.9	-26.2	28.37	LOW	1.52	0.47	5.3	6.9	-26.2	28.37	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.18	0.49	2.96	3.02	-23.8	23.31	VERY LOW	1.18	0.49	2.96	3.02	-23.8	23.31	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.48	0.66	3.34	8.24	-11.46	25.47	LOW	1.48	0.66	3.34	8.24	-11.46	25.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.07	0.63	1.84	2.05	-11.17	17.31	MODERATE	1.07	0.63	1.84	2.05	-11.17	17.31	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	lopinavir-ritonavir	1.56	0.37	6.64	NA	NA	NA	VERY LOW	0.61	0.17	2.14	NA	NA	NA	LOW	1.06	0.51	2.21	0.6	-22.19	18.45	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.37	0.81	2.52	7.85	-4.35	23.25	VERY LOW	1.37	0.81	2.52	7.85	-4.35	23.25	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
(hydroxy)chloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.99	2.57	14.73	23.02	12.46	36.76	LOW	5.99	2.57	14.73	23.02	12.46	36.76	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.85	0.48	1.58	-4.41	-22.63	13.54	LOW	0.85	0.48	1.58	-4.41	-22.63	13.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.6	1.11	13.6	18.97	2.09	34.47	LOW	3.6	1.11	13.6	18.97	2.09	34.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.17	0.39	3.63	0.88	-37.58	24.44	LOW	1.17	0.39	3.63	0.88	-37.58	24.44	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
(hydroxy)chloroquine	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.32	0.03	3.92	-92.29	-444.22	21.33	VERY LOW	0.32	0.03	3.92	-92.29	-444.22	21.33	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	3.45	0.53	25.99	56.25	-17.5	241.39	VERY LOW	3.45	0.53	25.99	56.25	-17.5	241.39	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	2.7	0.49	17.13	52.37	-18.36	237.51	VERY LOW	2.7	0.49	17.13	52.37	-18.36	237.51	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3
inhaled and intranasal corticosteroid	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	3.38	0.62	20.55	57.59	-9.72	242.68	VERY LOW	3.38	0.62	20.55	57.59	-9.72	242.68	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	ivermectin	NA	NA	NA	NA	NA	NA	NA	2.44	0.51	13.36	51.4	-13.82	235.58	LOW	2.44	0.51	13.36	51.4	-13.82	235.58	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled and intranasal corticosteroid	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	2.41	0.45	14.26	49.95	-19.71	234.83	VERY LOW	2.41	0.45	14.26	49.95	-19.71	234.83	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	molnupiravir	NA	NA	NA	NA	NA	NA	NA	3.15	0.66	17.4	57.2	-7.31	241.66	VERY LOW	3.15	0.66	17.4	57.2	-7.31	241.66	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
inhaled and intranasal corticosteroid	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	13.75	2.47	86.71	72.37	8.33	256.65	VERY LOW	13.75	2.47	86.71	72.37	8.33	256.65	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.95	0.4	10.92	44.94	-22.27	229.4	LOW	1.95	0.4	10.92	44.94	-22.27	229.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled and intranasal corticosteroid	remdesivir	NA	NA	NA	NA	NA	NA	NA	8.32	1.23	65.98	68.31	2.74	253.03	VERY LOW	8.32	1.23	65.98	68.31	2.74	253.03	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	2.71	0.41	18.72	50.23	-26.86	236.25	VERY LOW	2.71	0.41	18.72	50.23	-26.86	236.25	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled and intranasal corticosteroid	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.73	0.05	14.34	-42.95	-408.13	189.55	VERY LOW	0.73	0.05	14.34	-42.95	-408.13	189.55	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3
inhaled corticosteroids	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.78	0.19	3.03	-3.87	-34.61	31.28	VERY LOW	0.78	0.19	3.03	-3.87	-34.61	31.28	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.98	0.25	3.61	1.34	-22.83	34.72	LOW	0.98	0.25	3.61	1.34	-22.83	34.72	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.71	0.21	2.24	-4.84	-23.54	27.57	LOW	0.71	0.21	2.24	-4.84	-23.54	27.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.7	0.18	2.57	-6.3	-35.05	28.54	LOW	0.7	0.18	2.57	-6.3	-35.05	28.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2

ADMISSION TO HOSPITAL																														
Comparison		Direct estimate							Indirect estimate								Network estimate													
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE						
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading		
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.92	0.26	2.93	0.95	-16.86	33.25	VERY LOW		0.92	0.26	2.93	0.95	-16.86	33.25	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	3.97	0.97	15.43	16.12	-0.13	47.85	LOW		3.97	0.97	15.43	16.12	-0.13	47.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.57	0.16	1.83	-11.31	-34.06	21.97	LOW		0.57	0.16	1.83	-11.31	-34.06	21.97	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.39	0.46	12.85	12.07	-9.4	44.81	LOW		2.39	0.46	12.85	12.07	-9.4	44.81	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.78	0.16	3.49	-6.02	-47.34	31.26	LOW		0.78	0.16	3.49	-6.02	-47.34	31.26	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
inhaled corticosteroids	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.21	0.02	3.15	-99.19	-452.52	19.42	VERY LOW		0.21	0.02	3.15	-99.19	-452.52	19.42	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
interferon beta (subcutaneous)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.26	0.43	3.56	5.22	-17.9	32.69	VERY LOW		1.26	0.43	3.56	5.22	-17.9	32.69	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.91	0.38	2.14	-0.97	-18.77	25.42	VERY LOW		0.91	0.38	2.14	-0.97	-18.77	25.42	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.89	0.31	2.54	-2.42	-30.25	26.84	VERY LOW		0.89	0.31	2.54	-2.42	-30.25	26.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.16	0.49	2.91	4.83	-11.62	31.67	VERY LOW		1.16	0.49	2.91	4.83	-11.62	31.67	Indirect	MODERATE	Not serious	Very serious	VERY LOW	B, Inconsistency, Imprecision		
interferon beta (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.08	1.67	15.49	20	4.63	45.58	VERY LOW		5.08	1.67	15.49	20	4.63	45.58	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.72	0.29	1.79	-7.44	-29.08	20.42	VERY LOW		0.72	0.29	1.79	-7.44	-29.08	20.42	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.05	0.76	13.31	15.94	-4.49	42.73	VERY LOW		3.05	0.76	13.31	15.94	-4.49	42.73	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.99	0.27	3.73	-2.14	-42.45	30.09	VERY LOW		0.99	0.27	3.73	-2.14	-42.45	30.09	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon beta (subcutaneous)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.27	0.02	3.55	-95.32	-448.58	21.78	VERY LOW		0.27	0.02	3.55	-95.32	-448.58	21.78	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	RoB, Imprecisionx3		
interferon lambda (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.72	0.33	1.57	-6.18	-20.61	12.76	LOW		0.72	0.33	1.57	-6.18	-20.61	12.76	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.71	0.27	1.88	-7.64	-33.22	14.72	LOW		0.71	0.27	1.88	-7.64	-33.22	14.72	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.92	0.43	2.14	-0.39	-13.45	18.97	VERY LOW		0.92	0.43	2.14	-0.39	-13.45	18.97	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
interferon lambda (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.05	1.45	11.73	14.78	3.29	32.47	LOW		4.05	1.45	11.73	14.78	3.29	32.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.58	0.26	1.33	-12.65	-31.74	8.39	LOW		0.58	0.26	1.33	-12.65	-31.74	8.39	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.43	0.65	10.2	10.73	-6.87	30.08	LOW		2.43	0.65	10.2	10.73	-6.87	30.08	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.79	0.23	2.82	-7.36	-46.18	18.81	LOW		0.79	0.23	2.82	-7.36	-46.18	18.81	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.22	0.02	2.76	-100.53	-453.13	14.55	VERY LOW		0.22	0.02	2.76	-100.53	-453.13	14.55	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.99	0.46	2.1	-1.45	-25.74	15.75	LOW		0.99	0.46	2.1	-1.45	-25.74	15.75	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.28	0.81	2.18	5.79	-4.7	17.72	LOW		1.28	0.81	2.18	5.79	-4.7	17.72	Indirect	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision		
ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.59	2.46	13.21	20.97	12.2	30.85	LOW		5.59	2.46	13.21	20.97	12.2	30.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
ivermectin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.8	0.47	1.38	-6.47	-23.4	8.47	MODERATE		0.8	0.47	1.38	-6.47	-23.4	8.47	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.35	1.05	12.3	16.91	1.08	29.23	LOW		3.35	1.05	12.3	16.91	1.08	29.23	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.09	0.37	3.27	-1.17	-39.04	19.89	LOW		1.09	0.37	3.27	-1.17	-39.04	19.89	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
ivermectin	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.3	0.03	3.61	-94.35	-446.62	19.26	VERY LOW		0.3	0.03	3.61	-94.35	-446.62	19.26	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.3	0.61	2.98	7.25	-8.9	31.86	VERY LOW		1.3	0.61	2.98	7.25	-8.9	31.86	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
lopinavir-ritonavir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	5.69	2.06	16.28	22.42	7.42	45.74	LOW		5.69	2.06	16.28	22.42	7.42	45.74	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
lopinavir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.81	0.36	1.83	-5.01	-26.31	20.99	LOW		0.81	0.36	1.83	-5.01	-26.31	20.99	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	3.41	0.93	14.32	18.37	-1.48	43.12	LOW		3.41	0.93	14.32	18.37	-1.48	43.12	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.11	0.33	3.95	0.28	-40.02	31.05	LOW		1.11	0.33	3.95	0.28	-40.02	31.05	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
lopinavir-ritonavir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.3	0.03	3.88	-92.89	-445.41	24.15	VERY LOW		0.3	0.03	3.88	-92.89	-445.41	24.15	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
molnupiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	4.37	1.82	10.28	15.17	6.75	23.43	VERY LOW		4.37	1.82	10.28	15.17	6.75	23.43	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
molnupiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.62	0.35	1.06	-12.26	-29.12	1.3	VERY LOW		0.62	0.35	1.06	-12.26	-29.12	1.3	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	2.62	0.79	9.53	11.12	-4.52	21.93	VERY LOW		2.62	0.79	9.53	11.12	-4.52	21.93	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
molnupiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.85	0.28	2.56	-6.97	-44.83	13.18	VERY LOW		0.85	0.28	2.56	-6.97	-44.83	13.18	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2		
molnupiravir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.23	0.02	2.82	-100.14	-452.9	13.19	VERY LOW		0.23	0.02	2.82	-100.14	-452.9	13.19	Indirect	MODERATE	Not serious	Extremely serious	VERY LOW	Inconsistency, Imprecisionx3		
nirmatrelvir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.14	0.06	0.34	-27.43	-43.03	-15.02	LOW		0.14	0.06	0.34	-27.43	-43.03	-15.02	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
nirmatrelvir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.6	0.15	2.59	-4.06	-18.59	4.58	LOW		0.6	0.15	2.59	-4.06	-18.59	4.58	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
nirmatrelvir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.19	0.05	0.72	-22.14	-59.5	-3.19	LOW		0.19	0.05	0.72	-22.14	-59.5	-3.19	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
nirmatrelvir-ritonavir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.05	0	0.68	-115.32	-467.31	-2.58	VERY LOW		0.05	0	0.68	-115.32	-467.31	-2.58	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
prophylactic-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA	NA	4.21	1.27	15.82	23.38	5.3	40.82	LOW		4.21	1.27	15.82	23.38	5.3	40.82	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
prophylactic-dose anticoagulation	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.37	0.45	4.22	5.29	-33.33	29.85	LOW		1.37	0.45	4.22	5.29	-33.33	29.85	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation	0.53	0.04	7.89	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA		0.37	0.04	4.52	-87.88	-439.52	26.14	Direct	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
remdesivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.32	0.07	1.52	-18.08	-56.42	5.36	LOW		0.32	0.07	1.52	-18.08	-56.42	5.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
remdesivir	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.09	0.01	1.36	-111.26	-463.35	2.46	VERY LOW		0.09	0.01	1.36	-111.26	-463.35	2.46	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		
serine protease inhibitors	therapeutic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.27	0.02	4.03	-93.18	-445.53	28.06	VERY LOW		0.27	0.02	4.03	-93.18	-445.53	28.06	Indirect	HIGH	Not serious	Extremely serious	VERY LOW	Imprecisionx3		

ADVERSE EVENTS LEADING TO DISCONTINUATION

Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
aspirin	standard care/placebo	NA	NA	NA	0.00	-0.55	0.56	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.02	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	standard care/placebo	NA	NA	NA	0.00	-1.00	1.00	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.02	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	standard care/placebo	NA	NA	NA	0.01	-0.05	0.07	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.01	0.02	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	standard care/placebo	NA	NA	NA	0.00	-0.56	0.56	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
doxycycline, ivermectin	standard care/placebo	NA	NA	NA	0.01	-1.00	1.00	HIGH	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.04	Direct	HIGH	Not serious	Not Serious	HIGH	
ensitrelvir	standard care/placebo	NA	NA	NA	0.00	-0.56	0.56	HIGH	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.03	Direct	HIGH	Not serious	Not Serious	HIGH	
favipiravir	standard care/placebo	NA	NA	NA	0.01	-0.01	0.04	MODERATE	NA	NA	NA	-0.18	-0.31	-0.06	MODERATE	NA	NA	NA	0.01	0	0.02	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	standard care/placebo	NA	NA	NA	0.13	-0.52	0.80	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.01	0.09	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	standard care/placebo	NA	NA	NA	0.01	-1.00	1.00	HIGH	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.03	Direct	HIGH	Not serious	Not Serious	HIGH	
HIV reverse transcriptase inhibitor	standard care/placebo	NA	NA	NA	0.04	-0.54	0.64	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.04	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	standard care/placebo	NA	NA	NA	0.02	-0.01	0.05	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	0	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	standard care/placebo	NA	NA	NA	-0.01	-0.28	0.26	HIGH	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	Direct	HIGH	Not serious	Not Serious	HIGH	
ivermectin	standard care/placebo	NA	NA	NA	0.02	-0.01	0.07	HIGH	NA	NA	NA	0.04	-0.05	0.12	MODERATE	NA	NA	NA	0.01	0	0.02	Direct	HIGH	Not serious	Not Serious	HIGH	
lopinavir-ritonavir	standard care/placebo	NA	NA	NA	0.02	-0.54	0.59	MODERATE	NA	NA	NA	0.08	0.02	0.15	HIGH	NA	NA	NA	0.04	0.02	0.08	Indirect	HIGH	Not serious	Not Serious	HIGH	
molnupiravir	standard care/placebo	NA	NA	NA	0	-0.03	0.02	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.01	0.01	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
nirmatrelvir-ritonavir	standard care/placebo	NA	NA	NA	0	-0.26	0.27	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.02	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
prophylactic-dose anticoagulation	standard care/placebo	NA	NA	NA	0.02	-0.17	0.21	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.02	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
remdesivir	standard care/placebo	NA	NA	NA	0.02	-0.25	0.29	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.01	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
serine protease inhibitors	standard care/placebo	NA	NA	NA	0.01	-0.56	0.57	HIGH	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.06	Direct	HIGH	Not serious	Not Serious	HIGH	
statins	standard care/placebo	NA	NA	NA	0	-1	1	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
vitamin D	standard care/placebo	NA	NA	NA	0	-0.56	0.57	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
VV116	standard care/placebo	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.03	MODERATE	NA	NA	NA	-0.01	-0.05	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	aspirin, statins	NA	NA	NA	0.01	-1	1	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	colchicine	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.04	MODERATE	NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE	NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	ensitrelvir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.04	MODERATE	NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.02	MODERATE	NA	NA	NA	-0.01	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.09	0.01	MODERATE	NA	NA	NA	-0.04	-0.09	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.03	MODERATE	NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.03	MODERATE	NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.05	MODERATE	NA	NA	NA	0.01	-0.02	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.02	MODERATE	NA	NA	NA	-0.01	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.08	-0.01	MODERATE	NA	NA	NA	-0.04	-0.08	-0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.03	MODERATE	NA	NA	NA	0.01	-0.02	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.03	MODERATE	NA	NA	NA	0.01	-0.02	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.04	MODERATE	NA	NA	NA	-0.01	-0.06	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	statins	NA	NA	NA	0	-1	1	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.04	MODERATE	NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.06	MODERATE	NA	NA	NA	0.01	-0.03	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.03	MODERATE	NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.03	MODERATE	NA	NA	NA	-0.01	-0.05	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	ensitrelvir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE	NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.10	0.01	MODERATE	NA	NA	NA	-0.04	-0.1	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.03	MODERATE	NA	NA	NA	-0.01	-0.05	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.03	MODERATE	NA	NA	NA	-0.01	-0.05	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.05	0.01	MODERATE	NA	NA	NA	-0.02	-0.05	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE	NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.05	-0.09	-0.01	MODERATE	NA	NA	NA	-0.05	-0.09	-0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.03	MODERATE	NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.02	MODERATE	NA	NA	NA	-0.01	-0.05	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.07	0.03	MODERATE	NA	NA	NA	-0.02	-0.07	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	statins	NA	NA	NA	0	-1	1	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.05	0.04	MODERATE	NA	NA	NA	0	-0.05	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin, statins	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.05	MODERATE	NA	NA	NA	0.01	-0.04	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE	NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	ensitrelvir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.02	MODERATE	NA	NA	NA	-0.01	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.09	0.01	MODERATE	NA	NA	NA	-0.04	-0.09	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.03	MODERATE	NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.01	MODERATE	NA	NA	NA	-0.01	-0.03	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.05	MODERATE	NA	NA	NA	0.01	-0.02	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB

ADVERSE EVENTS LEADING TO DISCONTINUATION																													
Comparison		Direct estimate							Indirect estimate								Network estimate												
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating		Reasons for downgrading
colchicine	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.01	MODERATE		NA	NA	NA	-0.01	-0.03	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.08	-0.01	MODERATE		NA	NA	NA	-0.04	-0.08	-0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.01	0.03	MODERATE		NA	NA	NA	0	-0.01	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.03	MODERATE		NA	NA	NA	0.01	-0.02	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.02	0.02	MODERATE		NA	NA	NA	0	-0.02	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.02	MODERATE		NA	NA	NA	-0.01	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.03	MODERATE		NA	NA	NA	-0.01	-0.06	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
colchicine	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.03	MODERATE		NA	NA	NA	-0.01	-0.05	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	ensitrelvir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.03	MODERATE		NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.10	0.01	MODERATE		NA	NA	NA	-0.04	-0.1	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE		NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.00	-0.04	0.03	MODERATE		NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.08	-0.01	MODERATE		NA	NA	NA	-0.04	-0.08	-0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.03	MODERATE		NA	NA	NA	-0.01	-0.06	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.04	MODERATE		NA	NA	NA	0	-0.05	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
corticosteroids (systemic)	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.06	MODERATE		NA	NA	NA	0.01	-0.04	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	ensitrelvir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.05	HIGH		NA	NA	NA	0.01	-0.04	0.05	Indirect	HIGH	Not serious	Not Serious	HIGH		
doxycycline, ivermectin	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.04	MODERATE		NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.03	-0.09	0.03	MODERATE		NA	NA	NA	-0.03	-0.09	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.05	HIGH		NA	NA	NA	0	-0.04	0.05	Indirect	HIGH	Not serious	Not Serious	HIGH		
doxycycline, ivermectin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.05	MODERATE		NA	NA	NA	0.01	-0.04	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.03	MODERATE		NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.06	HIGH		NA	NA	NA	0.02	-0.02	0.06	Indirect	HIGH	Not serious	Not Serious	HIGH		
doxycycline, ivermectin	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.03	HIGH		NA	NA	NA	0	-0.04	0.03	Indirect	HIGH	Not serious	Not Serious	HIGH		
doxycycline, ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.03	-0.08	0.01	MODERATE		NA	NA	NA	-0.03	-0.08	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.05	MODERATE		NA	NA	NA	0.01	-0.02	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.04	MODERATE		NA	NA	NA	0.01	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.06	0.05	HIGH		NA	NA	NA	0	-0.06	0.05	Indirect	HIGH	Not serious	Not Serious	HIGH		
doxycycline, ivermectin	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.06	MODERATE		NA	NA	NA	0.01	-0.04	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
doxycycline, ivermectin	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.03	0.07	MODERATE		NA	NA	NA	0.02	-0.03	0.07	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	favipiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.09	0.02	MODERATE		NA	NA	NA	-0.04	-0.09	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	HIGH		NA	NA	NA	0	-0.04	0.04	Indirect	HIGH	Not serious	Not Serious	HIGH		
ensitrelvir	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	HIGH		NA	NA	NA	0.01	-0.03	0.05	Indirect	HIGH	Not serious	Not Serious	HIGH		
ensitrelvir	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	HIGH		NA	NA	NA	-0.01	-0.04	0.02	Indirect	HIGH	Not serious	Not Serious	HIGH		
ensitrelvir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.08	0	MODERATE		NA	NA	NA	-0.04	-0.08	0	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.04	MODERATE		NA	NA	NA	0.01	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE		NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.04	HIGH		NA	NA	NA	-0.01	-0.06	0.04	Indirect	HIGH	Not serious	Not Serious	HIGH		
ensitrelvir	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.05	MODERATE		NA	NA	NA	0	-0.04	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
ensitrelvir	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.06	MODERATE		NA	NA	NA	0.01	-0.04	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	fluvoxamine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.03	-0.08	0.02	MODERATE		NA	NA	NA	-0.03	-0.08	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE		NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.04	MODERATE		NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
(hydroxy)chloroquine	favipiravir	NA	NA	NA	0.02	-1	1	MODERATE	NA	NA	NA	0	-0.02	0.03	MODERATE		NA	NA	NA	0	-0.02	0.03	gorithm in ap	MODERATE	Not serious	Not Serious	MODERATE		
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.01	0.05	MODERATE		NA	NA	NA	0.02	-0.01	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.02	MODERATE		NA	NA	NA	0	-0.02	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	lopinavir-ritonavir	NA	NA	NA	-0.22	-1	1	HIGH	NA	NA	NA	-0.02	-0.06	0.01	MODERATE		NA	NA	NA	-0.04	-0.07	0	Direct	HIGH	Not serious	Not Serious	HIGH		
favipiravir	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.01	0.03	MODERATE		NA	NA	NA	0.01	-0.01	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.01	0.03	MODERATE		NA	NA	NA	0.01	-0.01	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.03	MODERATE		NA	NA	NA	0.01	-0.02	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.02	MODERATE		NA	NA	NA	0	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE		RoB

ADVERSE EVENTS LEADING TO DISCONTINUATION																													
Comparison		Direct estimate							Indirect estimate								Network estimate												
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
favipiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.04	MODERATE		NA	NA	NA	-0.01	-0.05	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
favipiravir	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.04	MODERATE		NA	NA	NA	0.01	-0.02	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
favipiravir	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
favipiravir	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.06	MODERATE		NA	NA	NA	0.02	-0.02	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	fluvoxamine, inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	-0.02	0.09	MODERATE		NA	NA	NA	0.03	-0.02	0.09	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.02	0.09	MODERATE		NA	NA	NA	0.04	-0.02	0.09	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	-0.02	0.08	MODERATE		NA	NA	NA	0.03	-0.02	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.05	0	0.11	MODERATE		NA	NA	NA	0.05	0	0.11	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	-0.02	0.08	MODERATE		NA	NA	NA	0.03	-0.02	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.06	0.05	MODERATE		NA	NA	NA	0	-0.06	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.01	0.09	MODERATE		NA	NA	NA	0.04	-0.01	0.09	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.01	0.1	MODERATE		NA	NA	NA	0.04	-0.01	0.1	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.01	0.09	MODERATE		NA	NA	NA	0.04	-0.01	0.09	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	-0.02	0.08	MODERATE		NA	NA	NA	0.03	-0.02	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	-0.04	0.09	MODERATE		NA	NA	NA	0.03	-0.04	0.09	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.02	0.1	MODERATE		NA	NA	NA	0.04	-0.02	0.1	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	-0.02	0.1	MODERATE		NA	NA	NA	0.04	-0.02	0.1	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.05	-0.01	0.11	MODERATE		NA	NA	NA	0.05	-0.01	0.11	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.06	HIGH		NA	NA	NA	0.02	-0.02	0.06	Indirect	HIGH	Not serious	Not Serious	HIGH	
fluvoxamine, inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.03	HIGH		NA	NA	NA	0	-0.04	0.03	Indirect	HIGH	Not serious	Not Serious	HIGH	
fluvoxamine, inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.08	0	MODERATE		NA	NA	NA	-0.04	-0.08	0	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.04	MODERATE		NA	NA	NA	0.01	-0.02	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.04	MODERATE		NA	NA	NA	0.01	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.04	MODERATE		NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.03	MODERATE		NA	NA	NA	0	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.04	HIGH		NA	NA	NA	-0.01	-0.06	0.04	Indirect	HIGH	Not serious	Not Serious	HIGH	
fluvoxamine, inhaled corticosteroids	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.05	MODERATE		NA	NA	NA	0.01	-0.04	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine, inhaled corticosteroids	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.03	0.06	MODERATE		NA	NA	NA	0.02	-0.03	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE		NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.06	MODERATE		NA	NA	NA	0.02	-0.02	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE		NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.04	-0.08	0	MODERATE		NA	NA	NA	-0.04	-0.08	0	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.04	MODERATE		NA	NA	NA	0.01	-0.02	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.04	MODERATE		NA	NA	NA	0.01	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.04	MODERATE		NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE		NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.04	MODERATE		NA	NA	NA	-0.01	-0.06	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE		NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.05	MODERATE		NA	NA	NA	0	-0.04	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
HIV reverse transcriptase inhibitor	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.03	0.06	MODERATE		NA	NA	NA	0.02	-0.03	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.01	0.06	MODERATE		NA	NA	NA	0.02	-0.01	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.02	MODERATE		NA	NA	NA	0	-0.02	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	lopinavir-ritonavir	NA	NA	NA	-0.03	-1	1	MODERATE	NA	NA	NA	-0.04	-0.1	0.02	MODERATE		NA	NA	NA	-0.03	-0.06	0	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	0	0.04	MODERATE		NA	NA	NA	0.01	0	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.01	0.04	MODERATE		NA	NA	NA	0.02	-0.01	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.01	0.04	MODERATE		NA	NA	NA	0.01	-0.01	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.03	MODERATE		NA	NA	NA	0	-0.02	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.04	MODERATE		NA	NA	NA	0	-0.05	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.04	MODERATE		NA	NA	NA	0.01	-0.02	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
(hydroxy)chloroquine	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.07	MODERATE		NA	NA	NA	0.02	-0.02	0.07	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.05	0.01	HIGH		NA	NA	NA	-0.02	-0.05	0.01	Indirect	HIGH	Not serious	Not Serious	HIGH	
inhaled corticosteroids	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.06	-0.1	-0.02	MODERATE		NA	NA	NA	-0.06	-0.1	-0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE		NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.02	MODERATE		NA	NA	NA	-0.01	-0.05	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.06	0.01	MODERATE		NA	NA	NA	-0.02	-0.06	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.07	0.03	HIGH		NA	NA	NA	-0.02	-0.07	0.03	Indirect	HIGH	Not serious	Not Serious	HIGH	
inhaled corticosteroids	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.05	0.03	MODERATE		NA	NA	NA	-0.01	-0.05	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.03	MODERATE		NA	NA	NA	-0.01	-0.06	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
inhaled corticosteroids	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.05	MODERATE		NA	NA	NA	0	-0.05	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
ivermectin	lopinavir-ritonavir	NA	NA	NA	-0.01	-1	1	HIGH	NA	NA	NA	-0.04	-0.07	0	MODERATE		NA	NA	NA	-0.03	-0.07	0	Direct	HIGH	Not serious	Not Serious	HIGH	
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	0	0.03	MODERATE		NA	NA	NA	0.01	0	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.01	0.04	MODERATE		NA	NA	NA	0.01	-0.01	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
ivermectin	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.01	0.03	MODERATE		NA	NA	NA	0.01	-0.01	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.03	MODERATE		NA	NA	NA	0	-0.02	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.04	HIGH		NA	NA	NA	0	-0.05	0.04	Indirect	HIGH	Not serious	Not Serious	HIGH	
ivermectin	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.02	0.04	MODERATE		NA	NA	NA	0.01	-0.02	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
ivermectin	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE		NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB

ADVERSE EVENTS LEADING TO DISCONTINUATION																																	
Comparison		Direct estimate							Indirect estimate							Network estimate																	
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE									
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading						
ivermectin	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.06	MODERATE	NA	NA	NA	0.02	-0.02	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.05	0.01	0.08	MODERATE	NA	NA	NA	0.05	0.01	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.05	0.01	0.08	MODERATE	NA	NA	NA	0.05	0.01	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	0.01	0.08	MODERATE	NA	NA	NA	0.04	0.01	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	0	0.07	MODERATE	NA	NA	NA	0.03	0	0.07	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.03	-0.02	0.08	MODERATE	NA	NA	NA	0.03	-0.02	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	0	0.08	MODERATE	NA	NA	NA	0.04	0	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.04	0	0.09	MODERATE	NA	NA	NA	0.04	0	0.09	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
lopinavir-ritonavir	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.06	0.01	0.1	MODERATE	NA	NA	NA	0.06	0.01	0.1	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.02	0.02	MODERATE	NA	NA	NA	0	-0.02	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.02	MODERATE	NA	NA	NA	0	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.01	MODERATE	NA	NA	NA	-0.01	-0.04	0.01	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.06	0.03	MODERATE	NA	NA	NA	-0.02	-0.06	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.03	MODERATE	NA	NA	NA	0	-0.03	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE	NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
molnupiravir	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE	NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
nirmatrelvir-ritonavir	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.03	0.02	MODERATE	NA	NA	NA	-0.01	-0.03	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
nirmatrelvir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
nirmatrelvir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.02	-0.06	0.03	MODERATE	NA	NA	NA	-0.02	-0.06	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
nirmatrelvir-ritonavir	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.03	MODERATE	NA	NA	NA	-0.01	-0.04	0.03	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
nirmatrelvir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.04	MODERATE	NA	NA	NA	0	-0.05	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
nirmatrelvir-ritonavir	VV116	NA	NA	NA	0.01	-1	1	MODERATE	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.04	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB						
prophylactic-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.04	0.02	MODERATE	NA	NA	NA	-0.01	-0.04	0.02	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
prophylactic-dose anticoagulation	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	-0.01	-0.06	0.04	MODERATE	NA	NA	NA	-0.01	-0.06	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
prophylactic-dose anticoagulation	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.03	0.04	MODERATE	NA	NA	NA	0	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
prophylactic-dose anticoagulation	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.04	0.04	MODERATE	NA	NA	NA	0	-0.04	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
prophylactic-dose anticoagulation	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.06	MODERATE	NA	NA	NA	0.01	-0.03	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
remdesivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.04	MODERATE	NA	NA	NA	0	-0.05	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
remdesivir	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.04	MODERATE	NA	NA	NA	0.01	-0.03	0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
remdesivir	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.03	0.05	MODERATE	NA	NA	NA	0.01	-0.03	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
remdesivir	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.02	0.06	MODERATE	NA	NA	NA	0.02	-0.02	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
serine protease inhibitors	statins	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.06	MODERATE	NA	NA	NA	0.01	-0.04	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
serine protease inhibitors	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.07	MODERATE	NA	NA	NA	0.01	-0.04	0.07	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
serine protease inhibitors	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.02	-0.03	0.08	MODERATE	NA	NA	NA	0.02	-0.03	0.08	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
statins	vitamin D	NA	NA	NA	NA	NA	NA		NA	NA	NA	0	-0.05	0.05	MODERATE	NA	NA	NA	0	-0.05	0.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
statins	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.06	MODERATE	NA	NA	NA	0.01	-0.04	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						
vitamin D	VV116	NA	NA	NA	NA	NA	NA		NA	NA	NA	0.01	-0.04	0.06	MODERATE	NA	NA	NA	0.01	-0.04	0.06	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB						

VENOUS THROMBOEMOLISM

Comparison		Direct estimate							Indirect estimate							Network estimate										Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
intermediate-dose anticoagulation	standard care/placebo	0.77	0.2	3.02	-1.90	-6.72	16.55	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.76	0.2	3	-0.08	-6.74	17.03	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
prophylactic-dose anticoagulation	standard care/placebo	0.28	0.09	0.94	-6.00	-7.67	-0.47	LOW	NA	NA	NA	NA	NA	NA	NA	0.12	0.02	0.5	-7.1	-8.26	-4.17	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
therapeutic-dose anticoagulation	standard care/placebo	0.52	0.13	2.09	-4.03	-7.29	9.00	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.2	0.02	1.01	-5.97	-8.21	0.23	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
intermediate-dose anticoagulation	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	6.62	0.91	82.87	7.02	-0.25	24.39	VERY LOW	6.62	0.91	82.87	7.02	-0.25	24.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
intermediate-dose anticoagulation	therapeutic-dose anticoagulation	0.24	0.01	7.27	NA	NA	NA	VERY LOW	3.54	0.34	56	NA	NA	NA	VERY LOW	3.84	0.47	50.35	5.89	-3.43	23.4	Direct	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation	1.06	0.02	62.19	NA	NA	NA	VERY LOW	0.55	0.04	7.19	NA	NA	NA	VERY LOW	0.58	0.04	7.53	-1.13	-7.5	2.8	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision

CLINICALLY IMPORTANT BLEEDING

Comparison		Direct estimate							Indirect estimate							Network estimate										Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
intermediate-dose anticoagulation	standard care/placebo	1.44	0.32	6.46	1.49	-2.27	18.01	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.08	0.25	4.67	1.38	-2.51	12.11	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
prophylactic-dose anticoagulation	standard care/placebo	3.28	1.08	9.9	7.60	0.27	29.03	MODERATE	NA	NA	NA	NA	NA	NA	NA	4.92	1.66	17.17	16.6	2.27	52.15	Direct	HIGH	Not serious	Very serious	LOW	Imprecision
therapeutic-dose anticoagulation	standard care/placebo	2.11	0.57	7.94	3.72	-1.46	22.78	MODERATE	NA	NA	NA	NA	NA	NA	NA	1.98	0.53	7.49	5.01	-1.62	21	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
intermediate-dose anticoagulation	prophylactic-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.22	0.03	1.32	-15.21	-50.79	2.49	MODERATE	0.22	0.03	1.32	-15.21	-50.79	2.49	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision
intermediate-dose anticoagulation	therapeutic-dose anticoagulation	0.15	0.02	1.2	NA	NA	NA	LOW	2.25	0.09	100.93	NA	NA	NA	VERY LOW	0.54	0.09	3.31	-3.63	-19.55	8.18	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
prophylactic-dose anticoagulation	therapeutic-dose anticoagulation	2.15	0.28	16.59	NA	NA	NA	LOW	2.72	0.3	25.21	NA	NA	NA	VERY LOW	2.49	0.55	12.16	11.58	-7.73	45.62	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision

LENGTH OF HOSPITAL STAY																												
Comparison		Direct estimate							Indirect estimate							Network estimate						GRADE					Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)			Final rating	Relative estimate			Absolute estimate (per 1,000)								
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
ACEi/ARB	standard care/placebo	NA	NA	NA	-0.45	-1.62	0.81	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.17	-1.82	1.62	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
aspirin	standard care/placebo	NA	NA	NA	0	-1.31	1.31	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	-2.33	2.32	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	standard care/placebo	NA	NA	NA	0.33	-1	1.66	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.33	-2.02	2.68	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	standard care/placebo	NA	NA	NA	0.52	-0.88	1.92	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5	-1.5	2.51	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	standard care/placebo	NA	NA	NA	-1.33	-2.63	-0.03	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.33	-3.67	1	Direct	MODERATE	Not serious	Serious	LOW	RoB
favipiravir	standard care/placebo	NA	NA	NA	-0.65	-1.45	0.13	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.63	-2.05	0.73	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	standard care/placebo	NA	NA	NA	-0.92	-3.41	0.97	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.61	-2.18	0.57	Direct	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
Interferon alpha	standard care/placebo	NA	NA	NA	0.13	-1.19	1.45	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.13	-2.21	2.48	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous)	standard care/placebo	NA	NA	NA	0.78	-0.55	2.12	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.79	-1.58	3.12	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
ivermectin	standard care/placebo	NA	NA	NA	-0.24	-1.32	0.71	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.4	-1.8	0.95	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
lopinavir-ritonavir	standard care/placebo	NA	NA	NA	1.77	0.34	3.19	HIGH	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.76	-0.64	4.19	Direct	HIGH	Not serious	Serious	MODERATE	
nirmatrelvir-ritonavir	standard care/placebo	NA	NA	NA	-0.3	-1.48	0.7	MODERATE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.5	-2.62	1.43	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
remdesivir	standard care/placebo	NA	NA	NA	0.61	-0.11	1.35	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.64	-1.04	2.34	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
statins	standard care/placebo	NA	NA	NA	0	-1.31	1.31	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	-2.34	2.35	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
vitamin D	standard care/placebo	NA	NA	NA	-1.36	-3.11	0.08	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.57	-3.31	0.03	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	aspirin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.18	-2.97	2.81	LOW	NA	NA	NA	-0.18	-2.97	2.81	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	aspirin, statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.51	-3.33	2.5	LOW	NA	NA	NA	-0.51	-3.33	2.5	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.68	-3.25	2.05	LOW	NA	NA	NA	-0.68	-3.25	2.05	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.15	-1.66	4.14	LOW	NA	NA	NA	1.15	-1.66	4.14	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.45	-1.67	2.78	MODERATE	NA	NA	NA	0.45	-1.67	2.78	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.45	-1.57	2.92	LOW	NA	NA	NA	0.45	-1.57	2.92	Indirect	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
ACEi/ARB	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.31	-3.13	2.7	LOW	NA	NA	NA	-0.31	-3.13	2.7	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.96	-3.78	2.04	MODERATE	NA	NA	NA	-0.96	-3.78	2.04	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.22	-1.88	2.54	MODERATE	NA	NA	NA	0.22	-1.88	2.54	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.95	-4.8	1.11	MODERATE	NA	NA	NA	-1.95	-4.8	1.11	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.33	-2.16	3.16	MODERATE	NA	NA	NA	0.33	-2.16	3.16	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ACEi/ARB	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.82	-3.16	1.67	LOW	NA	NA	NA	-0.82	-3.16	1.67	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.18	-2.99	2.81	LOW	NA	NA	NA	-0.18	-2.99	2.81	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ACEi/ARB	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.4	-0.88	3.95	LOW	NA	NA	NA	1.4	-0.88	3.95	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	aspirin, statins	NA	NA	NA	-0.33	-1.56	0.9	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.33	-2.7	2.01	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.5	-3.57	2.54	LOW	NA	NA	NA	-0.5	-3.57	2.54	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.33	-1.98	4.61	LOW	NA	NA	NA	1.33	-1.98	4.61	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.62	-2.05	3.37	LOW	NA	NA	NA	0.62	-2.05	3.37	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.6	-1.85	3.53	LOW	NA	NA	NA	0.6	-1.85	3.53	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecisio
aspirin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.13	-3.45	3.17	LOW	NA	NA	NA	-0.13	-3.45	3.17	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.79	-4.09	2.53	LOW	NA	NA	NA	-0.79	-4.09	2.53	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.39	-2.26	3.13	LOW	NA	NA	NA	0.39	-2.26	3.13	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.77	-5.12	1.57	VERY LOW	NA	NA	NA	-1.77	-5.12	1.57	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5	-2.46	3.68	LOW	NA	NA	NA	0.5	-2.46	3.68	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.64	-3.53	2.23	LOW	NA	NA	NA	-0.64	-3.53	2.23	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	statins	NA	NA	NA	0	-1.21	1.21	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	-2.33	2.34	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.56	-1.23	4.5	LOW	NA	NA	NA	1.56	-1.23	4.5	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	colchicine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.17	-3.25	2.91	LOW	NA	NA	NA	-0.17	-3.25	2.91	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.66	-1.67	4.97	LOW	NA	NA	NA	1.66	-1.67	4.97	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.96	-1.73	3.74	LOW	NA	NA	NA	0.96	-1.73	3.74	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.93	-1.54	3.89	LOW	NA	NA	NA	0.93	-1.54	3.89	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecisio
aspirin, statins	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.2	-3.1	3.52	LOW	NA	NA	NA	0.2	-3.1	3.52	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.46	-3.77	2.9	LOW	NA	NA	NA	-0.46	-3.77	2.9	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.72	-1.95	3.49	LOW	NA	NA	NA	0.72	-1.95	3.49	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.44	-4.8	1.94	LOW	NA	NA	NA	-1.44	-4.8	1.94	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.83	-2.16	4.03	LOW	NA	NA	NA	0.83	-2.16	4.03	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.31	-3.2	2.58	LOW	NA	NA	NA	-0.31	-3.2	2.58	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	statins	NA	NA	NA	0.33	-0.9	1.56	LOW	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.33	-2.03	2.7	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
aspirin, statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.89	-0.89	4.87	LOW	NA	NA	NA	1.89	-0.89	4.87	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.84	-1.24	4.91	LOW	NA	NA	NA	1.84	-1.24	4.91	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.13	-1.28	3.62	LOW	NA	NA	NA	1.13	-1.28	3.62	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.12	-1.14	3.75	LOW	NA	NA	NA	1.12	-1.14	3.75	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecisio
colchicine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.37	-2.69	3.48	LOW	NA	NA	NA	0.37	-2.69	3.48	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.28	-3.36	2.82	LOW	NA	NA	NA	-0.28	-3.36	2.82	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.9	-1.51	3.37	LOW	NA	NA	NA	0.9	-1.51	3.37	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.26	-4.38	1.88	LOW	NA	NA	NA	-1.26	-4.38	1.88	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.01	-1.74	3.96	LOW	NA	NA	NA	1.01	-1.74	3.96	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.14	-2.75	2.49	LOW	NA	NA	NA	-0.14	-2.75	2.49	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.5	-2.56	3.6	LOW	NA	NA	NA	0.5	-2.56	3.6	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.07	-0.46	4.78	LOW	NA	NA	NA	2.07	-0.46	4.78	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	favipiravir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.71	-3.38	2.04	LOW	NA	NA	NA	-0.71	-3.38	2.04	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.73	-3.19	2.21	LOW	NA	NA	NA	-0.73	-3.19	2.21	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecisio
doxycycline	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.46	-4.75	1.84	LOW	NA	NA	NA	-1.46	-4.75	1.84	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.12	-5.42	1.2	VERY LOW	NA	NA	NA	-2.12	-5.42	1.2	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.94	-3.6	1.81	LOW	NA	NA	NA	-0.94	-3.6	1.81	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-3.1	-6.46	0.27	VERY LOW	NA	NA	NA	-3.1	-6.46	0.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.82	-3.82	2.35	LOW	NA	NA	NA	-0.82	-3.82	2.35	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision

LENGTH OF HOSPITAL STAY																														
Comparison		Direct estimate							Indirect estimate							Network estimate												Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
doxycycline	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.97	-4.84	0.9	LOW	NA	NA	NA	-1.97	-4.84	0.9	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.33	-4.63	1.99	LOW	NA	NA	NA	-1.33	-4.63	1.99	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.23	-2.56	3.19	LOW	NA	NA	NA	0.23	-2.56	3.19	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
(hydroxy)chloroquine	favipiravir	NA	NA	NA	-0.33	-2.04	1.37	MODERATE	NA	NA	NA	0.18	-2.76	2.45	LOW	NA	NA	NA	0.02	-1.93	1.62	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
favipiravir	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.76	-3.51	1.94	LOW	NA	NA	NA	-0.76	-3.51	1.94	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.41	-4.17	1.28	MODERATE	NA	NA	NA	-1.41	-4.17	1.28	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.24	-2.18	1.72	MODERATE	NA	NA	NA	-0.24	-2.18	1.72	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
favipiravir	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.39	-5.22	0.36	LOW	NA	NA	NA	-2.39	-5.22	0.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
favipiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.12	-2.5	2.38	MODERATE	NA	NA	NA	-0.12	-2.5	2.38	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.26	-3.51	0.88	LOW	NA	NA	NA	-1.26	-3.51	0.88	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.62	-3.38	2.07	LOW	NA	NA	NA	-0.62	-3.38	2.07	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.94	-1.19	3.14	LOW	NA	NA	NA	0.94	-1.19	3.14	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
(hydroxy)chloroquine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.73	-3.67	1.74	LOW	NA	NA	NA	-0.73	-3.67	1.74	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecision
(hydroxy)chloroquine	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.38	-4.33	1.09	LOW	NA	NA	NA	-1.38	-4.33	1.09	Indirect	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.22	-2.31	1.55	LOW	NA	NA	NA	-0.22	-2.31	1.55	Indirect	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
(hydroxy)chloroquine	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.37	-5.38	0.17	VERY LOW	NA	NA	NA	-2.37	-5.38	0.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	Inconsistency, Imprecisionx2
(hydroxy)chloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.1	-2.62	2.18	LOW	NA	NA	NA	-0.1	-2.62	2.18	Indirect	MODERATE	Not serious	Serious	LOW	Inconsistency, Imprecision
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.24	-3.65	0.71	LOW	NA	NA	NA	-1.24	-3.65	0.71	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecision
(hydroxy)chloroquine	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.6	-3.55	1.88	LOW	NA	NA	NA	-0.6	-3.55	1.88	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecision
(hydroxy)chloroquine	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.95	-1.28	2.97	LOW	NA	NA	NA	0.95	-1.28	2.97	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Inconsistency, Imprecision
Interferon alpha	interferon beta (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.66	-3.96	2.69	LOW	NA	NA	NA	-0.66	-3.96	2.69	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.52	-2.15	3.28	LOW	NA	NA	NA	0.52	-2.15	3.28	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.64	-4.99	1.74	LOW	NA	NA	NA	-1.64	-4.99	1.74	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.64	-2.37	3.82	LOW	NA	NA	NA	0.64	-2.37	3.82	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.51	-3.4	2.38	LOW	NA	NA	NA	-0.51	-3.4	2.38	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.13	-3.17	3.45	LOW	NA	NA	NA	0.13	-3.17	3.45	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.69	-1.09	4.66	LOW	NA	NA	NA	1.69	-1.09	4.66	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.18	-1.53	3.93	MODERATE	NA	NA	NA	1.18	-1.53	3.93	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
interferon beta (subcutaneous)	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.98	-4.39	2.39	MODERATE	NA	NA	NA	-0.98	-4.39	2.39	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
interferon beta (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.29	-1.72	4.47	MODERATE	NA	NA	NA	1.29	-1.72	4.47	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
interferon beta (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.15	-2.78	3.03	LOW	NA	NA	NA	0.15	-2.78	3.03	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous)	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.78	-2.55	4.1	LOW	NA	NA	NA	0.78	-2.55	4.1	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon beta (subcutaneous)	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.35	-0.44	5.31	VERY LOW	NA	NA	NA	2.35	-0.44	5.31	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
ivermectin	lopinavir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-2.16	-4.98	0.59	MODERATE	NA	NA	NA	-2.16	-4.98	0.59	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.12	-2.27	2.61	MODERATE	NA	NA	NA	0.12	-2.27	2.61	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.03	-3.26	1.1	LOW	NA	NA	NA	-1.03	-3.26	1.1	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ivermectin	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.39	-3.14	2.28	LOW	NA	NA	NA	-0.39	-3.14	2.28	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
ivermectin	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.17	-0.94	3.37	LOW	NA	NA	NA	1.17	-0.94	3.37	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
lopinavir-ritonavir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.27	-0.8	5.52	LOW	NA	NA	NA	2.27	-0.8	5.52	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
lopinavir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.13	-1.83	4.08	LOW	NA	NA	NA	1.13	-1.83	4.08	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
lopinavir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.77	-1.58	5.15	VERY LOW	NA	NA	NA	1.77	-1.58	5.15	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
lopinavir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	3.32	0.49	6.36	MODERATE	NA	NA	NA	3.32	0.49	6.36	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
nirmatrelvir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-1.14	-3.89	1.39	LOW	NA	NA	NA	-1.14	-3.89	1.39	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
nirmatrelvir-ritonavir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-0.5	-3.7	2.49	LOW	NA	NA	NA	-0.5	-3.7	2.49	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
nirmatrelvir-ritonavir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.05	-1.55	3.66	LOW	NA	NA	NA	1.05	-1.55	3.66	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
remdesivir	statins	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.64	-2.24	3.53	LOW	NA	NA	NA	0.64	-2.24	3.53	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
remdesivir	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.2	-0.09	4.66	LOW	NA	NA	NA	2.2	-0.09	4.66	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
statins	vitamin D	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	1.56	-1.21	4.52	LOW	NA	NA	NA	1.56	-1.21	4.52	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision

TIME TO SYMPTOM RESOLUTION

Comparison		Direct estimate							Indirect estimate							Network estimate											Reasons for downgrading
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	
aspirin	standard care/placebo	1.06	0.3	3.74	0.53	-6.30	24.70	LOW	NA	NA	NA	NA	NA	NA	NA	1.06	0.73	1.53	0.7	-2.41	4.82	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
azithromycin	standard care/placebo	0.55	0.23	1.31	-4.06	-6.91	2.78	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.54	0.41	0.71	-4.06	-5.27	-2.58	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
colchicine	standard care/placebo	0.83	0.48	1.47	-1.54	-4.71	4.22	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.82	0.65	1.04	-1.57	-3.19	0.39	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	standard care/placebo	0.6	0.17	2.13	-3.59	-7.47	10.19	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.6	0.41	0.88	-3.48	-5.32	-1.05	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
doxycycline	standard care/placebo	1	0.28	3.53	0.00	-6.45	22.80	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1	0.69	1.44	0.15	-2.77	3.97	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline, ivermectin	standard care/placebo	0.81	0.23	2.86	-1.73	-6.95	16.78	LOW	NA	NA	NA	NA	NA	NA	NA	0.81	0.55	1.19	-1.59	-4.05	1.71	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
favipiravir	standard care/placebo	0.77	0.61	0.97	-2.09	-3.51	-0.30	MODERATE	0.66	0.4	1.07	-3.08	-5.37	0.6	MODERATE	0.76	0.65	0.88	-2.17	-3.15	-1.08	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
fluvoxamine	standard care/placebo	0.97	0.28	3.44	-0.24	-6.52	21.96	LOW	NA	NA	NA	NA	NA	NA	NA	0.97	0.68	1.4	-0.09	-2.91	3.6	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
HIV reverse transcriptase inhibitor	standard care/placebo	1.04	0.29	3.68	0.36	-6.35	24.12	LOW	NA	NA	NA	NA	NA	NA	NA	1.04	0.72	1.51	0.54	-2.55	4.59	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	standard care/placebo	0.92	0.78	1.08	-0.71	-1.97	0.75	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.92	0.8	1.06	-0.69	-1.81	0.56	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	standard care/placebo	0.97	0.78	1.19	-0.29	-2.00	1.72	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.96	0.78	1.18	-0.29	-1.94	1.64	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
Interferon alpha	standard care/placebo	0.86	0.24	3.07	-1.23	-6.81	18.64	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.86	0.58	1.28	-1.06	-3.77	2.58	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
interferon lambda (subcutaneous)	standard care/placebo	1	0.56	1.77	0.00	-3.92	6.94	LOW	NA	NA	NA	NA	NA	NA	NA	1	0.74	1.35	0.11	-2.31	3.15	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
intermediate-dose anticoagulation	standard care/placebo	1	0.28	3.53	0	-6.45	22.81	LOW	NA	NA	NA	NA	NA	NA	NA	1	0.69	1.44	0.16	-2.76	4	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
ivermectin	standard care/placebo	0.92	0.82	1.04	-0.69	-1.62	0.33	MODERATE	NA	NA	NA	NA	NA	NA	NA	0.92	0.82	1.04	-0.69	-1.66	0.37	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
lopinavir, ritonavir	standard care/placebo	0.99	0.28	3.5	-0.11	-6.5	22.52	LOW	1.49	0.94	2.39	4.44	-0.58	12.54	MODERATE	1.16	0.86	1.57	1.58	-1.23	5.12	Direct	HIGH	Not serious	Very serious	LOW	Imprecisionx2
molnupiravir	standard care/placebo	0.74	0.58	0.93	-2.37	-3.77	-0.66	HIGH	NA	NA	NA	NA	NA	NA	NA	0.74	0.62	0.88	-2.34	-3.45	-1.07	Direct	HIGH	Not serious	Not Serious	HIGH	
niclosamide	standard care/placebo	0.76	0.41	1.41	-2.17	-5.27	3.68	LOW	NA	NA	NA	NA	NA	NA	NA	0.76	0.54	1.06	-2.07	-4.11	0.51	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
nirmatrelvir-ritonavir	standard care/placebo	1	0.28	3.56	0	-6.47	23.02	VERY LOW	NA	NA	NA	NA	NA	NA	NA	1	0.67	1.49	0.2	-2.96	4.42	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
remdesivir	standard care/placebo	0.92	0.51	1.7	-0.68	-4.37	6.31	VERY LOW	NA	NA	NA	NA	NA	NA	NA	0.93	0.68	1.26	-0.56	-2.89	2.37	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
serine protease inhibitors	standard care/placebo	1.01	0.83	1.27	0.13	-1.55	2.42	MODERATE	0.67	0.38	1.2	-2.94	-5.58	1.76	VERY LOW	0.98	0.82	1.18	-0.12	-1.59	1.58	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
umifenovir	standard care/placebo	0.69	0.39	1.22	-2.77	-5.5	1.95	VERY LOW	0.81	0.53	1.23	-1.74	-4.24	2.07	VERY LOW	0.73	0.57	0.92	-2.41	-3.85	-0.71	Direct	MODERATE	Not serious	Not Serious	MODERATE	RoB
VV116	standard care/placebo	NA	NA	NA	NA	NA	NA	NA	1	0.58	1.74	0.36	-3.80	6.59	VERY LOW	1	0.58	1.74	0.36	-3.8	6.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	azithromycin	NA	NA	NA	NA	NA	NA	NA	1.95	1.23	3.07	4.76	1.32	9.05	VERY LOW	1.95	1.23	3.07	4.76	1.32	9.05	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	colchicine	NA	NA	NA	NA	NA	NA	NA	1.29	0.83	2	2.27	-1.41	6.66	VERY LOW	1.29	0.83	2	2.27	-1.41	6.66	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.76	1.03	3.01	4.18	0.24	8.7	VERY LOW	1.76	1.03	3.01	4.18	0.24	8.7	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
aspirin	doxycycline	NA	NA	NA	NA	NA	NA	NA	1.06	0.63	1.78	0.55	-4.41	5.59	VERY LOW	1.06	0.63	1.78	0.55	-4.41	5.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.31	0.77	2.24	2.29	-2.26	7.10	LOW	1.31	0.77	2.24	2.29	-2.26	7.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.4	0.94	2.08	2.87	-0.43	7.09	VERY LOW	1.4	0.94	2.08	2.87	-0.43	7.09	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.09	0.65	1.83	0.79	-4.04	5.78	LOW	1.09	0.65	1.83	0.79	-4.04	5.78	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	1.02	0.6	1.72	0.16	-4.98	5.34	LOW	1.02	0.6	1.72	0.16	-4.98	5.34	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.15	0.77	1.71	1.39	-1.98	5.64	LOW	1.15	0.77	1.71	1.39	-1.98	5.64	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.1	0.72	1.68	0.99	-2.68	5.42	LOW	1.1	0.72	1.68	0.99	-2.68	5.42	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	1.23	0.71	2.11	1.76	-3.04	6.70	VERY LOW	1.23	0.71	2.11	1.76	-3.04	6.7	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.06	0.66	1.7	0.59	-3.78	5.35	LOW	1.06	0.66	1.7	0.59	-3.78	5.35	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	intermediate-dose anticoagulation	1.06	0.33	3.43	NA	NA	NA	LOW	NA	NA	NA	NA	NA	NA	NA	1.06	0.73	1.53	0.54	-2.99	4.19	Direct	HIGH	Not serious	Serious	MODERATE	Imprecision
aspirin	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.15	0.78	1.69	1.39	-1.92	5.60	LOW	1.15	0.78	1.69	1.39	-1.92	5.6	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.91	0.57	1.46	-0.88	-5.62	4.10	LOW	0.91	0.57	1.46	-0.88	-5.62	4.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.44	0.95	2.17	3.04	-0.33	7.27	LOW	1.44	0.95	2.17	3.04	-0.33	7.27	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.4	0.85	2.29	2.77	-1.31	7.36	LOW	1.4	0.85	2.29	2.77	-1.31	7.36	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.06	0.61	1.82	0.50	-4.75	5.71	VERY LOW	1.06	0.61	1.82	0.5	-4.75	5.71	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.15	0.71	1.86	1.27	-3.03	6.02	VERY LOW	1.15	0.71	1.86	1.27	-3.03	6.02	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.08	0.71	1.62	0.82	-2.74	5.17	LOW	1.08	0.71	1.62	0.82	-2.74	5.17	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
aspirin	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.46	0.94	2.26	3.11	-0.45	7.44	VERY LOW	1.46	0.94	2.26	3.11	-0.45	7.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
aspirin	VV116	NA	NA	NA	NA	NA	NA	NA	1.06	0.54	2.04	0.34	-6.62	6.26	VERY LOW	1.06	0.54	2.04	0.34	-6.62	6.26	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
azithromycin	colchicine	NA	NA	NA	NA	NA	NA	NA	0.66	0.46	0.95	-2.49	-4.80	-0.30	MODERATE	0.66	0.46	0.95	-2.49	-4.8	-0.3	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	0.9	0.56	1.45	-0.58	-3.28	1.79	LOW	0.9	0.56	1.45	-0.58	-3.28	1.79	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.54	0.35	0.86	-4.21	-8.21	-0.94	MODERATE	0.54	0.35	0.86	-4.21	-8.21	-0.94	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	0.67	0.42	1.08	-2.47	-5.97	0.41	LOW	0.67	0.42	1.08	-2.47	-5.97	0.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
azithromycin	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.72	0.53	0.98	-1.89	-3.53	-0.13	MODERATE	0.72	0.53	0.98	-1.89	-3.53	-0.13	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.56	0.36	0.88	-3.97	-7.85	-0.78	MODERATE	0.56	0.36	0.88	-3.97	-7.85	-0.78	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.52	0.33	0.83	-4.60	-8.82	-1.18	MODERATE	0.52	0.33	0.83	-4.6	-8.82	-1.18	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.59	0.44	0.8	-3.38	-5.12	-1.54	MODERATE	0.59	0.44	0.8	-3.38	-5.12	-1.54	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.56	0.4	0.8	-3.77	-6.06	-1.56	MODERATE	0.56	0.4	0.8	-3.77	-6.06	-1.56	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.63	0.39	1.02	-3.00	-6.82	0.10	LOW	0.63	0.39	1.02	-3	-6.82	0.1	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
azithromycin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.54	0.36	0.82	-4.17	-7.43	-1.32	MODERATE	0.54	0.36	0.82	-4.17	-7.43	-1.32	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.54	0.35	0.86	-4.22	-8.25	-0.94	MODERATE	0.54	0.35	0.86	-4.22	-8.25	-0.94	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.59	0.44	0.8	-3.37	-4.99	-1.62	MODERATE	0.59	0.44	0.8	-3.37	-4.99	-1.62	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.47	0.31	0.7	-5.64	-9.38	-2.47	MODERATE	0.47	0.31	0.7	-5.64	-9.38	-2.47	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.74	0.53	1.02	-1.72	-3.49	0.14	LOW	0.74	0.53	1.02	-1.72	-3.49	0.14	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.72	0.47	1.1	-1.99	-4.85	0.53	LOW	0.72	0.47	1.1	-1.99	-4.85	0.53	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.54	0.34	0.88	-4.26	-8.66	-0.76	MODERATE	0.54	0.34	0.88	-4.26	-8.66	-0.76	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.59	0.39	0.89	-3.50	-6.67	-0.73	MODERATE	0.59	0.39	0.89	-3.5	-6.67	-0.73	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.55	0.4	0.77	-3.94	-6.03	-1.87	MODERATE	0.55	0.4	0.77	-3.94	-6.03	-1.87	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
azithromycin	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.75	0.52	1.08	-1.65	-3.76	0.43	LOW	0.75	0.52	1.08	-1.65	-3.76	0.43	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
azithromycin	VV116	NA	NA	NA	NA	NA	NA	NA	0.54	0.29	1	-4.42	-10.73	0.01	LOW	0.54	0.29	1	-4.42	-10.73	0.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
colchicine	corticosteroids (systemic)	NA	NA	NA	NA	NA	NA	NA	1.36	0.87	2.16	1.91	-0.99	4.62	LOW	1.36	0.87	2.16	1.91	-0.99	4.62	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.82	0.53	1.27	-1.72	-5.85	1.82	VERY LOW	0.82	0.53	1.27	-1.72	-5.85	1.82	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.01	0.65	1.6	0.02	-3.62	3.18	LOW	1.01	0.65	1.6	0.02	-3.62	3.18	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.08	0.82	1.44	0.60	-1.35	2.78	LOW	1.08	0.82	1.44	0.6	-1.35	2.78	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.84	0.55	1.31	-1.48	-5.5	1.97	VERY LOW	0.84	0.55	1.31	-1.48	-5.5	1.97	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.79	0.51	1.23	-2.11	-6.48	1.56	VERY LOW	0.79	0.51	1.23	-2.11	-6.48	1.56	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.89	0.67	1.18	-0.88	-2.94	1.37	LOW	0.89	0.67	1.18	-0.88	-2.94	1.37	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision

TIME TO SYMPTOM RESOLUTION																													
Comparison		Direct estimate							Indirect estimate								Network estimate												
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE					
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
colchicine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.85	0.62	1.17	-1.28	-3.80	1.28	LOW	0.85	0.62	1.17	-1.28	-3.8	1.28	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.95	0.6	1.51	-0.51	-4.47	2.86	LOW	0.95	0.6	1.51	-0.51	-4.47	2.86	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.82	0.56	1.2	-1.68	-5.09	1.45	VERY LOW	0.82	0.56	1.2	-1.68	-5.09	1.45	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.82	0.53	1.27	-1.73	-5.87	1.80	VERY LOW	0.82	0.53	1.27	-1.73	-5.87	1.8	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.89	0.68	1.16	-0.88	-2.82	1.31	LOW	0.89	0.68	1.16	-0.88	-2.82	1.31	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.71	0.48	1.03	-3.15	-7.04	0.27	VERY LOW	0.71	0.48	1.03	-3.15	-7.04	0.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.11	0.83	1.5	0.77	-1.30	3.03	LOW	1.11	0.83	1.5	0.77	-1.3	3.03	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.08	0.72	1.63	0.50	-2.54	3.34	LOW	1.08	0.72	1.63	0.5	-2.54	3.34	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.82	0.51	1.31	-1.77	-6.27	1.98	VERY LOW	0.82	0.51	1.31	-1.77	-6.27	1.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
colchicine	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.88	0.6	1.31	-1.00	-4.36	2.04	LOW	0.88	0.6	1.31	-1	-4.36	2.04	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.83	0.62	1.12	-1.45	-3.80	0.99	LOW	0.83	0.62	1.12	-1.45	-3.8	0.99	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.13	0.81	1.59	0.84	-1.51	3.29	LOW	1.13	0.81	1.59	0.84	-1.51	3.29	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
colchicine	VV116	NA	NA	NA	NA	NA	NA	NA	0.82	0.45	1.49	-1.93	-8.38	2.73	VERY LOW	0.82	0.45	1.49	-1.93	-8.38	2.73	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	doxycycline	NA	NA	NA	NA	NA	NA	NA	0.6	0.35	1.02	-3.63	-7.89	0.15	VERY LOW	0.6	0.35	1.02	-3.63	-7.89	0.15	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	0.74	0.43	1.28	-1.89	-5.68	1.59	VERY LOW	0.74	0.43	1.28	-1.89	-5.68	1.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	favipiravir	NA	NA	NA	NA	NA	NA	NA	0.79	0.52	1.2	-1.31	-3.47	1.31	LOW	0.79	0.52	1.2	-1.31	-3.47	1.31	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.62	0.36	1.05	-3.39	-7.53	0.34	VERY LOW	0.62	0.36	1.05	-3.39	-7.53	0.34	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.58	0.34	0.99	-4.02	-8.49	-0.11	MODERATE	0.58	0.34	0.99	-4.02	-8.49	-0.11	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.65	0.43	0.98	-2.8	-5.03	-0.11	MODERATE	0.65	0.43	0.98	-2.8	-5.03	-0.11	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.62	0.4	0.97	-3.2	-5.88	-0.28	MODERATE	0.62	0.4	0.97	-3.2	-5.88	-0.28	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.7	0.4	1.21	-2.42	-6.53	1.24	VERY LOW	0.7	0.4	1.21	-2.42	-6.53	1.24	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.6	0.37	0.98	-3.59	-7.16	-0.17	MODERATE	0.6	0.37	0.98	-3.59	-7.16	-0.17	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.6	0.35	1.03	-3.64	-7.93	0.15	LOW	0.6	0.35	1.03	-3.64	-7.93	0.15	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
corticosteroids (systemic)	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.65	0.43	0.98	-2.79	-4.93	-0.19	MODERATE	0.65	0.43	0.98	-2.79	-4.93	-0.19	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.52	0.32	0.84	-5.06	-9.06	-1.36	MODERATE	0.52	0.32	0.84	-5.06	-9.06	-1.36	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	0.81	0.53	1.24	-1.14	-3.38	1.53	LOW	0.81	0.53	1.24	-1.14	-3.38	1.53	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.79	0.48	1.32	-1.41	-4.63	1.76	LOW	0.79	0.48	1.32	-1.41	-4.63	1.76	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.6	0.35	1.05	-3.68	-8.31	0.3	LOW	0.6	0.35	1.05	-3.68	-8.31	0.3	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
corticosteroids (systemic)	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.65	0.39	1.06	-2.92	-6.43	0.45	LOW	0.65	0.39	1.06	-2.92	-6.43	0.45	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
corticosteroids (systemic)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.61	0.4	0.93	-3.36	-5.91	-0.53	MODERATE	0.61	0.4	0.93	-3.36	-5.91	-0.53	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
corticosteroids (systemic)	umifenovir	NA	NA	NA	NA	NA	NA	NA	0.83	0.53	1.31	-1.07	-3.59	1.76	LOW	0.83	0.53	1.31	-1.07	-3.59	1.76	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
corticosteroids (systemic)	VV116	NA	NA	NA	NA	NA	NA	NA	0.6	0.31	1.17	-3.84	-10.34	1	VERY LOW	0.6	0.31	1.17	-3.84	-10.34	1	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	doxycycline, ivermectin	NA	NA	NA	NA	NA	NA	NA	1.24	0.73	2.1	1.74	-2.64	6.33	VERY LOW	1.24	0.73	2.1	1.74	-2.64	6.33	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.32	0.89	1.97	2.33	-0.8	6.25	LOW	1.32	0.89	1.97	2.33	-0.8	6.25	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
doxycycline	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	1.03	0.61	1.72	0.24	-4.47	4.98	LOW	1.03	0.61	1.72	0.24	-4.47	4.98	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.96	0.57	1.62	-0.39	-5.37	4.53	VERY LOW	0.96	0.57	1.62	-0.39	-5.37	4.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.08	0.73	1.6	0.84	-2.35	4.82	LOW	1.08	0.73	1.6	0.84	-2.35	4.82	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.04	0.68	1.58	0.44	-3.09	4.6	LOW	1.04	0.68	1.58	0.44	-3.09	4.6	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	1.16	0.68	1.98	1.21	-3.46	5.94	VERY LOW	1.16	0.68	1.98	1.21	-3.46	5.94	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1	0.62	1.6	0.04	-4.19	4.56	LOW	1	0.62	1.6	0.04	-4.19	4.56	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1	0.6	1.68	-0.01	-4.85	4.81	LOW	1	0.6	1.68	-0.01	-4.85	4.81	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.09	0.74	1.59	0.84	-2.28	4.78	LOW	1.09	0.74	1.59	0.84	-2.28	4.78	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.86	0.54	1.38	-1.43	-6.04	3.29	VERY LOW	0.86	0.54	1.38	-1.43	-6.04	3.29	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.36	0.9	2.04	2.49	-0.71	6.46	VERY LOW	1.36	0.9	2.04	2.49	-0.71	6.46	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.32	0.8	2.16	2.22	-1.71	6.56	VERY LOW	1.32	0.8	2.16	2.22	-1.71	6.56	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1	0.58	1.72	-0.04	-5.17	4.94	VERY LOW	1	0.58	1.72	-0.04	-5.17	4.94	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.08	0.67	1.75	0.72	-3.44	5.18	VERY LOW	1.08	0.67	1.75	0.72	-3.44	5.18	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.02	0.68	1.53	0.27	-3.13	4.35	LOW	1.02	0.68	1.53	0.27	-3.13	4.35	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.38	0.89	2.14	2.57	-0.84	6.65	LOW	1.38	0.89	2.14	2.57	-0.84	6.65	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
doxycycline	VV116	NA	NA	NA	NA	NA	NA	NA	1	0.51	1.93	-0.21	-7.06	5.5	VERY LOW	1	0.51	1.93	-0.21	-7.06	5.5	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	favipiravir	NA	NA	NA	NA	NA	NA	NA	1.07	0.71	1.61	0.58	-2.14	4	LOW	1.07	0.71	1.61	0.58	-2.14	4	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline, ivermectin	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.83	0.49	1.41	-1.5	-5.98	2.84	LOW	0.83	0.49	1.41	-1.5	-5.98	2.84	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline, ivermectin	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.78	0.45	1.33	-2.13	-6.92	2.38	LOW	0.78	0.45	1.33	-2.13	-6.92	2.38	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline, ivermectin	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.88	0.58	1.32	-0.91	-3.7	2.56	MODERATE	0.88	0.58	1.32	-0.91	-3.7	2.56	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline, ivermectin	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.84	0.54	1.3	-1.3	-4.46	2.37	MODERATE	0.84	0.54	1.3	-1.3	-4.46	2.37	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline, ivermectin	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.94	0.54	1.63	-0.53	-4.91	3.76	LOW	0.94	0.54	1.63	-0.53	-4.91	3.76	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.81	0.5	1.31	-1.7	-5.64	2.37	LOW	0.81	0.5	1.31	-1.7	-5.64	2.37	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline, ivermectin	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.81	0.47	1.38	-1.75	-6.33	2.65	LOW	0.81	0.47	1.38	-1.75	-6.33	2.65	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline, ivermectin	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.88	0.59	1.31	-0.9	-3.6	2.51	MODERATE	0.88	0.59	1.31	-0.9	-3.6	2.51	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline, ivermectin	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.7	0.43	1.13	-3.17	-7.54	1.15	LOW	0.7	0.43	1.13	-3.17	-7.54	1.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
doxycycline, ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.1	0.72	1.67	0.75	-2.04	4.21	MODERATE	1.1	0.72	1.67	0.75	-2.04	4.21	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline, ivermectin	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.07	0.64	1.77	0.48	-3.11	4.37	MODERATE	1.07	0.64	1.77	0.48	-3.11	4.37	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline, ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.81	0.46	1.41	-1.79	-6.7	2.78	VERY LOW	0.81	0.46	1.41	-1.79	-6.7	2.78	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
doxycycline, ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.87	0.53	1.43	-1.03	-4.91	2.97	LOW	0.87	0.53	1.43	-1.03	-4.91	2.97	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline, ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.82	0.54	1.25	-1.47	-4.5	2.13	MODERATE	0.82	0.54	1.25	-1.47	-4.5	2.13	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
doxycycline, ivermectin	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.11	0.71	1.75	0.82	-2.19	4.4	LOW	1.11	0.71	1.75	0.82	-2.19	4.4	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
doxycycline, ivermectin	VV116	NA	NA	NA	NA	NA	NA	NA	0.81	0.41	1.58	-1.95	-8.63	3.4	VERY LOW	0.81	0.41	1.58	-1.95	-8.63	3.4	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	fluvoxamine	NA	NA	NA	NA	NA	NA	NA	0.78	0.52	1.15	-2.08	-5.9	0.95	LOW	0.78	0.52	1.15	-2.08	-5.9	0.95	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
favipiravir	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.73	0.49	1.09	-2.71	-6.87	0.56	LOW	0.73	0.49	1.09	-2.71	-6.87	0.56	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
favipiravir	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	0.82	0.67	1.01	-1.49	-3.08	0.08	LOW	0.82	0.67	1.01	-1.49	-3.08	0.08	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.78	0.61	1.01	-1.89	-4.04	0.1	LOW	0.78	0.61	1.01	-1.89	-4.04	0.1	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	0.88	0.57	1.34	-1.11	-4.86	1.83	LOW	0.88	0.57	1.34	-1.11	-4.86	1.83	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.76	0.54	1.06	-2.28	-5.46	0.39	LOW	0.76	0.54	1.06	-2.28	-5.46	0.39	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision

TIME TO SYMPTOM RESOLUTION																														
Comparison		Direct estimate							Indirect estimate								Network estimate													
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE						
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading
favipiravir	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.76	0.51	1.13	-2.33	-6.28	0.79	LOW	0.76	0.51	1.13	-2.33	-6.28	0.79	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
favipiravir	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.82	0.68	1	-1.48	-2.93	-0.04	MODERATE	0.82	0.68	1	-1.48	-2.93	-0.04	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
favipiravir	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.65	0.46	0.91	-3.75	-7.42	-0.74	MODERATE	0.65	0.46	0.91	-3.75	-7.42	-0.74	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
favipiravir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.03	0.81	1.3	0.17	-1.43	1.72	LOW	1.03	0.81	1.3	0.17	-1.43	1.72	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	niclosamide	NA	NA	NA	NA	NA	NA	NA	1	0.69	1.43	-0.1	-2.87	2.21	LOW	1	0.69	1.43	-0.1	-2.87	2.21	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.76	0.49	1.16	-2.37	-6.7	0.98	LOW	0.76	0.49	1.16	-2.37	-6.7	0.98	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
favipiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.82	0.58	1.15	-1.61	-4.7	0.97	LOW	0.82	0.58	1.15	-1.61	-4.7	0.97	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.77	0.61	0.97	-2.05	-4.01	-0.21	MODERATE	0.77	0.61	0.97	-2.05	-4.01	-0.21	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB
favipiravir	umifenovir	0.95	0.29	3.1	NA	NA	NA	VERY LOW	1.11	0.8	1.55	NA	NA	NA		1.04	0.81	1.34	0.24	-1.5	1.84	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
favipiravir	VV116	NA	NA	NA	NA	NA	NA	NA	0.76	0.43	1.33	-2.54	-8.8	1.78	VERY LOW	0.76	0.43	1.33	-2.54	-8.8	1.78	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	HIV reverse transcriptase inhibitor	NA	NA	NA	NA	NA	NA	NA	0.94	0.55	1.57	-0.63	-5.61	4.2	LOW	0.94	0.55	1.57	-0.63	-5.61	4.2	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.06	0.71	1.56	0.6	-2.52	4.45	MODERATE	1.06	0.71	1.56	0.6	-2.52	4.45	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.01	0.67	1.54	0.2	-3.23	4.26	MODERATE	1.01	0.67	1.54	0.2	-3.23	4.26	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	1.13	0.66	1.93	0.97	-3.65	5.59	VERY LOW	1.13	0.66	1.93	0.97	-3.65	5.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.97	0.61	1.56	-0.2	-4.37	4.23	MODERATE	0.97	0.61	1.56	-0.2	-4.37	4.23	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.97	0.58	1.63	-0.25	-5.02	4.47	LOW	0.97	0.58	1.63	-0.25	-5.02	4.47	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.06	0.72	1.55	0.6	-2.43	4.4	MODERATE	1.06	0.72	1.55	0.6	-2.43	4.4	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.84	0.52	1.34	-1.67	-6.25	2.94	LOW	0.84	0.52	1.34	-1.67	-6.25	2.94	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.32	0.88	1.98	2.25	-0.86	6.1	MODERATE	1.32	0.88	1.98	2.25	-0.86	6.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision
fluvoxamine	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.28	0.78	2.09	1.98	-1.85	6.2	LOW	1.28	0.78	2.09	1.98	-1.85	6.2	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
fluvoxamine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.97	0.56	1.67	-0.29	-5.37	4.59	VERY LOW	0.97	0.56	1.67	-0.29	-5.37	4.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.05	0.65	1.7	0.48	-3.64	4.85	LOW	1.05	0.65	1.7	0.48	-3.64	4.85	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
fluvoxamine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.99	0.66	1.48	0.03	-3.29	3.97	MODERATE	0.99	0.66	1.48	0.03	-3.29	3.97	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
fluvoxamine	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.34	0.87	2.07	2.32	-1.01	6.27	VERY LOW	1.34	0.87	2.07	2.32	-1.01	6.27	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
fluvoxamine	VV116	NA	NA	NA	NA	NA	NA	NA	0.97	0.5	1.87	-0.45	-7.31	5.19	VERY LOW	0.97	0.5	1.87	-0.45	-7.31	5.19	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	(hydroxy)chloroquine	NA	NA	NA	NA	NA	NA	NA	1.13	0.76	1.68	1.22	-2.1	5.41	LOW	1.13	0.76	1.68	1.22	-2.1	5.41	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	1.08	0.71	1.66	0.82	-2.82	5.19	LOW	1.08	0.71	1.66	0.82	-2.82	5.19	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	1.2	0.7	2.08	1.6	-3.16	6.49	VERY LOW	1.2	0.7	2.08	1.6	-3.16	6.49	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	1.04	0.64	1.68	0.43	-3.9	5.16	LOW	1.04	0.64	1.68	0.43	-3.9	5.16	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1.04	0.62	1.75	0.38	-4.57	5.4	LOW	1.04	0.62	1.75	0.38	-4.57	5.4	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.13	0.76	1.67	1.23	-2.04	5.39	LOW	1.13	0.76	1.67	1.23	-2.04	5.39	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.9	0.55	1.44	-1.04	-5.75	3.9	LOW	0.9	0.55	1.44	-1.04	-5.75	3.9	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.41	0.93	2.14	2.88	-0.47	7.1	MODERATE	1.41	0.93	2.14	2.88	-0.47	7.1	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision
HIV reverse transcriptase inhibitor	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.37	0.84	2.25	2.61	-1.43	7.14	LOW	1.37	0.84	2.25	2.61	-1.43	7.14	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
HIV reverse transcriptase inhibitor	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.04	0.6	1.8	0.34	-4.88	5.55	VERY LOW	1.04	0.6	1.8	0.34	-4.88	5.55	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.12	0.69	1.83	1.1	-3.18	5.78	VERY LOW	1.12	0.69	1.83	1.1	-3.18	5.78	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
HIV reverse transcriptase inhibitor	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.06	0.7	1.6	0.66	-2.87	4.97	MODERATE	1.06	0.7	1.6	0.66	-2.87	4.97	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
HIV reverse transcriptase inhibitor	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.43	0.92	2.23	2.95	-0.58	7.26	LOW	1.43	0.92	2.23	2.95	-0.58	7.26	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision
HIV reverse transcriptase inhibitor	VV116	NA	NA	NA	NA	NA	NA	NA	1.04	0.53	2.02	0.18	-6.77	6.07	VERY LOW	1.04	0.53	2.02	0.18	-6.77	6.07	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	inhaled corticosteroids	NA	NA	NA	NA	NA	NA	NA	0.96	0.75	1.23	-0.4	-2.64	1.68	MODERATE	0.96	0.75	1.23	-0.4	-2.64	1.68	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	1.07	0.7	1.63	0.37	-3.42	3.37	LOW	1.07	0.7	1.63	0.37	-3.42	3.37	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
(hydroxy)chloroquine	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.92	0.66	1.28	-0.79	-4.02	1.95	MODERATE	0.92	0.66	1.28	-0.79	-4.02	1.95	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.92	0.62	1.36	-0.84	-4.85	2.35	MODERATE	0.92	0.62	1.36	-0.84	-4.85	2.35	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	ivermectin	NA	NA	NA	NA	NA	NA	NA	1	0.83	1.21	0	-1.55	1.58	MODERATE	1	0.83	1.21	0	-1.55	1.58	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.79	0.57	1.1	-2.26	-5.98	0.82	MODERATE	0.79	0.57	1.1	-2.26	-5.98	0.82	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision
(hydroxy)chloroquine	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.25	0.99	1.57	1.65	-0.04	3.33	MODERATE	1.25	0.99	1.57	1.65	-0.04	3.33	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.22	0.85	1.74	1.38	-1.44	3.79	MODERATE	1.22	0.85	1.74	1.38	-1.44	3.79	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.92	0.6	1.41	-0.88	-5.25	2.53	VERY LOW	0.92	0.6	1.41	-0.88	-5.25	2.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
(hydroxy)chloroquine	remdesivir	NA	NA	NA	NA	NA	NA	NA	1	0.71	1.4	-0.12	-3.26	2.52	LOW	1	0.71	1.4	-0.12	-3.26	2.52	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
(hydroxy)chloroquine	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.94	0.75	1.18	-0.56	-2.61	1.37	MODERATE	0.94	0.75	1.18	-0.56	-2.61	1.37	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
(hydroxy)chloroquine	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.27	0.96	1.68	1.73	-0.31	3.63	LOW	1.27	0.96	1.68	1.73	-0.31	3.63	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
(hydroxy)chloroquine	VV116	NA	NA	NA	NA	NA	NA	NA	0.92	0.52	1.62	-1.05	-7.38	3.32	VERY LOW	0.92	0.52	1.62	-1.05	-7.38	3.32	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	Interferon alpha	NA	NA	NA	NA	NA	NA	NA	1.12	0.71	1.74	0.77	-3.21	4.12	LOW	1.12	0.71	1.74	0.77	-3.21	4.12	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
inhaled corticosteroids	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.96	0.67	1.38	-0.4	-3.85	2.7	MODERATE	0.96	0.67	1.38	-0.4	-3.85	2.7	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.96	0.63	1.47	-0.45	-4.62	3.05	MODERATE	0.96	0.63	1.47	-0.45	-4.62	3.05	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.05	0.82	1.32	0.4	-1.57	2.55	MODERATE	1.05	0.82	1.32	0.4	-1.57	2.55	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.83	0.57	1.19	-1.86	-5.76	1.54	LOW	0.83	0.57	1.19	-1.86	-5.76	1.54	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2
inhaled corticosteroids	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.31	0.99	1.72	2.05	-0.03	4.27	MODERATE	1.31	0.99	1.72	2.05	-0.03	4.27	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.27	0.86	1.87	1.78	-1.28	4.61	MODERATE	1.27	0.86	1.87	1.78	-1.28	4.61	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.96	0.61	1.51	-0.48	-5.01	3.23	VERY LOW	0.96	0.61	1.51	-0.48	-5.01	3.23	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
inhaled corticosteroids	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.04	0.72	1.51	0.28	-3.08	3.32	LOW	1.04	0.72	1.51	0.28	-3.08	3.32	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
inhaled corticosteroids	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.98	0.75	1.28	-0.17	-2.54	2.24	MODERATE	0.98	0.75	1.28	-0.17	-2.54	2.24	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision
inhaled corticosteroids	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.33	0.97	1.82	2.13	-0.24	4.54	LOW	1.33	0.97	1.82	2.13	-0.24	4.54	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
inhaled corticosteroids	VV116	NA	NA	NA	NA	NA	NA	NA	0.96	0.53	1.72	-0.65	-7.08	3.96	VERY LOW	0.96	0.53	1.72	-0.65	-7.08	3.96	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	interferon lambda (subcutaneous)	NA	NA	NA	NA	NA	NA	NA	0.86	0.53	1.42	-1.17	-5.29	3.19	VERY LOW	0.86	0.53	1.42	-1.17	-5.29	3.19	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	0.86	0.5	1.48	-1.22	-5.94	3.44	VERY LOW	0.86	0.5	1.48	-1.22	-5.94	3.44	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	ivermectin	NA	NA	NA	NA	NA	NA	NA	0.94	0.62	1.42	-0.37	-3.31	3.38	LOW	0.94	0.62	1.42	-0.37	-3.31	3.38	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.74	0.45	1.22	-2.64	-7.14	1.93	VERY LOW	0.74	0.45	1.22	-2.64	-7.14	1.93	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.17	0.76	1.81	1.28	-1.73	5.06	VERY LOW	1.17	0.76	1.81	1.28	-1.73	5.06	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.14	0.68	1.91	1.01	-2.77	5.2	VERY LOW	1.14	0.68	1.91	1.01	-2.77	5.2	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.86	0.49	1.51	-1.26	-6.31	3.57	VERY LOW	0.86	0.49	1.51	-1.26	-6.31	3.57	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2
Interferon alpha	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.93	0.56	1.54	-0.5	-4.53	3.8	LOW	0.93	0.56	1.54	-0.5	-4.53	3.8	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision
Interferon alpha	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.88	0.57	1.36	-0.94	-4.16	2.97	LOW	0.88	0.57	1.36	-0.94	-4.16	2.97	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision

TIME TO SYMPTOM RESOLUTION																														
Comparison		Direct estimate							Indirect estimate								Network estimate													
		Relative estimate			Absolute estimate (per 1,000)				Relative estimate			Absolute estimate (per 1,000)					Relative estimate			Absolute estimate (per 1,000)			GRADE						
Treatment 1	Treatment 2	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating	Point estimate	CI lower limit	CI upper limit	Point estimate	CI lower limit	CI upper limit	Final rating		Point estimate	CrI lower limit	CrI upper limit	Point estimate	CI lower limit	CI upper limit	Starting evidence	Starting rating	Incoherence	Imprecision	Final rating	Reasons for downgrading		
Interferon alpha	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.19	0.75	1.89	1.35	-1.87	5.25	VERY LOW		1.19	0.75	1.89	1.35	-1.87	5.25	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
Interferon alpha	VV116	NA	NA	NA	NA	NA	NA	NA	0.86	0.44	1.69	-1.42	-8.2	4.18	VERY LOW		0.86	0.44	1.69	-1.42	-8.2	4.18	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
interferon lambda (subcutaneous)	intermediate-dose anticoagulation	NA	NA	NA	NA	NA	NA	NA	1	0.62	1.6	-0.05	-4.6	4.16	MODERATE		1	0.62	1.6	-0.05	-4.6	4.16	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
interferon lambda (subcutaneous)	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.08	0.79	1.5	0.8	-1.86	3.97	MODERATE		1.08	0.79	1.5	0.8	-1.86	3.97	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
interferon lambda (subcutaneous)	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.86	0.56	1.31	-1.47	-5.77	2.65	LOW		0.86	0.56	1.31	-1.47	-5.77	2.65	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.36	0.96	1.92	2.45	-0.3	5.67	MODERATE		1.36	0.96	1.92	2.45	-0.3	5.67	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision		
interferon lambda (subcutaneous)	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.32	0.85	2.06	2.18	-1.37	5.84	LOW		1.32	0.85	2.06	2.18	-1.37	5.84	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
interferon lambda (subcutaneous)	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1	0.61	1.64	-0.09	-4.95	4.31	LOW		1	0.61	1.64	-0.09	-4.95	4.31	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
interferon lambda (subcutaneous)	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.08	0.7	1.66	0.67	-3.16	4.51	LOW		1.08	0.7	1.66	0.67	-3.16	4.51	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
interferon lambda (subcutaneous)	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.02	0.72	1.44	0.23	-2.77	3.58	MODERATE		1.02	0.72	1.44	0.23	-2.77	3.58	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
interferon lambda (subcutaneous)	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.38	0.94	2.02	2.52	-0.45	5.87	LOW		1.38	0.94	2.02	2.52	-0.45	5.87	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision		
interferon lambda (subcutaneous)	VV116	NA	NA	NA	NA	NA	NA	NA	1	0.53	1.86	-0.25	-6.91	4.97	VERY LOW		1	0.53	1.86	-0.25	-6.91	4.97	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
intermediate-dose anticoagulation	ivermectin	NA	NA	NA	NA	NA	NA	NA	1.09	0.74	1.6	0.85	-2.26	4.8	MODERATE		1.09	0.74	1.6	0.85	-2.26	4.8	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
intermediate-dose anticoagulation	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.86	0.53	1.38	-1.42	-6.05	3.33	LOW		0.86	0.53	1.38	-1.42	-6.05	3.33	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
intermediate-dose anticoagulation	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.36	0.9	2.04	2.5	-0.7	6.5	MODERATE		1.36	0.9	2.04	2.5	-0.7	6.5	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision		
intermediate-dose anticoagulation	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.32	0.8	2.16	2.23	-1.69	6.57	LOW		1.32	0.8	2.16	2.23	-1.69	6.57	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
intermediate-dose anticoagulation	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1	0.58	1.72	-0.04	-5.18	4.95	VERY LOW		1	0.58	1.72	-0.04	-5.18	4.95	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
intermediate-dose anticoagulation	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.08	0.67	1.74	0.72	-3.43	5.21	VERY LOW		1.08	0.67	1.74	0.72	-3.43	5.21	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
intermediate-dose anticoagulation	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.02	0.68	1.53	0.28	-3.13	4.38	MODERATE		1.02	0.68	1.53	0.28	-3.13	4.38	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
intermediate-dose anticoagulation	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.38	0.89	2.13	2.57	-0.82	6.68	LOW		1.38	0.89	2.13	2.57	-0.82	6.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision		
intermediate-dose anticoagulation	VV116	NA	NA	NA	NA	NA	NA	NA	1	0.52	1.92	-0.2	-7.09	5.53	VERY LOW		1	0.52	1.92	-0.2	-7.09	5.53	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
ivermectin	lopinavir, ritonavir	NA	NA	NA	NA	NA	NA	NA	0.79	0.57	1.09	-2.27	-5.92	0.73	MODERATE		0.79	0.57	1.09	-2.27	-5.92	0.73	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision		
ivermectin	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.25	1.01	1.56	1.65	0.06	3.19	HIGH		1.25	1.01	1.56	1.65	0.06	3.19	Indirect	HIGH	Not serious	Not Serious	HIGH			
ivermectin	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.22	0.85	1.73	1.38	-1.38	3.69	MODERATE		1.22	0.85	1.73	1.38	-1.38	3.69	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
ivermectin	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.92	0.61	1.4	-0.89	-5.21	2.45	VERY LOW		0.92	0.61	1.4	-0.89	-5.21	2.45	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
ivermectin	remdesivir	NA	NA	NA	NA	NA	NA	NA	1	0.71	1.39	-0.12	-3.21	2.44	LOW		1	0.71	1.39	-0.12	-3.21	2.44	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
ivermectin	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.94	0.75	1.16	-0.57	-2.53	1.25	MODERATE		0.94	0.75	1.16	-0.57	-2.53	1.25	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
ivermectin	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.27	0.97	1.66	1.72	-0.23	3.52	LOW		1.27	0.97	1.66	1.72	-0.23	3.52	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
ivermectin	VV116	NA	NA	NA	NA	NA	NA	NA	0.92	0.52	1.61	-1.05	-7.33	3.25	VERY LOW		0.92	0.52	1.61	-1.05	-7.33	3.25	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
lopinavir, ritonavir	molnupiravir	NA	NA	NA	NA	NA	NA	NA	1.57	1.11	2.24	3.92	0.84	7.62	HIGH		1.57	1.11	2.24	3.92	0.84	7.62	Indirect	HIGH	Not serious	Not Serious	HIGH			
lopinavir, ritonavir	niclosamide	NA	NA	NA	NA	NA	NA	NA	1.53	0.98	2.39	3.65	-0.16	7.75	MODERATE		1.53	0.98	2.39	3.65	-0.16	7.75	Indirect	HIGH	Not serious	Very serious	LOW	Imprecision		
lopinavir, ritonavir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	1.16	0.71	1.91	1.38	-3.65	6.17	VERY LOW		1.16	0.71	1.91	1.38	-3.65	6.17	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
lopinavir, ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.26	0.81	1.94	2.14	-1.91	6.41	VERY LOW		1.26	0.81	1.94	2.14	-1.91	6.41	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
lopinavir, ritonavir	serine protease inhibitors	1.47	0.45	4.82	NA	NA	NA	VERY LOW	0.97	0.63	1.47	NA	NA	NA			1.18	0.87	1.6	1.7	-1.2	5.15	Indirect	HIGH	Not serious	Very serious	LOW	Imprecisionx2		
lopinavir, ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.6	1.09	2.36	3.99	0.71	7.82	MODERATE		1.6	1.09	2.36	3.99	0.71	7.82	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB		
lopinavir, ritonavir	VV116	NA	NA	NA	NA	NA	NA	NA	1.16	0.62	2.17	1.22	-5.56	6.77	VERY LOW		1.16	0.62	2.17	1.22	-5.56	6.77	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
molnupiravir	niclosamide	NA	NA	NA	NA	NA	NA	NA	0.97	0.67	1.41	-0.27	-3.08	2.14	MODERATE		0.97	0.67	1.41	-0.27	-3.08	2.14	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
molnupiravir	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.74	0.47	1.14	-2.54	-6.88	0.89	LOW		0.74	0.47	1.14	-2.54	-6.88	0.89	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision		
molnupiravir	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.8	0.56	1.14	-1.77	-4.91	0.88	LOW		0.8	0.56	1.14	-1.77	-4.91	0.88	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
molnupiravir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.75	0.58	0.96	-2.22	-4.26	-0.28	HIGH		0.75	0.58	0.96	-2.22	-4.26	-0.28	Indirect	HIGH	Not serious	Not Serious	HIGH			
molnupiravir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.02	0.75	1.37	0.07	-1.96	2	LOW		1.02	0.75	1.37	0.07	-1.96	2	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
molnupiravir	VV116	NA	NA	NA	NA	NA	NA	NA	0.74	0.41	1.31	-2.7	-9.04	1.68	VERY LOW		0.74	0.41	1.31	-2.7	-9.04	1.68	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
niclosamide	nirmatrelvir-ritonavir	NA	NA	NA	NA	NA	NA	NA	0.76	0.45	1.27	-2.27	-6.95	1.84	VERY LOW		0.76	0.45	1.27	-2.27	-6.95	1.84	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
niclosamide	remdesivir	NA	NA	NA	NA	NA	NA	NA	0.82	0.52	1.29	-1.5	-5.08	2.01	VERY LOW		0.82	0.52	1.29	-1.5	-5.08	2.01	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
niclosamide	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.77	0.53	1.13	-1.95	-4.62	1.01	MODERATE		0.77	0.53	1.13	-1.95	-4.62	1.01	Indirect	HIGH	Not serious	Serious	MODERATE	Imprecision		
niclosamide	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.04	0.7	1.57	0.34	-2.32	3.31	LOW		1.04	0.7	1.57	0.34	-2.32	3.31	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
niclosamide	VV116	NA	NA	NA	NA	NA	NA	NA	0.76	0.4	1.44	-2.43	-8.98	2.52	VERY LOW		0.76	0.4	1.44	-2.43	-8.98	2.52	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
nirmatrelvir-ritonavir	remdesivir	NA	NA	NA	NA	NA	NA	NA	1.08	0.65	1.79	0.76	-3.56	5.59	VERY LOW		1.08	0.65	1.79	0.76	-3.56	5.59	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
nirmatrelvir-ritonavir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	1.02	0.66	1.57	0.32	-3.29	4.76	LOW		1.02	0.66	1.57	0.32	-3.29	4.76	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
nirmatrelvir-ritonavir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.38	0.87	2.2	2.61	-0.99	7.07	LOW		1.38	0.87	2.2	2.61	-0.99	7.07	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecision		
nirmatrelvir-ritonavir	VV116	1	0.31	3.25	NA	NA	NA	VERY LOW	NA	NA	NA	NA	NA	NA	NA		1	0.69	1.45	-0.17	-4.36	3.02	Direct	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
remdesivir	serine protease inhibitors	NA	NA	NA	NA	NA	NA	NA	0.94	0.66	1.35	-0.44	-3.37	2.82	LOW		0.94	0.66	1.35	-0.44	-3.37	2.82	Indirect	MODERATE	Not serious	Serious	LOW	RoB, Imprecision		
remdesivir	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.27	0.86	1.89	1.85	-1.05	5.13	VERY LOW		1.27	0.86	1.89	1.85	-1.05	5.13	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
remdesivir	VV116	NA	NA	NA	NA	NA	NA	NA	0.92	0.49	1.73	-0.93	-7.58	4.22	VERY LOW		0.92	0.49	1.73	-0.93	-7.58	4.22	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
serine protease inhibitors	umifenovir	NA	NA	NA	NA	NA	NA	NA	1.35	1	1.83	2.29	0.06	4.53	MODERATE		1.35	1	1.83	2.29	0.06	4.53	Indirect	MODERATE	Not serious	Not Serious	MODERATE	RoB		
serine protease inhibitors	VV116	NA	NA	NA	NA	NA	NA	NA	0.98	0.55	1.75	-0.48	-6.85	4.06	VERY LOW		0.98	0.55	1.75	-0.48	-6.85	4.06	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		
umifenovir	VV116	NA	NA	NA	NA	NA	NA	NA	0.73	0.4	1.32	-2.78	-9.16	1.74	VERY LOW		0.73	0.4	1.32	-2.78	-9.16	1.74	Indirect	MODERATE	Not serious	Very serious	VERY LOW	RoB, Imprecisionx2		

Living Network Meta-Analysis Protocol and Extended Methods

Therapies for treatment and prophylaxis of COVID-19: introduction and methods for a living systematic review and network meta-analyses

An international collaborative project

July 2020

Correspondence to
Reed AC Siemieniuk
reed.siemieniuk@medportal.ca

Abstract

Objectives: To compare the effects of therapies for prophylaxis and treatment of COVID-19
Design: Living systematic review and network meta-analysis (NMA).
Data sources: U.S. Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database, which includes 25 electronic databases.
Study selection: We will include randomized clinical trials (RCT) in which persons exposed to COVID-19 or with suspected, probable or confirmed COVID-19 were treated with pharmaceuticals or blood products aimed at prophylaxis or treatment. Pairs of independent reviewers will screen in duplicate title and abstract and full text of potentially eligible articles.
Methods: After duplicate data abstraction, we will conduct a Bayesian-random effects network meta-analysis for each of the outcomes of interest. We will assess the risk of bias of the included studies using a modification of the Cochrane Risk of Bias 2.0 tool, and the certainty of the evidence using the GRADE approach for NMA. We will classify the interventions in groups from the most to the least effective/ harmful following GRADE guidance using a minimally contextualized approach.
Publication and Updating of Results: We will publish and update the results in *The BMJ* and magicapp.org. We will update the living NMA when the question is no longer of clinical importance, or new evidence that might impact on the conclusions is unlikely to be forthcoming.

Background

COVID-19 is a rapidly evolving global health emergency. As of 27 May 2020, over 5.6 million people have been infected and of these, 335,000 have died,[1] resulting in an enormous perceived need to implement a possibly effective intervention. Public figures,[2] guideline bodies,[3] and government agencies [4] have suggested using interventions without established benefit. Clinicians have responded to these suggestions by administering such interventions to large numbers of patients.[5]

With many teams conducting randomized clinical trials (RCTs) of drug interventions—over 1,000 intervention trials registered as of 10 May 2020 [6]—evidence on the comparative effectiveness of drug interventions will emerge rapidly. The new environment will amplify the need for evidence based medicine: distinguishing trustworthy from untrustworthy evidence, interpreting the results, and judging net benefits of interventions against standard treatment and one another.[7]

Reliable guidance for COVID-19 will require adherence to standards of trustworthy clinical practice guidelines,[8] including methodically rigorous and rapidly updated evidence summaries. Such summaries will identify interventions with sufficient evidence of net benefit to warrant use. Establishing absence of net benefit in previously highly touted interventions may be equally important. Further, if studies suggest that more than one intervention provides net benefit, clinicians and patients will face the challenge of deciding which intervention to use.

Our living systematic review and network meta-analysis (NMA), updated in real time, will answer this urgent demand for trustworthy evidence on the available therapeutic options. This systematic review is part of the *BMJ Rapid Recommendations* project, a collaborative effort from the MAGIC Evidence Ecosystem Foundation (www.magicproject.org) and *The BMJ*. Our living NMA will thus directly inform *BMJ Rapid Recommendations*,[9] providing trustworthy, actionable, and living guidance to clinicians and patients soon after new and potentially practice-changing evidence is made available. The living NMA will be freely available in user-friendly formats, through *The BMJ* and MAGICapp (www.magicapp.orsg), and ready for re-use and adaptation at national and local levels.

Methods

Structure and organization

The team working in the development of this living systematic review and NMA is composed of the following groups:

a. Oversight group composed of experts in the clinical area and systematic review methodology (RAC, TA, GHG, BR, FL, SM, PV). The role of this team is to ensure that the process follows the highest methodological standards, and that the decisions made are clinically sensible and keep consistency with the needs of the *BMJ Rapid Recommendations*.
b. Core systematic review team leaders. This group is composed of methodologists leading teams in charge of study identification (JB), data abstraction (DZ), data analysis (LG), and assessment of certainty of the evidence and presentation (RBP).
c. Reviewers. This team is composed of clinicians, graduate students, methodologists, and biostatisticians conducting or providing advice for screening, data abstraction, and assessments of certainty of the evidence.

In addition, decisions in this protocol have been made considering the requirements from the *Rapid Recommendations* guideline panel, which includes patients.

Eligibility criteria

We will include RCTs in which persons exposed to COVID-19 or with suspected, probable, or confirmed COVID-19 are treated with pharmacologic or blood products aimed at prophylaxis or treatment. We will include trials in which researchers compare any intervention against another or against no intervention, placebo, or standard of care, and report any outcome. We will include trials that report results regardless of publication status (peer-reviewed, in press, or pre-print, but not news reports alone) or language. There will be no restrictions on acuity of disease, nor setting.

We will include trials of pharmaceuticals, blood products, vitamins, minerals and, if the drug is one specific molecule, Chinese medicines. We will exclude quasi-randomized studies and randomized trials evaluating external organ support, plasma exchange, oxygen delivery, ventilation strategies, vaccination, nutrition, traditional Chinese herbal medicines (that typically include more than one molecule or a molecule without specific molecular weighted dosing), exercise/rehabilitation, psychological and educational interventions, personal protective equipment, or any other non-drug supportive care interventions.

Data sources and searches

We will search the U.S. Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database for eligible studies—the most comprehensive database of COVID-19 research articles from December 2019 and which is maintained by the Stephen B. Thacker CDC library [10]. We will update our search daily Monday to Friday to match the update schedule of the database. The database includes 25 bibliographic and grey literature sources: Medline (Ovid and PubMed), PubMed Central, Embase, CAB Abstracts, Global Health, PsycInfo, Cochrane Library, Scopus, Academic Search Complete, Africa Wide Information, CINAHL, ProQuest Central, SciFinder, the Virtual Health Library, LitCovid, WHO COVID-19 website, CDC COVID-19 website, Eurosurveillance, China CDC Weekly, Homeland Security Digital Library, ClinicalTrials.gov, bioRxiv (preprints), medRxiv (preprints), chemRxiv (preprints), and SSRN (preprints).

We will filter the results from the CDC's database through a validated and highly sensitive machine learning model to identify RCTs.[11] We will track preprints of RCTs until publication and data updated to match that in the peer-reviewed publication when discrepant. In addition, we will search six Chinese databases on a biweekly basis: Wanfang, CBM, CNKI, VIP, Chinese Medical Journal Net (preprints), and ChinaXiv (preprints). The search terms for COVID-19 developed by the CDC have been adapted to the Chinese language. For the search of the Chinese literature, we will also include search terms for randomized trials. The search strategy is available in the Supplementary Material.

We will also monitor living evidence retrieval services on an ongoing basis. Two such services are the Systematic and Living Map on COVID-19 Evidence by the Norwegian Institute of Public Health, in collaboration with the Cochrane Canada Centre at McMaster University,[12] and the Living Overview of Evidence (L·OVE) by Epistemonikos Foundation.[13] Our publication will be accompanied with a public call for information sharing, with hopes that investigators will initiate contact and share information when available. RCTs may also be identified organically through informal networks.

Study selection

Pairs of reviewers will independently and in duplicate screen titles and abstracts followed by full texts. A third reviewer will adjudicate conflicts.

Data extraction

For each eligible trial, two reviewers, who have undergone training and have completed calibration exercises, will extract data independently and in duplicate using a standardised, pilot-tested data extraction form. Discrepancies will be resolved by discussion, and when necessary adjudicated by a third person. The study characteristics and baseline participant information that will be extracted is presented in Box 1.

Box 1. Study characteristics and baseline participant information that will be extracted

- Geographic location
- Physical location (outpatient, inpatient, intensive care)
- Patient and public involvement in the study design or interpretation
- Funder (public, private)
- Number randomized
- Number randomized to each intervention
- Dose, frequency, route of administration, and duration for each intervention
- Number who received each intervention
- Mean age
- Percent male
- Severity of illness (non-severe, severe, critically ill)
- Mean oxygen saturation on room air, or mean baseline amount of supplemental oxygen
- Percent receiving mechanical ventilation at baseline
- Percent current and former smokers

- Percent with hypertension
- Percent with underlying chronic respiratory condition including chronic obstructive pulmonary disease (COPD), asthma, and others
- Percent with diabetes
- Percent taking angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)
- Mean alanine aminotransferase (ALT)
- Mean C-reactive protein (CRP)
- Mean d-dimer
- Mean lactate dehydrogenase (LDH)
- Mean lymphocyte count, and percent with lymphopenia

Outcomes

We will begin by focusing on the patient-important outcomes listed below, based on the WHO's candidate core outcome set.[14] The list of outcomes may be modified at the discretion of the BMJ *Rapid Recommendations* standing panel of experts, which includes frontline healthcare workers and patient-partners. As harms are typically specific to individual pharmacologic therapies, these outcomes will be selected at the time they are needed to support specific linked Rapid Recommendations. We will extract the outcome data closest to the prespecified outcome time point.

The initial outcomes examined for the studies of treatment will include:

- Mortality (time frame: closest to 90 days)
- Mechanical ventilation in patients not initially mechanically ventilated (time frame: closest to 90 days)
- Duration of hospitalization
- Admission to hospital (time frame: closest to 28 days)
- Adverse effects leading to discontinuation of the intervention (time frame: closest to 28 days)
- Time to symptom resolution
- Time until the amount of SARS-CoV2 viral particles is below the threshold set by the RCT authors for being likely no longer infectious (as a surrogate for transmissibility)
- Undetectable nCoV-19 by PCR (time frame: closest to 7 days and not less than 4 days or more than 10 days)

The initial outcomes examined for the studies of prophylaxis will include:

- Symptomatic SARS-CoV2 infection (time frame: closest to 28 days)
- Mortality (time frame: closest to 90 days)
- Admission to hospital (time frame: closest to 28 days)
- Adverse effects leading to discontinuation of the intervention (time frame: closest to 28 days)
- Time to symptom resolution (those not infected will be considered 0)

Other outcomes that will be extracted and reported from the trials, but not initially reviewed will include:

- Ventilator-free days (time frame: 28 days)
- Venous thromboembolism (time frame: closest to 90 days)
- Clinically important bleeding (time frame: closest to 90 days)

Risk of bias assessments

Following calibration exercises, two reviewers, working independently and in duplicate, will use the Clinical Advances Through Research and Information Translation (CLARITY) revisions of the Cochrane tool for assessing risk of bias in randomized trials (RoB 2.0) to rate trials as either 'low risk of bias', 'some

concerns – probably low risk of bias', 'some concerns – probably high risk of bias' and 'high risk of bias', across the following domains: bias arising from the randomization process, bias due to departures from the intended intervention, bias due to missing outcome data, bias in measurement of the outcome, bias in selection of the reported results.[15 16] The response choice 'some concerns' was modified to include a judgement about whether the concerns probably do or do not result in high risk of bias.[16] We will not consider judgements about applicability when considering risk of bias because applicability is judged separately within indirectness domain of the GRADE framework.[17] In addition, the modified tool includes an additional domain to assess risk of bias related to RCTs stopping early for benefit.[18] Reviewers will resolve discrepancies by discussion, and when not possible, adjudication by a third-party research methodologist. A detailed guide for our risk of bias assessments is available in the Supplementary Material. If the body of evidence is rated as high risk of bias for missing data only (i.e., no serious concerns with any other of the risk of bias domains), we may perform sensitivity analyses with worst plausible assumptions to see if results remain robust to missing data.

Treatment nodes

We will perform three separate network meta-analyses: i) pharmacologic treatments for patients with suspected or confirmed COVID-19, ii) blood products for treatment of patients with suspected or confirmed COVID-19, and iii) pharmacologic prophylactic therapy for people exposed to COVID-19.

Treatments will be grouped into common nodes based on molecule but not dose or duration: we will include all doses and durations of the same medication in a single treatment node. When an intervention includes more than one medication, it will be included as a separate node. We will include drugs from the same class within the same node. Chloroquine and hydroxychloroquine will be included in the same node for COVID-19 specific effects and separated for disease-independent adverse effects. Prespecified nodes include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, anti-interleukin-6 agents (i.e., tocilizumab, sarilumab), glucocorticoids, interferons, JAK inhibitors, statins, antiplatelet agents, and anticoagulants. Antibiotics will be grouped into nodes by class (e.g., macrolides, beta-lactams). The NMA oversight group and the linked Rapid Recommendation panels will make final decisions on how to group treatment nodes.

Data synthesis

We will perform random-effects pairwise meta-analysis for each comparison for each outcome using the Bayesian framework. We will use a plausible prior for variance parameter,[19] and uniform prior for the effect parameter. We will calculate Ratio of Means (RoM) and corresponding 95% credible intervals (CrIs) for continuous outcomes in which we expect variationa cross populations (time to symptoms resolution and time to viral clearance) and mean differences (MDs) and corresponding 95% credible intervals (CrIs) for other continuous outcomes. For dichotomous outcomes, we will calculate odds ratios (ORs) with corresponding CrIs. Absolute effects will be calculated based on the ORs and baseline risk of standard of care.[20] We will create a funnel plot to assess the publication bias when 10 or more studies are available for a specific direct comparison.[21]

We will conduct a random-effects network meta-analysis using the Bayesian framework with same priors for the variance and effect parameters.[19] We will use three Markov-chains with 100,000 iterations after an initial burn-in of 10,000 and a thinning of 10. We will assess the convergence based on trace plots and the Brooks-Gelman-Rubin statistic, with an acceptable threshold of <1.05 for all nodes. If convergence is not achieved, then we will use 500,000 iterations and a burn-in of 50,000 iterations and a thinning of 10. We will use automated generation of node-splitting models to assess local incoherence and to obtain indirect estimates.[22] We will estimate ranking probabilities and calculate surface under the cumulative ranking curves (SUCRA). For all dichotomous outcomes, we will calculate the absolute treatment effects of the network estimates based-on the odds ratios and the baseline risk using the transitive risks model.[23] To obtain

the baseline risk, we will use the highest quality prognostic evidence available at the time of publication, typically based on a systematic review of prognostic studies.[24]

When networks are sparse, between-study heterogeneity variances are often imprecisely estimated. That may generate implausibly wide credible intervals from network estimates, even when the direct and indirect estimates are coherent.[25] When this occurs, we will conduct sensitivity analyses by using empirically informative priors,[26] and fixed effects models.[25] Another situation in which implausibly wide confidence intervals occur is with random effects when the number of studies is small and the heterogeneity is considerable, particularly when study size varies markedly. This is a second situation in which we may opt for fixed effect models.

Pairwise meta-analysis will be conducted using the bayesmeta package of R version 4.0.0 (RStudio, Boston, MA).[27] All network meta-analyses will be performed using the *gemtc* package of R version 4.0.0 (RStudio, Boston, MA),[28] absolute effects in networks will be calculated using *R2jags* package of R version 4.0.0 (RStudio, Boston, MA)[29]. *networkplot* command of Stata version 15.1 (StataCorp, College Station, Texas, USA) will be used to draw the network plots with thickness of edges of the nodes based on inverse variance.[30] The foundational R code that we will use is available in the Supplementary Material.

Subgroups and sensitivity analyses

We will conduct sensitivity analyses and network meta-regression to explore factors that may modify the comparative effect estimates. Specific analyses will be guided by the linked *Rapid Recommendation* guideline panels with the directive to explore a limited number of pre-defined subgroup effects with a specified rationale and anticipated direction of the effect. When sufficient heterogeneity in risk of bias exists, we will perform subgroup analyses comparing studies at low versus high risk of bias. We will classify all studies with at least 1 domain judged at high risk of bias or probably high risk of bias as a high risk of bias study. Ultimately, we will base decisions regarding the credibility of subgroup analyses on the ICEMAN instrument,[31] and follow GRADE guidance on how to deal with low, intermediate, and high credibility subgroup effects.[32]

For all outcomes, we will first include both peer-reviewed and non-peer reviewed data, and then perform a sensitivity analysis by restricting to peer-reviewed publications. When the guideline panel makes a recommendation about a drug class with more than one drug, we will consider performing a sensitivity analysis with individual molecules rather than drug class as the nodes.

Certainty assessment

We will evaluate the certainty of evidence using the GRADE approach for network meta-analysis.[33-35] We will rate the certainty for each comparison and outcome as high, moderate, low, or very low, based on considerations of risk of bias, inconsistency, indirectness, publication bias, intransitivity, incoherence, and imprecision. If and when sufficient effective treatments are available we will, for each outcome, use the GRADE framework to make conclusions by classifying the interventions in groups from the most to the least effective using a minimally contextualized approach.[36]

Updating

Full results will be updated at minimum every two weeks on webpages hosted by BMJ.com and magicapp.org. A summary of the interim results, risk of bias assessments, individual study data summaries, and the date of the search will be posted in a table within the online publication. Results will be updated more frequently if the project steering committee or the linked BMJ Rapid Recommendations guidelines panel judges that there is sufficient new information to possibly change practice and requests an earlier update. Updates will be submitted to international indexes through the mechanism for corrections but labelled as updates. Old versions and details of any changes will be dated and documented in the Supplementary Material. It may be necessary to adjust some of the processes, outcomes, and analytic

methods based on the data. The systematic review team will decide together whether changes to the pre-specified protocol are needed and these changes will be documented in the methods section of the updated review.

External review
A standing peer-review committee editorial staff at The BMJ, clinical experts, patients, and statistician(s) will be tasked with providing feedback on the protocol and initial publication, and a subcommittee will peer review updates. The systematic review team will respond to these comments on an urgent basis. Comments from peer reviewers and responses will be made public. The study webpage will include functionality for comments to be made by any member of the public. The systematic review team will endeavor to respond to all public comments in a timely manner.

Publication
The papers will be published in a traditional format for systematic reviews and network meta-analyses. In addition, results will be published in interactive evidence summary and decision aid formats for multiple comparisons and pairwise comparisons on MAGICapp (www.magicapp.org). The publication will include infographics that highlight the key messages from the current state of the evidence.

Determining the end of project
The project will terminate at the discretion of the project oversight group, which includes representation from the MAGIC Evidence Ecosystem Foundation, The BMJ, the WHO, and international collaborators with clinical and research expertise. We anticipate that the project will end when the question is no longer of clinical importance, or new evidence that might impact on the conclusions is unlikely to be forthcoming. If the influx of new RCT results slows, then the project oversight committee may choose to decrease the frequency of updates.

Data access
All extracted data will be made available publicly at the time of the updates to be shared and used freely.

Changes to the protocol
All changes to the protocol are reported in Table 1 and will be updated as necessary.

Discussion
Our living network meta-analysis will provide up to date information to interested users, including healthcare workers, patients, healthcare agencies, guideline bodies, and governments. It will directly inform joint clinical practice guidelines from BMJ Rapid Recommendations.

We anticipate several challenges. First, living systematic reviews require substantial dedication and human resources.[37] To address this, we will organize our large team into smaller groups with specific responsibilities, including i) a study identification team, ii) a data extraction and management team, iii), a data analysis team, iv) a grading and publications team, and v) an oversight team. In addition, *The BMJ* will recruit a standing external review committee that will become familiar with the research methods and respond quickly to updates.

Second, the need for recurrent updates conflicts with traditional publication formats. Frequent updates resulting in new publications can have a devastating effect on a journal's impact factor. It may also be confusing for users who want to find the most recent update. To solve this problem, we plan to i) have a reference website with the links to the latest versions, ii) use headers on previous versions stating that they are outdated with a link to the current version, iii) use PubMed's corrections mechanism so that the updated publication keeps the same digital object identifier (DOI) and PubMed identification number.

Evidence summaries will also be published online with MAGICapp (www.magicapp.org) developed for the purpose of dynamic updating and with electronic publication formats not subject to the limitations of traditional publishing formats thus allowing presentation of evidence summaries in multilayered user-friendly formats.[38]

Third, the optimal methodological and statistical methods may change as the number of RCTs and participants increases. In particular, early NMAs are likely to be sparse, and we may have to use specific analytic methods to accommodate these situations.[25] Our oversight committee and semi-independent guideline panels will provide direction and guidance on whether and how the methods should be adopted to the current situation.

Another major concern with living systematic reviews is limitations in the evidence included, in particular bias. We will assess risk of bias of each study using a standardized tool,[15 16] and assess risk of bias for each comparison using the GRADE framework.[33 34] Publication bias is of particular concern with living reviews: studies with positive results are more likely to be published at all, and when published are likely to be published earlier.[39] We will use the GRADE approach, which considers publication bias, to rate certainty for the estimated effect for each comparison.[21] Clinical practice guideline panels of whom the majority will be independent of this review, will consider this issue when making recommendations for practice, and their scrutiny may bear on certainty of evidence judgements.[9]

There are at least two other groups planning a similar living systematic review and NMA.[40 41] More than one group performing similar analyses will allow controlled replication and the scientific community to assess reproducibility of the findings. Our review has advantages over the alternatives, including the use of and experience with GRADE for NMA, an established platform in the *BMJ Rapid Recommendations* project; an established collaboration with and early involvement of the publisher (*The BMJ*); and interpretation from a semi-independent *BMJ Rapid Recommendations* guideline panels; inclusion of a dedicated search of the Chinese literature; and co-publication in MAGICapp through its interactive multilayered evidence presentation format.

Conclusions

The COVID-19 pandemic necessitates rapid interpretation of new evidence addressing therapeutic and prophylactic options. Our living systematic review and NMA will provide a reference point for those interested in the most trustworthy evidence regarding these therapies. Our project will facilitate the movement of evidence into practice much sooner than traditional publication methods.

Table 1. Changes to the protocol

Date	Change	Rationale
15 July 2020	Network analyses will only include treatment nodes with at least 100 patients or at least 20 events.	Early analyses with sparse data resulted in implausible and uninformative effect estimates.
9 October 2020	We will conduct our daily search for relevant studies using the WHO COVID-19 database.	The CDC COVID-19 Research Articles Downloadable Database merged with the WHO covid-19 database.

20 February 2021	We no longer search the Chinese databases.	These databases have not provided studies that meaningfully altered the evidence for any intervention.
2021	We no longer assess risk of bias related to RCTs stopping early for benefit as an additional domain in our modified tool.	Sensitivity analyses suggested that this risk of bias domain did not meaningfully change the results.
1 December 2021	We no longer extract the following baseline information: percent taking angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), mean alanine aminotransferase (ALT), mean C-reactive protein (CRP), mean d-dimer, mean lactate dehydrogenase (LDH), mean lymphocyte count, and percent with lymphopenia.	These baseline characteristics did not seem to be effect modifiers for any of the drugs studied.
3 December 2021	Decision to split the pharmacological treatments network into two separate networks based on baseline disease severity: mild to moderate covid-19 and severe to critical covid-19. To do so, we will use the following hierarchy to classify trials as mild/moderate or severe/critical: 1. WHO criteria (oxygen saturation ≥90% on room air, respiratory rate ≤30, and no respiratory distress, acute respiratory disease syndrome (ARDS), sepsis, or septic shock will be considered mild/moderate)[42] 2. Author definition 3. Respiratory support (infection not requiring respiratory support (e.g., supplemental oxygen, non-invasive ventilation, invasive ventilation) will be considered mild/moderate) If authors classify participants receiving respiratory support as mild/moderate, we will use respiratory support to classify participants. For trials of mixed disease severity, we will first attempt to extract subgroup data if reported. If subgroup data is not reported, we will: 1. Use a threshold of 80% to determine which network the trial belongs to 2. If less than 80% of participants belong to one specific group, we will consult with content experts to determine if the trial can be included and if yes, in which network	Evidence has suggested that different interventions are more effective at certain stages of covid-19.

	For any trial of unclear disease severity, we will consult with content experts to determine if it should be included. In subsequent publications, we will describe how each included trial was classified.	
16 December 2021	Began extracting vaccination status as part of baseline patient characteristics.	Requested by the linked WHO guideline panel, because of increasing access to vaccines and the possibility that vaccination status might be an effect modifier for some drugs.
2021	We no longer conduct sensitivity analyses restricted to data from only peer-reviewed publications.	These sensitivity analyses never found any meaningful difference in pooled effects. Additional analyses have also found consistent results.[43]
28 April 2022	We will include all studies of pharmacological treatments for covid-19 but will only extract data from trials investigating interventions of interest, as determined by a steering committee of clinicians. An intervention is considered to be of interest if it meets any of the following criteria: - The drug is promising - There is strong public or policymaker interest in the drug - The intervention is recommended by the WHO steering group - The drug is specific to COVID-19 We ensure our judgments are consistent for all drugs in a given drug class. If one of the drugs in a drug class (i.e., the "flagship" drug) meets the criteria above, then all drugs in that class are included as interventions of interest. If the "flagship drug" fails to meet the criteria above, then none of the drugs in that class are considered to be of interest. We will document all excluded interventions and include this information in subsequent publications.	To prioritize interventions of interest to decision-makers thereby ensuring our conclusions are relevant while maintaining feasibility.
1 January 2023	We will exclusively monitor living evidence retrieval services, using the COVID-19 Living Overview of Evidence (L·OVE) by the Epistemonikos Foundation to retrieve relevant studies on a weekly basis. Prior to switching to this database alone, we will implement a one-month overlap period to ensure no studies are lost and that this database provides comparable results.	This database searches 42 databases, trial registries, and preprint servers and has been found to include 100% of covid-19 related randomised trials.[44] Using this database has drastically reduced the amount of human resources needed to screen titles and abstracts.

11 May 2023	We updated our risk of bias guidance document. We no longer consider lack of blinding alone to be a reason to rate as "probably high risk" for deviations from intended interventions. Instead, blinded trials are rated as low risk and unblinded trials as probably low risk unless there are important imbalances in co-intervention at which point any trial, irrespective of blinding status, is rated as high risk of bias. All previous RoB judgements were updated to reflect this change.	Based on the findings of a methodological study of covid-19 trials which did not find compelling evidence that blinded trials produced different results.[45]
1 June 2023	The mild/moderate network will analyze the following outcomes: mortality, mechanical ventilation, admission to hospital, adverse events leading to discontinuation, venous thromboembolism, clinically important bleeding, length of hospital stay, time to symptom resolution. We will continue to extract data for all outcomes described in the protocol.	We will prioritize outcomes most relevant for patients with non-severe covid-19.
Ongoing	There have been changes to the composition of the core team and the sub team leads.	Team member turnover over time.

References

1. John Hopkins University. Coronavirus Resource Center 2020 [Available from: https://coronavirus.jhu.edu/map.html accessed April 27 2020.
2. Wong JC. Hydroxychloroquine: how an unproven drug became Trump's coronavirus 'miracle cure'. *The Guardian* 2020 07/04/2020.
3. Ye Z, Rochwerg B, Wang Y, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. *CMAJ* 2020 doi: 10.1503/cmaj.200648 [published Online First: 2020/05/01]
4. U.S. Food and Drug Administration. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. In: (HHS) USDoHaHS, ed., 2020:1-8.
5. Kim AHJ, Sparks JA, Liew JW, et al. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. *Ann Intern Med* 2020 doi: 10.7326/m20-1223 [published Online First: 2020/04/01]
6. Cytel. Global Coronavirus COVID-19 Clinical Trial Tracker 2020 [Available from: https://www.covid19-trials.org/ accessed 6 MAy 2020.
7. World Health Organization. SUBJECT IN FOCUS: providing timely and accurate information to dispel the 'infodemic'. Coronavirus disease 2019 (COVID-19) Situation Report. Geneva, Switzerland, 2020.
8. Institute of Medicine. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Washington, DC: National Academy Press (US) 2011.

9. Siemieniuk RA, Agoritsas T, Macdonald H, et al. Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191. doi: 10.1136/bmj.i5191 [published Online First: 2016/09/30]
10. The Stephen B. Thacker CDC Library. COVID-19 Research Articles Downloadable Database: U.S. Centers for Disease Control and Prevention (CDC); 2020 [Available from: https://www.cdc.gov/library/researchguides/2019novelcoronavirus/researcharticles.html accessed 6 May 2020.
11. Marshall IJ, Noel-Storr A, Kuiper J, et al. Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guide. *Res Synth Methods* 2018;9(4):602-14. doi: 10.1002/jrsm.1287 [published Online First: 2018/01/10]
12. Norwegian Institute of Public Health. NIPH systematic and living map on COVID-19 evidence 2020 [Available from: https://www.nornesk.no/forskningskart/NIPH_mainMap.html accessed 6 May 2020.
13. EPISTEMONIKOS Foundation. Living Overview of Evidence (L·OVE) 2020 [Available from: https://iloveevidence.com/ accessed 6 June 2020 2020.
14. WHO Working Group on the clinical characterization of COVID-19 infection. A candidate core outcome measure set for clinical research during the SARS-CoV-2/COVID-19 pandemic. Geneva, Switzerland: World Health Organization, 2020:1-16.
15. Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)* 2019;366:l4898. doi: 10.1136/bmj.l4898 [published Online First: 2019/08/30]
16. Busse J, Guyatt G. Modification of Cochrane tool to assess risk of bias in randomized trials. 2013. https://distillercer.com/wp-content/uploads/2014/02/Tool-to-Assess-Risk-of-Bias-in-Randomized-Controlled-Trials.docx (accessed 6 Mar 2020).
17. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. *J Clin Epidemiol* 2011;64(12):1303-10. doi: 10.1016/j.jclinepi.2011.04.014 [published Online First: 2011/08/02]
18. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *Jama* 2010;303(12):1180-7. doi: 10.1001/jama.2010.310 [published Online First: 2010/03/25]
19. Röver C. Bayesian random-effects meta-analysis using the bayesmeta R package. *arXiv preprint arXiv:171108683* 2017
20. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383-94. doi: 10.1016/j.jclinepi.2010.04.026 [published Online First: 2011/01/05]
21. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. *Journal of clinical epidemiology* 2011;64(12):1277-82. doi: 10.1016/j.jclinepi.2011.01.011 [published Online First: 2011/08/02]
22. van Valkenhoef G, Dias S, Ades AE, et al. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7(1):80-93. doi: 10.1002/jrsm.1167 [published Online First: 2015/10/16]
23. Spineli L, Brignardello-Petersen R, Heen A, et al. Obtaining absolute effect estimates to facilitate shared decision making in the context of multiple comparisons. Global Evidence Summit. Cape Town, South Africa, 2017.
24. Foroutan F, Guyatt G, Zuk V, et al. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *Journal of clinical epidemiology* 2020;121:62-70. doi: 10.1016/j.jclinepi.2019.12.023 [published Online First: 2020/01/27]
25. Brignardello-Petersen R, Murad MH, Walter SD, et al. GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse

networks. *J Clin Epidemiol* 2019;105:60-67. doi: 10.1016/j.jclinepi.2018.08.022 [published Online First: 2018/09/27]
26. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *Int J Epidemiol* 2012;41(3):818-27. doi: 10.1093/ije/dys041 [published Online First: 2012/03/31]
27. Röver C. Bayesian random-effects meta-analysis using the bayesmeta R~package. *Journal of Statistical Software* 2020;93(6):1-51. doi: 10.18637/jss.v093.i06
28. gemtc: Network Meta-Analysis Using Bayesian Methods [program]. R package version 0.8-4 version, 2020.
29. R2jags: Using R to Run 'JAGS' [program]. R package version 0.6-1 version, 2020.
30. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654 [published Online First: 2013/10/08]
31. Schandelmaier S, Briel M, Varadhan R, et al. A new instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses *CMAJ [In Press]* 2020
32. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol* 2011;64(12):1294-302. doi: 10.1016/j.jclinepi.2011.03.017 [published Online First: 2011/08/02]
33. Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. *J Clin Epidemiol* 2018;93:36-44. doi: 10.1016/j.jclinepi.2017.10.005 [published Online First: 2017/10/21]
34. Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *Bmj* 2014;349:g5630. doi: 10.1136/bmj.g5630 [published Online First: 2014/09/26]
35. Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, et al. GRADE approach to rate the certainty from a network meta-analysis: Addressing Incoherence. *J Clin Epidemiol* 2018 doi: 10.1016/j.jclinepi.2018.11.025 [published Online First: 2018/12/12]
36. Brignardello-Petersen R, Florez I, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualized framework [Submitted for publication}. 2020
37. Elliott JH, Synnot A, Turner T, et al. Living systematic review: 1. Introduction-the why, what, when, and how. *Journal of clinical epidemiology* 2017;91:23-30. doi: 10.1016/j.jclinepi.2017.08.010 [published Online First: 2017/09/16]
38. Agoritsas T, Heen AF, Brandt L, et al. Decision aids that really promote shared decision making: the pace quickens. *BMJ (Clinical research ed)* 2015;350:g7624. doi: 10.1136/bmj.g7624 [published Online First: 2015/02/12]
39. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database Syst Rev* 2009(1):Mr000006. doi: 10.1002/14651858.MR000006.pub3 [published Online First: 2009/01/23]
40. Boutron I, Chaimani A, Devane D, et al. Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review. *Zenodo* 2020. http://doi.org/10.5281/zenodo.3744600 (accessed 10 May 2020).
41. Juul S, Nielsen N, Bentzer P, et al. Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). *Syst Rev* 2020;9(1):108. doi: 10.1186/s13643-020-01371-0
42. Lamontagne F, Agarwal A, Rochwerg B, et al. A living WHO guideline on drugs for covid-19. *BMJ* 2020:m3379. doi: 10.1136/bmj.m3379
43. Zeraatkar D, Pitre T, Leung G, et al. Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. *BMJ Med*. 2022;1(1):e000309. Published 2022 Oct 3. doi:10.1136/bmjmed-2022-000309

44. Verdugo-Paiva F, Vergara C, Ávila C, et al. COVID-19 Living Overview of Evidence repository is highly comprehensive and can be used as a single source for COVID-19 studies. *Journal of clinical epidemiology* 2022;149 doi: 10.1016/j.jclinepi.2022.05.001
45. Zeraatkar D, Pitre T, Diaz-Martinez JP, et al. Impact of Allocation Concealment and Blinding in Trials Addressing Treatments for COVID-19: A Methods Study. *American Journal of Epidemiology* 2023 doi: 10.1093/aje/kwad131

Detailed Risk of Bias Assessment Guidance

Bias from the randomization process	
Issues to consider: Random sequence generation Allocation concealment	
Definitely low risk of bias	Trials that assign participants to alternative interventions using a randomly generated sequence and maintain allocation concealment. Examples of methods for developing a randomly generated allocation sequence include a random number generator, random number table, coin tossing, shuffling cards or envelopes, and throwing dice. If a trial is described as 'randomized' without any additional details related to how the allocation sequence was developed, we will assume that the allocation sequence was appropriately developed. Examples of methods for maintaining allocation concealment include using central allocation via a computer or phone system, pharmacy-controlled allocation, opaque sealed envelopes, and sequentially numbered drug containers. *Note that an explicit description of random sequence generation is not necessary for a rating of low risk of bias.*
Probably low risk of bias	Trials in which healthcare providers were blind to the intervention but which provide no information on allocation concealment and in which there are no major baseline imbalances. *Note that an explicit description of random sequence generation is not necessary for a rating of probably low risk of bias.*
Probably high risk of bias	Trials in which healthcare providers were not blind to the intervention and which provide no information on allocation concealment. Trials in which there are substantial baseline differences between trial arms that suggest a problem with the randomization process but there are no other limitations related to randomization.
Definitely high risk of bias	Trials in which allocation is by judgment of the clinician, by preference of the participant, by availability of the intervention, based on the results of a laboratory test, or other non-random rules (e.g., birthdate, etc.). Trials in which investigators enrolling participants could possibly foresee the arm to which each subsequent patient would be randomized, such as allocation using an open allocation schedule (e.g. a list of random numbers), assignment envelopes used without appropriate safeguards (e.g. use of unsealed, non-opaque or not

	sequentially numbered envelopes), alternation between arms, case record number, or any other explicitly unconcealed procedure, rate as high risk.
Bias due to deviations from the intended intervention	
Issues to consider: Blinding of healthcare providers/clinicians and participants Imbalances in cointerventions or behaviors	
Definitely low risk of bias	Therapy trials in which healthcare providers are blind to the intervention administered and in which there are no important differences in administered co-interventions between arms at the time of randomization (i.e., within 2-3 days). Therapy trials that are described as double or triple blind. Prophylaxis trials in which participants are blind to the intervention that they have been randomized and in which there are no important differences in administered co-interventions between arms at the time of randomization (i.e., within 2-3 days). Prophylaxis trials that are described as double or triple blind.
Probably low risk of bias	Therapy trials in which healthcare providers are not blind to the intervention administered and in which there is no important difference in administered co-interventions between arms at the time of randomization (i.e., within 2-3 days). Prophylaxis trials in which participants are not blind to the intervention that they have been randomized and in which there is no important difference in administered co-interventions between arms at the time of randomization (i.e., within 2-3 days).
Probably high risk of bias	
Definitely high risk of bias	Therapy trials where there are important differences in administered co-interventions. Prophylaxis trials where there are important differences in social distancing and risk-taking behaviors or where healthcare providers were very involved and counselled patients on social distancing, risk-taking behaviors, or testing for COVID-19.
Bias due to missing data	
Issues to consider: Missing outcome data Loss to follow-up	
Definitely low risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) < 10%.

	For in-patient trials, we will assume low risk of bias due to missing data unless otherwise specified.
Probably low risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) is between 10% to 15% and missing outcome data is unlikely to be related to the true outcome and there is no imbalance in numbers of or reasons for missing data across intervention groups.
Probably high risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) is between 10% to 15% and missing outcome data is likely to be related to the true outcome or there are imbalances in numbers of or reasons for missing data across intervention groups.
Definitely high risk of bias	Trials in which missing outcome data (including outcome data that has been imputed) > 15%.
Bias due to measurement of the outcome	
Issues to consider: Blinding of outcome adjudicators Objectivity of outcome *Note that the judgments may differ across outcomes.*	
Definitely low risk of bias	Trials in which patients are blind to the intervention and in which outcomes are patient-reported. Trials in which outcomes are measured by a third-party (investigator or clinician) and in which the third-party is blind to the intervention. Trials in which the outcomes are objective (e.g., mortality, infection with COVID-19 confirmed by a positive RT-PCR swab, mechanical ventilation, admission to hospital, duration of hospital stay, ICU length of stay, ventilator free days, duration of mechanical ventilation, time to clinical improvement if clinical improvement is measured via objective criteria, viral clearance, time to viral clearance). Trials that are described as double or triple blind.
Probably low risk of bias	
Probably high risk of bias	
Definitely high risk of bias	Trials in which patients are not blind and in which outcomes are patient-reported (e.g., time to symptom resolution). Trials in which outcome adjudicators are not blind and the outcomes are not objective (e.g., adverse effects leading to discontinuation, transfusion-related acute lung injury, transfusion-associated circulatory overload, allergic reactions, infection with suspected/symptomatic COVID-19, venous thromboembolism, time

	to symptom resolution including fever, time to clinical improvement if the criteria for clinical improvement are not objective).
Bias in selection of the reported results	
Issues to consider: Selective reporting of timepoints Selective reporting of outcome measures *Note that we are only interested in selective reporting for the outcomes for which we are extracting data.* *Note that the judgments may differ across outcomes.*	
Definitely low risk of bias	Results for outcomes that were analyzed and reported according to a pre-specified statistical analysis plan or protocol (including the timepoint for the measurement of the outcome).
Probably low risk of bias	Results for outcomes that were analyzed and reported but that were not prespecified in a statistical analysis plan or protocol but the timepoint at which results are reported is consistent with the timepoint for other outcomes in the trial report or there is little reason to believe the outcome was selectively reported. Please note that outcomes that were not prespecified in a protocol or statistical analysis plan and that are reported in the trial preprint or publication should be rated at probably low risk of bias unless there are other important reasons to suspect that results for those outcomes were selectively reported (e.g., results are presented at timepoints that don't match the timepoints reported for other outcomes).
Probably high risk of bias	Results for outcomes that were analyzed and reported but that were not prespecified in a statistical analysis plan or protocol but the timepoint at which results are reported is not consistent with the timepoint for other outcomes in the trial report or there are other reasons to believe that the outcome is selectively reported.
Definitely high risk of bias	Results for outcomes that were analyzed and reported for which there are inconsistencies with the statistical analysis plan or protocol. These inconsistencies may include outcome measures of interest or the timepoints for the measurement of outcomes.
Bias due to competing risks	
Issues to consider: Competing risks due to early termination (only for continuous outcomes)	
Definitely low risk of bias	Results are very unlikely to have been affected by competing risk due to death. For example, the intervention arm increased the risk of death but the duration of hospitalization is shorter in the control arm.
Probably low risk of bias	Results are unlikely to have been affected by competing risk due to death.

	For example, the intervention arm increased the risk of death but the duration of hospitalization is slightly shorter in the control arm or there is no appreciable difference between arms.
Probably high risk of bias	Results are likely to have been affected by competing risk due to death. For example, the intervention arm increased the risk of death and the duration of hospitalization is appreciably lower in the intervention arm. Note that for outcomes such as ICU length of stay and duration of ventilation in which only patients admitted to the ICU or patients are ventilated may be included in analyses, even small imbalances in deaths across trial arms may lead to bias due to competing risks because patients who die are also likely the ones who were admitted to the ICU or ventilated. While patients who die may make up only a small proportion of the total patients included in the trial, they may make up an appreciable proportion of patients who are admitted to the ICU and who are ventilated.
Definitely high risk of bias	Results are very likely to have been affected by competing risk due to death. For example, the intervention arm increased the risk of death and the duration of hospitalization is much lower in the intervention arm.

Results of Studies Captured after Analysis Date

Intervention	Comparator	Outcome	NMA Result*	New Studies	Individual Studies Effect Estimate**	n	Assessment of Consistency
(hydroxy)chloroquine	standard care/placebo	mortality	OR = 1.06 (0.68 to 1.55)	Chen_6	RD = 0 (120 fewer to 120 more)	30	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = 10.09 (-2.84 to 23.95)	Chen_6	RD = 70 (-100 to 230)	30	consistent, not convincingly different from standard care
		time to symptom resolution	MD = -0.690 (-1.810 to 0.560)	Chen_6	MD = -0.33 (-1.82 to 1.16)	30	consistent, not convincingly different from standard care
ACEi/ARB	standard care/placebo	mortality	OR = 1.19 (0.66 to 2.17)	Huang_3	OR = 1.36 (0.05 to 34.13)	114	consistent, not convincingly different from standard care
		mechanical ventilation	OR = 0.87 (0.49 to 1.59)	Huang_3	OR = 2.29 (0.11 to 48.96)	114	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	NA	Huang_3	RD = 10 fewer (40 fewer to 60 more)	114	outcome not previously analyzed for this comparison
		length of hospital stay	MD = -0.170 (-1.820 to 1.620)	Huang_3	MD = 0.00 (-1.43 to 1.43)	80	consistent, not convincingly different from standard care
corticosteroids (systemic)	standard care/placebo	admission to hospital	OR = 0.43 (0.20 to 0.90)	Amra_2	OR = 1.41 (0.29 to 6.80)	75	inconsistent, NMA estimate suggests an intermediate benefit (low certainty) while new study suggests treatment is not convincingly different from standard care
		adverse events leading to discontinuation	RD = -0.01 (-14.28 to 14.53)	Amra_2	RD = 0 fewer (70 fewer to 70 more)	75	consistent, not convincingly different from standard care
colchicine	standard care/placebo	mortality	OR = 0.58 (0.33 to 1.01)	Hejazi	RD = 0 (50 fewer to 50 more)	80	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = 0.75 (-7.39 to 11.78)	Hejazi	RD = 0 fewer (50 fewer to 50 more)	80	consistent, not convincingly different from standard care
		time to symptom resolution	MD = -1.570 (-3.190 to 0.390)	Hejazi	MD = -0.45 (-2.08 to 1.18)	80	consistent, not convincingly different from standard care
ensitrelvir	standard care/placebo	admission to hospital	NA	Yotsuyanagi	OR = 0.5 (0.03, 8.05)	1808	outcome not previously analyzed for this comparison
		mortality	RD = 145 more (3 fewer to 997 more)	Yotsuyanagi	RD = 0 (0 fewer to 0 more)	1808	consistent, not convincingly different from standard care

		mechanical ventilation	NA	Yotsuyanagi	RD = 0 (0 fewer to 0 more)	1808	outcome not previously analyzed for this comparison
		adverse events leading to discontinuation	RD = 4.17 (-15.14 to 22.85)	Yotsuyanagi	RD = 10 more (0 fewer to 10 more)	1808	consistent, not convincingly different from standard care
		time to symptom resolution	NA	Yotsuyanagi	MD = -1.07 (-2.61, 0.47)	1731	outcome not previously analyzed for this comparison
favipiravir	standard care/placebo	mortality	OR = 3.75 (0.91 to 21.6)	Iwata	RD = 0 (50 fewer to 50 more)	84	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = 8.05 (-2.2 to 18.54)	Iwata	RD = 20 more (40 fewer to 90 more)	84	consistent, not convincingly different from standard care
fluvoxamine	standard care/placebo	admission to hospital	OR = 0.73 (0.44 to 1.15)	Siripongboonsitti	OR = 1.45 (0.45, 4.65)	327	consistent, not convincingly different from standard care
				Wannigama#	OR = 0.03 (0.01, 0.06)	498	inconsistent, NMA estimate suggests not convincingly different from standard care (moderate certainty)
				Naggie_4	OR = 0.5 (0.04, 5.49)	1175	consistent, not convincingly different from standard care
		mortality	OR = 0.68 (0.3 to 1.51)	Siripongboonsitti	RD = 0 (10 fewer to 10 more)	327	consistent, not convincingly different from standard care
				Wannigama#	RD = 0 (10 fewer to 10 more)	498	consistent, not convincingly different from standard care
				Naggie_4	RD = 0 (0 fewer to 0 more)	1175	consistent, not convincingly different from standard care
				Reiersen	RD = 0 (10 fewer to 10 more)	547	consistent, not convincingly different from standard care
		mechanical ventilation	OR = 0.77 (0.38, 1.58)	Siripongboonsitti	RD = 0 (10 fewer to 10 more)	327	consistent, not convincingly different from standard care
				Wannigama#	OR = 0.02 (0, 0.31)	498	inconsistent, NMA estimate suggests not convincingly different from standard care (moderate certainty)
				Reiersen	OR = 3.04 (0.12, 75.06)	547	consistent, not convincingly different from standard care
		time to symptom resolution	MD = -0.090 (-2.910 to 3.600)	Naggie_4	MD = 0 (-0.71, 0.71)	1134	consistent, not convincingly different from standard care

HIV reverse transcriptase inhibitors	standard care/placebo	mortality	NA	de Souza	OR = 0.72 (0.16, 3.29)	179	outcome not previously analyzed for this comparison
inhaled corticosteroids	standard care/placebo	mortality	RD = 148 more (3 fewer to 997 more)	Mettananda	OR = 0.99 (0.06, 16.02)	385	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = -9.73 (-30.26 to 10.18)	Mettananda	RD = 0 (10 fewer to 10 more)	385	consistent, not convincingly different from standard care
		time to symptom resolution	MD = -0.290 (-1.940 to 1.640)	Mettananda	MD = -0.67 (-1.43, 0.09)	385	consistent, not convincingly different from standard care
interferon beta (nebulised)	standard care/placebo	admission to hospital	NA	Jagannathan_2	OR = 0.13 (0.02, 1.12)	220	outcome not previously analyzed for this comparison
		mortality	OR = 0.63 (0.07 to 5.57)	Jagannathan_2	RD = 0 fewer (20 fewer to 20 more)	220	consistent, not convincingly different from standard care
		time to symptom resolution	NA	Jagannathan_2	MD = 3.33 (0.13, 6.53)	220	outcome not previously analyzed for this comparison
ivermectin	standard care/placebo	admission to hospital	OR = 0.85 (0.61 to 1.18)	Hayward	OR = 0.35 (0.24, 0.50)	5413	inconsistent, NMA estimate suggests not convincingly different from standard care (moderate certainty)
		mortality	OR = 0.75 (0.48 to 1.18)	Hayward	OR = 0.38 (0.11, 1.34)	5413	consistent, not convincingly different from standard care
				Mikamo	RD = 0 fewer (0 fewer to 0 more)	1029	consistent, not convincingly different from standard care
		mechanical ventilation	OR = 0.66 (0.4 to 1.07)	Hayward	OR = 2.52 (0.26, 24.21)	3950	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = 5.74 (-1.1 to 16.07)	Mikamo	RD = 10 more (0 fewer to 10 more)	1029	consistent, not convincingly different from standard care
		time to symptom resolution	MD = -0.690 (-1.660 to 0.370)	Mikamo	MD = 0.05 (-0.61 to 0.71)	726	consistent, not convincingly different from standard care
				Hayward	MD = -1 (-1.36, -0.64)	3362	inconsistent, NMA estimate suggests not convincingly different from standard care (moderate certainty)
molnupiravir	standard care/placebo	admission to hospital	OR = 0.66 (0.44 to 0.92)	Schilling_2	RD = 0 fewer (30 fewer to 30 more)	149	inconsistent, NMA estimate suggests an intermediate benefit (low certainty)

		time to symptom resolution	MD = -2.340 (-3.450 to -1.070)	Bernal	MD = -2 (-4.24, 0.24)	1408	inconsistent, NMA estimate suggests provides an intermediate benefit (high certainty)
nirmatrelvir-ritonavir	standard care/placebo	admission to hospital	OR = 0.15 (0.07 to 0.32)	Schilling_2	RD = 0 fewer (30 fewer to 30 more)	142	inconsistent, NMA estimate suggests among the best (moderate certainty)
		adverse events leading to discontinuation	RD = -5.6 (-18.05 to 8.63)	Hammond	RD = 20 fewer (0 fewer to 30 more)	1288	consistent, not convincingly different from standard care
		length of hospital stay	MD = -0.500 (-2.620 to 1.430)	Hammond	MD = 0.13 (-0.28, 0.02)	1288	consistent, not convincingly different from standard care
remdesivir	standard care/placebo	admission to hospital	OR = 0.25 (0.07 to 0.77)	Schilling	OR = 0.31 (0.01, 7.84)	131	inconsistent, NMA estimate suggests an intermediate benefit (moderate certainty)
		time to symptom resolution	MD = -0.560 (-2.890 to 2.370)	Schilling	MD = 03.34 (-9.38, 2.70)	131	consistent, not convincingly different from standard care
serine protease inhibitors	standard care/placebo	mortality	RD = 844 more (0.15 fewer to 997 more)	Okugawa	RD = 0 fewer (140 fewer to 140 more)	29	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = 15.53 (-23.16 to 53.74)	Okugawa	RD = 0 fewer (140 fewer to 140 more)	29	consistent, not convincingly different from standard care
VV116	standard care/placebo	mortality	RD = 314 more (3 fewer to 997 more)	Fan_2	RD = 0 fewer (0 fewer to 0 more)	1347	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = -13.07 (-39.58 to 14.62)	Fan_2	RD = 0 (10 fewer to 10 more)	1347	consistent, not convincingly different from standard care
		time to symptom resolution	MD = 0.360 (-3.800 to 6.590)	Fan_2	MD = -2 (-3.52, -0.48)	1296	inconsistent, NMA estimate suggests not convincingly different from standard care (very low certainty)
vitamin D	standard care/placebo	mortality	OR = 1.09 (0.43 to 2.9)	Partap	RD = 0 fewer (20 fewer to 20 more)	156	consistent, not convincingly different from standard care
		mechanical ventilation	OR = 1.01 (0.41 to 2.59)	Partap	OR = 1.01 (0.14, 7.40)	145	consistent, not convincingly different from standard care
		adverse events leading to discontinuation	RD = 1.13 (-29.83 to 31.86)	Partap	RD = 0 fewer (20 fewer to 20 more)	156	consistent, not convincingly different from standard care
		length of hospital stay	MD = -1.570 (-3.310 to 0.030)	Partap	MD = 1 (-0.41, 2.41)	148	consistent, not convincingly different from standard care

		time to symptom resolution	NA	Partap	MD = 0 (-1.82, 1.82)	132	outcome not previously analyzed for this comparison
leritrelvir	standard care/placebo	admission to hospital	NA	Zhan	RD = 0 fewer (0 fewer to 0 more)	1359	new intervention, not previously analyzed
		mortality	NA	Zhan	RD = 0 fewer (0 fewer to 0 more)	1359	new intervention, not previously analyzed
		adverse events leading to discontinuation	NA	Zhan	RD = 0 fewer (0 fewer to 10 more)	1349	new intervention, not previously analyzed
simnotrelvir	standard care/placebo	mortality	NA	Cao	RD = 0 fewer (0 fewer to 0 more)	1139	new intervention, not previously analyzed
		adverse events leading to discontinuation	NA	Cao	RD = 0 fewer (10 fewer to 20 more)	1139	new intervention, not previously analyzed
		time to symptom resolution	NA	Cao	MD = -1.5 (-2.47, -0.53)	1007	new intervention, not previously analyzed
GST-HG171, ritonavir	standard care/placebo	mortality	NA	Lu	RD = 0 fewer (0 fewer to 0 more)	1213	new intervention, not previously analyzed
		adverse events leading to discontinuation	NA	Lu	RD = 0 fewer (20 fewer to 10 more)	1227	new intervention, not previously analyzed
fluoxetine	standard care/placebo	admission to hospital	NA	Jittamala	RD = 0 fewer (10 fewer to 10 more)	271	new intervention, not previously analyzed
		mortality	NA	Jittamala	RD = 0 fewer (10 fewer to 10 more)	271	new intervention, not previously analyzed
		adverse events leading to discontinuation	NA	Jittamala	RD = 0 fewer (10 fewer to 10 more)	271	new intervention, not previously analyzed
bemnifosbuvir	standard care/placebo	admission to hospital	NA	Horga_2	OR = 0.27 (0.08, 0.96)	207	new intervention, not previously analyzed
		mortality	NA	Horga_1	OR = 0.19 (0.01, 3.99)	81	new intervention, not previously analyzed
			NA	Horga_2	RD = 0 fewer (20 fewer to 20 more)	207	new intervention, not previously analyzed
		adverse events leading to discontinuation	NA	Boffito	RD = 60 more (30 fewer to 140 more)	100	new intervention, not previously analyzed
				Horga_1	RD = 50 fewer (160 fewer to 60 more)	80	new intervention, not previously analyzed

				Horga_2	RD = 40 fewer (110 fewer to 20 more)	212	new intervention, not previously analyzed
		time to symptom resolution	NA	Boffito	MD = 0.16 (-1.09, 1.41)	100	new intervention, not previously analyzed
				Horga_1	MD = -1 (-7.71, 5.71)	81	
nirmatrelvir-ritonavir	VV116	admission to hospital	NA	Yang	OR = 1.34 (0.37, 4.84)	353	outcome not previously analyzed for this comparison
		mortality	RD = 316 fewer (1000 fewer to 2 more)	Yang	OR = 0.29 (0.01, 7.27)	353	consistent, not convincingly different from each other
		adverse events leading to discontinuation	RD = 7.14 (-16.22, 31.72)	Yang	RD = 20 more (10 fewer to 50 more)	353	consistent, not convincingly different from each other
favipiravir	molnupiravir	admission to hospital	OR = 1.61 (0.84, 3.25)	Salvadori	OR = 3.02 (0.31, 29.12)	965	consistent, not convincingly different from each other
		mortality	OR = 18 (3.21, 149)	Salvadori	OR = 3.01 (0.12, 74.13)	965	consistent, NMA results classify both as not convincingly different from standard care
		adverse events leading to discontinuation	RD = 8.70 (-3.19, 22.02)	Salvadori	RD = 0 fewer (10 fewer to 0 more)	969	consistent, not convincingly different from each other
molnupiravir	nirmatrelvir-ritonavir	admission to hospital	OR = 4.37 (1.82, 10.28)	Schilling_2	RD = 0 fewer (30 fewer to 30 more)	123	inconsistent, NMA estimate suggests nirmatrelvir-ritonavir is among the best while molnupiravir provides an intermediate benefit
		time to symptom resolution	MD = -2.54 (-6.88, 0.89)	Schilling_2	MD = -0.33 (-6.79 to 6.13)	122	consistent, not convincingly different from each other

OR = odds ratio; RD = risk difference; MD = mean difference

* all risk differences are presented per 1000 patients throughout the table

** when there were 0 events in both arms, a risk difference was calculated